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PHASE III CLINICAL STUDY OF TRAMADOL
HYDROCHLORIDE/ACETAMINOPHEN
COMBINATION TABLET IN PATIENTS
WITH CHRONIC OSTEOARTHRITIS PAIN
OR CHRONIC LOW BACK PAIN – A RANDOMIZED
WITHDRAWAL, DOUBLE-BLIND, PARALLEL-
GROUP, PLACEBO-CONTROLLED STUDY
Takashi Matsushita1, Miki Hasebe2, Akira Nishimura3
1Teikyo University, School of Medicine, Orthopedic Surgery,
2Janssen Pharmaceutical K.K., Pain Science, 3Janssen Phar-
maceutical K.K., Site Management, Tokyo, Japan
Objective(s): The objective of this study was to evaluate the
efficacy and safety of the tramadol hydrochloride (TRAM)/
acetaminophen (APAP also known as paracetamol) combi-
nation tablet (JNS013: 37.5 mg of TRAM and 325 mg of
APAP); an analgesics for controlling a variety of pain con-
ditions by having a different mechanism of action from that
of nonsteroidal anti-inflammatory drugs (NSAIDs), in Jap-
anese patients with chronic pain caused by the osteoarthritis
(OA) of the knee or low back pain (LBP) poorly controlled
with NSAIDs.
Material &Methods: The study was a phase III randomized/
withdrawal study for 11 weeks. 277 patients out of 321
entered into an open run-in phase received JNS013. 187 out
of 277 entered into a double-blind period having been ran-
domized to receive either JNS013 (n=94) or placebo (n=93).
Results: Primary efficacy endpoint, the time from the start
of the double-blind period to the occurrence of inadequate
analgesia (withdrawal data), was significantly longer in the
JNS013 group than the placebo group (p=0.0001), confirm-
ing the superiority of JNS013 over placebo. Analyzing the
withdrawal data by OA and LBP, the superiority of JNS013
over placebo was kept for each condition. Secondary effi-
cacy endpoints included assessing patient's QOL using
RDQ for LBP, WOMAC for knee OA and SF-36. The
scores tabulated improved after a 2-week treatment with
JNS013 in the open run-in phase. In the subsequent dou-
ble-blind period RDQ and WOMAC scores tended to im-
prove in the JNS013 group; however, they tended to worsen
or remained unchanged in the placebo group. Improvement
of QOL of patients with pain from OA or LBP was sug-
gested. Adverse events characteristic to opioid analgesics
including nausea, somnolence, vomiting and constipation
were frequently seen in the open run-in phase but there were
no significant safety concerns in the double-blind period.
Conclusion(s): JNS013 appears to be highly promising as a
drug for the control of chronic pain.
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EFFECTS OF INTRAARTICULAR COMBINED
TREATMENT WITH CORTICOSTEROID AND
CHONDRATIN CONTAINING PRODUCTS IN
PATIENTS WITH KNEE JOINT OSTEOARTHRITIS
Modassar T Awan, Igor P Bogdanovich
Central City Clinic, Department of Surgery, Mogileov, Belarus
Objective(s): Osteoarthritis of knee joint is the most com-
mon location of degenerative disease of joints. More than
60% of women in their post menopause years complain of
knee joint pain and edema. Patients especially of regions
where total knee replacement is not being carried out more
often, depend upon the conservative treatment.
Material & Methods: All patients were presented with pain
during walking more than 150 m and edema at the end of
day. All patients were used to take NSAIDs for pain relief
and chondroitin sulfate tablets everyday before our study
started. All patients were divided in two groups on the basis
of roentgen findings. Group A 5 patients with stage II;
Group B 5 patients with stage III. The 1.0 ml triamcinalone
solution was injected intraarticularly in knee joint once in all
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patients and after a period of 7 days the treatment with 1 ml
solution of chondroitin sulfate intraarticularly injection was
started. 5 injections were injected in a patient after a day,
total 10 days course.
Results: After 3 months the following result was observed
on the appearance of pain during walking: Group A, 3
patients (60%), pain after 300 m, 2 patients (40%) pain after
200 m. Group B, 1 patient (20%), pain after 300 m, 2
patients (40%) pain after 200 m and 2 patients (40%) pain
after 150 m. The intake of NSAIDs after 3 months was also
noted as follow: 6 patients, no NSAIDs intake (60%); 3
patients, dose reduced by half (30%); 1 patient continuously
taking NSAIDs (10%).
Conclusion(s): It can be concluded that the combined treat-
ment with corticosteroids and chondroitin containing products
intraarticularly significantly improves the walking distance
without pain almost in all patients, i.e., 8 patients, (80%) can
walk more than before (>150 m) as compared to 2 patients
(20%). It also significantly reduces the demand for NSAIDs
intake (90% compared to 10%). Thus overall stabling the
disease progression and markedly delays the need of knee
joint replacement especially in regions with limited resources.
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A PHASE III, OPEN-LABEL, LONG-TERMCLINICAL
TRIAL OF TRAMADOL HYDROCHLORIDE/
ACETAMINOPHEN COMBINATION TABLET
IN PATIENTS WITH CHRONIC PAIN
Junji Chiba1, Yasuo Inoue1, Akira Nishimura2, Miki
Hasebe3
1Tokyo Women's Medical University Medical Center East,
Orthopedic Surgery and Rheumatology, 2Janssen Pharma-
ceutical K.K., Site Management, 3Janssen Pharmaceutical
K.K., Pain Science, Tokyo, Japan
Objective(s): JNS013 was a combination tablet containing
37.5 mg of tramadol hydrochloride and 325 mg of acetamin-
ophen controlling a various pain by having different mecha-
nism of action from that of nonsteroidal anti-inflammatory
drugs (NSAIDs). The aim of this study was to evaluate effi-
cacy and safety of 52-week administration of JNS013 in
chronic pain patients with nociceptive pain from low back
pain, osteoarthritis of the knee or, rheumatoid arthritis and
neuropathic pain from postherpetic neuralgia, diabetic neuro-
pathic pain and so on, poorly controlled with NSAIDs.
Material & Methods: This study was a phase III open-
label, noncontrolled study. 143 out of 190 patients received
JNS013 orally and 97 patients completed the study. Anal-
gesic effects assessed by VAS24 and overall pain relief on a
6-category scale (worsening to complete relief) and
improvements of QOL assessed by SF-36 were evaluated.
Results: JNS013 showed analgesic effects immediately af-
ter administration and it persisted until Week 52. Absolute
changes in VAS24 score from the pre-observation period was
-22.3±21.19 mm on Week 4 of treatment (Treatment Period
I). This parameter further improved during Treatment Period
II, being -35.5±23.17 mm and -36.6±21.94 mm on Week
28 and 52, respectively. There were no marked differences
in absolute changes in VAS24 score by each condition. The
frequencies of patients in whom overall pain relief was rated
as “moderately” or better increased over time (Week 4,
45.3%; Week 28, 67.6%; Week 52, 72.9%). The frequencies
of patients rated as “moderately” or better on Week 52
ranged from 63.2% to 87.5% in all conditions. The score
for each subcategory of SF-36 increased over time during
the treatment period. Summary scores for both physical and
mental components increased over time until Week 52. In
safety analysis, rate of adverse events was 96.3%. Major
adverse events were nausea, vomiting and constipation,
dizziness and drowsiness frequently seen initially, which
subsided over time (less than 10%).
Conclusion(s): These results suggest that long term (52
weeks) use of JNS013 is tolerated to noncancer chronic pain
patients.
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PLAIN VITAMIN D OR ALFACALCIDOL AS
FOLLOW-UP TREATMENT OF POSTMENOPAUSAL
OSTEOPOROSIS AFTER CONTINUOUS LONG-
TERMONCEWEEKLY BISPHOSPHONATE INTAKE
Johann D Ringe1, Erich Schacht2
1Klinikum Leverkusen, University of Cologne, Medical
Clinic 4, Leverkusen, North Rhine-Westphalia, Germany,
2Zorg, Zürch Osteoporosis Research Group, Zollikerberg,
Canton of Zurich, Switzerland
Objective(s): Long-term oral bisphosphonate (BP) therapy
of osteoporosis may be associated with negative effects on
bone quality. A “drug holiday” after about 5 years of treat-
ment is suggested. There is however very limited experience
with follow-up treatments. We designed this study to com-
pare plain vitamin D with alfacalcidol as treatments during
such a “drug holiday”.
Material & Methods: In a 2 year, comparative study based
on retrospective chart analysis we compared 2 different follow-
up treatments in 85 women with postmenopausal osteoporosis
after an average oral BP intake of 4.2 years. Group A (n=42)
received plain vitamin D 800 IU+calcium 1200mg/d, group B
(n=43) alfacalcidol 1 μg+calcium 500 mg/d. BMD was mea-
sured at onset and after 12 and 24 months at the lumbar spine,
femoral neck and total hip by DXA (LUNAR). Parallel to
BMD measurements lateral spine morphometry was per-
formed to assess prevalent and incident vertebral fractures.
Furthermore incidence of falls (2 years before and during the
trial), back pain (VAS 0-10), adverse events and prevalent
and incident nonvertebral fractures were documented.
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Results: The 2 groups had well matched baseline character-
istics. BMD at LS did not change significantly during the 2
years of follow-up in A, but increased significantly in B by
+2.1% (B vs. A p<0.01) in spite of cessation of BP therapy.
At the two femur sites we found slight decreases with plain
vitamin D and significant increases in the alfacalcidol
group. The average number of falls per patient year was
reduced significantly only in group B (p<0.05). The number
of patients with new vertebral fractures was not significantly
different between A and B after 2 years, but there was a
significantly lower rate of non-vertebral fractures in the
alfacalcidol group (p<0.05). Furthermore there was a sig-
nificantly stronger decrease in average back pain score in
patients receiving alfacalcidol. The numbers of adverse
events did not differ between the 2 follow-up groups.
Conclusion(s): This retrospective pilot study shows very
clearly that switching treatment of postmenopausal osteopo-
rosis from long-term bisphosphonate to alfacalcidol plus
calcium is superior to plain vitamin D plus calcium.
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IS THEREACORRELATIONBETWEENSYMPTOMS
AND BONE SCINTIGRAPHIC FINDINGS IN
PATIENTS WITH COMPLEX REGIONAL
PAIN SYNDROME?
Shaher T El Hadidi1, Abedallatif AlSharif2, Fadi Al Hadidi1,
Ameer S Abdulsahib1, Alaa YAkel1, Jihad M Ajlouni1
1Jordan University Hospital, Orthopedic Department,
2Jordan University Hospital, Nuclear Medicine Department,
Amman, Jordan
Objective(s): Complex Regional pain syndrome (CRPS) is
characterized by pain in combination with sensory, vasomo-
tor, sudomotor, trophic and motor abnormalities. The diag-
nosis of CRPS is based primarily on clinical criteria and the
presence of distinct signs and symptoms. The role of bone
scintigraphy in the diagnosis of these patients has been
limited by its variable sensitivity. In this study we aim to
look if the presence of specific symptoms or symptom
subgroups in patients with clinically diagnosed CRPS cor-
relates with scintigraphic findings in bone scan.
Material & Methods: We retrospectively reviewed clinical
records of patients referred for bone scintigraphy with the
clinical diagnosis of CRPS during the period December
2006 - February 2011. Patients were classified into 4 distinct
subgroups according to the presence of specific symptoms
namely sensory subgroup, sudomotor and /or edema sub-
group, vasomotor subgroup and finally motor and/or trophic
changes subgroup. We looked specifically for the correla-
tion between these specific symptoms and scintigraphic
bone findings.
Results: 37 patients referred for bone scintigraphy with the
clinical diagnosis of CRPS and were enrolled in the study. The
presence of vasomotor symptoms and (motor and/or trophic
changes) was significantly higher in patients with positive
bone scintigraphy (P-value 0.0133, 0.018, respectively). There
was no other statistically significant correlation between the
presence of specific symptoms or symptom subgroup on one
hand and the result of bone scintigraphy on the other hand.
Conclusion(s): The probability of positive bone scintigraphy
increased significantly in patients with vasomotor symptoms
and in patients with motor and/or trophic changes. This may
contribute to the reported variability of the diagnostic perfor-
mance of bone scintigraphy in CRPS patients.
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MISSED OPPORTUNITIES FOR PREVENTION OF
HIP FRACTURE IN OLDER PATIENTS
Emilija M Dubljanin-Raspopovic, Mirko Grajic, Natasa
Mujovic, Nela Ilic
Clinical Center of Serbia, Clinic for Physical Medicine and
Rehabilitation, Belgrade, Serbia
Objective(s): Osteoporotic fractures are a major cause of
morbidity in the population. Therefore, fracture prevention
strategies should be a major concern, and one of the prior-
ities in the primary health care system. The aim of the study
was to assess fracture and fall risk factors, and fracture risk
level in patients with acute hip fracture, and to evaluate if
there was adequate osteoporosis treatment prior to fracture
in this group of patients.
Material & Methods: Fracture and fall risk factors were
assessed in 343 patients ≥65 years hospitalized due to acute
hip fracture at the Clinic for Orthopaedic Surgery and Trau-
matology, Serbia during a 12 month period. Fall risk factors
were assessed with FRAX® algorithm, and patients were
classified in respect to fracture risk level.
Results: Hip fracture occurred in majority of patients in the
high risk group (74.2%), where no additional MKG testing was
needed. Less than 10% patients had a diagnosis of osteoporosis
before injury, while less than 2% were treated. Cognitive
impairment (95.3%), visual impairment (58.2%), decreased
activities of daily living index (51.8%), and depression
(47.1%) were the most frequently observed fall risk factors.
Conclusion(s): The results of our investigation reveal in-
sufficient identification of clinical fracture risk factors in the
primary care setting, inadequate treatment of osteoporosis,
and consequently ineffective prevention of hip fractures in
the geriatric population. FRAX® introduction into clinical
practices enables more effective acknowledgment of
patients with elevated fracture risk, even if bone density
measurement is not available. The results of this study have
a special significance for everyday clinical practice, because
they impose a need for reviewing existing approaches in
osteoporosis prevention, and precise definement of hip pre-
vention strategies.
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COMPARINGDAILY STRONTIUMRANELATEWITH
ONCE WEEKLY ALENDRONATE IN THE TREAT-
MENT OF POSTMENOPAUSAL OSTEOPOROSIS
Corina Galesanu, Natalia Lisnic, Alexandru Florescu, Andra
Iulia Loghin, Adrian Aancute, Valentin Zaharia
University of Medicine and Pharmacy "Gr.T.Popa",
Endocrinology, Iasi, Romania
Objective(s): The bisphosphonates are considered as a first-
line therapy for the treatment of postmenopausal osteoporosis.
Alendronate 70 mg the most commonly used failed to reduce
the risk of fractures. Strontium ranelate is the first antiosteopor-
otic agent that appears to simultaneously increase bone forma-
tion and decrease bone resorption having demonstrated its
efficacy to decrease the risk of fractures. The objective of this
prospective observational study was to compare the effective-
ness of alendronate and strontium ranelate in postmenopausal
osteoporotic women bymeasuring the effects on BMD change.
Material & Methods: We enrolled 150 postmenopausal
osteoporotic women. Their mean age was 66.05 years old
(range: 44-76) and their mean menopausal age was 47.8±
3.7 years old. There were no differences in the basal character-
istics between groups. The drugs used included weekly 70 mg
alendronate in 78 patients (group 1) and daily 2 g strontium
ranelate in 72 women (group 2). BMD was measured by
DXA-BMD at lumbar spine L1-L4, total hip and femoral neck
at baseline and after 1-2 and 3 years of treatment.
Results: The BMD change under the two medicines is
presented in the Table 1.
Table 1
BMD(g/cm2)/
treatment
Baseline 1 year 2 years 3 years
Lumbar spine Alendronate 0.739 0.759 0.770 0.782
gain% +2.7 +4.1 +5.8
Strontium ranelate 0.718 0.754 0.775 0.792
gain% +5.0 +7.9 +10.3
Total hip Alendronate 0.824 0.840 0.853 0.867
gain% +1.9 +3.5 +5.2
Strontium ranelate 0.679 0.692 0.702 0.715
gain% +1.9 +3.3 +5.2
Femoral neck Alendronate 0.664 0.673 0.679 0.687
gain% +1.3 +2.2 +3.4
Strontium ranelate 0.584 0.593 0.600 0.607
gain% +1.5 +2.7 +3.9
In our study we found that the treatment with strontium rane-
late during 3 years induced a significantly increased in BMD in
lumbar spine. Comparing both groups we did not find signif-
icant differences in BMD at total hip and femoral neck.
Conclusion(s): The both medicine increased significantly
the BMD in lumbar spine, total hip and femoral neck after 3
years given the baseline; strontium ranelate was more effec-
tiveness on lumbar spine like alendronate. It is possible that
the different way of action of the two drugs to explain the
magnitude of difference in BMD change at lumbar spine.
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GENDERDIFFERENCES INTHEEFFECTOFBEING
OBESE OR OVERWEIGHT ON GEOMETRIC
INDICES OF HIP BONE STRENGTH IN LEBANESE
ADOLESCENTS AND YOUNG ADULTS
Rawad El Hage1, Christophe Jacob1, Elie Moussa1, Rafic
Baddoura2, Denis Theunynck3
1University of Balamand, Physical Education, Deir El
Balamand, El Koura, Lebanon, 2Hôtel-Dieu Hospital, St
Joseph University, Rheumatology, Beirut, Lebanon, 3EA
4110, Laboratoire RELACS, Université du Littoral Côte
d'Opale, STAPS, Dunkerque, France
Objective(s): The aim of this study was to investigate
whether gender may influence the effect of being obese or
overweight on geometric indices of hip bone strength in a
group of Lebanese adolescents and young adults.
Material & Methods: This study included 138 Lebanese
subjects (61 females and 77 males) aged from 13-25 years.
The girls were divided into three groups: Obese (n=13), Over-
weight (n=20), and Normal weight (n=28) using international
cutoffs for BMI. The boys were divided into three groups:
Obese (n=27), Overweight (n=22), and Normal weight (n=
28) using international cutoffs for BMI. Weight and height were
measured, and BMI was calculated. Body composition and
BMD were assessed by DXA. To evaluate hip bone strength,
DXA scans were analyzed at the narrow-neck (NN), the inter-
tochanteric (IT), and the femoral shaft (FS) by the Hip Structure
Analysis (HSA) program. Cross-sectional area (CSA), an index
of axial compression strength and section modulus (Z), an index
of bending strength were measured from hip BMD profiles.
Results: In both females and males, body weight, lean mass
and BMI were significantly higher in obese and overweight
subjects compared to normal weight peers (P<0.05). In both
females and males, CSA and Z of the three regions (NN, IT
and FS) were significantly higher in obese and overweight
subjects compared to normal-weight peers after adjusting
for age (P<0.05). In males, obese subjects displayed lower
NN CSA, FS CSA and FS Z values compared to overweight
and normal weight subjects after adjusting for body weight
(P<0.05). However, in females, there were no differences
among obese, overweight and normal weight subjects
concerning HSA variables after adjusting for body weight.
Conclusion(s): This study suggests that the effect of obesity
on geometric indices of hip bone strength in adolescents and
young adults is influenced by gender. During growth and
early adulthood, obese males but not obese females do not
increase their hip bone strength indices to fully compensate
for their excessive weight.
S88 Osteoporos Int (2012) 23: (Suppl 2):S85–S386
Disclosures: This study was supported by a grant from the
research council of the University of Balamand.
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COMORBIDITY INDICES FOR CLINICAL
TRIALS: DEVELOPING AN INDEX USING
THE FREEDOM TRIAL IN WOMEN WITH
POSTMENOPAUSAL OSTEOPOROSIS
Stuart Silverman1, Andrea Wang2, Hema Viswanathan3,
Yu-Ching Yang2, Cesar Libanati4, Michelle Geller4, Luanda
Grazette5, Andreas Grauer4, David Macarios3, Michael
Nevitt6, Dennis Revicki7, Ethel Siris8, Steven Boonen9
1Cedars-Sinai Medical Center, Bone Center of Excellence,
Beverly Hills, CA, US, 2Amgen Inc, Global Biostatistical
Science, Thousand Oaks, CA, US, 3Amgen Inc, Global
Health Economics, Thousand Oaks, CA, US, 4Amgen Inc,
Clinical Development, Thousand Oaks, CA, US, 5Universi-
ty of Southern California, Keck School of Medicine, Los
Angeles, CA, US, 6University of California San Francisco,
Department of Epidemiology and Biostatistics, San Francisco,
CA, US, 7United BioSource Corporation, Center for Health
Outcomes Research, Bethesda, MD, US, 8Columbia Universi-
ty Medical Center, Department of Medicine, New York, NY,
US, 9Leuven University, Division of Geriatric Medicine and
Center for Metabolic Bone Disease, Leuven, Belgium
Objective(s): Comorbidities are important considerations in
adjusting for risk of outcomes in clinical trials, however,
comorbidity indices currently available are not designed for
use with clinical trial data. We adapted and applied two pub-
lished algorithms to develop comorbidity indices for a clinical
trial enrolling postmenopausal women with osteoporosis.
Material & Methods: FREEDOM (Cummings, 2009) en-
rolled women aged 60-90 years with total hip or lumbar spine
DXA T-score<-2.5 and not<-4.0 at either site. Comorbidity
indices were calculated using methods described by Wolfe
(Wolfe, 2010) and Sangha (Sangha, 2003). We present results
based on the Wolfe method as it allowed for weighting of
disorders. The modified index included pulmonary disorders,
cardiovascular disorders, hypertension, diabetes, depression,
gastrointestinal ulcer or disorders, and cancer. The index ranges
from 0-8; higher scores indicate greater comorbidity. Four clini-
cians independently reviewed subjects' medical history data
based on MedDRA preferred terms corresponding to each
comorbid condition. Any disagreements were adjudicated by a
fifth clinician who facilitated discussions to reach consensus.
Spearman correlations between the index and subject character-
istics expected to be associated with comorbidities were
examined.
Results: A total of 7808 subjects were included in this study;
60% of subjects had ≤1 comorbidity. The mean modified
Wolfe comorbidity index was 1.4 (SD: 1.3) for all subjects.
The comorbidity index distribution was: 0, 29.2% of the
population; 1, 29.9%; 2, 23.5%; 3, 10.8%; 4, 4.5%; 5, 1.7%;
and 6-7, 0.3%. Correlations between the comorbidity index
and baseline characteristics are shown in the table.
Baseline characteristics Correlation with the
modified Wolfe
Comorbidity Index*
p-value
Number of medications 0.54 < 0.0001
Osteoporosis Assessment
Questionnaire (OPAQ)
physical function dimension
-0.28 < 0.0001
OPAQ emotional status
dimension
-0.28 < 0.0001
EuroQol-5 Dimensions (EQ-
5D) visual analog scale
-0.26 < 0.0001
OPAQ back pain -0.22 < 0.0001
BMI (kg/m2) 0.16 < 0.0001
Age (years) 0.16 < 0.0001
*Fracture history in the originalWolfe algorithm was excluded
from the calculation because FREEDOMwas a fracture study.
Conclusion(s): The modified Wolfe comorbidity index was
found to be significantly correlated with the number of
medications and impaired health status at baseline. The
index may be adapted for clinical trial data, and would allow
for the appropriate adjustment of covariates in the evalua-
tion of clinical trial outcomes.
Disclosures: This abstract was supported by Amgen Inc.
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A PREDICTIVE TOOL FOR ORAL
BISPHOSPHONATE THERAPY DISCONTINUATION
WITHIN INCIDENT USERS: A POPULATION-
BASED COHORT STUDY
Gemma Round1, M Kassim Javaid1, Andrew Judge1, Xavier
Nogués2,3, Nigel K Arden1, Andrew Farmer4, Cyrus
Cooper1,5, Adolfo Diez-Perez2,3, Daniel Prieto-Alhambra1,2,3,6
1University of Oxford, Nuffield Department of Orthopaedics,
Rheumatology and Musculoskeletal Sciences, Oxford, UK,
2Institut Municipal d'Investigacions Mèdiques (IMIM), Parc
de Salut Mar, Internal Medicine - URFOA, Barcelona, Spain,
3Instituto Carlos III - FEDER, Red Temática de Investigación
Cooperativa en Envejecimiento y Fragilidad (RETICEF), Bar-
celona, Spain, 4University of Oxford, Primary Health Care,
Oxford, UK, 5University of Southampton, MRC Lifecourse
Epidemiology Unit, Southampton, UK, 6Institut Català de la
Salut - Universitat Autònoma de Barcelona, Primary Health
Care Research (IDIAP Jordi Gol), Barcelona, Spain
Objective(s): Although oral bisphosphonates can reduce frac-
tures by 50%, patients need to adhere to therapy for 5 years to
obtain full benefit. We investigated a list of potential predictors
for therapy discontinuation. Based on these, we designed a
predictive tool to help clinicians identify patients at high risk
of discontinuation.
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Material & Methods: We screened the SIDIAP database to
identify incident users of oral bisphosphonates between 1/01/
2006 and 31/12/2007. SIDIAP includes pharmacy invoice data
and clinical information for about 5.5 million people in Cata-
lonia (Spain) as recorded by general practitioners. Exclusion
criteria: Paget disease, under 40 years of age or bisphosphonate
treatment in the previous two years. Prognostic factors were
determined a priori: age, gender, nationality, BMI, smoking
status, alcohol drinking, previous fracture, pre-existing comor-
bidities, and number of pre-existing medications. Medication
possession ratios were calculated for participants with an exist-
ing prescription for statins or antihypertensives. Multivariable
backwards-stepwise selection Cox regression was used to iden-
tify key predictors (p-entry 0.049; p-exit 0.05). Patients in the
highest quintile of predicted hazard for discontinuation were
considered high risk. Internal validity, discrimination and cali-
bration for the final model were confirmed using bootstrapping.
Results: 26,118 patients were recruited, and 25,851 (98.9%)
completed up to 5 years of follow-up. Cumulative incidence
of discontinuation was 49.9% (49.3-50.5), and 73.7% (73.1-
74.3) at years 1 and 5, respectively. The final tool (HR and
score for each predictor) is presented below:
Table 1 Predictors of Therapy Discontinuation
Predictor N Adjusted HR Risk Score
Gender Male 5541 2.08 [2.00-2.16] 100
Age 40-60 years 7407 1.08 [1.05-1.12] 11
>80 3164 1.33 [1.27-1.39] 38
Nationality Non-national 392 1.29 [1.15-1.44] 33
BMI <18.5 kg/m2 147 1.06 [0.87-1.28] 6
25.0-29.9 9256 1.04 [1.00-1.09] 6
30.0-34.9 5242 1.09 [1.04-1.15] 12
35 and over 1941 1.25 [1.18-1.34] 30
Not available 4411 1.14 [1.08-1.20] 17
Smoking Current 2467 1.19 [1.13-1.25] 23
Ex 1852 1.01 [0.95-1.07] 1
Not Available 2842 1.11 [1.05-1.16] 14
Alcohol Drinking Never/Mild 281 1.08 [0.94-1.24] 11
Not Available 5958 1.26 [1.10-1.45] 32
Previous Fracture No Fracture 21946 1.27 [1.20-1.36] 34
>6 Months ago 4172 1.13 [1.04-1.22] 17
Pre-existing Dementia 333 1.28 [1.13-1.45] 35
Pre-existing Renal Failure 2038 1.06 [1.01-1.12] 8
Pre-existing Diabetes 3577 1.06 [1.003-1.12] 8
Pre-existing Atrial Fibrillation 1019 1.11 [1.03-1.20] 14
Pre-existing Osteoporosis no 19663 1.34 [1.29-1.39] 39
Pre-existing Osteoarthritis no 22373 1.05 [1.003-1.09] 7
Pre-existing Vitamin D Deficiency no 26011 1.39 [1.07-1.81] 44
Pre-existing Rheumatoid Arthritis or Lupus no 25445 1.29 [1.17-1.43] 34
Number of Pre-existing Comorbidities 1 6087 1.09 [1.05-1.14] 12
2 1164 1.14 [1.05-1.24] 18
3 or more 120 1.46 [1.19-1.78] 51
Number of Pre-existing Prescriptions 0 7100 1.89 [1.35-2.65] 86
1 8926 1.54 [1.10-2.15] 58
2 6783 1.32 [0.95-1.83] 37
3 2668 1.13 [0.81-1.57] 16
4 590 1.06 [0.75-1.49] 6
5 51 REF group 0
MPR for Statins (if taken) MPR<20% 604 1.45 (0.07) 51
MPR≥20% 7596 1.19 (0.03) 24
MPR for Antihypertensives (if taken) MPR<20% 1323 1.36 (0.05) 41
MPR≥20% 9711 1.24 (0.03) 29
TOTAL SCORE
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A total risk score of 327 or higher indicates high risk of
discontinuation. A score of 327 or higher identified the 20%
earliest failures with 39% sensitivity and 86% specificity.
Optimism-corrected area under the curve to predict failure at
1 year was 64%.
Conclusion(s): Therapy discontinuation rates among inci-
dent oral bisphosphonate users are high. We propose a
predictive tool to identify patients at risk for discontinua-
tion, who could be targeted either for interventions to im-
prove adherence or for parenteral therapies.
Disclosures: ISCI 2010 Grant EC10-080, Government of
Spain
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THE RELATIONSHIP BETWEEN BONE MINERAL
DENSITY AND INSULIN RESISTANCE IN
KOREAN POPULATION STUDY
Woong H Choi, Sang M Hong
Hanyang University Hospital, Endocrinology, Sungdong
Gu, Seoul, Korea
Objective(s): The relationships between insulin resistance
and BMD are not clear. Therefore, we conducted a cross-
sectional study to examine the relationship between insulin
resistance and BMD among Korean population which was
divided with glucose level.
Material & Methods: This study is based on the Korea
National Health and Nutrition Examination Survey
(KNHANES) IV (2008). BMD and body composition
were measured by DXA method. Insulin resistances
were obtained by HOMA-IR equation. We divided the
population according to fasting glucose level (NGT,
IFG, DM). The relationship between BMD and
HOMA-IR were analyzed with multiple regression mod-
els which were adjusted with age, body weight, body
fat mass, body lean mass, alcohol drink, exercise level
and 25(OH) vitamin D level.
Results: Among 3290 persons, 1368 (41.6%) persons
were men and 1922 (58.4%) persons were women. In
whole population, HOMA-IR Showed positive correla-
tions with total body BMD and lumbar BMD in men
but not femur BMD in men and all BMD in women.
However, NGT group showed negative correlation with
all site BMD in both gender and IFG group also have
negative relations with BMD in total body BMD of men
(B=-0.007, p<0.001) and femur BMD in women (B=-0.013,
p<0.001) even after adjust all factor that were mentioned
above. However BMD and insulin resistance had no relation-
ships in DM.
Conclusion(s): In this study, BMD were decreased with the
increase of insulin resistance in normal fasting glucose. And
with the increase fasting glucose, these relations were weak-
ening (IFG) and disappeared (DM).
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CHANGES IN BONE TURNOVER MARKERS
BY ORAL ALENDRONATE IN LONG-TERM
SURVIVORS AFTER KIDNEY TRANSPLANTATION
Atsushi Suzuki1, Sakura Yamamoto1, Hitomi Sasaki2,
Megumi Shibata1, Sahoko Sekiguchi-Ueda1, Nobuki
Hayakawa1, Kiyotaka Hoshinaga2, Mitsuyasu Itoh1
1Fujita Health University, Division of Endocrinology and
Metabolism, Department of Internal Medicine, 2Fujita
Health University, Department of Urology, Toyoake, Aichi,
Japan
Objective(s): Post kidney transplantation (KTx) recipients
are of frequently suffered from secondary or tertiary hyper-
parathyroidism, which could deteriorate bone metabolism.
Bone loss during the first year after transplantation is most
pronounced, but bone density development in long-term
transplant recipients is still controversial. In the present
study, we explored the effect of 3-year treatment with oral
alendronate (ALN) on bone metabolism in long-term
survivors after KTx.
Material & Methods: Subjects: Post-KTx recipients were
recruited (n=24, M/F=12/12, age, 52.0±7.8 years old).
Mean duration after renal transplantation was 10.8±3.4
years. All the patients were prescribed methylprednisolone
with various immunosuppressive agents.
Results: Before the treatment with oral ALN (35 mg/week),
mean concentrations of intact parathyroid hormone (iPTH) and
25-hydroxyvitamin D (25-OHD) were 139.2±71.4 pg/ml and
20.8±4.1 ng/ml, respectively. After 36 months with ALN
treatment, mean iPTH levels slightly increased (+20.9%) by
ALN. The treatment with ALN significantly reduced bone
specific alkaline phosphatase (-35.4%), serum type I collagen
N-terminal telopeptide (-31.2%) and osteocalcin (-55.6%) lev-
els. On the other hand, ALN did not affect serum creatinine
(+5.5%), calcium (+1.8%), phosphate (+1.3%), 25-OHD
(+10.9%) or 1,25(OH)2 vitamin D (+5.1%) levels.
Conclusion(s): These findings suggest us that hyperpara-
thyroidism exists even in long-term survivor after KTx, and
ALN effectively reduce bone turn over in these patients.
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NEUROPATHIC PAIN IN PATIENTS WITH
OSTEOARTHRITIS
Iryna Yu Golovach1, TatianaM Chipko1, Diana V Golovach2,
Olena O Lazorenko1, Sergej V Vershynin2, Anastasia M
Vlasenko1, Victor M Matijko1
1Clinical Hospital Feofania, Rheumatology and Nephrology,
Kyiv, 2National Medical University, Radiology, Ivano-
Frankivsk, Ukraine
Objective(s): Chronic pain is the most typical clinical pre-
sentation of osteoarthritis (OA). Today, the exclusively
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nociceptive nature of OA pain is being reconsidered, and
neuropathic and psychogenic aspects are increasingly dis-
cussed. To improve diagnostics of a pain syndrome at OA
and to advance approaches to drug therapy for better out-
comes, surveys were conducted to identify neuropathic
components in the chronic pain structure.
Material & Methods: We recruited 112 patients with OA
(male:female ratio 1:5), aged 45-72 (average 62.3±4.7). OA
duration ranged from 5-26 years (average 13.2±8.1 y).
Using the DN4 neuropathic pain questionnaire, we divided
patients with OA into two groups: first group – patients with
no NP (0-3 points), second group – patients with NP (4-
8 points). We performed clinical, neurological and rheuma-
tologic examination and administered the quality of life
(EQ-5D), LANSS and Beck depression.
Results: In OA patients 34.8% had signs of NP by DN4. In
OA patients with NP were older than patients without NP
(68.6±4.7 vs. 49.3±10.6 y, p<0.05), had longer disease
duration (13.6±7.6 y vs. 9.8±6.3 y, p<0.05), had synovitis
and R-stage 3-4 (69.6% vs. 30.4%), and had higher func-
tional disability (stage 2-3 84.9% and 71.6%, accordingly).
We found no significant differences between the two groups
in quality of life. NP presented with numbness 93.4%,
tingling 88.7%, “electric shock” 74.2% and creeping
71.7% in the second group, and 25.8%>31.7%>38.3%>
14.7% in the first group, accordingly. As compared to
patients with high DN4 scores, patients who scored 4-5
points on DN4 demonstrated higher depression. LANSS
measuring scale was used to differentiate nociceptive and
neuropathic pain syndromes. In the questioning by LANSS
42 (37.5%), patients gained more than 12 points, indicating
that they have neuropathic pain. NP is more often diagnosed
in women, with 2 and 3 stages of osteoarthritis, while
reactive synovitis is present as well.
Conclusion(s): More than a third of patients with OA may
have elements of NP, which is the cause of insufficient
response to standard therapy, aimed at elimination of noci-
ceptive pain. Questioning allows us to identify neuropathic
pain in patients with OA and thus improves treatment
results.
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OSTEOPOROSIS AND TARGETED BREAST
CANCER THERAPIES
Antonio Bazarrra-Fernandez
La Coruña University Hospital Trust, ObGyn, La Coruña,
Spain
Objective(s): Researchers looked at women aged 50-79
taking a combination of conjugated equine estrogens 0.625
mg and medroxyprogesterone acetate 2.5 mg. This con-
firmed the long held assumption that HRT prevents osteo-
porotic fractures. HRT was widely prescribed to women to
relieve the menopausal symptoms. Researchers found that
women who took the hormones had an increased risk of
developing breast cancer. Aim was to search for new
answers in the link between breast cancer, osteoporosis
and targeted breast cancer therapies.
Material & Methods: We have performed a bibliography
review in a worldwide basis and from our own experience.
Results: While the exact cause of breast cancer is not
known, 1 in 8 women risk of undergoing it increases with
age, with 81% of cases occurring in women aged 50 years
and over. Risk factors associated with the disease could be
viruses, environmental factors or others acting on breast
cell. Women in developed countries are at increased risk of
breast cancer compared with women from less developed
countries. A large part of this variation can be explained by
the fact that women in developed countries have fewer
children on average and a limited duration of breastfeeding,
it is said. But in reality reproductive factors that influence
breast cancer risk do not explain it. Breast cancer is one of
the few cancers where incidence rates are higher for more
affluent women and there is a clear trend of decreasing rates
from least to most deprived groups. Postmenopausal osteo-
porosis usually affects women over the age of 60. The
leading cause of osteoporosis is a lack of estrogens in
women and opposite drugs. Osteoporosis, affects 1 in 2
women, is now three times more common that breast cancer.
Bisphosphonates may contribute to fewer breast cancers.
The cell cycle consists of four phases. DNA and RNA
viruses have been shown to be able to cause cancer and
referred to as carcinogens.
Conclusion(s): The natural lack of estrogen does not decrease
breast cancer incidence. Targeted breast cancer therapies are to
be studied. Viruses can attack cells in different phases and that
could explain the different breast cancer types.
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HYPOVITAMINOSIS D ASSOCIATIONS WITH
ADVERSE METABOLIC PARAMETERS ARE
ACCENTUATED IN PATIENTS WITH DIABETES
MELLITUS TYPE 2: A BMI-INDEPENDENT
ROLE OF ADIPONECTIN?
Nasser M Al-Daghri1, Omar S Al-Attas1, Majed Alokail1,
Khalid M Alkharfy2, Abdulaziz Alothman3, Hossam Draz1,
Yousef Al-Saleh4, Sobhy Yakout1, Shaun B Sabico1
1King Saud University, Prince Mutaib Chair for Biomarkers
of Osteoporosis, 2King Saud University, College of Pharmacy,
3King Saud University, College of Applied Medical Colleges,
4King Saud University for Health Sciences, College of
Medicine, Riyadh, Saudi Arabia
Objective(s): Hypovitaminosis D has been associated with
an increased prevalence of diabetes mellitus type 2 (DMT2)
and metabolic syndrome manifestations. The purpose of this
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study was to examine the association between 25-hydrox-
yvitamin D (25-OHD) levels and indices of insulin resis-
tance, including adipocytokines, in a Saudi population with
or without DMT2.
Material & Methods: A total of 266 subjects (153 DMT2
and 113 healthy controls) aged 26-80 years old were ran-
domly selected from the existing Biomarkers Screening in
Riyadh Program (RIYADH Cohort). Subjects were assessed
clinically, anthropometry was performed, morning blood
chemistries, including fasting glucose, triglycerides, total
cholesterol, LDL-C, and HDL-C were obtained. HOMA-
IR was calculated, and serum 25-OHD, leptin, adiponectin,
resistin, insulin, hsCRP, and TNFα concentrations were
measured using specific assays.
Results: In DMT2 subjects, negative correlations between
25-OHD and BMI, fasting glucose, insulin, HOMA-IR,
cholesterol, LDL-C and hsCRP were observed, while a
positive correlation between 25-OHD and adiponectin was
detected. The later remained significant after controlling for
BMI. Interestingly, only weak and nonsignificant associa-
tions between 25-OH-VitD and metabolic parameters were
observed in the control group, whereas, when the entire
population was examined, negative correlations were evi-
dent primarily between 25-OH-VitD and fasting glucose,
HOMA-IR, total cholesterol, LDL-C. These associations
remained significant after controlling for BMI.
Conclusion(s): These results suggest that hypovitaminosis
D associations with metabolic disturbances are accentuated
in DMT2. The BMI-independent positive correlation be-
tween 25-OH-VitD and adiponectin suggests a potential role
for this adipocytokine as a link between 25-OH-D and
insulin resistance in patients with DMT2.
Disclosures: The authors are grateful to King Abdulaziz
City of Science and Technology (KACST Grant no: AT-
29-38), Riyadh, KSA for funding the study and the Prince
Metab Bin Abdullah Bin Abdul Aziz Research Chair on
Osteoporosis for technical support.
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RENAL STONES AND CALCIFICATIONS
IN PATIENTS WITH PRIMARY
HYPERPARATHYROIDISM: ASSOCIATIONS
WITH BIOCHEMICAL VARIABLES
Jakob S Linde1, Elin Waldhauer1, Lars Rolighed2, Leif
Mosekilde1, Peter Vestergaard1
1Aarhus University Hospital THG, Department of Endocri-
nology and Internal Medicine, 2Department of Surgery,
Aarhus, Denmark
Objective(s): To study the prevalence of renal stones and
nephrocalcinosis in patients with primary hyperparathyroid-
ism (PHPT) and to appraise biochemical variables as risk
factors for developing renal calcifications.
Material & Methods: Cross-sectional study in all patients
(n=177) undergoing diagnostic evaluation and surgery for
PHPT at the Department of Endocrinology and Internal
Medicine and the Department of Surgery, Aarhus University
Hospital between 2007-2009. All patients underwent rou-
tine spiral CT scans of the abdomen to determine presence
or not of renal calcification before parathyroid surgery.
Biochemical measurements included plasma levels of ion-
ized calcium (Ca2+), phosphate, creatinine, 25-hydroxyvi-
tamin D (25OHD), calcitriol (1,25(OH)2D), alkaline
phosphatase, and PTH. We also measured urinary NTx/
creatinine ratio and 24 h urinary excretions of calcium and
creatinine. Finally we calculated creatinine clearance, tubu-
lar reabsorption of calcium (TRCa%) and urine calcium/
creatinine ratio (CaE mmol/mmol).
Results: A total of 45 patients (25.4%, 95% CI: 19.0-
31.4%) had renal stones (15.3%) and/or renal calcifications
(10.2%) on the CT scans. Compared to those without calci-
fication (n=132), the group with calcification had a signif-
icantly lower plasma creatinine level (67.0±25.1 vs. 74.6±
17.5 μmol/l, 2p=0.03). Moreover, CaE was higher in PHPT
patients with renal calcification than in PHPT patients with-
out (0.91±0.28 vs. 0.74±0.40 mmol/mmol, 2p=0.02). The
other measured or derived biochemical variables were sim-
ilar in the two groups. No biochemical variable was predi-
cative for renal calcifications in a multiple regression
analysis.
Conclusion(s): We found a high prevalence of renal calci-
fications among PHPT patients, but no deterioration of renal
function. The occurrence of calcifications was related to low
plasma creatinine and a high urine calcium/creatinine ratio.
However, biochemical markers in general were poor predic-
tors for the risk of renal stones or nephrocalcinosis indicat-
ing that routine image diagnostics may be needed for the
identification of these complications in order to establish
indication for surgery and ensure proper treatment.
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BURDEN AND MEDICAL NEEDS IN OLDER
PATIENTS WITH HIP FRACTURES AND MUSCLE
ATROPHY OR WEAKNESS
Julia Green1, Lindsay Hallett1, Yang Zhao2, Julie Birt2,
Talia Foster1
1United BioSource Corporation, Evidence Review and
Synthesis, Lexington, MA, 2Eli Lilly and Co., Global
Health Outcomes, Indianapolis, IN, US
Objective(s): The number of hip fractures worldwide is
expected to reach 2.6 million in 2025. Hip fractures sub-
stantially increase risk of death, and muscle atrophy/weak-
ness is associated with an increased risk of hip fracture. Our
systematic review assessed disease burden and medical
needs related to muscle atrophy/weakness in older patients
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with hip fractures in the US, Canada, Australia, and five
countries (UK, Germany, France, Italy, and Spain) in
Europe.
Material & Methods: Using keywords related to muscle
atrophy/weakness and hip fracture, we systematically
searched English-language, Medline- and Embase-indexed
literature published between 5/2001-5/2011 and materials
available from governmental or professional organizations.
Included articles pertained to epidemiologic, economic, hu-
manistic, and treatment burden of muscle atrophy/weakness
(defined as evaluations of muscle atrophy, strength, or perfor-
mance) in adults ages 50+ with hip fracture. Excluded articles
were molecular biology and genetic studies, case reports, and
evaluations of muscle atrophy/weakness in <20 patients.
Results: Thirty-four articles examined muscle atrophy/weak-
ness in hip fracture patients aged 50+ years. Most focused on
the natural history of muscle weakness and function or non-
pharmaceutical interventions for improving strength or per-
formance post-fracture. Functional status and muscle strength
are diminished one month to two years post-fracture. Substan-
tial differences in strength between operated and nonoperated
limbs may contribute to poor mobility during recovery. Phys-
ical therapy (PT) and exercise improve strength and function.
With few clinical trials, efficacy of specific regimens remains
ill-defined. Treatment guidelines on hip fracture, available
only from the UK, do not recommend specific settings and
PT types. No studies describe real-world treatment patterns for
PT regimens that restore muscle strength. Length of stay
associated with hip fracture varies across countries (range: 5-
7 days in US to 40 days in UK orthopedic rehabilitation units
postsurgical repair).Data gaps include estimates of prevalence
or incidence, productivity or work loss, and costs related to
muscle strength or function.
Conclusion(s): Muscle atrophy/weakness after hip fracture
is disabling, but its collective impact on the frequency, cost,
or treatment of hip fractures remains unknown. With few
rehabilitation strategies restoring muscle strength and func-
tion to pre-surgical levels, more effective interventions are
needed to speed recovery.
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THE ROLE OF COUNSELLING AND OTHER
FACTORS INCOMPLIANCEOF POSTMENOPAUSAL
OSTEOPOROSIS PATIENTS TREATED WITH
ALENDRONATE 70
Ewa J Sewerynek1,2, Wanda Horst-Sikorska3, Wioletta
Stepien-Klos1, Agnieszka Antkowiak1, Malgorzata Janik1,
Karol Cieslak1, Michalina Marcinkowska3, Michal Stuss1,2
1Medical University in Lódz, Department of Endocrine
Disorders and Bone Metabolism, Lódz, 2WAM Clinical
Hospital; Medical University in Lódz, Outpatient Clinic of
Osteoporosis, Lódz, 3Medical University of Poznan, Department
of Family Medicine, Poznan, Poland
Objective(s): More than 50% of subjects with chronic dis-
eases, including osteoporosis, discontinue treatment during
the first year of its administration. The aim of this study was
to assess the role of patient counselling, nurse assistance and
effects of biochemical examinations on adherence to alendr-
onate 70 administration over the period of 12 months by
women with postmenopausal osteoporosis.
Material & Methods: Compliance and persistence to alendr-
onate 70 therapy was assessed in a prospective study of 123
postmenopausal women, followed up for one year. The
patients were divided into 4 groups (Controls, Counselled
Group, Biochemical Group and Nurse Assisted Group) with
monitoring every 6 months; in the Nurse Assisted Group,
additional phone contact was made after 3 and 9 months of
treatment. After 12 months, compliance and persistence were
analyzed. The Medication Possession Ratios (MPRs), was
regarded as optimal when its value exceeded 80%.
Results: The compliance to alendronate 70 therapy was
54.03% in the control group and the mean persistence with
medication was 197 days. MPR>80%was observed in 37.5%,
and, after one year, 43.75% patients were found persistent with
the therapy. In the remaining groups both compliance and
persistence were higher but not statistically significant, com-
pared to the control group (Counselled Group: 75.71% and
276.17 days,MPR>80%was observed in 65.52% and 68.97%
persisted with therapy; Biochemical Group: 68.29%, 249.2
days, MPR>80% - 64.52%, with 64.52% of patients persisted;
Nurse Assisted Group: 71.18%, 259.71 days, MPR>80% -
61.29% and 61.29% women persisted with therapy). Neither
patient's age, education, diet, nor physical activity did influ-
ence compliance with prescribed therapy. The most common
reason to discontinue therapy was either the side effects of
prescribed treatment or smoking.
Conclusion(s): The obtained results suggest that better ad-
herence with medical recommendations is observed in
patients who receive additional interest, e.g., counselling,
biochemical tests or nurse care. The critical elements for
therapy discontinuation were its side effects and smoking.
Disclosures: The study was sponsored by the Scientific
Polpharma Foundation (Medical University Grant No.
501-91-269).
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THE ASSOCIATION OF BODY MASS INDEX AND
BONE MINERAL DENSITY IN A MALE POPULA-
TION REFERRED FOR DUAL-ENERGY X-RAY
ABSORPTIOMETRY SCAN IN ISFAHAN, IRAN
Mohammad Reza Salamat1,2, Amir Hossein Salamat2,
Khadijeh Kompani2
1Isfahan University of Medical Sciences, Department of
Medical Physics and Medical Engineering, 2Isfahan Osteo-
porosis Diagnosis Center, Department of Research, Isfahan,
Islamic Republic of Iran
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Objective(s): In this study the relation between BMI and
BMD of a male population was investigated.
Material & Methods: In this study 224 male patients from
Isfahan province of Iran who showed no sign of secondary
osteoporosis underwent a bone densitometry scan using a
Norland XR-46 (Norland Co, Fort Atkinson, WI, USA), to
examine the relationship between their BMI and BMD. De-
mographic and osteoporosis related risk factors were gathered
on a computer based questionnaire. The subjects were divided
into three groups according to the WHO classification of BMI
(Table-1). ANOVA test showed no significant difference in
age of the three groups. Each patient underwent a standard hip
and AP spine BMD scan and osteoporosis/osteopenia was
diagnosed based on the definition of WHO.
Table 1
Group Number of
Subjects
BMI Ranges
(kg/m2)
BMI
Classification
Age
(Years)
Mean±SD
1 94 18.50<BMI<
24.99
Normal 63.9±8.1
2 92 25≤BMI<30 Overweight 62.2±7.7
3 38 BMI≥30 Obese 64.0±7.7
Results: ANOVA test on the mean total standardized BMD
(sBMD) showed significant difference in hip and spine
regions between groups 1 and 2 (P<0.004), and 1 and 3
(P<0.001) but no significant difference was found between
groups 2 and 3. BMD was classified as osteoporotic/osteo-
penic in 94.7% of people within group 1, 82.6% among
people in group 2, and 81.6% among people in group 3. Of
all subjects 28 (12.5%) had normal bone density while 196
(87.5%) were diagnosed as osteoporotic/osteopenic.
Table 2
Group Hip Total sBMD (g/cm2) AP Spine Total sBMD (g/cm2)
1 0.879±0.10 0.994±0.16
2 0.929±0.14 1.078±0.18
3 0.954±0.13 1.130±0.16
Conclusion(s): The results of the study suggest that
patients classified as overweight/obese have a signifi-
cantly higher BMD value in comparison to patients with
normal BMI.
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BONE MINERAL DENSITY AMONG RA-PATIENTS
TREATED WITH TOCILIZUMAB
Lali Kilasomia, Nana Kirvalidze, Lana Lagvilava, Mede
Kopaliani, Ekaterine Jabua
"Medulla - Chemotherapy and Immunotherapy Clinic",
Rheumatology, Tbilisi, Kartli, Georgia
Objective(s): According to the latest data during rheuma-
toid arthritis osteoporosis develops along with the inflam-
matory process which should be explained by common
pathogenetic mechanisms existing between these two
illnesses.
Material & Methods: 75 patients diseased with rheumatoid
arthritis, 68 women and 7 men aged from 28-64, were under
medical observation. In all cases the diagnosis corresponded
to ARA of 1987 and EULAR of 2010 criteria. Among
examined patients osteoporosis and osteopenic syndrome
were revealed in 82% of cases. Diagnosis of osteoporosis
was fulfilled by means of DXA (Hologic – 1000).
Results: As a result of performed studies it has been stated
that the lowest index of BMD is marked in the proximal and
femoral neck, in the distal part of forearm. A correlative link
has been revealed between a high index of CRP and a low
index of BMD (p=0.04). During one year all patients un-
derwent a medical treatment with intravenous tocilizumab
(8 mg/kg), once a month. It should be taken into consider-
ation that all patients with RA-diagnosis were taking a stable
dose of methotrexate, 12.5 mg/week.
Conclusion(s): After one year of treatment the condition of
all patients was evaluated. Remission (DAS 28 <2.72) was
marked in 72% of patients. An pain syndrome became
nominal, quality of life took a turn for the better, but the
most interesting thing was that the increase of BMD was
noticed among the patients treated with tocilizumab. In 48%
in the proximal part of a femoral neck the increase was equal
to 4.2%. 54% of BMD index improved in lumbar spine and
was equal to 5.7%. None of the patients underwent an
antiosteoporotic medical treatment. Is it possible that tocili-
zumab could have an antiosteoporosis effect?
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ZOLENDRONICACID:MAXIMUMEFFECTIVENESS –
MINIMUM SIDE EFFECTS
Nana I Kirvalidze, NanaMBagishvili, Maia SMgaloblishvili,
Luba L Lagvilava, Lali O Kilasonia
"Medulla - Chemotherapy and Immunotherapy Clinic",
Rheumatology, Tbilisi, Kartli, Georgia
Objective(s): In recent years the area of use of zolendronic
acid increased significantly. It started with postmenopause
osteoporosis, although today men actively undergo medical
treatment with zolendronic acid.
Material & Methods: The purpose of the presented work
was evaluation of zolendronic acid effectiveness in the cases
of different clinical forms of osteoporosis. During 3 years
220 patients underwent medical treatment – 160 women and
70 men, aged from 40-70. Among examined patients 80
patients were diagnosed with postmenopause osteoporosis
(group 1); in 55 cases it was a thyroid osteoporosis (group
2); in 21 patients osteoporosis developed simultaneously
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with a rheumatoid arthritis (group 3); drug addiction was
revealed in 14 men with low BMD (group 4); 60 men
suffered from hypogonadotropic osteoporosis (group 5).
Diagnosis of osteoporosis was fulfilled by means of DXA
QDR-Hologic 1000. All patients received an intravenous
zolendronic acid infusion once a year, along with an every-
day use of a calcium and vitamin D combined preparation
(1000-1500 mg/day) during the year.
Results: After a three year course of medical treatment a
fracture risk in the proximal part of a femoral neck de-
creased: in group1for 56%; in group 2 for 60%; in group 3
for 68%; in group 4 for 70%. The increase of a bone mineral
solidity index in a femoral neck equalled to 5.2-6.1% - the
highest index among the men patients, i.e., in group 5.
Conclusion(s): After a three year course of medical treat-
ment a fracture risk in the proximal part of a femoral neck
decreased: in group 1for 56%; in group 2 for 60%; in group
3 for 68%; in group 4 for 70%. The same tendency is
revealed in the decrease of fractures of peripheral bones: in
group 1 for 24%; in group 2 for 30%; in group 3 for 32%; in
group 4 for 52% and in group 5 for 62%. The increase of a
bone mineral solidity index in a femoral neck equalled to
5.2-6.1% - the highest index among the men patients, i.e., in
group 5.
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SARCOPENIA AND OSTEOPENIA AMONG
70-80 YEAR OLD FINNISH WOMEN: PREVALENCE
AND ASSOCIATION WITH FUNCTIONAL
PERFORMANCE
Radhika Patil1, Kirsti Uusi-Rasi1, Pekka Kannus1,2, Saija
Karinkanta1, Matti Pasanen1, Harri Sievänen1
1The UKK-Institute for Health Promotion Research, Accident
and Osteoporosis Prevention, 2University of Tampere, School
of Medicine, Tampere, Finland
Objective(s): Consensus diagnostic criteria for age-related sar-
copenia have recently been published by the European Work-
ing Group on Sarcopenia in Older People (EWGSOP) and the
International Working Group on Sarcopenia (IWG). However,
recommended cut-off points for outcome variables differ for
each. The WHO definition of osteopenia rests on DXA-mea-
sured femur T-score. This study assessed the prevalence of
sarcopenia and osteopenia among a sample of 70-80 year old
independently living Finnish women with normal or somewhat
declined functional ability (n=409), compared the consensus
diagnostic criteria for sarcopenia and examined the associations
between sarcopenia, osteopenia and functional ability.
Material & Methods: Femoral BMD and body composi-
tion were measured with DXA. Skeletal muscle mass index
(SMI) was defined as appendicular skeletal muscle mass/
height2. Gait speed and handgrip strength defined physical
performance and muscle strength. Prevalence of sarcopenia
was determined by the EWGSOP criteria (using the pres-
ence of low muscle mass, strength and performance for
diagnosis) and the IWG (low walking speed and muscle
mass). Data analyses included independent samples t-tests
to test differences in functional performance according to
muscle mass and multiple regression to study correlates of
muscle mass.
Results: Prevalence of sarcopenia was 0.9% (n=4) and
2.7% (n=11) according to the EWGSOP and IWG, respec-
tively. Three of the four EWGSOP sarcopenic women ful-
filled IWG criteria as well. Nine women had bilateral hip
prostheses, and 36% (n=144) of the remaining 400 women
had femur T-score<-1. Two of the four sarcopenic women
also had osteopenia. Women with greater walking speed
(≥0.8 m/s) had significantly lower weight and fat mass
percentage, higher lean mass percentage and better func-
tional performance. Women with a low SMI(<5.5 kg/m2)
weighed significantly less, with no significant differences in
other outcome measures. SMI, walking speed and grip
strength significantly correlated with each other. BMI and
grip strength explained 57.5% of the variance in SMI.
Conclusion(s): Our study suggests that when using the
above described EWGSOP and IWG definitions, sarcopenia
is infrequent among older home-dwelling Finnish women
while every third of these women had osteopenia.
Disclosures: Academy of Finland
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PREVALENCE OF FRACTURE RISK FACTORS IN
WOMENWITHOSTEOPOROSISANDOSTEOPENIA:
RESULTS FROM THE PROSPECTIVE OBSERVA-
TIONAL SCIENTIFIC STUDY INVESTIGATING
BONE LOSS EXPERIENCE IN THE UNITED
STATES (POSSIBLE US™) TREATMENT COHORT
Nicole Yurgin1, Sally Wade2, Sacha Satram-Hoang3, David
Macarios1, Marc Hochberg4
1Amgen Inc., Global Health Economics, Thousand Oaks,
CA, 2Wade Outcomes Research and Consulting, Health
Economics, Salt Lake City, UT, 3Q.D. Research, Inc.,
Health Economics, Granite Bay, CA, US, 4University of
Maryland, School of Medicine, Division of Rheumatology
& Clinical Immunology, Baltimore, MD, US
Objective(s): To describe the prevalence of fracture risk
factors in a cohort of postmenopausal women receiving
osteoporosis treatment. Subject-reported on-study fractures
for women with and without multiple risk factors were also
compared.
Material & Methods: From October 2005 - January 2007,
134 primary care physicians enrolled 5015 postmenopausal
women receiving pharmacologic and/or calcium/vitamin D
therapy for bone loss into the POSSIBLE US™. Analyses
included women with a physician-reported diagnosis of
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osteoporosis or osteopenia at entry. Risk factors based on
FRAX® were identified from physician- and patient-
reported data at entry: age >70; fracture history since age
50; minimum T-score (hip/spine)≤-2.5 at diagnosis; BMI
<18.5; rheumatoid arthritis; parental history of hip fracture;
current smoking; and oral glucocorticoid use within the past
6 months. Subjects provided on-study fracture data using
semiannual self-administered questionnaires over ≤3 years
of follow-up. Osteoporosis-related fractures were identified
using a published classification schema (Warriner, 2011).
Results: Data for women diagnosed with osteoporosis (N=
1916; mean age: 67.8 years; 87% white) and osteopenia (N
=2513; mean age: 62.2 years; 90% white) were analyzed.
Multiple risk factors were more common than single risk
factors among osteoporotic women, (54% vs. 35% of
women, p<0.0001), but not osteopenic women (14% vs.
34%, p<0.0001). Age >70 was the most common risk factor
(osteoporotic: 35%; osteopenic: 35%) followed by T-
score≤-2.5 at diagnosis in the osteoporotic group (24%)
and low BMI (11%) in the osteopenic group. At least one
on-study fracture was reported in 12% of osteoporotic com-
pared with 9% of osteopenic women (p=0.0059). Osteopo-
rosis-related fractures were more common in women with
multiple risk factors compared with those with one risk
factor in both osteoporotic (10% vs. 6%; p=0.0092) and
osteopenic women (11% vs. 5%; p<0.0001).
Conclusion(s): In this treatment cohort, 1 in 2 osteoporotic
and nearly 1 in 7 osteopenic women had multiple risk
factors for fracture. Osteoporosis-related fractures were sig-
nificantly more common in women with multiple risk
factors.
References: Warriner et al. J Clin Epidemiol 2011;64:46.
Disclosures: Aalok Nadkar/Patrick Ventura analyzed the
data. Mandy Suggitt/Erica Rockabrand provided editorial
assistance. This study was sponsored by Amgen Inc.
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OSTEOPOROSIS AWARENESS AND
KNOWLEDGE OF GREEK MEN
Stylianos Papalexandris1,3, Alexandros Gerakis2, Christos
Zilidis3
1Royal South Hants Hospital, Orthopaedic Department,
Southampton, UK, 2Hippokration Hospital, Orthopaedic
Department, Thessaloniki, Greece, 3Open University of
Cyprus, Faculty of Economics and Management, Nicosia,
Cyprus
Objective(s): The aim of the study was to estimate the level
and quality of knowledge Greek adult men have about
osteoporosis, its risk factors and the available preventive
measures.
Material & Methods: The study was performed at the
Orthopaedic Outpatients Department of a tertiary military
hospital in Thessaloniki, Greece, between April-July 2011.
330 men were enrolled in the study. Healthcare professio-
nals were not included in the study. The research tools were
the revised Facts on Osteoporosis Quiz (FOOQ) and the
Male Osteoporosis Knowledge Quiz (MOKQ). It was the
first time they were both translated into Greek. They consist
of 20 and 6 questions/statements, respectively, with “yes”,
“no” or “don't know” answer options. Only correct answers
score 1 point. Statistical analyses were conducted with the
SPSS 19 software. Pearson's coefficient, ANOVA, Tuckey
Honestly Significant Difference and t tests were used to
reveal any correlation between age and other demographic
parameters with the level of knowledge.
Results: The mean age of the participants was 28.3 years
(SD=8.18), ranging between 18- 65 ears. The median age was
26 years. 148 men (44.8%) had a higher education degree, but
only 43 (13%) of the participants had been informed about
osteoporosis in the past. The average score for the FOOQ was
7.67 (SD=3.58) and the maximum score was 17 points. A
subgroup of six questions of the FOOQ (FOOQ-female) refers
to female osteoporosis. The mean score for these questions
was 1.28 (SD=1.37) points. There were men who answered
wrong all the questions of the FOOQ. The average score for
the MOKQ was 1.13 (SD=1.23). Each question of the
MOKQ was answered correctly by less than 50% of the
participants. Scores at theMOKQ and the FOOQ-female were
comparable, with a Spearman's correlation coefficient of 0.48
(p<0.001). The level of knowledge on osteoporosis was pos-
itively correlated with the profession, the level of education
and previous information about the disease.
Conclusion(s): The findings prove the poor level of knowl-
edge and highlight the necessity of implementing education-
al and health promotion programmes, in order to eventually
improve osteoporosis prevention among men.
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THE IMPACT OF MENOPAUSE AND HRT IN
GINGIVAL TISSUE AND ALVEOLAR BONE
Robert Qirko1, Margareta Qirko2, Emoke Stenova3, Albert
Cakoni1
1Tirana University "Queen Geraldine" Hospital, Obstetrics
& Gynecology, Tirana, Albania, 2Albania University,
Dentistry, Tirana, Albania, 3Comenius University Hospital,
Internal Medicine, Bratislava, Slovakia, Slovenia
Objective(s): Menopause is an unavoidable change that ev-
ery woman will experience, assuming she reaches middle age
and beyond. Many women arrive at their menopause transi-
tion years without knowing anything about what they might
expect. Hormonal changes during menopause influence oral
cavity and womenmay experience unpleasant symptoms. The
aim of this study is to show the effect of HRT in preventing the
changes in gingival tissue and alveolar bone.
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Material & Methods: We examined 64 menopause women
aged from 49-64 years old. Half of them received HRT from 6
months to 2 years. We evaluated the gingival tissue, alveolar
bone loss and by a questionnaire the mouth burning syn-
drome, xerostomia and altered taste perception. Osteoporosis
evaluation was conducted by rheumatologic specialist.
Results: Gingival atrophy was present in 19 patients un-
treated with HRT and 3 patients treated with HRT. Xerosto-
mia was present in 18 patients of the first group and in only
2 patients of the second group, while mouth burning syn-
drome and altered taste perception were not present in
patients treated with HRT. We found a correlation between
osteoporosis and alveolar bone loss. Hormonal changes
during menopause may cause hypertrophic inflammatory
changes, which were noted in 5 patient of the first group
and 2 patients of the second group.
Conclusion(s): Hormonal changes during menopause effect
gingival tissue and alveolar bone. HRT will improve signif-
icantly the clinical situation and symptoms of oral cavity in
general. Osteoporosis correlates with alveolar bone loss.
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BONE STRUCTURE, BONE MINERAL DENSITY,
AND FRACTURE: A 15-YEAR FOLLOW-UP IN A
DENTAL CLINIC
Grethe Jonasson1, Margareta Ahlqwist2
1Research and Development Centre, Primärvård och
Tandvård, Borås, 2Institute of Odontology The Sahlgrenska
Academy, Dept. of Oral and Maxillofacial Radiology,
Gothenburg, Västra Götaland, Sweden
Objective(s): To follow up fracture rate 15 years after an
osteoporosis information intervention.
Material & Methods: 134 women who had participated in a
previous study in 1996 answered a fracture questionnaire in
2011. Initial age ranged between 20-75 years; mean age: 48.3±
10.3 years. In the first investigation all women received infor-
mation about osteoporosis, the importance of appropriate diet
and exercise. Dental radiographs and BMD measurements
were obtained. The BMD method was DXA examinations of
the forearms. The radiographic alveolar bone structure was
evaluated with a visual index as sparse or nonsparse trabecu-
lation, and digitally by the alveolar bone texture. This method
used a statistical description of features such as the repeated
occurrence of grey-scale configurations (transition from tra-
beculae to intertrabecular spaces, edges and spots), to classify
the radiographic images into four groups. Kruskal Wallis non-
parametric test was used to test differences between groups.
Results: Fracture rate was 21.3%. The fractured women had
significantly lower BMD (T-score: -1.43) than nonfractured
women (T-score: -0.86; p=0.014). Mean BMD in sparse
trabeculation group was significantly lower (T-score: -2.0)
than in the nonsparse group (T-score: -0.80, p<0.0001).
Odds ratio for getting a fracture when having osteoporosis
1996 was 3.1, p=0.052. Sparse trabeculation was found in
15% of the women. This group had a significantly higher
fracture rate than the nonsparse group (40%><17%; p=
0.02). Odds ratio for getting a fracture when having sparse
trabeculation 1996 was 3.3, p=0.023. When adding age in
the logistic regression analysis OR for sparse trabeculation
remained significant predictor of fracture (OR=2.8; p<0.05;
age: OR=1.04; p=0.09). However, for osteoporosis diagno-
sis as fracture predictor the adding of age decreased OR to
2.08 (p=0.25). Bone texture was significantly better in the
nonfractured group than in the fractured group (2.2 vs. 1.6;
p=0.03). Odds ratio for using bone texture as fracture pre-
dictor was 4.32 (p=0.019).
Conclusion(s): In this sample with few fractures, bone
texture and sparse trabeculation was a slightly better predic-
tor of fracture than the osteoporosis diagnosis.
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THE RELATIONSHIP BETWEEN THE
RADIOLOGICAL PARAMETERS FROM PLAIN
HIP RADIOGRAPHS AND THE BONE MINERAL
DENSITY IN A KOREAN POPULATION
Gun-Il Im, Pan-Gun Park, Sang-Won Moon
Dongguk University Ilsan Hospital, Orthopaedics, Goyang,
Gyeoggi-Do, Republic of Korea
Objective(s): Radiological parameters from the plain radio-
graphs might be used to provide information on osteoporo-
sis of the proximal femur. The purpose of this study was to
investigate the association of the Singh index, CTI and CC
(calcar-to-canal) ratio with BMD as well as their relation-
ship with the physical parameters to assess their potential as
an indirect indicator of osteoporosis.
Material & Methods: The BMD, Singh index, CTI and CC
ratio as well as the physical parameters [age, gender, height,
and BMI were obtained from hip radiographs and the clinical
records of 150 Korean adults. Linear relationships between
the areal BMD of the femoral neck and the parameters as well
as between each parameter were obtained. To determine the
association of the BMD with the radiological parameters,
multiple regression analyses were performed after adjusting
for the four physical parameters.
Results: The CTI was positively associated with the BMD (p=
0.019), whereas the Singh index (p=0.125) or CC ratio (p=
0.585) was not. The CTIwas negatively associatedwith age (p=
0.03) and positively associated with height (p=0.019) and BMI
(p=0.004). The CC ratio was also positively associated with age
(p=0.0001) and negatively associated with height (p=0.024).
Conclusion(s): Of three parameters available from plain
radiograph, only CTI was significantly associated with
BMD. CTI can provide a tool for rapid assessment of
osteoporosis from plain hip radiographs.
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Disclosures: This work was supported by the research grant
from the National Research Foundation of Korea (2011-
0000057).
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THE IMPROVEMENT ON THE FUNCTIONAL
PARAMETERS OF PATIENTS WITH KNEE
OSTEOARTHRITIS USING TWO THERAPEUTIC
EXERCISES
Dana-Maria ID Dimulescu1,2, Gheorghe I Chiriti1,2
1University of Medicine and Pharmacy "Carol Davila",
Medical Rehabilitation, 2National Institute of Rehabilita-
tion, Physical Medicine and Balneoclimatology, Medical
Rehabilitation, Bucharest, Romania
Objective(s): The aim of this study is to evaluate the ther-
apeutic effects of two muscle-strengthening exercises on the
functional parameters of patients with knee osteoarthritis.
Material & Methods: The study included nineteen patients
with knee osteoarthritis, using three random groups: in group I
were included 30 patients with isotonic muscle strengthening
exercise, in group II were included 30 patients with isometric
muscle strengthening exercise, and group III (30 patients) was
control group. For the evaluation of the functional parameters
were used: Visual Analog Scale, muscular testing, gait speed,
Lequesne Index, before and after treatment.
Results: In patients with knee osteoarthritis of groups I and
II, were improved the pain, the disability and gait speed,
after treatment.
Conclusion(s): Isometric exercise were used for initial
strengthening in patients with knee osteoarthritis and iso-
tonic exercise were used for improving joint stability.
References: 1. Huang MH, Lin YS, Jang RC, Lee CL
(2003) A comparison of various therapeutic exercises on
the functional status of patients with knee osteoarthritis.
Semin Arthritis Rheum. 2. Roddy E, Zhang W, Doherty M
(2005) Aerobic walking or strengthening exercise for oste-
oarthritis of the knee? A systematic review. Ann Rheum Dis.
3. Shelbourne KD, Biggs A, Gray T (2007) Deconditioned
knee: The Effectiveness of a Rehabilitation Program that
Restores Normal Knee Motion to Improve Symptoms and
Function. N Am J Sports Phys Ther.
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THE INTERACTING EFFECTS OF COGNITIVE
COMPLIANCE AND REHABILITATION ON THE
ELDERLY PATIENTS WITH LOW BACK PAIN
Gheorghe I Chiriti1,2, Dana-Maria ID Dimulescu1,2, Gilda
Mologhianu1,2, Adriana Sarah Nica1,2
1University of Medicine and Pharmacy "Carol Davila", Med-
ical Rehabilitation, 2National Institute of Rehabilitation, Phys-
icalMedicine and Balneoclimatology,Medical Rehabilitation,
Bucharest, Romania
Objective(s): Carrying out a randomized, prospective study
regarding the efficiency of the programme for physical and
kinetic rehabilitation using two groups of elderly patients
with: LBP, radiculopathy, canal stenosis and operated disc
herniation, with or without cognitive dysfunctions. Identifi-
cation the role that the decrease of mental and cognitive
compliance plays in emphasizing the decline of the physical
functional ability of these patients.
Material & Methods: The study was performed to
NIRPMB, in two groups (group I – a study group and group
II – the control group), either of 50 patients, males and
females, elderly, with LBP, radiculopathy, canal stenosis
and operated disc herniation. Distinction between the two
group was made based on the Folstein test, after a screening:
in the control group (group II) included patients with a
greater score than 15 points, in the study group (group I)
included patients with a lower score than 15 points. The
clinical and functional parameters assessed: pain, physical
and cognitive dysfunctions, disabilities, quality of life. We
also used the scales: VAS, MMSE, GDS, Zigmond-Snaith
Anxiety Scale, muscular and articular testing, Tinetti Gait
Scale, Tinetti Balance Scale, ADL 24.
Results: The improvement recorded were: pain with 41.6%
(group I) and 51% (group II); physical dysfunctions with
28.1% (group I) and 37.1% (group II); cognitive dysfunc-
tions with 37.2% (group I) and 47.8% (group II); disabilities
with 48.9% (group I) and 57.3% (group II), quality of life
with 39.1% (group I) and 48.2% (group II).
Conclusion(s): Improvement of pain, physical and cogni-
tive dysfunctions, disabilities, quality of life for both groups
after physical-kinetic program was applied to the two groups
of elderly patients with low back pain. Higher percentages
recorded at the control group (without cognitive disorders)
highlighted the negative effects of cognitive disorders, de-
pression and anxiety in the evolution of the score for the
parameters that we mentioned.
References: 1. Haggman S et al (2004) Phys Ther 84:1157.
2. Jarvik JG et al (2005) Spine 30:1541.
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THE ROLE OF OPEN AND CLOSED KINETIC
CHAIN EXERCISES AT THE PATIENTS WITH
KNEE OSTEOARTHRITIS
Gheorghe I Chiriti1,2, Dana-Maria ID Dimulescu1,2
1University of Medicine and Pharmacy "Carol Davila",
Medical Rehabilitation, 2National Institute of Rehabilita-
tion, Physical Medicine and Balneoclimatology, Medical
Rehabilitation, Bucharest, Romania
Objective(s): The aim of this study is to evaluate the
pain, the dysfunction and the disability in the patients
with knee osteoarthritis, using open and closed kinetic
chain exercises.
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Material & Methods: The study included 16 patients with
knee osteoarthritis: in group I were included open kinetic
chain exercises, in group II were included closed kinetic
chain exercises. Reevaluation was made at 6 months. For
the evaluation of the functional parameters were used: pain,
dysfunction and disability.
Results: In patients with knee osteoarthritis of groups I and
II, were improved the pain, dysfunctions and disability, after
treatment.
Conclusion(s): Open kinetic chain exercises were used for
initial treatment in patients with knee osteoarthritis.
References: 1. French HP, Keogan F, Gilsenan C,Waldron L,
Oconnell P (2010) Measuring patient satisfaction with ex-
ercise therapy for knee osteoarthritis: evaluating the utility
of the physiotherapy outpatient survey. Musculoskeletal
Care. 2. Thorstensson CA, Roos EM, Petersson IF, Ekdahl
C (2005) Six-week high-intensity exercise program for
middle-aged patients with knee osteoarthritis: a randomized
controlled trial. BMC Musculoskelet Disord. 3. Fransen M,
McConnell S, Bell M (2002) Therapeutic exercise for
people with osteoarthritis of the hip or knee. A systematic
review. J Rheumatol.
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THE ROLE OF POSTURAL THERAPY IN
IMPROVEMENT SELF-ASSESSMENT OF HEALTH
CONDITION AND QUALITY OF LIFE AT THE
PATIENTS WITH ANKLE FRACTURES
Dana-Maria ID Dimulescu1,2, Gheorghe I Chiriti1,2
1University of Medicine and Pharmacy "Carol Davila",
Medical Rehabilitation, 2National Institute of Rehabilita-
tion, Physical Medicine and Balneoclimatology, Medical
Rehabilitation, Bucharest, Romania
Objective(s): We intended to study the efficiency of a
selected physical and kinetic rehabilitation methodology,
with emphasis on postural evidence based therapy, using
objective and quantifiable evaluation criteria at the patients
with ankle fractures.
Material & Methods: The study was performed to
NIRPMB, in two groups (group I – a study group and group
II – the control group), either of 50 patients, males and
females, with post traumatic afections (fractures) of ankle.
Distinction between the two group was made based on the
physical and kinetic rehabilitation methodology: study
group was emphased on postural therapy. The clinical and
functional parameters assessed: pain, physical and cognitive
dysfunctions, disabilities, self-assessment of health condi-
tion, quality of life. We also used the scales: VAS, muscular
and articular testing, Hamilton Scale, movement ability,
absenteeism and work ability, ADL 24.
Results: The improvement recorded were: the pain with
45.7% (group I) and 36.8% (group II); physical dysfunctions
with 27% (group I) and 19.6% (group II); cognitive dysfunc-
tions with 39.7% (group I) and 32% (group II); disabilities
with 36.6% (group I) and 29.5% (group II), self-assess-
ment of health condition with 29.2% (group I) and 21.3%
(group II), quality of life with 36.9% (group I) and 28.9%
(group II).
Conclusion(s): Improvement of pain, physical and cogni-
tive dysfunctions, disabilities, self-assessment of health con-
dition, quality of life for both groups after physical-kinetic
program was applied to the two groups of patients with
ankle fractures. Higher percentages recorded at the study
group (emphasis on postural therapy) showed the role of
postural therapy in the physical and kinetic rehabilitation
methodology.
References: 1. Bhandari M, Sprague S (2004) J Orthop
Trauma 18:338. 2. Chaiwanichsiri D, Lorprayoon E (2005)
J Med Assoc Thai 88(Suppl 4):S90. 3. Dimulescu DM
(2008) Terapia posturala în afectiunile aparatului locomotor,
Editura Universitatii din Bucuresti. 4. Simanski CJ, Maegele
MG (2006) J Orthop Trauma 20:108.
P134
SERUM LEVELS OF CARTILAGE OLIGOMERIC
MATRIXPROTEINASATHERAPEUTIC INDICATOR
FOR ONGOING TREATMENT OF KNEE
OSTEOARTHRITIS
Utkarsh Shahi1, Neha T Shahi2, Farzana Mahdi3, Amit
Ray1, Jayant Bajpayi1
1Era's Lucknow Medical College and Hospital, Department
of Orthopaedics, 2Department of Microbiology, 3Department
of Biochemistry, Lucknow, India
Objective(s): Osteoarthritis is commonest form of arthritis,
a leading cause of disability in older adults. Various treat-
ment options present, ranging from lifestyle modification to
knee replacement. Questions like “What is the effect of
ongoing treatment over disease? At what stage, patient
requires change of therapy?” are still need to be answered.
It is highly required to develop an investigatory modality,
providing information about efficacy of ongoing treatment.
Aim of present study is to estimate and compare serum
levels of Cartilage Oligomeric Matrix Protein (COMP) for
assessing efficacy of ongoing treatment and disease prog-
nosis in patients having knee osteoarthritis.
Material & Methods: A prospective randomized control
trial, conducted within a period of one year recruiting 100
cases. All cases were asked to fill WOMAC questionnaire
and get a bilateral knee radiograph done for confirming
severity of disease with Kellgren Lawrence grading scale.
5 ml venous blood sample were drawn from cases and
serum COMP level was estimated by ELISA. The value of
COMP obtained was compared with WOMAC score and
KL grading scale. Cases were then divided into mild,
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moderate and severe grade and prescribed medications
according to standard management guidelines of OARSI
with few modifications, depending upon disease severity.
Follow up was done after every four weeks assessing efficacy
of treatment and disease progression.
Results: Out of 100 cases screened, there were 32% mild,
61% moderate and 7% severe cases. The serum COMP
levels corresponded to the severity of disease, as higher
the severity, more the value of serum COMP. During follow
ups, serum COMP levels responded differently to different
treatment modalities, with a generalized decreasing trend in
most of the groups.
Conclusion(s): A directly proportional relation between the
severity of disease and serum COMP levels is observed. The
estimated serum COMP level followed a decreasing trend
with most of the treatment modalities, which corresponded
to the functional improvement, symptomatic relief and grad-
ually increasing WOMAC score in the cases. Hence estima-
tion of serum COMP levels is reliable therapeutic indicator
to assess efficacy of ongoing treatment and disease progres-
sion in knee osteoarthritis.
P135
PREDICTION OF TOTAL KNEE REPLACEMENT
IN A 6-MONTH MULTICENTRE CLINICAL TRIAL
WITH CHONDROITIN SULFATE IN KNEE
OSTEOARTHRITIS: RESULTS FROM A
4-YEAR OBSERVATION
Jean-Pierre Raynauld1, Johanne Martel-Pelletier1, Marc
Dorais2, François Abram3, Boulos Haraoui1, Denis
Choquette1, Frédéric Morin4, Louis Bessette5, André
Beaulieu6, Jean-Pierre Pelletier1
1University of Montreal Hospital Research Centre
(CRCHUM), Notre-Dame Hospital, Osteoarthritis Research
Unit, Montreal, 2StatSciences Inc., Senior Biostatistician,
Notre-Dame-de-l'Île Perrot, 3ArthroLab Inc., Imaging Re-
search & Development, Montreal, 4Centre de Recherche
Musculo-Squelettique, Rheumatologist, Trois-Rivières,
5GRMO, Groupe de Recherche en Rhumatologie et
Maladies Osseuses, Sainte-Foy, 6Université Laval, Faculty
of Medicine, Sillery, QC, Canada
Objective(s): To identify predictive factors for the incidence
of total knee replacement (TKR) during long-term follow-up
of knee OA patients who formerly received treatment with
chondroitin sulfate (CS) or placebo in a multicentre trial
using clinical and magnetic resonance imaging (qMRI) data.
Material & Methods: Knee OA patients participating in a
previous 6-month randomized, double-blind controlled trial
evaluating the impact of CS (400 mg b.i.d.) vs. placebo who
had serial MRI acquisitions of the symptomatic knee[1] were
recently contacted to evaluate retrospectively the incidence
of TKR of the study knee. A subgroup of patients (n=70)
who had taken all the study medication and had all clinical
and MRI evaluations were selected for this post hoc retro-
spective analysis. Of this cohort, 51 patients were reachable
for TKR incidence. The assessment was done blindly to
treatment allocation with a standardized phone interview.
Results: Patients' mean age was 62.9 years, 61% were female
and average BMI was 30.6 kg/m2. A total of 7 (6 target knees
and 1 contralateral) TKRs (13.7%) were performed on this
subpopulation in the timeframe of 3-4 years after completion
of the original study. Interestingly, more TKRswere performed
within the placebo group (n=5) than the CS group (n=2) (71%
vs. 29%, p=0.15, logistic regression). Predictors of long-term
TKRs for the target knee were investigated by comparing the
patients who had TKR (n=6) of the target knee to those who
did not (n=45), using data at baseline or the change at 1 year.
At baseline, the strongest predictors of TKR were WOMAC
pain (p=0.02, logistic regression), stiffness (p=0.01) and func-
tion (p=0.04), bone marrow lesions of the medial tibia (p=
0.03), and C reactive protein level (p=0.03). Changes at 1 year
in medial cartilage volume (p=0.05) and WOMAC stiffness
(p=0.01) also predicted the occurrence of TKR.
Conclusion(s): These data demonstrate that, from a knee
OA clinical trial, it is possible to predict a “hard” outcome
such as TKR using clinical and qMRI data. Moreover, CS
appeared to protect cartilage volume loss and improved
clinical parameters.
References: [1]Wildi LM, et al. Ann RheumDis 2011;70:982.
Disclosures: Supported by a grant from Bioibérica, Spain.
P136
FRAX™ ARGENTINA IN WOMEN WITH
RHEUMATOID ARTHRITIS: COMPARATIVE
STUDY WITH THE FRAX™ SPANISH MODEL
Osvaldo D Messina1, Maritza Vidal1, Estela Chiuzzi2,
Fernando Erana1, Luis F Somma2, Griselda Redondo2,
Norma G Villa2
1IRO, Rheumatology, 2Cosme Argerich Hospital,
Rheumatology, Buenos Aires, Argentina
Objective(s): FRAX™ in a tool designed by WHO to
calculate 10-year risk of fracture. The aim of this study
was to compare the Spanish model and the Argentine model
applied to a population of patients with rheumatoid arthritis
(RA) whose previously to the development of the argentine
model were studied using the FRAX™ Spanish model.
Material & Methods: Argentine FRAX™ were applied to
women with adult onset RA, aged between 40-90 years. Data
were compared to the Spanish model obtained in a previous
study by our group to the same population. Future risk (FR) for
neck fracture (NF) and major osteoporosis (MO) were deter-
mined using the Spanish and the Argentine model of FRAX™.
Results: 205 women were included, mean age 59.8 years
(40-85 years) BMI mean 26.24 (14.3-40.7). BMD FN mean
Osteoporos Int (2012) 23: (Suppl 2):S85–S386 S101
T-score - 1.39, SD 1.08 (-4.12 - 1.47). 157 patients were GC
users (76.6%), 34 had history of fractures (16.6%), 15
patients had familial history of neck fractures (7.3%), smok-
ing 44 pat (21.5%) and 4 patients consumed alcohol (2%),
14 pat (6.8%) had causes of secondary osteoporosis. FR of
neck fracture and MO were compared using the Spanish and
the Argentine model. FRAX™ Argentina: FR for NF: mean
4.54%, SD: 7.66, median 1.30. FR for MO mean: 11.01%,
SD 10.66, median 7.00. When compared to the Spanish
model we found that 10-year absolute risk for NF and MO
was statistically higher using the Argentine FRAX model
(test of Wilcoxon range p<0.001 for NF and MO. More
frequently found risk factors were glucocorticoids, smoking
and history of previous fractures.
Conclusion(s): Comparing the Spanish model with the Ar-
gentine model, developed later, FR for NF and for MO were
significantly higher using the Argentine model in patients
with RA.
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USE OF HEALTH-RELATED QUALITY OF LIFE
(HRQOL) MEASURES TO PREDICT HEALTH
UTILITY (HU) IN POSTMENOPAUSAL
OSTEOPOROTIC WOMEN: RESULTS FROM
THE MULTIPLE OUTCOMES OF RALOXIFENE
EVALUATION (MORE) STUDY
Russel Burge1, Wei Shen1, April N Naegeli1, Janangir
Alam1, Stuart Silverman2, Deborah T Gold3
1Eli Lilly and Company, Global Health Outcomes, Indianap-
olis, IN, 2Cedars Sinai Medical Center, Department of Medi-
cine, Beverly Hills, CA, 3Duke Medical Center, Psychiatry and
Behavioral Science, Durham, NC, US
Objective(s): To examine associations between HU and
HRQoL at baseline in 1245 osteoporotic postmenopausal
women who participated in the MORE study.
Material & Methods: The EuroQol 5D (EQ-5D) and EU
Foundation of Osteoporosis Quality-of-Life Assessment
(QualEFFO) measures of HU and disease-specific HRQoL,
respectively, were administered to 551 European (EU)
women while the McMaster Health Utility Index (HUI)
and Osteoporosis Patient Assessment Questionnaires
(OPAQ) measures of HU and disease specific HRQoL, were
administered to 694 non-European (non-EU) women. The
Nottingham Health Profile (NHP) was administered to all
women to assess health status. Pearson's correlation coeffi-
cients identified correlations between HU and HRQoL,
while stepwise regression models identified independent
and unique HRQoL domains that predicted HU. Model
performance for predicting HU was assessed by the amount
of variance explained using R2.
Results: Mean age was 67.5 and 68 years for the EU and
non-EU cohorts. Mean baseline scores were slightly lower
for EU vs. non-EU cohorts on all NHP domains (5 vs. 10,
emotional reaction; 12 vs. 17, energy; 10 vs. 14, physical
mobility; 12 vs. 19, pain; 19 vs. 24, sleep; 3 vs. 5, social
interaction). In both cohorts, HRQoL and HU scores were
significantly correlated, particularly for important domains
related to pain, physical function, emotional and mental
health. In the EU cohort, 4 QualEFFO domains (daily ac-
tivities, pain, mental health, mobility) were significantly
correlated with EQ-5D scores (p<0.05) while in the non-
EU cohort, 5 OPAQ domains (walking/bending, fear of
falls, level of tension, back pain, fatigue) were significantly
correlated with HUI scores (p<0.05) - variance explained
was 61% and 41%, respectively. In the EU cohort 4 of the
NHP domains (pain, physical mobility, emotional reaction,
and energy) were significantly correlated with EQ5-D
scores and in the non-EU cohort all 6 NHP domains were
significantly correlated with HUI scores (p<0.05) - variance
explained was 53% and 44%, respectively.
Conclusion(s): These results demonstrate that disease-specif-
ic HRQoL measures (OPAQ, QualEFFO) and generic (NHP)
are significant predictors of HU scores (EQ5-D and HUI).
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BONE MINERAL DENSITY IN HAEMODIALYSIS
PATIENTS: A STRONG RELATIONSHIP WITH AN
HISTORY OF FRACTURE
Guillaume Jean1, Eric Bresson2, Christie Lorriaux1, Brice
Mayor1, Patrick Deleaval1, Jean-Marc Hurot1, Charles
Chazot1
1Nephrocare Tassin Charcot, Hemodialysis, Sainte
Foy-Les-Lyons, 2Clinique Protestante, Radiology, Caluire,
France
Objective(s): Diagnosis of osteoporosis (OP) is mainly
based on BMD. Haemodialysis (HD) patients are exposed
to secondary hyperparathyroidism (SHPT) and sometimes
to steroid therapy that may favor OP. The objective of this
study was to measure BMD in HD patients and to find the
associated factors, especially the history of fractures.
Material & Methods: All prevalent HD patients were in-
cluded. Wrist Z-score was applied as marker of SHPTand Hip
T-score as marker of OP. Patients were compared according to
their wrist Z-score and Hip T-score<or≥-2.5. Routine biolo-
gy, osteoprotegerin (OPG), FGF-23, bone alkaline phospha-
tase (BALP), β-crosslaps (CTX), Whole PTH, treatments and
previous history of nontraumatic fractures from less than 10
years were recorded. An ROC curve analysis was applied
between DMO score and history of fracture.
Results: 161 HD patients were studied, 67.2±13 y.o, 45% of
female gender, on dialysis since 45 months (median), diabetics
in 35% of cases. Administrated treatments were alfacalcidol
(45%), calcifediol (94%), CaCo3 (15%) and sevelamer (39%).
Mean hip T-score was -2.2±1.4, wrist Z-score was -1.2±2. In
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logistic regression, OP (hip T-score<-2.5) associated factors
were: male gender, history of fracture, low BMI and body
weight. SHPT (wrist Z-score<-2.5) associated factors were:
alfacalcidol treatment, history of fractures, higher nPCR and
serum OPG and greater dialysis vintage. ROC curve analysis
for the associationwith fractures showed a best cut off for wrist
Z-score of -2.5 (sensibility 52.8%, specificity 84.6%) and hip
T-score of -2.2 (sensibility 82.9%, specificity 47.1%). Factors
associated with fractures were age, chronic liver disease and
wrist Z-score<-2.5 (RR 3.1).
Conclusion(s): Wrist Z-score (29%) and hip T-score (50%)
are frequently in the OP range in HD prevalent patients. The
low mineral density was not associated with some expected
factors like iPTH, female gender, steroid therapy or para-
thyroidectomy. The cut off for the association with fracture
for T- and Z-score is close to that reported for general
population. For HD patients with low BMD, the fracture
prevention must lead to correct some modifiable factors
related to nutrition and mineral metabolism.
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THE SIGNIFICANCE OF THE QUANTITATIVE
CHARACTERISTICS OF NICOTINISM IN RELATION
TO THE LEVEL OF FEMALE SKELETON DAMAGE
Hana Pospíšilová1, Ivana Zofková1, Michaela Dušková1,
Hana Hruškovicová1, Katerina Šimunková1, Martin Hill1,
Luboslav Stárka1, Eva Králíková2
1Institute of Endocrinology, Clinical Endocrinology and
Steroid Department, 2Center for the 3rd Medical Department,
General Hospital, Center for Tobacco Dependance, Prague,
Czech Republic
Objective(s): Nicotinism has a serious negative effect on
skeleton. Skeletal disability pathogenesis is multifactorial. It
consists in the direct activation of osteoclastic resorption,
decreased bone formation and bone matrix damage. This direct
effect is modulated by the state of total hormonal homeostasis,
neonatal parameters, musculoskeletal balance, the presence of
some major system diseases and a general lifestyle (diet,
physical activity). Many correlational studies with human has
proved a negative relation of smoking to bone density and
quality, however in some other papers these results has not
been confirmed. The relation between these parameters has not
been proved, likewise in some other authors' studies. The aim
of the study was to monitor the influence of the length of
smoking, a number of cigarettes smoked and the age of the
first use of cigarettes on the whole-body bone density.
Material & Methods: Whole-body densitometry determin-
ing bone and soft tissues using DXAwas measured with 40
women, where 22 women were premenopausal (average age
35±8) and 18 women postmenopausal (average age 57±5).
All probands had been smoking in the long term continu-
ously until the day of examination. Partial correlations
adjusted to constant age and physical activity were used to
evaluate relations between the smoking intensity indicators
on one side and anthropometric characteristics and bone
quality indicators on the other side.
Results: Monitoring the effect of smoking upon whole-body
bone density and the volume of muscle mass with women, we
have not proved statistically significant relation of the whole-
bodymass to the number of cigarettes smoked, or to the length
of smoking, or to the age of the first use of cigarettes.
Conclusion(s): Though the study is not fully comparable
with those monitoring the relation of smoking to bone
density of the selected high risk skeleton localities, funda-
mentally it comes up with the identical results when com-
pared with other studies.
Disclosures: Supported by IGA MZCR 12340-5 grant, and
by project "Advanced education of own staff in clinical and
molecular endocrinology" (CZ.2.17/1.1.00/32386).
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FACTORS ASSOCIATEDWITH CHANGES IN BONE
MINERAL DENSITY IN HAEMODIALYSIS
PATIENTS
Guillaume Jean1, Eric Bresson2, Patrick Deleaval1,
Jean-Marc Hurot1, Brice Mayor1, Christie Lorriaux1,
Charles Chazot1
1Nephrocare Tassin Charcot, Hemodialysis, Sainte
Foy-les-Lyon, 2Clinique Protestante, Radiology, Caluire,
France
Objective(s): Haemodialysis (HD) patients display a higher
risk for fracture as compared to the general population and
this risk has been associated with low BMD score. We
aimed at assessing the BMD evolution and the associated
factors in a stable HD population in one centre.
Material & Methods: Between 2006 (T0) and 2009 (T3), 2
BMDs were performed recording the results of the femoral
neck (FN) and the ultradistal radius (UDR) bone density.
Patients with a decreased BMD (BMD-) were compared to
patients with stable or increased BMD scores (BMD+). A
radiological vascular calcification (VC) score (0-3) was applied.
Results: 77/95 patients at T0 were still dialyzing in our centre
at T3 and were recorded for analysis. Mean age was 67±10
(30-80) years, 50%were of female gender, 33%were diabetic,
in dialysis since 75±82 months with a 3x5 to 3x8 h schedule.
Mean FN BMD decreased of -8.5±11% (0.7±0.1 to 0.63±0.1
g/cm2), UDR BMD decreased of -9.4±14% (0.49±0.1 to
0.43±0.1 g/cm2). As compared to BMD+, FN-BMD- patients
(64%) had more frequently peripheral artery disease (27 vs.
7%), more severe VC score (1.57±2 vs. 1.17±2), a decrease
of serum FGF-23 (-2800 vs. +3800 RU/ml), an increased
serum PTH (+120±250 vs. +28±120%) and were taking
more frequently sevelamer (50 vs. 26%). Patients with
UDR-BMD- (72%) have an increased serum PTH (+108±
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250 vs. -8±44%), more severe VC score (1.55±2 vs. 1.1±2)
and were less frequently treated with CaCO3 (2 vs.15%).
Conclusion(s): The decrease of BMD is frequently ob-
served in HD patients after 3 years. We failed to found
any relationship with age, gender and BMI but mostly with
vascular calcification and increased PTH possibly related
with less calcium intake.
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RADIOGRAPHIC EVALUATION OF THE NEW
BONE TISSUE AFTER RHBMP-2 APPLICATION IN
RATS SUBMITTED TO CHRONIC ALCOHOLISM
João Paulo Mardegan Issa1, Bruna Gabriela dos Santos
Kotake1, Antonio Augusto Ferreira Carvalho2, Leda Maria
Pescinini Salzedas2, Ricardo Calzzani1, Mamie Mizusaki
Iyomasa1
1University of São Paulo, Morphology, Stomatology and Phys-
iology, Ribeirão Preto, 2Paulista State University, Pathology
and Clinical Propaedeutic, Araçatuba, Sao Paulo, Brazil
Objective(s): Alcoholism may cause changes in bone struc-
ture and is considered a reduction factor on bone formation,
whereas the rhBMP-2 is a morphogenetic protein known to
play an important role on bone repair processes and induce
bone formation. Thus, the aim of the present study was to
investigate radiographically the action of chronic alcoholism
in bone defects (5 mm of diameter) recuperation after
rhBMP-2 insertion, pure or combined to a collagen matrix.
Material & Methods: It was used 80 male Wistar rats (250
g) divided equally into 8 groups, and sacrificed after 4 and 6
weeks. Animals were submitted to the following treatments:
1) water "ad libitum", 2) alcohol "ad libitum", 3) water "ad
libitum"+5 μg rhBMP-2, 4) alcohol "ad libitum"+5 μg
rhBMP-2, 5) water "ad libitum"+collagen sponge (carrier),
6) alcohol "ad libitum"+collagen sponge (carrier), 7) water
"ad libitum"+5 μg rhBMP-2 / collagen sponge, 8) alcohol
"ad libitum"+5 μg rhBMP-2 / collagen sponge. After these
treatments, animals were sacrificed considering the respec-
tive periods of time, and the samples submitted to radio-
graphic analysis using the X-ray machine GE-100 (General
Electric, Milwaukee, USA) operating at 70 kVp, 10 mA, 12
pulses, and analyzed by the Digora digital system (Soredex,
Orion Corporation, Helsinki, Finland).
Results: Data were statistically analyzed using Kruskal-
Wallis and Dunn's Multiple Comparisons. At 4 weeks, there
was no difference (p>0.05) for the used treatments, howev-
er, at 6 weeks, the groups that received rhBMP-2 with or
without the carrier, and independent of the alcoholism in-
duction, showed higher radiographic density compared with
other groups, p<0.05.
Conclusion(s): We conclude that the rhBMP-2 was able to
recover the surgical area in this experimental model, showed
by the radiographical method used.
Disclosures: The authors are grateful to FAPESP for
financial support.
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DISTAL RADIUS BONE STRENGTH ESTIMATED
BY FINITE ELEMENT ANALYSIS BASED
ON QCT IMAGES
Kyle K Nishiyama1,2, David D McErlain1,2, Clara Sandino1,2,
Steven K Boyd1,2
1University of Calgary, Schulich School of Engineering,
2University of Calgary, Roger Jackson Center for Health
and Wellness Research, Calgary, AB, Canada
Objective(s): The distal radius is one of the most common
sites for osteoporotic fractures and using tools such as
pQCT and HR-pQCT, bone strength can be estimated using
FE analysis. Since access to these tools is still limited, it is
valuable to use clinical QCT as a basis to accurately estimate
bone strength. Thus, the purpose of this study was to vali-
date estimates of bone strength at the distal radius using FE
analysis based on QCT images.
Material & Methods: Twelve fresh-frozen distal radii (6
left, 6 right; 4 female, 2 male; Age: 74.0±12.9 yrs) were
thawed and scanned with QCT (GE Discovery CT750HD;
120 kVp, 60 mAs) and, as the gold standard, HR-pQCT
(Scanco Medical XtremeCT, AG). QCT images were semi-
automatically contoured to find the endosteal surfaces using
Stradwin (v4.3, Cambridge, UK) [1]. HR-pQCT images (82
μm isotropic voxels) were segmented and contoured based
on the standard manufacturer protocol. A matching 24.6 mm
section of the distal radius was extracted from both the QCT
and HR-pQCT images. Inhouse software was used to cali-
brate the QCT data based on a hydroxyapatite calibration
phantom (B-MAS200, Kyoto Kagaku, Japan) and rescale
the images to 0.625 mm isotropic voxels. Density values
were converted to Young's modulus values [2]. HR-pQCT
images were directly converted to FE models and assigned a
Young's modulus of 6829 Mpa [3]. Uniaxial compression to
1% strain was applied and linear models were solved using
FAIM (v5.3 Numerics88; Calgary, Canada).
Results: Bone strength (ultimate stress, MPa) was estimated
for both sets of models. A linear regression analysis was
performed relating the QCT estimates to the HR-pQCT
measurements resulting in a R2 value of 0.91.
Conclusion(s): This work provides insight into the ability
of FE models based on QCT to estimate bone strength at the
distal radius. This study is limited to linear FE analysis and
the boundary conditions applied do not exactly represent
those that would occur during a fall on an outstretched arm.
Future work will apply advanced constitutive properties in
the FE model in order to better predict bone strength.
References: [1] Treece, Med Image Anal, 2010. [2] Keyak,
J Biomech, 1998. [3] MacNeil, Bone, 2008
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WOMEN WITH INSUFFICIENT 25-HYDROXYVI-
TAMIN D WITHOUT HYPERPARATHYROIDISM
HAVE ALTERED BONE TURNOVER AND GREATER
INCIDENCE OF VERTEBRAL FRACTURES
Shota Ikegami1, Mikio Kamimura2, Shigeharu Uchiyama3,
Hiroyuki Kato3
1Yodakubo Hospital, Department of Orthopaedic Surgery,
Nagawa, 2Center for Osteoporosis and Spinal Disorders,
Kamimura Orthopaedic Clinic, Department of Orthopaedic
Surgery, 3Shinshu University, Department of Orthopaedic
Surgery, Matsumoto, Nagano, Japan
Objective(s): The connection of 25-hydroxyvitamin D [25
(OH)D] with bone metabolism is reported to occur indirectly
through PTH activity. However, we hypothesized that 25(OH)
D insufficiency raises the risk of bone fracture independent of
PTH, since 25(OH)D insufficiency is not always accompanied
by hyperparathyroidism. The aim of this study was to show a
direct association between 25(OH)D, bone turnover markers,
and fractures that was independent of PTH.
Material & Methods: We measured serum 25(OH)D in a
group of 330 postmenopausal osteoporotic women who did
not have secondary hyperparathyroidism. We analyzed the
effects of 25(OH)D insufficiency [25(OH)D <20 ng/mL] on
the expression of several bone markers, including serum
bone alkaline phosphatase (BAP), osteocalcin (OC), urinary
N-terminal telopeptide of type-I collagen and free deoxy-
pyridinoline (DPD), and inorganic phosphorus (IP), as well
as on the prevalence of vertebral fractures.
Results: OC/BAP ratios and IP levels were significantly lower
and DPD was significantly higher in 25(OH)D insufficient
patients. These effects were independent of age, PTH, and esti-
mated glomerular filtration rate (eGFR). 25(OH)D insufficiency,
a low OC/BAP ratio, and low IP were related to the presence of
prior vertebral fractures independent of PTH, BMD, and eGFR.
Conclusion(s): We propose that 25(OH)D insufficiency is
associated with a low OC/BAP ratio and high DPD in
postmenopausal osteoporosis patients without hyperpara-
thyroidism. This pathological condition is associated with
an increased incidence of prior vertebral fractures indepen-
dent of PTH, BMD, and eGFR.
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NUTRITIONAL FACTORS INFLUENCE BONE
MICROARCHITECTURE DURING GROWTH
Negar Shahmoradi, Sandra Iuliano-Burns, Xiao-Fang Wang,
Ali Ghasem-Zadeh, Roger Zebaze, Qingju Wang, Ego Seeman
Austin Health, Repatriation Hospital, Depts of Endocrinology
and Medicine, Melbourne, Victoria, Australia
Objective(s): The skeleton is responsive to environmental
factors during growth, in part perhaps due to the intense
cellular activity of modeling and remodeling which assemble
its structure during the first two decades of life. High resorp-
tive modeling (not followed by formation at the same loca-
tion) and perhaps remodeling activity excavate the medullary
canal determining cortical thickness together with periosteal
apposition. At the ends of long bones, endochondral apposi-
tion and condensation of growth plate trabeculae form the
metaphyseal cortex with varying degrees of porosity deter-
mined by the differing tempo of longitudinal and appositional
growth. We hypothesized that a higher intake of calcium,
vitamin D and protein during childhood are associated with
attainment of a more robust appendicular skeleton; thicker and
less porous cortices and a smaller medullary canal.
Material & Methods: We measured tibial macro- and
microarchitecture using HR-pQCT. Dietary intakes were
assessed using 3-day weighed-food diaries.
Results: Cross-sectional study of 62 healthy boys and girls
aged from 6-18 years (mean 11 years) of whom 53.2% were
prepubertal, 27.4% peripubertal and 19.4% postpubertal.
Intakes were calcium (803 mg, range 216 to 1623), vitamin
D (2.89 μg, range 0.6-9.9) and protein (82 g, range 25.9-
208). Results were expressed as mean, 95% CI. In a General
Linear Model multivariate analysis, the effect size (ES)
estimated from the partial beta2 is greater between cortical
vBMD and calcium intake (ES=0.025%, 95% CI, -0.095 to
0.022) and vitamin D intake (ES=0.054%, 95%CI, -18.5 to
0.72). Protein intakes explained the greatest effect size (ES=
0.054, 95% CI, 0.107-3.206%) on total cross sectional area
of the tibia compare to other bone macro- and microarchi-
tecture results.
Conclusion(s): Two factors limit the power of this study, the
small sample size and the range of nutritional intakes which
may be above those defining 'insufficiency'. Within these
constraints we infer that ensuring adequate protein intake
may benefit the attainment of peak bone microstructure
during growth.
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DENOSUMAB DISCONTINUATION AND
ASSOCIATED FRACTURE RISK: A FREEDOM
TRIAL ANALYSIS
C Roux1, J P Brown2, J-E Beck Jensen3, N Gilchrist4, C
Recknor5, O Törring6, M Austin7, AWang7, A Grauer8, P-R
Ho8, R Wagman8
1Paris Descartes University, Rheumatology Department,
Paris, France, 2CHUQ-CHUL Research Centre, Department
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bury Geriatric Medical Research Trust, Christchurch, New
Zealand, 5United Osteoporosis Centers, Gainesville, GA, US,
6Karolinska Institutet Södersjukhuset, Department of Clinical
Science, Stockholm, Sweden, 7Amgen Inc., Biostatistics,
8Amgen Inc., Clinical Development, Thousand Oaks, CA, US
Osteoporos Int (2012) 23: (Suppl 2):S85–S386 S105
Objective(s): In FREEDOM, denosumab 60 mg every 6
months decreased the risk of fractures at 3 years vs. placebo.1
Discontinuation of denosumab treatment is associated with
transient increases in bone remodelling and declines in
BMD,2,3 but the effect on fracture risk is not well character-
ized. This analysis was conducted to understand fracture inci-
dence in an osteoporotic population after treatment cessation.
Material & Methods: We evaluated FREEDOM subjects
who discontinued treatment after 2-5 doses of investigational
product, either denosumab or placebo, and continued study
participation for ≥7 months (≥6 months since last dose+1-
month study visit window). Off-treatment observation began
7months after last dose and lasted approximately 6-24months.
Results: The 797 subjects (470 placebo, 327 denosumab)
evaluable for this assessment had similar age, prevalent frac-
ture, and BMD T-scores (lumbar spine and total hip) at base-
line. During treatment, more subjects treated with placebo
than denosumab sustained a fracture and had significant
decreases in BMD. Initiation of alternative therapy after last
dose was more common in placebo than denosumab-treated
subjects (42% vs. 28%). After treatment discontinuation, sim-
ilar percentages of subjects in both groups sustained a new
fracture (9% placebo, 7% denosumab; fracture rate/100 sub-
ject-years 13.5 and 9.7, respectively; HR 0.82; 95% CI 0.49,
1.38, adjusted for baseline age and total hip BMD T-score).
There was no apparent difference in fracture occurrence pat-
tern between treatment groups during the off-treatment period.
Conclusion(s): In this analysis, there was no excess fracture
risk after treatment cessation of denosumab vs. placebo
during the off-treatment period for up to 24 months.
References: 1. Cummings NEJM 2009. 2. Miller Bone
2008. 3. Bone JCEM 2011.
Disclosures: Study sponsored by Amgen Inc.
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IS BODY SHAPE ASSOCIATED WITH LOW
BONE DENSITY
John A Shepherd1, Joseph Wilson1, Serghei Malkov1, Bo Fan1
1University of California at San Francisco, Radiology and
Bioimaging, 2California Pacific Medical Center, San
Francisco Coordinating Center, San Francisco, CA, US
Objective(s): BMI, weight, and lean mass are all known
risk factors for either low bone density or fracture risk. Our
objective was to identify body shape indices that may be
associated of low bone density as a visual indicator of risk.
Material & Methods: Our study population was the
NHANES 199-2004 data release providing body composition
and bone density measures on a cross-section of the US
population. Using the whole-body DXA scans, we converted
the fat, lean, and bone mas measures of the total body and
subregions to calibrated volumes using algorithms previously
developed in our lab. The measures derived were absolute
volumes in L for total body, arms, legs, trunk, and head. We
also represented shape indices for combinations of these val-
ues including %trunk, %arms, %legs, trunk/legs ratio, arms/
legs ratio. Logistic regression was used determine the associ-
ation of each of these shape parameters to whole body BMD
after adjusting for age, ethnicity, sex, and BMI.
Results: We found that there were unique body shapes for
men and women of any ethnicity, and for black, white, and
Hispanic Americans. In general, we found that white men and
women had the largest overall body sizes for all ages vs. other
ethnicities. Average body size also decreased for all partici-
pants at approximately the age of menopause for women (50
yrs) and andropause for men (60 yrs). Absolute trunk volumes
showed similar trends to whole body. However, percent of
trunk volume to total volume remained constant after the
meno- and andropause ages implying that shape remained the
same after these ages even though absolute body sizes were
decreasing. Total trunk volume was significantly associated
with BMD even after controlling for other known associations.
Conclusion(s): Body shape indices are associated with
BMD independent of lean mass and other BMD predictors.
Body shape may play an independent role in fracture risk or
provide an anthropomorphic description of risk of fracture.
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TERIPARATIDE AND ANTIRESORPTIVE
COMBINATION TREATMENT SUBSEQUENT TO 9
MONTHS OF TERIPARATIDE MONOTHERAPY
Christian Muschitz1, Astrid Fahrleitner-Pammer2, Roland
Kocijan1, Christina Bittighofer1, Angela Trubrich1, Friederike
Kuehne1, Reinhart Waneck3, Heinrich Resch1
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1St. Vincent Hospital, Medical Department II - Vinforce,
Vienna, 2Dept of Internal Medicine, Medical University Graz,
Division of Endocrinology andMetabolism, Graz, Styria, 3 St.
Vincent Hospital, Department of Radiology, Vienna, Austria
Objective(s): Increased bone formation in the absence of
accelerated resorption is resulting in a marked rapid anabolic
response to teriparatide (TPTD). Due to coupling mecha-
nisms, the sustained increase of bone formation and ongoing
anabolic effects are accompanied by significantly increased
bone resorption. Our aim was to investigate the effects of the
addition of antiresorptives to the second half of TPTD cycle
when resorption is already also markedly elevated.
Material & Methods: We prospectively randomized 117
postmenopausal women (mean age 71.7±8.5 years, T-score
L1-L4 -2.45±1.38; 91.5% with prevalent fractures) after 9
months of TPTD treatment into three different open-label
groups for another 9 months: alendronate (ALN, 70 mg/week,
41 patients), raloxifene (RAL, 60 mg/day, 34 patients) or no
medication (TPTD mono, 42 patients) on top of ongoing
TPTD treatment. Serum level of PINP and CTX as well as
DXA measurement at the spine, total hip and femoral neck
BMDwere evaluated at TPTD treatment initiation, at baseline
of randomization to antiresorptive therapy as well as at 3, 6
and 9 months during the combination treatment.
Results: After 18 months of TPTD treatment, lumbar spine
BMD increase was significantly higher in the ALN (+0.08
g/cm2, p=0.046) and RAL (+0.09 g/cm2, p=0.026) group
when compared with the TPTD mono group (+0.05 g/cm2).
In the total hip region, addition of RAL (+0.03 g/cm2) did not
alter the BMD effects of TPTD monotherapy (+0.03 g/cm2),
but addition of ALN induced a more pronounced increase in
total hip BMD (+0.05 g/cm2 ) than RAL (p=0.026) or TPTD
alone (p=0.048). Elevation of PINP and CTX was signifi-
cantly lower in the ALN and RAL group at the end of the 18
months treatment when compared to TPTD treatment alone.
Conclusion(s): Our data suggest that addition of ALN to the
second 9 months of TPTD treatment cycle results in aug-
mented BMD increase. This BMD increase may reflect
either favorable balance of bone formation and resorption
towards more formation or increased secondary mineraliza-
tion of newly formed bone matrix.
References: Black DM et al. N Engl J Med 2003;349:1207.
Cosman F et al. J Bone Miner Res 2011;26:503.
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TREATMENT WITH PTH 1-84 IN MALE PATIENTS
WITH SEVERE OSTEOPOROSIS – RESULTS FROM
A PROSPECTIVE 24 MONTH OPEN-LABEL TRIAL
Christian Muschitz1, Judith Haschka1, Roland Kocijan1,
Christina Bitighofer1, Angela Trubrich1, Astrid Fahrleitner-
Pammer2, Heinrich Resch1
1St. Vincent Hospital, Medical Department II - Vinforce,
Vienna, 2Medical University Graz, Division of Endocrinology
and Metabolism - Department of Internal Medicine, Graz,
Styria, Austria
Objective(s): Recent findings support the hypothesis of os-
teoblast dysfunction in male osteoporosis This study investi-
gated the effect of PTH 1-84 in severe male osteoporosis.
Material & Methods: 26 men (mean age 63.3±14.3 ys)
were prospectively assigned to daily subcutaneous injections
of 100 μg of PTH 1-84 for 24 months. 81% had prevalent
fractures including vertebral fractures (20 pts, mean 3±1.8),
nonvertebral fractures (11 pts) and hip fractures (5 pts). 6 pts
had long term steroid medication (9.3±5.3 ys). 20 pts had
prior antiresorptive treatment (6.3±2.6 ys) and 6 were treat-
ment naïve (low BMD, ≥2 CRFs). Primary objectives were
the gain of BMD at lumbar spine and hip and the changes of
bone turnover markers (P1NP, S-CTX). Secondary objectives
were reduction of new osteoporotic fractures and the evalua-
tion of safety and tolerability. Patients had BMD measure-
ments (DXA), X-ray of spine, assessment of P1NP, S-CTX at
baseline and at months 6, 12, 18 and 24. A visual analogue
scale (VAS) was assessed for general health.
Results: The increase of lumbar BMD at month 12 was
6.51% and at month 24 13.98%, at femoral neck from
1.17% and 8.5% and at total hip 1.5% and 7.72% compared
to baseline (P<0.0001 for all). P1NP rapidly increased up to
421% at month 12 and remained till to the end of the
observation period; S-CTX increased between 181% and
322% (maximum 347% at month 12) [P<0.001 for all].
One patient (GIOP) had a new morphometric vertebral
fracture and one patient sustained a hip fracture after a major
trauma (accident).PTH 1-84 was generally well tolerated.
VAS score declined from 7.5 to 3.2 (P<0.05).
Conclusion(s): Our data suggest that PTH 1-84 rapidly
increases BMD at different skeletal sites regardless of prior
long-term treatment with bisphosphonates or steroid medi-
cation. The bisphosphonate induced suppression of the bone
turnover does not seem to reduce the anabolic effect of PTH
in male patients with severe osteoporosis.
References: Patsch JM, Kohler T, Berzlanovich A, et al. J
Bone Miner Res 2011;26:1584.
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Objective(s): Fracture risk in osteoporotic patients depends
on BMD and clinical risk factors (CRFs). DXA of spine and
hip is considered gold standard for BMD assessment. Due to
frequent degenerative conditions in spine or hip calcaneal
DXL (DXA and laser) is an easily obtainable and transport-
able alternative.
Material & Methods: Vertebral fracture risk was evaluated
in an analysis of 591 females and males (mean age 64.4±9.2
years) without any prior osteoporotic medication except
calcium/vitamin D comparing BMD measurements by
DXL and DXA and CRFs with/without BMD. 160 had
radiological verified vertebral fractures. Areas under ROC
curve (AUC), univariate and multiple logistic regressions
were calculated.
Results: Detection rates for subjects with diminished BMD
according to WHO criteria were higher with DXL compared
to DXA. AUC for detection of vertebral fractures was com-
parable for DXL at calcaneus and DXA at femoral neck
(AUC: DXL 0.6654, DXA 0.6669). Odds ratio for vertebral
fracture risk prediction was generally weak for DXA femo-
ral neck (0.613) and DXL (0.521). Univariate logistic re-
gression among CRFs without BMD revealed age, prevalent
fragility fracture, and BMI significantly associated with
increased fracture risk. (AUC=0.805). Combining BMD
and CRFs, a prognostic improvement in case of DXA at
femoral neck (AUC 0.8694, p=0.0227), DXL at calcaneus
(AUC 0.8690, p=0.0594), and DXA at total hip (AUC
0.8610, p=0.0617) was found.
Conclusion(s): DXL was more sensitive compared to
DXA for identification of subjects with vertebral fragil-
ity fractures, but both methods had less power than
CRF alone. Combination of CRFs with BMD measure-
ments by DXL or DXA further increased the discrimi-
natory capacity for detection of patients at risk for
vertebral fracture.
References: 1. Muschitz C, Patsch J, Buchinger E, et al
(2009) Wien Klin Wochenschr 121:528. 2. Thorpe JA, Steel
SA (2006) Br J Radiol 79:336. 3. Brismar TB, Janszky I, Toft
LI (2010) J Osteoporos 875647. doi:10.4061/2010/875647.
P150
CONSERVATIVE TREATMENT RESISTENCE
OF PAINFUL SHOULDER IN OLDER PATIENTS
Daniela ID Poenaru, Delia G Cinteza, Victorita H Marcu
National Institute of Physical and Rehabilitation Medicine,
Rehabilitation, Bucharest, Romania
Objective(s): Identifying underlying sonographic alteration
in conservative treatment resistance of painful shoulder in
older patients (over 60 years old) in ambulatory practice.
Material & Methods: 78 patients (130 painful shoulders)
over 60 years old, with pain in the shoulder for the first time,
who underwent diagnostic and therapy course for 2 weeks
and failed to improve. Inclusion criteria: age over 60, the
first pain episode, failure of the 2 weeks conservative treat-
ment (oral analgesic and physical therapy). Exclusion crite-
ria: preexisting trauma, preexisting sportive activity with
shoulder impact, inflammatory rheumatic disease, central
and peripheral motor deficiencies with upper limb involve-
ment, situations implying cane utilization. We defined treat-
ment failure as a difference between VAS at first
presentation (VASi) and VAS at the end of the conservative
treatment (VASa) less or equal to 2. Patients underwent
clinic and sonographic shoulder examination.
Results: 54% women, unilateral (33%) or bilateral (67%)
shoulder pain. Mean VASi 8.94, mean VASa 8.62. Shoulder
sonography: cuff rotator lesions (4%), bursitis (4%), long
head biceps tendon lesions (3%), acromioclavicular osteo-
arthritis (44%), effusion in the lung head biceps sheet (with-
out tendon alteration 67%), degenerative lesion of the
humeral head (90%).
Conclusion(s): Osteoarthritic changes of acromioclavicu-
lar and glenohumeral joints are frequently found in
older patients with conservative treatment failure of
painful shoulder.
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IMPROVING MANAGEMENT OF LOW TRAUMA
FRACTURES IN A TERTIARY HOSPITAL: THE
FRACTURE CAPTURE PROJECT
Sandra Iuliano, Thuy Vu, Cherie Chiang, Emily Gianatti,
Emma Hamilton, Mathis Grossman, Ego Seeman, Jeffrey
Zajac
Austin Health/University of Melbourne, Endocrinology,
West Heidelberg, Victoria, Australia
Objective(s): Follow up after admission for a low trauma
fracture is low with a previous audit of the Austin Hospital
indicating that less than 1% of inpatients were discharged
with treatment related to a fragility fracture, and only 6%
had follow up investigation. We aimed to determine if a
designated fracture identification and treatment program
improved treatment rates following a low trauma fracture.
Material & Methods: Patients admitted through the emer-
gency department (ED) with a low trauma fracture (hip,
spine upper and lower limbs) were identified weekly. Inpa-
tients had clinical assessment and biochemical investiga-
tions for secondary causes of osteoporosis. Treatment was
commenced according to standardised guidelines. After dis-
charge, endocrine clinic review was scheduled following
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outpatient DXA and pathology assessments. Patients dis-
charged directly from the ED were contacted via mail to
undergo secondary screening. Follow up reminder letters
were sent to patients who failed to respond.
Results: Over a 24 month period, 955 females (mean age
74.8±11.4 years) and 325 males (mean age 71.1±11.8
years) with fragility fractures were identified. 587 were
inpatients (309 hip, 35 wrist, 243 other) and 693 discharged
directly from the ED (18 hip, 294 wrist, 381 other). 51% of
inpatients were discharged with treatment, compared to
<1% previously and 40% of inpatients underwent assess-
ment and clinic review compared to 6% observed in the
prior audit. 53% of those discharged directly from the ED
underwent investigations and clinic review compared to no
patients prior to the program. 14% elected to be treated by
their own GP or specialist. Of all the low trauma fracture
admissions, only 12% potentially went untreated (failed to
respond to correspondence).
Conclusion(s): Implementation of a dedicated bone fragility
identification and treatment program significantly improved
initiation of therapy. Whether this translates into improved
compliance and fracture risk reduction required further in-
vestigation.
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HIGH PREVALENCE OF VITAMIN D DEFICIENCY
AMONG PREGNANT WOMEN AT TERM AND
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Objective(s): Maternal vitamin D status is integral to fetal
development. There are few data from Greece, a country
with abundant sunshine, regarding the prevalence of vitamin
D deficiency in pregnancy. Our aim was to assess vitamin D
status of women at term and their neonates in a region of
Northern Greece.
Material & Methods: Maternal serum and cord blood
levels of calcium (Ca), 25-hydroxyvitamin D (25-0H-D),
alkaline phosphatase (ALP), phosphorus (P) and PTH were
studied in 60 mother-newborn pairs at term. The study was
conducted between February 2010 - March 2011. Dietary
habits and skin phototype (Fitzpatrick's classification) were
studied.
Results: Mean level of maternal serum 25(OH) D was
10.11±6.8 (6.2-21.2) ng/ml, significantly lower (P<0.001-
paired samples test) than that of cord blood 14.2±9.5(10.2-
23.8) ng/ml. Maternal serum 25-OH-D correlated positively
with cord blood 25-OH-D(r=0.79, P<0.001) (Spearman's
correlation). According criteria defining vitamin D deficien-
cy, 82.3% of mothers and 62.5% of neonates were vitamin
D deficient, respectively. Umbilical venous blood P was
significantly (P<0.001) higher than maternal blood levels
[5.2±1.2 (3.8-5.9) vs. 3.6±1.2 (2.9-3.8) mg/dl], while umbil-
ical PTH levels were significantly lower (P<0.001) than ma-
ternal levels [4.5±2.5(3.1-7.1) vs.22.1±9.1 (6.5-36.2) pg/ml].
No differences were found between maternal and cord blood
Ca and ALP levels (p=0.710). The intake of Ca and vitamin D
was uniformly low [283±103 mg/d and 48±24 IU/d], respec-
tively. Mothers who delivered during winter and spring had
lower 25-OH-D levels (P<0.001), than those who delivered
in summer and autumn [8.9±5.1 (4.2-11.1) vs. 9.6±6.8
(5.8-15.4)]. Finally, women with fair phototype had higher
25-OH-D (P<0.001) than women with darker phototypes.
Conclusion(s): We observed a high prevalence of hypovi-
taminosis D among pregnant women and their newborns in
Northern Greece. Further public health intervention and
vitamin D supplementation is needed to improve maternal
and neonatal vitamin D status.
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UTILITY OF FRAX AND Q-FRACTURE TOOLS
IN THE EVALUATION OF T2DM PATIENTS
Pedro Rozas-Moreno1,2, Rebeca Reyes-Garcia1, Antonia
Garcia-Martin1, Ines Luque-Fernandez1, Miguel Aguirre2,
Manuel Muñoz-Torres1
1Hospital Universitario San Cecilio, Bone Metabolic Unit,
Endocrinology, Granada, 2Hospital General de Ciudad Real,
Endocrinology, Ciudad Real, Spain
Objective(s): The WHO fracture risk assessment tool
(FRAX) is implemented in several guidelines andmost widely
used at present, although the presence of diabetes is not
included as a risk factor. Q-fracture includes the presence of
diabetes, and could be better in the evaluation of patients with
diabetes. Our objective was to evaluate the performance of
FRAX tool and Q-fracture in a group of T2DM patients.
Material & Methods: Cross-sectional study including 78
patients with T2DM. Lumbar spine and femoral BMD were
measured by DXA (Hologic QDR 4500). Ten-year major
osteoporotic fracture risk and hip fracture risk were calcu-
lated using FRAX tool and Q-fracture. Results were ana-
lyzed using SPSS 15.0.
Results: Mean age was 57.8 years (57.8±6.4). 44.8% were
females (n=35) and 55.2% males (n=43). 22.4% of patients
have densitometric criteria for osteoporosis and 9% had a
previous fracture. Prevalent radiographic vertebral fractures
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were detected in 27.7%. Medium FRAX index was 2.52±
1.95 for major osteoporotic fractures and 0.35±0.40 for hip
fractures. If BMD value was added to calculation medium
FRAX index was 2.77±2.38 for major osteoporotic frac-
tures and 0.35±0.59 for hip fractures. There were no differ-
ences between medium FRAX index calculated with or
without BMD. When treatment thresholds were applied
(7% ten-year probability for major osteoporotic fracture
and 3% ten-year probability for hip fracture) few patients
were selected for treatment. 2.6% of patients had a ten-year
probability for major osteoporotic fracture >7% and the
percentage rose to 5.1% when femoral neck BMD was
added (p 0.002). No patients had a ten-year probability for
hip fracture >3% and 2.6% meet criteria when femoral neck
BMD was added. Using Q-fracture, 3.8% of patients had
high fracture risk and 1.3% high risk of hip fracture.
Conclusion(s): In our group of T2DM patients a low per-
centage of T2DM patients are selected for treatment by
FRAX tool or by Q-fracture despite the high risk of fracture
demonstrated by high vertebral fracture rate. Additional
studies are needed to establish the performance of those
scales in the evaluation of fracture risk in T2DM patients.
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ALCOHOL-INDUCED OSTOPENIA IS LINKED TO
OSTEOCYTEAPOPTOSISANDLIPID INFILTRATION
INTO THE BONE
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Bone and Joint Research Laboratory, Adelaide, Australia,
4François Rabelais University, Department of Microscopy,
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Objective(s): Alcoholism is one of the main causes of sec-
ondary osteoporosis in men. Heavy alcohol consumption has
been shown to induce osteocyte apoptosis and excess fat. The
aim of this in vivo study in the rat was to study the relationship
between osteocyte apoptosis and lipid metabolism in bone.
Material & Methods: 24 male Wistar rats, 8 weeks old at
baseline, drank either a 35% v/v ethanol beverage (A) or
water (C) during 17 weeks. Body composition and BMD
were measured by DXA, osteocyte apoptosis was assessed
through cleaved caspase-3 and toluidine blue staining on
tibia sections. Fat content in osteocytes, bone marrow and
cortical bone microvessels was evaluated on tibia sections
stained with toluidine blue, nile red and on sections imaged
with transmission electron microscopy.
Results: After alcohol treatment, the number of apoptotic
osteocytes was increased, as shown by caspase-3 staining
(186.2±42.7 vs. 23.9±7.2 in A and C, p<0.001) and the higher
empty osteocyte lacunae in A vs. C. We observed lipid droplet
accumulation within the osteocytes (95.5±7.2 vs. 11.2±
13.1%, p<0.001) (Fig 1A and C), the bone marrow (29.3±
13.0 vs. 4.1±4.9%, p<0.001) and the cortical bone microves-
sels in A vs. C (21.3±15.5 vs. 0.2±0.5%, p <0.003) (Fig 1B).
There was an inverse correlation between BMD and osteocyte
apoptosis (r=-0.72, p=0.002) and strong significant correla-
tions between osteocyte apoptotic number and lipid droplet
accumulation in osteocytes (r=0.95, p<0.001), bone marrow
(r=0.65, p<0.02) and bone microvessels (r=0.83, p<0.005).
Conclusion(s): These data show that alcohol-induced bone
loss is associated with osteocyte apoptosis and lipid accu-
mulation in the bone tissue.
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BONE TISSUE MICROMECHANICAL PROPERTIES
ARE ALTERED INDEPENDENTLY OF MINERALI-
ZATION INOSTEOPOROTICWOMENLONG-TERM
TREATED ALENDRONATE
Yohann Bala1,2, Baptiste Depalle1,2, Thierry Douillard2,3,
Sylvain Meille2,3, Jérôme Chevalier2,3, Roland Chapurlat1,2,
Georges Boivin1,2
1UMR 1033, INSERM, Lyon, 2UCBL, Université de Lyon,
Lyon, 3MATEIS, CNRS 5510, INSA Lyon, Villeurbanne,
France
Objective(s): Given recent concern about long-term safety
of alendronate (ALN) therapy, the aim of the study was to
Figure 1
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evaluate the variations of intrinsic properties on iliac cortical
bone structural units (BSU).
Material & Methods: Biopsies were obtained in postmeno-
pausal osteoporotic (PMOP) women treated for 8±2 yrs with
ALN (n=6, age:69±2 yrs, ALNLT) and 5 age-matched untreat-
ed PMOP women. Quantitative microradiography1 of 100 μm-
thick sections from embedded bone samples allowed the mea-
surement of the degree of mineralization of bone (DMB) in 150
cortical BSUs chosen to get the widest range of DMB (95 and
55 in ALNLT and PMOP, respectively). Elastic modulus (E),
contact hardness (Hc), and the elastic and plastic energies of the
microradiographed BSUs were measured on sections using
high load (∼500mN) nanoindentation tests2,3.Mineral maturity,
crystallinity index and collagen maturity were assessed in same
BSUs using Fourier Transform InfraRed Microspectroscopy4.
Results: Mean DMB was similar between the 2 groups.
Compared to PMOP, prolonged ALN treatment was associat-
ed with lower E (-12%, p<0.0001) and Hc (-6%, p<0.05) and
higher collagen maturity (p<0.001). However, crystallinity
index, inversely proportional to crystal size/perfection, was
higher in ALNLT than in PMOP (25.29±0.76 vs. 24.78±
0.70, p<0.001), and was inversely correlated with E and Hc
(r=-0.43 and r=-0.54, p<0.001, respectively). Collagen ma-
turity was positively correlated to E and Hc in the two groups
(r ranged from 0.40-0.70, p<0.0001). Stepwise forward mul-
tiple regression including partial correlations revealed that in
ALNLT, crystallinity index had a significant entry in the defi-
nition of both E and Hc, contrary to PMOP. Treated bone was
also less able to plastically resist to deformation at constant
strain.
Conclusion(s): Long-term ALN treatment, while preserving
the whole bone strength, may alter the mineral crystallinity
and subsequently impair the mechanical behavior at BSU
level. This provides rational to include multiscale analysis
of material properties in the study of fragility associated
with prolonged bisphosphonate therapies.
References: 1.Boivin et al, Bone 43, 2008 / 2.Bala et al, J
Mech Behav BiomedMater 4, 2011 / 3.Oliver & Pharr, J Mater
Res 7, 1992 / 4.Farlay et al, J BoneMiner Metab 28:433, 2010.
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SUPPLEMENTATION IN POSTMENOPAUSAL
OSTEOPOROSIS TREATMENT: A DESCRIPTIVE
COHORT STUDY
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UMR 1033, Lyon, France
Objective(s): Adequate calcium/vitamin D supplementa-
tion should be taken in combination with antiresorptive
drugs in osteoporosis (OP) treatment. Despite existing
recommendations, supplementation appears to be insuf-
ficient. The objective of this study was to describe and
estimate co-prescription rates of calcium/vitamin D and
BMD testing among postmenopausal women initiating
an OP treatment.
Material &Methods: A retrospective cohort study in wom-
en over 50 years with an initial prescription claim for
bisphosphonates, raloxifene or strontium between May-Au-
gust 2010 was performed using a health insurance claims
database from the Rhône-Alpes area.
Results: Among 4415 women included, 77.0% had copre-
scription of calcium and/or vitamin D with initial OP treat-
ment, among which 2150 (49.7%) had both calcium/vitamin
D. A total of 23.0% of women were not supplemented. The
proportion of women with calcium and/or vitamin D (81.7%)
was significantly higher when OP treatment was a bisphosph-
onate compared to strontium (70.9%) or raloxifene (67.0%)
(p<0.05). Among women prescribed both calcium/vitamin D,
7.6% received a bisphosphonate and vitamin D±calcium
fixed-combination pack. GPs prescribed two-thirds of initial
supplementation treatment (66.9%). Whereas patients were
twice as likely to be prescribed supplementation when the
prescriber was a rheumatologist (OR=2, 95%CI=[1.57-
2.54]). A BMD test was performed in 39.5% of women before
initiating OP treatment.
Conclusion(s): Three-quarters of women initiating OP
treatment were supplemented with calcium and/or vitamin
D in agreement with current recommendations and repre-
sents a high coprescription rate.
Disclosures: The authors gratefully acknowledge the
contributions of Dr Roland Nublat and Dr Gilbert Weill,
medical officers at the French Health Insurance of the
Rhône-Alpes area.
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VITAMIN D SUPPLEMENTATION AMONG
YOUNG ADULTS WITH VITAMIN D DEFICIENCY:
A POPULATION-BASED COHORT STUDY
Pascal Caillet1, Anne Reymondier1, Véronique Ambrosi2,
Susan B Jaglal3, Anne-Marie Schott1
1Hospices Civils de Lyon, Pôle IMER, 2Direction régionale
du Service Médical de l'Assurance Maladie, Informationel,
Lyon, France, 3University of Toronto, Department of
Physical Therapy, Toronto, ON, Canada
Objective(s): Vitamin D (25(OH)D) deficiency is a world-
wide condition. Its treatment motivated elaboration of
guidelines, forged upon available study results. Although,
those results seem sometimes conflictuals and may lead
general practioners to uncertainty about guidelines validity.
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This study aims to describe how the need for supplementa-
tion is routinely addressed in middle-aged adults with good
general health status.
Material & Methods: We performed a retrospective co-
hort analysis using reimbursement data from the French
Insurance Healthcare System in the Rhône-Alpes area.
Subjects without any severe disease, aged 20-60 years
who performed a 25(OH)D assay between 1 December
2008 and 31 January 2009 were selected. Patterns of 25
(OH)D supplementation in selected patients who initiat-
ed a curative treatment after the assay were observed
through claims for pharmacy dispensation during seven
months of follow-up.
Results: 790 patients were included in the study, 80.7%
were women (n=638), mean age was 47.8 years (SD: 9.5)
and 41.5% (n=328) received 25(OH)D supplementation.
Over 116 different supplementation patterns were observed
in supplemented patients. The two most frequent (33.4%)
involved a one shot dose ranging from 100 000 to 200 000
UI of 25(OH)D3 over seven months.
Conclusion(s): Our results suggest a great variability sur-
rounding treatment of 25(OH)D deficiency in France in a
young community dwelling population. Moreover, that de-
ficiency is treated mostly in a curative way rather than
preventive way in at least one third of supplemented
patients.
P158
INITIAL RESULTS WITH ZOLEDRONIC ACID
IN A REFRACTURE PREVENTION PROGRAM
IN BRAZIL
Bernardo Stolnicki
Hospital Federal de Ipanema, PREVREFRAT Orthopaedic
Department, Rio de Janeiro, Brazil
Objective(s): To describe the initial results with the use of
zoledronic acid 5mg in PREVREFRAT (Refracture Prevention
Program).
Material & Methods: 69 patients with minimal trauma
fractures were assigned to receive yearly intravenous zole-
dronic acid at a dose of 5 mg and calcium and vitamin D
supplementation. The patients features, fractures, risk fac-
tors, associated diseases, densitometric values related to
fractures, serum vitamin D levels, adverse events and inci-
dence of new fractures are reported.
Results: 63 women and 6 men with minimal trauma frac-
tures were assigned to receive yearly intravenous zoledronic
acid at a dose of 5 mg. The main fracture was wrist fracture
(31.8%), vertebral fracture (27.5%), hip fracture (24.6%)
and other fracture (15.1%). 36% of patients had more than
one fracture. 48% of patients with non-vertebral fractures
and hip fractures had prior vertebral fracture. 45% of
patients with wrist fracture and 41% of the hip had prior
vertebral fracture. 5 patients with hip fracture had a prior
fracture of the wrist. 63.7% had no prior treatment for
osteoporosis. According to WHO criteria, 70% were classi-
fied as osteoporosis, 26% as osteopenia and 4% normal. All
fractures in the classified normal group were wrist fractures.
In osteopenia, 50% were wrist fractures and 22% were hip
fractures. 85.5% of the patients had vitamin D insufficiency
or deficiency. Two cases of flu-like (one patient did not
follow the prescription of paracetamol use) were found.
An adverse effect not directly related to zoledronic acid
use was a case of avascular necrosis of the femoral head
19 months after osteosynthesis of femoral neck fracture.
One patient had a new wrist fracture 45 days after infusion.
Conclusion(s): The high percentage of patients with hip
fractures who had previous fractures (fracture sentinel) rein-
forces that it is possible to decrease the rate of fractured
hips, showing that liaison services as PREVREFRAT are
rewarding. Despite the short follow-up, the low rate of new
fractures using a high persistence and compliance drug is
encouraging.
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COMPARISON OF ARTHROSCOPIC AND OPEN
ARTHROTOMY TREATMENT OF SEPTIC
ARTHRITIS OF THE KNEE IN THAI PATIENTS
Werasak Sutipornpalangkul, Witchate Pichaisak
Faculty of Medicine Siriraj Hospital, Mahidol University,
Department of Orthopaedic Surgery, Bangkok, Thailand
Objective(s): The aim of this study was to evaluate the
efficacy of arthroscopic debridement with that of open
arthrotomy for the treatment of septic arthritis of the knee.
Material & Methods: A retrospective study was performed
in 77 Thai patients who had been admitted and underwent
treatment with either arthroscopy debridement or open
arthrotomy in Department of Orthropaedic, Siriraj hospital
because of septic arthritis of the knee. The patient medical
records were reviewed. The demographics, underlying med-
ical condition, previous history of joint disease, clinical
presentation, laboratory and microbiological finding, length
of stay, operative detail, and postoperative complications
were compared between these two groups.
Results: Between 2002-2011, 77 patients with septic arthritis
of the knee were identified, out of which 44 patients were
underwent open arthrotomy and 33 underwent arthroscopic
debridement. No difference between two groups was observed
with regard to patients' characteristics and demographics data
(e.g., age, gender, weight, BMI, comorbidities, and pre-existing
joint disease). No differences were also observed with regard to
clinical presentation and laboratory investigations (e.g., onset,
affected knee, blood white blood cell, erythrocyte sedimenta-
tion rate, C-reactive protein, serum albumin, arthrocentesis
white blood cell, and arthrocentesis polymorphonuclear cells).
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The most common organisms were Streptococcus spp. (39%)
and Staphylococcus aureus (37%). Arthroscopic debridement
had less blood loss (p<0.01) and less postoperative complica-
tions (p<0.05) than open arthrotomy with a statistically signif-
icance, even though it was prolonged operative time (p<0.01).
However, there was no difference for the length of the hospital
stay between two groups (p>0.05).
Conclusion(s): Arthroscopic debridement is an effective
treatment for patients with septic arthritis of the knee, these
patients had less blood loss and lower complication rates than
did patients who had received open arthrotomy for treatment.
Disclosures: The authors thank the staff and surgeons of the
Siriraj Orthopedic department, Dr. Pisit Lertwanich, Dr.
Bavornrit Chuckpaiwong, Dr Ekavit Keyurapan, and Dr
Chanin Lamsam for their assistance in providing clinical data.
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ATYPICAL FEMORAL FRACTURES: FROM
THE PAIN WITHOUT FRACTURE TO THE
FRACTURE WITHOUT PAIN
Enrique Casado1, Ivonne Vázquez1, Marta Larrosa1, María
García-Manrique1, Pere Torner2, Jordi Gratacós1
1Corporació Sanitària i Universitària Parc Taulí, Rheumatology,
2Orthopaedics, Sabadell, Barcelona, Spain
Objective(s): To describe the clinical and radiological
features of patients with atypical femoral fractures diagnosed
in the last three years at the Hospital of Sabadell (Barcelona,
Spain).
Material & Methods: Descriptive study. All consecutive
patients admitted to the Orthopedics Department, Hospital
of Sabadell (reference population 400,000) from January
2008 - December 2010 were reviewed. After the confirma-
tion of an atypical fracture of the femur (major features1) the
patient clinical chart was reviewed, collecting some data
about demographics, osteoporosis treatment and phospho-
calcium metabolism parameters on admission.
Results: Eight atypical fractures of the femur in 6 patients
were registered. All patients were female. Mean age 76.7±
10.1 years (range 60-91). In all cases the fracture was
located in the femoral shaft. In two patients the fracture
was bilateral and in four patients unilateral (2 right, 2 left).
Six out of eight fractures were transverse and two were
oblique. Two patients had no previous symptoms and four
patients had previous limb pain (lasting 1-8 months). All
patients except one were receiving bisphosphonates: alendr-
onate (2 patients), ibandronate (2 patients), risedronate (1
patient). Patients under risedronate and ibandronate had
previously received other bisphosphonates for more than 7
years. The time of treatment with bisphosphonates in each
patient ranged between 3-12 years. Five patients (83%) had
hypovitaminosis D (25(OH)D <25 ng/ml), with a mean of
25(OH)D of 18±5.4 ng/ml. The only patient with normal
vitamin D levels was receiving chronic treatment with glu-
cocorticoids for pulmonary fibrosis.
Conclusion(s): Atypical fractures of the femur in our series
were located in the diaphysis and occurred in women over
60 years with hypovitaminosis D and treated with
bisphosphonates for more than 3 years. The clinical presen-
tation of these fractures was variable: some patients had an
incomplete fracture with previous limb pain and other
patients had a complete fracture without any previous
symptoms.
References: 1Shane E, Burr D, Ebeling PR, et al (2010) J
Bone Miner Res 25:2267.
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BENEFICIAL EFFECTSOF STRONTIUMRANELATE
COMPARED TO ALENDRONATE ON BONE MASS
AND STRENGTH PARAMETERS AT THE TIBIA
IN POSTMENOPAUSAL OSTEOPOROTIC WOMEN:
A 2-YEAR STUDY
Dieter Felsenberg1, Gisela Beller1, Carmelo Fiore2, George
Lyritis3, Andreas Kindmark4, Hendrikje Boerst1, Oliver
Bock1, Manfred Hartard5, Martin Runge6, Maria Luisa
Brandi7, Giuseppe Sergi8, Ingrid Bergström9
1Charite Campus Benjamin Franklin, Klinik und Poliklinik
für Radiologie und Nuklearmedizin - Zentrum für Muskel
und Knochenforschung, Berlin, Germany, 2Clinica Medica
Osp., Osp. Vittorio Emanuele, Catania, Italy, 3K.A.T
Hospital, LRMS, Kifissia, Greece, 4Uppsala University
Hospital, Medical sciences, Uppsala, Sweden, 5Centrum
für Diagnostik und Gesundheit, München, Germany,
6Aerpah-Klinik, Esslingen, Germany, 7Policlinico Careggi,
Medicina Interna, Firenze, Italy, 8Clinica Geriatrica -
Azienda ULSS n°16, Padova, Italy, 9Karolinska Universi-
tetssjukhuset Huddinge, Kliniken för Endokrinologi,
Metabolism och Diabetes, Stockholm, Sweden
Objective(s):We compared the effects of strontium ranelate
(SrRan) and alendronate (ALN) on bone mass, bone geom-
etry and bone strength measured by p-QCT in women with
postmenopausal osteoporosis.
Material & Methods: In this randomised, double-blind and
double-dummy study, 189 women were randomised to
SrRan 2 g/day or ALN 70 mg/week during 2 years. Bone
mass, geometrical and bone strength parameters were
assessed by p-QCT at the tibia and radius after 6,12,18 and
24 months of treatment in the ITT population.
Results: Baseline characteristics were similar between
groups with a mean age (±SD) of 67.6±5.7 years; L1-L4
and total hip T-scores of -3.1±0.6 and -2.0±0.8 respectively.
Over 2 years, L1-L4 BMD increased significantly by +8.5%
and total hip BMD by +5.7% in SrRan group compared with
6.8% and +2.6%, respectively, in ALN group. At the ultra-
distal tibia, total bone mineral content (BMC) increased
Osteoporos Int (2012) 23: (Suppl 2):S85–S386 S113
significantly by 3.3% and trabecular BMC by 2.3% in
SrRan group and by 1.7% and 1.3%, respectively, in ALN
group with a significant between-group difference in favor
of SrRan (p=0.001 and p=0.017). Regarding the bone
strength parameters measured at the distal tibia, the moment
of inertia (MI) and density-weighted MI increased by 1.2±
1.6% (p<0.001) and 1.7±2.1% (p<0.001), respectively, in
the SrRan group and by 0.5±1.8% (p=0.020) and 0.9±2.4%
(p=0.001) in the ALN group with a significant between-
group difference in favor of SrRan (p=0.018 and p=0.011,
respectively). Mean increases of 0.7±1.8% (p=0.003) for
the Section modulus and 1.3±2.4% (p<0.001) for Strength
Strain Index (SSI) were found in SrRan group, whereas no
change was observed in the ALN group with a significant
between-group difference in favour of SrRan (p=0.013 and
p=0.001 for section modulus and SSI, respectively). At the
radius level, no between-group differences were observed
regarding bone strength parameters, density-weighted MI
and SSI increased significantly in both groups. The two
treatments were well tolerated.
Conclusion(s): SrRan demonstrates greater effects on bone
mass and strength parameters at the tibia compared to ALN
in women with postmenopausal osteoporosis after 2-year
treatment. These findings consolidate the results of previous
studies supporting a benefit of SrRan on bone strength.
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THE ABSENCE OF THE DIAGNOSIS OF OSTEOPO-
ROSIS IN PATIENTS WITH HIP FRACTURES
DUE TO FRAGILITY
Asuncion Acosta, Berta Magallares, Montserrat Barceló,
Marta Coderch, Arturo Rodriguez de la Serna
Santa Creu i Sant Pau Hospital, Rheumatology, Barcelona,
Spain
Objective(s): The objective of this study is based on the
description of the medical features in patients with a history
of prior fracture by fragility.
Material & Methods: Description of the following varia-
bles: sex, age, prior diagnosis of osteoporosis and the pres-
ence of prior osteoporotic fractures in a population of
patients admitted to the Hospital for hip fractures from
December 2010 - November 2011.
Results: The sample includes 103 patients with an average
age of 82.43 (range: 55-93), of which 74.8% are female. 28
of 103 patients had prior diagnosis of osteoporosis, of which
one patient (3.84%) was male (P<0.001). 44 patients had a
previous fracture due to fragility (any location) and of these
23 had no previous diagnosis of osteoporosis.
Conclusion(s): 1.- Despite a history of prior fracture by
fragility (any location) only 50% of patients had been diag-
nosed of osteoporosis and 2.- of males with hip fractures
only 3.84% had a previous diagnosis of osteoporosis.
References: Cauley JA, Lui LY, Genant HK, et al
(2009) J Bone Miner Res 24:943. Klotzbuecher CM,
Ross PD, Landsman PB, Abbott TA (2000) J Bone
Miner Res 15:721.
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AGING OF ILIAC CORTICAL BONE IN NORMAL
WOMEN AND MEN
Anne-Sophie Bravo Martin1,2, Jean-Charles Giunta1,2,
Roland Chapurlat1,2, Georges Boivin1,2
1UMR 1033, INSERM, 2Equipe Qualité Osseuse et
Marqueurs Biologiques, Université de Lyon, Lyon,
France
Objective(s): In humans, bone structural changes with age
have been mainly described rather in cancellous bone than
in cortical bone (1). Thus, the aim of this study was to
evaluate, in a normal human population, the structural
changes with aging in cortical bone.
Material & Methods: Iliac bone samples were taken at
necropsy from 99 men and 68 women aged from 17-91
years, who died suddenly without apparent bone dis-
ease. This population is well distributed with similar
numbers of women before and after 50 years, and with
2/3 of men between 17 and 49 years. Undecalcified 100
μm-thick bone sections perpendicular to Haversian
canals were microradiographed (2). Cortical thickness,
cortical porosity, number of intact osteons, number of
fragments of osteons, Haversian canal diameter, cortical
mean wall thickness (MWT) and degree of mineraliza-
tion (DMB) were measured on calcified cortical bone
tissue.
Results: Cortical thickness decreases (p<0.01) and its
porosity increases (p<0.02) with age in both sexes.
These are explained by an increase of bone resorption
with time leading to enlarged cavities incompletely
refilled. The increase of cortical porosity with age can
also be partly due to an augmentation of the number of
Haversian canals in men (number of intact osteons, p<
0.05), and by the enlargement of Haversian canals in
women (p<0.01), especially after 50 years. In women,
the increase of the number of fragments of osteons (p<
0.0001), more marked from 50 years, results from in-
creased bone remodeling, leading to extension of inter-
stitial bone. To the contrary of trabecular MWT (3) but
in agreement with data on rib cortical osteons (4), iliac
cortical MWT does not change significantly with age in
men and women. Cortical DMB increases with age in
both sexes, but significantly only in men (p<0.0001).
Conclusion(s): To conclude, in women and men, aging and
unbalanced bone remodeling lead to cortical thinning, ex-
tended cortical porosity and increased amount of interstitial
bone.
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References: 1-Courpron et al. In: Meunier PJ ed., Bone
histomorphometry, 2nd Int Workshop, Lyon, 1976. 2-Boivin
and Meunier, Calcif Tissue Int 2002;70:503. 3-Lips et al,
Calcif Tissue Int 1978;26:13. 4-Frost, Calcif Tissue Res
1969;3:211.
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A NEW COLLABORATIVE ACUTE HIP UNIT
IMPROVES CARE OF OSTEOPOROSIS AND
ADHERENCE TO GUIDELINES
Abhaya Gupta, Srinivas Chenna, Alison Lorch
Glangwili Hospital, Medicine, Carmarthen, UK
Objective(s): To assess the impact of osteoporosis assess-
ment and management in a new acute hip unit. RCP and
NICE have recommended alendronic acid, calcium, vitamin
D as cost effective first line options following a fragility
fracture.
Material & Methods: A new 15 bedded ward was setup
at Glangwili Hospital Carmarthen, Wales, UK in June
2011 providing collaborative surgical and orthogeriatric
care. All hip fractures are admitted directly from Casu-
alty as fast track. A new clerking proforma, falls and
osteoporosis assessment proforma, operational policy,
protocols, evidence based osteoporosis algorithms,
standards of care (based on RCP,NICE,BOA,BGS,NOS,
NOGG,SIGN) were introduced with regular MDM meet-
ings led by orthogeriatrician and supported by Specialist
nurse.
Results:Prior to opening new Unit, UK National Hip Frac-
ture audit 2007 (joint project by BGS and BOA) showed
that only 32% patients had multifactorial risk assessment,
67% prescribed osteoporosis medications with inconsistent
approach towards investigation for secondary causes and
DXA referrals. Since June 2011, amongst 167 hip fracture
patients admitted to Acute Unit, 98% had assessment and
management of osteoporosis, all appropriate patients pre-
scribed calcium+vitamin D, majority received alendronic
acid, those <75 year age were referred for DXA scan,
majority had Bone profile test done, majority given leaflets
on osteoporosis, 1 patient noted as Bisphosphonate induced
Atypical femoral fracture.
Conclusion(s): A new acute hip fracture Orthogeriatric Unit
- first in Wales, UK, is providing ideal quality seamless care
driven by evidence based practice, to all elderly patients
hospitalised following their hip fracture in one single ward.
The Department of Health systematic prevention package
describes first objective towards Falls and Fracture preven-
tion is to improve care of hip fracture patients and this Unit
is able to achieve evidence based management of osteopo-
rosis and also comply with RCP and NICE hip fracture 2011
standards.
Disclosures: Hip fracture team
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A NEW CONSULTANT LED FRACTURE
LIAISON SERVICE
Abhaya Gupta, Alison Lorch, Srinivas Chenna
Glangwili Hospital, Medicine, Carmarthen, UK
Objective(s): Royal College of Physicians Audit have rec-
ommended nationwide Fracture Liaison services(FLS)for
secondary prevention of falls and fractures in UK. RCP
2007 Audit results locally showed only 12% had osteoporosis
assessment, 8% had DXA scan, 44% prescribed medications.
We assessed the impact of new Fracture Liaison service
started for assessment and management of osteoporosis
patients at a district hospital in Carmarthen, Wales, UK.
Material & Methods: A new secondary care service was
commenced from October 2010. Fragility fracture patients
>50 years attending A&E are proactively screened and appro-
priate patients seen in Consultant led clinic supported by spe-
cialist nurse. Referrals are also received from GPs/clinicians/
ward. Vertebral fractures are identified from hospital PACS and
advice sent to GPs. Inpatient fragility fractures are given advice
by Orthogeriatrician/specialist nurse. New treatment protocols
and available evidence based guidelines are being implemented.
Results: From October 2010 - December 2011, from 305
AE cards screened 123 were suitable for clinic. Including
referrals, total=211. Seen in clinic=110. Awaiting (40) de-
clined (47) Followed up(77). Spine PACS reports screened
(1469) advice letters to GPs sent for 156. Alendronate
calcium and vitamin D prescribed as first line for osteopo-
rosis. Other medications prescribed are strontium, risedro-
nate, zoledronate (34) denosumab (17) PTH (4). All had
standardised assessment on new proforma, written leaflets
provided, lifestyle and medication advice given.
Conclusion(s): A new and complete FLS –previously non-
existent has been established within existing resources to
close secondary fracture prevention management gap. Un-
like other FLS, this is highest quality Consultant led, uses
proactive case finding approach and fallers benefit from
orthogeriatricians expertise on comorbidity, polypharmacy.
A large inpatient and outpatient service is being provided
locally by enthusiasm, innovation and strong leadership of
Orthogeriatrician.
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FOURTEEN-MONTH CHANGES IN VOLUMETRIC
BMD OF RADIUS AND TIBIA UPON
ANTIDEPRESSANT DRUG ADMINISTRATION
IN YOUNG DEPRESSIVE PATIENTS
Laima Winterhalder1, Jolanda Widmer2, Daniel Aeberli2,
Priska Eser2, Peter Villiger2
1Private Psychiatric ClinicWyss, Psychiatrie, Münchenbuchsee,
2University Hospital, Rheumatologie of Rheumatology and
Clinical Immunology/Allergology, Bern, Switzerland
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Objective(s): Depression and using antidepressant drugs,
particularly SSRI, has been associated with lower areal
BMD at the hip and spine and increased fracture risk com-
pared to healthy controls. Most of the previous studies
included postmenopausal patients. Using pQCT, the aim of
the present study was to determine the longitudinal changes
in trabecular volumetric BMD in young depressive patients
under therapy with either SSRI vs. other antidepressants.
Material & Methods: Consecutive male and female (pre-
menopausal) patients on therapy with SSRI or non-SSRI (TCA
or NSRI) were recruited. pQCTmeasurements were performed
at baseline and after 12months at the distal 4% site of the radius
and tibia. Of the epiphyseal bone scans cross-sectional area
(CSA), total BMD and trabecular BMD (of the central 45% of
total CSA) were analysed. Diaphyseal scans at the radius and
tibia were performed at 66% from distal bone ends. From these,
cortical CSA, total bone CSA, and cortical BMD were mea-
sured. Cortical wall thickness was calculated on the basis of a
cylindric model. Reproducibility measurements resulted in a
smallest detectable difference for trabecular vBMD at the radi-
us of 4.74 mg/cm3 and of 3.92 mg/cm3 at the tibia.
Results: A total of 40 patients (34 females and 6 males)
were recruited, of whom 26 were on SSRI and 14 on non-
SSRI (TCA and SNRI) therapy. Mean age was 37 years and
mean follow-up period 13.9 months. Within the SSRI
group, none of the bone parameters changed between base-
line to follow-up measurement. Within the Non-SSRI group
trabecular vBMD increased by 1.8% at the distal radius (p=
0.021) and by 1.0% at the distal tibia (p=0.025). When
longitudinal changes were compared between the two
groups, trabecular vBMD at the distal radius and total
vBMD at the distal tibia increased significantly more in
the non-SSRI group (p=0.031 and 0.038, respectively).
Conclusion(s): This longitudinal prospective pQCT study
of the radius and tibia in young patients on antidepressant
drug therapy does not support previous findings that use of
SSRI and/or depression leads to bone loss. Under therapy
with TCA or SNRI a small increase in vBMD at the distal
radius and tibia was noted.
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ISTHEABILITYOFFRAXTOPREDICTFRACTURES
COMPARABLE IN OBESE AND NONOBESE
POSTMENOPAUSALWOMEN?
Melissa O Premaor1, Richard A Parker2, Li-Yung Lui3, Teresa
Hillier4, Kristine Ensrud5, Jane Cauley6, Juliet E Compston7
1Federal University of Santa Maria, Department of Clinical
Medicine, Santa Maria, Brazil, 2University of Cambridge,
Department of Public Health and Primary Care, Institute of
Public Health, Cambridge, UK, 3California Pacific Medical
Center Research Institute, Coordinating Center, San Fran-
cisco, CA, 4Kaiser Permanente Northwest, Center for
Health Research, Honolulu, HI, 5University of Minnesota,
Minneapolis VA Medical Center, Minneapolis, MN, 6Uni-
versity of Pittsburgh Graduate School of Public Health,
Department of Epidemiology, Pittsburgh, PA, US, 7Univer-
sity of Cambridge School of Clinical Medicine, Department
of Medicine, Cambridge, Cambridgeshire, UK
Objective(s): To compare FRAX-generated fracture proba-
bilities ability of fracture prediction between obese (BMI≥
30 kg/m2) and nonobese (BMI<30 kg/m2) postmenopausal
women in the Study of Osteoporotic Fractures (SOF) cohort.
Material & Methods: SOF is a prospective population-
based study of 9704 Caucasian older postmenopausal wom-
en followed up for a mean(SD) of 12.8(5.4) years. As
FRAX generates 10-year probabilities, the follow-up was
truncated to ten years. Data for FRAX clinical risk factors
and femoral neck BMD were available in 6252 women.
Incident fracture outcomes included hip fracture, major
osteoporotic fracture (hip, clinical vertebral, wrist, or
humerus), and any clinical fracture. Fracture probability
was estimated using FRAX. ROC curve analysis was
used to compare fracture prediction in obese and non-
obese women.
Results: 18.5% women in the cohort were obese. Incident
clinical fractures occurred during the follow-up period in
26.9% and 32.7% of obese and nonobese women, respec-
tively. FRAX-derived probabilities in women with incident
hip and major osteoporotic fractures were significantly low-
er in obese than in non-obese women (without BMD; 5.8 vs.
11.4% for hip and 17.6 vs. 23.6% for major osteoporotic
fracture p<0.0001); with BMD: 7.1 vs. 10.9% for hip and
18.2 vs. 23.3% for major osteoporotic fracture p<0.0001).
ROC analysis showed no significant differences in the abil-
ity of FRAX models without or with BMD to predict frac-
tures in obese and nonobese women (Table 1).
Table 1 Comparison of the area under the curve [AUC (95% CI)] from
receiver operating characteristic curve (ROC) for the FRAX algorithm
between obese and nonobese women
BMI<30 kg/m2 BMI≥30 kg/m2 P
FRAX algorithm not including BMD
Women with hip fractures 0.689 (0.665,0.714) 0.656 (0.587,0.725) 0.19
Women with any major
osteoporotic fracture
(hip, clinical vertebral,
wrist, and humerus)
0.630 (0.610,0.650) 0.633 (0.587,0.679) 0.13
Women with any clinical
fracture (non-vertebral
and clinical vertebral)
0.603 (0.586,0.620) 0.586 (0.547,0.624) 0.21
FRAX algorithm including BMD
Women with hip fractures 0.734 (0.711,0.757) 0.755 (0.698,0.812) 0.48
Women with any major
osteoporotic fracture
(hip, clinical vertebral,
wrist, and humerus)
0.675 (0.656,0.695) 0.696 (0.655,0.737) 0.18
Women with any clinical
fracture (non-vertebral
and clinical vertebral)
0.628 (0.611,0.645) 0.637 (0.600,0.674) 0.34
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Conclusion(s): The ability of FRAX to predict fracture in
obese postmenopausal women is similar to that in nonobese
women, although its relatively poor performance for non-
vertebral fractures indicates that addition of unmeasured risk
factors may improve prediction. Addition of BMD to FRAX
risk factors enhanced hip fracture prediction more in obese
than non-obese women, probably reflecting the differing
effect on fracture probability of BMI in the model with
and without BMD.
Disclosures: N. Réf.: JYR/11/3531/al - IOF-ECCEO12
Congress
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ASSOCIATION BETWEEN MALE OSTEOPOROSIS
AND CHRONIC PULMONARY OBSTRUCTIVE
DISEASE
Florina Livia Popa1, Mihaela Stanciu2, Adelina Banciu3,
Maria Rotaru4, Sergiu Brescan5, Ioan Gheorghe Totoian2
1Faculty of Medicine “Victor Papilian”; University “Lucian
Blaga” of Sibiu, Rehabilitation Clinic, 2Faculty of Medicine
“Victor Papilian”; University “Lucian Blaga” of Sibiu, En-
docrinology Clinic, 3Neuropsychiatric Clinical Hospital of
Sibiu, Neuropsychiatry Clinic, 4Faculty of Medicine “Victor
Papilian”; University “Lucian Blaga” of Sibiu, Dermatology
Clinic, Sibiu, Romania, 5Klinikum Ansbach, Germany, In-
ternal Medicine Clinic, Ansbach, Germany
Objective(s): The objective of this study was to analyze the
association between osteoporosis and chronic obstructive
pulmonary disease in male subjects.
Material & Methods: This prospective clinical study was
conducted in 2004-2008, on a sample of 230 men aged
between 35-85 years (mean age 66.22±11.72 years), clini-
cally and radiologic diagnosed with osteoporosis or osteo-
penia. The control group was composed of 200 men with
normal bone mass values determined by DXA method and
the evaluation of bone metabolism. The patients evaluation
consisted of: history and physical exam, simple radiographs
of dorsal and lumbar spine, measuring BMD of lumbar
spine and hip by DXA, common biochemical investigations,
evaluation of phosphocalcic metabolism, spirometry.
Results: Chronic obstructive pulmonary disease (COPD) was
observed in 15.65% of men (36 cases) from the study group
and 10 cases from the control group (5.0%) (p=0.000, OR=
3.5, 95%CI=1.7-7.3). In the study group obstructive ventilato-
ry dysfunction was moderate in 83.33% of patients and easy in
rest. In the control group all COPD cases had an easy ventilator
dysfunction. In the study group 11.11% of COPD patients were
underweight. It is known that this condition causes a decrease
in fat mass and BMD. Most subjects (55.55%) were normal
weight, 27.77% overweight and 5.55%were obese. Mean BMI
calculated in men with COPD in the study group was 23.86±
3.68, and in those without COPD 26.11±4.16 (p=0.003).
Osteoporotic vertebral fractures were found only in men
with moderate ventilatory dysfunction, with an incidence
of 55.55%.
Conclusion(s): COPD can be considered as a risk factor for
male osteoporosis. Osteoporotic vertebral fractures were
frequently observed in men with obstructive ventilatory
dysfunction. The study revealed that there is a close associ-
ation between the severity of COPD and FV.
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THE POSITIVE ASSOCIATION OF LIGNAN AND
FLAVONOID INTAKES WITH BONE MINERAL
DENSITY (BMD) INMEN FROM SOUTHERN CHINA
Elaine YN Cheung1, Ching-Lung Cheung2, Shivani Sahni3,
Annie WC Kung2, Kathryn CB Tan2
1United Christian Hospital, Department of Medicine, Hong
Kong, 2The University of Hong Kong, Department of
Medicine, Hong Kong, 3Hebrew Senior Life and Harvard
Medical School, Institute for Aging Research, Boston, US
Objective(s): There have been promising data showing that
phytoestrogens may prevent bone loss in postmenopausal
women. However there has been little data on the skeletal
effect of specific phytoestrogens among young men and
premenopausal women. The purpose of this study was to
examine the relationship between phytoestrogens intake
(isoflavones, coumestrol, flavonoids and lignans) and
BMD at femoral neck and spine in a cohort of Southern
Chinese young men and women.
Material &Methods: The participants of this cross-sectional
study included 386 Southern Chinese men and 957 women
aged 20-39 years. Linear regression analysis was used to
examine the association between phytoestrogens intake (as
continuous variable) adjusting for age, BMI, calcium intake,
smoking and drinking history, number of pregnancy (for
women), educational and exercise level, serum estradiol (for
women and men) or testosterone (for men) level. Analysis of
covariance was used to test for a linear trend across sex-
specific tertiles of phytoestrogens intake.
Results: The findings from linear regression and ANCOVA
were in agreement with each other. In particular, dietary lignan
intake (β=0.093; p=0.009) and flavonoid intake (β=0.075;
p=0.035) were significantly associated with lumbar spine
BMD in young men. Interestingly, isoflavone intake was neg-
atively associated (β=-0.024; p=0.011) with BMD at the
lumbar spine in young men. Lignan intake was further associ-
ated with BMD at femoral neck (p=0.04) in young men.
However, only marginally significant associations were ob-
served for lignan and flavonoid intake in women (P range:
0.062-0.093).
Conclusion(s): Our study showed positive associations be-
tween specific phytoestrogens intake and BMD in Southern
Chinese young men.
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MANAGEMENT OF HIPAND KNEE
OSTEOARTHRITIS (OA) IN ELDERLY PATIENTS
BY FRENCH RHEUMATOLOGISTS (RHS) AND
GENERAL PRACTITIONERS (GPS) (GERIAS STUDY)
Renee-Liliane Dreiser1, Benjamin Avio2
1Bichat Hospital, Rheumatology, 2Pharmacyst, Pharmacology,
Paris, France
Objective(s): To know decisions criteria and habits of pre-
scription in the management of OA of the lower limbs in
elderly population by RHs and GPs in France.
Material & Methods: Observational descriptive study, 113
French RHs and 583 GPs participating in different con-
gresses were asked to fulfil a questionnaire.
Results: The clinicians participating were 59% for GPs and
41% for RHs.
– 29% of patients seen by week with OA of lower limbs
are older than 85 years old. Knee OA is twice more
frequent than Hip OA. In these old people, GPs and
RHs quite always prescribe analgesics of level I (97%
and 100%) or of level II (91% and 99%).
– Theusual dosage of paracetamol prescribed is 3 g/d butwhen
necessary 34% of GPs and 24% of RHs prescribe 4 g/d.
– GPs and RHs also prescribe NSAIDS in case of failure of
analgesics of level I or II (74% and 75% of GPs; 54% and
83% of RHs). But they are only 39% for GPs and 24% for
RHs to start by NSAIDS before analgesics of level II.
– When practioners use NSAIDS, 88% of RHs always as-
sociate proton pomp inhibitors (PPI) but only 70% of GPs.
– SYSADOA are majorally prescribed by GPs and RHs a
part from flares (79% GPs, 94% Rhs) and quite 1/2 GPs
and 1/3 RHs also use them during flare.
– 60% of GPs send their older patients (≥ 75 y.) to the
rheumatologists for an intra-articular injection of hya-
luronic acid (86%) or corticoids (80%).
Conclusion(s): For both RHs and GPs the prescribing hab-
its are very close, the RHs generally prescribes higher dos-
age of paracetamol than GPs, they systematically use a PPI
compared to the GPs, for both prescribing drugs for OA in
elderly need special cautions especially with NSAIDs.
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SYSTEMIC TREATMENT WITH STRONTIUM
RANELATE ACCELERATES THE FILLING OFA
CRITICAL SIZE BONE DEFECT AND IMPROVES
THE INTRINSICQUALITYOFTHEHEALINGBONE
Giovanna Zacchetti, René Rizzoli, Patrick Ammann
Geneva University Hospital and Faculty of Medicine,
Division of Bone Diseases, Department of Rehabilitation
and Geriatrics, Geneva, Switzerland
Objective(s): Rapid bone defect filling with normal bone is
challenging in orthopedics and dentistry. Systemic treatment
with antiosteoporotic agents able to stimulate bone formation
may be useful. Strontium ranelate (SrRan), shown to decrease
bone resorption maintaining a high bone formation, represents
a potential agent able to stimulate bone defect filling.
Material & Methods: We set up a model of critical bone
defect in rat proximal tibia. Drilling of 2.5 mm diameter was
created in the secondary spongiosa of 6 month-old female
rats orally given SrRan (625 mg/kg/d, 5/7 days) or vehicle
for 4, 8 or 12 weeks (10 rats per group and per time point),
starting at the moment of surgery. The tibias were removed
and a region encompassing the bone defect was selected and
analyzed by μCT. To assess the material level properties of
the healing bone, the same tibias were then embedded in
methyl methacrylate and nanoindentation analysis was per-
formed across the defect (wet conditions).
Results: μCT analysis showed that SrRan treatment
significantly increased BV/TV and Tb.Th., and decreased
SMI of trabecular bone growing into the defect after 8 (3.4-,
1.3- and 0.6-fold, respectively) and 12 weeks (2.7-, 1.3-,
0.7-fold, respectively) of treatment vs. vehicle. Moreover,
SrRan treatment accelerated the growth of cortical bone over
the defect but with different kinetics vs. trabecular bone, as
effects were already significant after 4 weeks (1.6-fold vs.
vehicle). Nanoindentation analysis showed that SrRan treat-
ment significantly increased elastic modulus, hardness and
working energy both of trabecular bone growing from the
defect limit and cortical bone filling up the defect vs. vehicle,
from 4weeks (trabecular bone: 1.3-, 1.3-, 1.2-fold, respectively;
cortical bone: 1.4-, 1.4-, 1.3-fold, respectively).
Conclusion(s): We showed that SrRan accelerates bone
defect filling, improving firstly cortical and secondly trabec-
ular bone microarchitecture. In addition SrRan rapidly and
positively influences the quality of bone tissue healing in the
defect (both in trabecular and cortical compartments), by
increasing its capacity to withstand a plastic deformation.
SrRan thus represents a potential intervention to accelerate
and enhance the bone defect filling, with potential advan-
tages in dental or orthopedic surgery for bone healing after
tooth extraction or for implant osseointegration.
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BONE-SPECIFIC EPHB4 OVEREXPRESSION
PROTECTS CARTILAGE DURING
OSTEOARTHRITIS
Gladys Valverde-Franco1, David Hum1, Koichi Matsuo2,
Bertrand Lussier3, Jean-Pierre Pelletier1, Mohit Kapoor1,
Johanne Martel-Pelletier1
1University ofMontreal Hospital Research Centre (CRCHUM),
Notre-Dame Hospital, Osteoarthritis Research Unit, Montreal,
QC, Canada, 2School of Medicine, Keio University, Laboratory
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of Cell and Tissue Biology, Tokyo, Japan, 3University of
Montreal, Faculty of Veterinary Medicine, Clinical Sciences,
St-Hyacinthe, QC, Canada
Objective(s): Our in vitro studies[1,2] suggest that members
of the ephrin system, the ephrin-B2 ligand and its specific
receptor ephrin B4 (EphB4), positively impact the abnormal
metabolism of human OA subchondral bone osteoblasts and
chondrocytes. We evaluated the in vivo role of EphB4 in the
pathogenesis of OA, using bone-specific EphB4 overex-
pressing (TgEphB4) mice.
Material & Methods: The TgEphB4was confirmed by PCR
and Western blotting. Morphometry, morphological and ra-
diological evaluations were performed. OA was surgically
induced in 10-week-old male TgEphB4 and wildtype (WT)
mice by destabilization of the medial meniscus (DMM), and
medial compartment evaluations of cartilage performed using
histological and immunohistological means, and of subchon-
dral bone properties using histomorphometric and μCT.
Results: There was no gross phenotypic difference in bone
development between TgEphB4 and WT mice evaluated on
postnatal day 5 (P5) and 10 weeks. Histological evaluation at
8 and 12 weeks post-OA surgery revealed that TgEphB4 mice
had significantly less cartilage alteration than the WT mice in
both medial tibial plateau and femoral condyle. This was asso-
ciated with a significant reduction in both medial compartments
of operated TgEphB4 of aggrecan degradation products and
type X collagen. Type II collagen degradation products
and collagen fibril disorganization were also significantly
reduced in operated TgEphB4 compared to WT mice, but
only in the medial tibial plateau. The medial tibial plateau
subchondral bone demonstrated at both times post-surgery
that, compared to the WT, TgEphB4 mice had less joint
space narrowing, and significant reduction in sclerotic
subchondral bone, bone volume, and trabecular thickness.
Conclusion(s): This is the first in vivo evidence showing that
bone-specific EphB4 overexpression exerts a protective effect
on OA articular structural changes. This study first supports the
notion that this system could be targeted as a specific thera-
peutic approach for OA and, secondly, demonstrates that dur-
ing the OA process, the in vivo integrity of the overlying
articular cartilage is related to the subchondral bone properties.
References: [1] Kwan Tat S, et al. Arthritis Rheum
2008;58:3820. [2] Kwan Tat S, et al. Arthritis Res Ther
2009;11:R119.
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OSTEOPATHY IN ADULT PATIENTS WITH
β-THALASSAEMIA MAJOR
Marina Baldini1, Stella Forti2, Alessandra Orsatti3, Fabio
Massimo Ulivieri4, Lorena Airaghi5, Laura Zanaboni1,
Maria Domenica Cappellini1
1U.O. Medicina Interna 1 A, Fondazione IRCCS Ospedale
Maggiore Policlinico, Medicina Interna, 2U.O. Audiologia,
Fondazione IRCCS Ospedale Maggiore Policlinico, Neuro-
scienze, 3Università degli Studi di Milano, Fondazione
IRCCS Ospedale Maggiore Policlinico, Medicina Interna,
4Nuclear Medicine, Bone Metabolic Unit, Fondazione
IRCCS Ospedale Maggiore Policlinico, Servizi Diagnostici,
5U.O. Medicina Interna 1B, Fondazione IRCCS Ospedale
Maggiore Policlinico, Medicina Interna, Milan, Italy
Objective(s): Despite the major advances in diagnosis and
treatment of thalassemia major, bone demineralization is
still a common finding, even in optimally treated patients;
etiology is complex and incompletely known. We present
the preliminary data of a case-control study aiming to detect
the distinctive characteristics of thalassemic patients with
and without osteopathy and discover protective features,
tackling the problem from an innovative perspective.
Material & Methods: 30 thalassemic patients (pts) followed-
up at the Hereditary Anaemia Center of Fondazione Cà Granda
Policlinico ofMilan were enrolled; 15 pts (7males, 18 females,
33±6 years) had normal bone mineralization at DXA and 15
pts (7 males, 18 females, 33±7 years) presented osteoporosis
both at femur and lumbar spine. The groups were matched for
physical and hematological characteristics (gender, BMI, age
at first transfusion, serum ferritin, pretransfusional hemoglobin
levels); endocrinopathies were optimally corrected when pres-
ent. Statistical analysis was performed by Mann-Whitney,
McNemar and Mantel-Haenszel tests as indicated (p<0.05).
Results: The statistical comparison of the two groups of
thalassemic patients with and without osteopathy showed
significantly different serum concentrations of IGF-1 (133±
56 vs. 102±62 μg/l). Further, comparing the numbers of
patients with endocrine complications in the groups, a pro-
tective role of normal gonadic function against osteoporosis
emerged, and a similar influence of hypoparathyroidism.
Number (%) of patients with endocrine complications in the 2 groups
Patients without
osteopathy
Patients with
osteopathy
p
Hypoparathyroidism 6 (40) 2 (13) 0.04
Hypogonadism 9 (60) 13 (86) 0.02
Treatment-corrected hypothyroidism and diabetes did not
affect bone mineralization in this series.
Conclusion(s): Our study confirms the crucial role of endo-
crine complications in thalassemic osteopathy, confirming the
need for early and multi-disciplinary preventive intervention.
References: Vogiatzi MG et al (2009) J Bone Miner Res
24:543. Voskaridou E, Terpos E (2008) Pediatr Endocrinol
Rev 6(Suppl 1):86. Angelopoulos NG et al (2006) J Bone
Miner Metab 24:138
.
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THE EFFECT OF PHYSICAL EXERCISE ON
THORACIC HYPERKYPHOSIS IN OSTEOPOROTIC
ELDERLY WOMEN
Daniela CC Abreu, Mariana S Matos, Gustavo C Costa,
Deborah C Trevisan, Júlia G Reis
University of Sao Paulo, Biomechanics, Medicine and
Rehabilitation of Locomotor System, Sao Paulo, Brazil
Objective(s): To evaluate the effect of 3 months of muscle
strengthening training on degree of thoracic kyphosis in
osteoporotic (T-score<- 2.5 DP) women.
Material & Methods: 20 elderly women with osteoporosis
were divided into: Group 1 (n=10) women who performed
physical exercises and Group 2 (n=10) who did not perform
physical exercise. The thoracic kyphosis was evaluated by the
flexicurve method, which employs a flexible ruler to measure
the spine curvature in the sagittal plane. The flexible ruler is
shaped along the patient's back in the format of the kyphotic
curvature from spinal process C7 to T12. The flexicurve was
removed and placed on a graph paper so that the curvature
moulded on the flexible ruler could be transcribed. A straight
line (X-total) was traced from C7 to T12. A straight line
(called H) to determine the largest distance between curve
and X-total and another (X-middle) between T12 and the
point where H touches X-total were traced. To calculate the
angle of thoracic kyphosis, the values obtained were entered
into Microsoft Excel spreadsheet and then converted by a
third-degree polynomial function. Women from Group 1
performed muscular strengthening exercises twice a week
for 3 months, which consisted of warm-up, stretching, and
strengthening of quadriceps, ischiotibial, triceps surae, para-
vertebral, and abdominal muscles. The evaluation was per-
formed at the beginning of the study and after 3 months.
Results: Group 1 showed no significant difference in the
degree of thoracic kyphosis after 3 months of exercise (p>
0.36). However, group2 had a significant increase in the
degree of thoracic kyphosis (p<0.01) after the same period.
Conclusion(s): The exercise was effective in the mainte-
nance of the degree of thoracic kyphosis in osteoporotic
women.
Disclosures: The authors would like to thank the Research
Foundation of São Paulo (FAPESP, #2007/54596-0; #2007/
57685-4) for the support provided.
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HEALTHCARE UTILIZATION AND COSTS
AMONG PATIENTS WITH HIP FRACTURE
IN THE UNITED STATES
Yang Zhao1, Shih-Yin Chen2, Yuan-Chi Lee2, Ning Wu2
1Eli Lilly and Company, Global Health Outcomes, Indianapolis,
IN, 2United BioSource Corporation, Economic Analysis &
Solutions, Lexington, MA, US
Objective(s): To examine the demographics, clinical char-
acteristics, and healthcare utilization and costs among
patients with hip fractures in the United States.
Material & Methods: Medical and pharmacy claims
from a large US population with commercial insurance
(working adults and their dependents) or Medicare sup-
plemental insurance (elderly aged 65+) were analyzed
to identify patients aged 50+ who were hospitalized for
hip fracture (first hospitalization denoted as the index
stay) between 1/1/2006-9/30/2009. All patients selected
had continuous enrolment during the 12 months prior
to and after the index stay. Demographics, comorbid
medical conditions, and characteristics of the index stay
were summarized. Healthcare utilization and costs over
the 12 months pre- and post-index stay were also
examined.
Results: The study included 26,122 Medicare (mean
age: 82.3; 72.8% females) and 5100 commercially-in-
sured (mean age: 58.3; 61.9% female) patients who
were hospitalized for hip fracture. For both the Medi-
care and commercially insured patients, the most com-
mon comorbid medical conditions were hypertension
(49.6% and 38.3%), osteoarthritis (21.9% and 23.1%),
and diabetes (18.4% and 20.0%). The average length of
the index stay was 6.0 days (SD: 5.4) with an average
cost of $19,488 (SD: 21,120) for the Medicare patients;
the numbers for the commercially insured were 6.5 days
(SD: 6.5) and $31,335 (SD: 40,585). Many of the
Medicare and commercially insured patients were dis-
charged to home (34.3% and 60.8%), or a skilled nurs-
ing facility (SNF; 28.2% and 13.1%). During the 12
months after the index stay, 64.9% of the Medicare
patients had any SNF stay and 24.1% received physical
therapy (PT), while the frequency of use was reversed
for the commercially insured patients (PT: 62.0%; SNF:
24.4%). For both populations, the average healthcare
costs increased from the 12 months pre- to the post-
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index stay (Medicare: from $15,896 to $31,205; com-
mercially insured: from $27,236 to $42,961).
Conclusion(s): Among the Medicare or commercially
insured patients in the US, hip fracture is associated
with significant healthcare resource utilization and
costs.
Disclosures: This study was funded by Eli Lilly.
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ACCUMULATION OF METABOLIC RISK FACTORS
SUCH AS OVERWEIGHT, HYPERTENSION,
DYSLIPIDEMIA, AND IMPAIRED GLUCOSE
TOLERANCE RAISES THE RISK OF OCCURRENCE
AND PROGRESSION OF KNEE OSTEOARTHRITIS:
A 3-YEAR FOLLOW-UP OF THE ROAD STUDY
Noriko Yoshimura1, Shigeyuki Muraki2, Hiroyuki Oka1,
Hiroshi Kawaguchi3, Kozo Nakamura4, Toru Akune2
122nd Century Medical and Research Center, The University
of Tokyo, Department of Joint Disease Research, Tokyo,
222nd Century Medical and Research Center, The University
of Tokyo, Department of Clinical Motor System Medicine,
Tokyo, 3The University of Tokyo, Department of Orthopaedic
Surgery, Tokyo, 4National Rehabilitation Center for Persons
with Disabilities, Rehabilitation Services Bureau, Tokoro-
zawa, Saitama, Japan
Objective(s): To clarify the association between the occur-
rence and progression of knee osteoarthritis (KOA) with
components of metabolic syndrome (MS), including over-
weight (OW), hypertension (HT), dyslipidemia (DL), and
impaired glucose tolerance (IGT), using a large-scale popu-
lation cohort entitled ROAD (Research on Osteoarthritis/
osteoporosis Against Disability).
Material & Methods: Among 1690 participants (596 men,
1094 women; mean age 65.2 years old, range 23-94 years)
in mountain and seaside areas from the baseline ROAD
study recruited in 2005-2007, 1384 individuals (81.9%;
466 men, 918 women) completed the second survey includ-
ing knee radiography 3 years later. KOA was defined as
Kellgren-Lawrence (KL) grade ≥2 using paired X-ray films.
Based on changes in KL grades between the baseline and
second survey, cumulative incidence and progression of
KOA were determined. OW, HT, DL, and IGT at baseline
were assessed using standard criteria.
Results: The cumulative incidence of KOA among the 1384
completers over 3 years for the age groups ≤39, 40-49, 50-
59, 60-69, 70-79, and ≥80 years was 0.0%, 0.8%, 6.9%,
13.2%, 17.6%, and 25.0%, respectively. Progression in the
KL grades for either knee over 3 years was observed in
5.1%, 5.2%, 15.1%, 26.5%, 32.3%, and 49.4% of the par-
ticipants in these age groups, respectively. Logistic regres-
sion analyses after adjusting for age, gender, regional
differences, smoking, alcohol consumption, regular
exercise, and past history of knee injuries revealed that the
odds ratio (OR) for the occurrence of KOA significantly
increased according to the number of MS components present
(vs. no component; 1 component: OR 2.20; 2 components:
OR 2.84; 3 or more components: OR 9.95). Similarly, the
logistic regression analysis adjusted for the above variables
showed that the OR for progression of KOA in either knee
also significantly increased according to the number of MS
components present (vs. no component; 1 component: OR
1.38; 2 components: OR 2.31; 3 or more components: OR
2.79).
Conclusion(s): Accumulation of MS components is signif-
icantly related to both occurrence and progression of KOA.
MS prevention may be useful in reducing future KOA risk.
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REFERENCE INTERVALS FOR SERUM N-MID
OSTEOCALCIN CONCENTRATION MEASURED
WITH THE IDS-ISYS AUTOMATED SYSTEM
Anke Hannemann1, Nele Friedrich1, Christin Spielhagen1,
Rainer Rettig2, Matthias Nauck1, Henri Wallaschofski1
1Ernst-Moritz-Arndt University Greifswald, Institute of
Clinical Chemistry and Laboratory Medicine, 2Ernst-Moritz-
Arndt University Greifswald, Institute of Physiology,
Greifswald, Germany
Objective(s): Osteocalcin (OC) is a bone-specific protein
produced primarily by osteoblasts during bone formation.
The OC concentration is used to assess fracture risk and
monitor treatment of osteoporosis and other disorders of bone
metabolism. To adequately interpret the OC concentration, it
is necessary to calculate reference ranges from a healthy
reference population, adapted to a specific laboratory method.
Material & Methods: We established a healthy reference
population from the participants of the first follow-up of the
Study of Health in Pomerania. Serum OC concentrations
were measured from frozen aliquots with the IDS-iSYS N-
Mid Osteocalcin assay on the IDS-iSYS Automated System
(Immunodiagnostic Systems, Frankfurt am Main, Ger-
many). The coefficients of variation were 6.98% at low,
6.44% at medium, and 5.44% at high levels of control
material. The reference interval was defined as the central
95% range between the 2.5th and the 97.5th percentile. Age-
specific reference intervals were calculated for men aged 25-
80 years and for premenopausal women aged 25-54 years by
means of quantile regression. As in postmenopausal women
aged 50-80 years OC was not influenced by age, we calcu-
lated an age-independent reference interval.
Results: Median (1st-3 rd quartile) OC concentrations were
15.4 ng/ml (12.0-19.5 ng/ml) in 1119 men, 14.4 ng/ml (11.3-
18.5 ng/ml) in 545 premenopausal women, and 18.7 ng/ml
(13.7-25.6 ng/ml) in 502 postmenopausal women. Median OC
concentrations were highest in 25-29 year-old men and women,
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were stable during the middle ages, and rose again after 65 years
of age inmen, and at transition to postmenopause inwomen.We
observed that subjects with type 2 diabetes, intake of oral contra-
ceptives or hormone replacement therapy had lower OC con-
centrations than subjects without these conditions.
Conclusion(s): We present sex-specific reference intervals
for the serum OC concentration over a broad range of age
groups to assess bone metabolism.
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OSTEOPOROSIS IN HAEMOGLOBINOPATHIES
Teuta Cico Backa1, Sajmir Kullolli2, Manika Kreka3, Ilda
Harizi2, Elizama Petrela1, Anila Godo3, Eleni Anastasi3,
Jorida Zoga3, Evis Skuqi1, Alma Miloti1
1University Hospital Center "Mother Theresa", Rheumatol-
ogy Service, 2Harrison Diagnostic Center, Research, 3Uni-
versity Hospital Center "Mother Theresa", Haematology
Pediatric Service, Tirana, Albania
Objective(s): Estimation of the osteoporosis in haemoglobi-
nopathies.
Material & Methods: In the study were included patients
diagnosed with haemoglobinopathies, sickle cell, thalasse-
mia and sickle cell, and thalassemia, in the Diagnostic
Center Harrison. All patients were doing blood tests and
all parameters have been evaluated. DXA (osteodensitome-
tria) examination was performed to all patients.
Results: We studied 113 patients with haemoglobinopathies,
during the period May-November 2011. Eighteen of them were
diagnosed with sickle cell with mean age 12.6±4.9 years, 86
patients with thalassemia (mean age 15.6±7.8 years) and with
nine patients diagnosed with thalassemia & sickle cell (mean age
of 9.6±6.5 years). From theDXAexamination, 13.2%of patients
were diagnosed with osteoporosis, 33.8% of patients were diag-
nosed with osteopenia and 52.9% of patients were resulted as
normal. We found a statistically significant correlation between
osteopenia and thalassemia (p=0.031). Through the coefficient of
correlation of Kendal's, about all factors analyzed, it was found
that there was a significant correlation between osteoporosis and
treatment with cortisone for some time (p=0.006); between
osteoporosis and the presence of any fracture to people them-
selves (p=0.012) or their relatives (p=0.001), between osteopo-
rosis and if patients refer to have lost length in recent years (p=
0.002), and between osteoporosis and if the patients declared to
have a family history for osteoporosis (p=0.012). Through binary
logistic regression, it was found that people who take cortisone
over three months are 6 times more likely (OR: 6.25, 95% CI:
1.99-8.46) than those not receiving cortisone to suffer from
osteoporosis, those who have lost length in recent years are 2
timesmore likely (OR: 2.15, 95%CI: 1:20 to 4:13) to suffer from
osteoporosis, than those who have not lost a length.
Conclusion(s): Osteoporosis may affects patients with all
types of haemoglobonopathies at all ages.
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DRESS STYLE OF WOMEN AND VITAMIN D3
STATUS IN THE SUNNY UAE
Haider M Al Attia1, Mazin A Ibrahim2
1Al Noor Hospital, Rheumatology, 2Al Noor Hospital,
Internal Medicine, Abu Dhabi, United Arab Emirates
Objective(s): To determine the level of 25(OH) D in cohorts
of women with varying dressing style in the sunny UAE.
Material & Methods: 252 women were assayed for total
25-OH vit D (25-OH)D. None was on vitamin D supple-
ment. 96 were fully covered and veiled (Group 1), 104
covered but face exposed (Group 2) and 52 Western-dressed
women (Group 3). Age ranged from 15-87 years. 85% were
Middle Eastern and North African individuals. The rest
were heterogeneous. 51 and 68 in group 1& 2 indicated
their adherence to the dressing style for a mean of 24.1±
15.6 and 20.5±10.3 years, respectively, p=0.14. Group 3
lived in UAE for >2 years.
Results: Hypovitaminosis D (0-30 ng/ml) and the mean of 25
OH D were 90.5%, 94% and 82.5% and 19.4±7.85, 17.4±8.26
and 22.4±12.8 ng/ml in the three groups, respectively. Significant
differences were present between the prevalence of hypovitami-
nosisD and themean of 25OHDof group 2&3 (94%vs. 82.5%,
p=0.03 and 17.4±8.26 vs. 22.4±12.8 ng/ml, p=0.003). Values of
deficient D3 (12 ng/ml) were observed in 11 (11.5%), 22 (21%)
and 6 (11.5%) in the 3 groups respectively, p=NS. Those who
indicated the longevity of dressing style in group 2 had a mean of
25 (OH)D 16.6±5.1 vs. 19.9±7.95 ng/ml in group 1, p=0.008.
Conclusion(s): Hypovitaminosis D3 was highly prevalent
in those women with diverse demography irrespective to the
dressing style. The highest was surprisingly in covered but
face-exposed women. Western dressed women remained
vitamin insufficient but had significantly higher level as
compared to the covered but face-exposed women. The
outcome invites further work to determine the background
of the problem considering the women all reside in a year-
round sunny environment. For us there is more to the
problem of hypovitaminosis D in women in this community
than just a simple pattern and longevity of dressing style.
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REDUCED CORTICALTHICKNESS IN
DAUGHTERS OF WOMENWITH
OSTEOPOROTIC FRACTURES –
THE MODAM STUDY
Hoda Nagy, Stéphanie Boutroy, Elisabeth Sornay-Rendu,
Nicolas Vilayphiou, Roland Chapurlat, Pawel Szulc
INSERM UMR 1033, University of Lyon, Epidemiology of
Osteoporosis, Lyon, France
Objective(s): Daughters of women with fragility fractures had
lower areal BMD (aBMD) compared with daughters of women
without fractures. However, morphological basis underlying
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this difference is not known. We compared aBMD, bone size
and bone microarchitecture at the distal radius and tibia
assessed by HR-pQCT in women according to the fracture
status of their mothers.
Material & Methods: This study was performed on 156
women aged 47±10whosemothers sustained fragility fractures
and 240 women aged 41±11 whose mothers never sustained
fragility fracture. Bone architecture and volumetric density
(vBMD) were assessed at the distal radius and tibia using
HR-pQCT (Xtreme CT Scanco). Areal BMD was measured
at the spine, hip, and distal radius by DXA (Hologic 4500).
Results: Mothers who sustained fractures had lower aBMD
and impaired bone microarchitecture compared with mothers
without fracture. Women whose mothers sustained a fracture
had lower aBMD at the total hip (-3.2%) and mid-distal radius
(-2.8%) than women whose mothers never sustained fragility
fracture. Both the differences remained significant (p<0.05)
after adjustment for age, weight, height, menopausal status
and smoking. Women whose mothers sustained fragility frac-
tures had lower total vBMD at the distal radius (-5.5%, -0.29
SD) and distal tibia (-7.6%, -0.42 SD) compared with women
whose mothers did not sustain fractures. Differences remained
significant in the multivariable models (p<0.05 and p=0.002).
The daughters had lower cortical thickness and area at the distal
radius (-6.2%, -0.29 SD and -5.2%, -0.29 SD) and distal tibia
(-6.7%, -0.35 SD and -6.3%, -0.38 SD). The differences
remained significant in the multivariable models (radius: p<
0.05, tibia: p<0.005).Womenwhosemothers sustained fractures
had lower trabecular vBMD at the distal tibia (-6.8%, -0.32 SD,
p<0.01) with a more spaced and heterogeneous trabecular net-
work (p<0.03). Bone cross-sectional area did not differ between
the daughters according to their mothers' fracture status (p>0.4).
Conclusion(s): Daughters of women with fragility fractures
had lower cortical thickness and area at the distal radius and
tibia as well as lower aBMD at the hip and radius compared
with daughters of women who never sustained fragility
fracture. Our data strengthen the hypothesis of the genetic
determinism of bone microarchitecture in women.
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DURATION OF EXCESS MORTALITY AFTER HIP
FRACTURES IN OSLO, NORWAY: A LONG TERM
FOLLOW UP
Trine E Finnes1,2, Haakon E Meyer3,4, Jan A Falch3, Asle W
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Hamar, 2University of Oslo, Faculty of Medicine, Oslo,
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Objective(s): The aims of the studywere to estimate the duration
of excessmortality following hip fractures, and to investigate if the
duration has changed over the past decades in Oslo, Norway.
Material & Methods: Hip fracture patients identified in
previous incidence studies from three decades (1978/79,
1988/89, and 1996/97) in Oslo, were followed with respect to
all causes of mortality until 31.12.2007. Age- and sex-specific
mortality rates for the general population of Oslo from 1978-
2007 were provided by Statistics Norway. Expected survival
curves stratified for sex and predefined age groups were esti-
mated for each of the three cohorts. Time framed Kaplan-Meier
curves for 5 years intervals were compared with the
corresponding expected survival curves. Where the observed
curves started to parallel the expected curves, additional curves
for five- and one-year survival were made to judge when
mortality in hip fracture patients became the same as in the
background population. One sample log rank tests were used to
test for differences between the observed and expected curves.
Analyses were performed using SPSS 14.0 and R 2.10.1.
Results: The longest duration of excess mortality was observed
in women aged 65-84 years (Table), and lasted 22 years in
the1978-79 cohort. In contrast, the duration of excess mortality
lasted for only three years for women aged >85 years in the
1978-79 cohort. Men had all over a shorter duration of excess
mortality thanwomen. Except for in women aged >85, there was
a trend towards a shortening of the period with excess mortality.
Duration of excess mortality according to sex, age-group, and cohort
Sex Age-group,
years
Cohort n Duration of excess
mortality, years
Men 50-64 78/79 74 6
88/89 63 9
96/97 22 3
65-84 78/79 281 151
88/89 363 11
96/97 170 102
≥ 85 78/79 62 3
88/89 120 4
96/97 87 2
Women 50-64 78/79 180 17
88/89 107 12
96/97 38 9
65-84 78/79 1041 22
88/89 1243 14
96/97 549 10
≥ 85 78/79 299 3
88/89 723 7
96/97 388 8
1 Further analysis not possible due to few patients left. 2 End of follow up
at 10.7 years1
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Conclusion(s): A trend towards shorter duration of excess
mortality during the decades was observed. However, the
excess mortality after hip fracture still lasts for up to 10
years in hip fracture patients aged 65-85. Studies focusing
on modifiable risk factors for mortality after hip fractures
are warranted.
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VITAMIN D [(25 –OH) D] STATUS IN ABU DHABI:
IS THE WIDE SCREENING NEEDED?
Haider M Al Attia
Al Noor Hospital, Internal Medicine, Rheumatology, Abu
Dhabi, United Arab Emirates
Objective(s): To determine the status of 25 OH vitamin D in
patients assayed for the vitamin in Abu Dhabi.
Material & Methods: A review of 25 OH D records of
individuals living in Abu Dhabi who were screened in a hos-
pital in the first quarter of the year 2011. Hypovitaminosis D
was either deficiency (<12 ng/ml) or insufficiency (12-30 ng/
ml). The samples belonged to 587 individuals with age range
between 4 months to 81 years. 522 (89%) were Arabs. The rest
were heterogeneous individuals. 412 (72.5%) were females.
Results: 474 (80.5%) had hypovitaminosis D; 439 (74.5%)
were insufficient and 35(6%) were deficient. The prevalence
of each was statistically insignificant. Hypovitaminosis D was
determined in 135 males (77%) and in 339 females (82.5%).
The mean value of 25 OH D in the females was significantly
lower to that in males (18.9±5.13 vs. 20.7±5.07 ng/ml,
p=0.005). In pediatric males (<13 yrs), 25 (59.5%) had
hypovitaminosis vs.17 (41.5%) of sufficient level, p=0.12
yet the mean value was 21.5±7.19 vs.34±4.6 ng /ml, re-
spectively, p=0.0001. In pediatric females, 26(68%) were
insufficient and 12(32%) sufficient for the vitamin, p=
0.005 (mean of 20.8±4.91 vs.40.9±8.9 ng/ml, respectively),
p=0.0001. Only 22/135males (16.5%) underwent DXA scan-
ning, 12 of them had hypovitaminosis (54.5%), 9 of whom
(75%) exhibited low BMD vs. 3 (25%) with normal outcomes,
p=0.04. Among females 46/344 (13.5%) underwent DXA, 38
(82.5%) had hypovitaminosis, 23 of them (60.5%) exhibited
low BMD vs. 15 (39.5%) with normal outcomes, p=0.3.
Conclusion(s): A significant and common suboptimal
vitamin D [25-(OH)D] status was present in this popula-
tion of Abu Dhabi. Both genders (adults & children
alike) were affected almost equally, nonetheless, lower
levels of vitamin D were observed among the females
including their pediatric population. Few patients with
insufficiency were referred for DXA scanning reflecting
a degree of discrepancy in the referral pattern between
various medical disciplines. The results strongly recom-
mend a wide screening of vitamin D in the community
while attempting to determine the underlying causes of
the condition. A more frequent referral for DXA scanning is
also to be considered in those who have low levels of the
vitamin.
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EPIDEMIOLOGICAL SURVEY FRACTURE –
EVALUATIONOF PATIENTSWITHOSTEOPOROTIC
FRACTURESONORTHOPAEDIC DEPARTMENTS IN
EVERYDAY PRACTICE IN SLOVAKIA
Peter Maresch
Comenius University, I. Univ. Dept. of Orthop. and
Traumatol., Bratislava, Slovakia (Slovak Republic)
Objective(s): Epidemiological survey Fracture has been
designed to screen the patients with postmenopausal osteopo-
rosis after osteoporotic (wrist, vertebral or proximal femur)
fractures, treated at orthopedic departments. Objectives were
to 1) to screen the risk profile of patients on orthopedic depart-
ments, who suffered osteoporotic fracture; 2) to evaluate
satisfaction with the fracture healing and effect on quality of
life with strontium ranelate treatment after 6 weeks and 3
months.
Material & Methods: In the period between October-
December 2010, our project monitored treatment of
patients (women) with postmenopausal osteoporosis,
who suffered in this period osteoporotic fractures in
typical localities (vertebrae, hip, wrist). The survey was
joined by 13 centers with 169 patients. We analyzed the
amounts and localities of fractures, the way they were
attended to, subsequent treatment, occurrence of risk
factors and pharmacological treatment of osteoporosis.
The treatment with strontium ranelate started immediately
after surgical reparation of fractures.
Results: The average age of patients was 68.3±9 years.
Satisfaction with fracture healing after 6 weeks of treatment
with Strontium ranelate evaluated by doctors according the x-
rays represents 95.9%. The satisfaction increased to 98.2%
after 3 months. Mobility was evaluated for patients after
proximal femur fractures. After 6 weeks of strontium ranelate
treatment were 19% of patients self-mobile and 75% of
patients were mobile with assistance. After 3 months in-
creased number of self-mobile patients to 59.6%. After the
3-month treatment, side effects occurred in 7.9% of patients.
3.6% patients suffered a subsequent osteoporotic fracture
during the treatment.
Conclusion(s): The epidemiological survey confirmed
some well-known facts in osteoporotic fractures epidemiol-
ogy. It confirmed the occurrence of risk factors related to
osteoporotic fractures. The survey confirmed safety, positive
effect on quality of life and satisfaction with strontium
ranelate treatment for postmenopausal osteoporotic women
after fractures on orthopaedic departments.
References: Fracture Epidemiological survey 2011, P.
Maresch, Data on file
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EVALUATION OF STRESS FIELDS IN TRABECULAR
BONE LARGE SCALE FINITE ELEMENT
SIMULATIONS: INFLUENCE OF MODEL
PARAMETERS
Baptiste Depalle1, Roland Chapurlat1, Benyebka Bou-Saïd2,
Hélène Follet1
1Université de Lyon, INSERM, UMR1033, Lyon, 2Université
de Lyon, CNRS, INSA Lyon, LaMCoS UMR5259, Villeur-
banne, France
Objective(s): Numerical simulation using finite element mod-
els (FEM) has become more and more suitable to estimate the
mechanical properties of trabecular bone. The size and kind of
elements involved in the models, however, may influence the
results. The purpose of this study is to analyze element formu-
lation influence on the evaluation of mechanical stress applied
to trabeculae bone during a compression test simulation.
Material & Methods: Trabecular bone cores (D=8.2 mm,
L=15 mm) were extracted by necropsy from 18 L2 vertebrae
(mean age: 76±11, BV/TV=7.5±1.9%). Samples were μCT
scanned at 20 μm isotropic voxel size. μCT images have been
subsampled (20, 40 and 80 μm) to create 5.6 mm cubic FEM.
For each sample, six models of a compression test have been
created, two for each voxel size, with reduced and full inte-
gration formulation. Bone mechanical properties have been
supposed isotropic, homogenous, following a linear elastic
behavior law (Young modulus: 8 GPa, Poisson ratio: 0.3).
Results: Increasing voxel size led to microarchitecture mod-
ifications (loss of connectivity, trabeculae thickening) and
changed stress distribution in bone tissue. Even if apparent
mechanical properties were similar, stress concentrations were
altered. Increasing the voxel size leads to a higher underesti-
mation of stress magnitude and to a smoother distribution. This
trend was amplified with reduced integration formulation.
With 80 μm size reduced elements, as used clinically, few
stress variations were detectable. These observations also
depended on trabecular thickness. Less than 2 elements within
the trabeculae led to poor stress distribution assessment. The
figure presents VonMises stresses in a trabeculae depending of
both voxel size and elements formulation.
Conclusion(s): We found that the element size and the
integration formulation influence trabecular mechanical be-
havior evaluation. This statement should be accounted for in
clinical measurements.
Disclosures: This work was performed using HPC resources
from GENCI-CINES (Grant 2011035047).
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ESTABLISHING A NURSE LED SERVICE
FOR THE TREATMENT OF VITAMIN
D DEFICIENCY – IMPROVING
PATIENT OUTCOMES
Aoife McPartland, Maria Lynch, Bryan Whelan
Our Lady's Hospital, Rheumatology Department, Manorha-
milton, Co. Leitrim, Ireland
Objective(s): Justify the need for and examine the useful-
ness of a nurse led service for the treatment of vitamin D
deficiency.
Material & Methods: A total of 154 patients since Sept
2008 were referred to the day unit from rheumatology
clinics who were susceptible to hypovitaminosis D. Se-
rum 25-hydroxyvitamin D (25OHD), PTH, calcium, cre-
atinine and alkaline phosphatase were measured. These
samples were taken on ice and sent promptly to the
laboratory which is located off site. All results were
reviewed by the nurse manager and those with a
25OHD level ≤50 nmol/L were scheduled to attend the
day unit for treatment with cholecalciferol 300,000 IU.
Repeat sampling was done in 4 weeks post treatment.
All patients were educated individually and information
leaflets were provided
Results: A total of 82% (127 of the 154) of patients
were treated for vitamin D deficiency. On repeat sam-
pling after 4 weeks, an increase in Vitamin D levels
was observed in 98%. All of these patients were seen in
a nurse led clinic on our day unit where standard
protocol was followed and not in routine Rheumatology
clinics.
Conclusion(s): Our Nurse led service has resulted in the
effective treatment of hypovitaminosis D with efficient
detection and early intervention that does not increase
the burden on rheumatology clinics. The provision of
quality care, promptly and efficiently on a one-to-one
basis has led to improved patient care and an increased
patient knowledge and understanding of vitamin D
deficiency.
Elements with (a)-(c) non-reduced and (d)-(f) reduced formulation at
20, 40 and 80 μm.
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This service has developed organically over time but due to
its inherent efficiency it suggests a way in which the 'pan-
demic' of vitamin D deficiency can be tackled.
P186
THE GINERISK STUDY: A NONINTERVENTIONAL
EPIDEMIOLOGICAL STUDY OF MORE THAN 4000
SPANISH POSTMENOPAUSAL WOMEN WITH
OSTEOPOROSIS
Santiago Palacios1, José L Neyro2, Susana Fernández de
Cabo3, José Chaves4, Javier Rejas5
1Instituto Palacios de Salud y Medicina de la Mujer, Depart-
ment of Gynecology, Madrid, 2Hospital Universitario de
Cruces, Department of Obstetrics and Gynecology, Baracaldo,
Vizacaya, 3Pfizer, SLU, Medical Department, 4Pfizer, SLU,
Medical Department, 5Pfizer, SLU, HEOR Department,
Alcobendas, Madrid, Spain
Objective(s): Osteoporosis is a progressive, systemic skel-
etal disorder characterised by low bone mass and micro-
architectural deterioration of bone tissue, with a consequent
increase in bone fragility and susceptibility to fracture. The
primary objective of this study was to identify the clinical
profile of Spanish postmenopausal patients with a diagnosis
of osteoporosis. A secondary objective was to establish
possible associations between patients with osteoporosis
and the presence of risk factors for cardiovascular disease,
breast cancer and endometrial pathology.
Material & Methods: The GINERISK study is a cross-
sectional, epidemiological one-visit study designed to inves-
tigate the clinical characteristics and risk profiles of devel-
oping cardiovascular disease, breast cancer or endometrial
pathology in postmenopausal women (at least 12-month
after last menstrual period) with osteoporosis, above 18-
years old, who were attending outpatients clinics of Gyne-
cology in Spain. In addition to sociodemographics and
primary outcomes, bone densitometry, mammogram, cho-
lesterol and blood glucose levels, blood pressure, vaginal
ultrasound and HRQoL were recorded.
Results: Data were evaluable in 4157 of the 4517 (92%)
subjects included in the study. The mean age at diagnosis of
osteoporosis was 58.8 years, 49.8% (n=2070) had one or
more risk factors for bone fractures and 16.6% (n=692) had
two or more. Treatments of osteoporosis were recorded:
85.1% (n=3535) received treatment for osteoporosis,
83.6% of them (n=2956) received pharmacological treat-
ment for osteoporosis, and among them, 41.8% (n=1237)
were receiving SERMs. Data related to associated disease
risk were as follows: 20.1% (n=835) showed high cardio-
vascular risk (three or more CV risk factors); 9.2% (n=301)
had high endometrial risk (endometrial thickness ≥5 mm);
14.5% (n=423) had high risk of developing breast cancer in
the next 5 years (according to the Gail model).
Conclusion(s): This study has documented that a relevant
percentage of women with osteoporosis have also associated
a high risk of cardiovascular disease and endometrial and
breast cancer. These risks should be evaluated and taken into
consideration when choosing a treatment for osteoporosis in
postmenopausal women. The GINERISK study has provid-
ed a greater knowledge of the clinical profile of postmeno-
pausal osteoporotic patients and their associated risk factors,
meaning a comprehensive approach to their heathcare.
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IMPACT OF OSTEOPOROSIS AND BONE
FRACTURE ON HEALTH-RELATED QUALITY-OF-
LIFE IN POSTMENOPAUSALWOMEN:
THE GINERISK STUDY
Santiago Palacios1, Jose L Neyro2, Susana Fernandez de
Cabo3, Jose Chaves4, Javier Rejas5
1Instituto Palacios, Department of Gynecology, Madrid,
2Hospital de Cruces, Department of Obstetrics and
Gynecology, Baracaldo, Vizacaya, 3Pfizer, SLU, Medical
Department, 4Pfizer, SLU, Medical Department, 5Pfizer,
SLU, HEOR Department, Alcobendas, Madrid, Spain
Objective(s): Complaints regarding osteoporosis are caused
by fractures which are associated with decrease of physical
and social functions. SF-12v2 is a generic instrument
measuring Health-Related Quality-of-Life (HRQoL). The
Cervantes scale is a specific instrument measuring the im-
pact of menopause on women HRQoL, with higher scoring
showing higher impact (worse HRQoL). The objective was
to report the impact of osteoporosis with and without previ-
ous bone fracture (BF) on specific and generic HRQoL of
postmenopausal women.
Material & Methods: A cross-sectional, epidemiological
one-visit study (the GINERISK study) was designed to
investigate the risk of developing cardiovascular disease,
breast cancer or endometrial pathology along with HRQoL
in postmenopausal women (at least 12-month after last
menstrual period) with osteoporosis, above 18-years old,
who were attending outpatients clinics of gynecology in
Spain. Sociodemographics, bone densitometry (BD) and
HRQoL were recorded. HRQoL was assessed in duplicate
using the menopause specific self-administered 31-items
Cervantes scale and the generic SF-12v2 questionnaire.
Results: BD and HRQoL scores were recorded in 3,328
(80.1%) out of 4157 postmenopausal women, with a mean
(SD) age of 60.9 (7.4) years [range: 38-90]; 78.1% (n=
2599) with osteoporosis (bone densitometry<-2.5 T-score),
15.1% (n=502) with osteopenia (<-1.0 T-score>-2.5) and
the remaining 6.8% (n=227) formed the control group
(>-1.0 T-score). Osteoporosis with previous BF was associ-
ated with worst impact on HRQoL in comparison with oste-
oporosis without BF, osteopenia or normal postmenopausal
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women; mean Z-score (95% CI) in Cervantes total score of
+0.42 (0.32;0.51) vs. +0.10 (0.07;0.14), +0.17 (0.09;0.25) and
+0.12 (0.00;0.24), respectively (F=13.3, p<0.001). All
domains of the SF-12v2 were significantly more negatively
impacted in osteoporosis with BF patients than in the other
groups; p<0.001 in all cases. Osteoporotics with BF showed a
physical and mental summary componenT-scores located in
the percentiles 20th and 30th, respectively, of the Spanish
general population.
Conclusion(s): This study documented a loss of quality of
life in postmenopausal women with osteoporosis and bone
fracture in comparison with osteoporosis without bone frac-
ture, osteopenia or normal densitometry. Both, the meno-
pause-specific scale (The Cervantes scale) and the generic
HRQoL instrument (SF-12v2) showed ability to capture
such loss of quality of life.
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IS THE QUALITY-OF-LIFE IN
PHARMACOLOGICALLY TREATED
POSTMENOPAUSALWOMENWITHOSTEOPOROSIS
TYPE-OF-THERAPY DRIVEN? THE EFFECT OF
SELECTIVE-ESTROGEN-RECEPTORMODULATORS
Santiago Palacios1, Jose L Neyro2, Susana Fernández de
Cabo3, José Chaves4, Javier Rejas5
1Instituto Palacios, Department of Gynecology, Madrid,
2Hospital de Cruces, Department of Obstetrics and
Gynecology, Baracaldo, Vizacya, 3Pfizer, SLU, Medical
Department, 4Pfizer, SLU, Medical Department, 5Pfizer,
SLU, HEOR Department, Alcobendas, Madrid, Spain
Objective(s): Osteoporosis negatively impact patient´s
Health-Related Quality-of-Life (HRQoL). SERMs are
among the possible drug-based therapeutic strategies for
preventing bone fracture in postmenopausal women with
osteoporosis. The objective was to explore the HRQoL of
postmenopausal women with osteoporosis receiving a
SERM-based therapy in comparison with those not receiv-
ing such therapeutic strategy (bisphosphonates or other
drugs) for osteoporosis in daily medical practice.
Material & Methods: A cross-sectional, epidemiological
one-visit study (the GINERISK study) was designed to
investigate the risk of developing cardiovascular disease,
breast cancer or endometrial pathology along with HRQoL
in postmenopausal women (at least 12-month after last
menstrual period) with osteoporosis (lower spine and/or
hips bone densitometry<-2.5 T-score), above 18-years old,
who were attending outpatients clinics of gynecology in
Spain. HRQoL was assessed in duplicate using the meno-
pause specific self-administered 31-items Cervantes scale
(high scoring means worst QoL) and the generic SF-12v2
questionnaire (Z-scores). Comparisons were adjusted by
age, prior bone fracture, number of osteoporotic factors,
exercise and ongoing treatment with calcium or calcium+
vitamin D.
Results: BD and HRQoL scores were recorded in 3328
(80.1%) out of 4157 postmenopausal women, with a mean
(SD) age of 60.9 (7.4) years [range: 38-90]; 78.1% (n=
2599) with osteoporosis and 411 (15.8%) of them with
previous fragility fracture. 72.5% were receiving calcium/
calcium+vitamin D supportive therapy, 32.4% did exercise
regularly, and 1950 (75.0%) were being treated with a drug-
based therapy; SERMs in 787 (40.4%) women, while the
remaining 1163 with a bisphosphonate (84.8%) or other
drugs (12.7%). Sexuality domain of the Cervantes scale
was worsT-scored in women not receiving a SERM; mean
(95% CI) 12.7 (12.4;12.9) vs. 12.2 (11.8;12.5), p=0.015. In
general, physical QoL domains of the SF-12v2 were more
far from the mean in non-SERM patients, with physical
summary component significantly worsT-scored; -0.73
(-0.77;-0.68) vs. -0.64 (-0.71;-0.57), p=0.05, mainly due
to poorer general health; -0.95 (-1.00;-0.90) vs. -0.84
(-0.92;-0.76), p=0.02, and role physical; -0.56 (-0.60;-0.51)
vs. -0.47 (-0.53;-0.40), p=0.03.
Conclusion(s): This study documented a loss of quality of
life in postmenopausal women with osteoporosis not receiv-
ing a SERM-based therapy, mainly in their sexuality and
physical domains.
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A NEW CLINICAL APPROACH TO QUANTITATIVE
CT (QCT) BONE DENSITOMETRY WITH
ASYNCHRONOUS CALIBRATION
Gabriel R Bodeen, J K Brown, Alan Brett
Mindways Software, Inc, Austin, TX, US
Objective(s): Asynchronous calibration for QCT bone
densitometry permits extracting QCT measurements
from other abdominal/pelvic CT procedures with zero
additional radiation dose. Accuracy and precision in
CT bone densitometry have previously relied on simul-
taneous scanning of a calibration phantom with the
patient. We report here assessments of systematic and
random measurement differences between a prototype
commercial QCT device using asynchronous calibration
and a commercially available conventional QCT
device.
Material & Methods: Our retrospective cohort included
168 vertebrae from 78 subjects and 146 femoral scans from
73 subjects, ages ranged 3 to 97; the scans were from
multiple scanner models from each of four major manufac-
turers. BMD for each vertebra or femur was measured in
QCT PRO Version 5.0 (Mindways Software, Austin, TX,
USA) in its conventional mode and a new mode for
asynchronous calibration using independently acquired,
scanner-specific QA scans.
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Results: Vertebral BMD ranged from 13.4 mg/cc to 262.2
mg/cc. The linear least-squares regression line between cal-
ibration conditions lay slightly off unity, showing a consis-
tent bias wherein asynchronously calibrated BMD averaged
5.4% lower than conventional BMD. The SEE of this re-
gression was 5.0 mg/cc.
Results were similar in the proximal femur, with a correla-
tion above 0.98, an average decrease of 5.8% vs. conven-
tional BMD, and a SEE of 0.021 g/cm2 for data ranging
from 0.335-1.254 g/cm2. In addition, we assessed correla-
tions of the BMD measurement bias to CT manufacturer, X-
ray energy, and patient size. These revealed no statistically
significant trends.
Conclusion(s): The high correlations of asynchronously
calibrated BMD with conventional BMD suggest this ap-
proach has substantially equivalent accuracy in reproducing
T-Scores. A linear transformation suffices to correct the
measurement bias (possibly caused by differences in beam
hardening) without introducing significant variance. This
approach may provide new clinical utility in dual-use and
retrospective CT BMD screening.
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CALCIUM INTAKE PREDICTS BONE LOSS
AT THE DISTAL FOREARM IN AMUBLATORY
POSTMENOPAUSALWOMEN
Sunethra DC Thomas1,2, Howard A Morris1,2
1University of Adelaide, Department of Medicine, School of
Medicine, 2SA Pathology, IMVS, Chemical Pathology,
Adelaide, SA, Australia
Objective(s): Low calcium intakes lead to negative calcium
balance and low bone densities due to higher rates of bone
loss1,2. The low oestrogen status following menopause
increases the calcium requirement and may exacerbate bone
loss in those with low calcium intakes3. The present study
investigates whether postmenopausal women with lower
calcium intakes have higher rates of bone loss than those
with higher calcium intakes.
Material & Methods: Ambulatory postmenopausal women
(n=129) underwent bone density measurement (DXA) at
the lumbar spine, femoral neck, standard hip, proximal and
distal forearm at baseline and 6 monthly intervals for 18
months. They completed a food frequency questionnaire at
baseline and at 12 months. The calcium intakes were
grouped into tertiles [<910 mg/d (n=44); 911-1300 mg/d
(n=45); >1301 mg/d (n=40)]. Rates of bone loss for each
site at 6, 12 and 18 months for each tertile of calcium intake
were compared using ANOVA.
Results: Baseline bone densities did not differ significantly
between the tertiles of calcium intake. The rates of bone loss
did not differ significantly between the tertiles of calcium
intakes for the lumbar spine, femoral neck, standard hip or
the proximal forearm. The rate of bone loss at the distal
forearm at 12 months showed a significant difference between
tertiles of calcium intake (P=0.04). Calcium intakes did not
change from baseline when re-estimated at 12 months.
Conclusion(s): Baseline bone densities and the rates of
bone loss at the lumbar spine, hip and the proximal forearm
did not appear to be determined by the estimated calcium
intakes in this group of women. The rate of bone loss in the
distal forearm may be more sensitive to habitual calcium
intake than other sites.
References: 1. HeaneyRP. et al. J BoneMiner Res 1989;4:469.
2. Dawson-Hughes B. et al. Am J Clin Nutr 1987;46:685. 3.
Nordin BEC. et al. Am J Clin Nutr 2004;80:998.
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TREATMENT WITH 4JOINTZ REDUCES KNEE
PAIN OVER TWELVE WEEKS OF TREATMENT
IN PATIENTS WITH CLINICAL KNEE OSTEOAR-
THRITIS: A RANDOMISED CONTROLLED TRIAL
Laura L Laslett1, Stephen J Quinn2, Erica Darian-Smith1,
Michael Kwok1, Tanya Fedorova3, Lyn M March3, Graeme
Jones1
1University of Tasmania, Menzies Research Institute Tasmania,
Hobart, Tasmania, 2Flinders University, Clinical Effectiveness
Cluster, Adelaide, South Australia, 3University of Sydney,
Department of Rheumatology, Royal North Shore Hospital;
Institute of Bone and Joint Research, Sydney, New South
Wales, Australia
Objective(s): To assess the efficacy of topical 4jointz uti-
lizing Acteev technology (a novel and patented combination
of a standardized comfrey extract and a pharmaceutical
grade tannic acid, 3.5 mg/day), in subjects with symptom-
atic knee osteoarthritis.
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Material & Methods: This was a 12 week double-blind
randomised controlled trial. Adults aged 50-80 years (n=
133) with clinical knee OA according to the ACR criteria
were randomised to receive either 4jointz or placebo in
addition to existing medications. The primary outcome mea-
sure was the pain VAS at 12 weeks. Pain and function were
measured using a visual analogue scale (VAS) and the Knee
Injury and Osteoarthritis Outcome Score (KOOS) scale at
baseline, 4, 8 and 12 weeks. Inflammation was measured
using IL-6 and cartilage breakdown using CTX-2 at baseline
and 12 weeks.
Results: Pain scores had a greater reduction in the group who
received 4jointz compared to the group who received placebo
after 12 weeks using both the VAS (-9.9 mm, p=0.034) and the
KOOS pain scale (+5.7, p=0.047). Changes in IL-6 and CTX-2
were not significant (-0.1, p=0.96; -5.8, p=0.62). Reduction in
paracetamol daily dose (mg) in patients using paracetamol at
baseline was clinically (but not statistically) significant by
twelve weeks (-404 mg, p=0.35) Post hoc analyses suggested
that treatment may be most effective in women (VAS -16.8
mm, p=0.008) and those with milder radiographic osteoarthri-
tis (VAS -16.1 mm, p=0.009). Local rash was more common
amongst participants receiving 4jointz (19% vs. 1.6%, IRR
13.2, p=0.013), but only 22% (n=3) of participants with rashes
discontinued treatment. There were no changes in systemic
blood results and no differences in adverse events between
patients receiving 4jointz and placebo.
Conclusion(s): Topical treatment using 4jointz reduces
symptoms of osteoarthritis over 12 weeks of treatment.
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BMD DECREASES WITH INCREASING HbA1C
LEVELS: A CROSS-SECTIONAL STUDY
Jakob Linde1, Frank de Vries2,3, Marieke de Bruin2, Peter
Vestergaard1
1Aarhus University Hospital THG, Department of Endocrinol-
ogy and Internal Medicine, Aarhus, Denmark, 2University of
Utrecht, Utrecht Institute for Pharmaceutical Sciences, Utrecht,
3Maastricht University Medical Centre, Department of Clinical
Pharmacy & Toxicology, Maastricht, Netherlands
Objective(s): To investigate the effects of different blood
glucose levels on BMD.
Material & Methods: A total of 26,856 subjects had un-
dergone a DXA scan (13.5% men, 86.5% women, mean age
58.8±14.3 years, BMD in spine 0.931 g/cm2, spine T-score -
1.4±1.6, spine Z-score -0.1±1.6). Among these 1480 had
diabetes. We divided the diabetes patients in three groups
corresponding to their HbA1C level: a group consisting of
patients with HbA1C ≤0.070, a group consisting of patients
with HbA1C 0.071-0.080 and a group consisting of patients
with HbA1C ≥0.081. Vitamin D (plasma 25OHD) and urine
albumin/creatinine ratio were also measured.
Results: Among a total of 1480 patients we found a HbA1C
level of ≤0.070 in 850 patients (57%), of 0.071-0.080 in 368
(25%) patients and of ≥0.081in 262 patients (18%). The major-
ity of patients were women (84%, 81%, and 73%, respectively).
The HbA1C groups did not differ significantly in BMD of the
hip, BMD of the spine, BMD of the arm, weight, BMI, plasma
25OHD and urine albumin/creatinine ratio in a crude analysis
(p>0.05). However, in a multiple linear regression model ad-
justed for age, BMI and sex we found a lower BMD of the
spine (regression coefficient±SEM: -0.0071±0.0027 g/cm2 per
unit of HbA1C) and BMD of the hip, respectively, (-0.0070±
0.0027) (see also Table). No association was present between
BMD of the forearm and HbA1C (-0.2835±0.2999, p>0.05).
Table: Association between BMD (g/cm2) and HbA1C adjusted for
age, BMI and sex
Variable Lumbar spine
(n=1476)
Total hip
(n=1480)
Total forearm
(n=272)
Age (years) -0.0031±0.0003* -0.0031±0.0003* -0.0031±0.0004*
BMI (kg/m2) 0.0118±0.0006* 0.0116±0.0006* 0.0034±0.0006*
Sex (men vs.
women)
0.0904±0.0088* 0.0906±0.0089* 0.1073±0.0103*
HbA1c (%) -0.0071±0.0027* -0.0070±0.0027* -0.2835±0.2999
Multiple linear regression. *: p<0.05
Conclusion(s): Adjusted for age, BMI and sex we found an
association between higher HbA1C levels and a lower BMD
of the spine and BMD of the hip. No association was present
for the forearm. It seems that blood glucose (HbA1C) is a
predictor of lower BMD among diabetes patients, making
this a valuable tool regarding BMD status.
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RADIOLOGICAL AND CLINICAL PROFIL OF
OSTEOARTHRITIC PATIENTS UNDERGOING
OF TOTAL JOINT REPLACEMENT
A. Neuprez, G. François, O. Bruyère, V. Kovats, W. Kurth,
J.-P. Huskin, P. Gillet, J.Y. Reginster
University of Liège, Liège, Belgium
Objective(s): We analyzed the preoperative radiologic and
clinical status of 185 consecutive patients undergoing total joint
replacement for symptomatic osteoarthritis of the lower limb.
Material & Methods: Our cohort included 75 men and 110
women aged from 33-86 years (mean 65.2±10.5). 98 of them
received a total hip prosthesis and 87 of them a total knee
prosthesis. The mean duration of OA was 3173.9 days±
3381.8 (SD) or 8.6 years±9.3 years. They were all diagnosed
with primary OA following the ACR criteria.
Results: 172 pre-operative X-ray assessments were analyzed:
& 2.9% (n=5) were presenting with a KL-score of 1.
& 39.5% (n=68) were presenting with a KL-score of 2.
& 39.5% (n=68) with a KL-score of 3.
& 18% (n=31) with a KL-score of 4.
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The mean value EQ-VAS pain was 62.4±.2. The mean
WOMAC score values were 10.8±3.8 for pain, 4.6±1.8 for
stiffness, 4.6±1.8 for function. The total WOMAC score was
51.4±17.2.
Conclusion(s): Patients undergoing total joint replacement
in university setting, in Belgium, do present with a moderate
to severe OA.
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BIOCHEMICAL MARKERS OF BONE TURNOVER
FOR THE PREDICTION OF DEVELOPING
VERTEBRAL FRACTURES IN POSTMENOPAUSAL
WOMEN: THE JAPANESE POPULATION-BASED
OSTEOPOROSIS (JPOS) COHORT STUDY
Junko Tamaki1, Masayuki Iki1, Eiko Kadowaki1, Yuho Sato2,
Yasutaka Chiba3, Takashi Akiba4, Toshio Matsumoto5,
Harumi Nishino6, Sadanobu Kagamimori7, Yoshiko
Kagawa8, Hideo Yoneshima9
1Kinki University Faculty of Medicine, Department of Public
Health, Osaka-Sayama, Osaka, 2Jin-ai University, Department
ofHumanLife, Echizen, 3Kinki University Faculty ofMedicine,
Division of Biostatistics Clinical Research Center, Osaka-
Sayama, 4Kidney Center Tokyo Women's Medical University,
Department of Blood Purification and InternalMedicine, Tokyo,
5University of Tokushima Graduate School of Health Bioscien-
ces, Department of Medicine and Bioregulatory Sciences,
Tokushima, 6Toyama Pharmaceutical Association, Toyama,
7University of Toyama, Toyama, 8Kagawa Nutrition University,
Tokyo, 9Shuuwa General Hospital, Kasukabe, Japan
Objective(s): The aim was to evaluate the ability of bio-
chemical markers of bone turnover (BTM), to predict the
event of vertebral fracture.
Material & Methods: Participants were 390 postmenopaus-
al women ≥60 years old at the baseline survey in 1996 without
disease or medication affecting bone metabolism. Vertebral
fracture events were ascertained in the three follow-up surveys
(in 1999, 2002, and 2006). The outcome was the first vertebral
fracture event during the follow-up period diagnosed morpho-
metrically when a vertebra with ≥20% height reduction from
baseline satisfied the McCloskey-Kanis criteria or the defini-
tion of grade ≥2 fracture by the Genant method. Poisson
regression model was applied to estimate rate ratio (RR) per
1SD increase of log-transformed BTM values as at the base-
line: osteocalcin (OC) and bone-specific alkaline phosphatase
(BAP) in serum, and type I collagen crosslinked C-terminal
telopeptide (CTX), total deoxypyridinoline (tDPD) and free
deoxypyridinoline (fDPD) in urine.
Results: The number of subjects developed the vertebral
fracture event was 77 during the median follow-up time of
8.0 years (interquartile range [IQR], 4.5-10.0 years; total
person-years, 2744.5 PY). The median time from baseline to
the event was 4.5 years with IQR, 1.5-8.0 years. The RRs per
SD for BAP, tDPD, and fDPD indicated increased risk of
vertebral fractures with RR (95% CI) of 1.44 (1.16, 1.80),
1.31 (1.04, 1.65), and 1.38 (1.10, 1.74), respectively, after
adjustment for age, weight and femoral neck (FN) BMD.
The RRs for BAP and fDPD were 1.40 (1.08, 1.81) and
1.39 (1.07, 1.80), respectively adjusting for lumbar spine
BMD substituted for FN BMD. Among total subjects, the
362 women were followed at least once during 6 years from
baseline (1834.5 PY), while the event number was 47 with
median time from baseline to the event was 1.5 years. The RR
per SD for BAP was significant after adjustment for age,
weight, and FN or LS BMD during the 6 years (RR [95%
CI] of 1.39 [1.05, 1.85], 1.41 [1.01, 1.97], respectively).
Conclusion(s): BTM could predict for vertebral fractures
among postmenopausal Japanese women independently of
BMD during 10-year follow-up period.
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EXPERIENCE OF STRONTIUM RANELATE IN THE
TREATMENT OF OSTEOPOROSIS IN A TERTIARY
REFERRAL CENTRE IN THE UK
Milad Khedr, Irene Appianing, Petko Ivanov, Irina Cozma,
Stanka Nikolova, Vinita Mishra, Lakshminarayan Ranganath,
Eileen Marks
Royal Liverpool University Hospital, Department of Clinical
Chemistry and Metabolic Medicine, Liverpool, UK
Objective(s): To assess the outcomes of using strontium
ranelate (SrRan) in a busy tertiary osteoporosis clinic.
Material & Methods: Using electronic clinic records, we
identified all patients commenced on SrRan between
1.1.2008 and 31.12.2008. Clinic visit records and DXA
reports were reviewed. DXA scans were performed on a
Lunar Prodigy®. Calcium and Vitamin D intake was rou-
tinely assessed and optimized for all patients.
Results: 61 patients were identified. Of those, 35 (57%)
patients continued SrRan beyond a year (mean±SD=25±7
months). No fracture was reported in these patients. Table 2
summarizes the treatment outcomes in this group.
Table 1: Baseline demographics and characteristics
Variable All (n=61) On SrRan
†(n=35)
Off SrRan
‡(n=26)
Age (year)§ 67.46±10.99 66.23±10.93 69.12±11.07
Females, n (%) 57 (93.4) 31 (88.6) 26 (100)
Vertebral Fractures, n (%) 12 (19.7) 6 (17.1) 6 (23.1)
Nonvertebral Fracture,
n (%)
15 (24.6) 8 (22.9) 7 (26.9)
Previous treatment, n
OBPs 37§§ 23 14§§
IVBPs 15 6 9
HRT 2 1 1
Raloxifene 1 1 0
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More than one treatment
including teriparatide
4 2 2
No treatment (at the time
when SrRan was
considered)
4 2 2
§Value for age is shown as mean±SD. †continued therapy
beyond 1 year. ‡discontinued treatment ≤1 year. OBPs: Oral
bisphosphonates, IVBPs: Intravenous bisphosphonates,
HRT: Hormone Replacement Therapy. §§Two patients were
tried on OBPs after finishing IVBPs course.
"Off SrRan" Group: Reasons for stopping treatment were
side effects (n=22): gastrointestinal (n=15), rash (n=1),
bone pain (n=1), renal angle pain (n=1), nocturnal leg
cramps (n=1) and unspecified intolerance (n=3). Other
reasons were deterioration in chronic kidney disease (n=1)
and deterioration in BMD (n=1). In 2 cases, no clear reason
was stated.
"On SrRan" Group: Reasons for changing from previous
treatment to SrRan were deterioration of BMD on previous
treatment (n=11), gastrointestinal side effects of BPs (n=8),
having fractures while on previous treatment (n=1), been on
OBPs or IVBPs for a long time (n=7), worsening back pain
(n=1) and worsening breathlessness (n=1). In one case, the
patient keen to try SrRan after been on IVBPs. No reason
was stated in 3 cases.
Table 2: Treatment outcomes in those who continued SrRan beyond 1 year
Variable Baseline*
(n=27)
Follow up**
(n=27)
P-value
L2-L4 BMD (g/cm2) 0.904±0.156 0.939±0.198 0.09
Femoral Neck
BMD (g/cm2)
0.780±0.107 0.802±0.111 0.0001
L2-L4 T-score -2.4±1.2 -2.1±1.4 0.03
Femoral Neck T-score -1.8±0.9 -1.6±0.8 0.0004
Values for variables are shown as mean±SD. *Time delay
from performing baseline BMD measurement until starting
Sr Ran was 7 months±6.7. **Follow up is defined from
when SrRan is started until follow up DXA is done: 25±7
months (Median 25 months).
Conclusion(s): SrRan improved T-scores in both the lumbar
spine and femoral neck. However, only the femoral neck
BMD improved significantly. Gastrointestinal side effects
were the main reason for discontinuation.
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USE OF PARATHYROID HORMONE FOR
THE TREATMENT OF THE NONUNION
Jesús Palencia, Hernández Rubén, García Virginia, Plata
María, Yagüe Fernando
Hospital Clínico Universitario, Orthopaedic Surgery and
Traumatology, Valladolid, Spain
Objective(s): The objective was analyze the usefulness of
PTH for the nonunion treatment in multioperated patients
with osteoporosis.
Material & Methods: This is a prospective and descriptive
revision which analyzes the evolution of three patients with
nonunion in osteoporotic bones.
Nonunion was defined as the absence of union after 6
months.
The criteria for inclusion in the study are:
– Patients with osteoporotic.
– Nonunion operated at least on three times, and the lack
of consolidation indicates a new intervention.
– Absence of factors that counter-indicates treatment with
PTH.
Patients were operated again with a new osteosynthesis,
autologous bone graft, electromagnetic therapy and PTH.
PTH treatment was with PTH (1-84) recombinant 100 μg in
subcutaneous injection once a day, for an average of 6
months. Revisions were in the 1st, 3 rd, 6th, 9th and 12th
months. The study variable was the presence or absence of
bone consolidation. The consolidation results were analyzed
using X-Ray and CT.
Results: The nonunion who met the inclusion criteria were:
– A 42 year old male with atrophic nonunion of femoral
shaft, osteoporosis associated with neurological injury
and inability to use the limb for 27 months.
– A 78 year old woman with atrophic nonunion proximal
femur.
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– A 61 year old woman with atrophic humeral shaft
nonunion with osteoporosis secondary to steroid
treatment.
After surgery and treatment with PTH, three nonunions
evolved towards the consolidation on a 6 months average.
The consolidation was assessed by X-Ray and CT studies.
Conclusion(s): PTH may be a useful therapeutic tool for the
treatment of nonunion in osteoporotic patients. Studies pub-
lished demonstrate that PTH treatment increases the volume
of callus, new bone formation and restoration of mechanical
skills.
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EFFECTS OF TERIPARATIDE ON CORTICAL
HISTOMORPHOMETRIC VARIBLES IN PATIENTS
RECEIVING LONG-TERM ALENDRONATE
THERAPY
Jan J Stepan1, Harald Dobnig2, Astrid Fahrleitner-Pammer2,
Yanfei L Ma3, Qing Q Zeng3, Xiaohai Wan3, Fernando
Marin4, Imre Pavo4
1Charles University Faculty of Medicine, Institute of Rheu-
matology, Prague, Czech Republic, 2Medical University, De-
partment of Internal Medicine, Graz, Austria, 3Lilly Research
Laboratories, Research Laboratories, Indianapolis, IN, US,
4Lilly Research Centre, Research Centre, Windlesham, UK
Objective(s): Teriparatide (TPTD) treatment increases
bone turnover and bone formation in patients previously
treated with potent antiresorptives, such as alendronate
(ALN). However, no histological information exists on
the effects of TPTD on cortical bone in the ALN pre-
treated patients. The aim of this post hoc analysis was
to investigate the changes in cortical microstructure and
dynamic histomorphometric indices in patients with os-
teoporosis with or without prior therapy with ALN, who
were treated with TPTD 20 μg/day subcutaneous for 24
months.
Material & Methods: 66 postmenopausal women with
osteoporosis, mean age (SD) of 68.0 (7.0) years and mean
BMDT-score of -1.7 (0.9) at total hip and -2.8 (0.8) at lumbar
spine; 62% with prevalent fractures) were included in the
study. 38 stopped previous ALN treatment (10 mg/day or
70 mg/week for a mean duration of 63.6 months), and
switched to TPTD, while 28 were osteoporosis pretreatment
naive (TN). 45 paired iliac crest biopsies were collected and
analyzed by μCT, static and dynamic histomorphometry at
baseline and after 24-month. Nonparametric signed-rank test
was used to compare the effect after TPTD treatment with
baseline within each group or for the overall population.
Results: In the ALN pretreated group, MS/BS (%) values
were lower than in the TN, at both the periosteal (baseline:
0.61±1.29 vs. 1.39±0.96; p=0.04; post-TPTD: 1.34±1.05 vs.
3.94±2.7; p<0.0001), and endocortical levels (baseline: 3.16
±5.05 vs. 6.19±5.07; p=0.06; post TPTD: 4.95±4.03 vs. 11±
9.57; p=0.005). In the pooled analysis, indices of periosteal
and endocortical dynamic variables, cortical thickness and
porosity increased significantly compared to baseline (Table).
Table: Change from baseline (%)
% Change in indices Pre-treatment naïve ALN pre-treated Pooled
3D Total cortical area 28 43 * 39 *
3D Cortical thickness 38 32 * 34 *
2D Cortical porosity 69 65* 67*
Periosteal MS/BS 184* 118* 164*
Periosteal BFR/BS 275* 312 282*
Endocortical MS/BS 78 57* 71*
Endocortical; BFR/BS 143 47 107*
*p<0.05, compared to baseline
Conclusion(s): Our results indicate the bone forming effects
of TPTD in the cortical bone in patients previously treated
with the ALN or treatment naive. The observed increase in
cortical porosity in both groups may be the consequence of
increased intracortical remodeling.
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EVALUATION OF THE EFFECT OF ADDING
CORTICOSTEROID TO VISCOSUPPLEMENTATION:
A PROSPECTIVE AND RANDOMIZED STUDY
Márcia U Rezende, Gustavo C Campos, Alexandre F Pailo,
Renato Frucchi, Thiago Pasqualim
IOT - FMUSP, Departamento de Ortopedia e Traumatologia,
São Paulo, Brazil
Objective(s): The objective is to assess if we can improve
the initial results of viscosupplementation by the addition of
corticosteroids to the procedure, watching for any interfer-
ence on the long-term results
Material & Methods:We evaluated 104 patients with knee
osteoarthritis (OA).All patients were receiving usual care,
and those who underwent to intraarticular injection or knee
surgery in the last 6 months, or had post-traumatic or rheu-
matoid arthritis were not included. We applied the visual
analogic scale of pain (VAS) and WOMAC and Lequesne
questionnaires. Patients were randomized into two groups of
52 patients each. Group 1 received a single intraarticular
injection of the knee with 6 ml of Hylan GF-20 alone.
Patients in group 2 received an intraarticular injection of
the knee with 6 ml of Hylan GF-20 and 1 ml (20 mg) of
hexacetonide triamcinolone. The questionnaires were ap-
plied prior to the injection (week zero) and at weeks 1, 4,
12 and 24 after the procedure.
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Results: The two groups were homogenous. Most patients
were female (76%). The mean age was 62,7 years old. The
average BMI of patients was 29.52. Most patients (34.6%)
had a level 3 Kellgreen and Lawrence radiological classifi-
cation for knee OA. At Week 1, Group 2 showed a marked
reduction for WOMAC and VAS scores, with a statistically
significant difference compared with Group 1 results. At
week 4, group 2 still had better results for WOMAC and
VAS compared to group 1, but with a p>0.05. The
WOMAC and VAS results for weeks 12 and 24 were similar
within the 2 groups. The Lequesne results had no statisti-
cally significant difference between the 2 groups at any
moment. However, each group had a statistically significant
improvement at weeks 1, 4, 12 and 24 compared to the
baseline. None of the individuals characteristics such as
age, genre, BMI or K&L classification had any effects on
the results. Adverse effects: 4.8% presented effusion and
19.2% related discomfort or pain, with no statistic difference
between groups.
Conclusion(s): We concluded that the addition of 1 ml of
triancinolone to viscosupplementation brings great improve-
ment to its early results and does not affect the long-term
results, so it should be performed.
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EFFECTS OF ROSEMARY CARNOSIC ACID ON
BONE METABOLISM
Hiromi Hagiwara1, Roshan Basnet1, Keitaro Hagiwara2
1Toin University of Yokohama, Biomedical Engineering,
2Tokyo Institute of Technology, Biological Sciences,
Yokohama, Kanagawa, Japan
Objective(s): In bone tissues, both the formation and main-
tenance of bone are controlled by bone forming osteoblasts
and bone resorbing osteoclasts, and an imbalance between
these two types of cell leads to the bone metabolic diseases,
such as osteoporosis and osteopetrosis. The formation of
bone involves a complex series of events that include the
proliferation and differentiation of osteoprogenitor cells and
eventually result in the formation of a mineralized extracel-
lular matrix. We used preosteoblastic cell MC3T3-E1. On
the other hand, osteoclasts are multinucleated giant cells
with the ability to resorb mineralized tissues. They are
formed from haematopoietic cells of the monocyte/macro-
phage lineage. The formation and activation of osteoclasts
are controlled by the combined action of the RANKL and
M-CSF. In the present study, we used a culture of mouse
spleen cells with stromal cell line ST2 had been treated with
activated vitamin D3. Polyphenols reportedly exert physio-
logical effects against diseases such as cancer, arterioscle-
rosis, hyperlipidaemia and osteoporosis. We previously
reported that quercetin from onion, curcumin from curcuma
longa, and apigenin from pasley and olive inhibit the min-
eralization of osteoblastic cells and the formation of osteo-
clasts. Recently, we examined effects of olive polyphenols
such as oleuropein, hydroxytyrosol, and tyrosol on bone
formation using cultured osteoblasts and osteoclasts, and
on bone loss in ovariectomized mice and we showed that
oleuropein and hydroxytyrosol enhanced bone formation in
vivo and in vitro. In the present study, we designed to clarify
the effects of rosemary carnosic acid on bone metabolism
using cultured osteoblasts and osteoclasts.
Material & Methods: We used preosteoblastic MC3T3-E1
cells as cultured osteoblastic cells. We also used coculture
system (ST2 cells and splenic cells) as the formation of
multinucleated osteoclastic cells.
Results: Carnosic acid inhibited the proliferation of preos-
teoblastic MC3T3-E1 cells. Furthermore, carnosic acid de-
creased in the activity of alkaline phosphatase and the
deposition of calcium in a dose-dependent manner. On the
other hand, this compound also inhibited the formation of
multinucleated osteoclasts in a dose-dependent manner.
Conclusion(s): Our findings indicate that carnosic acid may
have critical effects on the formation and maintenance of
bone.
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EVALUATION OF EFFICACY AND SAFETY OF
DENOSUMAB IN JAPANESE POSTMENOPAUSAL
WOMENWITH OSTEOPOROSIS – PHASE II (DOSE
RESPONSE) STUDY
Toshitaka Nakamura1, Toshio Matsumoto2, Toshitsugu
Sugimoto3, Masataka Shiraki4
1University of Occupational and Environmental Health,
Department of Orthopedics, Kitakyushu, Fukuoka, 2Univer-
sity of Tokushima Graduate School of Health Biosciences,
Department of Medicine and Bioregulatory Science,
Tokushima, 3Shimane University Faculty of Medicine,
Department of Internal Medicine 1, Izumo, Shimane,
4Research Institute and Practice for Involutional Diseases,
Shiraki Clinic, Azumino, Nagano, Japan
Objective(s): To examine the efficacy and safety of three
doses of denosumab (14, 60, and 100 mg) compared with
placebo in Japanese postmenopausal women with
osteoporosis.
Material & Methods: Multicenter, randomized, placebo
controlled study was planned and 226 subjects were ran-
domized (212 subjects received at least 1 dose). These
subjects were administered with the investigational product
subcutaneously every 6 months for 12 months (two doses)
and received daily supplements of at least 600 mg elemental
calcium and 400 IU vitamin D from the beginning of
screening through treatment period. Subjects were no older
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than 80 years old. All the subjects had a BMD T-score of -
2.5 to -4.0 at the L1-L4 spine or -2.5 to -3.5 at either of the
femoral neck or total hip.
Results: Denosumab treatments showed significant mean
percent increases from baseline to 12 months in BMD at
lumbar spine: 5.71% for 14 mg (n=53), 6.73% for 60 mg
(n=54) and 7.45% for the 100 mg (n=50) group, respec-
tively. All treatment groups showed a statistical difference
compared with 0.46% in the placebo group (n=55, p<
0.0001). All 3 denosumab cohorts had numerically greater
mean percent increases from baseline in BMD of the total
hip, femoral neck, and distal 1/3 radius at month 12 com-
pared with the placebo cohort, with p-values<0.05 for each
comparison, with the exception of the comparison of the
100 mg denosumab cohort at the distal 1/3 radius that it
trended towards statistical significance (p=0.054). Denosu-
mab significantly decreased the serum CTX-I and urinary
NTX-I/Cr by 8 days, and Bone ALP and osteocalcin by 3
months. No new vertebral fracture was observed in either
group. The overall incidences of adverse events, serious
adverse events, treatment-related adverse events, and with-
drawals due to adverse events were similar in the denosu-
mab groups and the placebo group. No one developed
antibodies to denosumab or developed ONJ.
Conclusion(s): Denosumab 60 mg could be an effective
dose for Japanese postmenopausal women with osteoporosis
as was shown in the Caucasian population.
References: T. Nakamura et al, Osteoporos Int 2011, in
press
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FACTOR INCREASING ADHERENCE TO
STRONTIUM RANELATE AT 2 YEARS
OF TREATMENT
Svetlana Rodionova1, Alla Krivova2
1N.N.Priorov Central Institute of Traumatology and
Orthopedics (CITO), Center of Osteoporosis, Moscow,
2Tver Government Medical Academy, Orthopedics, Tver,
Russian Federation
Objective(s): According to some researches, the necessity
for a daily administration of strontium ranelate reduces
complaints.
Material & Methods: The study includes 107 patients with
postmenopausal osteoporosis with the loss by BMD (T-
score) more than -2.5 SD, aged >55. Results of treatment
was assessed by the BMD at the lumbar spine (L2-L4) and
femoral neck, with new vertebral fractures, side effects and
complaints. Duration of observation was 2 years. All
patients received a daily strontium ranelate dose 2 g and
1000 mg of calcium with 200 IU of vitamin D3. The paired
Student's criterion with 95% CI was used for the analysis of
two measurements.
Results: In one-year treatment completed 64 of 107 patients
(59.8%). After 2-9 months from the beginning of treatment
43 patients stopped it. Of these, 18 patients (16.8%) due to
side effects: 13- gastrointestinal tract, symptoms were
detected during 1 or 3 months of starting treatment; in 3
cases (2.7%) increased frequency of hypertensive crises
(after 6 months from the beginning of treatment); in 2 cases
(1.8%) increased pain in the joints (prior to study entry in
both cases there was a deforming arthrosis of the knee and
hip joints). 20 patients stopped taking strontium ranelate in
the period of 2-3 months without reasons, but continued to
receive calcium and vitamin D3. Patients who were taking
drugs for 1 year manifested a significant increase of BMD at
the lumbar spine from 0.84±0.015 to 0.86±0.02 g/cm2 (p<
0.005) and at the femoral neck from 0.6932±0.01 g/cm2 to
0.71±0.01 g/cm2 (p<0.001). In the second year of treatment
the study started 64 people, completed 56 (87.5%). 8 women
stopped treatment in terms of 3-5 months for economic
reasons. After 2 years BMD significantly increased from
0.86±0.02 to 0.91±0.021 g/cm2 (p<0.005) and from 0.71±
0.013 to 0.72±0.014 g/cm2 (p<0.001) at the lumbar spine
and the femoral neck respectively. Accordingly within 2-
year treatment the increase of BMD at the lumbar spine was
about 8% and at the femoral neck about 4%.
Conclusion(s): The increasing of BMD after the first year
of treatment increased the adherence to receive strontium
ranelate on the second treatments year.
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EFFECTS OFALENDRONATE TOPICAL
APPLICATION AS A COMPONENT OFA
BIOCOMPOSITE MATERIAL ON OSTEOGENESIS
IN OSTEOPLASTY
Svetlana Rodionova, Alexander Torgashin
N.N.Priorov Central Institute of Traumatology and Ortho-
pedics (CITO), Center of Osteoporosis, Moscow, Russian
Federation
Objective(s): The fact that topical application alendronate
as a component of a biocomposite material can decrease the
rate of bone synthesis has been prevented their utilization in
orthopedic and traumatologic practice. Appropriate to assess
effect of topical application alendronate as a component of
biocomposite material on osteogenesis.
Material & Methods: Experiment was performed on 20
nonlinear female white mice divided into 2 groups. In the
experimental group defect of shin bone was filled with
nondemineralized freeze-dried bone implant combined with
biocomposite material containing alendronate 1 mg/ml. In
the control group biocomposite material was not containing
bisphosphonate. Experiment lasted 90 days. Results evalu-
ation was morphological (light microscope Zeiss Axioskop
40). Samples were stained with hematoxylin-eosin. BMD in
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experimental area and in the whole segment was assessed
with densitometer Hologic and analyzed with software
“Performing and Analyzing Small Animal Studies”. Rate
of osteogenesis and changes in the experimental areas were
graded according to the following scale: 1 – poor osteogen-
esis (area of bone defect is filled with loose connective
tissue and fragments of bone implant presented with osteo-
cytes-free bone trabeculas; 2 – moderate osteogenesis (area
of bone defect contains foci of newly synthesized mature
bone tissue around bone implant or marginal osteogenesis
on the cartilage basis with remnants of bone implant); 3 –
advanced osteogenesis (area of bone defect is filled with
newly synthesized mature bone tissue without remnants of
bone implant). Statistical analysis of data was performed on
SPSS software, level of statistical significance was set to p<
0.05.
Results: In the experimental group the mean index of oste-
ogenesis was 1.4, in the control group – 1.6. Difference in
results between groups was not statistically significant.
Conclusion(s): Topical application of alendronate 1 mg/ml
as a part of biocomposite material does not inhibit osteo-
genesis.
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THE ALENDRONATE EFFECT AFTER
ARTHROPLASTY IN WOMEN PRE AND
EARLY MENOPAUSAL PERIOD
Svetlana Rodionova, Timur Turgumbaev
N.N.Priorov Central Institute of Traumatology and Ortho-
pedics (CITO), Center of Osteoporosis, Moscow, Russian
Federation
Objective(s): The period of pre and early menopause is
"inevitable" risk factor for increased periprosthetic bone loss
after arthroplasty. Appropriate to assess the effect of alendr-
onate on bone mass (BMD) Gruen zones during the first 15
months after arthroplasty.
Material & Methods: 43 patients with dysplastic coxarth-
rosis (age 48-53) after athroplasty were divided into 2
groups. 12 of them have been taking alendronate 70 mg/
week and 1000 mg of calcium daily during 1 year, 31 -
control group received only 1000 mg of calcium. The first
study of the BMD Gruen zones performed 1 month after
surgery, then every 3 months, the last - after 15 months.
Results: 15 months after surgery in patients treated with
alendronate, in all zones except R4 BMD was increase
significantly (t-test for one sample) above the ratio relative
to the 1-month. Increasing of BMD in the R1 and R6 zones,
respectively, was 7.7±3.05% (0.05>p≥0.01) and 8.8±
4.13% (p=0.06), in the R2 and R3 areas, respectively,
5.4±1.4% (p<0.01) and 5.6±2.6% (p=0.059). The increas-
ing of BMD at the R5 and R7 zone was: 2.2±2.8% and 2.25±
2.3%. BMD deficit remained only in the zone R4. In the
control group BMD deficit was maintained in all zones,
except for R2 and R3. In the R7, R5 and R6 areas
(p=0.067) BMD deficit was significantly highest to the base-
line values. The safety chance of deficiencies in the treatment
group was low and ranged from 0.09-0.2 in all zones, except
for R4. In the control group chance was significantly higher
(0.8-1.42).
Conclusion(s): During the first 12 months after joint
replacement in women pre and early menopause which
were received alendronate, bone around the femoral
components increased significantly, creating the condi-
tions for the secondary (biological) stability formation
of the implant.
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SERUM SCLEROSTIN LEVELS ACROSS AWIDE
RANGE OF BONE TURNOVER
Maria P Yavropoulou, Antoon H Van Lierop, Neveen AT
Hamdy, Socrates E Papapoulos
Leiden University Medical Center, Department of Endocri-
nology & Metabolic Diseases, Leiden, Netherlands
Objective(s): Evidence has been accumulating on the role
of osteocytes, as players in the regulation of bone remodel-
ing. One of the main products of these ubiquitous cells,
sclerostin, regulates bone formation through inhibition of
the Wnt signaling pathway. Circulating sclerostin levels
have been evaluated in healthy individuals, but data are
scarce regarding different ranges of bone turnover. To ad-
dress this issue we evaluated serum sclerostin levels in
patients with Paget's disease of bone (PD) with predomi-
nantly increased bone resorption at different stages of dis-
ease activity, and in patients with prostate cancer (PC)
metastatic to the skeleton with predominantly increased
bone formation at different levels of skeletal involvement.
Material & Methods: Sclerostin levels were measured in 94
patients with PD, 28 patients with PC and 77 healthy individ-
uals. Patients with PD and PC had bone scintigraphy to
establish the extent of skeletal involvement. Bone turnover
was evaluated by measuring serum levels of procollagen type
1 amino-terminal propeptide (P1NP) in all individuals studied
and β-carboxyterminal crosslinking telopeptide of type I col-
lagen (β-CTX) only in patients. None of the patients had renal
or liver dysfunction, vitamin D deficiency, or other diseases
known to affect bone metabolism.
Results: The population studied had a wide age range (20-88
years) and a wide range of bone turnover with serum P1NP
ranging from 8.4-1872 ng/ml and β-CTX ranging from 50-
3120 pg/ml. Patients with PD and with PC had significantly
higher serum sclerostin levels (53.58±22.4 pg/ml and 57.55±
24.7 pg/ml, respectively) compared to healthy controls (40±
12.8 pg/ml) (p<0.001). Serum sclerostin levels significantly
correlated with age (r=0.238. p<0.001) and with P1NP (r=
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0.295, p<0.001), but not with β-CTX (r=0.094, p=0.303)
across the wide range of bone turnover.
Conclusion(s): Circulating sclerostin levels are significant-
ly increased in patients with increased bone turnover, re-
gardless of underlying disease pathology, whether
predominantly increased bone resorption as in Paget's dis-
ease or predominantly increased bone formation as in meta-
static prostate cancer. Sclerostin levels also significantly
correlate with bone formation but not resorption markers
across a wide range of bone turnover.
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EFFECTIVENESS OF STRONTIUM RANELATE
IN THE TREATMENT OF POSTMENOPAUSAL
OSTEOPOROTIC WOMEN: OUR EXPERIENCE
INTO DAILY CLINICAL PRACTICE
María-Jesús Moro-Álvarez1, Manuel Díaz-Curiel2, Marjorie
Andrade2, Ignacio Mahillo-Fernández3, Concepción De la
Piedra4
1Hospital Central Cruz Roja, Internal Medicine, Metabolic
Bone Disease Unit, 2Fundación Jiménez Díaz, Internal
Medicine, Metabolic Bone Disease Unit, 3Fundación Jiménez
Díaz, Investigación-Epidemiología. IIS, 4Fundación Jiménez
Díaz, Department of Clinical Biochemistry, Madrid, Spain
Objective(s): This is an observational study to investigate
BMD response in a “real-world” population of patients
treated with strontium ranelate (SR) for the osteoporosis to
confirm that this drug is actually effective in clinical practice
as well.
Material & Methods: 74 women were recruited into the
study: 16 were taking raloxifene or bisphosphonate (prior
antiresorptive treatments group) and 58 had not received
any previous treatment (naive group). Mean age were 68
years. They received SR 2 g/day during 2 years. The bone
turnover markers assessed were P1NP and CTX (Elecsys
2010, Roche Diagnostics). BMD was measured by DXA
Hologic® QDR 4500 (c.v. in vivo 1.2%), at lumbar spine
(L2-L4) (LS), femoral neck (FN) and total hip (TH). Statis-
tical analysis included: descriptive summaries of each vari-
able, comparisons between variables by Student’s t-test for
paired samples and correlation analysis (Spearman).
Results: At baseline bone markers were lower in the
prior antiresorptive treatment group, consistent with these
antiresorptive effects, but the differences were not statis-
tically significant. One year after switching to SR, there
was a significant increase of 42.25% and 6.55% in P1NP
and CTX, respectively. And after 2 years: 41.28% and
14.48%. However in the naive group, after 1 year of
treatment there was a significant decrease of 7.85% in
CTX and 8.19% in P1NP. And after 2 years, there was a
decrease of 16.07% in CTX and 14% in P1NP. These
differences between groups were not statistically
significant. SR increased the BMD significantly at 2
years in LS 7.57%, FN 3.15% and TH 5.40%. When
we compared between both groups, naive and non-naive,
we did not find significant differences in BMD. There
were not a correlation between changes in bone turnover
markers and the BMD effects.
Conclusion(s): This study, in clinical practice population,
demonstrates that the treatment with SR in postmenopausal
osteoporotic women produces a significant increase of the
bone mass at LS, FN and TH. And we observed that these
effects do not depend on the received previous treatment, so
that the use of an antiresorptive therapy before the treatment
with SR does not decrease the effectiveness of this drug.
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PREVALENCE OF BAKER'S CYSTS IN
ELDERLY PATIENTS WITH PAINFUL
PRIMARY OSTEOARTHRITIS OF THE KNEE:
A FUNCTIONAL AND ULTRASOUND STUDY
Rodica M Traistaru, Roxana Popescu, Adrian Bighea,
Daniela Matei
University of Medicine and Pharmacy, Physical Medicine
and Rehabilitation Department, Craiova, Dolj, Romania
Objective(s): To investigate the prevalence of the Baker's cyst
(a fluid distension of a bursa between the gastrocnemius and
semimembranosus tendons via a communication with the knee
joint) in elderly patients with primary painful knee osteoarthri-
tis (KOA) and to established the correlation between functional
parameters and musculoskeletal ultrasound aspects.
Material & Methods: Prospective clinical, functional and
musculoskeletal ultrasound findings in 70 elderly
patients with primary painful KOA diagnosed by ACR
criteria were studied. The relationship between the Bak-
er's cyst and the variables joint effusion, synovitis and
functional parameters were analyzed. In all patients,
ultrasound examination was performed with the HD 11
XE Ultrasound System Philips, with the linear sound of
12.5 MHz. We used the VAS scale for pain and the
WOMAC index for functional status.
Results: Baker's cyst was found in 38 (54%) of knees or 32
(45%) of 70 patients. Only 9 of 38 cysts has been diagnosed
clinically. 10 patients (14%) had a simple Baker cyst - an
anechoic mass, sharply defined posterior wall, with posteri-
or acoustic enhancement that communicates with the knee
joint. A complex popliteal cyst - with internal echoes within
the hypo echoic mass was found in 22 (31%) patients. Joint
effusion and synovitis were detected in 54 (78%) and 44
(63%) of knees, respectively. We established a highly sig-
nificant correlation between the presence of Baker's cyst
with knee effusion and synovitis (p<0.001). There was also
a significant correlation of the presence of Baker's cyst with
WOMAC and VAS scales scores (p<0.01 and p<0.05).
S136 Osteoporos Int (2012) 23: (Suppl 2):S85–S386
Conclusion(s): Though it may be missed clinically, the
Baker's cyst is common finding in elderly KOA patients.
Therefore, ultrasound exam of knee is a very helpful imag-
ing technique in the evaluation of a popliteal mass in the
elderly patients and should be more widely employed by
clinicians in the diagnosis of Baker's cyst. According to our
results, the presence of Baker's cyst is an important deter-
minant for the WOMAC function, pain and stiffness scores
in elderly KOA patients.
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COMPLIANCE AND SATISFACTION WITH
STRONTIUM RANELATE VS. BISPHOSPHONATE
(ALENDRONATE) FOR THE TREATMENT OF
POSTMENOPAUSAL OSTEOPOROSIS IN
VENEZUELA: AN OPEN-LABEL, PROSPECTIVE,
NON RANDOMIZED OBSERVATIONAL STUDY
Luis J Lunar1, Marlen A Brakamonte2, Maria E Serafin3
1Louis Braille Foundations, Endocrinology, 2Universidad
Bolivariana, Department of Family Medicine, 3Clinica
Venezuela, Endocrinology, Caracas, Venezuela
Objective(s): This study was a 1-year, longitudinal, obser-
vational, naturalistic, multicentric, open label study with 3
investigators, designed to evaluate compliance and satisfac-
tion associated with strontium ranelate vs. bisphosphonate
(alendronate) in postmenopausal women, older than 60,
with postmenopausal osteoporosis for 12 months in Vene-
zuela. Patients were divided in two groups for analysis:
Group 1 was strontium ranelate: 2 g od. plus calcium citrate
1500 mg od vs. Group 2: alendronate: 70 mg weekly plus
calcium citrate 1500 mg od. Statistical significance was set
at p≤0.05.
Material & Methods: Results are expressed as mean±SD,
unless otherwise stated. Strontium ranelate was prescribed for
treatment of osteoporosis in 928 women and alendronate was
prescribed for the same purpose in 436 women. Women who
received strontium ranelate were younger than those who re-
ceived alendronate (68.6±6.3 vs. 69.8±7.1 years old; strontium
ranelate and alendronate, respectively; p=0.007, Student’s t-test).
Results: After 12 months of treatment, 80% of patients
who had initiated strontium ranelate and 65% of patients
on alendronate were present at the last visit. Patient
satisfaction, evaluated by a visual analog scale, from 1-
100, was statistically different between groups after 12
months of treatment (82.9±14.5 vs. 68.8±17.4; strontium
ranelate and alendronate, respectively; p<0.001, Stu-
dent’s t-test).
Conclusion(s): The compliance with strontium ranelate was
higher to compliance with the bisphosphonate used in this
study, and there was a better treatment satisfaction with
strontium ranelate, after one year of treatment, in this ob-
servational study in Venezuela.
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WHY IS IMPORTANT TO EMPHASIZE THE
RISK FACTORS FOR MALE OSTEOPOROSIS –
OBSERVATIONAL STUDY
Rodica M Traistaru, Roxana Popescu, Otilia Rogoveanu,
Ana Maria Bumbea
University of Medicine and Pharmacy, Physical Medicine
and Rehabilitation Department, Craiova, Dolj, Romania
Objective(s): In the last few years the problem of osteoporosis
in men has been recognized as an important public health issue,
particularly in light of estimates that the number of men above
the age of 70 will double between 1993-2050. After age 50, 6%
of all men will suffer a hip fracture as a result of osteoporosis.
In older men, age-related bone loss is assumed to be the cause
and several risk factors have been linked to osteoporosis in
men. In our observational study we tried to evidence the
importance of risk factors for development and evolution of
osteoporosis in patients with disabling hip fractures.
Material & Methods:We studied 42 men aged between 62-
78 years, with established hip fracture; 31 patients presented
generalized osteoporosis (defined as T-score≤-2.5 SD); 11
men had local (total hip) osteoporosis. 29 patients were treated
with antiresorptive drugs, 33 with calcium, vitamin D or both
and 9 patients got no treatment. We followed the correlations
between osteoporosis and different parameters: age, cortico-
steroids treatment, immobilization, rehabilitation program,
smoking and other unhealthy lifestyle habits.
Results: We found a significant correlations between gener-
alized and local osteoporosis and the following parameters:
the age patient (R 0.735), the functional Steinbroker class (R
0.721) and immobilization or inadequate physical exercise (R
0.697); no important correlations were found between osteo-
porosis and unhealthy lifestyle habits (smoking, excessive
alcohol use, low calcium intake); the values of correlation
and predictivity were significant for the patients with cortico-
steroids therapy for chronic lung diseases.
Conclusion(s): BMD loss occurs early in the men with hip
fracture, emphasizing that osteoporosis management should
be considered early in the rehabilitation program. The indi-
vidual patient with osteoporosis could be identified by either
a case findings strategy based on risk factor assessment for
osteoporosis or screening of all men.
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PREDICTION OF OSTEOPOROTIC FRACTURE
RISK BASED ON DAILY ACTIVITY AND HEALTH
STATUS OF THE ELDERLY IN HIROSHIMA
COHORT
Saeko Fujiwara1, Naomi Masunari2, Atsushi Harada3
1Radiation Effects Research Foundation, Dpt. Clinical Studies,
Hiroshima, 2Iwaki Meisei University, Faculty of Pharmacy,
Iwaki, Fukushima, 3National Center for Geriatrics and
Gerontology, Restorative Medicine, Obu, Aichi, Japan
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Objective(s): To determine if activities of daily living
(ADL) and health status of the elderly predict future
osteoporotic fracture in a ten-year follow-up study using a
population-based cohort.
Material & Methods: A population-based community
cohort of 1278 women with mean age of 74.9±4.8 (65-87
years) were enrolled in a prospective and longitudinal cohort
study in Hiroshima, Japan, that followed the subjects over a
10-year period. At health examinations conducted between
2000-2003, the subjects underwent measurements of spine
and hip BMD using DXA (Hologic QDR-4500), and a
questionnaire survey including information about ADL,
self-reported heath status, and pain. The subjects were fol-
lowed through biennial health examinations including chest
x-ray and others until 2010. Incident thoracic vertebral
fracture was assessed by lateral chest x-ray image at the
time of these biennial health examinations. Incident osteo-
porotic fracture cases were collected on the basis of inter-
views by trained nurses and physicians during biennial
health examinations. Association between osteoporotic frac-
ture and the questionnaire responses was analyzed by Cox
regression model.
Results: During the 10-year follow-up period, 23.6%, 2%,
and 26.5% of women developed new thoracic vertebral
fracture, hip, or “any osteoporotic fracture,” respectively.
Lower ADL, represented by such survey responses as
“difficulty preparing meals” and “difficulty reaching an
object just above your head,” predicted hip fracture risk,
and back and lumbar pain at rest or during exercise
predicted osteoporotic fracture, after adjustment was made
for age, sex, radiation dose, BMD, and prior vertebral
fracture. Hazard ratios were 4.76 (95% CI, 1.38-16.38)
for “difficulty preparing meals” and 2.10 (0.86-5.05) for
“difficulty reaching an object just above your head.” After
excluding women who had prior spine fracture at base-
line, pain at rest remained a significant predictor of oste-
oporotic fracture (HR=1.44, 1.13-1.84), but there was no
longer association between back or lumbar pain during
exercise and osteoporotic risk.
Conclusion(s): Elderly women with difficulty in ADL and
those with back pain had high risk of hip and osteoporotic
fracture.
Disclosures: This study was also supported by research
funding for Longevity Sciences (23-22) from the National
Center for Geriatrics and Gerontology (NCGG).
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COMPARISON OF CHANGE IN BONE RESORPTION
AND BONE MINERAL DENSITY WITH ONCE-
WEEKLY ALENDRONATE AND DAILY
STRONTIUM RANELATE: A RANDOMISED,
PLACEBO-CONTROLLED STUDY
Luis J Lunar1, Marlen A Brakamonte2, Maria E Serafin3
1Louis Braille Foundations, Endocrinology, 2Universidad
Bolivariana, Family Medicine, 3ClinicaVenezuela, Endocri-
nology, Caracas, Venezuela
Objective(s): To compare the effects of alendronate 70 mg
once weekly (OW) and strontium ranelate 2 g once day (OD)
on biochemical markers of bone turnover and BMD in post-
menopausal women with osteoporosis and type 2 diabetes.
Material & Methods: This was a 3-month, randomised,
double-blind, placebo-controlled study with a double-blind
extension to 18 months. The study enrolled 249 postmeno-
pausal women (alendronate 99, strontium ranelate 150 who
were ≥60 years of age at outpatient centres.
Main Outcome Measures: The primary endpoint was reduc-
tion in urine N-telopeptides of type 1 collagen (NTx) corrected
for creatinine level at 6 months. Secondary parameters included
change in BMD at the spine and hip at 6, 12 and 18 months,
NTx at 1, 6, 12 and 18 months, and serum bone-specific
alkaline phosphatase (BSAP) at 1, 6, 12 and 18 months. Ad-
verse experiences (AEs) were recorded throughout the study
for an assessment of treatment safety profiles and tolerability.
Results: Over 3 months, strontium ranelate produced a sig-
nificantly greater mean reduction in urine NTx than did
alendronate (-52% vs. -32%, p<0.001), which wasmaintained
at 12 months. Strontium ranelate produced a significantly
greater mean BMD increase than did alendronate at 6 months,
and it was maintained at 12 months at the lumbar spine (4.8%
vs. 2.8%, p<0.001) and total hip (2.7% vs. 0.9%, p<0.001), as
well as at the trochanter and femoral neck. Significant reduc-
tions in BSAP with strontium ranelate compared to alendro-
nate were maintained over the 12 months of treatment. Study
size did not allow for meaningful assessment of differences in
fracture rates. Tolerability was generally higher between
strontium ranelate vs. alendronate, and the incidence of upper
GI AEs causing discontinuation and oesophageal AEs was so
much higher in the alendronate vs. strontium ranelate groups.
Conclusion(s): In this study, strontium ranelate 2 g OD
produced a 50% greater reduction in bone resorption as
measured by urine NTx and significantly greater increases
in lumbar spine and hip BMD than did alendronate 70 mg
OW.
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EFFECT OF LOCAL BMD REFERENCE DATA ON
THE FRACTURE RISK ASSESSMENT USING FRAX
ALGORITHM
Dimuthu T Muthukuda1, Chathuranga L Fonseka2,
Anomali S Vithanagamage2, Amila Rathnapala3, Sarath
Lekamwasam2
1Kurunegala Teaching Hospital, Endocrine & Diabetes Unit,
Kurunegala, 2Faculty of Medicine, University of Ruhuna,
Department of Medicine, Galle, 3National Hospital of Sri
Lanka, Endocrine & Diabetes Unit, Colombo, Sri Lanka
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Objective(s): To determine the effect of local reference data
on fracture risk assessment using FRAX algorithm based on
T-scores
Material & Methods: A sample of 100 healthy young
females (20-30 years) was recruited by a random num-
ber generation method from a defined mixed urban and
rural geographical area representative of the Sri Lankan
population. The femoral BMD was assessed to derive
the reference T-scores for the local population. 225
postmenopausal women (34-85 years) referred for
DXA evaluation for osteoporosis, were used for fracture
risk categorization using FRAX algorithm. Medical
records were reviewed to obtain clinical risk factors.
Each patient was assessed for the fracture risk using
the FRAX tool for the US Caucasians, US Asians and
Singapore Indians based on T-scores of the NHANES
and local reference data. Major osteoporotic fracture risk
probabilities (MOFP) were compared statistically using
paired t-test.
Results: Mean (SD) femoral neck T-scores using NHANES
and local reference data were -2.24 (0.88) and -1.49 (1.47),
(p<0.001), respectively. Mean (SD) MOFP calculated using
US Caucasian FRAX model were 13.04 (7.23) when
NHANES reference data were used and 11.34 (7.78) when
the local reference data were used (p<0.001). In using US
Caucasian model, 39 patients had MOFP>20 when assessed
using NHANES reference data and 35 patients had MOFP>
20 when assessed by the local reference data (misclassifica-
tion was only 3 out of 225 patients). The corresponding
figures when US Asian model was used were 5 and 9. For
Singapore model the corresponding values were 13 and 13.
Conclusion(s): Using local reference data instead of
NHANES data to calculate T-scores of the femoral neck
did not make a significant impact on the risk categorization
using FRAX model.
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OSTEOGENESIS IMPERFECTAANDOSTEOPOROSIS:
HOWANDWHEN TO TREAT? CASE REPORT
Sofija Subin Teodosijevic1, Jelena Zvekic Svorcan2, Vladimir
Arbutinov1, Miodrag Damjanov1
1General Hospital "Dr Djordje Joanovic", Rheumatology,
Zrenjanin, 2Special Hospital for Rheumatic Diseases,
Rheumatology, Novi Sad, Vojvodina, Serbia
Objective(s): Osteogenesis imperfecta (OI) is an autoso-
mal dominant disease, caused by defect in the gene that
produces type I collagen. The aim of our research is to
show our treatment dilemmas in patient with OI and
osteoporosis.
Material & Methods: Female patient, 41 years of age, 144
cm high, weight 62 kg, BMI 29.9 g/cm2, regular periods, 2
childbirths, nonsmoker, with osteogenesis imperfecta type I
diagnosed in the childhood when she had 17 fractures. She
has typical signs of the disease - mild short stature, blue
sclera, thin skin, hearing loss, scoliosis of the spine, right
tibia deformities, low muscle tone, joint laxity and osteoar-
thritis of the right knee, which was the main reason she
came to our clinic.
Results: She was first examined in 2008, when osteodensi-
tometry was performed: T- score L2-L4 -3.0; Z-score -2.9;
BMD 0.829 g/cm2; T-score right femur total -1.2; Z-score
-1.0; Ca++ 1.01; osteocalcin 20.4 ng/ml; crosslaps 268.1 pg/
ml; ALP normal; treated with bisphosphonates during 1 year
and with 1000 mg Ca and 800 ij vitamin D daily. Next time
she came in 2011 because her orthopedist recommended
surgical treatment of the right knee and tibia. Densitometry
T-score L2-4 -3.2; Z-score -31; BMD 0.814 g/cm2; T-score
right femur -1.3; Z-score -1.1; Ca++ 0.99; osteocalcin 30.4
ng/ml; crosslaps 145 pg/ml. We decided to repeat the same
treatment with bisphosphonates and supplementation with
Ca and vitamin D.
Conclusion(s): Nearly all people with OI have osteoporosis,
since they do not develop appropriate bone mass at any age.
There are no recommendations or guidelines for treatment of
osteoporosis in OI patients. Some authors recommend use of
bisphosphonates in the childhood, and others in postmeno-
pausal period. The treatment goal is to increase bone mass
through exercise, maintaining a healthy body weight, proper
calcium and vitamin D intake, restriction of caffeine, alcohol
and smoking. Indications for usage of bisphosphonates, ter-
iparatide and selective estrogen receptor modulators still re-
main controversial. Decision must be made individually, with
long-term follow-up of changes in BMD, age and bone turn-
over markers.
P213
SAVE AWOMEN TODAY, BUILD A FUTURE
TOMORROW
Hamzeh Riyad Al-Dqour
MSD, Merck & Co., Inc., GHH, Amman, Jordan
Objective(s): To highlight the utility of World Health Bank
(WHB) initiative in the Osteoporosis settings.
Material & Methods: In depth literature review was carried
out using the keywords; Osteoporosis, Electronic Medical
Records (EMR), Patient-Centered healthcare.
Results: - Healthcare sector, across the globe, hardly struggles
to adopt new capacities in the shape of mandatory reforms.
– Being osteoporotic patient reveals the social context of
practicing medicine, in which; the treatment plan been
built all around the patients' needs.
– Establishing a convenient tool for tackling the health
status, starting directly upon confirmed being a fetus,
play major role in osteoporosis-intervention process.
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Conclusion(s): World Health Bank (WHB) provides the
integrated tool for accurate and timely data mining, which
aids in the decision making process, ensuring the best prac-
tices are developed and implemented when managing the
silent disease's settings; Osteoporosis.
References: JW Hill, AW Langvardt (2010) Business
Horizons 53:87. MW Leonard, A Frankel (2010) Patient
Education and Counseling 80:288. R Thakur R, et al (2011)
J Bus Res doi:10.1016/j.jbusres.2011.02.022
Disclosures: For the woman who gave me birth and from
whom I learned expressing my deep gratitude to life's gift;
the Women!
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THE CHAOS FALLS CLINIC IN PREVENTING
FALLS AND INJURIES AMONG HOME-DWELLING
OLDER ADULTS: A RANDOMISED CONTROLLED
TRIAL
Mika Palvanen1, Pekka Kannus1,2,3, Maarit Piirtola1, Seppo
Niemi1, Jari Parkkari4, Markku Järvinen2
1UKK Institute for Health Promotion Research, Injury & Os-
teoporosis Research Center, 2University of Tampere, Medical
School Division of Orthopaedics and Traumatology, 3Tampere
University Hospital, Department of Trauma, Musculoskeletal
Surgery and Rehabilitation, 4UKK Institute for Health Promo-
tion Research, Tampere Research Center of Sports Medicine,
Tampere, Finland
Objective(s): The study assessed the effectiveness of the
multifactorial Chaos Clinic Falls Prevention Programme on
rate of falls and related injuries in home-dwelling older adults.
Material & Methods: A pragmatic, randomised controlled
trial was conducted in home-dwelling people aged 70 years or
more with high risk of falling and fall-induced injuries.
Participants (n=1314) were randomised into intervention
group (n=661) and control group (n=653). The intervention
included a multifactorial, individualised 12-month falls
prevention programme concentrating on general physical
activity, strength and balance training, medical review and
referrals, medication review, proper nutrition (protein,
calcium, vitamin D), and home hazard assessment and
modification. When necessary, mobility assistive devices
were recommended. The control group received a general
injury prevention brochure. Both groups were followed-up
for one year. The negative binomial and the Cox proportional
hazard regression models were used in analysing rate of falls,
fallers, and fall-induced injuries (intention-to-treat basis).
Results: During the follow-up, the rate of falls was signifi-
cantly lower in the intervention group (95 falls per 100 person-
years [PY]) than in the controls (131 falls per 100 PY), the
incidence rate ratio (IRR) being 0.72 (95% CI 0.61-0.86,
P<0.001, NNT 3). The hazard ratio of fallers in the interven-
tion group compared with the controls was 0.78 (95% CI 0.67-
0.91, P=0.001, NNT 6). Respectively, the IRR of fall-induced
injuries in the intervention group was 0.74 (95% CI 0.61-0.89,
P=0.002, NNT 5). The IRR of fractures also favoured the
intervention group (0.77, 95% CI 0.48-1.23, p=NS).
Conclusion(s): The multifactorial Chaos Clinic Falls Pre-
vention Programme was effective in preventing falls of
older adults. The programme reduced the rate of falls and
related injuries by almost 30%.
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FEATURES OF CHANGES IN BONE REMODELING
BY THE COMBINED USE OF IBANDRONATE AND
ALFACALCIDOL AT THE PATIENTS WITH
POSTMENOPAUSAL OSTEOPOROSIS
Svetlana Rodionova, Aleksey Elovoy-Vronskiy
N.N.Priorov Central Institute of Traumatology and Orthopedics
(CITO), Center of Osteoporosis, Moscow, Russian Federation
Objective(s): Extent suppression of the intensity bisphosph-
onate bone formation remains a debate subject. Appropriate to
compare the intensity of decrease the bone resorption markers
and bone formation using ibandronate in combination with
alfacalcidol at the patients with postmenopausal osteoporosis
Material & Methods: During 12 months the 57 women’s
age from 56-86 years, with the duration of postmenopause >1
year, and low serum vitamin D3 level have been received once
in 3 month ibandronate IV and daily 0.75-1.25 μg of alfacal-
cidol (the doses correction was depended from bloods calcium
level) with 1500 mg of calcium carbonate per os daily. After
12 month from the beginning bone density measurements
were done with using x-ray absorptiometry. Every 3 month
blood calcium and urinary phosphor levels were analyzed and
once in 6 month sCTX and osteocalcin, DPD of urine levels
were analyzed too. The paired Student's criterion with 95% CI
was used for the analysis of two measurements.
Results: After 12 month from the beginning of treatment was
a significant increase of BMD in spine (L1-L4) at 4% from
0.820±0.041 to 0.854±0.042 (p=0.0001) and femoral neck at
2.7% from 0.719±0.036 to 0.739±0.034 (p=0.049). After 6
month the sCTX level significantly decreased from 0.59±0.08
to 0.2± 0.12 ng/ml (p=0.019) and at 12 moth this
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measurement resulted 0.18±0.08 ng/ml (p=0.00001). After 6
months from the beginning of therapy the value of DPD urine
decreased from 7.0±0.68 to 5.7±0.76 nmol/l and did not
significantly changed with the result 5.0±0.72 (p=0.002)
nmol/l to 12 month. After 6 month the osteocalcin blood level
didn't significantly changed and after 1 year decreased from
21.5±4.2 to 13.5±2.8 ng/ml (p=0.0001). The changes of
bone metabolism markers were in reference range.
Conclusion(s): Accordingly decrease in the rate of resorp-
tion under the influence of ibandronate and alfacalcidol
ahead decrease bone formation at 6 months, which provides
marked increase in BMD.
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BONE ALKALINE PHOSPHATASE AND
OSTEOCALCIN AS MARKERS OF OSTEOPOROSIS
IN POSTMENOPAUSALWOMEN WITH BREAST
CANCER AND BONE METASTASES
Franco Lumachi1, Laura Loriggiola2, Filippo Marino3,
Renato Tozzoli4, Davide A Santeufemia5, Stefano MM
Basso6
1University of Padua, School of Medicine, Department of
Surgical & Gastroenterological Sciences, 2University of
Padua, School of Medicine, 3University of Padua, School of
Medicine, Department of Pathology, Padova, 4S. Maria degli
Angeli Hospital, Department of Clinical Pathology, 5S. Maria
degli Angeli Hospital, Clinical Oncology, Pordenone, 6S.
Maria degli Angeli Hospital, Chirurgia 1, Friuli, Italy
Objective(s): Breast cancer (BC) is a heterogeneous tumor
that occurs predominantly in elderly women. The overall
estimated number of new BCs in the USA in 2011 was
232,000, accounting for about one-third of cases of cancer in
women. It continues to be one of the most common causes of
cancer death. BC frequently metastasizes to the skeleton, and
it is estimated that 85% of individuals with advanced disease
harbor bone metastases (BM). Bone alkaline phosphatase
(BAP) and osteocalcin are widely used to check the response
to therapy in patients with progressive bone disease. The aim
of this study was to evaluate whether a correlation exists
between bone remodeling serum markers BAP and osteocal-
cin, and BMD in women with BC and BMs.
Material & Methods: Data from a group of 18 postmeno-
pausal women (median age 65 years, range 54-74 years)
who have undergone surgery for invasive BC and succes-
sively developed BMs were retrospectively analyzed. Lum-
bar spine (L2-L4) BMD using DXA, and serum BAP and
osteocalcin were measured in all patients. According to the
WHO criteria, 13 patents (subgroup A) had mild or moder-
ate osteoporosis (T-score -2.5 through -4 SD), while 5
(subgroup B) had severe osteoporosis (T-score of<-4 SD).
Results: Age (62.2±5.6 vs. 68.8±4.2 years, p=0.061),
baseline BAP (27.8±7.3 vs. 34.8±7.4 U/L, p=0.088) and
osteocalcin (22.8±7.4 vs. 31.4±8.7 ng/mL, p=0.081) did
not differ significantly (subgroup A vs. B). There was no
relationship between age, BMD, BAP and osteocalcin se-
rum levels in subgroup B, while in the subgroup A, only a
week correlation (R=0.72, p=0.018) between BAP and
osteocalcin was observed, and no relationship (p=NS)
between BMD, age, and serum markers was found.
Conclusion(s): In patients with BMs from advanced BC,
the action of local osteolytic factors, such as PTHrP, togeth-
er with direct bone resorption by lytic metastasis, may cause
a severe bone disease. In postmenopausal women with BC
and BMs the effects on bone of age and cancer together
likely overlap, and the relationship between age, BMD, and
bone remodeling serum markers is not maintained.
References: Lumachi F et al. Anticancer Res 2009;29:1551.
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OSTEOPROTEGERIN GENE POLYMORPHISM
AND THE RISK OF LOW BONE MASS IN TYPE 1
DIABETIC PATIENTS
Alla P Shepelkevich1, Helena A Kholodova1, Svetlana I
Marchuk1, Natalia S Kabak1, Volha V Zhukouskaya2,
Sergei S Korytko3
1Belarusian State Medical University, Internal Disease Chair
No 1, Minsk, Belarus, 2University of Milan, Department of
Endocrinology, Milan, Italy, 3Republican Medical Rehabilita-
tion and Balneotherapy Centre, Department for Radiology,
Minsk, Belarus
Objective(s): Osteoporosis has a complex etiology and
is considered to be a multifactorial polygenic disease.
There are more than 100 genes which predispose to low
bone mass and poor bone quality. Meanwhile osteopro-
tegerin plays a central role in the processes of bone
formation and bone resorption. Our aim was to investi-
gate the frequency of occurrence of OPG (-209 G/A)
and OPG (-245 T/G) SNPs and its association with
BMD in type 1 diabetics.
Material & Methods: 51 examined patients were divided
into two groups: the first one includes 33 patients with
normal BMD (Z-score more than -1.5: L1-4 0.03; femoral
neck 0.03; total 0.38) and the second one includes 18
patients with low BMD (Z-score less than -1.5: L1-4 -
1.37; T neck -1.75; total -1.48). BMD was measured by
DXA. QIAamp DNA Blood Mini Kit (Qiagen, USA) was
used to purify DNA from whole blood, gene polymorphisms
were detected in sequence analysis. Patients with comorbid-
ities and conditions associated with low BMD were exclud-
ed from the study.
Results: 29 (88%) patients with OPG (-209 G/A) GG ge-
notype were detected in the group with normal BMD vs. 12
(67%) patients in the second group (p=0.001). Meanwhile
there were 4 (12%) and 6 (33%) patients with OPG (-209 G/
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A) GA genotype in the first and the second group corre-
spondingly (p=0.001). OPG (-245 T/G) TT genotype were
revealed 29 (88%) patients in the group with normal BMD
and 12 (67%) patients in the group with low BMD) (p=
0.001). OPG (-245 T/G) TG genotype was revealed in 4
(12%) patients with normal BMD and 6 (33%) patients in
the second group (with low BMD) (p=0.001). Patients with
OPG (-209 G/A) GA and OPG (-245 T/G) TG genotypes
have significantly lower BMD in spine (p=0.021 and p=
0.044, respectively) and femoral neck (p=0.035 and p=
0.044, respectively), total hip (p=0.044 and p=0.044, re-
spectively) regions than in patients with OPG (-209 G/A)
GG genotype and OPG (-245 T/G) TT genotypes,
respectively.
Conclusion(s): The results of the study reflect the high
frequency of OPG (-209 G/A) and OPG (-245 T/G) SNPs
in type I diabetic patients with low BMD. Our results
potentially explain the possible mechanisms of bone loss
in these patients.
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THE BONE HEALTH CLINIC: SUCCESSES
OF AN EVIDENCE-BASED SERVICE IN
PROVIDING SCREENING, PREVENTION
AND TREATMENT OF OSTEOPOROSIS
IN THE NORTHWEST
REGION, IRELAND
Mohamed Ahmed1, Bridie Rooney1, Bernie McGowan2,
John Doherty1
1Sligo General Hospital, The Bone Health Clinic, 2The
North Western Rheumatology Unit, Our Lady's Hospital,
Research Department, Manorhamilton, Sligo, Ireland
Objective(s): To audit the service provided by the bone
health clinic at Sligo General Hospital (SGH) in providing
the required care standard for screening, prevention and
treatment of patients with or at high risk of osteoporosis.
Material & Methods: Data was collected from October
2007 - February 2011 on adult patients attending the Bone
Health Service at SGH. Patient-related information and
BMD results were recorded in the DXA dataset. Treatment
recommendations were set depending on the risk profile and
the densitometry result.
Results: A total of 2196 patients attended the Bone Health
Service at SGH between October 2007 - February 2011, of
whom 82.5% were female. The mean age was 67.4 years
(±10.3).The indication for DXA assessment was docu-
mented in 88.5% of referrals (n=1942). A history of low
trauma fracture was the commonest indication (25.5%) fol-
lowed by screening of postmenopausal women for osteopo-
rosis (20%).
Most of the requests (45%) for DXA scanning came from
Internal Medicine Specialists (n=873). GP open access referrals
accounted for 31.1% (n=605).Other sources included the Frac-
ture clinic and the Fracture Liaison service (20.8%/n=407). One
third of our cohort were diagnosed with osteoporosis (n=730)
and of those 45.5% had severe osteoporosis.44.6% of our
patients were osteopenic (n=981) with less than one quarter
having normal BMD (n=484). Antiresorptive therapy was ini-
tiated in 19.9% of cases (n=389) with an additional 13.7% (n=
267) advised to continue their current antiresorptive treatment.
300 patients (15.3%) were advised to commence calcium/vita-
min D supplements and 287 patients (14.7%) were encouraged
to optimize their dietary calcium and vitamin D intake.
Conclusion(s): Over a three year period, the bone health
clinic at SGH provided a successful evidence based service
for the early detection, prevention, treatment and follow-up
of patients with or at high risk of osteoporosis.
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ASSOCIATION BETWEEN ABDOMINAL FAT MASS
MEASURED BY CTAND BONE MINERAL DENSITY
IN KOREAN MEN
Hyun Su Kim, DongWook Shin, Ho Chun Choi, Belong Cho
Seoul National University Hospital, Department of Family
Medicine, Seoul, Republic of Korea
Objective(s): The protective effect of total fat mass on
BMD has been challenged and the effect of central obesity
on bone has been shown inconsistently. The aim of the
present study was to investigate the association between
abdominal fat mass and BMD.
Material & Methods: A total of 634 subjects who under-
went abdominal CT during health check-ups were studied.
BMD was measured at lumbar spine (L-spine) by using
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DXA. Abdominal fat mass including visceral, subcutaneous
and total fat was measured and calculated by CT. We exam-
ined the effect of central obesity on BMD by multiple
regression after adjusting age, body weight, physical activ-
ity, smoking, alcohol intake and vitamin D level in serum.
Results: The median age was 50 years (interquartile range,
26-60 years). L-spine BMD showed a positive correlation
with body weight, and a negative correlation with waist cir-
cumference by bivariate correlation analysis. Multiple regres-
sion analysis after adjusting age, body weight, physical
activity, smoking, alcohol intake and vitamin D level in serum
showed that body weight and waist circumference were sig-
nificant determinants of the L-spine BMD (R2=0.124, P<
0.001). Although when we performed bivariate correlation,
central obesity such as visceral, subcutaneous and total fat had
the positive correlation with L-spine BMD. However, multi-
ple regression after adjusting age, body weight, physical ac-
tivity, smoking, alcohol intake and vitamin D level in serum
showed that total and subcutaneous fat had the negative cor-
relation with L-spine BMD. In addition, there was no signif-
icant association visceral fat and L-spine BMI.
Conclusion(s): In this Korean male population, L-spine
BMD showed a consistently positive correlation with
weight and a negative correlation with waist circumference,
especially total and subcutaneous fat.
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EFFICIENCY OF COLLAGEN INJECTIONS "GUNA
MDs" IN PATIENTS WITH GONARTHROSIS,
ASSESSED CLINICALLY AND BY ULTRASOUND
Rodina Nestorova1, Rasho Rashkov2, Valentina Reshkova2,
Nadejda Kapandjieva3
1Rheumatology Centre "St. Irina", Sonography Department,
Sofia, 2MBAL "St. Ivan Rilski", Rheumatology Clinic "St.
Ivan Rilski", Sofia, 3MBAL Russe, Rheumatology Depart-
ment, Russe, Bulgaria
Objective(s): This study is to investigate the effectiveness
of collagen injections Guna-Knee+Guna-Matrix on pain
and daily functioning in symptomatic knee osteoarthritis
III-IV X-ray stages by Kellgren.
High frequency ultrasonography is an approved imaging tech-
nique for diagnosis of joint swelling and monitoring of therapy.
Material & Methods:We studied 25 patients aged between
62-79. All patients are clinically evaluated by joint assess-
ment, as well as by standard X-ray and ultrasonography of
the knee. Questionnaires completed by the patients before
treatment, 60th and 90th day evaluation of pain at rest using
a 10-point visual analog scale (VAS), pain assessment dur-
ing movement of the knee in 10-point VAS, assessment of
the Lequesne index on gonarthrosis/ algo-functional index/
and evaluation of the efficacy of the treatment according to
the patient and the physician were performed. All patients
had sonographic examination of both knees with Mindray
M5(China) scanner with multifrequency linear transducer
(8-12 MHz) at beginning and 30 days after completion of
the treatment. We applied a combination of GUNA MD-
Knee and GUNA MD-Matrix periarticularly, 10 ampoules
in the following scheme: during the first 2 weeks - 2 appli-
cations per week and during the next 6 weeks - 1 application
per week in a single course of treatment 8 weeks.
Results: Pain at rest and pain during movement are signifi-
cantly reduced and the effect on pain remains after treatment.
There is a statistically significant improvement in the index of
Lequesne. Total of 68% of patients gave a very good and better
assessment of efficacy, which coincides with the opinion of the
physician. Of all patients 60% were without joint swelling 30
days after treatment, which is sonographically proved.
Conclusion(s): Periarticular administration of collagen injec-
tions GUNA-MDs inGonarthrosis III-IV Rö stage significant-
ly affects pain, swelling and functional activity of the knee,
thereby increasing the quality of life of the patient. The effec-
tiveness of GUNA-MDs continues after discontinuation of
treatment. No side effects were registered throughout the
whole course of treatment with GUNA-MDs.
Disclosures: Olivier Meyer: Président du comité de sécurité
(safette committee) du ranelate de strontium, Membre du
comité de surveillance DRESS du ranelate de strontium
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RECURRENTFRACTURESAFTERPERCUTANEOUS
VERTEBROPLASTY OVER 1 YEAR:
COMPARISONWITH MEDICATION
Sang Beom Kim, Kyeong Woo Lee, Jong Hwa Lee, Min Ah
Kim
Dong-A University College of Medicine, Physical Medicine
and Rehabilitation, Busan, Korea
Objective(s): To compare the long term outcomes of per-
cutaneous vertebroplasty (PV) with medication for vertebral
compression fractures (VCF).
Material & Methods: This retrospective study compared
patients treated by PV for VCF (group A) with patients treated
by medication only for the same condition (group B) over a
year. Medication group received oral bisphosphonate and
calcium citrate. We reviewed 44 patients with vertebral frac-
tures who underwent PV between June 2006 - April 2010. We
also reviewed 60 patients with vertebral fractures who under-
went medical treatment without PV between June 2006 - April
2010. Pain reduction and newly diagnosed VCF were evalu-
ated. Pain was measured using visual analogue scale (VAS).
Additional VCF was evaluated by follow up radiograph.
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Results:
General Characteristics of Patients
Variables Group A (N=44) Group B (N=60)
Sex (M : F) 6 : 38 9 : 51
Mean duration
after VCF (months)
31.4±12.5 (13~60) 27.4±15.6 (13~81)
Age (years) 71.0±9.0 71.5±6.9
Height (cm) 154.1±8.8 156.7±6.9
Weight (kg) 54.7±10.6 54.7±10.6
44 patients (6 males, 38 females, 71±9 years) were in group
A and 60 patients (9 male, 51 female, 71.5±6.9 years) were
in group B. The mean duration after VCF was 31.4±12.5
months in group A and 27.4±15.6 months in group B. There
was no significant difference in the sex, age and the duration
after onset between two groups. In group A, 15 (34.1%)
patients suffered newly developed VCF. In group B, 20
(33.3%) patients suffered newly developed VCF. There
was no significant difference in the incidence of newly
developed VCF between the two groups. Also incidence
of new adjacent level fractures between two groups did
not show significant difference. VAS reduction was more
prominent within 1 week after PV (P<0.05).
Conclusion(s): Compared with medication, PV provided
immediate pain reduction and did not increase the incidence
of additional VCF.
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THE PREVALENCE OF COGNITIVE IMPAIRMENT
IN ELDERLY HIP FRACTURE PATIENTS
SangBeomKim,KyeongWooLee, JongHwaLee,MinAhKim
Dong-A University College of Medicine, Physical Medicine
and Rehabilitation, Busan, Korea
Objective(s): To examine the prevalence of cognitive im-
pairment in elderly people with hip fracture.
Material & Methods: Experimental group were consisted
with 21 hip fracture patients aged over 60 years. Control
group were 21 age-matched inpatients without hip fracture.
We measured cognitive impairment using the Mini Mental
State Examination (MMSE). Subjects were interviewed us-
ing questionnaire including past history of neurologic dis-
order or dementia and location of fracture occurred.
Results: The mean age of enrolled both group were 77±4
years. The mean MMSE score in the control group was 26.2
and experimental group was 20.3. The MMSE score of the
experimental group was significantly lower than the control
group (p<0.001*). Eight patients(38%) of the experimental
group had known dementia or old cerebral vascular accident
(CVA) history and none of the control group had dementia or
CVA history. Seven patients(33%) of the experimental group
had first detected cognitive impairment during investigation.
Overall, 15 patients (71%) of the experimental group had
severe cognitive impairments. Most patients (71%) of the
experimental group had history of fracture in their own house,
and these patients had more severe cognitive impairment
(mean MMSE score: 19) than patient with outside trauma
history (mean MMSE score 23.5, p<0.001*).
General Characteristics of Patients
Character Number of the
Experimental group
Number of the
Control
Total Number 21 (Male: 9,
Female: 12)
21 (Male: 7,
Female: 14)
Mean Age 77±4 years 72±4 years
Previous Cognition
impairments
8 0
Fracture in house 15 0
Conclusion(s): Many elderly patients with hip fracture had
more cognitive impairment than other peer group without
hip fracture. And most hip fractures happen in one's own
house. Detection of cognitive impairment and education is
important to prevent hip fracture in old generation.
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PRINCIPLES OF DIAGNOSIS AND MANAGEMENT
FOR ACUTE JUNCTION SYNDROME PATIENTS
Anton S Povzun
Saint-Petersburg Scientific Research Institute of Emergency
Care n.a. I.I. Dzhanelidze, Nephrologu and Rheumatology,
Saint-Petersburg, Russian Federation
Objective(s): Acute junction syndrome (AJS) appears as a
complex of clinical symptoms follow up several nosological
issues.
Material & Methods: Patient's condition is characterized
by intensive inflammation and/or pain syndromes, which
requires his hospitalization. Acute junction syndrome term
should be used as a medical diagnosis for prehospital period
of medical care due to necessity of patient concentration in
the specialized units and for providing medical diagnosis
and successful medical care. Due to minimization of inpa-
tient period pain relieve and verification of the clinical
picture should be done simultaneously in specialized units
of emergency multiple care hospitals.
Results: In according to this conception AJS patients are
hospitalized and managed in Research Institute of Emergency
Care n.a. I.I. Dzhanelidze. From the beginning of patient ad-
mission we use the special diagnostic algorithmwith a complex
of diagnostic procedures provided to decrease time of differen-
tial diagnosis and verification of concrete nosological form of
disease. All 349 patients firstly divided to neurological, trau-
matological, infection diseases, oncological and rheumatolog-
ical groups. Inside each group further verification is required.
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Certain diagnostic approach used to divide AJS patients in
rheumatology group. First, clinical, laboratory and instrumental
investigation separates arthrosis and arthritis subgroups. After
that we use X-ray examination and immunological investiga-
tion to verify the concrete nosological form of connective tissue
diseases. During all diagnostic period from the beginning of
hospitalization patients receive nonspecifically treatment in-
cluding NSAIDs. After verification of diagnosis patients begin
to receive DMARDs and other etiological treatment.
Conclusion(s): Earliest diagnosis verification in AJS
patients allows accelerate the beginning of etiological treat-
ment that improves the disease outcome.
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ASSOCIATION BETWEEN CALCIUM-REGULATING
HORMONES PTH, 25(OH)D AND IGF-I, AND BMD
INELDERLYWOMENWHOWERENOTESTROGEN
OR BISPHOSPHONATES USERS
Franco Lumachi1, Laura Loriggiola2, Valentina Camozzi3,
Renato Tozzoli4, Stefano MM Basso5
1University of Padua, School of Medicine, Department of
Surgical & Gastroenterological Sciences, 2University of
Padua, School of Medicine, 3Istiututo Oncologico Veneto
(IOV), IRCCS, Bone Metabolism Unit, Padova, 4S. Maria
degli Angeli Hospital, Department of Clinical Pathology, 5S.
Maria degli Angeli Hospital, Chirurgia 1, Pordenone, Italy
Objective(s): Secondary hyperparathyroidism is a frequent
condition in elderly women, and represents a risk factor for
increased bone resorption. Measurement of BMD is current-
ly considered of diagnostic value to predict an individual
long-term fracture risk, and BMD values correlate with
several demographics and anthropometric parameters, and
with markers of bone metabolism and calcium-regulating
hormones. The aim of this study was to evaluate the rela-
tionship between BMD, BMI, PTH, vitamin D (25(OH)D),
and IGF-I in elderly women.
Material & Methods: A group of 31 postmenopausal wom-
en over age 65 (median 68 years, range 65-74) who were not
bisphosphonates, estrogen, calcium or vitamin D users, and
had no history of fracture, were enclosed in the study. The
following parameters have been recorded: age, age at menar-
che and menopause, weight, height, BMI (kg/m2), systolic and
diastolic blood pressure. Lumbar spine (L2-L4) BMD (g/cm2)
using DXA, serum albumin, calcium, PTH (ng/L), 25(OH)D
(nmol/L), and IGF-I (μg/L) were measured in all patients.
Results: The main results are reported in the Table. There
were no hypertensive patients, and both s-albumin and s-cal-
cium were within the normal range (41-47 g/L, and 2.10-2.55
mmol/L, respectively). There was an inverse correlation be-
tween age and both 25(OH)D (R=-0.50, p=0.020) and IGF-I
(R=-0.7, p<0.0001), and between BMD and PTH (R=-0.48,
p=0.027). Moreover, a significant relationship between IGF-I
and both BMD (R=0.64, p=0.0016) and PTH (R=0.48, p=
0.026) was found, while IGF-I did not correlate with 25(OH)D
(R=0.16, p=0.47) and BMI (R=-0.89, p=0.70). Age at men-
arche and menopause were independent parameters (p=NS).
Age
(years)
Age at
menarche
and
menopause
(years)
BMI
(kg/
m2)
BMD
(g/
cm2)
PTH
(ng/
L)
25(OH)
D
(nmol/
L)
IGF-I
(μg/
L)
Mean 68.4 12.8/49.6 25.1 0.790 72.1 48.6 117.4
SD 2.2 1.6/4.2 2.1 0.058 12.5 19.2 63.1
Conclusion(s): In this group of elderly women there was a
strong relationship of osteoporosis (expressed as BMD val-
ues) to calcium-regulating hormones, such as PTH and IGF-
I, while BMI and 25(OH)D seem to be independent of bone
mineralization status.
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RELATIONSHIP BETWEEN BONE REMODELING
SERUMMARKERSANDBMD IN PREMENOPAUSAL
WOMENWITH ADVANCED BREAST CANCER
Franco Lumachi1, Laura Loriggiola2, FilippoMarino3, Renato
Tozzoli4, Davide A Santeufemia5, Stefano MM Basso6
1University of Padua, School of Medicine, Department of
Surgical & Gastroenterological Sciences, 2University of
Padua, School of Medicine, 3University of Padua, School
of Medicine, Department of Pathology, Padova, 4S. Maria
degli Angeli Hospital, Department of Clinical Pathology, 5S.
Maria degli Angeli Hospital, Clinical Oncology, 6S. Maria
degli Angeli Hospital, Chirurgia 1, Pordenone, Italy
Objective(s): In cancer patients, metastatic bone disease is
not uncommon, and the prevalence of bonemetastasis (BM) is
high especially among patients with prostate and breast cancer
(BC). BMs may usually complicate with different skeletal
morbidity, such as pain, spinal cord compression, pathologic
fracture, and malignancy-related hypercalcemia. Early detec-
tion of BM is usually obtained by imaging study procedures,
but bone turnover serummarkers measurement may be useful.
The aim of this study was to assess the relationship between
bone formation markers bone alkaline phosphatase (BAP),
osteocalcin, and amino-terminal propeptide of type I collagen
(PINP), bone resorption marker carboxyterminal crosslinked
telopeptide of type I collagen (CTx) and PTH, and BMD in
premenopausal women with advanced BC and BMs.
Material & Methods: A group of 19 women (median age 45
years, range 34-51) with BC and BMs were enrolled in the
study. All patents underwent lumbar spine (L2-L4) BMD mea-
surement using DXA. BAP (U/L), osteocalcin (ng/mL), PINP
(ng/mL), CTx ng/mL), and PTH (ng/L) serum levels were also
assayed. According to BMD results, patients were considered as
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having osteopenia (T-score>-2.5 SD, Group 1=11 patients) or
osteoporosis (T-score<-2.5 but>-4 SD, Group 2=8 patients).
Results: No correlation was found (Group 1 vs. 2) between
BMD and BAP (R=-0.50, p=0.13 vs. R=-0.48, p=0.21), osteo-
calcin (R=-0.23, p=0.51 vs.R=-0.41, p=0.19), PINP (R=-0.41,
p=0.22 vs. R=-0.32, p=0.43), CTx (R=0.46, p=0.18 vs.
R=0.15, p=0.51), and PTH (R=0.19, p=0.64 vs. R=0.20,
p=0.56) in both Groups. The figure shows the relationship be-
tween BMD, osteocalcin and BAP in Group 1 (left) and 2 (right).
Conclusion(s): In premenopausal women with BC and
BMs, lumbar spine BMD values are independent of bone
turnover serum markers levels, both in patients with osteo-
penia and in those with osteoporosis. Bone resorption by
lytic micrometastasis could be the cause of further bone
impairment.
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USEFULNESS OF ICTP AND TRACP5b
MEASUREMENTS IN WOMEN WITH BONE
METASTASES FROM BREAST CARCINOMA
AND SEVERE OSTEOPOROSIS: PRELIMINARY
RESULTS
Franco Lumachi1, Laura Loriggiola2, FilippoMarino3, Renato
Tozzoli4, Davide A Santeufemia5, Stefano MM Basso6
1University of Padua, School of Medicine, Department of
Surgical & Gastroenterological Sciences, 2University of
Padua, School of Medicine, 3University of Padua, School
of Medicine, Department of Pathology, Padova, 4S. Maria
degli Angeli Hospital, Department of Clinical Pathology, 5S.
Maria degli Angeli Hospital, Clinical Oncology, 6S. Maria
degli Angeli Hospital, Chirurgia 1, Pordenone, Italy
Objective(s): Bone is the first site of distant metastases in
patients with breast cancer (BC). Bone lysis induced by cancer
cells invading the bone and promoting degradation of mineral
matrix, together with the production of PTH-like peptides,
represent the mechanisms of cancer-induced hypercalcemia.
Bone metastases (BMs) are a frequent complications in BC.
They are usually detected by whole body bone scintigraphy,
which unfortunately presents low sensitivity and specificity,
visualizing areas of increased osteoblastic activity. In patients
with BMs a number of urinary and serum markers are altered.
Tartrate-resistant acid phosphatase (TRACP5b), specifically
derived from osteoclasts, is a promising marker of bone re-
sorption. Moreover, increased concentrations of carboxyter-
minal telopeptide of type I collagen (ICTP), a crosslinked
product of collagen I degradation, have been observed in
patients with BMs. The aim of this preliminary study was to
evaluate the usefulness of TRACP5b, ICTP and bone alkaline
phosphatase (BAP) in patients with BMs from BC and severe
osteoporosis.
Material & Methods: A group of 12 women (median age
66 years, range 56-72 years) with BC, severe osteoporosis,
and radiologically confirmed isolated BMs (cases), and 15
age- and stage-matched women without BMs (controls),
were retrospectively reviewed. All patients underwent serial
measurement of TRACP5b, ICTP, and BAP. The cut-off
values considered were 3.6 U/L, 4.2 U/mL, and 68 U/mL
for TRACP5b, ICTP, and BAP, respectively. Odds ratios
(OR) calculation with the 95% CI, Fisher exact probability
test, and Student's t-test were used to compare variables.
Results: The mean levels of TRACP5b, ICTP, and BAP
(cases vs. controls) were 6.2±2.8 vs. 3.2±1.2 (t=3.62, p=
0.0014) U/L, 8.3±6.4 vs. 4.2±1.6 (t=2.32, p=0.029) U/mL,
and 151.3±98.6 vs. 72.5±26.4 (t=2.87, p=0.0085) U/mL,
respectively. The corresponding OR were 7.20 (95% CI
1.06-48.64, p=0.043), 6.41 (95% CI 1.09-37.73, p=
0.041), and 1.60 (95% CI 0.32-7.84, p=0.42), respectively,
while the OR for TRACP5b and ICTP together was 9.77
(95% CI 1.55-61.64, p=0.014).
Conclusion(s): Our preliminary study shows that in osteopo-
rotic patients with BC the elevation of both TRACP5b and
ICTP correspond to a 9.8-fold higher risk of having BMs.
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POLYMORPHISMS OF THE HUMAN IL-1
RECEPTOR ANTAGONIST GENE AND FOREARM
BONE MINERAL DENSITY IN POSTMENOPAUSAL
WOMEN
Jivka T Ivanova1, Mihail A Boyanov2, Andon K Toshev1
1Medical University Sofia, Biology, 2Alexandrovska Hospi-
tal, Medical University Sofia, Endocrinology Clinic, Sofia,
Bulgaria
Objective(s): The objective of this case-control study was
to investigate the association between the forearm BMD and
the IL1RA gene polymorphisms.
Material & Methods: 400 postmenopausal Bulgarian
women participated. BMD was measured at the forearm
by X-ray absorptiometry on a DTX-100 device (Osteometer
Meditech, USA). A PCR product was isolated. The alleles
were scored according to their length: A1 – 410 bp – 4
repeats; A2 – 240 bp – 2 repeats; A3 – 500 bp – 5 repeats;
A4 – 325 bp – 3 repeats; A5 – 595 bp – 6 repeats. All
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analyses were evaluated for statistical significance (χ2-test
and T-test).
Results: Four alleles were observed – A1, A2, A3 and A4.
The A1A1 genotype was more common in cases with low
BMD than in controls with normal BMD (95% vs. 90%, χ2
p<0.01). The A2A2 genotype was equally distributed
among cases and controls (both 5%). The other two geno-
types (A3A3 and A4A4) as well as A1A3 were present only
in controls with normal BMD. The A2A2 genotype was
associated with higher BMD and the A1A1 - with lower
BMD at both forearm sites. The odds ratio for low BMD in
the presence of the A1A1 genotype was 2.11. The etiolog-
ical factor reflecting the association between the polymor-
phism and the disease was 0.50.
Conclusion(s): In our study sample the IL1RA genetic
polymorphisms were associated with the forearm BMD.
This genetic polymorphism may become a useful genetic
marker for the study of osteoporosis.
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RELATIONSHIPBETWEENCLINICALSARCOPENIA
AND POSTMENOPAUSAL OSTEOPOROSIS,
FRACTURES AND FALLS
Samu Sjöblom1, Juha Suuronen1, Toni Rikkonen1, Joonas
Sirola1,2, Heikki Kröger1,2
1University of Eastern Finland, Bone and Cartilage Research
Unit (BCRU), 2Kuopio University Hospital, Department of
Ortopaedics and Traumatology, Kuopio, Finland
Objective(s): The aim of the study was to examine the
relationship between clinical sarcopenia and osteoporosis.
Material & Methods: Study sample: a population-based
cohort of 591 Finnish postmenopausal women (mean age
67.9; range 65-72) from the Osteoporosis Fracture Preven-
tion (OSTPRE-FPS) study. Outcome measures: BMD and
total body scan were assessed by DXA. The study sample
was divided into three categories according to WHO BMD
criteria: normal (n=276), osteopenia (n=289) and osteopo-
rosis (n=26). Furthermore, the study sample was divided
into sarcopenic and nonsarcopenic groups according to
quartiles of relative skeletal muscle mass index (RSMI)
(appendicular muscle mass (kg)/height (m)2), hand grip
strength (kPa) and walking speed. Nonsarcopenic women
were not in the lowest quartile in any measurement (RSMI,
grip strength or walking speed) whereas sarcopenic women
were in the lowest quartile of RSMI and either muscle
strength or walking speed or in both.
Fractures were assessed based on self-reports according to
postal inquiry and falls were registered by telephone interviews.
Results: Multinomial regression analysis revealed that in
comparison to non-sarcopenic women, sarcopenic women
had 12.9 times higher odds of having osteoporosis (p≤
0.001, OR=12.9; 95% CI=3.1-53.5). In comparison to
women within the highest grip strength quartile, women
within the lowest quartile strength had 11.7 times higher
odds of having osteoporosis (p=0.001, OR=11.7; 2.6-53.4).
Sarcopenic women had 2.7 times higher odds of having
fractures compared to nonsarcopenic women (p=0.005,
OR=2.732; 1.4-5.5). Sarcopenic women had also 2.1 times
higher odds of having falls during the last year compared to
nonsarcopenic women (p=0.021, OR=2.1; 0.3-0.8). Finally,
the adjustment with age, BMI, physical activity and hor-
mone therapy (HT) did not significantly alter these results.
Conclusion(s): Clinical sarcopenia was significantly asso-
ciated with osteoporosis. Grip strength was the most signif-
icant measurement to show association between sarcopenia
and osteoporosis, falls and fractures.
Disclosures: The study was supported by Kuopio Universi-
ty Hospital EVO-grants and Ministry of Education and
Culture.
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SOFT TISSUE BODY COMPOSITION AND
FUNCTIONAL RECOVERY FOLLOWING A
FRAGILITY FRACTURE OF THE HIP: AN
OBSERVATIONAL STUDY OF 502 WOMEN
Marco Di Monaco1, Carlotta Castiglioni1, Elena De Toma2,
Luisa Gardin2, Silvia Giordano2, Roberto Di Monaco3, Rosa
Tappero1
1Presidio Sanitario San Camillo, Osteoporosis Research
Center and Division of Physical Medicine and Rehabilita-
tion, 2Presidio Sanitario San Camillo, Service of Occupa-
tional Therapy, 3University, Department of Social Science,
Torino, Italy
Objective(s): To investigate the association between lean
and fat components of soft tissue body composition and
functional recovery in hip-fracture women.
Material & Methods: We investigated 502 of 560 women
admitted consecutively to our rehabilitation hospital following
a fragility fracture of the hip. Soft tissue body composition was
assessed by DXA, 20.1±6.9 (mean±SD) days after fracture
occurrence. Appendicular LM (aLM)was calculated as the sum
of LM in arms and legs. Fat mass (FM) was calculated as the
sum of FM in arms, legs, and trunk. Because metal implants
(prostheses, plates, nails, and screws) affect the regional assess-
ment of body composition, measures of soft tissue from unfrac-
tured legs were substituted for measures of soft tissue in
fractured legs as previously described: corrected aLM=(LM
in unfractured leg x 2)+LM in arms; corrected FM=(FM in
unfractured leg x 2)+FM in arms+FM in trunk. To adjust both
aLM and FM for body size we divided them by height squared.
Functional recoverywas assessed by using Barthel index scores
both before and after inpatient rehabilitation.
Results: At bivariate correlation, aLM/ht2 was neither sig-
nificantly correlated with Barthel index scores after
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rehabilitation nor with their change during rehabilitation (ρ
=0.01, p=0.79, and ρ=-0.06, p=0.20, respectively). Aweak
correlation was found between FM/ht2 and Barthel index
scores after rehabilitation (ρ=0.129; p=0.004), but not be-
tween FM/ht2 and the change in the functional score (ρ=-
0.01; p=0.84). The inclusion of both aLM/ht2 and FM/ht2
together with age in a linear multiple regression model did not
show any significant associations between either lean or fat
compartments and function. Finally, corrected aLM adjusted
for height and FM (residuals) was not significantly associated
with the functional scores.
Conclusion(s): Measures of neither aLM nor FM assessed
by DXA after hip fracture were consistently associated with
the short-term functional outcome in women. Data suggests
that qualitative changes of the muscle tissue, which are not
captured by DXA scans, may play a pivotal role in affecting
recovery to function in activities of daily living following a
fracture of the hip.
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PATHOPHYSIOLOGY OF DRUG INDUCED
OSTEOPOROSIS: THE TRABECULAR, THE
CORTICAL AND THE BROKEN
Yasser El Miedany1, Nadia El Arousy1, Sally Youssef1,
Maha El Gaafary2, Deborah Palmer3
1Ain Shams University, Rheumatology and Rehabilitation,
2Ain Shams University, Community, Environmental and
Occupational Medicine, Cairo, Egypt, 3North Middlesex
University Hospital, Rheumatology, London, UK
Objective(s): To study the change of BMD, both axial (hip
and spine) and peripheral (forearm), in drug induced osteo-
porosis and its impact on clinical practice. Also, to assess
the association of BMD measurement and low trauma
fractures.
Material & Methods: Data of 81 cancer prostate men
(71.1±5.4 yr) treated with hormone antagonist therapy
(HAT), as well as 74 breast cancer (64.7±6.1 yr) treated
with HAT were compared to 165 subjects (85 men and
80 women) of matching sex and age. All patients had
BMD measurement at the spine, hip and forearm at
baseline and 1-year whereas at 2-years of therapy 56
male and 48 from the active groups had repeat DXA
scan. Vertebral morphometry was also carried out.
Results: By the end of 2 years, in the active male group:
BMD assessment revealed osteoporosis in: 59.3%, 9.8%
and 6.1% at the distal forearm, hip and spine, respectively,
in comparison, in 7.4%, 3.5% and 5.9% in the control
group. In the active female group BMD assessment revealed
osteoporosis in: 48.6%, 13.5% and 16.2% at the 3 sites,
respectively, in comparison to 31.1%, 8.1% and 14.9% in
the control female group. In both the men and women
groups, the mean T-scores in the active groups at the distal
forearm (p<0.01) and hip (p<0.03) were significantly less
than the control groups. In the active groups: 19/155
(12.3%) sustained low trauma fractures, 31.6% had low
trauma fracture at the forearm, 15.8% at the spine, 5.3% at
the ankle, 15.8% at the hip or pelvis, and 31.6% at other
sites.
Conclusion(s): Patients treated with HAT have a high prev-
alence of osteoporosis. The use of peripheral BMD mea-
surement appears to identify more patients with bone loss
earlier in the course of therapy and suggests its use in the
evaluation of patients receiving HAT. The association of
BMD loss with fracture was site specific. In view of the
fact that the ratio between cortical and trabecular bones
varies according to the site, the prevalence of osteoporosis
and fractures among the patients assessed in this work raises
the possibility that cortical bone loss might be key factor in
drug induced osteoporosis.
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POSTMENOPAUSAL DISABILITY PENSION
IMPAIRS BONE AND MUSCLE HEALTH
Juha Suuronen1, Samu Sjöblom1, Joonas Sirola1,2, Toni
Rikkonen1, Risto Honkanen1, Heikki Kröger1,2
1University of Eastern Finland, Bone and Cartilage Re-
search Unit (BCRU), 2Kuopio University Hospital, Depart-
ment of Orthopaedics and Traumatology, Kuopio, Finland
Objective(s): The aim of the study was to investigate rela-
tionship between postmenopausal disability pension (DP)
and BMD as well as muscle strength.
Material & Methods: Study population consisted of 3222
Finnish postmenopausal (mean age 53.4 years, range 48-
59.6 years) women from the OSTPRE-study in Kuopio,
Finland. Femoral neck (FN) BMD was measured with
DXA in 5-year intervals from 1989. In all 2227 women
accomplished the 15-year follow-up. Grip strength (GS)
measurements were carried out parallel with DXA using
hand-held dynamometer. GS was divided into quartiles.
Disability pension (DP) records were gathered from the
Finnish social insurance institution (KELA) registers from
1955-1995. Of the study population 1208 women were on
disability pension before year 1995. Disability pension
records were divided into eight major disability subgroups
using International Classification of Diseases (ICD-9).
Results: Women on DP (BMD 0.92 g/cm2 at baseline and
0.86 g/cm2 at 15-year measurement) had significantly higher
bone loss rate in comparison to women not on DP (BMD 0.93
g/cm2 at baseline and 0.88 g/cm2 at 15-year) with significance
of linear trend (F-test) p=0.001. “Diseases of the respiratory
system” and “Diseases of the nervous system and sense
organs” – DP groups had the lowest BMD at 15-year mea-
surement and the highest bone loss rate. Adjustment for age,
calcium daily intake, BMI, alcohol intake, hormone therapy,
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daily physical activity and smoking did not significantly alter
the differences. Furthermore women were divided into quar-
tiles of GS. At baseline 39.1% of the women onDPwere in 1st
quartile (weakest) and 14.0% in 4th quartile (strongest) where-
as 17.6% of nonpensioners were in 1st quartile and 29.3% in
4th quartile (p=<0.001). At 15-year 33.4% of the women on
DP were in 1st quartile and 18.9% in 4th quartile whereas
21.2% of nonpensioners were in 1st quartile and 27.8% in 4th
quartile (p≤0.001).
Conclusion(s): Disability pension is associated with post-
menopausal bone loss and decreased grip strength. Bone
loss and muscle strength differ between different DP mor-
bidity categories.
Disclosures: The study was supported by Kuopio Universi-
ty Hospital EVO-grants and Ministry of Education and
Culture.
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OSTEOPOROSIS AWARENESS AND 10 YEAR
PROBABILITY OF FRACTURE FROM FRAX®
AMONG FEMALE BREAST CANCER SURVIVORS
Ding-Cheng Chan1,2, Keh-Sung Tsai2,3,4, Jaw-Shan Hwang5,
Rong-Sen Yang6
1National Taiwan University Hospital, Department of Geron-
tology and Geriatrics, 2National Taiwan University Hospital,
Department of Internal Medicine, 3National Taiwan University
Hospital, Department of Laboratory Medicine, 4National
Taiwan University Hospital, Bei-Hu Branch, Taipei, 5Chang
Gung Memorial Hospital, Division of Endocrinology and
Metabolism, Department of Internal Medicine, Taoyuan
County, 6National Taiwan University Hospital, Department
of Orthopedic Surgery, Taipei, Taiwan
Objective(s): To report the osteoporosis awareness and
predicted fracture risks among female breast cancer survi-
vors who never receive osteoporosis treatments participating
in a patient support group event.
Material & Methods: During the 2011 Taiwan Breast
Cancer Alliance “Pink October” event, questionnaires about
osteoporosis awareness and FRAX® tool were distributed.
The answers on FRAX® questions were entered into the
Taiwanese calculator onsite to generate the10-year probabil-
ity of fractures. All participants were provided with the
osteoporosis/fracture education booklets and free consulta-
tions by on-site physicians. Participants who had high risks
defined as predicted major osteoporotic fracture ≥20% or
hip fracture ≥3% in 10-year were asked to visit their primary
care physicians for considering osteoporosis treatments.
Among the 942 returned questionnaires, 842 female
participants with complete information were included
for data analysis. Comparisons were made between
those below or above 50 years of age, a surrogate for
menopausal status.
Results:Mean age was 55.1±9.0 years with 212 (25.2%) <50
years old. Only 29.9% knew that the mortality rate of osteo-
porosis was similar to that of stage 4 breast cancer and 2/3
(67.1%) knew that breast cancer treatment would accelerate
bone loss. Over half (55.5%) knew that 41% of Taiwanese
women older than 50 years of age had osteoporosis. Nearly 9/
10 (92.4%) plan to visit a physician if they have high osteo-
porosis or fracture risks. Close 1/5 (18.8%, hip) and 5.6%
(major osteoporotic) were considered high risks from
FRAX®. Compared to younger survivors (<50 y/o), older
participants (≥50 y/o) had better awareness for the above three
osteoporosis knowledge questions. They were also shorter in
height, having higher BMI, higher prevalence of previous
fracture, parent hip fracture, and secondary osteoporosis.
More older participants were considered high risk (24.4%
vs. 1.9%, for hip fracture, 7.1% vs. 0.9% for major osteopo-
rotic fracture, both p<0.001) than younger participants.
Conclusion(s): In general, breast cancer survivors who nev-
er receive osteoporosis treatment had inadequate awareness
in osteoporosis. However, 1/5 of them and 1/4 of postmen-
opausal women had high risk of fracture predicted by
FRAX®. Knowing the fracture risks would increase
patient's willingness to visit a physician to consider appro-
priate treatments.
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THE EFFECTS OF HEALTH MANAGEMENT
INTERVENTION ON POSTMENOPAUSAL
OSTEOPOROSIS WOMEN TREATMENT
Hua Lin, Xin Chen, Xiufen Zhu, Chen Qian
Drum Tower Hospital, The Center of Research for Metabolic
Bone Disease, Nanjing, China
Objective(s): To evaluate the effects of an intervention
programme of health management, targeted to osteoporosis
patients in clinical therapy.
Material & Methods: Randomized controlled trial with
one-year follow-up, carried out in the study. A total of 120
postmenopausal osteoporosis women were enrolled. The
120 postmenopausal osteoporosis subjects were randomized
to either the intervention group (A, n=60,) or the control
group (B, n=60). Both groups were treated by Alendronate
Sodium. Group A: Education program performed once a
season for the intervention group, at baseline, the interven-
tion group was given general information about lifestyle and
osteoporosis risk. This was done either individually or in
one group session (30 min to 1 h), and some printed material
was delivered. The message included healthy and balanced
diet, exposure to sunlight (30 m-2 h/d, and more than 8 h/w),
and respect to physical fitness (30 m-1 h/d, and more than 3-
5times/w), and supplement calcium 600 mg and VitD 125 IU
daily. Group B: nonintervention controls. The first outcome
was comparison of compliance in follow up. The second
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outcomes were changes in BMD. During one year of inter-
vention, BMD was measured by DXA on lumbar spine and
hip at pre-intervention and 12 months after intervention.
Results: After one year, 51 subjects in group A and 38
subjects in group B completed the follow-up. Groups A had
much better compliance than group B. BMD on lumbar spine
and the hip were significantly increased in both groups, com-
pared with themselves at pre-intervention. There was no sig-
nificant difference between group A and group B. But the
changes of BMD on lumbar (0.042±0.067/0.026±0.070, p=
0.029) and the changes of BMD on Words region (0.029±
0.129/0.023±0.143, p=0.041) have statistical significance.
Conclusion(s): For alendronate sodium treatment, health man-
agement ensures the effectiveness of therapy and also increase
the compliance of patients. It's a very important assurance of
curative effect for long-time treatment of osteoporosis.
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EFFICACY OF MONTHLY AND WEEKLY ORAL
BISPHOSPHONATES IN THE TREATMENT OF
POSTMENOPAUSAL OSTEOPORSIS
Lihua Bao1, Hua Lin2, Yongjun Li1
1First Affiliated Hospital, Nanjing Medical University, Nu-
clear Medicine, 2Nanjing Drum Tower Hospital, The Center
of Research for Metabolic Bone Disease, Nanjing, China
Objective(s): To estimate the clinical effect and treatment
adherence of ibandronate and alendronate in postmenopaus-
al osteoporosis.
Material & Methods: This study enrolled 64 postmeno-
pausal women aged 47∼80 years with BMD at baseline
lumbar spine or femoral neck or total hip T-score≤-2.5.
The people were randomly assigned to two groups. 32 in
each group: group I, oral ibandronate 150 mg per month;
and group II, oral alendronate 70 mg per week. All patients
received calcium 500 mg and vitamin D 200 IU daily for
one year. All patients were examined by DXA (lumbar, hip)
before and after treatment. At same time biochemical
markers of bone turnover rate were determined.
Results: Substantial increases in lumbar spine BMD were
seen in group I: 6.25% and 9.64% after half year and one year
treatment, respectively, those in group II were 6.82% and
11.4%, respectively. There was significance difference in
two groups comparison with pretreatment(P<0.05). In both
group, the BMD of hip locations also increased but without
significance(P>0.05). SerumCTX-1 levels decreased dramat-
ically in both groups. In group I, there was 9.4% women
discontinued treatment compared to 21.9% in the group II.
Conclusion(s): Once-monthly oral ibandronate is at least as
effective alendronate for increasing BMD and for inhibiting
osteoclastic activity in treatment postmenopausal osteopo-
rosis. Once-monthly administration may be more conve-
nient for patients and improve therapeutic adherence,
thereby enhancing therapeutic outcomes.
References: 1. Cotte FE, Fardellone P, Mercier F, et al (2010)
Osteoporos Int 21:145. 2. Rabenda V,Mertens R, Fabri V, et al
(2008) Osteoporos Int 19:811. 3. Anthony IS. Ronald DE,
Joseph DK, et al (2009) Bone 44:423. 4. McClung MR,
Bolognese MA, Sedaratic F, et aI (2009) Bone 44:418.
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ROLE OF SERUM SCLEROSTIN ON BONE
METABOLISM IN PATIENTS WITH TYPE 2
DIABETES MELLITUS
Antonia Garcia-Martin1, Rebeca Reyes-Garcia1, Pedro
Rozas-Moreno1,2, Sonia Morales-Santana2,3, Beatriz García-
Fontana1, Manuel Muñoz-Torres1
1University Hospital San Cecilio, Endocrinology Division
(RETICEF), Granada, 2Hospital Ciudad Real, Endocrinolo-
gy Division, Ciudad Real, 3University Hospital San Cecilio,
Proteomic Research Service (FIBAO), Granada, Spain
Objective(s): Type 2 diabetes mellitus (T2DM) is associat-
ed with an increased risk of fragility fractures. The patho-
physiological mechanisms are complex. The role of the Wnt
pathway and its endogenous antagonist sclerostin should be
clarified. The aims of this study were to evaluate serum
sclerostin in T2DM patients and to analyze its relationship
with bone metabolism.
Material & Methods: This was a cross-sectional study. We
compared serum sclerostin in T2DM group (n=76) and
control group (n=54) and we evaluated its relationship with
bone turnover markers, BMD and morphometric vertebral
fractures.
Results: Sclerostin levels were significantly higher in T2DM
patients than control subjects (p<0.001) and in T2DM males
than in T2DM females (p<0.001). Serum sclerostin was pos-
itively correlated with age in males T2DM (p=0.031) and
with serum creatinine in T2DM group (p<0.001). Sclerostin
concentrations were positively associated with duration of
T2DM (p=0.064) and HbA1c (p=0.074) independently of
age in T2DM patients. Sclerostin was inversely related to
bone turnover markers bone alkaline phosphatase, carboxy-
terminal crosslinked telopeptide of type I collagen and tar-
trate-resistant acid phosphatase 5b (p<0,05) and positively
related to lumbar spine, femoral neck and total hip BMD (p
<0.05) in T2DM group. Sclerostin was significantly lower in
osteoporotic than nonosteoporotic patients with T2DM (p=
0.041). There was no relationship according to morphometric
vertebral fractures. In linear regression analysis, gender, study
group, age, serum creatinine and BMD were predictive of
sclerostin levels (p<0.05).
Conclusion(s): Circulating sclerostin is increased in T2DM
independently of gender, age, renal function and BMD. Also
we found a relationship between serum sclerostin and dura-
tion of T2DM, HbA1c, bone turnover markers, BMD and
osteoporosis in T2DM patients.
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References: García-Martín A, Rozas-Moreno P, Reyes-García
Ret al (2011) J Clin Endocrinol Metab [Epub ahead of print].
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SERUM C-REACTIVE PROTEIN AND BONE
MINERAL DENSITY IN A GROUP OF
POSTMENOPAUSALWOMEN
Katarina A Simic Pasalic1, Andjela S Gavrilovic2
1Institute of Rheumatology, Clinical Rheumatology 4A,
2Railway Health Care Institute, Department for Neurology,
Belgrade, Serbia
Objective(s): Increased circulating levels of high sensitivity
c-reactive protein (hsCRP) have been proposed as indepen-
dent predictor of cardiovascular events, more recently asso-
ciated with decreased BMD and increased bone turnover.
We aimed to investigate the relationship between serum
hsCRP levels and BMD parameters at central skeletal sites
in a group of postmenopausal women.
Material & Methods: The study included 450 postmeno-
pausal women who underwent DXA testing on Hologic
QDR 2000 device. BMD parameters: BMD (g/cm2), T
(SD) and Z(SD) score were measured. We took demograph-
ic, medical history, laboratory testing data, including hsCRP
(nephelometry, r.v: <5 U/ml). Two subgroups were formed
according to hsCRP levels, one with normal hsCRP
(NCRP), another with elevated hsCRP levels (HCRP). We
examined correlations of hsCRP levels and DXA parame-
ters on both skeletal sites and compared two subgroups with
regard to DXA parameters obtained. The variables were
analysed by appropriate statistic tests.
Results: A total of 450 women were analysed, aged 59.4±
6.2 years, menopause duration 11.1±5.93 years. Mean se-
rum hs CRP value in group NCRP (n=251) was 1.9±1.28
U/ml, while in HCRP group (n=199) 16.6±12.21 U/ml, p=
0.000. The subgroups were comparable in term of demo-
graphics, medical history of no serious concomitant disease,
risk factors for osteoporosis and other laboratory findings,
except hsCRP. Mean BMD (L1-L4) in NCRP was (0.968±
0.1793), while in other (0.901±0.1682) g/cm2, p=0.7, mean
T-score (-0.94±1.412) vs. (-0.81±1.618), p=0.68. We found
mean BMD on femoral neck in group with NCRP (0.73±
0.134) vs. (0.74±0.138) SD in HCRP group, p=0.6. Mean
neck T-score in NCRP group was (-2.14±1.024) vs. (-
2.1±1.195) p=0.5. Among correlations observed, statis-
tically significant were found between serum homocys-
teine, creatinine and hsCRP levels in HCRP subgroup
(both, p=0.01).
Conclusion(s): Increased hsCRP levels are not associated
with significant decrease of BMD in apparently healthy
postmenopausal women. Elevated hsCRP is positively cor-
related with serum homocysteine and creatinine in subgroup
of women with elevated hsCRP.
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INTRA-ARTICULAR ADMINISTRATION
OF HYLASTAN SGL80 IN PATIENTS
WITH SYMPTOMATIC KNEE
OSTEOARTHRITIS: PRELIMINARY
DATA OF A MULTICENTER
COHORT STUDY
SCulotta1, R Crimaldi2, ADelle Sedie3, E Bizzi4, UMassafra4,
F Giovannangeli4, A Migliore4
1Ospedale di Livorno, Unità di Ortopedia, Livorno, 2Istituto
Clinico Sant'Ambrogio Milano, Unità Operativa di Anestesia,
Milano, 3Università di Pisa, Unità Operativa di Reumatologia,
Pisa, 4S.Pietro Fatebenefratelli Hospital, Unità Operativa di
Reumatologia, Rome, Italy
Objective(s): Hylastan SGL80 is a mixture of hylastan gel,
sodium hyaluronate gel (HA) chemically cross-linked with
divinilsulfone and a liquid-based HA in the gel-liquid ratio
80:20, contained in a 5 ml syringe preloaded with about 4
ml of soft-gel. The mechanical/viscoelastic properties of
Hylastan SGL80 are similar to those of the synovial fluid
and higher than those of unmodified hyaluronan-based
solutions.
Material & Methods: We performed a multicenter cohort
study with a follow-up of 12 months and obtained prelim-
inary data on the effectiveness and safety of Hylastan
SGL80 in knee OA. We enrolled adult patients with knee
OA grade 1-4 Kellgren-Lawrence and treated them with a
single intra-articular infiltration Hylastan SGL80 (4
ml). The follow-up visits were performed at baseline,
3, 6 and 9 months evaluating the infiltration index
Lequesne and VAS pain. Safety was assessed by record-
ing any adverse event.
Results: We enrolled 101 patients, 56 males and 45
females. Each patient underwent to a single intra-artic-
ular infiltration of Hylastan SGL80 for every knee af-
fected by OA. Preliminary results showed a statistically
significant improvement from baseline at 3 and 6
months in terms VAS pain (p<0.001), and at 3 months
with a slight decrease at 6 months in terms of Lequense
Index.
Efficacy profile of Hylastan SGL80 in knee OA
Baseline 3 months 6 months 9 months
Pain VAS
(mean±SD)
6.71±1.4 2.83±1.2 4.28±1.4 2.7±0.4
Lequesne Index
(mean±SD)
15.51±3.3 10.58±4.04 12.19±4.5 8.54±1.6
Number of patients
reaching followup
visit
101 101 80 7
Osteoporos Int (2012) 23: (Suppl 2):S85–S386 S151
Infectious or other complications were not reported.
Conclusion(s): Our data suggest that a single intra-articular
infiltration of Hylastan SGL80 in knee joint affected by OA
is well tolerated and effective in reducing pain for up to 6
months and in improving the functionality to 3 months.
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ASSESSMENT OF THE BIOCHEMICAL MARKERS
OF BONE TURNOVER IN GONADAL DISGENESIAS
IuliaMBistriceanu1, Mihaela N Popescu2, Smaranda Adelina
C Preda3, Simona M Bondari4, Dan A Bondari5, Aurora C
Covei6, Magda Elvira I Preda1, Marian I Bistriceanu2
1Emergency Hospital, Department of Endocrinology,
2University of Medicine and Pharmacy, Department of
Endocrinology, 3University of Medicine and Pharmacy,
The Faculty of Dentistry, 4University of Medicine and Phar-
macy, Department of Radiology, 5University of Medicine
and Pharmacy, Department of Psychiatry, 6Hospital Philan-
thropy, Department of Endocrinology, Craiova, Romania
Objective(s): All defects formation of embryonic gonads
were grouped under the gonadal disgenesias. The etiol-
ogy of gonadal disgenesias role of sex chromosomes is
well established as the default condition for the devel-
opment of gonads and enzymatic battery providing spe-
cific hormone biosynthesis. Gonadogenesis alteration
process (morphological disgenesia) has multiple implications:
biosynthesis disrupt hormonal processes, altered responsive-
ness to hormones gonadal structures and disorder in clinical
aspect sexualization process. Exclusion of sex hormones in
the body economy, seriously affecting bone structure, the
main cause of hypogonadal osteoporosis.
Material & Methods: The study was performed on 20
cases with gonadal disgenesias whose ages were between
12-28 years, including female phenotype with Turner syn-
drome (14 cases) and Klinefelter's syndrome (6 cases). Were
assessed biochemical markers of bone turnover (serum
osteocalcin and CrossLaps) and BMD was assessed by
DXA.
Results: Osteoporosis was detected in 10 cases, osteopenia
in 7 cases and the remaining patients BMD and biochemical
markers were within normal limits.
Conclusion(s): 1) A study of biochemical markers of
bone turnover and BMD is required for all cases with
gonadal disgenesias. 2) Early diagnosis of osteoporosis/
osteopenia, hormone replacement requires specific clini-
cal forms, which are first line therapeutic attitude to
prevent fragility fractures. 3) Given that 85% of the cases we
studied had osteopenia and osteoporosis, hormone replace-
ment therapy is necessary association with specific means
bone remineralization.
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INCIDENCE OF OSTEOPOROSIS STUDY IN
PREMATURE OVARIAN FAILURE
Iulia M Bistriceanu1, Marian I Bistriceanu2, Mihaela N
Popescu2, Smaranda Adelina C Preda3, Simona M Bondari4,
Dan A Bondari5, Aurora C Covei6, Magda Elvira I Preda1
1Emergency Hospital, Department of Endocrinology,
2University of Medicine and Pharmacy, Department of
Endocrinology, 3University of Medicine and Pharmacy,
The Faculty of Dentistry, 4University of Medicine and
Pharmacy, Department of Radiology, 5University ofMedicine
and Pharmacy, Department of Psychiatry, 6Hospital Philan-
thropy, Department of Endocrinology, Craiova, Romania
Objective(s): At patients with premature ovarian failure,
follicular endowment is very low and therefore is deficient
ovarian hormonogenesis. As the number of follicles is low-
er, the lifetime of the ovary is reduced, representing a
clinical spectrum from total or partial absence of pubertal
sexualisation by early onset climacteric. The disruption of
ovarian hormones that control bone homeostasis, is disturb-
training report bone resorption with decreased bone mass
and osteoporosis.
Material & Methods: The study was conducted on 48
patients whose age ranged between 20-38 years. Inves-
tigations were focused on the study hormonology FSH,
LH, PRL, oestradiol, progesterone. Pelvic ultrasound
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was also performed utero-ovarian. At all patients the
BMD was assessed by DXA. As biochemical markers
of bone turnover were studied and serum osteocalcin
CrossLaps by ELISA.
Results: Hormonal dosages showed low levels of oestradiol
and progesterone, but those of gonadotrophic hormones
(LH, FSH) were between 210-385 mUI/ml (upper limit of
normal: 0.110-190 mUI/ml). BMD measurement showed
the presence of osteoporosis in 22 cases, representing
45.8% of all cases investigated. BMD is correlated with
biochemical markers of bone turnover.
Conclusion(s): 1) A study of BMD and biochemical markers
of bone turnover in premature ovarian failure, it must be
conducted regularly to identify patients who rapidly lose bone
mass and increased risk of osteoporosis. 2) The estrogen-
progestive substitution represents the therapeutic attitude
which is the first choice for premature ovarian failure to
prevent osteoporosis, metabolic or visceral complications. 3)
Patients with osteoporosis will be associated the antiresorbtion
or proformation medication to prevent fragility fractures.
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STUDY OF BMD AND BIOCHEMICAL MARKERS
OF BONE TURNOVER IN HYPOGONADISM
HYPOGONADOTROP
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Dan A Bondari5, Aurora C Covei6, Magda Elvira I Preda1
1Emergency Hospital, Department of Endocrinology,
2University of Medicine and Pharmacy, Department of
Endocrinology, 3University of Medicine and Pharmacy,
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Pharmacy, Department of Radiology, 5University of
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Objective(s): Bone, being a loyal following the sexualizing,
sexualized body growth and reshuffling his general. The
role of hormonal factors is very important for bone growth
and consolidation. Physiological stages of the game is di-
rectly proportional to bone functionality gonads. Change of
bone mass during osteogenesis recognizes three stages:
growth, consolidation and reduction of its
Material & Methods: The study was performed on 13
cases with hypogonadism hypogonadotrop, of which sexual
infantilism pituitary dwarfism 3 cases; adiposo-genital syn-
drome, 8 cases and 2 cases anterior pituitary tumor. Were
evaluated biochemical markers of bone turnover osteocalcin
and CrossLaps, and BMD was assessed by DXA
Results: Osteoporosis was evident in 5 cases with pituitary
dwarfism and osteopenia in anterior pituitary tumor and 4
cases adiposo-genital syndrome
Conclusion(s): The paper suggests two major objectives in
therapeutic strategy of osteoporosis/osteopenia cases with
hypogonadism hypogonadotrop: a. Early diagnosis of go-
nadal failure in the adoption of measures for the prevention
of bone changes already in the prepubertal, pubertal and
post pubertal, to stabilize or increase bone mass and age
appropriate sex; b. Solution of substitution associated estro-
gen-progestogen therapy/androgen medication with the anti-
resorption or proformation medication.
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ANTHROPOMETRIC CHARACTERIZATION
AND BODY COMPOSITION IN SPANISH
CLIMATERICAL WOMEN WITH OSTEOPENIA
AND OSTEOPOROSIS. RELATION WITH THE
ANSWER AND IMPLICATION IN THE
PHARMACOLOGICAL TREATMENT
Consuelo Prado1, Manuel Diaz-Curiel2, Ricardo Garcia1,
Veronica Calabria1, Miguel Torralba2, Daisy Navarro3
1University Autonoma, Biology, Madrid, 2Fundación
Jimenez-Diaz, Metabolismo Oseo, Madrid, Spain, 3Univer-
sidad De Ciencias Medicas, Facultad Fajardo, La Habana,
Ciudad De La Habana, Cuba
Objective(s): Due to long periods of treatment once osteo-
porosis is manifested, it is necessary to provide new factors
that optimize social and individual quality of life. Thus the
objective of the study is to know if the somatic status and
body composition of women have impact on the effective-
ness of pharmacological treatment and their adherence to the
same.
Material & Methods: Study carried out in Madrid, with 150
women aged between 40-80 years. Follow-up a longitudinal
study was done according with two direct measures about
anthropometry, body composition and densitometry with a
temporary lapse of 12 months. The scheduled data followed
the bioethical Helsinki Protocol. The somatic characterization
was performed according to the International Biological Pro-
gram (IBP), Tetrapolar Bioimpedance was used to determin-
ing body composition and DXA (lumbar spine (L2-L4) and
neck of femur) for assessment of bone situation. Four groups
of women according to the annual bone evolution have been
established: increase in bone density in lumbar or neck of
femur, decrease in lumbar spine or neck of femur
Results: At the global level the situation in BMD remains
with a very discreet increase (after CL: 0.770±0.64, current:
0.775±0.68) 0.615 Prior CF±0.47, current 0.617±0.46)
However if evidence has been found statistically significant
that in groups consisting of women with similar treatments
have achieved an increase in bone density are those which
have most precocious age of menarche, later menopause.
The study shows that among women with bone recovery
have greater weight, higher BMI, perimeters and fatty
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percentages significantly higher than those women without
bone recovery (F=4.38 P>0.01 weight, F=3.85 p>0.05).
Conclusion(s): Menstrual history as well as body composi-
tion characteristics can be used as predictive of bone recov-
ery or risk of fracture. The best tracking of treatment have
been found among women treated with risedronate (100%)
in women with favorable progression in CL and those that
have not progressed in CF. The short sample with another
therapy focus on the requirement of more studies with
another alternative therapy as strontium derivates.
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RESEARCH BONE MINERAL DENSITY IN
TURNER SYNDROME
Iulia M Bistriceanu1, Marian I Bistriceanu2, Mihaela N
Popescu2, Smaranda Adelina C Preda3, Simona M Bondari4,
Dan A Bondari5, Aurora C Covei6, Magda Elvira I Preda1
1Emergency Hospital, Department of Endocrinology, 2Uni-
versity of Medicine and Pharmacy, Department of Endocri-
nology, 3University of Medicine and Pharmacy, The Faculty
of Dentistry, 4University of Medicine and Pharmacy, De-
partment of Radiology, 5University of Medicine and Phar-
macy, Department of Psychiatry, 6Hospital Philanthropy,
Department of Endocrinology, Craiova, Romania
Objective(s): The study was performed on 10 cases with
Turner syndrome with female phenotype. Cytogenetic in-
vestigation (sexual chromatin, karyotype, chromosomal
heel) confirmed the diagnosis of Turner syndrome. Hormo-
nological explorations were focused on the study: FSH, LH,
estradiol, progesterone.
Material & Methods: BMD was measured by DXA. Scan-
ning was done at the radius, hip and lumbar spine in ante-
roposterior incidence. It is estimated that measurement of
bone mass in the spine and hip are better for predictability of
fracture risk than those in the peripheral skeleton. The result is
expressed as BMD in g/cm2 and T- and Z-scores osteoporosis
and osteopenia diagnosis was established according to criteria
recommended by WHO, on the basis of age heterogeneity
score T. Because patients with Turner syndrome, we evaluated
Z-score for BMD assessment and got out of the age factor
calculation. Hormonological investigations showed insignifi-
cant values feminizing hormone (estradiol, progesterone) and
hypothalamic-pituitary debaclu (very high LH and FSH). It is
widely accepted that in Turner syndrome, renal impairment by
anovarie estroprogesteronic early puberty is evident from the
absence of puberty sexualization when the body does not have
definitive sexuality processing.
Results: By osteodensitometry, osteoporosis was confirmed
in 7 cases, and osteopenia in 3 cases. Z-score values were
between -1.73 and - 4.44 SD.
Conclusion(s): Therefore, we consider that the assessment
of BMD and markers concomitant hormone in patients with
Turner syndrome, we provide useful information on the
process of bone remodeling. In conclusion, to prevent fra-
gility fractures, hormone replacement therapy is necessary
association with the proformation medication.
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THERAPEUTICAL ATTITUDE DIFFERENTIATED
IN HYPOGONADAL OSTEOPOROSIS
Iulia M Bistriceanu1, Marian I Bistriceanu2, Mihaela N
Popescu2, Smaranda Adelina C Preda3, Simona M Bondari4,
Dan A Bondari5, Aurora A Covei6, Magda Elvira ME
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1Emergency Hospital, Department of Endocrinology, 2Uni-
versity of Medicine and Pharmacy, Department of Endocri-
nology, 3University of Medicine and Pharmacy, The Faculty
of Dentistry, 4University of Medicine and Pharmacy, De-
partment of Radiology, 5University of Medicine and Phar-
macy, Department of Psychiatry, 6Hospital Philanthropy,
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Objective(s): There are many treatment options in osteopo-
rosis induced gonadal failure (ovarian or testicular), and
choosing appropriate therapy should be based on the fol-
lowing principles: efficiency, confounding effects extrasche-
letice, cost-benefit.
Material & Methods: Casuistry included in our study is
represented by 57 patients, of which the late puberty (26
cases) and premature ovarian failure (31 cases).
Results: For cases with delayed puberty - hypogonadism
hypergonadotrop (gonadal disgenesias) and hypogonadism
hypogonadotrop - the major objectives of hypogonadal pro-
phylaxis were carrying insurance sexualisation process,
bone stability during ontogenesis, control factors that induce
osteoporosis and its consequences (osteoporotic fractures).
For cases with premature ovarian failure have followed:
evaluation of patients with increased risk of osteoporosis,
secondary osteoporosis causes exclusion, selection of ap-
propriate treatment. Treatment options include both patients
with delayed puberty and premature ovarian failure for
cases: nonpharmacological approach and intervet therapeu-
tic pharmacological agents against pathogenic mechanism
of osteoporosis hypogonadal.
Estrogen-progesterone replacement therapy is the attitude of
the first line in premature ovarian failure, to prevent osteo-
porosis, metabolic and visceral complications. For cases
with delayed puberty, associated therapeutic substitution
solution estrogen-progesterone/androgen antiresorptive
medications (bisphosphonates) or proformatores.
Conclusion(s): In our study, we observed a decrease in T-
score 14-16% after 6 months of treatment with strontium
ranelate in patients with premature ovarian failure. In other
cases with Turner syndrome (4) and premature ovarian
failure (7) we treated for 3 months at doses of 35 mg
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risedronate/wk. It noticed a decrease in serum CrossLaps
and osteocalcin by 38.5% to 41.3% compared to baseline.
Regular assessment of biochemical markers of bone turn-
over (osteocalcin, CrossLaps) and BMD (DXA) provides
useful information on the effectiveness of therapy.
P244
MODULATION IMMUNO-ENDOCRINE ON BONE
METABOLISM
Iulia M Bistriceanu1, Marian I Bistriceanu2, Mihaela N
Popescu2, Smaranda Adelina C Preda3, Simona M Bondari4,
Dan A Bondari5, Aurora C Covei6, Magda Elvira I Preda1
1Emergency Hospital, Department of Endocrinology, 2Uni-
versity of Medicine and Pharmacy, Department of Endocri-
nology, 3University of Medicine and Pharmacy, The Faculty
of Dentistry, 4University of Medicine and Pharmacy, De-
partment of Radiology, 5University of Medicine and Phar-
macy, Department of Psychiatry, 6Hospital Philanthropy,
Department of Endocrinology, Craiova, Romania
Objective(s): One of the most evocative similarities between
the endocrine and immune system, is the mechanism regulat-
ing Ag, respectively specific hormone receptor. The similarity
between Ig and hormones can be extended to the functional
structure: containing hormones as Ig-binding regions, and
regions of printing function such as Fc fragment and Ig.
Material & Methods: Moreover, reasoned opinions have
appeared that the effect of hormones on immune cells would
be relatively proportional to receptor number local to them.
It is estimated that the main physiological role of sex hor-
mones on immune system activity is to help achieve an
appropriate balance in the treatment of immune complexes.
This balance is dynamic and antagonistic actions resulting
from the balance between male and female sex hormones.
Results: The stimulation of estrogen production and con-
version of IgM→IgG immunoglobulin by B cells increase
"Self" and control of part of the phenotypic expression of
IgM (by mediation chromosome X). Progesterone tends to
"suppress" immune reactivity with anti-estrogenic effects.
May decrease in vitro T cell proliferation, but increase the
number of CD 8 cells without diminishing function nonre-
sponder. Androgens have immunosuppressive effects (in-
verse to estrogen) because decreases immunoglobulin
production by decreasing B cell stimulation and immune
complexes. Cytokines influence bone cell metabolism by
mediating interactions between physiological and patholog-
ical bone and immune system, the action of circulating
hormones osteotropi. A fundamental characteristic of most
cytokines is their immunomodulatory activity. IL-1, was the
first cytokine "immune" identified as having the following
bone metabolism: activates bone cell replication, stimulate
bone resorption, coupled with osteoformatores resorption,
stimulates collagen synthesis and increased synthesis of IL-
6 with a role in resorption. How IL-1 stimulates IL-6 pro-
duce by osteoblastic cells and marrow stomata, it is possible
that interactions of these cytokines to pathological bone
resorption implication only, but also in normal bone
remodeling.
Conclusion(s): Knowing the intimate mechanisms of im-
mune-endocrine modeling of bone metabolism, open new
perspectives in the management of osteoporosis.
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NEW MECHANISMS ACCOUNTING FOR A FINE
TUNING REGULATION OF OSTEOBLAST AND
OSTEOCLAST ACTIVITY
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Objective(s): To study if the interplay among c-Src, IL-6
and IGFBP5 is involved in maintaining osteoblasts in an
immature status.
Material & Methods: Primary osteoblasts (OBs) were
treated with the c-Src inhibitor PP1, recombinant human
IL-6 and soluble IGFBP5 to study the impact on OB differ-
entiation by RT-PCR and Western blot analysis. Osteoclast
(OC) precursors and mature OCs were treated with soluble
IGFBP5 to analyse their formation and activity. Mice were
treated with the c-Src inhibitor CGP76030, to evaluate IL-6
expression in tibias by RT-PCR and bone parameters by
histology/histomorphometry.
Results: WT, hIL-6 overexpressing transgenic (TG) and in-
flammatory agents-treated mice subjected to CGP76030 treat-
ment showed reduced STAT3 activation and IL-6 mRNA in
whole bones. Histomorphometric analysis demonstrated that
treatment with CGP76030 significantly improved TG mice
bone phenotype, demonstrating the anabolic and antiresorptive
effects of the c-Src inhibitor. BALB/c-nu/nu mice intracardia-
cally injected with MDA-MB231 and treated with CGP76030
showed decreased incidence of bone metastases, with a reduc-
tion of both human (derived byMDA-MB231) and mouse IL-
6 in sera and in the bone metastasis tissue. IL-6-treated OBs
increased c-Src activation in long-term treatment, suggesting
the involvement of mediators. Although IGF-1 could be in-
strumental to link IL-6 and c-Src pathways, IL-6-treated OBs
showed no changes of IGF-1, while IGFBP5 mRNA was
increased. IGFBP5-treated OBs showed increased c-Src acti-
vation, proving a role for IGFBP5 in IL-6/c-Src interplay.
Since c-Src inhibition increased IGFBP5 mRNA, we analysed
the IGFBP5 promoter, identifying a responsive element for
Runx2, that was upregulated by c-Src inhibition. Consistently,
Runx2 overexpression increased IGFBP5 mRNA in OBs. To
test if this effect depended on OB maturation, IGFBP5 was
administered to subconfluent (immature) and overconfluent
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(mature) OBs. At variance with subconfluent cells, in
overconfluent OBs c-Src was barely expressed and, hence,
insensitive to IGFBP5-induced activation. To test if in this
context other cells were targeted by IGFBP5, OC precur-
sors and mature OCs were treated with IGFBP5, which
induced an increase of both osteoclastogenesis and bone
resorption
Conclusion(s): These results suggest a novel role for
IGFBP5 in bone homeostasis that could provide new
insights in the pathogenesis of inflammation-related and
cancer-related bone pathologies.
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STRUCTURE AND PARTICULARITIES OF
DOCTOR- (OSTEOPOROSIS) PATIENT
INTERACTION IN 3 ROMANIAN OUTPATIENT
CLINICS
Andrea Ildiko Gasparik1, Zoltan Abram2, Eniko Albert-
Lorincz3, Salvina Mihalcea4, Botond Tokes2, Maria Farcas4
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Objective(s): To assess structure and characteristics of com-
munication during the consultations of supposed - osteopo-
rosis patients.
Material & Methods: Descriptive study, using quantitative
and qualitative analysis of doctor-patient interactions in 60
outpatient visits of 3 rheumatologists, in state clinics.
We measured time-structure of visits (duration of: the
initial patient-report, patient's- and doctor's questions,
explanation of diagnosis, recommendation for treatment
and lifestyle changes) as well as some qualitative pat-
terns of doctor-patient interaction (status/authoritarian
pattern, depth of interaction, eye contact, offering a sit
while discussing, summarising important information at
the end of the visit, etc.).
Results: Duration of patients report was on average less than
1 min, while average time spent with one patient 3.6 min,
there was average 4 doctor-questions and less than one asked
by the patient. Explanations of the doctor took less than 2 m,
including diagnosis, treatment and recommendations for lab-
oratory or radiology investigations, where necessary. There
were no questions regarding risk factors and no recommenda-
tions regarding lifestyle changes. None of the 3 doctors asked
patients if they have any further questions.
Conclusion(s): Results can be explained with the time
pressure, due to the large number of patients waiting for
the doctor. It is more difficult to explain the way, patients
were pleased and satisfied with the visits. They were not
active (no or few questions), showed no willingness to
participate in decision making or to have a more in depth
discussion with the doctor. Further investigations are
needed to clear how these patterns differ when the same
doctors work in their private clinic, how these parameters
relate to social status of patients, and how they influence
patient satisfaction, implication in decision making and
health outcome.
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CLINICAL PRESENTATION OF PRIMARY
HYPERPARATHYROIDISM IN THE CANARY
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Gran Canaria, Las Palmas, Spain
Objective(s): Primary hyperparathyroidism (PHPT) has a
variable clinical expression. In the developed countries,
asymptomatic hypercalcemia is the most frequent clinical
finding although some other manifestations as urolithiasis,
depression, osteoporosis and fragility fractures are often
described. The objective of this study is to compare the
clinical presentation of PHPT in the last 20 years in Gran
Canaria, Canary Islands.
Material & Methods: Group I was conformed by 105
patients who were diagnosed of a PHPT from 1989 to
1999 and Group II were 116 patients who were diag-
nosed from 2000-2009. A questionnaire was filled and a
complete physical examination was performed to every
patient. A standard biochemical profile was done to
every patient, including 25-hidroxivitamin D, intact
PTH, calcium, phosphate, creatinine, total proteins.
Bone densitometry was also performed to every patient
and X-rays of the hands and dorsal and lumbar spine
were also performed.
Results: Results are shown in Tables 1 and 2.
Table 1. Basal characteristics of the population studied
1989-1999 2000-2009 p-value
Number (Male/Female) 105 (6/99) 116 (8/108) 0.012
Age (years) 61.2±10.4 58.7±9.6 0.012
Height (cm) 156±6.7 158.3±6.2 0.008
Weight (kg) 70.5±12.7 74±12.8 0.042
BMI (kg/m2) 28.9±5.4 29.2±4.8 0.662
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The clinical pattern of PHPT has changed very little in the last 20
years. The clinical manifestations are very similar with the ex-
ception of age. Indeed, the patients have more weight and height.
Conclusion(s): The clinical pattern of PHPT has changed a
little in the last 20 years. Patients are now diagnosed at an earlier
age, and have greater height and weight than patients diagnosed
a decade ago, but the clinical manifestations are similar in this
decade compared to the previous one. Asymptomatic hypercal-
cemia is doubtless the most frequent clinical feature.
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PREVALENCE OF HYPOVITAMINOSIS D IN
ELDERLY MEN WITH HIP FRACTURES
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Objective(s): Vitamin D deficiency is a well known clinical
finding in women suffering from hip fractures, who leads to
the development of a secondary hyperparathyroid. Less
studies have been published on men. We compare the prev-
alence of hypovitaminosis D in men and females admitted in
the hospital because of a hip fracture.
Material & Methods: Cross-sectional observational study,
performed in patients suffering from hip fracture, who were
attended at the Hospital University Insular, Gran Canaria,
between May 2005 - June 2009. We performed a question-
naire to every patient, including risk factors for falls and for
osteoporosis. A physical examination was also done. We
also performed a lateral X-ray of the dorsal and lumbar
spine, and a complete analytical study, including renal
function, vitamin D and parathyroid hormone (intact PTH)
by immunochemoluminiscence.
Results: Results are shown in Tables.
Basal characteristics of the population studied.
Men Women p-value
Number 76 175
Age (years) 79.5±10.3 76.4±12.6 0.04
Weight (kg) 72.3±10.2 68.4±9.2 0.01
Height (cm) 162.3±4.5 158.6±5.2 0.01
BMI (kg/m2) 27.2±5.6 28.5±4.8 0.125
Comparison of 25-HCC and PTH values between men and women
with hip fracture
Men Women p-value
25-HCC (ng/mL) 15.3±10.5 20.5±11.6 0.001
PTH (ng/mL) 67.4±21.7 61.5±17.4 0.03
Serum calcium (mg/dL) 9.6±0.4 9.5±0.3 0.213
Serum phosphate (mg/dL) 3.7±0.7 3.6±0.5 0.412
Total proteins (g/L) 6.8±0.5 6.9±0.5 0.568
Creatinine (mg/dL) 0.9±0.2 0.8±0.2 0.162
Vitamin D values were lower, and serum PTH were higher,
in men suffering from hip fractures compared to women
with the same disease. 58.3% of the men and 51.1% of the
women had vitamin D lower than 20 ng/mL.
Conclusion(s): Globally, men suffering from hip fracture
have lower values of vitamin D than women with the same
disease. Almost 60% of men suffering from hip fracture
present 25-HCC levels lower than 20 ng/mL, compared to
51% of the women, they also present higher values of serum
PTH which leads to the developing of a secondary hyper-
parathyroidism, who could produce more bone loss and
increase the risk of suffering new fractures in the future.
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ATYPICAL SUBTROHANTERIAN FRACTURE: AN
EASY TO FIND SITUATION IN A PARTICULAR
PATIENT WITH COMPROMISED BONE
STRUCTURE TREATED FOR OSTEOPOROSIS
Carmen Barbu1,2, Laura Chivu2, Cristina Stefan2, Dariana
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Catalina Poiana1,4, Simona Fica1,2
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Objective(s): Underline the importance of the bone struc-
ture abnormalities in the etiology of atypical subtrochanteric
fracture (ATF).
Material & Methods: A 38 yrs woman after 2 years of
continuously antiresorbtive treatment.
Table 2. Clinical manifestations of PHPT listed by decade
Clinical Manifestation 1989-1999 2000-2009 p-value
Number 105 116 NA
Hypercalcemia 87.1 91 0.649
Increased serum PTH 100% 100% NA
Chronic renal failure 4.1% 3.5% 0.916
Weakness/Fatigue 29.8% 42.5% 0.107
Urolithiasis 34% 28% 0.448
Arterial hypertension 46.1% 51% 0.574
Depression 65.6% 59.3% 0.470
Osteitis fibrosa 6.1% 3.7% 0.495
Gastrointestinal disturbances 26.9% 30.2% 0.759
Fragility fractures 12.4% 14.3% 0.841
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Results: Medical history: at age of 20 yrs had bone and joint
generalized pain treated for short term with NSAIDs and
prednisone 15 mg daily (2 months). No clear etiology of the
pain was revealed at that moment; at 28 yrs was admitted in the
hospital for went limp, pelvic pain. Radiographic findings:
bilateral consolidated symphysis fractures, wedge-shaped ver-
tebral body T5. L2-L4 DXA Z-score=-2.14 SD. Bone scintig-
raphy - multiple areas of uptake in the ribs and vertebral
bodies. Serum calcium and PTH ruled out the diagnosis of
primary hyperparathyroidism (Ca=10mg/dl, PTH=15 pg/ml).
No other endocrine dysfunction was revealed by further inves-
tigations. Bilateral spontaneous osteonecrosis of the femoral
neck was diagnosed and bilateral prosthesis was recommended
(postponed by the patient). Oral bisphosphonate was started at
age 29. In the next 5 years bilateral forearm fractures and 18
cm decreased in height occurred due to multiple vertebral
fractures. At age 34, histopathology showed generalized fi-
brous cystic osteitis. Next 2 years treatment was stopped
(pregnancy and nursing). 2009 first admitted in our depart-
ment: reevaluation for endocrine diseases without abnormal
results, no connective tissue or celiac disease. Serum vitamin
D, calcium, phosphate, PTH and IGF1 were normal. Bone
resorbtion markers near the upper normal limit. 2009-
2010: 5 mg intravenous zoledronic acid per year associated
with strontium ranelate, and parenteral vitamin D3: no
change in BMD, no new vertebral fractures; the patient
experienced a right forearm fracture in 2009 and a right
ATF in February 2011.
Conclusion(s): In spite of not very typical features, all the
data leads to the diagnosis of fibrous dysplasia. Intravenous
5 mg yearly zoledronic acid improved the clinical aspect and
lowered significantly the fracture incidence. In our opinion,
the background of the patient (progressive FD and osteo-
necrosis of the hips) claims a bigger impact on the ATF
etiology comparing to a relative short period of continuous
bisphosphonate (last 2 yrs) treatment.
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THE IMPORTANCE OF RISK FACTORS FOR
OCCURRENCE OF THE OSTEOPOROTIC
FRACTURES IN PATIENTS WITH LOW
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Objective(s): The osteoporotic bone is a bone with lower
bone density and as such with predispositions for fracture
occurrence. The aim of the study was to detect risk factors
and establish their importance for the occurrence of osteo-
porotic fractures in patients with low bone density.
Material & Methods: The prospective clinical study in-
cluded 1245 patients, treated during the period from Janu-
ary-July 2011 in Special Hospital for Rheumatic Diseases in
Novi Sad. The tested group consisted of 96% women (1193/
1245) and 4% men (52/1245), with average age of 63 years.
All patients have undergone the osteodensitometric exami-
nation (DXA) at lumbar spine and at the hip; by means of
which BMD was measured and expressed as the T-score.
Exclusion factors in this study were premenopausal women
and men under 50 years of age. Results are interpreted
according to the valid definition of osteoporosis. All patients
were surveyed regarding risk factors responsible for the
occurrence of osteoporosis and/or osteoporotic fractures.
For statistical analysis purpose the Bonlink data processing
program was used.
Results: BMD on the osteoporosis level was present in
16% of patients, on the osteopenia level in 66%, and
regular T-score was present in 18% of patients. The most
common risk factor was early menopause 28.27%, previ-
ous fractures 23.29%, family history of fractures 13.73%,
treatment by glucocorticoids 9.64%, smoking 14.06%,
autoimmune diseases 7.63%, rheumatoid arthritis 5.70%,
low BMI 3.53% and alcohol consumption 0.88%. Oste-
oporotic fractures occurred in 35.26% of patients, from
which vertebral fractures were in 40% and nonvertebral
in 60% of patients. The most frequent fractures were in
patients with T-score at the osteopenia level 63%, then
followed fractures at the osteoporosis level 26% and
finally the least percent of fractures 11% in patients with
regular T-score.
Conclusion(s): In order to star therapy in time and to
prevent new fractures it is necessary to evaluate risk factors
responsible for occurrence of osteoporotic fractures.
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EFFICACY OF STRONTIUM RANELATE ON BACK
PAIN RELIEF COMPARE TO ALENDRONATE IN
MANAGEMENT OF POSTMENOPAUSAL
OSTEOPOROSIS
Stanislava Alexandrova Alimanska, Snezana Sergeeva
Tersiiska, Mariela Gencheva Geneva-Popova
Medical Institute, Clinic of Rheumatology, Plovdiv, Cambodia
Objective(s): Osteoporosis, is a skeletal disorder that ad-
versely affects bone strength, is common among postmeno-
pausal women primarily due to reduced ovarian estrogens.
The pain and pathology fracture are most common problem
that make patients search for help. The present study was
taken up to evaluate the effect on pain improvement of
strontium ranelate in the management of postmenopausal
osteoporosis compare to alendronate.
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Material & Methods: This retrospective study conduct
on 40 postmenopausal women with lumbar spine BMD
>2.5 SD below the young adult reference range, ten of
them with vertebral fracture. 20 of the participants re-
ceived strontium ranelate 2 g plus 800 IU Vit.D per day
orally, (Group I) and 20 patients received alendronate 70
mg/5600 IU Vit.D per week, (Group II). The subjects
were studied for one year. The patients were assessed on
every three months for pain improvement with VAS and
OPAQ-SV for back pain. The data was analyzed by
descriptive statistics methods.
Results: The analgesic effect of strontium ranelate starts on
3 d month and on the sixth month is significantly greater
than those of alendronate. This greater reduction in back
pain is obvious and on 12th month. VAS and OPAQ-SV
have comparable results for back pain and both can be used
for studying the patients for pain relief.
Conclusion(s): Strontium ranelate has early effect on pain
improvement in cases of postmenopausal osteoporosis and
thus has a beneficial effect compare to those of alendronate.
Strontium ranelate is a promising and good alternative to
alendronate for the management of back pain in postmeno-
pausal osteoporosis.
References: 1. Riggs BL, Parfitt M J Bone Miner Res,
2005;20:177. 2. Reginster JY, Seeman E, de Vernejoul
MC, et al J Clin Endocrinol Metab 2005;90:2816. 3.Reginster
JY, Felsenberg D, Boonen S, et al Arthritis Rheum
2008;58:1687.
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OSTEOPOROTIC FRACTURE IN RHEUMATOID
ARTHRITIS (RA): A STUDY OF INCIDENCE,
PREDICTIVE FACTORS AND ECONOMIC BURDEN
FROM A 25 YEAR RA INCEPTION COHORT
Elena Nikiphorou1, Josh Dixey1, Peter Williams1, Stephen
Morris2, Adam Young1
1ERAS, St Albans City Hospital, Rheumatology, St Albans,
Hertfordshire, 2University College London, Epidemiology
& Public Health, London, UK
Objective(s): To examine incidence rates, economic burden
of, and predictive markers for osteoporotic fracture in
patients with RA in a well described 25 yr inception cohort.
Material & Methods: The Early RA Study (ERAS)
recruited 1465 patients from 1986-1998 in 9 UK centres.
Standard clinical, radiological and laboratory measures were
performed yearly for a maximum 25 yrs (median 10 yrs).
Yearly assessments recorded comorbidities and inpatient
hospital episodes, including fracture sites, and orthopaedic
interventions (OPCS codes). Clinical databases were sup-
plemented and crossvalidated with national databases, the
National Joint Registry (data available from 2003-2011),
Hospital Episode Statistics (data 1997-2011), and the
National Death Register (data 1986-2011). Only patients who
moved abroad orwere not registered with a general practitioner
would be absent in the two latter databases. Treatment
regimens followed guidelines of the era, mainly conventional
DMARD therapies, ±steroids, and latterly biologics.
Results: 176 fractures occurred in 126 patients (8.6%): hip
(59,4%), wrist (23,1.5%), vertebral (11,0.8%), others in 33
(2.2%) patients. 12 hip fractures required hip replacements
and 47 dynamic hip screw surgery. There were no immedi-
ate postoperative deaths but hip and vertebral fractures were
recorded as contributory causes of death in 11 and 2, re-
spectively. Fracture incidence rates and direct costs will be
displayed graphically indicating a moderately early compli-
cation of RA, e.g., hip fracture was median 10 yrs (IQR 5-
15) from baseline. Average direct costs of hip fracture
surgery were £4890 depending on inpatient stay (mean 15
days), posing a significant health economic burden. Fracture
prediction included traditional risk factors (age, gender) and
for hip fracture, risks also included disease severity meas-
ures in 1st year: steroids (OR 1.8, 95%CI 1.1-3.1), erosions
(OR 1.9, 95%CI 1.2-3.3), high HAQ (OR 1.9, 95%CI 1.1-
3.5) & ESR (OR 1.8, 95%CI 1.1-3.1), low haemoglobin
(OR 2.09, 95%CI 1.2-3.4), the latter unexpected as not
normally included in predictive models for RA outcomes.
Conclusion(s): Osteoporotic fracture complicated RA in 8.6%
over 25 yrs. 4% had hip fractures, half by 10 yrs of RA and all
requiring major orthopaedic interventions and health costs.
Risk factors for hip fracture included disease severity measures,
prompting more active therapies for RA & bone protection.
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VITAMIN D RECEPTOR GENE POLYMORPHISM
IN RELATION TO VITAMIN D AND PARATHYROID
HORMONE LEVELS IN POSTMENOPAUSAL
WOMEN
Vivek Dixit1, Himanshu Jha1, Naushad A Khan1, R L
Tripathi2, Dinesh K Dhanwal1
1Maulana Azad Medical College, Medicine, New Delhi,
2University College of Medical Sciences & GTB Hospitals,
Biochemistry, Delhi, India
Objective(s): To assess the relationship between 25(OH) D
and PTH in postmenopausal women. To study the vitamin D
receptor (VDR) gene polymorphisms in postmenopausal
women.
Material & Methods: 50 postmenopausal women were
included after careful clinical history and physical examina-
tion. Serum PTH and serum vitamin D estimation was
analysed by radioimmunoassay (RIA) methods using Dia-
Sorin (USA) kits and baseline laboratory investigations
were done by autoanalyser using standard methods. Ge-
nomic DNA was extracted from whole blood by phenol
chloroform extraction method. The frequencies of Taq1
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and Apa1 alleles were determined by using PCR and restric-
tion fragment length polymorphisms technique (RFLP).
Results: The mean age of the subjects was 56.66±5.35. The
base line laboratory investigations, i.e., S.Albumin, ALT, AST,
ALP, urea, creatinine, calcium and phosphorus were 0.518±
0.21, 22.04±9.25, 26.84±18.99, 139.72±77.68, 29.44±17.13,
1.094±1.22, 9.202±0.59 and 3.908±1.07, respectively. The
mean serum 25(OH) D levels were 14.07±10.72.
Table. Clinical characteristics of the study population
Sl. No. Parameters Values (Mean±SD)
1 Age 56.6±5.35
2 25(OH)D 14.07±10.72
3 iPTH 80.8±68.2
4 S.calcium 9.20±0.59
5 Phosphorous 3.90±1.07
6 ALP 139.72±77.68
7 S.Creatinine 1.094±1.22
8 Urea 29.44±17.13
9 ALT 22.04±9.25
10 AST 26.84±18.99
11 T.Billurubin 0.51±0.21
The mean serum intact PTH (iPTH) was 80.85±68.22. 35
Subjects were identified as hypovitaminodosis, 10 were
found to be insufficient and only 5 subjects were having
optimum level of Vitamin D. Secondary hyperparathyroid-
ism were observed in 29 subjects with strong inverse corre-
lation among PTH/Vitamin D. All subjects had raised levels
of serum alkaline phosphatase (ALP). Vitamin D deficiency
was found in 58% of population. Result of VDR polymor-
phism reveals that the polymorphic allele, i.e., Aa (ApaI)
was found to be prevalent. Genotype (aa) was identified
only in three subjects. Similarly, another genotype tt (TaqI)
was also predominant except in two subjects denote (Tt).
Conclusion(s): Our study reveals that VDR gene polymor-
phisms are associated with low vitamin D levels in Indian
postmenopausal women and also seems to be a strong
genetic determinant. We found the inverse correlation be-
tween PTH and vitamin D.
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ABDOMINALWEIGHT IS INDEPENDENTLY AND
INVERSELY ASSOCIATED WITH BONE MASS
OF OVERWEIGHT LATINAWOMEN
Afrooz Afghani1
1University of Southern California, Preventive Medicine, Los
Angeles, 2Trident University International, Health Sciences,
Cypress, CA, US
Objective(s): The link between central adiposity and osteo-
penia has not been shown in adult women. In particular, the
association between abdominal weight and BMD and bone
mineral content (BMC), independent of total weight,
remains uncertain.
Material &Methods: Trunk weight, total body fat mass, lean
mass, BMC andBMDof 33 premenopausal Latinawomen age
22-51 years from Los Angeles, California was measured using
DXA.Waist circumference (WC) was measuredwithout cloth-
ing at the smallest circumference of the torso.
Results: Partial correlations controlling for total body fat
mass and lean mass revealed a significant inverse relation-
ship between BMC and WC (r=-0.59, p<0.005) but not
between BMD and WC (r=-0.24, p=0.20). Similarly, while
controlling for total body fat and lean mass, BMC was
inversely associated with trunk fat mass (r=-0.77, p<
0.001), with trunk lean mass (r=-0.64, p<0.001) and with
total trunk mass (r=-0.77, p<0.001); results were nonsig-
nificant for BMD.
Conclusion(s): Although general obesity may prevent oste-
oporosis, these findings suggest that abdominal obesity (i.e.,
trunk weight) specifically and independently may adversely
influence bone mass.
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CALCIUM INTAKE IN GREEK POPULATION
Efi V Grigoriou1, George P Trovas2, Symeon T Tournis2,
Katerina A Katsalira2, Antonis Galanos2, George VZ
Dedoussis1, Nikolaos D Papaioannou2
1Harokopio University, Department of Dietetics and Nutri-
tion, 2School of Medicine, University of Athens, Laboratory
for Research of the Musculoskeletal System, Athens, Greece
Objective(s): Calcium and vitamin D are key nutrients for
the prevention and treatment of osteoporosis, in adequate
intake according to the recommendations. Various studies
have shown that calcium balance in human body is optimal
when the daily intake is about 1000-1200 mg. The purpose
of this study is to assess the daily dietary calcium intake in a
sample of Greek women from various parts of the country.
Material & Methods: The recruitment of the population
was part of the events carried out by the Hellenic Society for
the Support of Patients with Osteoporosis in rural and urban
areas throughout Greece, with the goal of collecting data for
the detection of risk factors associated with osteoporosis and
informing the public about the disease. Demographic char-
acteristics were collected and there was an estimation of the
daily calcium intake using a food frequency questionnaire.
Results: 10,216 volunteers were interviewed with mean
age 58.77 years (range 18-97), weight (kg) 71.06±12.51
(mean±SD), height (m) 1.61±0.07 and BMI (kg/m2)
27.50±4.84. The calcium intake was categorized as follows:
<400 mg in 21.8%, 400-800 mg in 28.1%, 800-1200 mg in
21.4% and >1200 mg to 28.7% of all volunteers. Further
analysis by age group showed that lower intake of 400 mg
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per day presented in 24.7% of those under 40 years and in
16.4% of those 80 years of age.
Conclusion(s): Approximately 50% of the volunteers had
daily calcium intake below 800 mg with women less than 40
years of age having a higher percentage of intake less than 400
mg compared with women over 80 years of age. A large
percentage of women do not receive the adequate amount of
calcium from the diet, which is an essential nutrient for bone
health, and such a fact makes essential the need for public
awareness about the foods they could consume in order to
meet the daily needs for calcium intake according to their age.
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REPRODUCIBILITY OF AVERTEBRAL
DEFORMITY TOOL (VDT) USING AN ACTIVE
SHAPE MODELLING WORKFLOW TOOL
Colin G Miller1, Alan Brett2, Eric Bogner4, Monique Tan3,
Rebecca Cope1, Melanie Beke3, Jane Haslam2, Joes Staal2,
Peter Steiger2, Curtis W Hayes5
1BioClinica, Medical Affairs, Newtown, PA, US, 2Optasia
Medical, Optasia Medical, Manchester, Lancashire, UK,
3Novartis Pharmaceuticals, Aclasta Global Team, East
Hanover, NJ, 4Hospital Special Surgery, Radiology, New
York, NY, 5Virginia Commonwealth University, Radiology,
Richmond, VA, US
Objective(s): There is a need for enhanced radiographic
measurement techniques for diagnosis and prevalence of
vertebral deformities (VD). A novel 95 point annotation of
vertebrae from radiographs has previously been described1.
This study assess the inter- and intrareader reproducibility of
this novel clinical workflow tool that uses model-based
shape recognition technology for semi-automated annota-
tion of the T4-L4 vertebrae using digitized plain-film
radiography.
Material & Methods: Lateral spine radiographs of 163
subjects with suspected VD, obtained from the Canadian
Multicenter Osteoporosis Study (CaMos) were indepen-
dently assessed by two radiologists (R1 and R2) using a
semi-automated protocol based on a previously described
95 point delineation1. This VD Tool (VDT) was applied
using a read system developed by BioClinica and embed-
ded software from Optasia. VD was independently assessed
based on the Genant scoring system. Inter- and intra-reader
variability was reported as the root mean square of succes-
sive differences (RMSSD) with 95% CIs.
Results: The mean reproducibility T4-L4 spine in mask
displacement in mm (%) for R1 ranged between 0.53
(1.87%)-0.94(2.77%), and for R2 between 0.87(3.46%)-
1.53(5.27%). The inter-reader variability ranged from
0.87-1.34 mm. The inter-reader variability ranged from
3.17-4.57%. Intra- and inter-reader reproducibility by mm
displacement as mean (95% CI).
Intra- and inter-reader reproducibility by mm displacement as mean
(95% CI
LEVEL R1 R2 Inter-Reader
T4 0.64 (0.62-0.65) 0.87 (0.85-0.89) 1.06 (1.02-1.09)
T5 0.53 (0.52-0.54) 0.97 (0.95-1.01) 0.96 (0.95-1.02)
T6 0.54 (0.53-0.56) 0.99 (0.94-1.03) 0.81 (0.79-0.86)
T7 0.56 (0.55-0.59) 1.02 (0.98-1.06) 0.87 (0.85-0.90)
T8 0.61 (0.60-0.64) 1.13 (1.09-1.17) 1.06 (1.04-1.11)
T9 0.65 (0.63-0.69) 1.18 (1.13-1.22) 1.03 (1.01-1.08)
T10 0.58 (0.57-0.61) 1.25 (1.19-1.30) 1.08 (1.03-1.21)
T11 0.71 (0.68-0.75) 1.29 (1.23-1.33) 1.29 (1.25-1.35)
T12 0.90 (0.86-0.94) 1.34 (1.28-1.39) 0.97 (0.94-1.01)
L1 0.94 (0.89-0.98) 1.53 (1.44-1.65) 1.10 (1.06-1.16)
L2 0.65 (0.62-0.67) 1.36 (1.27-1.44) 1.13 (1.10-1.19)
L3 0.73 (0.70-0.75) 1.22 (1.16-1.27) 1.18 (1.15-1.24)
L4 0.82 (0.79-0.84) 1.49 (1.44-1.53) 1.34 (1.30-1.40)
Conclusion(s): We report good reproducibility of com-
prehensive 95 point annotation using this tool: the
results are similar or superior to other studies employing
standard 6 point markup to assess VD. This VDT may
serve as a robust mark-up tool for clinical studies of
vertebral fracture.
References: Brett A, Miller CG, Hayes CW, et al, Spine
2009;34:2437.
Disclosures: The authors would like to thank and acknowl-
edge the use of the radiographs obtained by the CaMOS
research study team.
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THE APPLICATION OF IBANDRONATE IN
MULTIMODALITY THERAPY OF PERIODONTAL
DISEASE
Iryna Mazur, Viktoriia Peredrii, Zoryana Gosteva
National Medical Academy of Post-Graduate Education
Named after PL Shupyk, Dentistry, Kiev, Ukraine
Objective(s): Periodontal disease is being characterized by
progressive destruction of bone tissue. To improve the effi-
ciency of treatment received by patients affected with peri-
odontal disease via remodeling of bone tissue metabolism
and resorption process of alveolar bone. Over a period of 15
years in our clinic we administer bisphosphonates in the
treatment of periodontitis, such as ibandronic acid is being
used by us during 3 years
Material & Methods: Examination and treatment of 188
patients affected with periodontal disease (90 females - aver-
age age: 46±4.6; 98 males - average age: 45±4.2) was pro-
vided. The quantitative dissection of alveolar bone level was
conducted on panoramic X-Ray. Blood analysis identified
markers of bone metabolism- osteocalcin and deoxypyridino-
line. The patients received initial periodontal treatment and
once in 3 month supportive treatment. Ibandronic acid – 1 pill
Osteoporos Int (2012) 23: (Suppl 2):S85–S386 S161
per month per three-month course of treatment was addition-
ally prescribed to the main group (48 females and 50 males).
Prescription of ibandronic acid based on the high level of
resorption of bone tissue of skeletal system. Third generation
calcium baseline therapy was prescribed – 1 pill twice a day
per six-month course of treatment.
Results: Among 100% of patients in the main group was
not revealed any exacerbation of disease, among 16.6%
(15 persons) (p<0.005) in the control group exacerbation
of periodontitis was revealed. According to the data from
radiostereometry index of decrease of alveolar bone level
in the main group made up (4.12±1.23) mm. After
treatment was provided it is observed that index of
alveolar bone level increased by 14% (3.29±1.15 mm;
P<0.05). Decrease of alveolar bone level in control group
before treatment made up (4.09±1.14) mm, after 12 months –
(4.36±1.23) mm. After 12 months resorption of alveolar bone
was observed – deoxypyridinoline made up (4.71±0.42) in
comparison with the index before treatment – (6.37±0.68)
nmol (P<0.05). Processes of bone tissue formation have im-
proved. Before treatment index of osteocalcin made up 20.12±
0.34 ng/ml – before treatment in comparison with 27.45±0.38
ng/ml (P<0.05) after treatment. In control group these indexes
varied unreliably.
Conclusion(s): The application of ibandronic acid has nor-
malized bone tissue metabolism of patients affected with
periodontitis.
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VITAMIN D LEVELS IN OLDER THAN 50 YEARS
OF AGE IN URUGUAY: RESPONSE TO
SUPPLEMENTATION WITH VITAMIN D
Margarita Calegari, Jaime Hernandez, Vilma Chijani, Selva
Lima, Miguel Albanese, Idivia Martino, Renée Souto, Alicia
Vaglio, Juan Acosta
Sociedad Uruguaya de Reumatología, Osteopathy Study
Group of the Uruguayan Society of Rheumatology, Monte-
video, Uruguay
Objective(s): To estimate the distribution at base line of the
levels of serum vitamin D (VD) in people aged older than 50
years and to evaluate the modification after supplementation
of 2000 IU of vitamin D3.
Material & Methods: 25OH VD3(VD3) basal level was
measured in 372 women and 72 men older than 50 years
without medical conditions or under treatment with drugs-
induce osteopenia and without receiving VD at a higher
dose than 200 IU in the past six months. According to Hollis
(1) it was considered VD3 sufficiency levels above 30 ng/ml,
hypovitaminosis between 20-30 ng/ml, insufficiency 10-
20 ng/ml and deficiency below 10 ng/ml. Results were ana-
lysed according to sex and age group (<65 and >66 years of
age). 2000 IU of VD3 was prescribed to those with serum
levels below 30 ng/ml during 5 months. A this time a second
determination of VD3 level was performed.
Results: 78.16% of the population older than 50 y had VD3
serum levels below 30 ng/ml and almost 30% below 20 ng/ml.
Mean concentration was 24.6 ng/ml. There was statistical
difference between those <65 years who had 26 ng/ml and
those >66 years who had 22.4 ng/ml (p<0.001). 80% of the
women and 72% of the men had serum levels below suffi-
ciency. Mean concentration of VD3 after supplementation
increased from 24.6 to 36.9 ng/ml with no toxic levels found.
Conclusion(s): 78.16% of the population older than 50 years
of age in Uruguay have VD3 levels below 30 ng/ml and a
mean concentration of 24.6 ng/ml. Similar percentages were
found in both sexes. There was a significant difference in the
mean concentration of VD3 levels in the age groups consid-
ered. Supplementation with 2000 IU of VD3 is considered to
be effective increasing the mean level of VD3 from 24.6 to
36.9 ng/ml. Nontoxic levels of VD3were found in any subject.
References: 1. Hollis BW, et al. Am J Clin Nutr 2004;79:717.
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EFFECTS OF SODIUM INTAKE ON
NON-VERTEBRAL FRACTURES IN
POSTMENOPAUSALWOMEN
Kiyoko Nawata1,2, Mika Yamauchi1, Shin Takaoka1,
Toshitsugu Sugimoto1
1Shimane University Faculty of Medicine, Internal Medicine
1, Izumo City, 2The University of Shimane, Health and
Nutrition, Matsue City, Japan
Objective(s): Increased Na intake is positively correlated
with urinary Ca excretion, and related to negative Ca balance.
Excessive Na intake has been reported to be associated with
increases in bone resorption markers and decrease of BMD.
However, it remains unknown whether excessive Na intake is
related to the risk of fracture. We therefore examined the
relationship between Na intake and the risk of fracture and
investigated whether this relationship was influenced by
BMD, bone metabolic markers, and intake of other nutrients.
Material & Methods: Subjects were 213 healthy postmen-
opausal women who had undergone osteoporosis screening.
Levels of Ca, P, intact PTH, 25(OH)D, N-terminal propep-
tide of type I collagen (PINP) and C-terminal crosslinked
telopeptide of type I collagen (CTX), were measured. The
BMD of the lumbar spine (L2-4) and femoral neck (FN) was
measured using DXA, the presence or absence of morpho-
logical vertebral fracture was determined, and the presence
or absence of existing non-vertebral fracture was determined
through physician interviews. Nutrient intakes (proteins, Ca,
Mg, P, Na, vitamin D, vitamin K) were calculated using the
Food Frequency Questionnaire (FFQ).
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Results: Mean values of age and BMI were 63±8 years and
22.9±3.1 kg/m2, respectively. Na intake was 5211±1697 mg,
which was higher than the levels reported in the National
Health and Nutrition Survey Japan 2009 (4055 mg). Levels
of intact PTH, 25(OH)D, PINP, and CTX were 46±15 pg/ml,
16.3±4.4 ng/ml, 54.3±16.5 ng/ml, and 0.40±0.15 ng/ml,
respectively, and levels of L2-4 and FN BMD were 0.84±
0.15 g/cm2 (Z-score 0.3±1.1, T-score -1.5±1.3) and 0.62±
0.09 g/cm2 (0.1±1.0, -1.5±0.8), respectively. Na intake was
not correlated with BMD and bone metabolic markers. Logis-
tic regression analysis of the effects of nutrient intake (divided
into quartiles) on the risk of fracture revealed that highest Na
intake group (mean value 7561±1035 mg) was a significant
risk factor for nonvertebral fracture (odds ratio, 3.4 (95%CI:
1.3-9.1), p<0.05) even after adjustments for age, BMI, intact
PTH, 25(OH)D, CTX, BMD, and intake of other nutrients.
Conclusion(s): These findings suggest that excessive Na
intake is a risk factor independent of BMD and bone meta-
bolic markers. It is important to consider excessive Na
intake in diet therapy for osteoporosis.
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OSTEO METABOLIC ABNORMALITIES IN
PATIENTS WITH BETA THALASSEMIA TREATED
WITH BLOOD TRANSFUSION AND IRON
CHELATION THERAPY
Giovanni Iolascon, Annarita Capaldo, Fabrizio Luciano,
Gioconda Di Pietro, Francesca Gimigliano
Second University of Naples, Orthopaedics and Rehabilita-
tion Medicine, Naples, Italy
Objective(s): Patients with β-thalassemia major and thalas-
semia intermedia, treated with blood transfusion and iron
chelation therapy, can gradually develop osteopenia and
osteoporosis. Genetic factors, endocrine disorders associat-
ed to beta-thalassemia, and the toxic effects of iron overload
can interfere with bone remodeling inducing osteoclastic
activity and/or inhibiting osteoblastic activity by RANKL/
OPG pathway. Even though iron overload in the bone could
lead to intervertebral disc calcifications, iron chelation ther-
apies as well seem to increase bone loss and spinal defor-
mities. The aim of our prospective cohort study was to
evaluate osteoporosis and intervertebral disc calcifications
in patients with thalassemia major and intermedia treated
with blood transfusion and iron chelation therapy.
Material & Methods: We recruited 32 subjects (≥18 y.o.),
referring to the Department of Orthopeadics and Rehabili-
tation Medicine, affected by β-thalassemia major or inter-
media and in treatment with regular blood transfusions and
iron chelation therapy. Thirty subjects (7 males and 23
females) had Cooley's disease (β-thalassemia major) and 2
(both females) had thalassemia intermedia. All patients
underwent DXA examination for BMD measurements and
X-rays of the dorsal and lumbar spine for the identification
of intervertebral disc calcifications and spinal deformities.
Results: The mean age of our cohort was 30.5 (min 18; max
46). Nineteen subjects presented BMD values consistent with
a diagnosis of osteoporosis and 13 with osteopenia. Fourteen
subjects presented spinal deformities: 8 of them had only one
deformity while the other 6 had multiple deformities. Twenty-
one subjects presented intervertebral disc calcifications: 14
had dorsal calcifications, one lumbar calcifications, and 6
had both dorsal and lumbar calcifications. Eleven patients
presented both spinal deformities and intervertebral disc cal-
cifications: 10 of them were osteoporotic and one osteopenic.
Conclusion(s): Our results show that there is a decrease in
BMD in all patients, the 59% had values consistent with a
diagnosis of osteoporosis. The 44% presented at least one
spinal deformity. The 66% presented intervertebral disc
calcifications. One third of our population presented all the
examined osteo metabolic abnormalities together (low
BMD, spinal deformities and disc calcifications).
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EFFECTS OF EXERCISES ON BACK PAIN,
DEPRESSION AND QUALITY OF LIFE TO
OSTEOPOROTIC PATIENTS
Adrian C Bighea, Simona Patru, Iulia R Marcu, Roxana
Popescu
University of Medicine and Pharmacy of Craiova, Physical
Medicine and Rehabilitation, Craiova, Romania
Objective(s): While antiosteoporotic drug therapy addresses
to BMD, an exercises programme may have an important
impact on back pain and disability to these patients.
In this randomized controlled clinical trial we want to de-
termine the effects of exercises in reducing back pain, de-
pression and improving physical function and quality of life
to osteoporotic patients.
Material &Methods: The patients were randomly assigned
to a control group (n=20) and an exercises group (n=20). In
the control group the patients received only bisphosphonates
(stable dose for at least 6 months). In the exercises group the
patients followed the drug therapy and a standardized pro-
gressive exercises programme for improving posture, spine
mobility, trunk control and strengthen spine extensors,
abdominals and lower limb muscles (45 min, 3 times/week,
6 weeks). The assessment was made baseline and after 6
weeks using: a visual analogue scale (100 mm) for back
pain, Beck Depression Inventory and Qualeffo-41 a ques-
tionnaire especially developed for measuring quality of life
to patients with osteoporotic vertebral deformities.
Results: Back pain on VAS was reduced by 45.7% in the
exercises group and only by 12.5% in the control group. The
Osteoporos Int (2012) 23: (Suppl 2):S85–S386 S163
intervention group showed significantly greater improvements
in the Qualeffo-41 scores compared with the control group,
especially on pain and social function subscales. There was a
significant difference between groups in the Beck Depression
Inventory: the exercises group showing an improvement (14.7
vs. 10.3) and the control group deteriorating (14.2 vs. 14.9).
Conclusion(s): The results support the benefits of exercises
in the clinical management of osteoporosis. The exercises
program was well accepted by subjects and no adverse
events were reported.
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CALCIUM-SENSING RECEPTOR
POLYMORPHISMS INFLUENCE ON BONE
MINERAL DENSITY AND BONE METABOLISM
MARKERS IN PATIENTS WITH PRIMARY
HYPERPARATHYROIDISM
Ekaterina A Pigarova1, Liudmila Ya Rozhinskaya1, Anatoly
N Tiulpakov2, Svetlana S Mirnaya1, Anna V Belyaeva1,
Natalia G Mokrysheva1
1Endocrinology Research Centre, Neuroendocrinology and
Osteopathies, 2Endocrinology Research Centre, Laboratory
of Department of Hereditary Endocrine Diseases, Moscow,
Russian Federation
Objective(s): Calcium-sensing receptor (CaSR) polymor-
phisms are associated with different calcium handling in
healthy individuals but little is known about their role in
pathological conditions of calcium metabolism. Thus our
aim was to characterize the influence of CaSR polymorphisms
on blood and urine calcium levels, BMD and markers of bone
metabolism in primary hyperparathyroidism.
Material & Methods: Our study included 135 patients with
PH (68 M/72 F, median age 59 [Q25 - 49 years; Q75 - 66
years], which underwent genetic testing for A986S, R990G
and Q1011E polymorphisms of CaSR (extraction of leuko-
cyte DNA, amplification of coding region of exon 7, direct
sequencing of PCR ampliclons). We also evaluated Ca con-
centrations, PTH, osteocalcin (OK) and β-crosslaps (CTX),
BMD (Prodigy, Lunar).
Results: We found no differences in Ca and PTH levels
between wild genotype and studied polymorphisms in
hyperparathyroid state. 986AS,S genotype was associated
with lower levels of OK 33.1 vs. 55.90 ng/ml (p=0.04) and
CTX 0.66 vs. 1.11 ng/ml (p=0.02), loss of Ca regulation of
PTH levels (r=0.11, p=0.56 vs. r=0.59, p=0.00000001)
and lower BMD at radius 33% 0.459 vs. 0.520 g/cm3
(p=0.03). Patients with 990RG,G genotype had lower levels
of CTX 0.8 vs.1.2 (p=0.04), higher BMD in premenopausal
women and lower BMD in women in menopause. No differ-
ences were associated with 1011QE,E genotype.
Conclusion(s): A986S and R990G polymorphisms of CaSR
seem to play pathological role in Ca and bone metabolism in
primary hyperparathyroidism.
Disclosures: The work was supported by grant of President
of Russian Federation MK-2852.2010.7.
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PREVALENCE OF VITAMIN D DEFICIENCY AND
INSUFFICIENCY IN SERBIAN WOMEN
POPULATION
Jelena N Elez1, Filip D Gojkovic2, Jelena M Vasic2, Violeta
D Culafic Vojinovic1, Vera S Lukic3
1Railway Health Care Center, Internal Medicine, 2Railway
Health Care Center, Physical Medicine and Rehabilitation,
3Railway Health Care Center, Byochemic Laboratory, Bel-
grade, Serbia
Objective(s): Vitamin D deficiency and insufficiency are
quite prevalent among women in Serbia. The aims were to
assess the level of vitamin D and prevalence of vitamin D
deficiency and insufficiency and to improve supplementation
which will improve vitamin D status in women. Vitamin D
levels in peripheral blood have been assessed at 130 women,
aged 29-79 years (median 56.7±1.2) in Railway Health Care
Center in Belgrade.
Material &Methods: Patients have been split into 5 groups
according to the age: 20- 39, 40-49, 50-59, 60-69 and 70-79
years old, all of them were women. Vitamin D levels were
assessed with the 25-OH Vitamin D EIA Kit by means of
the Immundiagnostic Enzyme-Immuno-Assay (EIA) for quanti-
tative determination of 25-OH Vitamin D in human serum and
plasma.
Results: Results in groups: 25-OH vitamin D level in group
29-39 yrs was 63.7±8.5 nmol/l; in 40-49 yrs -52.6±4.7 nmol/
l; in 50-59 yrs-59.4±9.6 nmol/l; in 60-69 yrs-57.0±7.3 nmol/
l; in 70-79 yrs-64.8±7.3 nmol/l. Average value throughout the
assessed population was 57.5±5.3 nmol/l. Deficiency has
been found in 0%, 11%, 11%, 3%, 0% of cases (“younger”
to “older” group, respectively). Insufficiency; 40%, 68%,
62%, 72%, 69% of cases. Normal values of 25(OH) vitamin
D have been determined in 60%, 21%, 27%, 25%, 31% (same
group breakdown). In total diagnosis of vitamin D deficiency
was established in 7% of the subjects, insufficiency in 66%;
normal values in 27% of the population of question.
Conclusion(s): Vitamin D deficiency and insufficiency
occurs with high frequency among women in Serbia.
Lack of sun exposure and poor intake are suggested
explanations for this phenomenon. Improving vitamin D
status in the adult Serbian women population might be
an effective strategy to reduce morbidity and mortality of
osteoporosis.
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THE CORRELATION BETWEEN REDUCED
SERUM 25(OH)D AND FREQUENCY OF FALLS
AND FRACTURES IN PATIENTS WITH
OSTEOPOROSIS RESULT BONLINK PROGRAM
Tanja Jankovic, Jelena Zvekic Svorcan, Milianka Lazarevic,
Biljana Erdeljan
Special Hospital for Rheumatic Diseases, Rheumatology,
Novi Sad, Vojovina, Serbia
Objective(s): A reduced value of serum 25 (OH) D plays an
important role in the development of osteoporosis and oste-
oporotic fractures as well in the functional capacity of
skeletal muscle, which is reflected in the increased frequen-
cy of falls. The reduced value of serum 25 (OH) D is
considered to be below the value of 30 ng/ml (75 nmol/l).
The purpose of this study is to determine the correlation
between decreased serum 25 (OH) D and the frequency of
falls and fractures in patients with osteoporosis.
Material & Methods: The analysis included 229 patients
with osteoporosis, 208 women (90.8%) and 21 men (9.2%),
median age 65. The study was conducted during one year.
The patients were measured by serum 25 (OH) D ECLIA
method. In patients with reduced serum 25 (OH) D the
frequency of falls and fractures was determined on the basis
of anamnestic data and X-ray findings, through the analysis
of data from the "BONLINK" database, which is used for
entering patients' data with osteoporosis and data analysis.
Results: In 86 patients the measured value of serum vitamin
D was above 30 ng/ ml, while in 142 the value was less than
30 ng/ml. The median total serum 25 (OH) D measured was
30.91 ng/ml. For women the median value measured was
29.18 ng/ml and men 47.95 ng/ml. More than three falls per
year happened to 86 patients (60.6%) with a lower serum 25
(OH) D and low trauma fractures were found in 60 patients
(42.3%). The relation of the frequent falls and fractures was
65.11%, in other words 56 patients with frequent falls had
fractures. Vertebral fractures were found in 42.3%, while
nonvertebral fractures were more frequent and were
observed in 57.7% of patients. The most common localiza-
tion of the fracture was in the area of the forearm, recorded
in 38 patients (26.8%).
Conclusion(s): Our results suggest that a decreased serum
25 (OH) D is closely associated with the emergence and
frequency of falls and fractures. It is therefore necessary to
monitor it regularly and correct it through an adequate
intake in order to prevent future falls and fractures.
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THE BONE MINERAL DENSITY IN MINSK-CITY
HEALTHCARE PROFESSIONALS ACCORDING
TO THE DUAL X-RAY ABSORPTIOMETRY
Volha V Vadzianava1, Alla P Shepelkevich2, Sergei S
Korytko3, Natalya A Vasilieva3
1SIE "Belarusian Medical Academy of Postgraduate Educa-
tion", Department of Radiology, 2 IE "Belarusian State
Medical University", Department of Radiology, 3SI "Republic
Medical Rehabilitation and Balneotherapy Center", Depart-
ment of Radiology, Minsk, Belarus
Objective(s): To assess the BMD state in health care pro-
fessionals in Minsk city.
Material & Methods: BMD was assessed by DXA of the
axial skeleton in 137 (mean age 54 [48.6: 60.30] years, dura-
tion of menopause 7 [2:12] years) patients. The T-score was
used for the quantitative evaluation of BMD in postmeno-
pausal women, and the Z-score was used in the group of
women up to 45 years. The surveys for the presence of risk
factors for OP (including secondary forms of OP), evaluation
of anthropometric data: height, weight, BMI was conducted.
Results: The cohort of surveyed people n=137 included 86
(63%) physicians and 56 (41%) nurses. The total distribu-
tion of the bone density: 55 (40%) - norm, 56 (41%) -
osteopenia, 26 (19%) - osteoporosis. It should be noted that
all the patients were informed about osteoporosis. In order
to assess the impact of age-related changes in the status of
the BMD the surveyed women were divided into 4 groups.
Clinical and anthropometric data of Minsk city health care professionals
Groups Age, years Height, cm Weight, kg Spine BMD,
g/cm2
Z-score or
T-score
BMD femur neck,
g/cm2
Z-score or
T-score
Women under 45 (n=23) 40.8[32:43.9] 166.09+4.8 65.7+8.8 1.191+ 0.15 -0.06+1.25 0.985+ 0.15 -0.08+1.17
Women 45-55 (n=47) 50.37+2.33 162.48+4.98 68.37+10.6 1.107+ 0.17 -0.71+1.39 0.912+ 0.13 -0.6+1.05
Women 55-65 (n=50) 59.15[56.6:61.5] 159.89+5.47 75.9+12.77 1.046+0.14 -0.4+1.13 0.871+ 0.10 -0.098+0.81
Women over 65 (n=17) 69.36+3.11 157.59+4.4 74.4+13.5 1.018+0.17 -1.4+1.38 0.819+0.09 -1.34+0.79
The significantly (p<0.05) lower values of femur neck BMD in comparison with the spinal BMD among the women studied
were noted.
Osteoporos Int (2012) 23: (Suppl 2):S85–S386 S165
Conclusion(s): The increase of the rate of BMD loss with the
age (from 4% in the age under 45 years up to 82% in the age
over 65 years) was detected. The results of study reveal the
high prevalence of osteopenia (41%) and osteoporosis (19%)
in the healthcare professionals despite the awareness of risk
factors and methods for early diagnosis of OP.
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FUNCTIONAL HYPOPARATHYROIDISM IS
SEX-ASSOCIATED: AN OBSERVATIONAL STUDY
OF 909 HIP FRACTURE INPATIENTS
Marco Di Monaco1, Carlotta Castiglioni1, Fulvia Vallero1,
Roberto Di Monaco2, Rosa Tappero1
1Presidio Sanitario San Camillo, Osteoporosis Research
Center and Division of Physical Medicine and Rehabilita-
tion, 2University, Department of Social Science, Torino,
Italy
Objective(s): To investigate the association between sex
and functional hypoparathyroidism, i.e., the condition of
having inappropriate normal levels of PTH in the presence
of severe vitamin D deficiency, following a fragility fracture
of the hip.
Material & Methods: We investigated 909 of 981 inpa-
tients admitted consecutively to our rehabilitation hospi-
tal following a fragility fracture of the hip. In each
patient we assessed PTH (by two-site chemiluminescent
enzyme-labelled immunometric assay), 25-hydroxyvita-
min D (by immunoenzymatic assay), albumin-adjusted
total calcium, phosphate, magnesium, and creatinine on
a fasting blood sample 20.3±6.0 (mean±SD) days after
fracture occurrence. Glomerular filtration rate (GFR)
was estimated by the 4-variable Modification of Diet
in Renal Disease Study equation. Functional level was
assessed using the Barthel index. We excluded from the
study the patients with hypercalcemia or with an esti-
mated GFR<15 ml/min.
Results: Among the 909 patients, 571 (492 women and 79
men) had severe vitamin D deficiency (25-hydroxyvitamin
D levels <12 ng/ml). On the whole, 235 of these 571 patients
(41%) had secondary hyperparathyroidism, whereas the
remaining 336 (59%) had functional hypoparathyroidism
(normal PTH levels despite severe vitamin D deficiency).
The prevalence of functional hypoparathyroidism was signif-
icantly different between sexes (p=0.003): it was found in 302
of the 492 women (61%) and 34 of the 79 men (43%). The
significance of the between-sex difference was maintained
after adjustment for age, estimated GFR, phosphate, albu-
min-adjusted total calcium, albumin, magnesium, Barthel in-
dex scores, and 25-hydroxyvitamin D. Women had an
adjusted odds ratio for having functional hypoparathyroid-
ism=1.78 (95%CI 1.05-3.02; p=0.034).
Conclusion(s): Functional hypoparathyroidism was sig-
nificantly more prevalent in women than in men follow-
ing a fragility fracture of the hip. Higher tendency to
PTH excess may play a role in the known higher
occurrence of unfavorable outcomes found in hip frac-
ture men.
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VITAMIN D STATUS AMONG PATIENTS
SCREENED FOR OSTEOPOROSIS
I. Rápolthy1, V. Ferencz2, S. Mészáros2, V. Kellner1, C.
Horváth2
1PRODIA Central Laboratory of Székesfehérvár, Osteopo-
rotic Centrum, Székesfehérvár, 2Semmelweis University, 1st
Department of Medicine, Budapest, Hungary
Objective(s): Vitamin D deficiency is a common worldwide
condition. The serum 25-hydroxy vitamin D measurement is
the most accurate way to assess vitamin D deficiency. In this
study the authors determined the serum 25-hydroxy vitamin
D among Hungarian patients screened for osteoporosis.
Material & Methods: The vitamin D status has been mea-
sured among 1563 women and 169 men in a period from 1
December 2006 to 31 May 2008, in a subregion of Hungary
(Fejer County). The relationships between serum 25OH-D3
levels and metabolic bone markers, bone mineral content
have also been studied, as well as the possible effect of
vitamin D supplementation to bone fracture rate. The serum
25OH-D3 concentration was determined using ECLIA
method.
Results: Insufficient (0-60 nmol/l) serum 25OH-D3 level
was found in 63% of the investigated population. 25OH-D3
levels did not differ between the two genders. Our data
confirmed the well known seasonal variations in 25OH-D3
levels. Lower BMD was found among subjects suffered
from vitamin D deficiency. Poor vitamin D status caused
an increase in serum PTH levels, and an increase in fracture
rate, despite vitamin D supplementation which was inade-
quately dosed.
Conclusion(s): Our results suggest that patients with high
risk of osteoporosis frequently have vitamin D insufficiency
as well. Evaluation of vitamin D status and the intervention
with adequate dose of vitamin D supplementation is suggested
The prevalence of osteopenia and osteoporosis in different age groups
of women surveyed
Women surveyed Normal Osteopenia Osteoporosis
Women under 45 (n=23) 96% (22) 4% (1) -
Women 45-55 (n=47) 40.5% (19) 40.5% (19) 19% (9)
Women 55-65 (n=50) 22.0% (12) 54% (27) 24% (11)
Women over 65 (n=17) 18% (3) 47% (8) 35% (6)
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to have benefits in the effective antiporotic treatment as well
as in the prevention of falls and fractures.
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EFFICACY OF STRONTIUM RANELATE IN
COMPREHENSIVE TREATMENT OF
POSTMENOPAUSAL OSTEOPOROSIS WITH
EVALUATION OF VERTEBRAL BODIES
DEFORMITIES BY DXA
Volha V Vadzianava1, Alla P Shepelkevich2, Anatoly N
Mikhailov1
1SIE "Belarusian Medical Academy of Postgraduate Educa-
tion", Department of Radiology, 2 IE "Belarusian State
Medical University", Department of Endocrinology, Minsk,
Belarus
Objective(s): To evaluate the strontium ranelate efficacy in the
treatment of postmenopausal osteoporosis with dynamic as-
sessment of vertebral bodies (T4-L4) deformities by Genant's
semiquantitative method based on DXA.
Material & Methods: We examined 35 Minsk city women
(middle age 60.3 [57.4:64] years old, duration of menopause,
10 [7-16] years) with verified diagnosis of postmenopausal
OP. The patients were surveyed for the presence of risk factors
for OP including secondary forms of the disease. In 12 women
before and after the treatment were assessed vertebral defor-
mities using an LVA-application (lateral vertebral assess-
ment), which is characterized by high sensitivity comparable
with standard radiography. The deformities were assessed by
Genant's semiquantitative method and the index of the verte-
bral body, equal to 76-79% is weak deformity, 61-75% mod-
erate deformity and less than 61% expressed osteoporotic
deformity of vertebral bodies. During the follow-up after 12
months the evaluation criteria were the presence of new de-
formities and / or increase of the degree of the vertebral
deformity.
Results: Comparative analysis of BMD at lumbar spine
(L1-L4) and femoral neck before and after 12 months treat-
ment of OP with strontium ranelate and a combined prepa-
ration of calcium carbonate and cholecalciferol showed
significantly (L1-L4 p<0.00001; SB p=0.00078) increased
BMD in both areas. The maximum increase in BMD at the
lumbar spine in the dynamics of 12% and 8% was observed
among women who had borderline significance of the T-
score - 2.5, indicating the maximum efficiency at an earlier
stage of the disease. In 5 from12 women surveyed mild and
moderate deformities of the vertebral bodies T11, T12, L1
and L2 were identified. During the follow-up new deformi-
ties were not noted, all patients noted reduction of pain.
Conclusion(s): The results of the prospective randomized
clinical studies have confirmed the efficiency of strontium
ranelate in combination with a combined preparation of
calcium carbonate and cholecalciferol in the treatment of
postmenopausal osteoporosis with increasing BMD rates in
the lumbar spine and in the femoral neck with good tolera-
bility and patients' adherence to treatment.
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SHORT TERM PHYSICAL ACTIVITY MAY
INDUCE CHANGES IN BONE DENSITY AND
GEOMETRY EVEN AFTER LATE ADOLESCENCE
IN TALENTED FEMALE ATHLETES
Béatrice Ferry1,2, Eric Lespessailles3, Gaëlle Ducher6, Pierre
Rochcongar4, Martine Duclos5, Géraldine Naughton6, Daniel
Courteix2
1Université de Limoges, FST - STAPS, Brive la Gaillarde,
2Clermont Université, AME2P - Université Blaise Pascal,
Clermont-Fd, 3INSERM U658, IPROS, Orléans, 4CHU
Pontchaillou, Unité de Biologie et Médecine du Sport,
Rennes, 5CHU de Clermont-Fd, Service de Médecine du
Sport et des Explorations Fonctionnelles - Laboratoire de
Nutrition Humaine, Clermont-Fd, France, 6Australian Catholic
University, School of Exercise Science, Victoria, Australia
Objective(s): The aim of this study was to assess the
changes in hip structural parameters and BMD in high level
adolescent soccer players and swimmers at the period of late
adolescence.
Material & Methods: 26 girl swimmers (SWIM, 15.9±2
years) and 32 soccer players (SOC, 16.2±0.7 years) were
investigated before and after an 8-month training season.
Fifteen non active age-matched adolescents were enrolled at
baseline to serve as a reference group. Body composition and
areal BMDwere measured at the total body, lumbar spine and
total hip by DXA. Indices of bone geometry were extracted
from DXA scans using the hip structural analysis (HSA)
method. Anatomical (cross sectional area-CSA, endocortical
diameter-ED, periosteal diameter-WIDTH) and mechanical
parameters (CSMI, Z, buckling ration-BR) were analyzed. A
one way ANOVAwith repeated measures was performed.
Results: After 8 months of training, SOC had increased
their density at all the traditional bone sites whereas SWIM
did not. The SOC's changes were associated with an in-
crease of whole body lean mass. At the neck and total hip,
SWIM kept their baseline normal Z-score values and SOC
remained above the normal. The most important changes in
HSA parameters were observed at the femoral shaft. When
comparing the Z-score to the control group at this section,
SWIM who were normal for ED and WIDTH did not
change after the season. For the SOC group who started
already above the average range, CSA and WIDTH still
improved during this period. Z-score showed an improve-
ment of CSMI and Z at FS section for SOC (p<0.001),
without any change in the SWIM group. Remarkably SWIM
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had improved the Z-score of BR (p<0.005) while SOC did
not.
Conclusion(s): A training season of sport characterized by
impacts (SOC) is associated with bone geometry improve-
ment in late adolescent female despite expectations that this
period of growth represents a plateau in bone maturation.
Weight bearing physical activity can be an important con-
tributor to bone strength at the end of adolescence, as
observed during childhood.
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UNDERSTANDING AND USE OF THE 2010
OSTEOPOROSIS CANADA CLINICAL PRACTICE
GUIDELINES (OC CPG) BY CANADIAN PRIMARY
CARE PHYSICIANS (PCPs)
Alexandra Papaioannou1, Robert Josse2, Daniel Ngui3,
Bridget Burns4, Cheryl Colizza5, Suzanne Morin6
1McMaster University, Department of Medicine, Hamilton,
ON, 2University of Toronto, St Michael's Hospital, Department
of Medicine, Toronto, ON, 3University of British Columbia,
Department of Medicine, Vancouver, BC, 4Amgen Canada
Inc., Department of Medical Communication, Mississauga,
ON, 5Amgen Canada Inc., Department of Marketing, Missis-
sauga, ON, 6McGill University, Department of Medicine,
Montreal, QC, Canada
Objective(s): In October 2010, OC published updated CPG
for the diagnosis and management of osteoporosis in Can-
ada, emphasizing a shift to absolute fracture risk (AFR)
assessment. A survey of Canadian PCPs was conducted to
assess current awareness, understanding and use of the 2010
OC CPG.
Material & Methods: These data represent results from the
control group of an educational intervention program eval-
uating accredited CHE and practice assessment on under-
standing and use of the 2010 OC CPG. An online survey of
Canadian PCPs previously consenting to participate in sur-
veys was conducted in May 2011. Inclusion criteria: physi-
cians treating >10 postmenopausal osteoporosis (PMO)
patients/month. Level of understanding was gauged using
three patient cases with different fracture risk.
Results: • 304/2100 PCPs were eligible and completed the
survey
◦ 59% indicated they had started using the CPG
◦ 17% and 10% indicated they were using 2010 CAROC
(Canadian Association of Radiologist and Osteoporosis
Canada) or FRAX, respectively, as their primary approach
to evaluating PMO patients
◦ Most (66%) relied on BMD and risk factors
• Over 59% indicated that they obtain the 10-year AFR
assessment results from DXA reports. A follow-up question
asking which risk factors are used to calculate the AFR
yielded inconsistent results
• Only 22/304 (7%) correctly identified the appropriate risk
category of all three patient cases according to the CPG
◦ Most (82%) did not accurately assess the moderate-risk
patient
• Although most PCPs stated they use the OC CPG to guide
treatment decisions, many indicated they considered etidro-
nate (52%) or calcitonin (14%) as firstline therapies, con-
trary to CPG recommendations
Conclusion(s): Seven months after the launch of the 2010
OC CPG, a large proportion of Canadian PCPs indicate they
are using the guidelines and risk assessment tools. However,
PCPs may not apply the 10-year ARF accurately, particu-
larly in the case of moderate-risk patients, and treatment
recommendations may not be fully understood at this time.
Further education and strategies to integrate AFR and CPG
into clinical practice, including DXA reports, will likely
improve their understanding and use by PCPs in the future.
Disclosures: Research sponsored by Osteoporosis Canada
with financial support provided by Amgen Canada.
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A PROSPECTIVE 1-YEAR STUDY OF CARE
PROCESS AND FUNCTIONAL RECOVERY
FOLLOWING OSTEOPOROTIC HIP FRACTURES
Mohammad Auais1, Suzanne Morin2, Lois Finch1, Sarah
Ahmad1, Nancy Mayo1
1McGill University, School of Physical and Occupational
Therapy, 2McGill University, Medicine, Montreal, QC, Canada
Objective(s): To identify current practices and care gaps for
elderly patients admitted to a tertiary care trauma center
following an osteoporotic hip fracture, and to characterize
patients patterns of functional recovery over a 1-year period.
Material & Methods: 40 community-dwelling participants
with an osteoporotic hip fracture (age 65 years and older,
fall from standing height) were recruited and followed over
1-year. Patients were divided according to their pre-fracture
mobility: low, medium, and high. Recovery was defined in
2-ways: traditional definition based on return to pre-fracture
mobility; and acceptable based on ability to go up and down
stairs. Statistical analysis: Single-subject design approach
for analyzing small samples was used to identify sources
of variability in recovery over time.
Results: Gaps in services received during hospitalization
and at the time of discharge to the community were: (i)
63% had a surgical delay of more than 48-hours; (ii)
>75% had inadequate osteoporosis management; (iii) only
35% had a home visit within one week of return home; and
(iv) 40% did not receive instructions on fall prevention.
Using the traditional definition for recovery: 80%, 52%,
33% recovered from the low, medium, and high baseline
groups, respectively; 40%, 43%, 33% maintained this re-
covery up to 1-year. Using the definition for acceptable
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recovery, 20%, 43%, 71% recovered, respectively, and 10%,
38%, 57%maintained the recovery. The low group returned to
prefracture function around 6-weeks while the high group
returned around 6-months post-fracture. However, patients
generally lost functional improvement between 6-12 months,
following waning of rehabilitation services. Patients with
acceptable recovery had better health-related quality of life
over the study period than those without (p<0.01).
Conclusion(s): Despite the plethora of evidence-based guide-
lines specifically for osteoporosis management following hip
fracture, gaps exist in care practices across the continuum. The
extent of recovery depended on the definition used; however
we noted that, after initial improvement, the majority of
patients deteriorated after 6 months. An extended booster
rehabilitation program and planned contact with the health
care system may be indicated 6 months following the fracture
for community-dwelling survivors of hip fractures.
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EFFICACY OF GLUCOSAMINE SULFATE (GS)
IN HAND OSTEOARTHRITIS
Simona Patru, Iulia R Marcu, Adrian C Bighea, Roxana
Popescu
University of Medicine and Pharmacy of Craiova, Physical
Medicine and Rehabilitation, Craiova, Romania
Objective(s): Osteoarthritis (OA) frequently involves joints
of the hand leads to pain, stiffness, deformity, gradual loss
of function which decrease the ability to perform manual
tasks and diminish the quality of life. In this randomized
clinical study we want to compare the efficacy of two
currently preferred medications for symptomatic treatment
of OA: glucosamine sulfate and acetaminophen.
Material & Methods: 50 patients from Physical Medicine
and Rehabilitation outpatient clinic, who met the American
College of Rheumatology criteria for hand OAwere includ-
ed in the study, with mean age 61 years, 56% female. The
treatment arms were: GS 1500 mg, oral, once daily (25
subjects) and acetaminophen, one 1000 mg tablet two times
daily (25 subjects). The patients are assessed at baseline and
after 6 weeks, at the completion of the study using the
following parameters: hand joint pain (100 mm VAS), a
hand function test with short administration time, the
Moberg Picking-Up Test (MPUT) and the Short Form 36
Health Survey (SF- 36).
Results: The treatment groups were comparable in terms
of baseline characteristics. After 6 weeks of treatment
GS decreased the pain by 28% and acetaminophen by
24.2%. GS was significantly superior to acetaminophen
in improving hand function (better times to 6 weeks
MPUT, 12.8 s vs. 15.6 s). The Short Form 36 scores
were significantly improved in the GS group for phys-
ical functioning, role physical, mental health and role
emotional subscales. There were no significant differ-
ences between groups for general health, bodily pain,
vitality and social functioning subscale.
Conclusion(s): GS was at least as effective as acetamino-
phen in improving hand OA symptoms and increased joint
mobility and strength to HOA patients.
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THE EFFICACY AND TOLERABILITY OF
PLASTER "NANOPLAST FORTE" IN KNEE
OSTEOARTHRITIS TOPICAL THERAPY
Lev N Denisov, Elena S Tsvetkova
Research Institute of Rheumatology RAMS, Clinical Trials
Department, Moscow, Russian Federation
Objective(s): To evaluate the efficacy and tolerability of
nanoplast forte (NF) plaster in knee osteoarthritis (KOA)
topical treatment.
Material & Methods: In a multicentric double blind ran-
domized placebo controlled 2 weeks trial with 2 paralleled
groups, 120 pts (1:1 ratio), KOAwere included. The prima-
ry criterion of efficacy-decrease of pain according part A of
WOMAC index (≥50%). The secondary criteria-decrease:1)
daily dosage or withdrawal of NSAIDs; 2) everyday inten-
sity of pain(VAS, mm); 3) assessment of efficacy by pts and
physician separately (VAS, mm). Side effects were assessed
by rate and intensity. In both groups the plaster was applied
to the frontal surface of target joint every 12 h. Plaster NF
was made by very special technology (nanotechnology).
Results: Demographic and base-line clinical characteristics
were similar in both groups. The rate of 50% decrease of pain
(part A WOMAC index) in NF plaster group was 38.2%, in
placebo group-16.7% (p=0.013; Fisher test). Only in NF
plaster group pain during walking decreased statistically sig-
nificant (p=0.05; ANOVAmethod) already at 4-th day and at
final of treatment (Dannet test). Symptoms significantly im-
proved of the WOMAC index (stiffness subscale, functional
subscale and total WOMAC score) in NF group (p=0.035;
p=0.01, p=0.012; ANOVA method). The improvement
according to the opinion by pts and physicians was observed
in 82% in NF group and 43% in placebo group (p=0.01). In
NF group 23 pts could decrease or fully withdraw NSAIDs,
in placebo group only 7 (p=0.007; Fisher test). Two local
allergic reactions was noted only in placebo group.
Conclusion(s): Topical nanoplast forte therapy in KOA is
well tolerated and provide expressed analgesic effect during
decrease NSAIDs dosage.
P275
VITAMIN D DEFICIENCY IN CHILDREN
WITH A CHRONIC ILLNESS: SEASONAL AND
AGE-RELATED VARIATIONS IN VITAMIN
D CONCENTRATIONS
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Elisa Holmlund-Suila1, Outi Mäkitie1, Tuula Metso2, Sture
Andersson1, Heli T Viljakainen1,3
1University of Helsinki &Helsinki University Central Hospital,
Children's Hospital, 2Helsinki University Central Hospital,
Skin and Allergy Hospital, Helsinki, Finland, 3University of
Bristol, Musculoskeletal Research Unit, Bristol, UK
Objective(s): Although vitamin D deficiency is a world-
wide epidemic with multiple health effects, vitamin D status
is not routinely measured in children and adolescents with a
chronic illness.
The aim of the study was to evaluate overall vitamin D
status, and its association with age, gender, and season in a
large cohort of chronically ill Finnish outpatients at Child-
ren's Hospital, University of Helsinki, Finland.
Material & Methods: A register-based cross-sectional study
was carried out. Altogether 1351 children visiting paediatric
outpatient clinics during 2007-2010 had their vitamin D status
(S-25-OHD) determined. The subjects' ages varied between
0.2-18 years, and 51% of them were boys.
Results: Almost half of the S-25-OHD values were consistent
with subnormal vitamin D status: 23% of subjects had S-25-
OHD <37.5 nmol/L and 24% between 37.5-50.0 nmol/L. In
contrast, only 12% had a concentration>80 nmol/L. Age and
season, but not gender, were the most important determinants
for S-25-OHD concentration. For further analysis children
were divided into five age groups; 0-2, 2.1-6, 6.1-10, 10.1-
15, and 15.1-18 years. Mean S-25-OHD concentration dif-
fered between age groups (Kruskal-Wallis; p<0.001): the
highest concentrations were seen in the youngest and the
lowest values in the oldest age groups. A significant seasonal
variation in 25-OHD concentration was noted in children
older than 10 years. In the whole cohort summer concentration
was on average 12 nmol/L higher than in winter and preva-
lence of vitamin D deficiency (= S-25-OHD <37.5 nmol/L)
varied from 29% to 11% between winter and summer.
Conclusion(s): The finding that almost half of the Finnish
children with chronic illness had suboptimal vitamin D
status is alarming. Seasonal variation and inferior vitamin
D status was noted in adolescents compared with younger
children suggesting that imbalance between intake and re-
quirement emerges with age. Although vitamin D status is
improved during summer, part of the pediatric outpatients
remains vitamin D deficient. Clinicians should identify indi-
viduals at risk and actively recommend vitamin D supple-
mentation.
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ONCE YEARLY ZOLEDRONIC ACID AFTER
18 MONTHS OF PARATHYROID HORMONE (1-84)
FOR SEVERE OSTEOPOROSIS
Marco Invernizzi1, Stefano Carda2, Alessio Baricich1,
Maurizio Bevilacqua3, Carlo Cisari1
1University of Eastern Piedmont "A. Avogadro", Clinical and
Experimental Medicine, Novara, Italy, 2Centre Hospitalier
Universitaire Vaudois (CHUV), Department of Neurorehabi-
litation and Neuropsychology, Lausanne, Switzerland, 3Luigi
Sacco Hospital (Vialba)-University of Milan, Endocrinology
and Diabetes Unit, Department of Medicine, Milan, Italy
Objective(s): The use of full-length PTH1-84 as a treatment
for severe osteoporosis is limited to 18-24 months, depend-
ing on different country rules. The therapeutic strategy after
this treatment remain an important issue, and at present time
evidences about antiresorptive therapies other than alendro-
nate after PTH1-84 are lacking. For this reason we aimed to
determine whether once yearly 5 mg of intravenous zole-
dronic acid (ZOL) can maintain or increase gains in BMD at
hip site after 18 months of therapy with PTH1-84.
Material &Methods: 25 severe osteoporotic postmenopaus-
al women were treated consecutively with PTH1-84 mono-
therapy (100 μg daily) for 18 months followed by 5 mg ZOL
two months after having ended PTH1-84. BMD at femoral
neck and total hip were assessed with the use of DXA at
baseline, after 18 months of treatment and 1 year after ZOL
infusion. Bone biochemical turnover markers (serum CTX,
OC and B-ALP) were assessed at baseline, every 6 month
during PTH treatment and 1 year after ZOL infusion. Tolera-
bility was evaluated by adverse experience (AE) reporting.
Results: BMD increased at femoral neck by 5.8% (1.8%
after PTH1-84 and 4% after ZOL, respectively) and an
analogue improvement was observed at total hip. Bone
biochemical markers percentage modifications from base-
line are resumed in Table. Three patients (12%) experienced
self limiting adverse events in the first month of PTH1-84
treatment, while 11 (44%) of patients experienced a self-
limiting acute phase reaction after ZOL.
Bone Biochemical Markers Modifications
6 month 12 month 18 months 1 year after ZOL
OC + 228%* + 201%* + 180%* - 50%
CTX + 140%* + 232%* + 250%* - 70%*
B-ALP + 128%* + 198%* + 186%* - 28%
* p<0.01vs. baseline
Conclusion(s): Our data show that ZOL is a safe and
effective option not only to maintain but also to increase
BMD at the hip site after 18 months of PTH1-84.
References: Black DM, Bilezikian JP, Ensrud KE et al. N
Engl J Med 2005;353:555.
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PROPHYLAXIS OF HETEROTOPIC OSSIFICATION
VIA PREOPERATIVE IRRADIATION INDUCES
LOCAL INFLAMMATION
S170 Osteoporos Int (2012) 23: (Suppl 2):S85–S386
Paula Hoff1, Timo Gaber2, Martin Hahne1, Cindy Strehl1,
Monique Fangradt1, Katharina Schmidt-Bleek2, Ufuk
Sentürk3, Harun Badakhshi4, Gerd R Burmester1, Georg N
Duda2, Carsten Perka3, Frank Buttgereit1
1Charité University Hospital, Department of Rheumatology
and Clinical Immunology, 2Berlin-Brandenburg Center for
Regenerative Therapies, Bioenergetics and Glucocorticoids,
3Charité University Hospital, Center for Musculoskeletal
Surgery, 4Charité University Hospital, Department of Ra-
diotherapy, Berlin, Germany
Objective(s): Preoperative irradiation of the hip is an estab-
lished method to prevent heterotopic ossification. To ex-
plore the involvement of the immune system in heterotopic
ossification, we analyzed hematomas which resulted from
the transection of the femur in patients receiving a total hip
arthroplasty (THA), either untreated preoperatively (THA-
H, n=24) or having been irradiated preoperatively (THA-X-
H, n=20) in the hip region (7 Gy).
Material & Methods: We quantified (i) immune cell pop-
ulations by flow cytometry and (ii) cytokines and growth
factors by multiplex suspension array.
Results: While there were no differences in the frequencies
of granulocytes, lymphocytes or CD14+ monocytes/macro-
phages between the THA-H and THA-X-H groups, the
number of CD3+ T cells was significantly increased in the
THA-X-H when compared to THA-H (p<0.01) due to the
increased frequency of CD3+CD8+ cytotoxic T cells (p<
0.001). Moreover, we found significantly higher concentra-
tions of the pro-inflammatory cytokines IL-6 (p<0.001), IL-
8 (p<0.001) and IFNg (p<0.001) in the THA-X-H as com-
pared to THA-H. In contrast, the concentration of the an-
giogenic VEGF was significantly suppressed (p<0.01).
Conclusion(s): Here we show that (i) the immune cell
composition in THA-hematomas is altered by the preopera-
tive irradiation of the hip, (ii) the secretion of pro-inflam-
matory cytokines is induced by the preoperative irradiation
while (iii) the secretion of the angiogenic VEGF is sup-
pressed. The increased numbers of cytotoxic T cells and
the elevated concentrations of IL-6, IL-8 and IFNg are
indicative for a local inflammatory process. Interestingly,
high numbers of cytotoxic T cells in wound healing were
shown to be associated with impaired regeneration and thus
could also be suspected to mediate prevention of heterotopic
ossification. The suppressed VEGF secretion after preoper-
ative irradiation of the hip is considered a relevant aspect of
the modified regenerative capacity that may be related to
prevention of heterotopic ossification.
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FREQUENCY OF POLYMORPHISM OF VITAMIN D
RECEPTOR GENE IN PATIENTS WITH LOW BMD
Heorhi Ramanau1, Arkadiy Silin1, Ema Rudenka2
1Republican Research Centre for Radiation Medicine and
Human Ecology, Endocrinology, Gomel, 2Belarusian Med-
ical Academy of Post-Graduate Education, Center for Oste-
oporosis Prevention, Minsk, Belarus
Objective(s): The aim of the study is to provide the analysis
of polymorphism frequency of VDR gene in the group of
patients with low BMD.
Material & Methods: The BMD study was assessed with
DXA by "Lunar Prodigy GE" in lumbar spine (LS) L1-L4
and femoral neck (FN). The criterion for the inclusion into
the study was T-score less than -1,0 according to LS or FN.
The molecular genetic analysis was performed by RFLP-
PCR method (ApaI, BsmI and TaqI).
Results: 134 patients residing in Gomel area aged 64.2±9.8
were included into the study. Osteoporosis was revealed in
124 (92.5%) patients and osteopenia was indicated in
remained 10 (7.5%) patients. Total in study group low-
energy fractures of FN, vertebral and forearm were earlier
marked in 46 (34.3%) patients in the age older than 50 years
of old. As a result of the performed molecular genetic
analysis there was revealed that in patients with low BMD
values (T-score<-1.0) genotypes frequency made up by
allele A/a, B/b and T/t. Under the analysis of various gen-
otypes frequency in groups of patients by presence/absence
of fractures in anamnesis and BMD there were not revealed
statistically significant differences. In the group of patients
where in anamnesis the relatives had low-energy fractures,
genotype "tt" frequency was statistically higher than in
patients without family history (χ2=6.27; p=0.012). There
were marked statistically significant differences in "t" and
"b" alleles frequency in the group of patients who indicated
fractures at relatives. "t" allele frequency in the group of
patients with family history was statistically higher (χ2=
6.04; p=0.014) and made up 0.500 in comparison with the
patients without family history where "t" allele frequency
made up 0.314. "b" allele frequency in the same groups
made up 0.542 correspondingly in comparison with 0.336
(χ2=7.10; p=0.008).
Conclusion(s): The provided analysis of polymorphism
frequency of VDR gene in patients with low BMD showed
the prevalence of “t” allele frequency (χ2=6.04; p=0.014)
and “b” allele frequency (χ2=7.10; p=0.008) in the group of
patients with low-energy fractures family history.
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THE PATIENTS KNOWLEDGE ABOUT
OSTEOPOROSIS AND DOCTORS VIEW OF THE
SITUATION IN YEKATERINBURG, RUSSIA
Alla G Zakroyeva, Elena V Kozjemyakina, Ivan S
Skorokhodov
Ural State Medical Academy, USMA, Department of Family
Medicine, Yekaterinburg, Sverdlovskaya, Russian Federation
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Objective(s): To assess the awareness of patients with os-
teoporosis (OP) of their disease and compare this data with
the doctors judgment.
Material & Methods: Cross-sectional written questioning
of 128 OP patients (mean age 64 years, 95% CI 63-66,
mostly women) and 22 their doctors by recruited indepen-
dent interviewees.
Results: 84% and 88% of patients acc. knew about the
essence of OP and the goals of its treatment. 96% of doctors
indicated that inform their patients about it “always”. 70% of
patients could calculate the total expenses for treatment de-
spite 37% of doctors 'never” or “rare” discussed these items.
38% of patients were aware of different approaches of medi-
cation including annually, 58% knew about the risk of irreg-
ular treatment, 37% knew the adverse effects. But 12%, 22%
and 12% of doctors acc reported that “never or rare” touch on
these subjects in consultations. More than 90% of patients
were confident “Ca plus vitamin D intake is effective remedy
for fractures prevention in OP”, 57% wrote that OP pharma-
cotherapy allows refusing physical exercises. 100% and 77%
of doctors acc. reported that consider these aspects “always”
or “regularly”. 80% of patients pointed “regular visits to
doctor is an obligate part of treatment” and “I require a long-
term management”. But only 42% of doctors organize next
visits. There were no associations between patients' age, sex,
and duration of anti-OP treatment, probability of depression,
anxiety and quantity of correct answers.
Conclusion(s): We obtained the lack of patients awareness
of practical aspects of OP treatment that may influence on
compliance indirectly. Information that doctors give in con-
sultations is insufficient, weakly understandable or hard to
remember. Patients need a long-term management.
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CLINICAL AND ECONOMIC CHARACTERISTICS
OF HIP FRACTURE PATIENTS WITH AND
WITHOUT MUSCLE ATROPHY/WEAKNESS IN
THE UNITED STATES
Shih-Yin Chen1, Yang Zhao2, Yuan-Chi Lee1, Ning Wu1
1United BioSource Corporation, Economic Analysis & Solu-
tions, Lexington, MA, 2Eli Lilly and Company, Global Health
Outcomes, Indianapolis, IN, US
Objective(s): Patients recovering from hip fracture with
muscle atrophy/weakness (MAW) may have increased med-
ical needs than those without. This study assessed the prev-
alence of MAW among hip fracture patients and compared
the demographics, comorbid medical conditions, and health-
care costs and utilization among hip fracture patients with
and without MAW.
Material & Methods: Using large US administrative
claims databases, individuals aged 50+ with commercial
insurance (under age 65) or Medicare supplemental
insurance (65+ years old) who were hospitalized for hip
fracture between 1/1/2006-9/30/2009 were identified. The
first hospitalization for hip fracture was defined as the index
stay. Patients were categorized into three cohorts: individu-
als with medical claims associated with MAW over the 12
months pre-index stay (pre-MAW), patients whose first
MAW claim occurred during or within the 12 months after
the index stay (post-MAW), and patients without any MAW
claim (no-MAW). Demographics, comorbid medical condi-
tions measured via Charlson comorbidity index (CCI) over
the 12-month pre-index stay, and medical costs associated
with the index stay were assessed and compared between
groups. Multivariate regressions were performed to estimate
the medical costs incurred over the 12 months post-index
stay controlling for cross-cohort differences.
Results: There were 26,122 Medicare (pre-MAW: 839; post-
MAW: 2,761; no-MAW: 22,522) and 5,100 commercially-
insured (pre-MAW: 132; post-MAW: 394; no-MAW: 4,574)
patients included in this study. Patients in the pre-MAW cohort
had higher CCI (Medicare: 7.3 vs. 5.6 vs. 5.0; commercial: 8.0
vs. 4.9 vs. 4.2), and were more likely to have any hospitaliza-
tion (Medicare: 52.2% vs. 25.1% vs. 21.2%; commercial:
59.9% vs. 25.6% vs. 20.8%) during the 12 months pre-index
stay than those in the post-MAWand no-MAW cohorts (all p<
0.05). The medical costs associated with the index hip fracture
stay were also the highest for the post-MAW group in both
insurance populations. Controlling for cross-cohort differen-
ces, both pre-MAW and post-MAW cohorts had significantly
higher total healthcare costs (Medicare: $7,308 and $18,753;
commercial: $18,679 and $25,495) than the no-MAW cohort
(all p<0.01) during the 12-month post-index stay.
Conclusion(s): Among US patients with hip fractures, those
with MAW had higher healthcare costs than patients without
MAW.
Disclosures: This study was funded by Eli Lilly.
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ASSESSING TREATMENT EFFECT IN A KNEE
OSTEOARTHRITIS DMOAD TRIAL USING MRI:
CARTILAGE DEFECT SCORING VS.
QUANTIFICATION OF CARTILAGE VOLUME LOSS
Lukas M Wildi1, Johanne Martel-Pelletier1, François
Abram2, Thomas Moser3, Jean-Pierre Raynauld1, Jean-
Pierre Pelletier1
1University of Montreal Hospital Research Centre
(CRCHUM), Notre-Dame Hospital, Osteoarthritis Research
Unit, 2ArthroLab Inc., Imaging Research & Development,
3University of Montreal Hospital Centre (CHUM), Notre-
Dame Hospital, Department of Radiology, Montreal, QC,
Canada
Objective(s): To evaluate the impact of MRI sequences on
cartilage lesion assessment in knee OA patients as well as
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the sensitivity to change over time comparing cartilage
defect (semiquantitative) with cartilage volume loss (quan-
titative) methods.
Material & Methods: Two fat suppressed MRI sequences
were compared: a 3D gradient echo (GRE), a classic carti-
lage sequence, and an intermediate-weighted fast spin echo
sequence (IW-FSE). Knee OA MRI were from two studies
of 2 years duration each (cohort 1, n=55; cohort 2, n=143).
Cohort 2 included patients from a previous trial examining
the chondroprotective effect of licofelone vs. naproxen. For
both cohorts, a GRE sequence was used, and patients of
cohort 1 underwent an additional IW-FSE. Cartilage defects
(for both cohorts) and cartilage volume (for cohort 2 only)
were evaluated using the semi-quantitative and quantitative
methods, respectively, on the same patient.
Results: The cartilage defect assessment provided consis-
tent significantly higher scores in IW-FSE than in GRE
sequences both at baseline and 2 years (p<0.007). However,
the change at 2 years was not significantly different (p≥
0.134) between the two sequences. The standardized re-
sponse mean (SRM) of cartilage change was consistently
higher for the quantitative method (4.3-6 fold) than the
semi-quantitative method. Cartilage defecT-score change
between the two treatment groups revealed a trend toward
significance only in the medial tibial plateau (p=0.054),
whereas the change in cartilage volume loss demonstrated
a significant difference in the global knee (p=0.009), lateral
compartment (p=0.026), femur (p=0.015), and lateral fe-
mur (p=0.014).
Conclusion(s): Both MRI sequences show similar sensitiv-
ity to change over time in evaluating cartilage defects.
Interestingly, the quantitative cartilage volume assessment
is more sensitive than the semi-quantitative scoring for the
detection of treatment effect on OA cartilage changes.
Disclosures: Supported by grants from Merckle GmbH
(Ulm, Germany), ArthroLab Inc. (Montreal, Quebec, Can-
ada), the Swiss National Science Foundation and the Fon-
dation du CHUM (Montreal, Quebec, Canada).
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FAVOURABLE ECONOMIC IMPACT OF
HIGHER DAIRY INTAKE ON THE BURDEN
OF OSTEOPOROSIS
Freek JB Lötters1,2, Irene Lenoir-Wijnkoop3, Patrice
Fardellone4, René Rizzoli5, Emilie Rocher3, Marten J Poley1
1Erasmus University Rotterdam, Institute for Medical Tech-
nology Assessment (iMTA), 2Erasmus University Rotter-
dam, Institute of Health Policy and Management (iBMG),
Rotterdam, Netherlands, 3Danone, Danone Research, Palai-
seau, 4Centre Hospitalier Universitaire Amiens, Service de
Rhumatologie INSERMERI 12, Amiens, France, 5University
Hospital Geneva, Service des Maladies Osseuses, Geneva,
Switzerland
Objective(s): With the ageing of the population, health and
economic burden of osteoporosis are dramatically growing.
The economic impact of nutritional fracture prevention is
still not established.
We estimated the impact of increasing dairy consumption on
the burden of osteoporosis, in terms of public health out-
comes and costs.
Material & Methods: We constructed a model to estimate
hip fracture numbers which could be prevented by higher
dairy foods intakes. Dairy calcium was used to model the
effect on hip fractures. We calculated absolute hip fracture
numbers which could be prevented by increasing dairy
calcium intake, i.e. the Potential Impact Fraction (PIF). This
allowed us to determine costs avoided, considering hip
fracture healthcare reduction and higher dairy foods costs.
Disability-Adjusted Life Years lost (DALYs) were estimated
too. Separate analyses were done for France, The Nether-
lands and Sweden. We conducted sensitivity analyses on
DALYs lost and total costs avoided to verify the validity of
the assumptions applied.
Results: Hip fracture numbers which could be prevented each
year by higher dairy intakes was highest in France (2023),
followed by Sweden (455) and The Netherlands (132).
DALYs lost per year were respectively 6263, 1246 and 374.
In the first year after hip fracture, quality of life (QoL) average
loss was evaluated at 0.22, and at 0.08 in the following years.
Daily costs of an extra 600 mg calcium intake through addi-
tional dairy products were derived from the local market
product prices and calculated at €0.44, €0.64, and €0.68, for
the Netherlands, France, and Sweden, respectively.
Total costs that might be potentially avoided were largest in
France (∼€129 million), followed by Sweden (∼€34 million)
and The Netherlands (∼€6 million).
Conclusion(s): The burden of hip fractures related to low
calcium intake is significant. Increasing dairy consumption
is likely to be effective in decreasing this public health
burden and the associated health care expenditures. This
model appears to be robust and a valid method to assess
health, wellbeing and cost outcomes achieved by changes in
food products consumption, building thereby connections
between nutrition and health economics.
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BONE METABOLISMMARKER AS A DIAGNOSTIC
TEST FOR ENDOGENOUS HYPERCORTICISM
Zhanna E Belaya, Natalia V Dragunova, Alexander V Iljin,
Liudmila Y Rozhinskaya, Galina A Melnichenko
The National Research Center for Endocrinology, Neuroen-
docrinology and Bone Disease, Moscow, Russian Federation
Objective(s): Bone metabolism markers are not recommen-
ded for the diagnostics of postmenopausal osteoporosis
(PMO). However, the suppression of osteocalcin is almost
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obvious sign of endogenous Cushing's syndrome (CS). This
study evaluates osteocalcin as a diagnostic test for CS in
obese and overweight patients referred to exclude CS and
among patients with PMO and glucocorticoid induced oste-
oporosis (GIO) due to CS.
Material & Methods: Osteocalcin (OC) was measured in
fasting blood sample by elecrochemiluminiscence immuno-
assay (ECLIA) on Cobas e601 in overweight and obese
consecutive patients referred to exclude CS (n=106). Ret-
rospectively, osteocalcin was evaluated in 67 patients with
newly diagnosed PMO (presence of low traumatic fractures
and/or ≥–2.5 T-score DXA) and in 22 patients with newly
diagnosed CS older than 45 (presence of low traumatic
fractures and/or ≥–2.0 T-score DXA). Patients from referred
population provided late-night salivary cortisol test
(ECLIA), 1 mg overnight dexamethasone suppression test,
24 h urinary free cortisol and other tests that required in
dependence on etiology of CS. Eventually CS was con-
firmed by histology after surgery in all patients.
ROC-analysis was used to evaluate diagnostic performance
of OC test. Cutoff point was chosen based on maximal sum
of sensitivity and specificity.
Results: Among 106 patients of referred population (mean
age 38±14 years; BMI 36±7 kg/m2) CS was confirmed in 42
cases. Cutoff point for OC – 8.3 ng/ml revealed sensitivity
73.8% (95%CI 58.9-84.7%), specificity 96.9% (89.3-99.1%);
positive likelihood ratio 23.6 (95%CI 5.9-93.5), negative like-
lihood ratio 0.27 (0.16-0.45), diagnostic odds ratio 87.4 (18.2-
418.7). The total area under the ROC curve (AUC) was 0.859
(95%CI 0.773-0.945). In a retrospective part of the study OC
level was significantly lower in patients with CS (mean age
54.2±7.7) vs. patients with PMO (p<0.001) and was even
better as a diagnostic test for secondary osteoporosis due to
CS (AUC - 0.959 (95%CI 0.887-1.00)). A cut-off value of 8.3
ng/ml achieved sensitivity 95.4% (95%CI 78.2-99.2%), spec-
ificity – 98.5% (95%CI 92.0-99.7%).
Conclusion(s): Osteocalcin can be used as a diagnostic test
for endogenous hypercorticism in patients referred to ex-
clude CS and to differentiate GIO due to CS among PMO.
Disclosures: The Presidential Grant for Young Scientists
No. MK-6978.201
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EFFECT OF DISCONTINUATION OF IV
BISPHOSPHONATE ON LEVELS OF URINARY NTX
Diane E Powell, Tracey J Roberts, Michael WJ Davie
Robert Jones & Agnes Hunt Orthopaedic Hospital NHS Foun-
dation Trust, Charles Salt Centre for Human Metabolism,
Oswestry, Shropshire, UK
Objective(s): To examine the effect of IV bisphosphonate
(BP) treatment discontinuation in patients following long
term treatment.
Material & Methods: Subjects on an IV BP for >5 years
were reviewed at clinic. BMD and urinary N-telopeptide
crosslink of type I collagen (uNTx) were measured at the
review clinic and uNTx approximately 6 months after the
clinic. Data on BP treatment history and fracture history
were also collected. The uNTx levels in these subjects were
compared with the manufacturer's premenopausal reference
range (5-65 nM BCE/mM Cr).
Results: Data were collected on 42 subjects, 33 female and 9
male, aged 34-96 years (Mean=73.1) who had been treated
with zoledronate (Zol) or pamidronate (Pam). 39 subjects had
osteoporosis, 2 Paget's disease and 1 fibrous dysplasia. The
median time since infusion was 4 months at the time of the
clinic review and 1 year at follow-up. Subjects on Pam had
been on IV treatment for significantly longer than those on Zol
(8 years vs. 5 years; p<0.01). There were no significant differ-
ences in BMD levels or in time since infusion between Zol
and Pam subjects. Zol subjects had significantly lower uNTx
levels than Pam subjects at clinic (16.6 vs. 27.1; p<0.05) but
not at follow-up (28.3 vs. 30.6; ns). In the Pam group there
was a non-significant increase of 9% between the 2 uNTx
samples compared with a 24.8% increase in the Zol subjects
(p<0.05). The majority of subjects (36/42) had uNTx levels in
the lowest half of the premenopausal reference range at clinic,
of these 28 remained below the mean 1 year after the last
infusion, only 1 patient with Paget's disease had increased
above the premenopausal range. None of the subjects in the
upper half of the premenopausal range at clinic increased
above the upper limit at follow-up.
Conclusion(s): Discontinuation of BP treatment increased
uNTx levels in the Zol subjects more than those on Pam,
however, bone turnover remained suppressed. Further work
needs to be done to determine if turnover rate remains
higher in Zol subjects or the lower starting level means they
have more scope to rise.
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RESULTSOFFRACTURERISKEVALUATIONUSING
FRAX-ALGORITHM STANDARDIZED FOR ITALIAN
AND ROMANIAN IN ALBANIANWOMEN
Dorina Ruci1, Vilson Ruci2, Teuta Backa1, Artur Kollcaku1,
Ervin Rraoushi1
1Mother Teresa University Hospital, Rheumatology, 2Mother
Teresa University Hospital, Orthopedics, Tirana, Albania
Objective(s): The purpose of our work was to determinate
10-year fracture risk scores in postmenopausal women of
the Tirana population, based on the FRAX® algorithm,
standardised for the populations of Italy and Romania,
countries close and very similar to Albania with common
traditions (Italy) and socio-economic level (Romania).
Material & Methods: The study group included 205 post-
menopausal females (52-80), divided into four age subgroups.
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The patients compelled a questionnaire form, designed to
analyze osteoporosis risk factors and were then submitted to
femoral neck densitometry by a DXA scanner (GE-Lunar).
The 10-year fracture risk was assessed by the FRAX® meth-
od, using a calculator standardized for the populations of Italy
and Romania. FRAX® major (the risk of main osteoporotic
fractures) and FRAX® hip (the risk of femoral neck fractures)
were calculated, using obtained densitometry results (FMD,
FHD) and BMI (FM, FH).
Results: In women, history of osteoporotic fracture was
given by 52.4%, parental history of hip fracture by 9%,
smoking by 2.6%, glucocorticoid therapy was present in
4.4%, history of rheumatoid arthritis in 3.3%, secondary
osteoporosis in 14.2% and higher alcohol intake in 0.6%.
The average 10-years risk of major osteoporotic fracture
was 19.6% and 16.7%; the average 10-year risk of hip
fracture was 7.8% and 5.7% (Italian and Romanian data-
base, respectively). In each age subgroup, the highest T-
scores of 10-year fracture risk (FRAX® major, FRAX®
hip) were obtained, using the Italian-oriented calculator,
while the lowest ones were found applying the Romanian
version. The differences were not statistically significant.
Conclusion(s): 1. The outcome supports the need for a
Balkanic version including Greece Albania, Bulgaria and
Ex-Yugoslavian nations. 2. It is justifiable for the moment to
use both Italian and Romanian version with no major
differences.
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ASSESSMENT OF 10-YEAR PROBABILITY OF
OSTEOPOROTICFRACTURES INTHEPOPULATION
OF KAZAN (RUSSIA) BY USING FRAX PROGRAM
Artem G Vasilyev, Leysan I Myasoutova, Svetlana A
Lapshina
Kazan State Medical University, Department of Hospital
Therapy, Kazan, Russian Federation
Objective(s): To evaluate a 10-year probability of osteopo-
rotic fractures by using FRAX program.
Material & Methods: The study included 70 patients (35
men and 35 women) aged 40-90 years who have been
coming to the largest clinics of Kazan for various reasons
during the period from January-June 2011. In each clinic 10
patients (5 men and 5 women) were randomly selected. All
patients, included in the study, were invited to visit the City
Centre of Rheumatology for risk assessment and calculation
of the 10-year probability of osteoporotic fractures (femoral
neck and total) using FRAX program which validated for
these purposes. The epidemiological prevalence of risk fac-
tors in the Finnish population was used for the calculation.
DXA was performed for the determination of BMD at the
femoral neck. The 10-year probability of fracture was cal-
culated (adjusted for BMD at the femoral neck). The 10-
year probability of major fractures over 20% as well as the
one of hip fracture more than 3% were considered as thresh-
old of intervention (early antiosteoporotic therapy).
Results: The average age of study participants was 61.8±
21.3 years (women - 59.2±23.5 years, men - 63.5±18.1
years). The 10-year probability of major fractures more than
20% was observed in 15 (21.4%) people [11 (31.4%) wom-
en and 4 (11.4%) men]. The 10-year probability of hip
fracture over 3% was observed in 13 (18.5%) people [10
(28.6%) women and 3 (8.6%) men]. After the X-ray densi-
tometry the 10-year probability of major fractures more than
20% (adjusted for BMD at the femoral neck) was observed
in 19 (27.1%) people [13 (37.1%) women and 6 (17.1%)
men]. The 10-year probability of hip fracture over 3%
(adjusted for BMD at the femoral neck) was observed in
20 (28.6%) people [13 (34.3%) women and 7 (20%) men].
Conclusion(s): FRAX program is available to evaluate the
10-year probability of osteoporotic fracture and determine
the threshold for intervention in the individuals at risk. The
advantage of this program is the ability to determine the
likelihood of fracture in the absence of data on BMD at the
femoral neck.
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SHORT-TERM EFFECTS ON BONE TURNOVER
MARKERS OF A SINGLE HIGH-DOSE OF ORAL
VITAMIN D3
Cristian Caimmi, Giovanni Orsolini, Angelo Fassio, Ilaria
Piazza, Gaia Tripi, Luca Idolazzi, Silvia Zanoni, Maria R
Povino, Carmela Dartizio, Caterina Fraccarollo, Cristina
Bosco, Ombretta Viapiana, Maurizio Rossini, Silvano
Adami
University of Verona, Rheumatology Unit, Department of
Medicine, Verona, Italy
Objective(s): To investigate the short-term effects on bone
turnover markers of a single bolus of vitamin D3.
Material & Methods: 12 elderly subjects (8 women, 4
men; mean age=76±3 years) were given a single oral bolus
of 600,000 IU vitamin D3. Blood samples were taken at
baseline and 1, 3, 7, 14, 30, 60 and 90 days after vitamin D3
administration. 24 subjects served as controls. Main Out-
come Measures: Changes in serum levels of 25-hydroxyvi-
tamin D (25OHD), 1,25-dihydroxyvitamin D [1,25(OH)
2D], PTH, C-terminal-telopeptides of type I collagen
(sCTX), crosslinked N-telopeptide of type I collagen
(sNTX), osteocalcin and bone-specific alkaline phosphatase
(BAP).
Results: No relevant changes in 25OHD and bone turnover
markers were observed in the controls. In treated subjects
serum 25OHD attained a peak increment to 67.1±17.1 ng/ml
(p<0.001) at day 3. Subsequently, it slowly decreased to
35.2±5.8 ng/ml (p<0.01 vs. a baseline value of 21.7±
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5.6 ng/ml). Mean serum PTH concentration decreased
by 25-50% and serum 1,25(OH)2D rose by 25-50%.
Serum CTX and sNTX rose significantly at day 1 (p<0.01),
they attained a peak increment >50% at day 3 and they
subsequently decreased almost back to baseline values at
day 90. Serum osteocalcin slightly rose within the first 3 days
and then declined by day 60. No changes were observed in
serum BAP.
Conclusion(s): Our results indicate that the use of large
doses of vitamin D may be associated with acute increases
in sCTX and sNTX which may explain the negative clinical
results obtained by using intermittent high doses of vitamin
D to treat or prevent vitamin D deficiency.
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11 YEAR TREND OF OSTEOPOROTIC HIP
FRACTURES IN AN ASIAN POPULATION –
GENDER DIFFERENCES, RISK FACTORS AND
OUTCOMES WITH FOCUS ON ASIAN MALES
Wei Loong Barry Tan1, Siew Leng Low1, Wei Jie Christopher
Lim1, Dai Chao1, Liang Shen2, Shamal Das De1
1Yong Loo Lin School of Medicine, National University of
Singapore, Orthopaedic Surgery, 2Yong Loo Lin School of
Medicine, National University of Singapore, Biostatistics,
Singapore
Objective(s): Assess 11-year trend of osteoporotic hip frac-
tures in an Asian population, and to compare gender differ-
ences, risk factors and outcomes with focus on Asian males.
Material & Methods: Retrospective review of ICD9 820
(Hip Fracture) admissions to a tertiary hospital aged ≥50
from 2000-2010. Fractures were classified into “Neck of
femur” (NOF), and “Intertrochanteric/Subtrochanteric/Per-
trochanteric/Basicervical ” (non-NOF). Standardized tele-
phone interviews were conducted in the male population
to assess pre and post-fracture mobility status and mortality.
Results: 2698 patients were enrolled (1903 [70.5%] female,
795 [29.5%] male). Overall median age at fracture was 78
years (50-112). Median female and male age was 79 (50-
112) and 75 years (50-99), respectively. There was no sta-
tistically significant change in gender or racial distribution
of fractures per year in the 11 years (p=0.962, 0.671).
Females were overall older at time of fracture (p<0.0005).
There is an increasing trend in overall median age per year
over the past decade of boundary statistical significance (p=
0.088). Female median age at fracture displayed a statisti-
cally significant increasing trend (r=0.826, p=0.002). 1334
fractures (49.4%) were classified as NOF and 1364 (50.6%)
were non-NOF. Analysis showed that Male gender, Older
age, ischemic heart disease, Malay, Indian and Other races
conferred higher risk of non-NOF fractures (p<0.0005). 110
patients (84 [76.4%] female, 26 [23.6%] male) experienced
subsequent contralateral osteoporotic hip fracture. Median
number of years between index fracture and contralateral
fracture was 2.0 (0-8 years); 11 were on osteoporosis med-
ication. 298 (37.5%) males responded to the questionnaire.
222 (74.5%) were prefracture ambulant without walking
aid. Of these, 57 (25.7%) regained prefracture mobility,
124 (55.9%) required walking aids, 30 (13.5%) became
wheelchair-bound and 8 (3.6%) became bedbound after
treatment and rehabilitation. 1-year mortality in this group
was 5%.
Conclusion(s): Osteoporosis remains a problem in ageing
populations, with increasing trend in median age of fracture.
The ratio of male hip fractures appears to be higher in the
Asian population (1 in 3), with Asian males appearing to
have different mobility and mortality outcomes, although
further data collection is required to establish exact out-
comes. Non-NOF fractures appear to have distinct risk
factors.
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EFFECTS OF ZOLEDRONATE ACID AND
TERIPARTIDE ON BONE MICROARCHITECTURE,
REMODELING AND COLLAGEN CROSSLINKS:
COMPARISON BETWEEN ILIAC CREST AND
LUMBAR VERTEBRA IN EWES
Nathalie R Portero-Muzy1, Pascale M Chavassieux1, Mary
L Bouxsein2, Evelyne Gineyts1, Roland D Chapurlat1
1INSERM UMR 1033 and Université de Lyon, Lyon,
France, 2Orthopedic Biomechanics Laboratory, Beth Israel
Deaconess Medical Center and Harvard Medical School,
Boston, US
Objective(s): Iliac crest bone biopsies are used to assess the
mechanism of action of drug treatments, yet there are little
data comparing this site to sites prone to fracture. Thus, the
purpose of this study performed in ewes was to compare the
effect of short-term treatment with zoledronic acid or teri-
paratide on iliac crest and lumbar vertebrae microarchitec-
ture, collagen crosslink composition and bone remodeling.
Material & Methods: Three groups of 8 aged ewes re-
ceived either vehicle (CTRL) or a single injection of 10
mg of zoledronic acid (ZOL) or daily injections of 20 μg/d
of teriparatide (TPTD). After double tetracycline labeling, a
transiliac bone biopsy (IC) and L1 lumbar vertebrae (LV1)
were collected after 3 months. 3D-microarchitecture was
assessed by μCT and the content of both mature enzymatic
crosslinks pyridynoline (PYD), deoxypyridinoline (DPD)
and the nonenzymatic crosslink pentosidine (PEN) were
analyzed. Static and dynamic parameters of bone remodel-
ing were measured by 2D-histomorphometry.
Results: In CTRL, Ct.Th and BV/TV were significantly
higher while osteoid parameters, MS/BS, Ac.f were signif-
icantly lower in LV1 than IC. In addition, the ratio PYD/
DPD was 4 times higher in LV1 than IC. Regardless of the
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site, ZOL markedly depressed the bone turnover: the dimi-
nution of MS/BS, BFR/BS and Ac.f varied from -94 to -
98% vs. CTRL (p<0.01 to 0.001). A significant increase in
3D-BV/TV (20%, p<0.04), ConnD (30%, p<0.03) and
TbN* (8.3%, p<0.03) vs. CTRL was noted only in IC. After
ZOL treatment, the DPD content and the PYD/DPD ratio
significantly decreased in IC cortices but remained higher
than in LV1. TPTD treatment induced a significant increase
in cortical porosity in LV1 with a thinning of the trabeculae
at both sites (p<0.05). Static parameters of bone formation
and resorption were significantly augmented in LV1 (p<
0.05) with only a trend of increases in MS/BS and BFR/BS.
Conclusion(s): In conclusion, in adult ewes, ZOL's early
effects include markedly reduced bone turnover at the iliac
crest and lumbar vertebrae but improved bone microarchi-
tecture only at the iliac crest. In contrast, the early effects of
TPTD are observed only at the vertebrae. Distinguishing
bone sites to study the early effects of osteoporosis therapies
is meaningful.
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THE TALLER THEY ARE, THE MORE POROUS
THE SKELETON TO FALL HARDER UPON
Åshild Bjørnerem1, Roger Zebaze2, Ali Ghasem-Zadeh2,
Minh Bui3, Xiaofang Wang2, John L Hopper3, Ego Seeman2
1University of Tromsø, Department of Obstetrics and Gyne-
cology, Tromsø, Norway, 2University of Melbourne, Endo-
crine Centre, 3University of Melbourne, Centre for MEGA
Epidemiology, Melbourne, Australia
Objective(s): During growth, appendicular bones with a
larger total cross-sectional area (CSA) are constructed with
a thinner cortex minimizing the amount of material needed
to assemble the larger bone. Compressive strength and bone
area are conserved as the thinner cortex is distributed around
a larger perimeter. Resistance to bending is conserved as the
cortex is further from the neutral axis. Yet taller individuals
are at increased risk for fracture. The smaller cortical vol-
ume relative to external bone volume is the result of rela-
tively greater resorption on the endocortical envelope than
apposition on the periosteal envelope. If resorption is also
relatively greater than formation upon the intracortical en-
velope then the thinner cortex may also be constructed with
higher porosity.
Material & Methods: To test the hypothesis that taller
women have thinner cortices with higher intracortical po-
rosity we measured height, weight and distal tibial and
radial cortical microarchitecture using HR-pQCT (Scanco
Medical, Switzerland) in 185 pairs of female twins aged 40-
61 years in a cross-sectional study in Melbourne, Australia
2008-2009.
Results: Each SD (6 cm) increase in height was associated
with a 0.71 SD larger tibia total CSA, a 0.29 SD thinner
cortex, a 0.22 SD higher porosity and 0.30 SD lower cortical
vBMD after adjustment for age and BMI (p<0.001). Corti-
cal CSA and mass did not differ by height so taller persons
had a lower total and cortical vBMD. Similar results were
observed for the distal radius but associations were weaker
or not significant.
Conclusion(s): Taller women have thinner and more porous
cortices. After menopause, remodeling increases and is
higher in persons with higher intracortical porosity because
there are more surfaces available to initiate remodeling (1).
The higher remodeling may degrade the lower bone volume
fraction more rapidly accounting for the observation that
porosity reduces bone stiffness to the 7th power dispropor-
tionately increasing fracture risk (2).
References: 1. Bjørnerem Å et al. Bone. 2011;49:1125. 2.
Schaffler MB et al. J Biomech 1988;21:13.
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TRABECULAR BONE SCORE IN NORMAL
UKRAINIAN WOMEN OF DIFFERENT AGE
Vadyslav V Povoroznyuk, Nataliia I Dzerovych, Alla A
Palamarchuk, Anna S Musienko
Institute of Gerontology NAMS Ukraine, Department of
Clinical Physiology and Pathology of Locomotor Apparatus,
Kyiv, Ukraine
Objective(s): The aim of this study is evaluating Trabecular
Bone Score (TBS) in normal women of different age.
Material & Methods: We've examined 176 normal women
aged 40-79 years (mean age – 53.4±0.6 yrs; mean height –
163.5±0.5 cm; mean weight – 80.4±1.1 kg). The patients
were divided into the following age-dependent groups: 40-
49 yrs (n=53), 50-59 yrs (n=89), 60-69 yrs (n=17), 70-79
yrs (n=17). TBS (L1-L4), total body, lumbar spine, femoral
neck BMD, lean and fat masses were measured by DXA
using a densitometer Prodigy, GE.
Results: We have determined the significant decrease of
TBS (L1-L4) in women with age (40-49 yrs – 1.334±
0.016 mm-1; 50-59 yrs – 1.289±0.013 mm-1; 60-69 yrs –
1.194±0.034 mm-1; 70-79 yrs – 1.205±0.050 mm-1; F=
6.56; p=0.0003). BMD of spine is significantly increase
with age (BMD of spine: 40-49 yrs – 1.126±0.015 g/cm2; 50-
59 yrs – 1.234±0.013 g/cm2; 60-69 yrs – 1.343±0.053 g/cm2;
70-79 yrs – 1.348±0.100 g/cm2; F=4.04; p=0.008). BMD of
femoral neck didn't show significant differences. The signifi-
cant correlation was observed between TBS (L1-L4) and age,
fat and lean masses:
– TBS=1.64-0.007*Age; r=-0.34; t=4.41; p=0.00002.
– TBS=1.47-0.000005*Total fat (g); r=-0.37; t=4.86;
p=0.000003.
– TBS=1.90-0.00001*Lean mass (g); r=-0.59; t=8.98;
p<0.000.
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We did not find significant correlation between TBS and
BMD of spine and femoral neck:
– TBS=1.36-0.05*BMD of spine; r=-0.05; t=0.66; p=0.5.
– TBS=1.53-0.22*BMD of femoral neck; r=-0.16; t=
1.94; p=0.05.
Conclusion(s): The significant correlation between TBS
and lean mass indicates that bone quality can be associated
with muscular system. TBS was significantly decreased
with age. TBS is independent parameter which has potential
diagnostic value without BMD.
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HOW WE ARE TREATING OSTEOPOROTIC
HIP FRACTURES (OHF)? A NATIONWIDE
OBSERVATIONAL STUDY IN PORTUGAL
Carlos MFP Alves12, Sandra F Alves123, Maria F Pina2,3,4
1Faculdade de Medicina da Universidade do Porto, Depar-
tamento de Epidemiologia Clínica, Medicina Preditiva e
Saúde Publica, 2Instituto de Engenharia Biomédica - INEB,
Biomaterials, 3Instituto de Saúde Pública da Universidade
do Porto - ISPUP, Geoepidemiologia, 4Bioestatística e Bio-
informática, ESTSP-IPP, Área Científica Biomatemática,
Gaia, Porto, Portugal
Objective(s): Analyze changes in treatment of osteoporotic
hip fractures (OHF) in Portugal, between 2000-2008.
Material & Methods: Discharges with diagnosis of hip
fracture between 2000-2008 were collected from the nation-
al register of hospital discharges, mandatory for all Portu-
guese public hospitals. Chi-square test was used to access
independence between sex, age groups, treatment and fatal-
ity. Linear regression was used to access temporal trends.
Results: A total of 77,083 OHF were recorded. Crude
incidence rates (100,000 inhabitants) were 343.2 in females
and 125.2 in males. Surgery was part of the treatment in
90.4% of patients and 9.6% were treated conservatively.
Risk for conservative treatment was higher in men (OR=
1.43; CI95%: 1.43-1.47%) and lower in patients between
70-85 years (OR=0.72; CI95%: 0.67-0.87) compared to 50
years old patients. Patients treated conservative reduced
45.2% (CI95%: 53.1-37.3) from 2000-2008.
Internal fixation was the most common (89.0% of the cases)
treatment for trochanteric fractures, for neck fractures, total
or partial hip arthroplasties (THA or PHA) was used 69.7%
of the cases. Treatment with THA increased 21.1% (p=
0.030) in patients with neck fracture younger than 75.
Patients treated with THA had a mean age of 73.9 years
(CI95%: 73.1-73.6) and were significantly younger the than
the ones treated differently (p=0.039). The longer mean
length of hospital stay (LOHS) was observed for conserva-
tive treatment and for THA; being 18.3 days (CI 95%: 17.4-
18.7) and 16.1 days (IC95%: 15.9-16.5), respectively.
Patients treated conservatively had the highest mean score
in the Charlson-index, therefore they had more comorbid-
ities than patients treated surgically. In-hospital crude fatal-
ity rate for OHF was 5.5% and decreased 16.8% (p<0.018)
from 2000-2008. Fatality rate was 8.7% in men and 4.6% in
women, OR=1.89; CI95%: 1.86-1.92. Fatality rate was
23.1% in patients treated conservatively and 3.6% in
patients treated surgically, OR=6.33; CI95%: 6.18-6.48.
Conclusion(s): A significant decrease in fatality and in
patients treated conservatively was observed from 2000-
2008. An unexpected high number of patients treated con-
servatively were observed. No reasons for this fact were
found. A spatial analysis of conservatively treated patients
may help point reasons for this high prevalence.
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APPLICATION OF FRACTURE RISK ASSESSMENT
TOOL (FRAX) TO PREDICT NEED FOR DXA
SCANNING AND TREATMENT IN PATIENTS
WITH RHEUMATOID ARTHRITIS AT RISK
OF OSTEOPOROSIS
Svetlana H Hristova, SvetoslavPDimitrov, SimonaBogdanova,
Tanya K Shivacheva, Vladimir N Kadinov
University Hospital "St Marina", Rheumatology Department,
Varna, Bulgaria
Objective(s): To assess the accuracy of FRAX scores in RA
patients without actual femoral neck BMD in identifying at
risk needing BMD measurement and to establish the neces-
sity to treat patients with RA and osteopenia (T-score fem-
oral neck>-2.5).
Material & Methods: We calculated pre-BMD FRAX
scores in 72 postmenopausal women with RA estimated to
be at risk for having an osteoporosis and a high fracture risk.
A DXA scan was performed to every patient and a FRAX
score including the BMD was calculated.
Results: Calculation of pre-BMD FRAX scores reveals that
47 (65.28%) of the patients had a high 10-year fracture risk
and in the rest 25 (34.7%) the risk was defined as low (p<
0.05). After preforming a DXA scans only 19 (26.4%) of all
patients were evaluated as having an osteoporosis (T-score
femoral neck<-2.5). From the rest 53 after a calculation of
FRAX score including the BMD a number of 28 (52.8%)
patients with high 10-year fracture risk and need for treat-
ment is found. The clinical FRAX score together with the
FRAX score including the BMD demonstrate that from all
patients with RA those with high 10-year fracture risk are 47
(65.28%).
Conclusion(s): In patients with RA perceived to be at risk
of osteoporosis or osteopenia, the clinical FRAX score alone
can predict accurately the risk of osteoporotic fracture. The
usage of FRAX score alone have a high predictive value as
far as it concern the necessity of osteoporosis treatment.
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Calculating FRAX scores and/or its use with BMD
improves identification of patients with RA and high frac-
ture risk and implementation of adequate treatment.
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PREVALENCE OF SILENT VERTEBRAL
FRACTURES DETECTED BY VFA IN YOUNG
HYPERTHYROID MEN: PRELIMINARY RESULTS
Ana Paula Barbosa1,2,3,4, Mário Rui Mascarenhas1,2,3,4, Ana
Gonçalves4, António Gouveia Oliveira5, Vera Simões2,3,
David Santos Pinto3, Manuel Bicho2, Isabel do Carmo4
1Lisbon´s Faculty of Medicine, Endocrine & Metabolic Dis-
eases, 2Lisbon´s Faculty of Medicine, Center of Metabolism
& Endocrinology, Genetics Lab., 3CEDML-Clínica de Endo-
crinologia, Diabetes e Metabolismo de Lisboa, Lda, Osteopo-
rosis Unit, 4Santa Maria University Hospital, CHLN-EPE,
Endocrinology, Diabetes & Metabolism Department,
5FCMUNL, Biostatistic Department, Lisboa, Portugal
Objective(s): Vertebral fractures are among the most fre-
quent osteoporotic fractures and are often silent. Only a
third of them come to medical attention and up to 20% of
patients with an incidental vertebral fracture experience a
new fracture in the next year. Also, high morbidity and
mortality are associated. Hyperthyroidism is a risk factor
for reduced BMD as well as for osteoporotic fractures.
Vertebral fracture assessment (VFA) by DXA is a radiolog-
ical method of visualization of the spine, which confers
more commodity for the patient and less radiation exposure
than the conventional spine x-ray. The aim of this study was
to evaluate the prevalence of vertebral fractures using VFA
by DXA in patients with hyperthyroidism.
Material & Methods: A group of 48 men <50 years old
were divided and paired in hyperthyroidism (n=24) and
control (n=24) groups. The body lean and fat masses
(kg) and the BMD (g/cm2) at the lumbar spine (L1-L4),
proximal femur, distal radius and whole body were eval-
uated by DXA (QDR Discovery, Hologic). VFA was
used to detect fractures and those were classified accord-
ing to type (wedge, biconcave, crush) and severity (% of
deformity) by Genant’s semiquantitative method. No pa-
tient was previously treated for hyperthyroidism and/or
osteoporosis. In the controls, the BMD was qualified by
Z-score, according to the ISCD recommendations. Ap-
propriate tests were used and statistical significance was
considered for P<0.05.
Results: The mean age, stature, weight and BMI were
identical between the groups. The mean BMD at the total
hip (P=0.028) and at the whole body (P=0.025) were
reduced in the hyperthyroidism group.
There was a trend for a higher prevalence of reduced BMD
and osteoporosis in the hyperthyroidism group, as well as the
prevalence of osteoporotic fractures.
Conclusion(s): The results of this study using VFA technol-
ogy, may suggest that the changes in the BMD in young
hyperthyroid men may already lead to osteoporosis develop-
ment and fractures. These data also support the interest of
VFA in the routine of osteoporosis to detect precociously
silent fractures and so, consider treatment as soon as possible.
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EARLY IDENTIFICATION OF PATIENTS WITH
RAPID BONE LOSS FOLLOWING SPINAL CORD
INJURY, USING PERIPHERAL QUANTITATIVE
COMPUTED TOMOGRAPHY (PQCT)
Sylvie A Coupaud1,2, Alan N McLean2, David B Allan2
1University of Glasgow, Biomedical Engineering, 2Southern
General Hospital, NHS GCC, Scottish Centre for Innovation
in Spinal Cord Injury, Queen Elizabeth National Spinal
Injuries Unit, Glasgow, UK
Objective(s): We are developing bone densitometry proto-
cols to identify patients with significant bone loss early after
spinal cord injury (SCI), to enable targeted treatment against
osteoporosis in the future. Fragility fracture rates in the
paralysed limbs are high [1] at the trabecular-rich sites that
show the most rapid and extensive bone loss after SCI [2,3].
Material & Methods: Inpatients of the Queen Elizabeth
National Spinal Injuries Unit (Glasgow, UK) with motor-
complete SCI at neurological levels C4 and below are
scanned using pQCT within 5 weeks of injury (baseline),
and again at 4, 8 and 12 months post-SCI. Total BMD
(BMDtot), trabecular BMD (BMDtrab) and bone mineral
content (BMC) are calculated from unilateral scans at both
epiphyses of the tibia, and at the distal epiphyses of the
femur and radius.
Results: This is an ongoing study. Data are presented from
13 subjects: 8 paraplegia / 5 tetraplegia, all male, aged 17-72
years old. At baseline, mean (SD) BMDtot was 345.70
(24.42), 263.10 (33.21) and 293.10 (24.92) mg/cm3 in the
distal tibia, proximal tibia and distal femur, respectively. By
8 months post-injury, BMDtot had fallen to 293.59 (53.34),
202.36 (46.30) and 247.94 (39.72) mg/cm3, respectively.
Further regression analyses revealed some subjects with
statistically significant decreases in BMD and BMC in the
paralysed limbs (“FAST” bone losers), others with little/no
bone loss (“SLOW” bone losers).
Conclusion(s): Repeat pQCT bone scans within the first
year of SCI enable us to red-flag “FAST” bone losers,
providing a window of opportunity to apply preventative
treatments against further bone loss and fractures in vulner-
able patients. These data will inform osteoporosis manage-
ment in SCI and other patient groups.
References: [1] Vestergaard P. et al. (1998) Spinal Cord
36:790. [2] Morse L. et.al. (2009) Osteoporos Int 20:385.
[3] Eser P. et al. (2005) Arch Phys Med Rehabil 86:498.
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Disclosures:We wish to thank all the patients taking part in
this study.
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BALLOON KYPHOPLASTY VS. RF-KYPHOPLASTY
IN TREATING PATIENTS WITH OSTEOPOROTIC
COMPRESSION FRACTURES
Robert Pflugmacher, Rahel Bornemann,MoritzDeml,Koroush
Kabir, Dieter Christian Wirtz
Universitätsklinium Bonn, Klinik und Poliklinik für Ortho-
pädie und Unfallchirurgie, Bonn, Germany
Objective(s): Balloon kyphoplasty (BKP) has been proven
as an effective method of treating patients with vertebral
compression fractures (VCF). Due to the low viscosity of
the PMMA cement uncontrollable cement leakage with
corresponding risks is often the focus of discussions. The
Radiofrequency Kyphoplasty (RFK) is an innovative proce-
dure for which an ultra-high viscosity cement is used. For
the statistical comparison of the two methods of augmenta-
tion clinical and radiological data of 2 patient groups were
evaluated.
Material & Methods: As part of the treatment of patients
with conservative therapy-resistant osteoporotic vertebral
fractures a prospective study of RFK was performed. Mea-
surement parameters for efficacy and safety were the course
of pain intensity using a VAS scale and the ODI Score. The
radiological images were evaluated. The extent of cement
extrusion and the duration of operation time were compared.
There were 2 groups of patients chosen with the same
indication and average VAS prior to treatment. For the
BKP-group the same parameters like in the first group were
evaluated.
Results: For both groups 114 patients were selected. Prior to
treatment 84 mm on the VAS were calculated in both
groups. The decrease in VAS values was (RFK vs. BKP)
immediately after surgery, 58.8 mm vs.54.7 mm and 73.0
vs. 58.9 mm after 6 months. In both groups improvements in
the Oswestry scores were registered after 6 months without
a statistically significant difference. In both groups, the
middle part of the vertebral bodies was increased by an
average of 3.1 mm. RF yielded a decrease in the average
kyphosis angle of 4.4, the BKP resulted in about 3.8
degrees. Concerning cement leakage a key difference in
favor of the radio frequency kyphoplasty was detected
(6.1% vs. 27.8%). For RFK a shorter duration of operation
time was calculated (28.2 vs. 49.6 min).
Conclusion(s): The RFK has proven to be a clinically very
effective procedure that does somewhat better than BKP in
long-lasting pain relief. No differences could be detected
regarding improvement of functioning and the mean resto-
ration of mid- and anterior vertebral height. The RFK offers
the advantage of a lower proportion of cement extrusion.
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RADIOFREQUENCY (RF) KYPHOPLASTY IN THE
TREATMENT OF OSTEOLYTIC VERTEBRAL
FRACTURES DUE TO MULTIPLE MYELOMA
Robert Pflugmacher, Rahel Bornemann, Moritz Deml,
Thomas Karius, Koroush Kabir, Dieter Christian Wirtz
Universitätsklinikum Bonn, Klinik und Poliklinik für Ortho-
pädie und Unfallchirurgie, Bonn, Germany
Objective(s): Radiofrequency kyphoplasty (RFK) provides a
new minimally invasive procedure to treat vertebral compres-
sion fractures (VCF). The purpose of this study was to investi-
gate the functional outcomes, safety and radiographic outcomes
after the treatment of painful osteolytic vertebral fractures treated
with a novel minimally invasive procedure, RFK.
Material & Methods: 88 patients (50 females and 38 males)
with 158 osteolytic vertebral fractures were treated with RFK
using the StabiliT Vertebral Augmentation System (Dfine Inc,
San Jose, CA). The StabiliT System provides a navigational
osteotome to create a site and size specific cavity prior to
delivering ultrahigh viscosity cement with an extended work-
ing time (done by applying radiofrequency energy to the
cement immediately prior to entering the patient). 12 months
follow up in 60 patients (36 females and 24 males) with 110
treated vertebrae are reported. Pre- and postoperative, 3, 6 and
12 months clinical parameters (Visual Analogue Scale,
Oswestry Disability Index score), and radiological parameters
(vertebral height and kyphotic angle) were measured.
Results: The median pain scores (VAS) (p<0.001) and the
Oswestry Disability Score (p<0.001) improved significantly
from pre- to post-treatment and maintained at 3, 6 and 12
months follow up. Postoperative, 3, 6 and 12 months fol-
low-up RFK restored and stabilized the vertebral height and
avoided further kyphotic deformity. No symptomatic ce-
ment leaks or serious adverse events were seen in the RFK
group during 3-months of follow up. In 7 out of 158 verte-
brae (4.4%) a cement leakage into the disc or lateral wall
could be determined by radiograph postoperatively.
Conclusion(s): RFK is a very safe and effective minimally
invasive procedure for the treatment of osteolytic vertebral
fractures. RFK shows excellent clinical and radiological results
in the 3 and 6 months follow up. Site specific cavity creation
and delivery of ultra-high viscosity cement in RFK with ex-
tended working time resulted in the added benefits of height
restoration and lower cement leakages intra-operatively.
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EFFICACY OF AN INTRA-ARTICULAR
TREATMENT OF OSTEOARTHRITIS OF THE
KNEE WITH HYALURONAN (GO-ON®)
Roland Roth1, Christoph Kipshoven2
1Orthopedic Practice, Surgery, Essen, 2Rottapharm/Madaus
Madaus GmbH, Medical Department, Köln, Germany
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Objective(s): The aim of the study was to document the
efficacy and safety of the intra-articular treatment of osteo-
arthritis related complaints of the knee with the hyaluronan
product GO-ON® under real life conditions in an orthopedic
practice.
Material & Methods: All patients seen at the orthopedic
practice who were treated with the product during 2010 for
complaints related to osteoarthritis of the knee were includ-
ed in the study. The intra-articular treatment was realised
with hyaluronan only, i.e., no adjuvant for example cortico-
steroids or other were added. The established pain treatment
could be continued.
Results: Data of 115 patients (25% men, 75% women)
could be evaluated. According to Kellgren-Lawrence 11
(9.6%) patients were graded II, 77 (66.9%) III, and 27
(23.5%) IV. 88% of patients got 5 injections per joint, the
other were 3-4 injections. The injection was described as
very painful by 1.7% of the patients, as slightly painful by
7.8%, and as not painful by 90.4%. After completion of the
treatment 7.8% patients did not feel any change in pain, but
92.2% felt a clear improvement. No improvement of the
mobility was observed in 18.3% patients, in contrast to
81.7% who reported a noticeable improvement. Safety: No
patient reported an unpleasant effect due to the therapy, and
90.4% of the patients would repeat the therapy. There was
no adverse event in any patient. No treatment withdrawal
occurred.
Conclusion(s): The data documented in this survey confirm
the safety and clinical efficacy of the intra-articular treat-
ment of osteoarthritis related complaints with hyaluronan
(GO-ON®). The patient's satisfaction of more than 90%
shows a high effectiveness of this treatment option in cases
of osteoarthrosis of the knee. Therefore this treatment can be
considered as a safe and valuable method. Studies compar-
ing hyaluronan directly with other conservative treatments
of osteoarthritis symptoms should be performed.
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THE ASSOCIATION BETWEEN OBJECTIVELY
MEASURED PHYSICAL ACTIVITY AND KNEE
STRUCTURAL CHANGE USING MAGNETIC
RESONANCE IMAGING: THE TASOAC STUDY
Dawn Doré1, Tania Winzenberg1, Changhai Ding1,2, Petr
Otahal1, Jean-Pierre Pelletier3, Johanne Martel-Pelletier3,
Flavia Cicuttini2, Graeme Jones1
1University of Tasmania, Menzies Research Institute Tasma-
nia, Hobart, Tasmania, 2Monash University, Department of
Epidemiology and Preventive Medicine, Melbourne, Victoria,
Australia, 3University of Montreal Hospital Research Centre,
Osteoarthritis Research Unit, Montreal, QC, Canada
Objective(s): There is conflicting evidence regarding the
association between physical activity (PA) and knee
osteoarthritis (OA). The aim of this study was to exam-
ine the longitudinal association between objectively
assessed steps/day and knee structural change measured
using MRI.
Material & Methods: A total of 405 community-dwelling
older adults (49% male, mean age 63 years, range 51-79)
were measured at baseline and approximately 3.0 years later.
MRI of the right knee at baseline and follow-up was per-
formed to measure bone marrow lesions (BMLs), cartilage
volume, tibial bone area, cartilage defects, and meniscal
pathology. PA was assessed at baseline as steps/day deter-
mined by pedometer. The association between steps/day and
change in knee structures was determined using multiple
linear and logistic regression models. Multivariable models
were adjusted for age, sex, BMI, radiographic OA, history
of knee injury or surgery, and baseline knee structural ab-
normalities. The interactions between steps/day and baseline
knee structures on knee structural change was examined
using product terms (e.g., steps/day*baseline BML pres-
ence) in the multivariable models. Models were examined
for threshold effects.
Results: In a multivariable model, steps/day predicted car-
tilage defect increases in the whole population (odds ratio
(OR) 1.3/SD, P=0.035). Doing ≥10,000 steps/day was as-
sociated with BML increases (β=50 mm2, P<0.001) and
meniscal pathology score increases (OR 2.3, P=0.035),
especially in those with prevalent BMLs and meniscal pa-
thology at baseline. Steps/day was protective against carti-
lage volume loss, but only in those in the highest tertile of
cartilage volume at baseline (P=0.031). There was no asso-
ciation between steps/day and change in tibial bone area.
Conclusion(s): Steps/day was deleteriously associated
with knee structural change, especially in those who
were more active and have prevalent BMLs and menis-
cal pathology. This suggests patients with these abnor-
malities should avoid doing greater than 10,000 steps/
day; thus, alternatives to weight bearing activity may be
needed for patients in order to maintain PA levels
required for other aspects of health.
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THE CHANGE OF CORTICAL THICKNESS AND
BONE MINERAL DENSITY OF NECK IN
OSTEOPOROTIC FRACTURE OF FEMORAL NECK
Yi-Zhong Li, Hua-Feng Zhuang, Jin-Kuang Lin, Xue-Dong
Yao, Hai-Ming Yu
The Second Affiliated Hospital of Fujian Medical University,
Orthopedics, Quanzhou, Fujian, China
Objective(s): To study the change of cortical thickness and
BMD of neck in osteoporotic fracture of femoral neck.
Material & Methods: The proximal femur was examined
with CT scan for 76 patients. There were 42 patients
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with osteoporotic fracture of femoral neck in fracture
group including 12 males and 30 females. The patients'
age was 74.4±9.3 yrs. There were 34 patients including
12 males and 22 females in nonfracture group. The
patients' age was 63.3±9.3 yrs. The parameters were
defined from the CT films at T20 level (the neck at 20
mm higher than the apex of lesser trochanter) in the
normal side hip. The cortex ratio of T20 long diameter
and the cortex ratio of wide diameter of neck at T20
were calculated for the evaluation of the change of
cortical thickness of femoral neck[1]. BMD of femoral
neck was measured with DXA for evaluation of severity
of osteoporosis.
Results: The cortex ratio of T20 long diameter was 17.57±
3.54% in the fracture group and was 21.64±3.75% in non-
fracture group (P=0.000). The cortex ratio of wide diameter
of neck at T20 was 25.98±5.74% in the fracture group and
was 33.39±5.74% in nonfracture group (P=0.000). The
BMD of femoral neck was 0.590±0.084 g/cm2 in the frac-
ture group and 0.698±0.138 g/cm2, in the nonfracture group
(P<0.000).
Conclusion(s): BMD is a strong predictor of fracture risk.
The principal difficulty is that BMD alone has low sensitiv-
ity, so that the majority of patients who sustain fragile
fractures have a T-score above -2.5. Our study confirmed
that BMD was lower in the fracture group than in non-
fracture group in the patients aged ≤65 yrs. But there was
no significant change of BMD between fracture group and
non-fracture group in the patients aged >65 yrs. The cortex
ratio of T20 long diameter and of wide diameter of neck at
T20 were significantly lower in fracture group than in non-
fracture group in the patients aged >65 yrs. It suggest that
the thinned cortex of neck is a main factor leading to
osteoporotic fracture of femoral neck and may be effective
for predicting fracture risk.
References: 1.Li YZ et al. Osteoporos Int 2011;22(suppl 1):
s149.
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THE RELATIONSHIP BETWEENOSTEOARTHRITIS
AND VITAMIN D STATUS IN ELDERLY
Kazim Senel1, Esra Sahin1, Mahir Ugur1, Tuba Baykal2,
Akin Erdal1, Meltem Alkan Melikoglu3
1Ataturk University Medical Faculty, Physical Medicine and
Rehabilitation, Erzurum, 2Batman Regional Hospital, Physical
Medicine and Rehabilitation, Batman, 3Ataturk University
Medical Faculty, Rheumatology, Erzurum, Turkey
Objective(s): It has been suggested an inverse relation-
ship between osteoarthritis and osteoporosis. On the
other hand, the association between osteoarthritis and
vitamin D status has not yet been clearly investigated.
Low levels of vitamin D may have adverse effects on
calcium metabolism, osteoblastic activity, matrix ossifi-
cation, on bone density. It has been suggested that
decreased levels of vitamin D may impair the ability
of bone to respond optimally to processes in osteoar-
thritis and predispose to disease progression. The aim of
this study was to investigate vitamin D status in patients
with osteoarthritis.
Material & Methods: This study was carried out 31 (26
women and 5 men) consecutive patients with osteoar-
thritis according to clinical and radiologically findings
and 25 (20 women, 5 men) age and sex matched
healthy controls. The patients’ ages ranged from 50-81
years, mean 65.5 years. A standardized examination was
used to determine the clinical, laboratory and radiolog-
ical findings. We measured the serum 25-hydroxyvita-
min D (25(OH)D), PTH, alkaline phosphatase, calcium,
and phosphate levels in osteoarthritis patients and com-
pared those controls group. Serum 25(OH)D concentra-
tions were measured using Elecsys 25(OH)D) reactive
kit. According to current recommendations, serum 25
(OH)D levels <30 ng/ml, 20 ng/ml, and 9 ng/ml were
defined as vitamin D insufficiency, deficiency and oste-
omalacia, respectively.
Results: The mean serum 25(OH)D concentration was
significantly decreased in osteoarthritis patients com-
pared to controls (mean:12.76 ng/ml, 22.60 ng/ml, p<
0.01). There were no significant differences in PTH,
alkaline phosphatase, calcium and phosphate levels in
between two groups (p>0.05). Approximately 16% of
osteoarthritis patients (5 patients) had less than 30 ng/ml
of serum 25(OH) D levels. Vitamin D levels of less
than 20 ng/ml were found in 32% of patients (10
patients). 14 patients (45%) had less than 9 ng/ml of
serum 25(OH)D concentrations. Only two patients had
high than 30 ng/ml of serum 25(OH)D levels.
Conclusion(s): Our results have shown that serum 25(OH)D
levels is decreased in patients with osteoarthritis. We suggest
that it will be helpful to determine the vitamin D status in order
to predict the osteoporosis and/or osteomalacia risk and pro-
gression of the disease in osteoarthritis patients.
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THE RELATIONSHIP BETWEENOSTEOARTHRITIS
AND VITAMIN D STATUS IN ELDERLY
Kazim Senel, Esra Sahin, Mahir Ugur, Tuba Baykal, Akin
Erdal, Meltem Alkan Melikoglu
1Atatürk Univercity, Physical Medicine and Rehabilitation,
Erzurum, 2Regional Hospital, Physical Medicine and Reha-
bilitation, Batman, 3Atatürk Univercity, Rheumatology,
Erzurum, Turkey
Objective(s): Osteoarthritis is the most common form of
arthritis. It has been suggested an inverse relationship
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between osteoarthritis and osteoporosis. On the other
hand, the association between osteoarthritis and vitamin
D status has not yet been clearly investigated. Low
levels of vitamin D may have adverse effects on calci-
um metabolism, osteoblastic activity, matrix ossification,
on bone density. It has been suggested that decreased
levels of vitamin D may impair the ability of bone to
respond optimally to processes in osteoarthritis and pre-
dispose to disease progression. The aim of this study
was to investigate vitamin D status in patients with
osteoarthritis.
Material & Methods: This study was carried out 31 (26
women and 5 men) consecutive patients with osteoar-
thritis according to clinical and radiologically findings
and 25 (20 women, 5 men) age and sex matched
healthy controls. The patients’ ages ranged from 50-81
years, mean 65.5 years. A standardized examination was
used to determine the clinical, laboratory and radiolog-
ical findings. We measured the serum 25-hydroxyvita-
min D (25(OH)D), PTH, alkaline phosphatase, calcium,
and phosphate levels in osteoarthritis patients and com-
pared those controls group. Serum 25(OH)D concentra-
tions were measured using Elecsys 25(OH)D) reactive
kit. According to current recommendations, serum 25
(OH)D levels <30 ng/ml, 20 ng/ml, and 9 ng/ml were
defined as vitamin D insufficiency, deficiency and oste-
omalacia, respectively.
Results: The mean serum 25(OH)D concentration was
significantly decreased in osteoarthritis patients com-
pared to controls (mean:12.76 ng/ml, 22.60 ng/ml, p<
0.01). There were no significant differences in PTH,
alkaline phosphatase, calcium and phosphate levels in
between two groups (p>0.05). Approximately 16% of os-
teoarthritis patients (5 patients) had less than 30 ng/ml
of serum 25(OH) D levels. Vitamin D levels of less than
20 ng/ml were found in 32% of patients (10 patients). 14
patients (45%) had less than 9 ng/ml of serum 25(OH)D
concentrations. Only two patients had high than 30 ng/ml
of serum 25(OH)D levels.
Conclusion(s): Our results have shown that serum 25(OH)
D levels is decreased in patients with osteoarthritis. We
suggest that it will be helpful to determine the vitamin D
status in order to predict the osteoporosis and/or osteomala-
cia risk and progression of the disease in osteoarthritis
patients.
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PREDICTINGVERTEBRALBONESTRENGTHWITH
A QUANTITATIVE COMPUTED TOMOGRAPHY-
BASED FINITE-ELEMENT METHOD: CREATION
OF STRENGTH DATA ACCORDING TO AGE RANGE
IN A NORMAL POPULATION AND ANALYSIS
OF FACTORS AFFECTING STRENGTH
Masako Kaneko1, Isao Ohnishi2, Masahiko Bessho2, Kenji
Tobita1, Sakae Tanaka1, Kozo Nakamura3
1The University of Tokyo, Orthopaedic Surgery, Tokyo,
2Internarional University of Health and Welfare, Clini-
cal Medical Research Center, Ichikawa, Chiba, 3Nation-
al Rehabilitation Center for Persons with Disabilities,
Rehabilitation Service Bureau, Tokorozawa, Saitama,
Japan
Objective(s): Spinal aBMD only explains 50-80% of
vertebral strength, and the application of aBMD meas-
urements in isolation cannot accurately identify individ-
uals who are likely to eventually experience bone
fracture, due to the low sensitivity of the test. For
appropriate treatment intervention, a more sensitive test
of bone strength is needed. QCT based finite element
methods (QCT/FEM) may allow structural analyses tak-
ing these factors into consideration to accurately predict
bone strength (PBS). To date, however, basic data have
not been reported regarding the prediction of bone
strength by QCT/FEM with reference to age in a normal
population. The purpose of this study was thus to create
a database on PBS in a normal population as a prelim-
inary trial. With these data, parameters that affect PBS
were also analyzed.
Material & Methods: Participants in this study com-
prised individuals who participated in a health checkup
program with CT and for whom scan data were avail-
able for subsequent FEM analyses. Participants included
602 men, 342 women. Exclusion criteria were provided.
Scan data of L2 were isolated and taken from overall
CT data for each participant with simultaneous scans of
a calibration phantom. A 3-dimensional FE model was
constructed from the isolated data using software. FE
models were equipped with triangular shell elements for
the outer surface of the cortical bone and tetrahedral
solid elements with an edge size of 2 mm for the rest
of the bone. A uniaxial compressive load with a uni-
form distribution and uniform load increment was
applied.
Results: Mean PBS was lower in women than in men
for all age ranges. PBS in men and women significant-
ly decreased with age. Simple linear regression be-
tween age and PBS showed the annual rate of decline
in PBS was 54 N/year in men and 134 N/year in
women. Mean PBS in the 70-74 year age range was
73.3% of YAM in men and in women, was 48.9% of
YAM.
Conclusion(s): PBS was strongly dependent on age, while
physical status (height, weight, BMI) had less effect. These
results do not contradict the findings of the previous study
stating that “the risk of the vertebral body bone fracture is a
woman, and aging”.
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THE SAFETY OF BA058 IN POSTMENOPAUSAL
WOMEN WITH OSTEOPOROSIS: RESULTS
OF A PHASE 2 CLINICAL TRIAL
Gary Hattersley1, John Bilezikian2, Jonathan Guerriero1,
Prasanna Kumar3, Jose Zanchetta4, C Richard Lyttle1, Louis
St L O'Dea1
1Radius Health, Cambridge, MA, 2Columbia University
College of Physicians and Surgeons, New York, NY, US,
3MS Ramaiah Memorial Hospital, Bangalore, India,
4Instituto de Investigaciones Metabolicas, Buenos Aires,
Argentina
Objective(s): BA058 is a synthetic analog of PTHrP(1-34)
designed to give a greater anabolic effect than hPTH. A
phase 2 dose finding study was conducted to evaluate the
safety and efficacy of daily SC BA058 (20, 40 and 80 μg),
compared to placebo or teriparatide (20 μg).
Material & Methods: The study was conducted in 40
study centers in the USA, UK, Argentina and India.
After IRB approval and informed consent, 222 postmen-
opausal women with osteoporosis were randomized
(1:1:1:1) and 221 received at least one dose of study
drug. After the initial 6 months of treatment, eligible
patients were offered 6 additional months of their
assigned treatment. All patients received calcium and
vitamin D supplements. Safety was assessed by labora-
tory tests, radiology and the incidence and severity of
adverse events from the time of entry, until 30 days
after the last dose.
Results: 45 patients were randomized to receive placebo, 43
to 20 μg and 40 μg, and 45 each to 80 μg or teriparatide.
The mean age of all patients was 65. Treatment emergent
adverse events (TEAEs) were reported in 74% of patients.
The incidence of TEAEs was similar across the treatment
groups, ranging from 71% in the placebo group to 78% in
the teriparatide group. The most commonly reported events
were influenza (10.4%) and headache (10.4%), all other
events occurred in <10% of all patients. Seven patients
(3.1%) discontinued from the study due to an adverse event,
and serious adverse events (SAEs) were reported in 1.4%
patients. None of these were treatment related, and there
were no deaths. Mean serum calcium levels were consis-
tently higher in the teriparatide group compared to the
BA058 groups, with mean values continuing to rise in the
teriparatide group over time. The safety profile of BA058
was consistent through an additional 6 months of treatment
and no new safety signals were observed.
Conclusion(s): Treatment with BA058 80 μg resulted in
significant BMD gains at all measured sites. BA058 was
well tolerated. Safety events were comparable with blinded
placebo and consistent with medical events in a disease
population of this age and gender.
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MULTICENTER REPRODUCIBILITY
OF CORTICAL AND TRABECULAR
BONE QUALITY MEASURES ASSESSED
BY HR-PQCT
Andrew J Burghardt1, Jean-Baptiste Pialat1,2, Galateia J
Kazakia1, Stephanie Boutroy2,3, Janina Patsch1,4, Alexander
Valentinitsch1,4, Danmei Liu5, Eva Szabo6, Cesar E
Bogado7, Klaus Engelke8,9, Maria B Zanchetta7, Heather
Mckay5, Elizabeth Shane3, Steven K Boyd6, Mary L
Bouxsein10,11, RolandChapurlat2, SundeepKhosla12, Sharmila
Majumdar1
1University of California, San Francisco, Musculoskeletal
Quantitative Imaging Research Group, Department of Radi-
ology & Biomedical Imaging, San Francisco, CA, US,
2INSERM and Université de Lyon, Research Unit 1033 Team
1, Lyon, France, 3Columbia University Medical Center, Divi-
sion of Endocrinology, Department of Medicine, College of
Physicians and Surgeons, New York, NY, US, 4Medical Uni-
versity of Vienna, Department of Radiology, Vienna, Austria,
5University of British Columbia, Centre for Hip Health and
Mobility, Department of Orthopedics, Vancouver, BC, Canada,
6University of Calgary, Schulich School of Engineering,
Calgary, AB, Canada, 7de Investigaciones Metabólicas, Insti-
tuto, Buenos Aires, Germany, 8Inc., Synarc, Hamburg,
Germany, 9University of Erlangen, Institute of Medical Phys-
ics, Erlangen, Germany, 10Massachusetts General Hospital,
Endocrine Unit, Boston, MA, US, 11Harvard Medical School,
Department of Orthopedic Surgery, Boston, MA, US,
12College ofMedicine,MayoClinic, Division of Endocrinology,
Metabolism and Nutrition, Department of Internal Medicine,
Rochester, MN, US
Objective(s): To evaluate the feasibility of pooling data in
large-scale, multicenter HR-pQCT imaging trials, single and
multicenter reproducibility indices were determined for cor-
tical and trabecular bone quality measures across nine im-
aging centers.
Material & Methods: Reproducibility imaging experi-
ments were performed using structure and composition-
realistic phantoms constructed from multiple 1-cm sec-
tions of cadaveric radii. Single-center precision was
determined by repeat scanning over short (<72 h), in-
termediate (3-5 mo, spanning hardware repairs), and
long-term intervals (28 mo). Multicenter reproducibility
was determined by imaging the phantoms at nine dif-
ferent HR-pQCT centers. The root mean squared coef-
ficient of variation (RMSCV) for each interval and
across centers was calculated for standard density and
structure, cortical porosity, and μFE parameters.
Results: Single-center short-term RMSCVs. were <1% for all
parameters excepting Ct.Th (1.1%), Ct.Th.SD (2.6%), Tb.Sp.
SD (1.8%), and porosity measures (6-8%). Except Tb.Ar,
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intermediate-term RMSCVs. were not statistically different
from short-term values. Long-term variability was significantly
greater for all density measures (0.7-2.0%; p<0.05 vs. short-
term), Ct.Th (3.4%; p<0.01 vs. short-term), Ct.Po (15.4%; p<
0.01 vs. short-term), and Tb.Th (2.2%; p<0.01 vs. short-term).
Multicenter RMSCVs. were also significantly higher: 2-4% for
density and μFE measures (p<0.0001 vs. short-term), 2.6-
5.3% for morphometric measures (p<0.001 vs. short-term),
while Ct.Po was 16.2% (p<0.001 vs. short-term).
Conclusion(s): In the absence of subject motion, multicen-
ter precision errors for HR-pQCT parameters were generally
less than 5%. While this translates to 2-5x worse than ideal
short-term precision, phantom-based multicenter RMSCVs.
for most structure and biomechanical measures were com-
parable to in vivo reproducibility data reported previously.
The higher RMSCV for porosity metrics likely reflects the
large biological range of these features and greater sensitiv-
ity to resolution differences. The reference data generated in
this study will be used to evaluate, and ultimately recom-
mend correction procedures that could broadly translate to
multicenter study designs.
Disclosures: NIHR01AR060700 (AJB), NIH R01AG17762
(SM), Synarc Inc. (SM), France-Berkeley Fund (SM/RC)
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COMPARISON OF BMD VALUES AFTER
TROCHANTERIC FRACTURES TREATED
SURGICALLY VS. CONSERVATIVE
TREATMENTAT 30 MONTHS FOLLOW-UP
Dorina Ruci1, Teuta Backa1, Vilson Ruci2, Artid Duni2,
Alfred Cake2
1Mother Teresa University Hospital, Rheumatology, 2Mother
Teresa University Hospital, Orthopedics, Tirana, Albania
Objective(s): The purpose of this study was to evaluate the
possible effect on bone mass from different treatment meth-
ods in patients with fractures of trochanteric region.
Material & Methods: This study is conducted in a single
trauma service treating such fractures in the last three years.
In this study were involved 64 patients with fractures of
trochanteric region. Mean age 67.5 years (55-92). There
were 30 males, 34 females. The first group of 35 patients
was treated with internal fixation using DHS. The patients
were mobilized 24 hours after surgery. Full weight bearing
was achieved 10-12 weeks post-op. After 30 months follow-
up six patients died and only 29 completed the survey. The
second group of 29 patients was managed in conservative
way. Patients age in this group from 59-92 years old (mean
age 66.5 yrs). The treatment lasted for 10-12 weeks of abso-
lute bed rest in skeletal traction. After 30 months follow-up
nine patients died and only 20 completed the survey. All
patients did the first BMD of the contralateral hip measure-
ment with DXA (GE-Lunar) three months after fracture. The
Figure 1 Reproducibility of select HR-pQCT measures expressed as
RMSCV {%} over short- (<72 h), intermediate- (3–5 months), and
long-term (28 months) (black, dark grey, light grey, respectively) com-
pared to the muticenter reproducibility of nine different systems
(white). pTb.BMD: peripheral Tb.BMD; mTb.BMD: medullary Tb.
BMD: p/mTb.BMD: ratio of PTb.BMD to pTb.BMD: Ct.Th*: direct
3D cortical thickness: Ct.Th.SD: standard deviation of Ct.Th or corti-
cal heterogenesity: En.S: endocortical surface area: Tb.Sp.SD: stan-
dard of Inter-trabecular distances or trabecular heterogenesity; Ct.LF:
cortical load fraction (at distal or proximal boudaries).
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second measurement was done 6 months after the first mea-
surement. The next DXA were at intervals of 6 months until
last follow-up of 30 months.
Results: In the first group of patients we obtained signifi-
cant better results of BMD values. The first DXA measure-
ment resulted with mean differences of 12% of BMD values
in favor of ORIF group. During the following measurements
the gap of BMD values varied from 10-18%. Even after 30
months the surgical group had statistically better BMD
values. A new fracture appear at 5.8% of patients in the first
group for 30 months of follow up, comparative with 17.2%
in the second group.
Conclusion(s): Prolonged bed rest seems to accelerate
bone loss not only due to disuse osteopenia but also
from significant muscular atrophy in the conservative
treated group. Aggressive rehabilitation earlier weight
bearing better muscular activity are well known factors
which minimize bone loss during healing period in tro-
chanteric fractures.
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GLUCOSAMINE INDUCES INSULIN RESISTANCE
IN OVARIECTOMIZED RATS
Chung-Hwan Chen1, Lin Kang2, Fong-Ming Chang2
1Kaohsiung Medical University, Orthopaedics, Kaohsiung,
2National Cheng Kung University, Obstetrics and Gynecology,
Tainan, Taiwan
Objective(s): Glucosamine (GlcN) is a popular nutritional
supplement used to treat osteoarthritis in menopausal wom-
en. Menopausal women are at higher risk of type 2 diabetes
mellitus and metabolic syndrome due to ovarian hormone
deficiency. We used ovariectomized (OVX) rats as the mod-
el to investigate whether GlcN would induce IR in OVX rats
and the underlying mechanisms.
Material & Methods: The rats were divided into four
groups: (1) Sham-operated group (SHAM), (2) SHAM with
GlcN treatment (SHAM+GlcN), (3) OVX group, (4) OVX
with GlcN treatment (OVX+GlcN). GlcN were given intra-
peritoneally at 12 weeks after the surgical procedure for 2
weeks. The intraperitoneal glucose tolerance test (IPGTT)
was performed to measure plasma glucose and insulin, and
to calculate the clinical homeostasis model assessment-in-
sulin resistance (HOMA-IR) and glucose-insulin index.
Western blot analysis for detection of glucose transport
protein subtype 4 (GLUT4) expression in skeletal muscle
and histopathological examination for the changes in pan-
creatic islets were also performed.
Results: Fasting plasma glucose increased in the OVX with
GlcN group, and the fasting plasma insulin and HOMA-IR
were elevated more significantly in this group. In addition,
the plasma glucose, plasma insulin, HOMA-IR and glucose-
insulin index were significantly elevated only in the OVX
with GlcN group after intraperitoneal glucose injection,
implying that IR was induced by GlcN only in the female
rats without the protection of ovarian hormone. Also, we
found treatment with GlcN decreased the expression of
GLUT-4 in skeletal muscle and induced pancreatic islet
hypertrophy only in OVX rats.
Conclusion(s): The results demonstrate female rats do not
develop IR upon GlcN treatment except after ovariectomy.
Those who take GlcN after menopause or bilateral oopho-
rectomy should watch their blood glucose level closely,
especially after meals, but not the fasting glucose level.
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FUNCTIONAL STATE ASSESSMENT OF KNEE IN
RELATION TO THE THERAPY
Svetlana Kevic, Snezana Mikulic-Gutman
Clinical centre of Vojvodina, Clinic forMedical Rehabilitation
and Physical Medicine, Novi Sad, Vojvodina, Serbia
Objective(s): To determine the efficiency of applied therapy
and functional status of patients depending on the imple-
mented therapy.
Material & Methods: The study included 60 patients with
knee osteoarthrosis, whose established diagnosis was based
on ACR criteria. The patients were divided into two groups.
Group A: 30 of patients, in which we conducted outpatient
physical therapy that included laser therapy, IFE, EF with
Diclofen ampoules, ultrasound, MT, paraffin therapy with
kinesis treatment. The treatment was combined and it was
conducted over a period of 8 weeks. Group B: 30 of patients
who received three applications of i.a. 1% Hyaluronic Acid
injections over a period of 7 days, and then had a physical
procedure of MT, laser therapy, paraffin therapy and kinesis
therapy. The treatment also lasted for 8 weeks. All patients
were analyzed by a single questionnaire. They were also
clinically evaluated by the orthopedist and physiatrist.
Average age was 68.4, 80% female representation. Ra-
diological changes were assessed according to Kellgren-
Lawrence classification, 70% had stage III, stage II 30%.
Assessment of functional status before and after treat-
ment was performed according to the Oxford knee score.
The degree of pain was estimated with VAS before and
after the treatment.
Results: In A group, the average value of pain according to
VAS was 8 before the treatment, and it was 6 after the
treatment. The average value of the functional score was
22 before the treatment, and 31 after the treatment. In B
group the average value of pain according to VAS was 9
before the treatment, and 4 after the treatment. The average
functional status was 22 and 38 after the treatment.
Conclusion(s): Patients who received i.a.1% hyaluronic
acid injections and then performed physical therapy have a
significant reduction in pain after the treatment as well as
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improvement in functional status compared to patients who
carried out only the combined physical therapy.
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ADHERENCE TO BISPHOSPHONATES:
OUTCOMES AFTER SIX YEARS OF TREATMENT
Renato Pastore1, Mentuccia Daniela1, G Vanni Frajese2
1UOC Endocrinology, Ospedale San Giovanni Calibita -
Fatebenefratelli Isola Tiberina, Roma, 2Università degli
Studi di Cassino, Facoltà di Scienze Motorie e della Salute,
Cassino, Italy
Objective(s): Bisphosphonates (BP) are the first choice
treatment for osteoporosis. They effectively increase
BMD, reduce markers of bone resorption, and lower
the incidence of new fractures in patients with osteopo-
rosis-related fracture. However, the efficacy observed in
clinical trials may not be realized in a real life setting,
partly due to poor adherence to therapy, with a signif-
icant worsening of clinical outcomes. The aim of this
study conducted on an outpatient cohort is to quantify
the adherence to the osteoporosis treatment in real prac-
tice setting and to identify the factors that may affect it.
Material & Methods: 236 women (mean age 66.4 y; SD
9.3; range 44-88) who started treatment for osteoporosis
with BP after diagnosis of osteoporosis between January
2004 - December 2009 were examined. We assessed the
association between adherence to oral BP and incidence of
osteoporotic fractures. Adherence was quantified using the
Medication Possession Ratio (MPR) per year and the MPR
per visit for each patient. Adherence to treatment was de-
fined as having MPR≥80%.
Results: Adherence rates decreased from 53% for treatment
lasting 0-2 years to 43% for treatment lasting 2-4 years,
returning to 49% for treatment lasting more than 4 years.
In the whole sample mean MPR was 60.6% (41.4%).
Among the motivations of therapy dropout comorbidities,
self-made decision, GI intolerance and death were the most
frequent. Nonadherent patients had higher risk of fracture
(adjusted OR=3.4, 95% CI 1.1-10.5, p=0.032). Problems
incompliance were reported in 181 visits (37.8%) on 51
patients (21.61%). The mean MPR per year adherence was
associated with age <65 y (p=0.040), absence of comorbid-
ities (p=0.023), positive history of fracture (p 0.044); hav-
ing the same physician in follow-up (p 0.025).
Conclusion(s): Main determinants of low adherence de-
scribed in clinical trials and relationship of adherence
with fracture risk are confirmed in this real life study,
and it emerges the importance of the relationship be-
tween physician and patient in improving the adherence.
Adherence to BP in osteoporosis management is subop-
timal in a real life setting. A significant positive asso-
ciation exists between poor adherence and increased risk
of osteoporotic fractures which becomes augmented with
longer treatment duration.
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VITAMIN 25OHD3 VALUES IN HOMOZYGOTE
MUTATIONS VDR: CLINICAL VALUES
Pavel Novosad1, Petr Hrdý1, Petr Fojtík2, Radmila
Richterová3, Arpád Bóday3, Vladimír Palicka4
1Mediekos Labor, s.r.o., Osteological Center, Zlin, 2Vitkovice
Ostrava Hospital, Specialized Centre for GIT, Ostrava-Vitkovice,
3P&R LAB a.s., Laboratory od Molecular Biology, Novy
Jicin, 4Charles Univerzity, Univerzity Hospital Hradec
Kralove Osteocentre, Hradec Kralove, Czech Republic
Objective(s): The above listed workplaces have cooperated
on a common project on genetic examining. Total number of
patients reached 1008. This research provides evaluation of
945 patients where analyses have been completed in detail.
Material & Methods: In the complete work there are 4
basic polymorphisms in 3 genes (VDR, ESR1, and LRP5).
DNAwas isolated by kit MagAttract DNA Blood Mini M48
using automated isolator Biorobot M48 (Qiagen) from 200
μl noncoagulable blood samples provided by 945 patients.
4 polymorphisms in 3 genes were observed. In gene VDR
(vitamin D receptor) BsmI polymorphism (A>G substitu-
tion, rs 1544410), in ESRl gene (receptor 1 of estrogen)
polymorphism PvuII (T>C substitution, rs2234693) and
in LR5 gene (lipoprotein receptor-related protein5) poly-
morphisms Val667Met and Ala1330Val(rs3736228).
Concerning osteological parameters, entry parameters were
observed during a primary examination, DXA on GE iDXA
machine, laboratory parameters Ca, P, osteomarkers such as
osteocalcin, CTx, ALP-bone isoenzyme, PTH, weight,
height, BMI.
Results:
Total No. of probands=1008 n=945 Monitoring group n=50
VDR age - 58.7
n % age Vit250HD3
nM/L
Vit250HD3 nM/L - 58.3 nm/L
WT 351 34.3 55 58.5
HETERO 609 52.4 63.8 57.6 age Vit250HD3
nM/L
MUTATION 112 10.4 62.6 64.7
p<0.001
HETERO 62.8 56.2
COMB.MUT. 15 1.4 64.6 62.7
p<0.01
COMB.
HETERO
63.5 55.7
DEFLECTION 5 0.54 MUTATION
ESR 1
60.8 53.8
We are presenting results from an observation of homozy-
gote mutation of VDR gene. We have found considerably
higher values of vitamin 25(OH)D3 at these patients in
comparison with the rest of the probands. Consumption of
vitamin D was not significantly different in statistics. Our
work was focused on values of vitamin 25(OH)D3 in the
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specified groups of probands. See the chart above for the
characteristics.
Conclusion(s): In Bouillon et. al 2008 experiments prove
that when VDR is inactivated in mice (null mice) different
levels of metabolites of vitamin D are attained. Metabolite
1.25 vitamin D is increased, activity 1-alfa-hydroxylase is
increased and metabolite 24.25.OH2D3 is lowered. A sim-
ilar phenomenon has been observed with people. There can
be two clinical meanings of 25(OH)D3 increase in VDR
mutations: 1. Direct - in disturbing bone homeostasis; 2.
Indirect - intervention into calcification processes in vessels.
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SEQUENTIAL THERAPY AFTER PTH 1-84
TREATMENT: COMPARISON AMONG
BISPHOSPHONATES AND STRONTIUM RANELATE
Renato Pastore1, Daniela Mentuccia1, Vanni G Frajese2
1UOC Endocrinology, Ospedale S. Giovanni Calibita, Fate-
benefratelli, Isola Tiberina, Rome, 2Università degli Studi di
Cassino, Facoltà di Scienze Motorie e della Salute, Frosi-
none, Italy
Objective(s): PTH1-84 is a bone anabolic drug that
increases bone strength and reduces the risk of fractures.
Evidence in literature shows how is useful to use antiresorp-
tive drugs such as bisphosphonates, in severe osteoporosis
severe after PTH (1-34 or 1-84) treatment.
Material & Methods: This study was divided into two parts,
each of 18 months: the first one analyzed BMD changes by
DXA-BMD at the lumbar and femoral and serum osteocalcin
and β-CTX, monitoring their performance after 6,12 and 18
months in 61 women with severe postmenopausal osteoporo-
sis (mean age 71.0±8.5), treated for 18 months with PTH 1-
84. In the second phase of the study, 66.66% (40 of 61 treated
patients) was divided into 5 groups (each with 8 patients), who
received calcium (1 g/day) and vitamin D (5600 IU/week).
Patients, respectively, taking alendronate, risedronate weekly,
ibandronate monthly and strontium ranelate daily and in the
last group only vitamin D and calcium. After 18 months was
evaluated again BMD at the spine and femur.
Results: We observed a slight increase in femoral T-score
from baseline (-2.3±0.8 at baseline and -2.1±0.7 at the end
of treatment, (p=0,07, Wilcoxon test), more significant at
the lumbar spine (baseline=-3.3±0.9 and -2.7±1.2 at the
end of treatment (p<0.001, Wilcoxon test). Osteocalcin
values were increased (ANOVA, p<0.001), 4.4 times from
baseline at 6th month, 5.4 and 3.1, respectively, at 12th and
18th months (Bonferroni, p<0.001). β-CTX levels showed
an increase of 2.5 times from baseline at month 6th, 2.6 and
1,8, respectively at 12th and 18th months (p<0.001). After
18 months of therapy with other bisphosphonates, strontium
ranelate and calcium and vitamin D further significant
increases were evidenced in t-scores after ibandronate
(+0.9, 95% CI: +0.2, +1.5, p<0.05), ranelate (+0.8, 95%
CI: +0.4, +1.3, p<0.05), risedronate (+1.6, 95% CI: +1.0,
+2.3, p<0.05. Analysis of variance showed a significant
difference (p=0.008) between risedronate and Vit D.
Conclusion(s): Our data show PTH 1-84 efficacy and sug-
gest that in severe osteoporosis the treatment of choice
would include a first cycle of 18 months with PTH1-84,
followed by a subsequent cycle of therapy with antiresorp-
tive drugs or ranelate strontium.
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VITAMIN D RECEPTOR GENE BSMI
POLYMORPHISM AND BONE PHENOTYPE IN
POPULATION OF CENTRAL MORAVIA REGION
Petr Hrdy1, Pavel Novosad1, Petr Fojtik2, Radmila Richterova3,
Arpad Boday3
1Mediekos Labor Ltd., Osteological Centre, Zlin, 2Vitkovice
Hospital a.s., Centre Care for GIT, Ostrava, 3P&R Lab a.s.,
Laboratory of Molecular Biology, Novy Jicin, Czech Republic
Objective(s): During the recent years bone phenotype rela-
tion to gene candidates for osteoporosis has been observed.
Individual parameters of bone phenotype such as BMD,
bone microarchitecture, bone turnover markers (BTM) and
fractures can be determined by an interaction between these
candidate genes and external factors. Nowadays one of the
most followed candidate gene is a gene for vitamin D
receptor (VDR). One of the most followed polymorphisms
of this gene is polymorphism BsmI. We have been observ-
ing frequency of this polymorphism occurrence in relation
to parameters of bone phenotype.
Material & Methods: DNAwas isolated by kit MagAttract
DNA Blood Mini M48 using an automated isolator Bioro-
bot M48 (Qiagen) from 200ul non-coagulable blood sam-
ples. The principle of isolation is based on a separation by
magnetic spheres. Polymorphism BsmI was observed (A/G
substitution, rs 1544410) in a vitamin D receptor gene.
Detection of polymorphism BsmI was carried out by real-
time method PCR while using FRET sounds and by direct
sequencing on a sequenator ABI 3130 (Applied Biosystem).
Bone phenotypes (BMD, BTM, fractures) were then com-
pared with frequency of genotype occurrence as wildtype
with no mutation (bb), mutated heterozygote (Bb) or mutat-
ed homozygote (BB). BMD was measured in lumbar spinal
column and total hip using densitometer Lunar iDXA (GE
Healthcare).
Results: A cluster of 1051 patients from Central Moravia
region was analysed. We followed a frequency of polymor-
phism BsmI occurrence and its relation to individual param-
eters of bone phenotype. BMD in femoral neck and lumbar
spine area, BTM osteocalcin (OC) and β-crosslaps (CTx)
and fractures were analysed. Demographic characteristics of
individual genotype were with no significant difference. The
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acquired results show significantly lower BMD of homozy-
gote BB in femoral neck and lumbar spine area and a
significantly lower occurrence of fractures with patients of
genotype bb. Relation among BsmI polymorphism and
BTM were not proved.
Conclusion(s): Our results show that it is possible to ob-
serve slight but statistically significant relation among ob-
served vitamin D receptor gene BsmI polymorphism and
some parameters of bone phenotype.
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GENERAL HEALTH RELATED QUALITY OF LIFE
IN PATIENTS WITH OSTEOPOROSIS
Ksenija M Boskovic1, Snezana M Tomasevic Todorovic1,
Jelena S Zvekic Svorcan2, Dusica S Simic1, Aleksandar L
Knezevic1
1Clinical Center Vojvodina, Rehabilitation Clinic, 2Special
Hospital, Rheumatology, Novi Sad, Serbia
Objective(s): Osteoporosis is a systemic disorder character-
ized by decreased bone mass and microarchitectural deteri-
oration of bone tissue. Aim of the study to determine
influence the bone density decrease on the quality of life
of these patients.
Material & Methods: A number of 709 women, outpa-
tients, chosen by a method of random selection, was exam-
ined. Bone density was measured by osteodensitometry.
Quality of life was estimated through a general question-
naire SF36.
Results: Decreased bone density had 59.80% women -
osteopenia was found in 38.36% and osteoporosis in
21.43%. Insufficient level of physical activity was found
in 45.1% patients and in the group of patients with osteo-
porosis in 72% of patients. An early menopause was found
in 1/5 of patients. There were 24.5% patients who smoke
and 16.2% of patients moderately consumed alcohol. 13.5%
of patients was on a regular corticosteroid therapy. The
quality of life, estimated through a global physical aspect,
did not differ significantly between patients with normal and
decreased bone density (normal bone density 39.76; osteo-
penia 39.68; osteoporosis 38.01). The difference in the
psychological score was not significant between patients
with normal and decreased bone density (normal bone den-
sity 42.54; osteopenia 41.47; osteoporosis 41.12). A statisti-
cally significant difference was found only when a role of
physical functionality was evaluated (p=0.05) (normal bone
density 59.60; osteoporosis 52.86).
Conclusion(s): In the patients we evaluated, the most fre-
quent risk factor to influence the decrease of bone density
was insufficient physical activity. The quality of life of
patients with normal and decreased bone density was sig-
nificantly different when the role of physical functionality
was estimated.
References: 1. Boskovic K, et al. Balneoclimatologia YU ISSN
0350/5952, 2009;35(Suppl.3):7. 2. Zvekic Svorcan J, Boskovic
K, Lazarevic D, et al. Balneoclimatologia 2011;35:205. 3.Madic
D, Obradovic B, Maric D, et al. Vojnosanit Pregl 2010;67:386.
Disclosures: Physical activity has the most important im-
pact on the quality of life of patients with osteoporosis.
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DOES POST-FRACTURE THERAPY WITH BONE
CONSERVATION AGENTS PREVENT SECOND
FRACTURE? PRELIMINARY RESULTS FROM
A STUDY OF 10,608 MALES
Angela J Shepherd1, Alvah R Cass1, Brett Howrey1,2, Gregg
S Wilkinson1,2
1University of Texas Medical Branch, Family Medicine,
2University of Texas Medical Branch, Preventive Medicine
and Community Health, Galveston, TX, US
Objective(s): There are few studies of the effectiveness of
bone conservation therapy in achieving secondary preven-
tion of subsequent non-vertebral fragility fractures in men.
Our objectives in this study are: 1) determine the clinical
effectiveness of treatment with bone conservation agents in
preventing subsequent fractures among men after index
fragility fracture; 2) identify clinical characteristics associ-
ated with treatment; 3) estimate post-fracture risk of subse-
quent fracture among treated and untreated men.
Material & Methods: We used the claims of a large health
insurance company with enrollees throughout the United
States to identify 10,608 men 65 years and older who had
a claim for a fragility fracture during the period 2000-2005.
Patients' characteristics, diagnostic procedures, therapies,
comorbidities, and provider characteristics were compared
for fracture patients who initiated bone conservation agents
with those who did not following the index fracture and
used to estimate the occurrence of a subsequent fracture.
Results: A total of 492 (4.6%) patients initiated and 10,116
(95.4%) patients did not initiate post-fracture therapy. Treat-
ment for all bone conservation agents peaked in 2002-2003.
Mean age for initiators was 76.2 and 74.9 for noninitiators.
Among initiators, 16.1% experienced a subsequent fracture
compared with 10.7% of noninitiators (p<0.001). Initiators
were more likely than non-initiators to have a previous
diagnosis of osteoporosis (p<0.001) or COPD, or previous
treatment with tertiary tricyclics (p<0.001), SSRI antide-
pressants (p<0.001), and benzodiazepines (p<0.001), The
average time to subsequent fracture for initiators was 12.5
months and 13.4 months for noninitiators. The crude risk of
experiencing a subsequent fracture among initiators relative
to noninitiators was 1.6 (95% CI: 1.25-2.05) and 1.55 (95%
CI: 1.21-2.00) adjusted for the aforementioned covariates.
Conclusion(s): These preliminary results suggest that: few
men with a fragility fracture received post-fracture treatment
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with a bone conservation agent, 2nd fractures for initiators
tend to occur on average of 1 month sooner, and the relative
risk for a 2nd fracture is increased among patients who receive
treatment relative to those who do not receive treatment.
Disclosures: Claims data used in this study are contained in
the i3 Invisions database, which is maintained by Optumin-
sight, a member of the United Health Group.
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LACTOSE INTOLERANCE AS A RISK FACTOR
FOR OSTEOPOROSIS
Pavel Novosad1, Petr Fojtík2, Ondrej Urban3
1Mediekos Labor, s.r.o., Osteological Centre, Zlin, 2Vitkovice
Hospital a.s., Centre of Gastrointestinal Care, Ostrava-
Vitkovice, 3Ostrava Univerzity, Medical Faculty, Ostrava,
Czech Republic
Objective(s): To recognise calcium intake with patients
treated with osteoporosis and lactose intolerance.
Material & Methods: Patients currently treated with osteo-
porosis were asked about their lactose intolerance. Those who
replied positively were further examined in gastroenterological
clinic to prove their lactose intolerance. Genetic testing (LCT
gene, C/T 13910 and G/A 22018) was done and then weekly
questionnaire on dietary calcium intake was administered.
Results: There were 89 patients genetically examined. All
of those with positive reaction to lactose intolerance were
also genetically positive. From the whole group there were
72.5% homozygotes and 27.5% heterozygotes for both
polymorphisms. 40 patients turned in the calcium intake
questionnaire. 39 of those were women and 1 man, average
age was 61 years. Average calcium intake in the whole
group was 415 mg a day. Considerable individual differ-
ences were found, from 150-1150 mg/day. Average deficit
of calcium intake in the whole group was 800 mg/day.
Conclusion(s): We have proved a low calcium intake (415
mg/day) with patients of lactose intolerance. Large individ-
ual differences in daily intake were found. We can consider
this to be a risk factor of osteoporosis. Genetic examination
of lactose intolerance is simple and precise. It is appropriate
to calculate substitution calcium dose individually accord-
ing to patient's dietary intake.
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COELIAC DISEASE SCREENING OF PATIENTS
WITH OSTEOPENIA AND OSTEOPOROSIS
IN CENTRAL AND NORTHERN MORAVIA, THE
CZECH REPUBLIC
Pavel Novosad1, Petr Fojtík2, Ondrej Urban3
1Mediekos Labor, s.r.o., Osteological Centre, Zlin, 2Vitkovice
Hospital a.s., Centre of Gastrointestinal Care, Ostrava-
Vitkovice, 3Ostrava Univerzity, Medical Faculty, Ostrava,
Czech Republic
Objective(s): To prove validity of coeliac disease screening
for osteopenia and osteoporosis patients.
Material & Methods: Patients diagnosed with osteopenia
and osteoporosis were examined according to DXA. Serolog-
ical examination of tissue transglutamine - AtTGa was carried
out. Patients with positive results were further examined.
Results: Total number of 2245 patients was examined, from
which 2128 (95%) were women and 117 (5%) were men.
Positive serology was found with 50 patients (2.2%), further
examined by endoscopy were 45 (2.0%) patients. In a group
of patients with osteoporosis there were 2.14% with positive
serology, in osteopenia group 2.49% were positive. Average
age in the total group with confirmed coeliac disease was 47
years, in osteoporosis group 54 years and in osteopenia
group 40 years.
Conclusion(s): We have proved that prevalence of coeliac
disease in this target group of Central and Northern Moravia
population is 2.2-2.49% in comparison with general popu-
lation of the whole Czech Republic. It is four times higher
than expected in general population of the Czech Republic
where anticipated prevalence is 0.4-0.5%. It can thus be
deducted that screening in this target group is meaningful
and should be introduced in the common praxes.
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LONG-TERM IMPACT OF ADHERENCE TO ORAL
BISPHOSPHONATES ON OSTEOPOROTIC
FRACTURE INCIDENCE
JohnSSampalis1, JonathanDAdachi2, Emmanouil Rampakakis1,
Julie Vaillancourt3, Angela Karellis3, Christian Kindundu4
1McGill University & JSS Medical Research, Surgical Re-
search, Montreal, QC, 2McMaster University, Medicine,
Hamilton, ON, 3JSS Medical Research, Scientific Affairs,
St. Laurent, QC, 4Novartis Pharmaceuticals Canada Inc.,
Health Economics & Reimbursement Strategy, Dorval, QC,
Canada
Objective(s): Adherence to osteoporosis treatments is a
critical parameter resulting in suboptimal effectiveness in
real life practice. The long-term effect of adherence on
fracture risk has not been assessed.
Material & Methods: Retrospective study using provincial
health insurance claims databases to assess the association
between adherence to oral bisphosphonates (OBP) and in-
cidence of osteoporotic fractures in all Ontario patients with
osteoporosis between April 1996 - December 2009. Multi-
variate logistic regression models were used to assess the
association between OBP adherence and fracture risk. Treat-
ment duration was classified into two-year intervals. Com-
pliance was estimated with the medication possession ratio
(MPR) and persistence was defined as the length of contin-
uous therapy without a gap in refills >30 days.
Results: A total of 636,114 patients comprised the study
cohort with a mean age of 72 years and 84% being female.
S190 Osteoporos Int (2012) 23: (Suppl 2):S85–S386
Overall, the mean compliance for the total cohort was 0.72
(0.30) with 53.5% of the patients having a compliance of
>80% during the 14-year follow-up period. Among the
patients with 0-2 years of follow-up only 49.9% were com-
pliant. After this period, compliance declined steadily with
time from 58.9% in patients with 2-4 years of follow-up to
49.9% in patients treated for 12-14 years. With regards to
persistence, 24.6% of the total cohort was persistent during
the 14-year period. Persistence decreased steadily from
41.0% in patients with 0-2 years of treatment to 3.3% in
patients with 12-14 years of treatment. Significant associations
between high compliance and persistence and reduced fracture
risk over the entire 14-year period of the study were observed.
The overall odds ratio for categorical compliance (MPR>80%
or MPR≤80%), continuous compliance and persistence were
0.909 (95% CI: 0.893-0.925), 0.918 (95% CI: 0.893 and
0.944) and 0.804 (95% CI: 0.787-0.821), respectively.
Conclusion(s): In a real life setting, adherence to OBP in
osteoporosis management is suboptimal. A significant pos-
itive association exists between poor adherence and in-
creased risk of osteoporotic fractures which becomes
augmented with longer treatment duration.
Disclosures: This study was supported by a grant-in-aid by
Novartis Pharmaceuticals Canada Inc. and an in-kind sup-
port by JSS Medical Research Inc.
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MEDICATION BURDEN OF SAUDI ARABIAN
WOMEN RECEIVING ANTIRESORPTIVE
THERAPY
Mir Sadat-Ali, Bader Al-Shafie, Abdallah S Al-Omran,
Mohammed Q Azam
1University of Dammam, Orthopaedic Surgery, College of
Medicine, Dammam, 2King Fahd University Hospital, Phar-
macy, AlKhobar, Saudi Arabia
Objective(s): Osteoporosis is common among Saudi Arabi-
an population and successful treatment requires full compli-
ance. Patients who require antiresorptive therapy (ART)
such as oral bisphosphonates might suffer from other dis-
eases which require medications and this increases the Med-
ication Burden (MB) and end up in noncompliance of drugs
making them vulnerable to osteoporosis related fractures
(ORF). We decided to undertake this study to analyze the
concomitant medications which osteoporotic patients are
receiving at King Fahd University Hospital, AlKhobar.
Material & Methods: Osteoporotic patients receiving ART
at King Fahd University Hospital, AlKhobar were identi-
fied through the database of the QuadruMed Patients Care
system and was cross checked from the Radiology data
base of DXA scan and pharmacy drug dispensing system
between January 2009 - December 2009. Concomitant
medication is defined as use of other drugs for ≥30 days
with oral bisphosphonates, calcium and vitamin D. MB is
defined as mild (≤1 concomitant medication), moderate
burden (≥2 and ≤4 medications) and severe burden (≥5
medications). The demographic data such age, sex and
diagnosis was collected from the medical records. The
data was analyzed using SPSS (Statistical Package for
the Social Sciences), version 14.0, Chicago, Illinois.
Results: During the study period 516 patients were diag-
nosed to have osteoporosis and were and 473 were on ART.
Sixty-eight (14.4%) of the patients with the average age of
50.15±2.4 years were on 1 medication apart from ART,
vitamin D and elemental calcium, 129 (27.3%) with average
age of 51.6±9.7 years were taking 3.32 medications, and
276 (58.3%) with mean age of 62.1±10.7 years were on
8.02 concomitant medications. The most common concom-
itant medications in use were cardiac, endocrine and sys-
temic anti-inflammatory and analgesics in that order.
Conclusion(s): This study suggests that majority of the
Saudi women who are osteoporotic with oral bisphospho-
nate therapy have a concomitant medication burden of ≥5
other medications. To have a full compliance of the therapy
patients' medication burden should be considered before
choosing the route of treatment.
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MODALITIES OF PRESCRIPTION OF THE
SYMPTOMATICS SLOW-ACTING DRUGS FOR
OSTEOARTHRITIS (SYSADOA) IN THE
MANAGEMENT OF HIP AND KNEE
OSTEOARTHRITIS (OA)
Renee-Liliane Dreiser1, Benjamin Avio2
1Bichat Hospital, Rheumatology, 2Pharmacist, Pharmacology,
Paris, France
Objective(s): To describe when, how and why European
rheumatologists use the SYSADOA in the management of
OA of the lower limb.
Material & Methods: Cross-sectional prospective survey.
342 European rheumatologists (EU-RH) participating the
2009 EULAR congress were asked to fulfil a questionnaire
regarding their habits of prescription of the SYSADOA.
Results: The rheumatologists were males 55%. 62% de-
scribed their primary practice setting in hospital or clinic.
The average age was 46 years old.
& The average number of patients seen for hip OA is 16 by
week and 20 for knee OA.
& The data from the survey suggest that SYSADOA are
mainly used a part from acute episode 86% vs. 65%
during flare ups.
& The determinant for prescribing a SYSADOA is mainly
based on the international recommendation (EULAR,
OARSI) the medical literature and the congresses.
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& Drugs prescribed during the flare-ups: analgesics level I
83%, analgesics level II 87%, NSAIDs 96%, SYSA-
DOA 65%, topical corticoids 74% for knee OA, local
corticoids injections 90%, hyaluronic acid 57%.
& Drugs prescribed a part from the flare-ups: analgesics
level I 83%, NSAIDs 66%, SYSADOA 86%, topical
corticoids 72% for knee OA, local corticoids injections
45%, hyaluronic acid 83%.
& Treatments aims of rheumatologists: symptomatic effect
on pain 93%, functional improvement 96%, possible
structural effect 90%, reduction of total dosage of NSAIDs
95%, reduction of duration of NSAIDs treatment 92%.
& More than 90% of the EU-RHs expect a benefit on pain,
functional disability, possible structural effect and a
reduction of NSAIDs intake.
& Criteria for prescribing a SYSADOA: EULAR recom-
mendations 90%, OARSI recommendations 54%, med-
ical literature 93%, internet 81%, congresses 94%, sales
representatives 86%, advertising 59%.
& The criteria of choice are guided by the good tolerance
of the product (99%), the ease of administration for 82%
of rheumatologists, as well as by the status of medical
prescription for 91%.
Conclusion(s): The result of the survey shows that EU-RHs
mainly use SYSADOAs during chronic episodes of OA.
The expected effects are mainly the symptomatic and func-
tional improvements.
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SELF-REPORTED PREVALENCE AND
CORRELATES OF OSTEOPOROSIS IN WOMEN
AGED MORE THAN 50 YEARS: RESULTS FROM A
REPRESENTATIVE STUDY
Sonia Hammami1, Sondes Baccar2, Saoussen Zrour3,
Naceur Bergaoui3, Said Hajem2
1CHU Monastir, University of Monastir, Internal Medicine,
Monastir, 2National Institute of Public Health, National Insti-
tute of Public Health, Tunis, 3CHU Monastir, University of
Monastir, Rheumatology, Monastir, Tunisia
Objective(s): The aim of the present study was to determine
self-reported prevalence of osteoporosis and its correlates in
a representative community-based cohort of women aged
more than 50 years in Tunisia.
Material & Methods: The present study is a cross-sectional
community-based study carried out thought home question-
naire. This study was supported by grants from Sanofi
Aventis and the National Institute of Public Health. The
study population consisted of 997 women aged 50 years
and older. No response subjects (n=220). The diagnosis of
osteoporosis was established by home interviews regarding
self-reported osteoporosis, health-related information.
Results: Osteoporosis self-reported prevalence rate was 11.3%.
The prevalence of osteoporosis was higher for the women aged
more than 70 years (6.2% vs. 13.7%, p<0.01). Osteoporosis
was fond to significantly more prevalent among women using
steroids more than three months (OR=3.7; IC95% : 1.6-8.4).
Hormone post menopauses replacement therapy, high educa-
tional level and obesity seems to protect against osteoporosis
(OR, 0.40; 95% CI, 0.18-0.89), (OR, 0.64; 95% CI, 0.45-0.92),
(OR, 0.65; 95% CI, 0.36-0.98), respectively. Osteoporosis was
associated but not significantly with the presence of past frac-
ture history and early menopause (before 45 year). Only 45.5%
of women with osteoporosis receive treatment: calcium and
vitamin D (n=28), bisphosphonate (n=12).
Conclusion(s): Despite limitation of this study (we did not
perform bone densitometry, and therefore the prevalence
may been underestimated). The findings of the present study
on a representative sample of the women aged more than 50
years, showed that also when based on self-reported meas-
ures, osteoporosis is a significant public health problem.
Policymakers should be aware of this finding and allocate
resources accordingly.
References: Werner P, Archiv Gerontology Geriatrics
2003;37:277. Lígia Araujo Martini et al Rev Saúde Pública
2009;43(Supl. 2).
Disclosures: This study was supported by Sanofi Aventis,
the National Institute of Public health and The Association
of protection of elderly in Monastir.
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ALTERATIONS OF BONE MINERALIZATION
CHARACTERISTICS INDUCED BY
OSTEOARTHRITIS OVER TIME:
LONGITUDINAL STUDY
Joo Hyung Lee1, Paul Han2, Sung Jae Lee3, Han Sung
Kim2, Dohyung Lim1
1Sejong University, Department of Mechanical Engineering,
Seoul, 2Yonsei University, Department of Biomedical Engi-
neering, Wonju, Ganwon, 3Yonsei University, Department
of Biomedical Engineering, Kimhae, Gyungnam, Republic
of Korea
Objective(s): Bone mineralization on a microscopic scale is
major determinants of mechanical quality of trabecular bone.
However, longitudinal study to quantify alterations of bone
mineralization characteristics is sparse, particularly in osteo-
arthritis (OA) over time. The current study is, therefore, aimed
to quantify alteration patterns of bone mineralization charac-
teristics induced by OA over time, using in vivo μCT.
Material & Methods: Fourteen 8 week-old female Sprague
Dawley rats were randomly divided into control (n=7) and
OA (n=7) groups. Mice in the OA group were administered
monoiodoacetate into the knee joint cavity. The knee joint was
scanned by in vivo μCT at 0, 4, and 8 weeks after
S192 Osteoporos Int (2012) 23: (Suppl 2):S85–S386
administration and the trabecular bone was analyzed to
quantify alteration patterns of bone mineralization char-
acteristics. The linear attenuation coefficient was measured
and converted to bone mineralization. Bone mineralization
was then divided into four areas (0-0.3 g/cm3, 0.3-0.7 g/cm3,
0.7-1.0 g/cm3, >1.0 g/cm3) to quantify bone mineralization
alterations based on method suggested by Sato et al. (2000).
Immunohistological tests were performed additionally to
verify if OA was well corresponded to clinical condi-
tions. All procedures for specimen preparation were ap-
proved by Yonsei University School of Animal Care and
Ethics Committee.
Results: In terms of bone mineralization, no significant
difference was observed at 0 or 4 weeks (P>0.05), but
approximately 13-15% differences were occurred at 8 weeks
(P<0.05) between control and OA groups. In terms of
periodic changes of bone mineralization, both of control
and OA groups were hypermineralized at 4 weeks (P<
0.05), compared with a degree of bone mineralization at 0
weeks. At 8 weeks, control group was not significantly
changed (P>0.05) compared with a degree of bone miner-
alization at 4 weeks, but OA group was hypomineralized
(P<0.05). Local bone erosion, osteophytes, cartilage dam-
age, synovitis, and pannus formation were evident in histo-
logical images at 8 weeks after administration.
Conclusion(s): These findings indicate that longitudinal
track may be important for identifying alterations in bone
microarchitectural characteristics. The results also indicate
that longitudinal track may be important when contemplat-
ing the use of antiresorptive and anti-inflammatory agents
for the treatment of OA.
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RELATIONSHIP BETWEEN BODY COMPOSITION
AND PRIMARY OSTEOPOROSIS IN ELDERLY
EGYPTIANS
Ahmed K Mortagy, Sarah A Hamza, Salma M Elsaid,
Mahmoud Z Abdelwadoud
Ain Shams Faculty of Medicine, Geriatric Medicine, Cairo,
Egypt
Objective(s): To detect the relationship between body com-
position and primary osteoporosis in elderly Egyptians.
Material & Methods: A case-control study included 50
elderly females with primary osteoporosis compared with
50 controls. Each female was subjected to clinical assess-
ment, measuring of BMI and BMD by DXA using GE
Lunar DPX machine. Body composition was assessed using
the bioelectrical impedance analysis.
Results: Ther were significant difference between cases and
controls as regard BMI, total fat mass (TFM), fat percentage
(FP) and lean percentage(LP). No significant difference
were found as regard to total lean mass (TLM) or basal
metabolic rate (BMR). There was a significant correlation
between BMI and BMD; BMD was significantly higher
among subjects with BMI≥3.0
Conclusion(s): Significant difference between the cases and
controls as regard to weight and BMI, being higher in the
control group. TFM and FP were significantly lower in
patients with primary osteoporosis.
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EFFECTS OF IBANDRONATE FOR THE
MANAGEMENT OF
POSTMENOPAUSAL OSTEOPOROSIS
Branka M Arsenovic1, Miljanka M Vuksanovic2, Teodora
Beljic-Zivkovic3, Maja M Lazarevic4, Srdjan M Arsenovic5,
Snezana Djurica6
1Division of Endocrinology, Diabetes and Metabolism,
Zvezdara University Medical Center, Department of Osteopo-
rosis, 2Division of Endocrinology, Diabetes and Metabolism,
Zvezdara University Medical Center, Department of Osteopo-
rosis, Belgrade, Serbia, 3Division of Endocrinology, Diabetes
and Metabolism, Zvezdara University Medical Center, Depart-
ment of Osteoporosis, Belgrade, Serbia, 4 St Charles Hospital,
Department of Psychiatry, London, UK, 5University Hospital
“Dr Dragisa Misovic“, Department of Radiology, 6Faculty of
Medicine at the Belgrade University, School of Medicine,
Department of Endocrinology, Belgrade, Serbia
Objective(s): Osteoporosis is a metabolic bone disease
caused by reduction of the BMD that increases fracture risk.
The primary goals of osteoporosis therapy include prevention
of fractures and improvement of quality of life. Bisphospho-
nates are recommended as first line of therapy. The efficacy of
oral preparations may be limited, due to low bioavailability,
adverse effects and low compliance of patients. Hence, the
parenteral administration of bisphosphonates is a valuable
alternative. The aim of this study was to assess the effect of
ibandronate applied intravenously and orally.
Material & Methods: We examine 58 women who re-
ceived ibandronate tablets monthly and 32 women who
received ibandronate i.v. every 3 months, with calcium and
vitamin D supplementation. In all subjects DXA (Hologic
Explorer) was performed for diagnosis of osteoporosis at
start after one year of treatment.
Results: In women who received monthly ibandronate,
BMD at lumbar spine before treatment was 0.7±0.02 g/cm2,
T-score -3.21±0.14 SD. Hip BMD was 0.6±0.02 g/cm2,
T-score -2.61±0.18 SD. After a one year of treatment a
significance increase DXA parameters (BMD, T-score) at
the L1-L4 BMD 0.75±0.02 g/cm2 (r=0.997, p<0.001),
T-score -2.85±0.15 SD (r=0999, p<0.001) and hip BMD
0.62±0.02 g/cm2 (r=0.999 p <0.001), T-score -2.41±0.18
SD (r=0.998,p<0.001) were noticed. In women who received
i.v. ibandronate before treatment DXA parameter on lumbar
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spine was BMD 0.69±0.02 g/cm2, T-score -3.24±0.2 SD, while
hip BMD was 0.62±0.03 g/cm2, T-score -2.74±0.22 SD. After
one year of treatment a significance increase in DXA parameters
at the L1-L4: BMD was 0.73±0.02 g/cm2 (r=0.999, p<0.001),
T-score -3.02±0.23 SD (r=0.999, p<0.001). Hip BMD 0.64±
0.02 g/cm2, (r=0.999 p<0.001), T-score -2.35±0.19 SD
(r=0.999, p<0.001).
Conclusion(s): Both oral and parenteral application of
ibandronate are equally effective in treatment of osteoporosis.
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CHARACTERISTICS AND TREATMENT
INITIATION AMONG WOMEN DIAGNOSED WITH
OSTEOPOROSIS IN A UNITED STATES MANAGED
CARE POPULATION
Ankita Modi1, Tao Fan1, Shiva Sajjan1, Srinivasan
Rajagopalan2, Shuvayu Sen1
1Merck & Company, Global Health Outcomes, Whitehouse
Station, 2MedData Analytics, Data Analysis, Milltown, NJ, US
Objective(s): To describe characteristics and treatment ini-
tiation among women diagnosed with osteoporosis in a
managed care population.
Material & Methods: A retrospective cohort study using the
U.S. commercial managed care claims database records from
January 1, 2001 - December 31, 2010 (study period) was
conducted. Inclusion criteria were women, 50 years or older,
with a diagnosis of osteoporosis based on ICD-9 CM codes
during the study period and enrolled for at least one year
before and after the index diagnosis date. Index date was
defined as the first date of osteoporosis diagnosis in the study
period. Women who had a claim for Paget's disease, or a
prescription for an osteoporosis medication 12 months prior
to index date were excluded in the analysis. Osteoporosis
medications were identified based on NDC codes and includ-
ed alendronate, etidronate, ibandronate, risedronate, estro-
gens, calcitonin, raloxifene, zoledronic acid, and teriparatide.
Number and percent of individuals receiving pharmacological
treatment were determined in this population.
Results: Among 123,074 patients meeting study criteria with
a mean age of 62 years (sd: 9.75) and a Charlson comorbidity
score of 0.57 (sd: 0.98), a majority, 67% of the patients did not
receive any pharmacological treatments within the 1 year of
their diagnosis. 26% of subjects initiated treatment with
bisphosphonates and 6.5% initiated a form of treatment other
than bisphosphonates. Approximately 5.7% of the patients
had a history of fractures and about 29.8% women had a
history if gastrointestinal problems during the baseline.
Conclusion(s): This analysis showed that a significantly
large proportion of women with osteoporosis did not receive
any pharmacological treatment after being diagnosed with
osteoporosis which warrants a need for further understand-
ing of the reasons for non-treatment despite diagnosis.
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CHARACTERISTICS AND TREATMENT
INITIATION AMONG WOMEN DIAGNOSED
WITH OSTEOPOROSIS IN FRANCE
Ankita Modi1, Tao Fan1, Shiva Sajjan1, SrinivasanRajagopalan2,
Shuvayu Sen1
1Merck & Company, Global Health Outcomes, Whitehouse
Station, 2Meddata Analytics, Data Analysis, Milltown, NJ, US
Objective(s): To describe characteristics and treatment initi-
ation among women diagnosed with osteoporosis in France.
Material &Methods: A retrospective cohort study using
the Mediplus electronic medical records database in France
from January 1, 2001 - December 31, 2010 (study period) was
conducted. The study included women, 50 years or older, with
a diagnosis of osteoporosis based on ICD-9 CM codes during
the study period and were enrolled for at least one year before
and after the index date. Index date was defined as the first
date of osteoporosis diagnosis during study period. Women
who had a claim for Paget's disease, or a prescription for an
osteoporosis medication 12 months prior to index date were
excluded from the analysis. Osteoporosis medications were
identified based on NDC codes. Number and percent of
individuals receiving pharmacological treatment were deter-
mined in this population.
Results: Among 15,264 women meeting study criteria
with a mean age of 68 years (SD: 9.91) and a mean
Charlson comorbidity score of 0.24 (SD: 0.50), almost
half, 46.2% the women did not initiate any pharmaco-
logical treatments for osteoporosis within 1 year of their
diagnosis. 36% of women initiated treatment with
bisphosphonates and 17.9% initiated a form of treatment
other than bisphosphonates. Approximately 8.6% of the
sample had a history of fracture and about 2201
(14.42%) women had a diagnosis for gastroinstestinal
problem during the baseline
Conclusion(s): This analysis showed that nearly half of the
women with osteoporosis did not initiate any pharmacolog-
ical therapy for osteoporosis after being diagnosed with
osteoporosis which warrants a need for further understand-
ing of the reasons for nontreatment despite osteoporosis
diagnosis.
P327
ASSOCIATION OF GASTROINTESTINAL
PROBLEMS AND INITIATION OF OSTEOPOROSIS
TREATMENT: ANALYSIS OF ADMINISTRATIVE
CLAIMS OF A US MANAGED CARE POPULATION
Ankita Modi1, Tao Fan1, Shiva Sajjan1, SrinivasanRajagopalan2,
Shuvayu Sen1
1Merck & Company, Global Health Outcomes, Whitehouse
Station, 2Meddata Analytics, Data Analysis, Milltown, NJ,
US
S194 Osteoporos Int (2012) 23: (Suppl 2):S85–S386
Objective(s): To examine the association of gastrointestinal
(GI) problems with osteoporosis treatment initiation patterns
among women after having a diagnosis of osteoporosis.
Material & Methods: A retrospective cohort study using a
US managed care database from January 1, 2001 - Decem-
ber 31, 2010 was conducted. The index date was defined as
the date of first diagnosis of osteoporosis between January
1, 2002 -December 31, 2009 (study period). Study included
women, 50 years or older, with a diagnosis of osteoporosis
based on ICD-9 codes and enrolled for at least one year
before (baseline) and one year after the index diagnosis date
(follow-up). Subjects were excluded if they had a diagnosis
of Paget's disease, or a prescription for an osteoporosis
medication at baseline. GI problems were assessed as hav-
ing a GI symptom related ICD-9 diagnosis after osteoporo-
sis diagnosis and before treatment initiation in the follow-
up. The association of a GI problem on osteoporosis treat-
ment initiation was analyzed using multivariate logistic
regression model controlling for age, comorbidities, fracture
history, steroid use and NSAID history at baseline.
Results: 123,074 patients met the criteria with a mean age of
62 years and a Charlson comorbidity score of 0.57. Almost
24% of the patients had a GI problem. Among patients with a
GI problem post diagnosis and before treatment, only 10.5%
of patients subsequently received bisphosphonates, 4.3% re-
ceived non-bisphosphonates and a majority, 85.1% did not
receive any pharmacological osteoporosis treatment. Among
patients with GI problems at baseline, those who continued to
have GI problems in the period after diagnosis were less likely
to be initiated with a bisphosphonate vs. being on no treatment
(OR: 0.22, CI: 0.21-0.24) and were more likely to be initiated
with a non-bisphosphonate as compared to a bisphosphonate
(OR: 1.6, CI: 1.45-1.76). Similar association was seen among
subjects with no GI history at baseline and those who devel-
oped GI problems post diagnosis.
Conclusion(s): Almost 24% women experienced GI prob-
lems. Occurrence of a GI problem after osteoporosis diag-
nosis may be associated with the likelihood of not being
treated and increased likelihood of being treated with a non-
bisphosphonate as compared to bisphosphonates.
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RATE OF OSTEOPOROTIC FRACTURE OVER
TIME AMONG WOMEN WITH AT LEAST ONE
YEAR OF ADHERENCE TO OSTEOPOROSIS
THERAPY
Ankita Modi1, Jackson Tang2, Shuvayu Sen1
1Merck & Company, Global Health Outcomes, Whitehouse
Station, 2AsclepiusJT LLC, Data Analysis, New York, NY,
US
Objective(s): To examine the incidence of osteoporosis-
related fracture over 2 years of treatment among patients
who were adherent to osteoporosis therapy for at least 1
year.
Material & Methods: A retrospective observational study
using a USmanaged care database was conducted.Women 50
years or older who initiated treatment with oral bisphosph-
onates from 2001-2010 and were enrolled in the database
for 3 consecutive years, including a baseline year before
the index prescription, an adherence year (year 1), and a
follow-up year (year 2). Patients were excluded if they
had Paget's disease or a diagnosis of malignant neoplasm.
Adherence to therapy was defined as medication posses-
sion ratio greater than equal to 60% during year 1 (MPR=
total number of days' supply/365 days). Rate of osteopo-
rotic fracture was computed as number of osteoporotic
fractures per 1000 patient years among women compliant
to osteoporosis treatment for at least one year.
Results: Of 62,446 women who met eligibility criteria,
35,737 (57%) were adherent to osteoporosis therapy during
year 1 (mean [SD] age, 60.7 [8.4] years). During year 2,
24,342 (68%) remained adherent to therapy. Osteoporotic
fractures were recorded during the baseline year (before
initiating therapy) for 1507 (4.2%) patients; during year 1
(adherence year) for 1397 (3.9%) patients; and during year 2
for 1173 (3.3%) patients. In year 2, the fracture rate was 52/
1000 patient-years. Fracture rates even after 2 years of
compliance, i.e., compliance and study period were 3.2%
(51/1000 person years) during study period. Hip and other
nonvertebral fractures were most common, representing
over two thirds of all fractures in each year. Patients with a
history of fracture in the baseline period experienced a
higher rate of fracture in the study period (18%) as com-
pared to those without a history of fracture within the same
period (2.2%).
Conclusion(s): Rate of osteoporotic fracture during a
second year of follow-up was 3.3% despite having been
previously compliant to treatment for one year. Results
indicate an unmet need related to level of osteoporosis
control and an opportunity for newer therapies to help
address this need.
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INFLUENCE OF HIGH-IMPACT EXERCISE ON
BONE IN OSTEOPENIC OVARIECTOMIZED RATS
Rodrigo Okubo1, Ariane Zamarioli1, Vitor A Castania1,
Francisco J Paula2, Mario J Louzada3, Antonio C Shimano1
1University of Sao Paulo, Department of Biomechanics,
Medicine and Rehabilitation, 2University of Sao Paulo, De-
partment of Internal Medicine, 3Sao Paulo State University,
Department of Animal Support, Production and Health,
Ribeirao Preto, Sao Paulo, Brazil
Objective(s): We investigated the effects of jump training
on osteopenic bones post-ovariectomy.
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Material & Methods: This research was characterized as a
single-blind study. Forty 10-wk-old Wistar rats were divided
into the following four groups (n=10): sham sedentary (S-
S), ovariectomized sedentary (OVX-S), sham exercised (S-
E), and ovariectomized exercised (OVX-E). A 12-wk exer-
cise period was introduced in which the rats from the exer-
cised groups (S-E and OVX-E) jumped 20 times/day, 5
days/wk, with height of 40 cm. This was followed by 2-
mo after surgery. At the end of the exercise period, bone
formation marker (serum osteocalcin), FSH dosage, DXA,
bone histomorphometry and biomechanical tests were sta-
tistically analyzed (p-value<0.05).
Results: OVX groups showed higher values of FSH (p<
0.001) and body mass (p<0.05). The jump training signifi-
cantly increased the BMD of tibia, femur and L5 vertebra
(p<0.05). Ultimate load (p<0.05) of tibia, femur and L5
vertebra in the exercised groups were greater than in the
sedentary groups. Osteocalcin dosage also showed higher values
in the trained groups. (p<0.001). BV/TV, Tb.Th, Tb.N, OV.BV,
OS.BS, Ob.S/BS, O.Th, N.Ob/B.Pm parameters (p<0.05) also
showed higher values in the trained groups. Furthermore, Tb.Sp,
N.Oc/B.Pm, ES/BS, Oc.S/BS parameters were lower in these
exercised groups.
Conclusion(s): These findings suggest that jump exercise
increased bone strength. It also increased bone formation
and decreased bone resorption, which were detected by both
morphological and biochemical analyses, even under ovar-
ian hormonal deficiency.
Disclosures: Support: Foundation for Research Support of
the State of São Paulo (FAPESP), Brazil
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LIMITATIONS OF AREA UNDER THE ROC CURVE
Anders Odén, Helena Johansson, Eugene McCloskey, John
A Kanis
University of Sheffield, WHO Collaborating Centre for
Metabolic Bone Diseases, Sheffield, UK
Objective(s): Comparison of disease discriminants or event
predictors is an important aspect of assessing clinical utility.
The area under the receiver-operating-characteristic curve
(AUC) is the probability that the prediction variable for a
randomly chosen case will be a higher value than for a
randomly chosen individual without the disease. AUC is
often used to characterise the goodness of a predictor, but
has a number of limitations that should be acknowledged.
The aim of this study was to describe examples of these
limitations.
Material & Methods: In the simplest case, when the de-
pendent 0-1-variable is obtained instantly (without a follow-
up period) a predictor could for example be better at finding
the 10% with the highest (or lowest) risk of having the value
1 compared to a predictor with a higher AUC. Thus the
quantity AUC does not comprise a complete description of
the goodness.
Results: In the scenario when each individual has a follow-
up period, death may affect the AUC so a good predictor
gets a low AUC. By use of simulations we have constructed
an example where the predictor has an AUC of 0.70 if death
is not taken into consideration. When death is considered the
AUC is 0.50, which would falsely indicate that the predictor
is useless. Likewise, the AUC may be misleading in the
extreme situation with AUC=0.50 that could be the case
more generally when death is a competing event. The gra-
dient of risk per 1 SD of a variable is another measure of the
goodness of a predictor. The gradient is the hazard ratio
when comparing individuals, who differ 1 SD with respect
to the predictor. If the gradient of risk is constant over the
follow-up period, then the AUC will not be constant over
time but will increase with the follow-up period. For exam-
ple, the AUC could increase from 0.70 to 0.85 when the
follow-up period increases from 5 to 45 years.
Conclusion(s): The limitations of AUC should be consid-
ered and held in mind when used and interpreted. Often
more quantities have to be calculated to give a more com-
plete picture and sometimes AUC should be avoided.
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SERUM 25-HYDROXYVITAMIN D
CONCENTRATION AND BONE MINERAL
DENSITY IN LATE REPRODUCTIVE AGE WOMEN
Tatiana Karonova1,2, Elena Micheeva1, Marina Budanova2,
Elena Tsvetkova2, Idelya Mamina1, Olga Galkina1, Elena
Grineva2
1State Medical University n.a. I.I.Pavlov, Faculty Therapy,
2Almazov Federal Heart, Blood and Endocrinology Centre,
Institute of Endocrinology, St. Petersburg, Russian Federation
Objective(s): It is well known that vitamin D deficiency
is a risk factor for osteoporosis and fracture development,
however there are conflicting data about associations
between serum 25-hydroxyvitamin D level and BMD.
The objective of this study is to further investigate this
potential association.
Material & Methods: The effect of serum vitamin D level
on BMD was assessed in 270 healthy women of late repro-
ductive age (37-50 years, mean 46.1±4.5). Serum 25(OH)D
and PTH levels were determine by ELISA for all partici-
pants. DXA was performed to determine BMD and body
composition.
Results: Our results showed that vitamin D level was be-
tween 19.4-134.0 nMol/L in total study population. Vitamin
D insufficiency (lower than 75 nMol/L) and deficiency
(lower than 50 nMol/L) were found in 86.8% of women
regardless of the season when the examination were per-
formed. Vitamin D level was negatively associated with fat
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mass quantity (r=-0.35, p=0.06). The DXA results showed
that every 5th woman had a decreased BMD.
Study population based on DXA results
Parameters Normal BMD
(n=132)
Decreased BMD
(n=34)
p
Age, years 46.1±0.5 45.7±0.7
Weight, kg 79.7±1.7 74.3±2.1 <0.05
BMI, kg/m2 29.5±0.5 26.5±0.5 <0.05
25(OH)D, nMol/L 52.3±2.5 48.8±4.7
PTH, pg/mL 43.8±2.6 46.3±7.6
BMC L1-L4, g/cm2 1.285±0.012 1.176±0.008 <0.05
BMC Neck, g/cm2 1.054±0.009 0.896±0.007 <0.05
BMC Total, g/cm2 1.136±0.009 0.936±0.014 <0.05
BMD was higher in overweight and obese women than in
women with normal BMI (r=0.25, p=0.001). Correlation
analysis revealed a significant direct relationship between
serum vitamin D level and BMD (r=0.48, p=0.04) as well
as between serum PTH level and BMD (r=-0.52, p=0.01) but
only in women up to 40 years old, while in study subjects over
40 years old, this relationship could not be seen.
Conclusion(s): In conclusion our results showed that vitamin
D insufficiency is highly prevalent in healthy women popula-
tion and could be a potential risk factor for decreased BMD
but only in young women. Additional studies are required for
further assessment of vitamin D role in bone remodeling.
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THE RISK OF A SUBSEQUENT FRACTURE:
THE EFFECT OF TIME SINCE AN INITIAL
FRACTURE - THE TROMSØ STUDY
Luai A Ahmed1, Tineke ACM Laurs-van Geel2, Lone
Jørgensen1, Åshild Bjørnerem3, Jacqueline R Center4, Nina
Emaus1
1University of Tromsø, Department of Health and Care
Sciences, Faculty of Health Sciences, Tomsø, Norway,
2Maastricht University/Calphri, Department of General Prac-
tice, Maastricht, Netherlands, 3University of Tromsø, Depart-
ment of Clinical Medicine, Faculty of Health Sciences,
Tromsø, Norway, 4Garvan Institute of Medical Research,
Bone and Mineral Research Program, Sydney, Australia
Objective(s): To examine the risk of subsequent non-vertebral
fracture at specific time intervals after different types of initial
fracture.
Material & Methods: This study included data from the
Tromsø Study in Norway. During 15 years follow-up from
1994-2009, all fractures were ascertained by computerized
search in the radiological archives. The analyses included
2690 women and 1631 men (aged 25+ years) with at least
one fracture during follow-up. Initial fractures were classi-
fied into hip, major (proximal humerus, pelvis, distal femur
and proximal tibia), and minor (all other types except skull
and vertebrae). Rate ratios (RR) with 95% CIs of subsequent
fractures were calculated for intervals of 0-1, 1-2, 2-5, 5-10,
and >10 years after an initial fracture.
Results: In total, 612 women and 230 men suffered subse-
quent fractures. Within 5 years after initial fracture, 76% of
the subsequent fractures occurred after hip, 76% after major,
and 65% after minor fracture in women. In men, this was
88% after hip, 73% after major, and 67% after minor frac-
ture. In women, the RRs of subsequent fracture over the
entire follow-up period were 5.1 (4.3-6.0) after hip, 3.8 (3.2-
4.5) after major, and 2.4 (2.1-2.6) after minor fracture. In
men, RRs were 5.4 (3.9-7.3), 4.1 (2.8-5.7), and 1.9 (1.6-
2.2), respectively. In women, the RR at different time inter-
vals [Table] was highest at short term after hip and major
fractures and remained significantly higher until 10 years
after initial fracture. In men, the RR remained significantly
higher until 5 years after hip fracture and 10 years after
major fracture. In both sexes, the RRs after minor fracture
remained significantly increased throughout follow-up, par-
ticularly in women.
Rate ratios of subsequent fracture compared with initial fracture at
different time intervals after specific initial fracture locations in women
and men. The Tromsø Study.
Years after initial
fracture
Initial hip
fracture
Initial major
fracture
Initial minor
fracture
Women
0-1 6.0 (4.3-8.1) 4.8 (3.3-6.8) 2.3 (1.8-2.9)
1-2 5.0 (3.3-7.3) 4.3 (2.8-6.4) 2.5 (1.9-3.1)
2-5 4.6 (3.3-6.2) 3.5 (2.5-4.8) 2.4 (2.0-2.9)
5-10 5.4 (3.7-7.5) 3.4 (2.2-5.0) 2.3 (1.9-2.8)
>10 3.0 (0.6-8.7) 1.6 (0.3-4.7) 2.1 (1.4-3.1)
Men
0-1 7.7 (4.3-12.5) 6.2 (3.0-11.4) 2.7 (1.9-3.8)
1-2 8.2 (4.2-14.3) 5.5 (2.2-11.3) 1.9 (1.2-2.8)
2-5 3.7 (1.7-7.0) 2.5 (1.0-5.3) 1.9 (1.5-2.5)
5-10 2.6 (0.7-6.8) 3.8 (1.6-7.5) 1.4 (1.0-2.0)
>10 3.8 (0.1-21.1) 2.6 (0.1-14.7) 1.8 (1.1-3.0)
Conclusion(s): Subsequent fracture risk varies on time and
is highest immediately after the initial fracture. The influ-
ence of time should be taken into account in the prediction
of future fracture risk.
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RENAL EFFECTS OF TREATMENT WITH
ZOLEDRONIC ACID: RESULTS FROM THE
HORIZON-PFT EXTENSION STUDY
Paul D Miller1, Dennis M Black2, Josef Hruska3, Steven
Boonen4
1University of Colorado Health Sciences Center, Colorado
Center for Bone Research, Lakewood, CO, 2University of
Osteoporos Int (2012) 23: (Suppl 2):S85–S386 S197
California, San Francisco, Department of Epidemiology and
Biostatistics, San Francisco, CA, US, 3Novartis Pharma AG,
(Global) Medical Affairs, Basel, Switzerland, 4Leuven Uni-
versity, Department of Experimental Medicine, Leuven,
Belgium
Objective(s): To assess the impact on renal safety in the
HORIZON-PFT study of long-term treatment of post-
menopausal osteoporosis with once-yearly zoledronic
acid.
Material & Methods: In the core HORIZON-Pivotal
Fracture Trial (PFT), 7736 women with postmenopausal
osteoporosis were randomized to receive zoledronic acid
5 mg (ZOL) once yearly (IV administration over 15
minutes) or placebo for 3 years (Z3 and P3, respective-
ly). In the 3-year extension, 1233 postmenopausal wom-
en who received a once-yearly infusion of zoledronic
acid for 3 years in the core study were randomized to 3
additional years of ZOL (Z6, n=616) or placebo (Z3P3,
n=617). The results pertaining to the efficacy endpoints
in the extension have been published elsewhere1 this
presentation will focus on the results with respect to
renal function.
Results: In the core study, no long-term differences in
renal function were observed between the Z3 and the P3
groups. Mean changes from baseline in serum creatinine
and estimated creatinine clearance were almost identical
in the two treatment groups over the 3 years of the
study2. In the extension, there was a significantly larger
number of patients with increases in serum creatinine
>0.5 mg/dL from baseline in Z6 (n=18) vs. Z3P3 (n=4;
p=0.002). The majority of these increases occurred be-
tween infusion and the 9-to-11-day post-infusion follow-
up visit; all were transient and resolved with no overall
impact on renal function1. The mean changes from
baseline in calculated creatinine clearance were similar
in the Z6 and Z3P3 groups.
Conclusion(s): In the HORIZON-PFT study, treatment with
ZOL had no long-term impact on renal function.
References: 1. Black et al. J Bone Miner Res. 2011;27:243.
2. Boonen et al. Kidney Int. 2008;74:641.
Disclosures: The study is funded by Novartis Pharma AG,
Basel.
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PREVALENCE OF VTIMAMIN D INSUFFICIENCY
IN A POPULATION WITH A HISTORY OF
OSTEOPOROTIC FRACTURE IN PRIMARY CARE,
IN CATALONIA (SPAIN)
Daniel Martinez-Laguna1, Prieto-Alhambra Daniel1,2,3,
Soria-Castro Alberto1, Estrada-Laza Pilar1, Arias-Moliz
Isabel1, Nogues-Solan Xavier3
1Institut Catala De La Salut, Primary Health Care, 2IDIAP
Jordi Gol., Primary Health Care Research Institute, 3Parc De
Salut Mar, Clinical Medicine, Barcelona, Spain
Objective(s): Vitamin D insufficiency is a hidden pandemia
in the 21st century. The Spanish population, even when
exposed to high levels of UV radiation, is not safe from it.
Our aim was to evaluate the prevalence of vitamin D insuf-
ficiency in a cohort of noninstitutionalized patients with a
prevalent osteoporotic fracture in primary care.
Material & Methods:
– Study design: Nested cross-sectional study within a
multicenter cohort, carried out in 12 primary care prac-
tices located in urban areas around the region of Cata-
lonia (the VERFOECAP cohort study).
– Participants: the VERFOECAP study includes a ran-
dom sample of 194 patients with at least one prevalent
osteoporotic fracture. Among these, serum levels of 24-
hydroxy-D was measured in 166 subjects using the
standard methods as used in primary care laboratories.
These were categorized into: optimal (≥30 ng/mL),
insufficient (<30 but ≥20 ng/mL), deficient (<20 but
≥10) and severely deficient (<10).
– Sample size: Accepting an alpha risk of 0.93, in a
bilateral contrast and assuming a prevalence of 70%
(based on previous publications), a random sample of
81 subjects would ensure a precision of 10% in our
estimation. Our N doubles this number.
– Statistics: we used the binomial test to estimate point
prevalence and 95% CI of vitamin D insufficiency.
Results: 64 out of 166 patients (39%) had optimal levels of
vitamin D. Prevalence of vitamin D insufficiency was
61.4% [95%CI 53.6-68.9%]. Among these, 41 (24.7%)
were insufficient, 47 (28.3%) were deficient, and 14
(8.4%) were severely deficient. 51 patients had a history of
two fractures, 13 had had 3 and 4 at least 4 fractures.
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Vitamin D levels were not associated with number of
fractures.
Conclusion(s): Vitamin D insufficiency is highly prevalent
in primary care patients with a history of osteoporotic frac-
ture: more than 60% had suboptimal levels, and almost 30%
were deficient. Preventive strategies should be studied to
identify patients with vitamin D deficiency and supplement
them accordingly in our region.
Disclosures: VERFOECAP Research Group
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CLINICAL AND BIOCHEMICALVARIABLES
DETERMINING BMD IN
PRIMARY HYPERPARATHYROIDISM
Lars Rolighed1, Peter Vestergaard2, Peer Christiansen1,
Lene Heickendorff3, Tanja Sikjaer2, Lars Rejnmark2, Leif
Mosekilde2
1Aarhus University Hospital, Department of Surgery P,
2Department of Endocrinology and Metabolism, 3Depart-
ment of Clinical Biochemistry, Aarhus, Denmark
Objective(s): Primary hyperparathyroidism (PHPT) is a
known cause of secondary osteoporosis. Decreased BMD
is often present at the time of diagnosis especially at the hip
and forearm. The purpose of this retrospective study was to
analyze the association between different clinical and bio-
chemical variables and BMD in a large series of PHPT
patients.
Material & Methods: We identified all 1391 consecutive
patients undergoing parathyroid surgery at Aarhus University
Hospital, Denmark in a 15 year period from 01.01.96–
31.12.2009. We excluded patients operated for hyperparathy-
roidism secondary to renal disease and parathyroid implanta-
tion after thyroid surgery. With the unique Danish personal
identification number we retrieved preoperative biochemical
data including plasma levels of PTH, ionized calcium (Ca2+),
creatinine and 25-hydroxyvitamin D (25OHD), height, weight
and preoperative DXA measurements of the spine, hip and
forearm. A complete set of biochemical data were available on
785 patients.
Results: Median age was 62 years (range 13-91) and 638
(81%) patients were women. PTH (mean±SD) was 17.4±
24.3 pmol/l and 25OHD was 56±30 nmol/l. Women had
slightly lower Ca2+ (1.50±0.09 mmol/l) than men (1.53±
0.12 mmol/l, P<0.001) and also lower plasma creatinine
compared with men (P<0.001). Insufficient plasma
25OHD levels (<50 nmol/l) were found in 365 (46%)
patients.
Associations with BMD were calculated in a multiple re-
gression model. As expected BMD of the spine, hip and
forearm were negatively associated with age (P<0.001).
PTH was inversely associated with BMD of the forearm
(P<0.001), total hip (P=0.001) and spine BMD (P=0.025).
BMD of the spine, hip and forearm were not associated with
25OHD levels (NS), however, 25OHD was negatively as-
sociated with PTH (P<0.001).
Conclusion(s): In PHPT patients, DXA of the forearm is
recommended due to the negative association between PTH
and BMD of the forearm and the higher prevalence of
subnormal values. Plasma levels of 25OHD are inversely
related to PTH. However, levels of 25OHD did not correlate
to BMD of the spine, hip or forearm.
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THE IMPACT OF THE KNEE JOINT
MECHANICAL AXIS ANGLE ON THE FOOT
Halil Koyuncu, Filiz Yildiz Aydin
Physical Medicine and Rehabilitation, Istanbul University
Cerrahpasa Medical Faculty, Istanbul, Turkey
Objective(s): Pedobarography is a method of measurement
used in diagnosis and treatment follow-up of foot dis-
ease. In this study, we aimed to investigate the impact of
the knee joint mechanical axis angle on the foot. For foot
assessment, we made static and dynamic pedobarographic
measurements.
Material & Methods: Fifty patients who referred to phys-
ical medicine and rehabilitation clinic and diagnosed as
osteoarthritis in both knees were included in the study. The
femoral and tibial mechanical axis was drawn in full-length
lower extremity radiographs and the angle between them
was measured. Both total foot peak pressure, maximum
force, contact area and contact time parameters were calcu-
lated from the average with static and dynamic pedobaro-
graphic measurements.
Results: All of our patients were females and the mean age
was 58. The distribution of radiologic staging, 30% stage 2
and stage 3 was 56%. The mean angel was calculated as
177.2 on the right and 117.5 on the left. According to MA
76% in the right knee and 84% in the left knee varus
deformity was detected. A low positive correlation was
found between the right knee mechanical axis angle and
right foot contact area of dynamic assessment (r=0.320,
p<0.02). But this correlation could not be explained with
the available data. A low positive correlation was found
between the age of patients and both left and right foot
contact time of the dynamic pedobarographic parameters
(r=0.342, p<0.015; r=0.300, p>0.03). Moderate positive
correlation was found between patients BMI with the right
and left foot dynamic and right foot static maximum forces
(r=0.639, p<0.001, r=0.600, p<0.001, r=0.598, p<0.001).
Allow negative correlation was found between mechanical
axis angle of right and left knees and stage of osteoarthritis
(r=-0.310, p<0.02, r=-0.344, p<0.01)
Conclusion(s): As a result, age and BMI were found as
effective factors for pedobarographic measurements.
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IS ANXIETYASSOCIATEDWITH FRACTURE RISK
AND ADHERENCE TO TREATMENT? FINDINGS
FROM THE MRC SCOOP TRIAL
Nicholas C Harvey1, Janet Cushnaghan1, Wendy Lawrence1,
Georgia Ntani1, Karen Collins1, Liz Lenaghan2, Lee
Shepstone2, Eugene McCloskey3, John Kanis4, Cyrus
Cooper1
1University of Southampton, MRC Lifecourse Epidemiolo-
gy Unit, Southampton, 2University of East Anglia, Faculty
of Medicine and Health Sciences, Norwich, 3University of
Sheffield, Metabolic Bone Centre, Sheffield, 4University of
Sheffield, WHO Collaborating Centre for Metabolic Bone
Diseases, Sheffield, UK
Objective(s): We examined the relationships between anx-
iety, fracture risk and adherence to treatment in the MRC
Scoop Trial.
Material & Methods: The MRC SCOOP Trial is a multi-
centre, unblinded, pragmatic, RCT of a screening strategy
using the FRAX risk assessment instrument, in a sample of
12,486 women aged 70-86 years, recruited from 7 centres
within England. In those randomised to screening, a 10-year
fracture risk was computed from baseline information fol-
lowed by BMD by DXA in selected participants at higher
risk. This strategy yielded three groups within the screening
arm: low risk without DXA (LR), low risk after DXA
(LRD) and high risk after DXA (HRD). Anxiety [State-trait
Anxiety Inventory (STAI), range 20 (low anxiety) to 80
(high anxiety)] was assessed by postal questionnaire at
baseline (before randomisation) and at 6 and 12 months
post randomisation; adherence was assessed by asking
whether participants had stopped taking osteoporosis med-
ication if they had been prescribed it.
Results: The LR group contained 3170 participants (52.9%
of the treatment group); the LRD and HRD groups
contained 1926 (32.1%) and 898 (15%) participants, respec-
tively. The median anxiety score assessed at all three time
points was lower in those participants categorised as low
risk without DXA than in those categorised as low risk after
DXA or high risk after DXA. [median(IQR) STAI score at
baseline: LR:30(20-40); LRD:33.3(23.3-43.3); HRD:33.3
(23.3-43.3), p<0.001]. Amongst all participants who had
been prescribed osteoporosis medication, STAI score
assessed at baseline was lower in participants who were
adherent rather than non-adherent to osteoporosis medica-
tion at 12 months (baseline median(IQR) STAI=33.3(23.3-
43.3) in adherent vs. 38.3(26.7-43.3) in nonadherent partic-
ipants, p=0.08), with similar findings for STAI assessed at 6
months (p=0.058).
Conclusion(s): Anxiety score at all times was lowest in
lowest fracture risk group. Baseline and 6 month anxiety
score was greater in non-adherent than adherent patients at
12 months follow up. This suggests that greater levels of
anxiety may be associated with higher fracture risk and
poorer adherence to treatment, and that psychological fac-
tors might be profitably addressed in the assessment and
treatment of osteoporosis.
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ASSOCIATION BETWEEN THE MEDITERRANEAN
DIET ADHERENCE AND THE RISK OF HIP
FRACTURE IN ELDERLY PEOPLE
Catherine Feart1,2, Luc Letenneur1,2, Simon Lorrain1,2,
Vanessa Ginder3, Cécilia Samieri1,2, Damien Paineau3, Pascale
Barberger-Gateau1,2
1INSERM, U897, Department of Nutritional Epidemiology,
Bordeaux, 2Université Bordeaux Ségalen, Department of
Nutritional Epidemiology, Bordeaux, 3Danone Research,
Global Nutrition Department, Palaiseau, France
Objective(s): Hip fractures are relatively common in elderly
people and lead to severe consequences, such as persistent
pain and limited mobility. Nutrition may play a role in
preventing hip fractures and the promotion of healthy diets
could contribute to decreasing fracture risk in older persons.
Besides, the so-called Mediterranean Diet (MeDi) has al-
ready been associated with lower risks of death, cardiovas-
cular diseases, cancer and dementia. The objective was to
investigate the association between adherence to a MeDi
and the risk of occurrence of hip fractures in elderly com-
munity dwellers.
Material & Methods: The sample consisted of 1482 par-
ticipants from Bordeaux, France (932 women, 550 men)
aged 67 years and over included in the 3 C study, a pro-
spective cohort study of vascular risk factors of dementia.
The participants had a dietary survey in 2001-2002 and were
followed-up every two years for 8 years. Occurrence of hip
fracture was self-reported at each wave. Adherence to the
MeDi (scored as 0-9) was computed from a food fre-
quency questionnaire and 24-h recall. The MeDi score
was divided into three classes corresponding to low
(score 0-3), moderate (4-5) and high adherence (6-9)
and used as explanatory variable in a Cox regression
model adjusted for age, gender, education, marital status,
BMI, total energy intake, supplementation with calcium
and/or vitamin D, self-reported osteoporosis, osteoporosis
treatment and falling.
Results: After 8 years of follow-up, 57 incident hip frac-
tures were recorded. The MeDi score was not associated
with occurrence of hip fractures (p=0.50), either for mod-
erate (HR=1.34, p=0.41) or high adherence (HR=1.57,
p=0.24) compared to the reference category (low adher-
ence). Among MeDi components, high fruit consumption
was associated with an increased risk of hip fracture
(HR=1.93, p=0.04).
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Conclusion(s): The a priori healthy MeDi score was not
associated with a lower risk of occurrence of hip frac-
tures. Such a pattern highly loaded in fruit and vegetables
and inversely loaded in dairy products cannot be consid-
ered as a universal healthy dietary pattern when analyzing
the association between food intake and various health
statuses.
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QUANTITATIVE MORPHOMETRY ON SPINAL
X-RAYS: LONG-TERM PRECISION OF A NEW
WORKFLOW TOOL FOR MEASURING
VERTEBRAL BODY HEIGHT IN NONFRACTURED
VERTEBRAE
Klaus Engelke1, Bernd Stampa1, Peter Steiger2, Thomas
Fuerst3, Harry K Genant4
1Synarc, Hamburg, Germany, 2Medical Ltd, Optasia, Chea-
dle, UK, 3Synarc, Newark, CA, 4University of California,
Department of Radiology, San Francisco, CA, US
Objective(s): Vertebral body height assessed by 6-point
quantitative morphometry (QM) provides useful informa-
tion for the diagnosis of vertebral fractures. Here we evalu-
ated the long-term longitudinal precision of a new QM tool
(SpineAnalyzer, Optasia Medical Ltd, Cheadle, UK) in a
research setting for the measurement of vertebral body
height in nonfractured vertebrae.
Material & Methods: Lateral lumbar and thoracic x-rays
from 48 osteoporotic postmenopausal women (73.8±5.2 y,
femoral neck T-score=-2.7±0.6) without prevalent or inci-
dent fractures were retrospectively evaluated at two visits 3
years apart. T4-L4 levels were analyzed. First the de-
fault automatic placement provided by SpineAnalyzer
(SA) was compared with a standard manual 6-point
placement used as a reference standard. Then, if neces-
sary, automatic placements were corrected by an expe-
rienced QM reader. Standard QM was done by different
operators whereas the SA analysis was done by the
same operator. Anterior (HA), mid (HM) and posterior
(HP) heights were calculated from the 6 points using
standard algorithms. The root mean square coefficient of
variation (rmsCV) between the two visits was calculated
independently for the automatic SA, corrected SA and
the standard QM analysis for each of the 3 heights and
for each vertebral level.
Results: Long-term mean rmsCV±SD values (averaged over
all vertebral levels) for standard QM were 4.4±0.8% (HA),
4.0±0.7% (HM) and 4.7±0.7% (HP) compared to 4.7±1.5%
(HA), 4.1±1.3% (HM) and 4.0±1.0% (HP) for automatic SA.
Manual SA corrections affected predominantly T4, L1 and
L4. The corrections reduced rmsCV to 3.9±0.9% (HA), 3.4±
0.7% (HM) and 3.5±1.0% (HP). rmsCV was significantly
(paired T-tests) lower in automatic and corrected SA compared
to standard QM for all three heights of T10 and T8, and in
addition for HP of T9, T11 and T12 and for HM of T11.
Conclusion(s): Overall the longitudinal precision of SA
analysis over a period of 3 years was slightly superior to
QM in some but not in all thoracic vertebrae in particular for
the posterior heights. Precision was comparable in the lum-
bar vertebrae. The results show that SpineAnalyzer works
well in nonfractured vertebrae. However, the performance of
the tool on fractured vertebrae has not been tested here.
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ART THERAPY AS A PART OF GLOBAL CARE OF
OSTEOPOROSIS PATIENTS IN ZLÍN, THE CZECH
REPUBLIC
Marie Lhotová1, Pavel Novosad2, Jarmila Pribylová2, Pavla
Novosadová2, Hana Atcheson2
1Private Practice in Clinical Psychology, Osteology Academy,
Prague, 2Osteology academy Zlin, Osteology Academy Zlin,
Zlin, Czech Republic
Objective(s): The aim of the research study is to prove the
effectiveness of art-therapy in the treatment of the osteopo-
rosis patients, particularly with respect to compliance and
adherence.
Material & Methods: In our preparatory research study we
asked whether art therapy has the potential which should be
helpful for osteoporosis patients in terms of compliance and
adherence.
24 women (average age 68 years) who attended the art ther-
apeutic group from 2006-2011 were compared with a group of
osteoporosis women patients who were never provided psy-
chological care. Indicators of adherence, exercise, as well as
smoking, alcohol abuse and nutritional quality were followed.
As a possible indicator of bone density changes we use the
degree of depression and neuroticism. We assumed that
patients with osteoporosis who do not work in art therapeutic
group would experience more negative emotions than the
group of women who did participate in art therapy.
Results: The research found significant correlation between
art therapy and better interaction and cooperation of patients
in treatment with osteoporosis with medical staff.
Conclusion(s): The interest in art therapeutic methods
reflects the modern human need of more natural complex
therapies and harmonization, where the reason, sense, under-
standing and feeling, body and soul, male and female quality,
ability of introspection and activities have the same role. In
addition to active factors described in verbal psychotherapy,
the use of art in art therapy brings a number of specific issues.
– Artistic creation requires some physical activity and
develops sensomotoric integrity.
– Creative expression allows changes of style while re-
ducing the feeling of helplessness.
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– Art therapeutic work in most cases induces positive
emotions, helps to overcome apathy and forms more
active life approach.
– Art therapy is based on a mobilization of human crea-
tive potential and corresponds with the basic need of
self-actualization.
– Art therapy helps to verbalize difficulties on the basis of
artistic expression and so it is easier to get aware and to
better deal with them in an internal dialogue just as in a
cooperation with physicians.
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EFFICACY AND SAFETY OF COLLAGEN
INJECTION GUNA MDS IN OSTEOARTHROSIS
TREATMENT OF KNEE
Valentina S Reshkova1, Rasho K Rashkov2, Rodina L
Nestorova3
1UMBAL "St. Ivan Rilski", Clinic of Rheumatology,
2UMBAL "St. Ivan Rilski", Clinic of Rheumatology, 3Medical
Center "St. Irina", Rheumatology, Sofia, Bulgaria
Objective(s): Collagen injection GUNA MDs will replace,
strengthen and protect cartilage, tendons, ligaments, joint
capsule and all anatomical structures containing collagen
fibers. This leads to the relieving of localized pain or pain
in movement. To evaluate change in degree of pain at rest
and movement in Gonarthrosis before and after treatment
with GUNA MD-KNEE+GUNA MD-MUSCLE
To evaluate change in Lequesne Index before and after
treatment To evaluate efficacy of the GUNA MDs in
Gonarthrosis by patient and by physician.
Material & Methods: 36 patients were monitored:
– Male – 13
– Women – 23
– Age 55-70 years
– Case history, rheumatologic examination and proving of
gonarthrosis, X-ray stage 2 or 3, without swelling
– exclusion of inflammatory joint, systemic diseases,
gout, malignancy
– intra-articular injection in knee for gonarthrosis with
GUNA MD-KNEE (10 amp)+GUNA MD-MUSCLE
(10 amp)
Complete a questionnaire by the patient and assessment by
physician:
– before treatment
– on week 8th (at the end of treatment)
– on day 90th (30 days after treatment)
Results: More than 3 times decreasing of the average score
of pain at rest at the end of treatment as good effect was kept
30 days after withdrawal of therapy (p=0.000). Approx-
imately 2-fold decreased the average score for pain in
movement compared to the initial, as the reduction con-
tinues within the month after stopping treatment (p=
0.000). The average score for night pain decreased more
than 2.5 times on the third visit, compared with the
initial (p=0.001). The average score for pain on standing
decreased 3.5 times on the third visit, compared with the
initial (p=0.000). The average score for pain in walking
decreased more than 1.5 times on the third visit, com-
pared with the initial. The average score for the maxi-
mum walking distance decreased 1.5 times on the third
visit, compared with the initial. The average score for
completion of other activities decreased 1.4 times on the
third visit, compared to the initial.
Conclusion(s): With application of collagen injection
GUNA MDS in gonarthrosis treatment the assessment
of treatment efficacy on day 60th and 90th by patient
and by physician are identical as with the highest per-
centage are these having the highest assessment “very
good”.
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MICRO- AND MACROARCHITECTURAL CHANGES
AT THE TIBIA AFTER BOTULINUM TOXIN
INJECTION IN THE GROWING RAT
Béatrice Bouvard1, Guillaume Mabilleau2, Erick Legrand1,
Maurice Audran1, Daniel Chappard2
1Centre Hospitalier Universitaire, Rhumatologie, 2Centre
Hospitalier Universitaire, LHEA, IRIS, IBS, Angers,
France
Objective(s): To analyze bone micro- and macroarchitec-
ture of tibia in a disuse model in growing rats.
Material & Methods: 8-week-old Copenhagen rats were
injected intramuscularly with 1.5 units BTX in the quadri-
ceps muscle of the right hind limb. Saline injection was
done at the left hind limb to serve as control. Five rats were
killed at day 1 and represented the baseline group (D1), 5
rats were killed at day 14 (D14), 5 at day 21 (D21), 5 at day
28 (D28) and 5 at day 35 (35). For each group, muscle
surface, parameters of bone microarchitecture and macroarch-
itecture (including length, width and curvature of the tibia)
were measured using microtomography.
Results: Paralysis occurred as soon as day 2. At the left hind
limb, muscle surface area, cortical thickness, cross sectional
total area and growth in length significantly increased dur-
ing the time study. At the right hind limb, muscle surface
area, bone trabecular volume, and cortical thickness de-
creased as soon as day 14 associated with an increased
cortical porosity. Growth in length did not differ from left
side; cross sectional total area did not increase and the
diaphyseal cross section acquired a more rounded shape.
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There was no modification of the curvature between right
and left hind limbs during the time study.
Conclusion(s): In this murine model of unilateral muscle
paralysis in growing animals, we showed a rapid muscle
loss leading to a decreased growth in width; however
growth in length and curvature were unaltered.
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BONE MINERAL DENSITY AND LEVEL OF
VITAMIN D IN POSTMENOPAUSALWOMENWITH
AND WITHOUT HISTORY OF FRAGILITY
FRACTURES
Ema Rudenka1, Volha Samokhovec1, Alena Rudenka1,
Katsyarina Vasilenka2, Anastasiya Adamenka2
1Belarusian Medical Academy of Postgraduate Training,
Chair of Cardiology and Rheumatology, 2First Minsk City
Hospital, Minsk City Centre of Osteoporosis, Minsk, Belarus
Objective(s): The aim of our study was to evaluate the
prevalence of low BMD and vitamin D deficiency in post-
menopausal women with and without fragility fractures in
anamnesis.
Material & Methods: 240 postmenopausal women at age
49-80 years (mean age 61.7±8.8 years) living in two different
regions of Belarus (Minsk and Brest) were examined. BMD of
lumbar spine and hips was examined byDXA (Lunar Prodigy,
GE), serum levels of 25-hydroxyvitamin D were determined
using the chemiluminescent assay (Roche Diagnostica) during
the period of August-September 2011. The history of fragility
fracture was revealed by questioning.
Results: 29.5% of examined women had fragility fractures
at the age of 50 years and older. Among them 23% experi-
enced 1 osteoporotic fracture, 5% had 2 fractures, and 2.5%
had 3 and more osteoporotic fractures. Mean level of vita-
min D consisted 15.90±5.68 ng/ml. 95% of women were
characterized by low (<20 ng/ml) serum 25-hydroxyvitamin
D and only 5% had normal meanings of 25-hydroxyvitamin
D. According to the results of DXA 31% of the examined
had osteoporosis, 28% had osteopenia and 41% normal
showings of BMD. The comparative analysis of women
with and without history of fragility fracture revealed statis-
tically significant differences in age, weigh, height, decreas-
ing of height during life and BMD data of lumbar spine and
both femoral necks, but there were no revealed changes in
the content of serum 25-hydroxyvitamin D. It is important to
notice that despite high prevalence of vitamin D deficiency
we revealed statistically significant regional differences in
the content of 25-hydroxyvitamin D in examined women: it
was higher in women living in the southern region of the
country (Brest) (12.87±5.3 ng/ml) than in those living in the
central part (Minsk) (9.47±1.18 ng/ml).
Conclusion(s): We revealed statistically significant differ-
ences in age, anthropometric data and showings of DXA in
postmenopausal women with and without fragility fractures
in anamnesis. 95% of the examined women were character-
ized by low serum 25-hydroxyvitamin D, but there were
determined regional differences between the content of se-
rum 25-hydroxyvitamin D.
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HEALTH RELATED QUALITY OF LIFE IN
POSTMENOPAUSALWOMEN REFERRED
FOR BONE DENSITY ASSESSMENT
Sally Wilson, Christopher A Sharp, Michael WJ Davie
Robert Jones & Agnes Hunt Orthopaedic Hospital NHS Foun-
dation Trust, Charles Salt Centre for Human Metabolism,
Oswestry, Shropshire, UK
Objective(s): The effect of osteoporotic fracture on health
related quality of life (HRQoL) is acknowledged, but little
attention has been paid to the effect of low bone mass. This
cross-sectional study aimed to assess HRQoL in postmeno-
pausal women referred to a specialist metabolic bone clinic
for BMD assessment.
Material & Methods: We sampled 240 postmenopausal
women (65±3 y) who had completed the SF36v2 before a
BMD assessment. The SF36v2 comprises 36 questions,
relating to 8 domains of health, function and well-being,
which form a physical (PCS) and mental (MCS) summary
score. Patients were initially divided into two groups; those
who reported any postmenopausal fracture (n=86) and those
with no history of postmenopausal fracture (n=154). Anal-
yses were then conducted after stratifying these two groups
according to femoral neck BMD T-score values (osteopo-
rotic, osteopenic, and normal).
Results: Irrespective of BMD, physical function, role physi-
cal, social function domains, and the PCS scores were worse
in the fracture group compared with the no fracture group (p<
0.05), whereas the MCS scores were similar (p=0.460). After
controlling for age and BMI, in those patients with a fracture,
PCS scores tended to be worse in the those with an osteopo-
rotic BMD (31±16) compared with those with normal BMD
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(41±12) (p=0.056). These patients also tended to have higher
prevalence of vertebral and hip fractures (p=0.092). In
patients without fracture, no differences in HRQoL were
revealed between the groups stratified according to BMD.
Conclusion(s): In this preliminary study, patients with a
history of postmenopausal fracture had worse HRQoL (in
the physical domains) compared with those without fracture.
More specifically, fractures in the presence of osteoporosis
were associated with a worse PCS score than in those
without osteoporosis, which might be explained by the
higher presence of vertebral and hip fractures. Osteoporosis
in the absence of fractures had less impact on HRQoL.
These findings suggest that factors in addition to low
BMD and fractures, such as co-morbidities and frailty,
which may also impact upon HRQoL should be explored
in these patients.
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EFFECTS OF AGE ON GENETIC INFLUENCE ON
BMD AND BONE LOSS OVER 17 YEARS IN
WOMEN: A LONGITUDINAL TWIN STUDY
Alireza Moayyeri, Deborah Hart, Christopher J Hammond,
Timothy D Spector
King's College London, Department of Twin Research &
Genetic Epidemiology, London, UK
Objective(s): Rate of bone loss varies considerably between
early postmenopausal and older women and different mech-
anisms may be involved in each of these periods. In this
study we aimed to estimate the genetic component of bone
loss (heritability) in hip and spine across different ages.
Material & Methods: Starting in 1992 and during 17 years
of follow-up in TwinsUK and Healthy Ageing Twin Study
(HATS), 15,491 hip and lumbar spine DXA scans were per-
formed in 7056 twin volunteers. Out of these subjects, 2810
female twins aged >35 years with at least two DXA scans with
an interval period of >4 years were included in this analysis.
We utilised a mixed-effects random-coefficients regression
model to predict hip and spine BMD values for the included
twins in exact ages of 40, 45, 50, …, to 80 years based on the
available data in the close age ranges and with further adjust-
ment for baseline age, weight, height and years of hormone
replacement therapy as fixed-effects covariates. We then esti-
mated heritability of the changes in BMD measures between
these age ranges (40 to 45, 45 to 50, …) using univariate
variance component analysis.
Results: Consistent with previous studies, heritability esti-
mates for BMD were high and ranged from 63% to 88% at
the ages of 80 and 40 years, respectively. Heritability of
change of BMD was lower, generally ranging from 30-50%;
between 40 and 45 years of age genetic factors explained
47.0% (95% CI: 29-60%) of variance of BMD loss for total
hip, 44.4% (25-57%) for femoral neck, and 68.1% (56-76%)
for lumbar spine BMD loss. These estimates decreased with
increasing age, and there appeared no heritability of changes
after the age of 65 for total hip/femoral neck BMD and after
age of 70 for lumbar BMD.
Conclusion(s): While genetic factors appear to have an
important role in bone loss in early postmenopausal women,
their effects weaken with age and completely disappear with
advanced ageing. This is distinct from the behaviour of
genetic component of bone mass in the elderly women and
suggests involvement of different genetic mechanisms in the
process of bone loss with ageing.
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SECULAR TRENDS IN INCIDENCE OF
OSTEOPOROSIS-RELATED FRACTURES DIFFER
DEPENDING ON FRACTURE TYPE
Bjorn E Rosengren1, Magnus K Karlsson1, Ingemar F
Petersson2, Martin Englund2
1Dep of Orthopedics, Skåne University Hospital Malmö and
Dep of Clinical Sciences Malmö, Lund University, Clinical
and Molecular Osteoporosis Research Unit, Malmo, 2Dep of
Orthopedics and Clinical Sciences, Lund University, Mus-
culoskeletal Sciences, Lund, Sweden
Objective(s): During the recent decade the incidence of hip
fracture has been reported to decrease in most parts of the
world. However, if a similar decrease has occurred for other
types of osteoporosis-related fractures is unknown.
Material & Methods: Through the Skane Health Care Reg-
ister, a diagnosis-based register covering all in- and outpatient
health care data of residents in the County of Skane, Sweden
(1.2 million inhabitants), we registered typical osteoporosis-
related fractures of the hip (n=26 952), os pubis (n=4 215),
proximal humerus (n=12 445), wrist (n=23 068), proximal
tibia (n=3 336) and ankle (n=9 459) sustained by individuals
aged 50 years or older from year 1998 until 2009 (5.1 million
person-years). We calculated gender-specific age-standard-
ized incidence for each fracture type using one-year age- and
sex-specific population figures from the population register,
where the average population of the examined years was used
as the standard population. Trends of incidence were evaluat-
ed by linear regression, and we present data as means with
their 95% CI with two-tailed α-level set to 0.05.
Results: During the evaluated years, the age-standardized hip
fracture incidence decreased significantly in both women (-12
per 100 000 and year [95% CI -15, -9]) and men (-3 per 100
000 [95% CI-5, -1]). In contrast, during the same period the
annual incidence of proximal humeral fractures increased sig-
nificantly in women (4 per 100 000 [95% CI 0, 7]) and
nonsignificantly in men (1 per 100 000 [95% CI -0, 3]).
Furthermore, the incidence of pubic fractures increased signif-
icantly in men (1 per 100 000 [95% CI 0, 2]) but not in women
(0 per 100 000 [95%CI -2, 1]). The incidence of ankle fractures
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was stable in both men and women as was the annual
incidence of wrist fractures and proximal tibial fractures
(data not shown).
Conclusion(s): In this study covering the recent decade, the
different types of examined osteoporosis-related fractures
showed different secular trends in incidence. Hence, the
decrease in hip fracture incidence evident in this and other
studies cannot be extrapolated to all types of osteoporosis-
related fractures when estimating the future total burden of
fragility fractures in society.
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VERTEBRAL MORPHOMETRY, ITS
HETEROGENEITY AND ANTERIOR CORTICAL
RADIUS OF CURVATURE PREDICT LUMBAR
VERTEBRAL FRACTURE IN POSTMENOPAUSAL
WOMEN: THE OFELY STUDY
Jean-Paul Roux, Safaa Belghali, Elisabeth Sornay-Rendu,
Roland Chapurlat
UMR 1033, INSERM, Lyon, France
Objective(s): Vertebral morphometry is widely used to depict
vertebral fracture, but its value to analyze vertebral morphol-
ogy to predict vertebral fracture is poorly documented. The
aim of our study was to analyze vertebral anterior cortical
curvature (Ct.curv) and body height heterogeneity, in post-
menopausal women before incident vertebral fracture.
Material & Methods: A case control study from the
OFELY cohort was performed, including 29 postmeno-
pausal women with incident lumbar vertebral fractures
(mean age 71±9 years, mean time until fractures 9±4
years) age-matched with 57 controls without incident
fracture. Body height was not significantly different
between groups. Digital scans were performed on lateral
X-rays of lumbar spine (T12-L4) at baseline with a
spatial resolution of 0.26 mm/pixel. From these radio-
graphs, the following parameters were measured from
six digitized points: 1) the posterior, middle and anterior
vertebral height, 2) the heterogeneity of heights evalu-
ated by the coefficient of variation of these three values,
3) the anterior cortical radius of curvature. All measure-
ments were done by two observers, intra and inter
observers reproducibility were excellent with an ICC
of 0.99, 0.97 and 0.61, respectively.
Results: Mean vertebral heights were significantly lower
in the fracture group vs. the control one. The posterior
heights did not differ between the two groups. Only the
anterior and middle heights were significantly different
between the two groups in L4 and L3 vertebrae. No
significant differences were found in L1-L2 and T12.
The mean heterogeneity of vertebral height was signif-
icantly greater in the fracture group. In addition, fractured
patients presented with a significantly higher radius of
curvature.
Conclusion(s): In summary, our study confirms the as-
sociation between vertebral height and occurrence of
fracture in postmenopausal women. The heterogeneity
of vertebral heights and a higher anterior cortical radius
of curvature seem to be relevant variables associated
with fracture.
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WE HAVE ALWAYS BEEN OSTEOPOROTIC: BONE
MINERAL DENSITY IN A PORTUGUESE
IDENTIFIED SKELETAL SAMPLE
Francisco Curate1, Eugénia Cunha2, Joana Correia3, João
Pedroso de Lima3, Anabela Albuquerque3
1Research Center for Anthropology and Health, Department
of Life Sciences, 2University of Coimbra, Department of
Life Sciences, 3Coimbra University Hospitals, Nuclear
Medicine Service, Coimbra, Portugal
Objective(s): Commonly, osteoporosis has been perceived
as a “modern disease”. Recently, a vast array of paleopatho-
logical studies has shown that this disease was ubiquitous in
past communities. The diachronic modification of etiologi-
cal factors, like longevity, physical activity or diet, affected
the prevalence of osteoporosis and the so-called osteoporot-
ic fractures in the past. As such, it is important to understand
the epidemiology of this disease in historical populations;
with behaviors and customs that were unalike the modern
westernized lifestyle. The fundamental objective of this
study is to characterize the epidemiological patterns of os-
teoporosis in an identified Portuguese skeletal sample from
the 19th century.
Material & Methods: The sample studied comprised 196
individuals with known sex and age-at-death, buried at the
Cemitério da Conchada (Coimbra, Portugal). Individuals
were mostly manual workers with low socioeconomic
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status. BMD was evaluated in the proximal femur through
DXA.
Results: BMD decreased significantly with age-at-death,
both at the ROI "Total hip" (Pearson r=-0.591; p=0.000)
and the ROI "Neck" (Pearson r=-0.675; p=0.000). At the
"Total hip", peak bone mass (PBM) was achieved early (20-
29 years age group) in both sexes (female: BMD=0.930;
DP=0.11; 95% CI: 0.858-0.987 / male: BMD=1.045; DP=
0.09; 95% CI: 0.992-1.097). In the study group as a whole,
BMD was significantly greater in males ("Total hip": 0.882;
DP=0.16; 95% CI: 0.849-0.915 / "Neck": 0.757; DP=0.16;
95% CI: 0.725-0.789) when compared to females ("Total
hip": 0.780; DP=0.16; 95% CI: 0.747-0.813 / "Neck":
0.679; DP=0.16; 95% CI: 0.647-0.710). As expected, the
prevalence of osteoporosis in the proximal femur is greater
in women (29.6%; 95%CI 21.5-39.3{29/98} vs. 13.3%;
95%CI 7.9-21.1 {13/98}) and rises steeply with age. Com-
parisons with a modern Portuguese sample showed a com-
parable pattern of BMD reduction. Nonetheless, BMD is
usually lower in the skeletal sample.
Conclusion(s): In spite of enormous lifestyle differen-
ces, the epidemiological patterns of bone mass decrease
in a Portuguese skeletal sample from the 19th century
are strikingly similar to the ones observed in modern
populations. This study adds further data to the recent
notion that osteoporosis is a disease with deep roots in
the past.
Disclosures: Fundação para a Ciência e Tecnologia (Ref.
SFRH/BPD/74015/2010).)
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VITAMIN D STATUS IN HEALTHY BELARUSSIAN
CHILDREN
Aliaksei S Pachkaila1, Anastasia VAdamenka2
1Belarusian Medical Academy of Post-Graduate Education,
Chair of Polyclinic Pediatrics, 2City Centre of Osteoporosis,
Radiodiagnostics, Minsk, Belarus
Objective(s): To evaluate the status of vitamin D in healthy
Belarusian children.
Material & Methods: 49 healthy Belarusian boys (31) and
girls (18) aged 5-17 are included into the research (mean
age: 11.2 [7.8:13.8] years). Blood sampling was done in the
period of autumn-winter 2011/2012. All examined children
haven't received any vitamin and mineral preparations con-
taining vitamin D and artificial ultraviolet radiation and
natural insolation outside of permanent place of residence
during 3 months before the research. The level of 25-
hydroxyvitamin D3 (ng/ml) is defined by the method of
electrochemiluminescence immunoassay (analyzer – cobas
e, reagents – Roche Diagnostics). Statistical data processing
is carried out in the program Statistica 8, quantitative data is
presented in the following format: Me [LQ:UQ].
Results: Mean content of vitamin D in blood serum of the
examined children made up 13.26 [8.66:16.46] ng/ml. In
91% (45/49) of the examined the level of vitamin in blood
was less than 20 ng/ml, including 16 children with the value
less than 10 ng/ml and 3 children with the value less than 4
ng/ml (value below the detection limit). There is a consen-
sus opinion that the minimal vitamin D (25-OH) level for
bone health is between 20-32 ng/ml, which was registered in
9% (4/49) of the children examined by us. A more recent
consensus of experts leads to the conclusion that for general
health a desirable concentration of vitamin D (25-OH) is
≥30 ng/ml. The level of vitamin D exceeded this value only
in one child examined by us.
Conclusion(s): According to the results of our research
(which was one of the first studies of concentration of
vitamin D in Belarusian children) we can state that the
overwhelming majority of them (more than 90%) demon-
strate in the autumn-winter period the level of vitamin D in
blood that shows its insufficiency or deficiency. To study
this phenomenon on the level of healthy children's popula-
tion of Belarus a more large-scale epidemiological study is
needed in the future.
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CORRECTION OF VITAMIN D DEFICIENCY IN
PATIENTS AGED 80 YEARS AND MORE:
EFFICIENCY OF ORAL SEQUENTIAL 100 000 IU
VITAMIN D3 DOSES
Hélène Safar1, Laetitia Grandcollot2, SabrinaMakouf1, Laurent
Teillet2, Jean-Claude Souberbielle3, Jean-Laurent Le Quintrec1
1AP-HP, Hôpitaux Universitaires Paris-Ile de France Ouest,
Médecine Gériatrique 3 Hôpital Sainte Périne, 2AP-HP,
Hôpitaux Universitaires Paris-Ile de France Ouest, Méde-
cine Gériatrique 2 Hôpital Sainte Périne, 3AP-HP, Hôpital
Necker, Laboratoire d'Explorations Fonctionnelles, Paris,
France
Objective(s): Vitamin D deficiency is very common among
very old individuals (80 years and more).To date there is no
validated procedure to correct vitamin D deficiency in this
population. Procedure proposed by Souberbielle (1) has
been shown to correct vitamin D deficiency in 80% of
elderly individuals (mean age 64 years) (2). We tested this
procedure on very old patients.
Material & Methods: This prospective observational study
included all patients aged 80 years and more, hospitalised in
geriatric acute or rehabilitation units of a teaching geriatric
hospital in 2011, with a 25 OHD concentration <30 ng/ml.
Patients with disease or treatment influencing bone metab-
olism were excluded. Patients were given cholecalciferol
100 000 IU PO every two weeks, according to the baseline
25 OHD concentration: total doses varied from 200 000 IU
over 14 days to 400.000 IU over 42 days. Serum calcium,
S206 Osteoporos Int (2012) 23: (Suppl 2):S85–S386
phosphate, creatinine, albumin, 25 OHD and PTH were
measured at admission (DA) and at day 7, 30 and 60 after
completion of the correction procedure. All biological
assays were performed by the same laboratory. Complete
follow-up until D60 was dependent on duration of the
correction procedure and needed a hospital stay between
74-102 days.
Results:We included 372 patients (264women and 108men).
Mean age was 88.64±5.10 years. Mean BMI was 22.88±4.76
and mean eGFR (Cockroft) 46.15±18.85 ml/min. As follow-
up ended with hospital discharge, we obtained data from 149
patients at D7, 83 at D30 and 38 at D 60.
Results of vitamin D deficiency correction procedure
DA D7 D30 D60
25OHD (ng/ml)
( meanSD)
12.15
(7.71)
39.85
(10.80)∗
35.81
(8.53)∗
32.39
(9.28)∗
25OHD≥30 ng/ml
(% of patients)
0 79.9 73.4 47.4
PTH (pg/ml)
(meanSD)
52.51
(34.54)
36.35
(21.48)
37.34
(29.54)
32.42
(24.70)
PTH≥47 pg/ml
(% of patients)
44 24.5 20.5 10.5
∗: p<0.001 vs. DA
D7 25 OHD level was not correlated to baseline 25OHD
level, nor to BMI.
There was no hypercalcaemia.
Conclusion(s): Correction of vitamin D deficiency with 200
000 to 400 000 IU of cholecalciferol is effective in 80% of
very old patients, well tolerated and decreases PTH secretion.
References: (1) Souberbielle JC et al Ann Endocrinol
2009;69:501. (2) Rouillon V et al Rev Rhum 2009;76:983
(abstract O.04).
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LONG-TERM, REAL LIFE EFFECTIVENESS OF
ZOLENDRONIC ACID IN OSTEOPOROSIS
Michael Tsoukas1, Emmanouil Rampakakis2, Philip Tsoukas3,
John S Sampalis2, George Tsoukas4
1McGill University, Department of Endocrinology, 2McGill
University & JSS Medical Research, Division of Surgical
Research, 3Applied Medical Informatics Research, Medical
Department, 4McGill University Health Centre, Montreal
General Hospital, Montreal, Canada
Objective(s): Although the efficacy of zolendronic acid in
bone metabolism has been demonstrated in several con-
trolled clinical trials, data from longitudinal observational
studies are scarce. Such studies are essential in order to
assess the real-life effectiveness of therapeutic interventions
and demonstrate true population-based benefits.
Material & Methods: This was a retrospective chart review
database analysis with data obtained from four clinics on
patients initiating treatment with zolendronic acid. Changes
in BMD, ionized calcium (iCa), serum PTH, bone formation
markers (osteocalcin, alkaline phosphatase) and the bone
resorption marker type I collagen C-telopeptide were
assessed using linear mixed models with repeated measures.
Results: A total of 291 patients were included with a mean
(SD) age of 65.0 (10.2) years. Among these, 262 (90.0%)
patients were female. At baseline, the mean (SD) T-score
was -2.9 (1.0) and -2.3 (0.8) for the spine and femur,
respectively, and the mean (SD) zolendronic acid dose was
4.3 (0.78) mg. After one year of treatment with zolendronic
acid, patients experienced clinically and statistically signif-
icant improvements in spine (% change=2.09) and femur
(% change=2.05) BMD, which were further augmented
over 5 years (trend over time: Pspine=0.003, Pfemur<0.001).
Interestingly, significant differences in spine BMD were ob-
served based on the type of previous osteoporosis treatment
(P=0.009); patients having previously used only calcium and
vitamin supplements experienced the maximal benefit fol-
lowed by patients previously treated with osteoporosis hor-
mone replacement therapy or selective estrogen receptor
modulators, or oral bisphosphonates. Percent changes over
time in iCa, PTH, and bone biochemical markers upon adjust-
ment for baseline values were not statistically significant.
Conclusion(s): The results of this real life observational
study demonstrate that long-term treatment with zolendronic
acid over five years is effective in improving spine and
femur BMD in patients with osteoporosis, regardless of
previous osteoporosis treatment. However, patients previ-
ously primed with calcium and vitamin supplements expe-
rienced the maximal clinical benefit.
Disclosures: This study was supported by an in-kind sup-
port by JSS Medical Research Inc.
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IMPROVEMENT OF BALANCE AFTER HIP
FRACTURE IN ELDERLY REGARDING
MUSCULOSCELETAL COMORBIDITY
Natasa Radosavljevic1, DejanNikolic2,Milica Lazovic1, Ivana
Petronic2, Olivera Ilic-Stojanovic1, Zoran Radosavljevic3,
Dragana Milenkovic4
1Institute for Rehabilitation, Department of Rheumatology,
Belgrade, 2University Childrens Hospital, Physical Medicine
and Rehabilitation, Belgrade, 3Special Hospital for Internal
Medicine, Department of Urology, Mladenovac, 4Clinic for
Rehabilitation "Dr Miroslav Zotovic"c", Department of
Rheumatology, Belgrade, Serbia
Objective(s): It is estimated that 25-75% of elderly patients
after osteoporotic hip fractures are not able to achieve pre-
fracture level of functional independence, so they are in great
risk for next falls and fractures. The aim of our study was to
evaluate the influence of musculoskeletal comorbidity on
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restoring of balance after rehabilitation program measured in
patients above 65 with osteoporotic hip fracture.
Material & Methods: The prospective study included
192 patients over 65 years admitted in rehabilitation
facility after the hip fracture for post-acute rehabilitation.
They had individually planed rehabilitation program pre-
scribed by rehabilitation team. Participants functional
status was evaluated by the Berg Balance Scale test on
3 occasions regarding time of observation: at the admis-
sion, at discharge from the rehabilitation center and 3
months after discharge. Statistical analysis was performed
by using One-way ANOVA test, post hoc Scheffe tests
and students T-test.
Results: There is no significant difference between BBS
values for the patients with muscular impairment regard-
ing different degrees of severity graded by CIRS-G at
the admission but significant fluctuations were noticed
in the period after discharge and after 3 months of
follow-up. Preformed Post-hoc Scheffe test pointed out
that significant decline in BBS values for the patients
with muscular impairment was noticed tree months after
discharge between severity degrees 0/1 (p<0.05) as well
between severity degrees 0/3 (p<0.05). Patients after
hip fracture that were referred to rehabilitation facility
with different degrees of muscular impairment signifi-
cantly increased functional status measured by BBS
particularly between admission to rehabilitation center
and at discharge as well between admission and 3
months of follow-up. Study participants with lower
CIRS-G severity degrees showed significant improve-
ment even after discharge between the period from
discharge and 3 months of follow-up, while those with
severe degrees lacked such improvement after discharge.
Conclusion(s): Rehabilitation of elderly after hip fracture
should be mandatory for functional recovery regardless
the comorbidity and functional status. Influences of mus-
culoskeletal comorbidity and its severity should be con-
sidered by physicians as important factor for restoring of
balance.
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NUTRITIONAL CALCIUM HABITS
Xavier Grapton, Didier Leclere, Patrick Lemesle, Laurence
Poulain, Philippe Renard
1Liberal Cabinet, Colombes, 2Suresnes, 3Bois-Colombes,
4La Garennes Colombes, 5Courbevoie, France
Objective(s): Our patients are influenced by all medical
information, and even rumours. The aim of this study is to
analyse their habits and reactions concerning dairy products
and calcium.
Material & Methods: 305 patients questioned: 90% of
women, mean age 62 years, 97% from the île-de-France
region. 33.6% took osteoporosis medication or a vitamin
and calcium supplement. 66% underwent a bone densitom-
etry test (17.4%: osteopenia, 13%: osteoporosis). 24% had a
history of non-traumatic fracture and 13% had another os-
teoporosis risk factor. 32% practised a weight-bearing sport,
12.5% had lost more than 8 kg through diet.
Results: 80% of those questioned did not know the body's
calcium or nutritional requirements, but believe they have
a sufficient intake. Nutritional calcium intake is mainly
via yoghurts (37%). 56.4% have a nutritional calcium
intake of <900 mg/day. 25% think that soya milk has
the same benefits as cow's milk, hence the replacement
(50%). Those with a BMI of less than 19 have the lowest
nutritional calcium intake (740 mg/day on average). 40-
60-year-old patients are the most responsive to rumours
and lectures on milk. They are the ones who change their
nutritional habits with regard to dairy products. Before the
age of 40 years, patients are less responsive to medical
advice and are influenced by the cost of dairy products
and advertising. Less than 10% have no dairy intake
because of taste, fat content, high cholesterol concerns
and intolerances. Calcium is not dangerous (63%) but
can lead to disorders if taken in excess. The dairy prod-
ucts-calcium-osteoporosis relationship is well understood,
yet the onset of a fracture does not change people's habits
concerning calcium (71%). BMD results and medical ad-
vice have a strong impact (91%). 52% are ignorant of the
role of vitamin D for the bones, but do relate it to
calcium.
Conclusion(s): While campaigns for the consumption of
dairy products have helped promote their relevance in bone
health, they have not dispelled any concerns over gaining
weight or worsening cholesterol levels. Calcium is widely
approved <73%-89%> whatever the age to maintain bone
quality (41%) and fight osteoporosis (28%). Osteoporosis
and the risk of fracture are well-understood, hence the
determination to fight both.
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RELATIONSHIP OF VITAMIN D AND
PARATHYROID HORMONE WITH OBESITY
IN COMMUNITY DWELLING WOMEN
Vaidile Strazdiene1, Vidmantas Alekna1,2, Marija
Tamulaitiene2,3, Asta Mastaviciute2
1State Research Institute Centre for Innovative Medicine,
2Vilnius University, Medical Faculty, 3National Osteoporo-
sis Center, Vilnius, Lithuania
Objective(s): The aim of this study was to investigate the
association of serum vitamin D and PTH levels with BMI,
waist circumference and fat mass.
Material & Methods: This was a cross-sectional study on
women aged 40 years and older who consecutively had visited
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the National Osteoporosis Center (Vilnius, Lithuania). Meas-
urements of weight, height and waist circumference were
obtained, BMI was calculated. We divided all subjects to sub-
groups by BMI category (<25, 25 to <30, and ≥30kg/m2).
Total body DXA was used to evaluate fat mass (iDXA, GE
Lunar). Serum vitamin D (25(OH)D) and PTH were measured
by automated immunoassay (Cobas e411, Roche Diagnostic).
PTH and vitamin D values were divided into four percentile
groups. The statistical analysis was performed with SPSS
software for Windows (Version 18.0). All p-values less than
0.05 were considered as statistically significant.
Results: A total of 352 women aged 62.5±13.7 years were
included in this study: 119 (33.8%) were lean, 121 (34.4%)
were overweight and 112 (31.8%) were obese. The lowest
level of vitamin D (15.6±7.9 ng/ml) was found in obese
women comparing to overweight and lean women, although
not statistically significantly. The statistically significant dif-
ference was found for PTH: in obese women the highest values
(53.2±21.1 pg/ml) were found. We have found a weak nega-
tive correlation between vitamin D and BMI (r=-0.23, p=
0.016) in obese subjects only. PTH did not correlate with
BMI, waist circumference, and fat mass in all groups.
The highest BMI (29.7±6.4), waist circumference (94.4±
14.1 cm) and fat mass (31.5±9.8 kg) values were found
in the fourth PTH percentile group, comparing to other
percentile groups. There were no significant differences
of BMI, waist circumference and fat mass in vitamin D
percentile groups.
Conclusion(s): Our study supports the hypotheses that vi-
tamin D deficiency and increased PTH are associated with
obesity.
P355
BONE MINERAL DENSITY (BMD) AND
MICROARCHITECTURE ASSESSMENT BY
TRABECULAR BONE SCORE (TBS) AT THE SPINE
IN PATIENTS WITH RHEUMATOID ARTHRITIS
(RA) AND SYSTEMIC SCLEROSIS (SSC)
Eugénie Koumakis, Emese Toth, Marine Meunier, Emily
Maury, Yannick Allanore, André Kahan, Catherine Cormier
Cochin Hospital, APHP, Paris Descartes University, Rheu-
matology Department A, Paris, France
Objective(s): RA is a frequent chronic inflammatory rheu-
matic disease, and a frequent cause of secondary osteoporosis,
due to chronic inflammation and long-term glucocorticoid
therapy (GC). In SSc, the risk of osteoporosis may be less
important because of milder inflammation and fewer patients
receiving GC. The aims of our study were to examine BMD
and bone microarchitecture by TBS in female patients with
RA and SSc, to assess their associations with GC use and
prevalent fractures and to compare these parameters with a
control population.
Material &Methods: Single center cross-sectional study of
138 RA, 65 SSc patients and 227 controls with mean age of
61±11, 62±11 and 61±8 years respectively, mean BMI of
24.8±4.9, 26.5±4.8, and 24.2±3.8 kg/m2. All patients and
controls were female. BMDandTBSwere assessed at AP Spine
(L1-L4). In RA and SSc patients, the prevalence of fractures
was respectively 34.8% and 29.2% (p=0.53), mean BMD was
1.001±0.203 g/cm2 and 1.007±0.179 g/cm2 (p=0.76), and
mean TBS was 1.247±0.136 vs. 1.207±0.145 (p=0.13). Total
GC dose was higher in the RA population (35522±28599 mg
vs. 8630±14044 mg, p<0.0001).
Results: TBS and BMD were significantly lower in patients
with a history of fracture than in nonfractured patients and
controls, in both RA and SSc (p<0.05). In the combined
SSc and RA population (n=203), 22 out of 68 fractured
patients had a T-score at the spine and/or hip between -1 and
-2.5, and TBS was below 1.308 in 45.5% patients. In RA
and SSc patients receiving more than 5 mg/day of GC, TBS
and BMD were significantly lower than in controls (p<
0.005). These associations remained significant after adjust-
ing for BMI. Among SSc and RA patients receiving more
than 5 mg/day GC, TBS tended to be lower in SSc patients
(nonsignificant when adjusted for BMI).
Conclusion(s): Microarchitecture assessment by TBS helped
to differentiate between patients with and without fractures
and between patients with glucocorticoids and controls. TBS
detected 45.5% of fractured patients in the osteopenia zone on
BMD. TBS was lower in SSc than in RA suggesting that in
SSc there may be additional risk factors for osteoporosis other
than glucocorticoid therapy and systemic inflammation, such
as vascular alterations and fibrosis.
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SCLEROSTIN NEUTRALIZING MONOCLONAL
ANTIBODY DECREASES SIGNIFICANTLY THE
NUMBER OF PELVIC FRACTURES AND
IMPROVES MARKEDLY THE SIZE AND
INTERCONNECTIVITY OF LUMBAR
TRABECULAR BONE IN OIM/OIM MICE
Jean-Pierre Devogelaer1, Daniel Chappard2, Catherine
Behets3, Patrick Ammann4, Mike S Ominsky5, Daniel H
Manicourt1
1Université Catholique de Louvain, Rheumatology, Brus-
sels, Belgium, 2IRIS-IBS; CHU Angers, INSERM, U 922;
Bone Remodeling and Biomaterials, Angers, France, 3Uni-
versité Catholique de Louvain, Experimental Morphology,
Brussels, Belgium, 4University Hospital Geneva, Rehabili-
tation and Geriatrics, Geneva, Switzerland, 5Amgen Inc.,
Metabolic Disorders Research, Thousand Oaks, US
Objective(s): As trabecular bone strength depends on both
BMD and microarchitecture, we measured the effects of
sclerostin antibody (Scl-Ab) on the rate of fractures in axial
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skeleton as well as on the BMD and microarchitecture of
lumbar vertebral bodies in oim/oim (OI) mice.
Material & Methods: 5-7-week-old OI and wildtype (WT)
mice were treated with either Scl-Ab (25 mg/kg; n=14) or
vehicle control (PBS; n=19) twice a week for 10 weeks.
Mammography X-ray detected fractures of the axial skeleton
lumbar vertebral bodies (LVB) were scanned by pQCT to
measure BMD, and by μCT (Skyscan 1172) to measure
trabecular (Tb) bone volume (BV/TV), Tb thickness (Tb
Th), Tb number (Tb N), structure model index (SMI; lower
values=more platelike trabeculae) as well as two parameters
of Tb network connectivity, Tb bone pattern factor (Tb Pf;
lower values=more connections) and fractal dimension
(F D; higher values=more connections). Statistical analysis
included Kruskal-Wallis one-way analysis of variance
(ANOVA).
Results: Scl-Ab significantly reduced the number of pelvic
fractures in OI mice by 65% (mean±SD=0.4±0.5 per
mouse vs. 1.1±0.8 in PBS; p<0.02). This decrease corre-
sponded with significant improvements in LVB trabecular
bone parameters after Scl-Ab treatment (Table 1) including:
BMD (+55%), BV/TV (+111%), Tb Th (+40%), Tb N
(+48%) and Tb Pf (-43%). In WT mice, Scl-Ab therapy
was also associated with significant trabecular improve-
ments in BV/TV (+160%), Tb Th (+33%), Tb N (+96%)
and Tb Pf (-94%). Scl-Ab therapy significantly decreased
SMI in WT mice, but not in OI mice.
Parameter Site OI mice OI mice WT mice WT mice
Scl-Ab PBS Scl-Ab PBS
Fractures /mouse pelvis 0.4±0.5* 1.1±0.8 0 0
BMD LVB 541±23* 350±41 789±59* 454±68
BV/TV% LVB 20.9±2.5* 9.9±4.9 38.7±8.8* 14.9±3.6
Tb Th μm LVB 0.07±0.003* 0.05±0.005 0.08±0.007* 0.06±0.002
Tb N / mm LVB 3.1±0.3* 2.1±0.9 5.1±0.8* 2.6±0.6
SMI LVB 1.6±0.12 1.8±0.26 0.5±0.5* 1.5±0.2
Tb Pf LVB 12.6±2.2* 22.2±6.1 0.7±5.7* 12.8±3
F D LVB 2.13±0.01* 2.08±0.05 2.22±0.03* 2.14±0.03
*p<0.02 vs. PBS control
Conclusion(s): By increasing bone mass and connectivity
of trabecular LVB, Sc-Ab reduced the prevalence of frac-
tures of the axial skeleton in OI mice. Therefore, Scl-Ab
might be a promising therapy for human type III OI.
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THE IMPORTANCE AND THE DIFFERENCES
OF BONE MORPHOGENETIC PROTEINS
FOR OSTEOPOROTIC HIP FRACTURES
Vesile Sepici1, Aylin Sepici Dincel2, Ercan V Dincel3
1Gazi University, Faculty of Medicine, Department of Phys-
ical Medicine and Rehabilitation, 2Gazi University, Faculty
of Medicine, Health Research and Practice Center, 3Ministry
of Health, Ankara Training and Research Hospital, Clinic of
Orthopedics and Traumatology, Ankara, Turkey
Objective(s): Bone morphogenetic proteins (BMPs), which
are the major players of tissue repair, has become one of the
most exciting fields in rheumatologic and orthopedic re-
search. Today, the most important topic is the quality of life
after hip fractures. In our study we aimed to evaluate the
relationship between the levels of BMPs and osteoporotic
hip fractures in two different localizations in order to spec-
ulate on the prognosis of patients.
Material & Methods: The total of the study group were
included 62 patients with osteoporotic hip fracture. 38 of those
(Group 1; 23 female/15male, mean age 77.52±6.74 years) had
intertrochanteric fractures of hip and 24 of them (Group 2; 18
female/6 male, mean age 75.16±6.89 years) had collum fem-
oris fractures. All fractures were due to low energy trauma,
simple falls. None of the patients had neoplastic pathology of
bone, long-term corticosteroid usage, bone metabolism disease
or arthritis and any other metabolic disease. BMD measure-
ments were done with Lunar DXA. The measurements were
performed on the intact side of the hip. Human serum BMP-4
(pg/mL) values were determined by Cellsciences elisa kit,
BMP-7 (pg/mL) measurements were done by RayBio elisa kit.
Results: Neck, trochanter, wards and total BMD values were
in agreement for osteoporosis and no significant differences
between the two groups for all BMD values. The mean and
standard deviation values for BMP-4 and BMP-7 levels in
Group 1 (114.63±80.50, 86.91±54.31, respectively) and in
Group 2 (129.74±99.24, 77.77±52.80, respectively) were not
different. However for both groups only BMP-7 values were
statistically increased compared to healthy subjects.
Conclusion(s): BMPs have been shown to stimulate osteo-
blast proliferation and/or differentiation. During bone for-
mation, they can be local stimulators. Their primary task is
to shape and guide body morphology and to maintain its
integrity. Wnt signal transduction pathway is another bone
remodelling regulator which some of the cytokines and
BMPs mediate their effects on bone formation and resorp-
tion. The increased levels of BMP-7 which is an osteogenic
factor in vivo, is a bone stimulating agent and after trauma
elevated levels are adaptive or protective may reduce the
severity of the fracture.
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AREA- AND VOLUME-BASED QCT REFERENCE
DATA FOR THE PROXIMAL FEMUR
Chris Cann, Alan Brett, Gabriel Bodeen, J Keenan Brown
Mindways Software, Inc, Austin, TX, US
Objective(s): BMD estimates for the proximal femur using
DXA are currently considered standard for diagnosing osteo-
porosis in patients using BMD alone. The WHO reference
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standard for osteoporosis diagnosis is a T-score of -2.5 or less
at the femoral neck. QCT produces DXA-equivalent "CTXA"
areal BMD measurements at the proximal femur, but normal
reference values are required to calculate a T-score. We have
developed a normal reference BMD database for US Cauca-
sian women for use with the QCTCTXAHip software (Mind-
ways Software, Inc., Austin, TX) and compared it to
NHANES III DXA data.
Material & Methods: Our prospective cohort included 616
women aged 20-79 from 11 centers distributed across three U.
S. regions: 3 Pacific, 4 Midwest, and 4 Northeast. CT images
were analyzed with the CTXA Hip software. QCT data was
analyzed in a DXA-like format using the standard femoral
neck, trochanter, intertrochanter and total hip regions of inter-
est. Both area-based and volume-based data are presented for
these regions of interest. T-scores were calculated for CTXA
Hip and NHANES III data sets based on age 20-39 reference.
Results: There were no statistically significant differences
between measurements from different CT scanners. We found
no significant variation across centers, regions or ages in BMI
by ANOVA (α=0.05). The young reference means (±SD)
from the pooled age 20-39 data were 0.922±0.116 g/cm2 for
Total Hip, 0.795±0.111 g/cm2 Femoral Neck, 0.698±0.103
g/cm2 Trochanter, and 1.096±0.137 g/cm2 Intertrochanter.
The figure shows T-scores for Femoral Neck regions calculated
using CTXA Hip areal BMD, volumetric BMD data and
NHANES III data.
Conclusion(s): Area-based T-scores based on the reference
data presented here are virtually identical to those obtained
from the published NHANES III data, indicating this meth-
od can be used with WHO DXA T-score guidelines to
provide substantially the same clinical information at the
femoral neck as DXA.
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ASSESSMENT OF ADEQUACY OF VITAMIN D
SUPPLEMENTATION DURING PREGNANCY
Elzbieta Skowronska-Jozwiak, Agnieszka Tyszkiewicz,
Kinga Krawczyk-Rusiecka, Zbigniew Adamczewski,
Krzysztof Lewandowski, Andrzej Lewinski
Polish Mother's Memorial Hospital – Research Institute,
Department of Endocrinology and Metabolic Diseases,
Lodz, Poland
Objective(s): Deficiency of vitamin D in pregnancy leads to
higher rates of preeclampsia, preterm birth, bacterial vagi-
nosis, gestational diabetes and affects health of the child.
According to Polish recommendations, published in 2009,
vitamin D supplementation in pregnant women should be
provided from 2nd trimester of pregnancy in daily dose of
800-1000 IU if skin synthesis is not effective.
The aim of the study was to (1) estimate how many pregnant
women comply with those recommendations (2) to deter-
mine the 25(OH)D3 levels in pregnant women.
Material & Methods: The study included 88 pregnant
women, aged 20-40, between 12-35 weeks of gestation. 25
(OH)D3 was measured by a direct electrochemilumines-
cence immunoassay (Elecsys, Roche).
Results: 35% of pregnant women did not use any supplemen-
tation. Mean level of 25OHD was 28.83±14.84 ng/ml (range
4-77.5 ng/dl). Severe deficiency of vitamin D [25(OH)D3 <10
ng/ml] was found in 4/88 (4.5%) of investigated women –
none of these patients had taken any supplementation. Mod-
erate deficiency [25(OH)D3 between 10-20 ng/ml] was pres-
ent in 24/88 (27.3% subjects). Optimal level of 25(OH)D3
(over 30 ng/dl) was present in 33/88 (37.5% women). Hence,
in 53.4% of women taking vitamin D supplements, the levels
of 25(OH)D3 were still below 30 ng/dl.
Conclusion(s): Supplementation of vitamin D in investigat-
ed group was not adequate. Approximately 1/3 of pregnant
women did not take any supplements, while half of the
subjects who declared taking vitamin D failed to achieve
optimal serum 25(OH)D3 concentration.
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TRABECULAR AND CORTICAL
MICROARCHITECTURE IN POSTMENOPAUSAL
HIV-INFECTED WOMEN
Michael T Yin1, Aimee Shu2, Chiyuan A Zhang1, Stephanie
Boutroy3, Donald J McMahon1, David C Ferris4, Ivelisse
Colon1, Elizabeth Shane1
1Columbia University Medical Center, Medicine, New
York, NY, US, 2Baylor College of Medicine, Medicine,
Houston, TX, US, 3Universite de Lyon, INSERM U1033,
Lyon, France, 4Bronx Lebanon Hospital Center, Medicine,
Bronx, NY, US
Objective(s): To assess the effects of HIV infection and
antiretroviral therapy (ART) on trabecular and cortical
microarchitecture in postmenopausal minority women.
Material & Methods: A subgroup of 106 (46 HIV+, 60
HIV-) postmenopausal Hispanic and African American
women from an established cohort had areal BMD (aBMD)
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measured by DXA, and trabecular and cortical volumetric
BMD (vBMD) and microarchitecture measured by high-
resolution peripheral computed tomography of the radius
and tibia.
Results: HIV+women were slightly but not significantly
younger (58±1 vs. 61±1 yrs, p=0.08), and had lower
BMI (28±1 vs. 31±1 kg/m2, p<0.01). BMI-adjusted
aBMD Z-scores were lower in HIV+women at the
lumbar spine, total hip and ultradistal radius. Serum
N-telopeptide and C-telopeptide levels were also higher
in HIV+women. Trabecular and cortical vBMD were
similar between groups at the radius but cortical area
(105.5±2.4 vs. 120.6±2.0 mm2, p<0.01) and thickness
(956±33 vs. 1075±28 μm, p<0.01) were approximately
11-12% lower in HIV+women at the tibia. Differences
remained significant after adjusting for age and BMI
and stratifying by race/ethnicity. In contrast, cortical
porosity was similar in both groups.
Conclusion(s): HIV+postmenopausal women had lower
aBMD by DXA and higher levels of bone resorption
markers. They also had lower cortical area and thickness
at the tibia but similar cortical porosity than HIV-uninfected
controls. Early cortical bone loss in HIV+women in their
fifties, before cortical bone loss usually accelerates, raises
concerns for future fracture risk in postmenopausal HIV+
women.
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DENOSUMAB – IDENTIFICATION OF
APPROPRIATE PATIENTS
Victoria Robinson, Rosaleen Lannon, Conall Fitzgerald,
James Mahon, Nessa Fallon, Jahwad Azam, MC Casey, JB
Walsh
St James's Hospital, Bone Health and Osteoporosis Unit,
Mercers Institute for Research in Aging, Dublin, Ireland
Objective(s): Denosumab has been available for treat-
ment of severe osteoporosis in Ireland for 15 months.
We reviewed the selection criteria applied by our physi-
cians to prescribe denosumab and any reported side
effects.
Material & Methods:We retrospectively reviewed the first
82 patients who received denosumab in our Bone Health
Clinic. Data was collected from an existing database where
patients demographics, bone density and biochemistry
results are recorded. Prior medication and early side effects
are also recorded here.
Results: We identified 77 females and 5 males. Table 1
documents baseline demographic, biochemical and densito-
metric details of the 82 patients. The majority had severe
osteoporosis with 35% having vertebral fractures. Several
had suboptimal vitamin D levels with PTH levels at the
upper end of the normal reference range. Bone turnover
was within the normal reference range. The majority of
patients had stage 3 chronic kidney disease (CKD).
Summary of key characteristics of patients receiving denosumab.
Mean±SD
Age 75.9 yr±9.7
PTH 47.5 pg/ml±31 (15-65 pg/ml)
25(OH)Vit D 73.6 nmol/L±28 (optimal>75 nmol/L)
CTX 0.339 ng/ml±0.191 (0.016-1.008 ng/ml)
P1NP 51.1 ng/ml±46 (16-74 ng/ml)
Osteocalcin 29.0 ng/ml±38 (13-48 ng/ml)
T-score spine -2.67±1.87
T-score total hip -2.52±2.11
eGFR 55 ml/min±25
Of those who commenced denosumab, 40/82 had been
recently treated with at least one year’s course of bisphosph-
onates, 9 of whom were treated with iv zolendronic acid.
Other treatments were evista (n=5), strontium ranelate (n=7)
or rPTH 1-34 (n=14). Due to the presence of CKD 16 patients
received denosumab as first line treatment. The main factors
leading to commencement of denosumab were a lack of
response to previous treatments, intolerance (specifically GI
in 30%) of other treatments and noncompliance. Clinically
reported side effects were minimal: arthralgia (n=1), mild flu-
like illness (n=1) and rash (n=1).
Conclusion(s): Denosumab appears to be a very useful
addition to the armamentarium of treatments for severe
osteoporosis particularly in those with chronic kidney dis-
ease or GI conditions. Reported side effects have been rare
and largely mild in nature making it a safe option in our
elderly population.
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FRACTURE RISK EVALUATION IN PATIENTS
WITH OSTEO-ARTICULAR INVOLVMENT
DUE TO RHEUMATOLOGIC DISEASES AND
OSTEOPOROSIS USING TWO MODELS OF FRAX
Dan IA Nemes1,2, Roxana Onofrei1, Mihai Dragoi1,2, Daniel
Popa1,2, Elena Amaricai1, Liliana Catan1, George Puenea1,
Diana Andrei1, Razvan Dragoi1
1“Victor Babes” University of Medicine and Pharmacy, Med-
ical Rehabilitation, 2City University and Emergency Hospital,
Rehabilitation and Rheumatology, Timisoara, Timis, Romania
Objective(s): To compare the results obtained using FRAX-
Austria and FRAX-Romania in order to analyze the most
efficient assessment tool in evaluation of osteoporotic frac-
ture's probability in a territory with particular population's
characteristics.
Material & Methods: Group I comprise 1200 patients (1040
females, mean age 60.53 with rheumatoid arthritis, under
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specific treatment. Group II comprise 380 patients (290
females, mean age 58.44 with other inflammatory rheumato-
logic diseases. Group III comprise 570 patients (460 females,
mean age 67.94 with arthrosis. Patients have been diagnosed
with osteoporosis based on the DXA results, following specific
treatment. We evaluated in this study the 10-year probability of
osteoporotic fracture using FRAX.We have extended the group
evaluated in a previous study using FRAX-Austria and com-
pared the results with those obtained using FRAX-Romania.
Results:
The 10-year probability of a major osteoporotic fracture and
of a hip fracture was significantly higher when using
FRAX-Austria (p<0.005).
Conclusion(s): The 10-year probability of an osteoporotic
fracture in patients with rheumatologic diseases is significant-
ly lower when it was calculated with FRAX-Romania com-
pared with FRAX-Austria. It is to be emphasized that we
studied the population from western Romania, whose way of
life, structure and pathology are similar with Austrian popu-
lation. Romanian population is heterogeneous in terms of
structure, way of life and associated pathology, and FRAX-
Romania was developed taken in consideration only the pop-
ulation from southern Romania. Based on these facts, we
consider that for the calculation of fracture risk in western
Romanian population, FRAX-Austria suites the best. Patients
with rheumatologic diseases with osteo-articular implications
and associated osteoporosis have a risk of fracture. There were
no significant differences between the risk of an osteoporotic
fracture in patients with different rheumatologic conditions,
regardless the model of FRAX used in evaluation.
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PROSPECTIVE, RANDOMIZED CONTROL STUDY
OF USE OF ARTHROSCOPIC DEBRIDEMENT
WITH OR WITHOUT VISCO SUPPLEMENTATION
IN KNEE OSTEOARTHRITIS
Kiran KVAcharya, Vivek Pandey, Sripathi P Rao
Kasturba Medical College & Hospital, Manipal University,
Arthroscopy & Sports Injuries Service, Manipal, Karnataka,
India
Objective(s): We investigated the effectiveness of arthro-
scopic debridement followed by visco supplementation in
selected patients with knee osteoarthritis.
Material & Methods: The study included 82 patients
(mean age 55±5 years; range 40-70 years) who had knee
osteoarthritis according to the Kellgren Lawrence grade
I, II & III. At three weeks from arthroscopic treatment
(partial meniscectomy and debridement), the patients
were randomly assigned to single intra articular injection
of Hylan G-F 20 (n=41). Evaluations were made preop-
eratively, at three weeks and three weeks after injections
using a patient satisfaction questionnaire, visual analog
scale (VAS), and the WOMAC (Western Ontario and
McMaster Universities) osteoarthritis index. The results in
two groups, viscosupplementation and no viscosupplementa-
tion group were compared.
Results: All patients had significant improvement following
both arthroscopic treatment and visco supplementation. Fol-
lowing visco supplementation, patient satisfaction, WOMAC
and VAS scores were significantly improved in comparison
with no visco supplementation group. Use of concomitant
medication was significantly reduced in the visco supplemen-
tation group.
Conclusion(s): Our early results suggest that arthroscopic
debridement combined with visco supplementation is an
effective treatment option for selected patients with knee
osteoarthritis. However the long term results of 24 month
follow up are awaited.
References: 1. Kellgren J, Lawrence J. Ann Rheum Dis
1957;16:494. 2. American Academy of Orthopaedic Sur-
geons. Treatment of osteoarthritis of the knee (non-arthro-
plasty): Complete guide- line. Rosemont, IL: American
Academy of Orthopaedic Surgeons, 2008. 3. Wobig M,
Dickhut A, Maier R, Vetter G. Clin Ther 1998;20:410. 4.
Waddell DD. Arthroscopy 2010;26:105.
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OSTEOPOROSIS AWARENESS AND 10-YEAR
PROBABILITY OF FRACTURE FROM FRAX®
AMONG COMMUNITY HEALTH PROMOTION
EVENT PARTICIPANTS
Rong-Sen Yang1, Ding-Cheng Chan2,3, Keh-Sung Tsai3,4,5,
Jaw-Shan Hwang6
1National Taiwan University Hospital, Department of
Orthopedic Surgery, 2National Taiwan University Hospi-
tal, Department of Gerontology and Geriatrics, 3National
Taiwan University Hospital, Department of Internal
Medicine, 4National Taiwan University Hospital, Depart-
ment of Laboratory Medicine, 5National Taiwan Univer-
sity Hospital, Bei-Hu Branch, Taipei, 6Chang Gung
Memorial Hospital, Division of Endocrinology and Metab-
olism, Department of Internal Medicine, Taoyuan County,
Taiwan
The 10-year probability of a major osteoporotic fracture and hip
fracture using two models of FRAX.
10-year probability of a
major osteoporotic
fracture (mean range)
10-year probability
of a hip fracture
(mean range)
FRAX-Austria FRAX-Romania FRAX-Austria FRAX-Romania
Group I 16% (5.3-60%) 9.75% (2.1-44%) 7.5% (0.8-51%) 4.4% (0.2-37%)
Group II 14.5% (2.6-51%) 7.9% (1.5-24%) 5.2% (0.2-31%) 2.75% (0.1-15%)
Group III 15% (4.5-47%) 6.4% (0.6-42%) 7.2% (2.2-33%) 2.7% (0.2-29%)
Total 15% (2.6-60%) 8.4% (1.5-44%) 7% (0.2-51%) 3.7% (0.1-37%)
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Objective(s): To report the osteoporosis awareness and
predicted fracture risks among participants who never re-
ceive osteoporosis treatments from 16 community health
promotion events.
Material & Methods: From Aug-Oct 2011, MSD, Taiwan
in cooperation with 3 nongovernmental organizations held
16 community osteoporosis health promotion events. Ques-
tionnaires about osteoporosis awareness and FRAX® tool
were distributed. The answers on FRAX® questions were
entered into the Taiwanese calculator on-site to generate
the10-year probability of fractures. All participants were
provided with the osteoporosis/fracture education booklets
and free consultations by onsite physicians. Participants
who had high risks defined as predicted major osteoporotic
fracture ≥20% or hip fracture ≥3% in 10 years were asked to
visit their primary care physicians for considering osteopo-
rosis treatments. Among the 1248 returned questionnaires,
1240 had complete information for data analysis. Compari-
sons were made between elderly (≥65 years old) and younger
(<65 y/o) adults.
Results: Mean age was 57.8±13.7 years with 76.1% were
women. Only 35.7% knew that 1/3 of Taiwanese women
would have at least on osteoporotic fracture in their life time
and 49.4%) knew that osteoporosis is second only to car-
diovascular disease as a global healthcare problem. Nearly
9/10 (88.5%) plan to visit a physician if they have high
osteoporosis or fracture risks. Close 1/3 (30.4%, hip) and
1/9 (11.5% major osteoporotic) were considered high risks
from FRAX® calculator. Knowledge level did not vary by
age. However, compared with younger adults (n=868,
70%), older participants (n=372, 30%) were thinner, shorter
in height, having more previous fractures, more uses of
glucocorticoid, higher percentage of rheumatoid arthritis,
and secondary osteoporosis. Significantly more older par-
ticipants were considered high risk (83.6% vs. 7.6%, for hip
fracture, 35.5% vs. 1.2% for major osteoporotic fracture,
both p<0.001) than younger participants.
Conclusion(s): In general, community adults who never
receive osteoporosis treatment had inadequate osteoporosis
awareness. However, 1/3 of adults and 6/7 of older adults
had high risk of fracture predicted by FRAX®. Knowing the
fracture risks would increase patient's willingness to visit a
physician to consider appropriate treatments.
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ACTIVITY LIMITATIONS IN PERSONS WITH
OSTEOARTHRITIS IN MEXICO
Diana Avendaño-Badillo1, Francisco Franco-Marina2,
Carolina Duarte-Salazar1, Lorena P Martínez-Ramírez3
1Instituto Nacional de Rehabilitación, Orthopedic Rehabili-
tation, 2Instituto Nacional de Enfermedades Respiratorias,
Epidemiology, Mexico City, 3Hospital CIMA, Neurophysi-
ology, Chihuahua, Mexico
Objective(s): To describe the activity limitations present in
adult Mexicans with a recent diagnosis of osteoarthritis.
Material & Methods: We analyze data from a sample of
Mexican adults participating in the Mexican National Health
and Nutrition Survey (ENSANUT-2006), a probabilistic
multistage survey conducted in 2006. Several questions
were included in ENSANUT-2006 to assess for the presence
of osteoarthritis and the presence of current activity limita-
tions. In our analysis we included the following sociodemo-
graphic variables: Age, education, alcohol and cigarette
consumption and several chronic comorbidities. Variables
related to current activity limitation of any kind in persons
with osteoarthritis were identified through a logistic regres-
sion model.
Results: Among the 45,240 interviewed adults, 267 (0.6%)
reported osteoarthritis of recent diagnosis. Persons with
osteoarthritis of recent diagnosis had an average age of
59.3 years (sd=16.4), 71.6% of them were women, 72.3%
had lower education, 13.5% were current smokers and
24.3% reported alcohol consumption. High blood pressure
was the most frequently reported comorbidity by these
persons (29.2%). 23.7% reported a permanent activity lim-
itation, with 49.6% of them reporting a limitation to walk,
and 30.3% reporting daily life activity limitations. In the
logistic regression model age, permanent limitation and pain
were significantly associated to activity limitation of any
kind.
Conclusion(s): Adult Mexicans with osteoarthritis of recent
diagnosis are more frequently women, with roughly half of
them having a limitation to walk. Persons with osteoarthritis
of recent diagnosis and a current activity limitation of any
kind are more likely to be of older age, to have pain and to
have a permanent limitation.
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THE BENEFICIAL EFFECT OF ICARITIN ON
OSTEOPOROTIC BONE IS DEPENDENT ON THE
TREATMENT INITIATION TIMING IN ADULT
OVARIECTOMIZED RATS
Ge Zhang1, Songlin Peng2, Baosheng Guo1, Bao-Ting
Zhang3, Yixin He1, Xinsheng Yao4, Leungkim Hung1, Ling
Qin2, Wing-Nang Leung5
1The Chinese University of Hong Kong, Department of
Orthopedics & Traumatology, Hong Kong, 2Jinan Universi-
ty Second College of Medicine, Department of Spine Sur-
gery, Shenzhen, Guangdong, 3The Chinese University of
Hong Kong, School of Chinese Medicine, Hong Kong,
4Jinan University College of Pharmacy, Institute of Tradi-
tional Chinese Medicine & Natural Products, Guangzhou,
Guangdong, China
Objective(s): Epimedium-derived flavonoids (EFs) have
potential to treat established osteoporosis in postmenopausal
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women. The beneficial effect of EFs on osteoporotic bone
depends on intervention timing. Icaritin (ICT) was found to
be the intestinal metabolite of EFs. Whether the beneficial
effect of ICT on osteoporotic bone could be also dependent
on the intervention timing remains unknown. Objective was
to evaluate the effect of the treatment initiation timing of
ICT on osteoporotic bone in adult ovariectomized rats.
Material & Methods: Eighty 9-month-old female rats (n=8/
group) were sham-operated (Sham) or ovariectomized
(OVX). The OVX rats were further assigned to early and late
ICT treatment starting at month 1 (early treatment) and month
3 (late treatment) after ovariectomy, respectively. The vehicle-
treated Sham and OVX rats starting at month 1 and month 3
after surgery served as the corresponding controls (Sham and
OVX controls) for early and late ICT treatment. The treatment
lasted for 2 months (40 mg/kg/day). To serve as pretreatment
baseline controls, the Sham and OVX rats were immediately
sacrificed before early and late ICT treatment. The bone
turnover markers, trabecular architecture, bone remodeling
and bone biomechanical properties were analyzed with bio-
chemistry, μCT, histomorphometry and mechanical testing,
respectively. The population of bone marrow stromal cells
(BMSCs) and osteoblasts were evaluated with colony forma-
tion assays, respectively. The expression levels of osteoblast- /
osteoclast-related genes in bone marrow were assessed by
real-time PCR, respectively.
Results: At organ and tissue levels, early ICT treatment
remarkably restored the trabecular bone mass, trabecular
architecture and bone biomechanical properties toward
pretreatment Sham levels, and significantly increased
bone formation from pretreatment OVX level and mark-
edly inhibited bone resorption toward pretreatment
Sham level, whereas late ICT treatment failed. At cel-
lular and molecular levels, early ICT treatment signifi-
cantly increased the osteoblastic colonies and osteoblast-
related gene expressions from pretreatment OVX levels
and remarkably decreased osteoclast-related gene
expressions toward pretreatment Sham levels, whereas
late ICT treatment failed.
Conclusion(s): The beneficial effect of ICT treatment could
be dependent on the intervention timing in established oste-
oporosis induced by estrogen depletion.
Disclosures: Acknowledgments: This study was supported
by the Hong Kong Competitive Earmarked Research Grant
(478508).
P367
URINARY KETONES' POSITIVE ASSOCIATION
WITH BONE METABOLISM IN
POSTMENOPAUSAL KOREAN WOMEN
Duck Joo Lee, JE Sang Hyeon
AjouUniversity Hospital, FamilyMedicine, Suwon, Republic
of Korea
Objective(s): Our study aims to demonstrate the relation-
ship of ketone with bone metabolism in Korean women. To
do so, we measured urinary ketones, obesity indexes, BMD,
anthropometry, and performed laboratory tests related to
bone metabolism.
Material & Methods: We investigated the relationship
between osteoporosis and its potentially related metabolic
parameters in a cross-sectional analysis of 1198 Korean
women (492 premenopausal women and 706 postmeno-
pausal women). In our cross-sectional study, we examined
BMI, waist circumstance, obesity related factors, urinary
ketones, and BMD in Korean women after a fast lasting a
minimum of 8 h (N=1198).
Results: The positive urinary ketone groups in pre and post-
menopausal women showed better BMD than the negative
urinary ketone group. In premenopausal women, BMI, waist
circumstance, triglyceride, systolic blood pressure, insulin,
HOMA-IR (Homeostasis of measurement assessment-insulin
resistance), and alkaline phosphatase were negatively associ-
ated with ketonuria after adjusting for age, smoking, and
alcohol use. The odds of having ketones decreased in the
osteoporosis group, compared to the non-osteoporosis group
(OR=0.312, P=0.028 in postmenopausal women)
Conclusion(s): The presence of ketonuria after a fast lasting
at least 8 h may have metabolic benefits on BMD in post-
menopausal women.
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CO-MORBID MEDICAL CONDITIONS
ASSOCIATED WITH PREVELANT
HYPOPARATHYROIDISM: A
POPULATION-BASED STUDY
Bart L Clarke1, Cindy L Leibson2, Jane A Emerson2,
Jeanine E Ransom2, Hjalmar Lagast3
1Mayo Clinic, Department of Internal Medicine/Endocrinology,
2Mayo Clinic, Department of Health Sciences Research,
Rochester, MN, 3NPS Pharmaceuticals, Inc., Clinical Devel-
opment and Medical Affairs, Bedminster, NJ, US
Objective(s): Hypoparathyroidism (HypoPARA) is a rare
condition with widespread consequences, ranging from
asymptomatic presentation to fatal hypocalcemia. Population
estimates of prevalence of HypoPARA across the full range of
disease and associated patient characteristics are lacking.
Material & Methods: Using unique longitudinal, popula-
tion-based Rochester Epidemiology Project (REP) medical
records linkage resources, we 1) identified all persons resid-
ing in Olmsted County, MN, in 2009 with any diagnosis of
HypoPARA assigned by a REP provider since 1945, 2)
reviewed detailed medical records to confirm diagnosis of
HypoPARA and assign etiology, 3) assigned 2 age- and sex-
matched controls per confirmed case, and 4) obtained all
medical diagnoses from 2006-2008 to compare cases with
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controls for percent with any diagnosis in each chapter and
subchapter of the International Classification of Diseases,
Version 9, Clinical Modification (ICD-9-CM).
Results: There were 54 confirmed cases (prevalence=37/
100,000; 71% female; mean age 58±20 years); etiology=
78% postsurgical, 9% secondary, 7% familial, 6% idiopathic.
Cases were more likely than controls (p<0.05) to have ≥1
diagnosis within 7 of 17 chapters and 15 subchapters. Details
on specific chapter and subchapter differences are provided in
the table.
Comorbidities Associated With Hypoparathyroidism
Chapter Level Yes; (Subchapter Level) Yes
Infectious/Parasitic Diseases (Mycoses)
Neoplasms (Malignancies of Genitourinary Organs; Other/Unspecified
Malignancies; Benign Neoplasms)
Endocrine/Nutritional/Metabolic/Immunity Disorders (Disorders of
Thyroid Gland; Disorders of Other Endocrine Glands; Nutritional
Deficiencies; Other Metabolic/Immunity Disorders) (Disorders of
Thyroid Gland; Disorders of Other Endocrine Glands; Nutritional
Deficiencies; Other Metabolic/Immunity Disorders)
Genitourinary System Diseases (Other Diseases of the Urinary System)
Diseases of the Skin/Subcutaneous Tissue (Other Diseases of the Skin/
Subcutaneous Tissue)
Chapter Level Yes; (Subchapter Level) No
Respiratory Diseases; Congenital Anomalies
Chapter Level No; (Subchapter Level) Yes
Nervous System Diseases (Peripheral Nervous System Diseases)
Digestive Diseases (Other Diseases of Intestine/Peritoneum)
Circulatory System Diseases (Ischemic Heart Disease; Other Heart
Disease)
Musculoskeletal Diseases (Rheumatism Excluding the Back)
Chapter Level No; (Subchapter Level) No
Diseases of Blood/Blood Forming Organs; Mental Disorders;
Pregnancy Complications; Perinatal Conditions; Symptoms/Signs;
Injury/Poisoning
Table: Increased likelihood that persons with vs. those with-
out confirmed diagnosis of HPT had any diagnosed medical
condition within each ICD-9-CM chapter/subchapter.
Conclusion(s): These population-based data on confirmed
HypoPARA prevalence and case characteristics reveal that,
compared to unaffected peers, persons with HypoPARA
exhibit a substantial burden of comorbid disease across
multiple dimensions.
References: 1. Bilezikian JP, Khan A, Potts JT Jr, et al. J
Bone Miner Res 2011;26:2317. 2. Melton LJ, III. Mayo Clin
Proc 1996;71:266. 3. Shoback D. New Engl J Med
2008;359:391. 4. Marx SJ. New Engl J Med 2000;343:1863.
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OSTEOPOROSIS RISK FACTORS FOR
POSTMENOPAUSALWOMEN
Mariana I Cevei1, Dorina C Stoicanescu2
1University of Oradea, Faculty of Medicine and Pharmacie,
Psiho-Neuroscience and Rehabilitation Department, Ora-
dea, Bihor, 2University of Medicine and Pharmacie Victor
Babes, Preclinical Department, Timisoara, Timis, Romania
Objective(s): Osteoporotic fractures result in substantial
indirect and hidden costs. We aimed to detect major fracture
risk and hip fracture risk in a group of patients residing in
rural areas.
Material & Methods: Total lot consisted of 162 postmen-
opausal women: 80 patients from rural areas formed group I
and 82 from urban area formed group II. All filled out the
IOF One-Minute Osteoporosis Risk Test - 2007, the question-
naire consisting of 19 questions that evaluate osteoporosis risk
factors. The diagnosis of osteoporosis was established by
DXA investigation.
Results: The mean age was years 61.13±15.2, ranging
between 45 and 82 years. Mean risk factors was 2.1. The
incidence of risk factors in the 2 groups is presented in
Table 1.
Table 1. The distribution of risk factors in patients with osteoporosis
RISK FACTORS LOT I (n=80) LOT II (n=82)
Parents with osteoporosis 16.25% 37%
Early menopause 35% 67%
Kyphosis and height decrease 40% 44%
Smoking 5% 9.75%
Secondary osteoporosis 12.5% 24.4%
Underweight 10% 37.5%
Sedentarism 22.5% 62.5%
Less than 10 minutes sunlight
exposure/day
20% 24.4%
Frequent falling tendency 40% 65.8%
Average duration of menopause until the investigation was
184±32.4 months in the first group and 212±62.5 months in
the second group.
Conclusion(s): The analysis reveals that there are differ-
ences between risk factors for osteoporosis in postmeno-
pausal women in rural and urban areas. Family history of
osteoporosis, early menopause, secondary osteoporosis,
sedentary lifestyle and falling tendency are more common
in urban women. We strengthen the need to investigate risk
factors, BMD and fracture risk in postmenopausal women
for a proper treatment.
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EFFICACY OF PHYSICAL EXERCICE IN PATIENTS
WITH OSTEOPOROSIS
Adrian C Bighea, Iulia R Marcu, Simona Patru, Roxana
Popescu
University of Medicine and Pharmacy of Craiova, Physical
Medicine and Rehabilitation, Craiova, Romania
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Objective(s): The aim of this study was to assess the efficacy
of a 6 months ambulatory exercise program on functional
status and quality of life in women with postmenopausal
osteoporosis.
Material & Methods: The randomized controlled obser-
vational study included 81 patients with postmenopausal
osteoporosis, mean age 68.7±7.3 years, randomly
assigned to a control group (40 patients) and an exer-
cise group (42 patients). All patients were diagnosed
with osteoporosis based on DXA assessment and had
a stable cardiovascular status. All patients continued to
take their prescribed medication for osteoporosis. They
followed exercise programs based on increasing spinal
mobility, muscular strength and endurance, improving
balance, coordination, respiratory exercises. The patients
in the control group continued their daily living activi-
ties. The evaluation was made at the beginning of the
study and after 6 months based on spinal mobility,
muscular strength, pain assessment on a Visual Ana-
logue Scale (VAS) and quality of life evaluation using
SF-36 Questionnaire.
Results: The benefits of the kinetic programs were
shown by a significant improvement on spinal mobility
and muscular strength for spinal extensor and abdominal
flexor muscles. Pain, evaluated on a Visual Analogue
Scale, had a mean decrease of 3.56 points and the results
were also strong statistic significant (p<0.01). For SF-36
Questionnaire, the best results were obtained for vitality
(37.2% amelioration), mental health (20.8% ameliora-
tion) and body pain (53.5% amelioration) domains and
were also statistic significant (p<0.05). For muscular
strength, the values we obtained followed an ascendant
curve for all the tested muscular groups. The results for
the control group remained basically unchanged. The
compliance of the study participants was very good; only
three patients did not completed the 6 months training
program.
Conclusion(s): The physical exercise program improves
both functional status and quality of life in patients with
postmenopausal osteoporosis by increasing spinal mobility
and muscular strength and by reducing pain. Kinetic pro-
grams that combine aerobic exercise with exercises for
increasing muscular strength and endurance, balance and
coordination should be introduced in the rehabilitation pro-
grams of patients with osteoporosis without medical contra-
indications for moderate level exercise.
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REDUCED BONE MINERAL DENSITY (BMD) IN
HEALTHY MALE WHITE-COLLAR WORKERS IN
URBAN CHINA
Jicong Gui1, Brašic Robert James2, Xingdang Liu1, Congjin
Liu1, Guangqi Gao1
1Huashan Hospital, Fudan University, Department of Nuclear
Medicine, Shanghai, China, 2The Johns Hopkins University,
School of Medicine, Johns Hopkins Outpatient Center, Divi-
sion of NuclearMedicine, The Russell H.Morgan Department
of Radiology and Radiological Science, Baltimore, MD, US
Objective(s): Although the status of BMD and the preva-
lence of risk factors for osteoporosis have been evaluated in
mature men, the characteristics of osteoporosis in young
men are unknown. The aim of this study was to investigate
the status BMD in healthy, young and middle-aged male
white-collar workers in Shanghai.
Material & Methods: The medical records from April
2007- August 2011, of physical health examinations at
Huashan hospital in Shanghai were reviewed. The partici-
pants were 3991 healthy young white-collar males, aged 20-
59 years old, without disorders known to affect bone or
calcium metabolism. Their hip and spine BMD was mea-
sured by Hologic QDR Discovery-W DXA.
Results: The peak BMD occurred in the group aged 20-29
years (total hip 0.970±0.138 g/cm2, neck 0.829±0.138 g/
cm2, troch 0.695±0.111 g/cm2) (P<0.05). The prevalence of
osteoporosis and low bone density in this study was calcu-
lated according to not only Hologic-supplied Caucasian
cutoffs, but also Chinese cutoffs reported respectively from
three recent studies in Shanghai[1], Changsha[2], and Hong
Kong[3]. Even the lowest prevalence of low bone density
among the four results as high as 40.74% (aged 20-29),
42.63% (aged 30-39), 42.78% (aged 40-49) and 47.70%
(aged 50-59).
Conclusion(s): We conclude that low BMD is highly prev-
alent in young white-collar males in Shanghai, likely result-
ing from the unhealthy lifestyles of modern young Chinese
males in urban areas.
References: 1. ZL Zhang, YJ Qin, QR Huang, et al. Asian J
Androl 2006;8:419. 2. LJ Tan, SF Lei, XD Chen, et al. J
Bone Miner Metab 2007;25:114. 3. HS Lynn, EMC Lau, B
Au, PC Leung. Osteoporos Int 2005;16:1663.
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PREVENTIONOF FALLSAMONGOLDERPATIENTS
IN THE HOSPITAL ENVIRONMENT: A NURSE
LED PREVENTION PROGRAMME
Georgina Steen, NiamhMaher, Kara Fitzgerald, Nessa Fallon,
David Robinson, Miriam Casey, Joseph Harbison, Roseanne
Kenny, James B Walsh, Conal Cunnungham
St. James's Hospital, Mercer's Institute for Successful Ageing,
Dublin, Ireland
Objective(s): Falls are the leading cause of injury in the
older person (over 65 years). Research suggests that one
third of people over the age of 65, and half over the age of
80 have had a fall in the last year. One tenth of these have
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had multiple falls requiring hospitalisation. Falls are a lead-
ing cause of hospitalisation for the elderly and 7% of falls
result in injuries, with another 3% of falls result in hip
fractures 1-2.
Material & Methods: Since 2004, patients admitted to the
Medicine for the Elderly department (MedEl) are assessed
for falls risk. The “STRATIFY” tool identifies those deemed
at a high risk of falling. These patients are identified with I.
D. bracelet, bedside notification and are offered External
Hip Protectors. Patients who have fallen are further assessed
by the Clinical Nurse Specialist (CNS) who advises them
and the staff of how to prevent future falls. The role of the
CNS in falls prevention also includes an educational pro-
gram that includes the development of on-going staff train-
ing in falls prevention and a regular in-patient audit program
evaluating the effectiveness of our nursing practice.
Results: We looked at our fall rates in MedEL from 2004-
2011 and found that there was a 24% decrease in falls. The
current fall rates is 5.2 falls per 1000 bed days. Of the
patients who fell in 2011, 3% sustained a fracture in com-
parison to 13% sustaining a fracture in 2010.
Conclusion(s): Our results suggest that a thorough and
comprehensive assessment of patients reduced the number
of falls and injuries within our service. The future challenge
is a further reduction in fall rates and falls related injuries in
our department.
References: 1. Guideline for the prevention of falls in
older persons. American Geriatrics Society, British Geri-
atrics Society, and American Academy of Orthopaedic
Surgeons Panel on Falls Prevention. J Am Geriatr Soc
2001;49:664. 2. Rubenstein LZ, Powers C. Clin Geriatr
Med 2002;18:141.
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SEX SPECIFIC ASSOCIATIONS OF PHYSICAL
ACTIVITY ON PROXIMAL FEMUR BMD IN 9-10
YEARS OLD CHILDREN
Graça Cardadeiro1, Fátima Baptista1, Rui T Ornelas2, Luís
B Sardinha1
1Faculty of Human Movement, Technical University of
Lisbon, Exercise and Health Laboratory, Lisbon, 2University
ofMadeira, Centre of Social Sciences, Department of Physical
Education and Sport, Funchal, Portugal
Objective(s): The increase in femoral bone mass and strength
in pre and pubertal children has been reported as a response to
physical activity (PA) intervention programs, with the major-
ity of studies showing that femoral neck sensitivity (as a
surrogate of proximal femur sensitivity) tomechanical loading
is higher in boys than in girls. Thus, the purpose of this work
was to investigate sex specific associations between everyday
PA and BMD of three regions of proximal femur in pre and
early pubertal boys and girls aged 9-10 years.
Material & Methods: BMD at the femoral neck, trochanter
and intertrochanter regions, and lean mass of the whole
body were assessed using DXA in 161 girls (age: 9.7±0.3
yrs; body mass: 34.2±9.0 kg body height: 137.2±0.1 cm)
and 164 boys (age: 9.7±0.3 yrs; body mass: 34.1±7.1 kg
body height: 137.0±0.1 cm). PA was measured by acceler-
ometry. Multiple linear regression analyses were used to
explain the variance in BMD accounted for by PA at the
three regions of the proximal femur. Adjustments were
made for body height, total lean mass and pubertal status.
Results: Vigorous PA explained 3-5% of the variability in
BMD at all three subregions in boys. In girls, vigorous PA
explained 4% of the variability in intertrochanter BMD and
6% in trochanter BMD. PA did not contribute to the vari-
ance in FN differences in girls. An additional 10 minutes per
day of vigorous physical activity (the best single predictor of
BMD within physical activity variables) was associated with
a ~2% higher trochanteric and intertrochanteric BMD in
girls, while in boys it was related to a ~1% higher femoral
neck, trochanter, and intertrochanteric BMD (p<0.05).
Conclusion(s): Proximal femur response to weight-bearing
physical activity may differ between boys and girls aged 9-
10 years old, particularly in the femoral neck. Boys showed
a more homogeneous response among the three regions of
proximal femur, while a significant greater bone density in
the trochanteric and interthocanteric regions was observed
in the more active girls, compared with less active girls.
Disclosures: Funded by Portuguese Science and Technolo-
gy Foundation (SFRH/BD/38671/2007 and PTDC/DES/
115607/2009).
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ATYPICAL FRACTURES IN PATIENTS ON LONG
TERM IV BISPHOSPHONATE
Michael WJ Davie, Tracey J Roberts, Diane E Powell
Robert Jones & Agnes Hunt Orthopaedic Hospital NHS
Foundation Trust, Charles Salt Centre for Human Metabolism,
Oswestry, Shropshire, UK
Objective(s): Atypical femoral fractures are reported in
patients taking bisphosphonates (BP). The aim of this study
was to identify patients with these fractures in patients using
an IV BP Service.
Material & Methods: 799 patients were on IV BP. At
review radiographs of the femora were taken in patients
with thigh pain. Diagnosis was made if elevation or fracture
of the lateral cortex were present. BMD was measured at IV
treatment initiation and at the time of fracture. Duration and
dose of BP treatment were noted.
Results: 21 patients (2 m/19f: 2.6%) were found to have
femoral fractures. 15 had osteoporosis; 2 Osteogenesis Imper-
fecta and 4 had other diagnoses (cases of Paget's disease
excluded). Treatment with BP had been for 10.8±5.9 yr
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(range 2-23 years). 10 patients were on pamidronate and 11 on
zoledronate at time of fracture, including 8 who had converted
from other IV BPs. 17 patients had received pamidronate
(Total dose 2619±1407mg) and 11 zoledronate (10mg (range
2-60mg)) whilst 10 previously had oral BP. 2 patients were on
corticosteroids and 12 on a proton pump inhibitor. Osteopo-
rosis was present in 78.9% at treatment initiation in the LS and
32% at the FN and in 32% of subjects at LS and 21% at FN at
fracture. LS BMD had increased significantly (0.766 to 0.901
g/cm2; P<0.001) but not at the FN (0.640 vs. 0.638 g/cm2).
One patient had had radiographs of the pelvis for other reasons
in 2005 (no fracture) and also in 2008 when an asymptomatic
atypical fracture was present but not reported. In 2011 after 20
years of pamidronate she became symptomatic and required
surgical intervention.
Conclusion(s): IV BP treatment increased BMD at the spine
but not FN, in most subjects the latter site was not osteopo-
rotic at commencement or at fracture. Nonosteoporotic
BMD at the FN may be a risk factor for atypical fracture.
Most patients had received IV BP for many years. The need
for regular review is suggested by the patient in whom an
asymptomatic atypical fracture was overlooked, but the
frequency and method of review remains to be determined.
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ROLE OF INFLAMMATION IN CARTILAGE
DAMAGE, FUNCTIONAL STATUS AND
SYMPTOMS IN PATIENTS WITH KNEE
OSTEOARTHRITIS: AN ULTRASONOGRAPHY
STUDY
Vlado Skakic1, Vesna Bosnjakovic1, Jelena Jovanovic1,
Aleksandar Skakic2
1Institute for Treatment and Rehabilitation Niska Banja,
Rheumatology, 2Institute for Treatment and Rehabilitation
Niska Banja, Physical Medicine, 3Institute for Treatment and
Rehabilitation Niska Banja, Physical Medicine, 4Medical
Faculty Nis, Research, Nis, Serbia
Objective(s): To examine role of the inflammation on the
thickness of the cartilage. To correlate clinical pain with carti-
lage thickness and presence of the synovitis. To find correla-
tion between functional impairment and cartilage damage.
Material & Methods: 50 outpatients with painful knee OA
(41 female, mean age 63), have been examined in order to
establish influence of different factors on cartilage damage.
We had two groups (41-59 and 60-81) in order to find out
age differences in clinical parameters and cartilage thick-
ness. A rheumatologist recorded the presence of knee joint
pain, patient's assessment of knee pain using VAS scale, and
Lequesne Index of severity for knee OA (LI). Other rheu-
matologist, blinded to the clinical data, performed the knee
US examination, registering the presence effusion and thick-
ness of the cartilage of femoral trochlea of both condyles.
Results: Difference of cartilage thickness for medial and
lateral compartment, in female (1.7 mm and 1.8 mm), vs.
male group (1.8 mm and 1.9 mm) were statistically
nonsignificant. Female vs. male group (36 mm and 31
mm) had higher values of pain and LI of severity (6.8
and 7.8) statistically nonsignificant. Male group had
more effusions than female group, statistically nonsignif-
icant (28% and 24%). In older age group, cartilage
thickness was 1.6 mm for medial and 1.7 mm for lateral
condyle, significantly lower than in younger group (2.0
mm and 2.1 mm). Value of pain in older group vs.
younger (32 mm and 36 mm). Mean LI in older group
was 7.9 vs. younger group 6.9. We found effusion in
25% of knees. Cartilage thickness in knees with effusion
was (medial 1.6 mm, lateral 1.8 mm), in group without
effusion (1.8 mm and 1.9 mm) statistically nonsignifi-
cant. Pain and LI in group with effusion were (39 mm
and 8.3), in group without (34 mm and 7.4). Negative
correlations were demonstrated between the cartilage
thickness and age. Significant correlations were found
of pain and LI with age.
Conclusion(s): We didn't find correlation between knee
joint effusion and cartilage damage. Most important param-
eter which correlated with cartilage damage, pain and
Lequesne Index of severity of OA was age.
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LONG-TERM (3 YEARS) REPRODUCIBILITY FOR
THE RADIOLOGICAL ASSESSMENT OF KNEE
OSTEOARTHRITIS
Rita Deroisy1, Olivier Bruyère1, Deborah Gensburger2,
Roland Chapurlat2, Jean-Yves Reginster1
1CHU Liège, Unité d'Exploration de l'Os et du Cartilage,
Liège, Belgium, 2INSERM, Research Unit 1033 and Univer-
sity of Lyon, Lyon, France
Objective(s): To confirm that the reproducibility remains
stable over time for the radiological measurement of joint
space narrowing (JSN) in knee osteoarthritic patients.
Material & Methods: 70 females from the OFELY1 cohort
with radiological osteoarthritis (Altman scoring >2) per-
formed at baseline and 48 months later knee x-rays using a
standardized fluoroscopically semi-flexed with positioning
frame protocol. A single experienced reader, trained for a
validated2 semiautomated device, read twice 70 pairs of
knee x-ray with knowledge of time sequence in April
2009, 2010 and 2011. Intra reader precision was assessed
for JSN using an intraclass correlation coefficient (ICC), the
mean difference and limits of agreement on a Bland Altman
graph.
Reproducibility has been measured in 2009, 2010 and 2011
(Table I). 2009 was compared to 2010 and 2011. 2010 was
also compared to 2011 (Table II).
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Results: Cf Tables:
Table I: Reproducibility has been measured in 2009, 2010 and 2011
Table II: 2009 was compared to 2010, 2011 and 2010 compared
to 2011
Conclusion(s): This study shows that reproducibility of a
single experienced reader, using a semiautomated reading de-
vice is good and stable over time. This is an essential condition
to evaluate the cartilage loss in long term osteoarthritis studies.
References: 1. Delmas P. JBMR 1997;12:683. 2. Gensburger
D et al. Arthritis Rheum 2009;61:336.
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THE CLINICAL RESULT OF SURGICALLY
TREATED FEMUR FRACTURES AFTER
LONG-TERM BISPHOSPHONATE THERAPY
In-Soo Oh
Incheon St. Mary's Hospital, Orthopaedic Surgery, Incheon,
Korea
Objective(s): The purpose of this study is to analyze the
result of surgically treated atypical femur fractures after
long-term bisphosphonate therapy.
Material & Methods: Total 12 cases with using long-term
bisphosphonate therapy were enrolled. All of the patients were
female, and mean age was 67.3 years old. The examples of 11
cases represented subtrochanteric fractures, and the remaining
1 case showed distal shaft fracture in the femur. The internal
fixation of fractures was decided based on the characteristics
of types of fracture. The proximal femoral nailing was used in
7 cases, and dynamic hip screws and compression plate were
used in 4 cases of subtrochanteric fractures. For the fracture in
the shaft of femur, two plates were used and fixed with screws.
Among the total of 12 cases, allogenic iliac bone graft was
done in 7 cases. The bone density of the patients was mea-
sured. In addition, dates of use of bisphosphonate and of bony
union after the surgery were numerically calculated.
Results: The mean T-score was found as -2.1 in the neck of
femur and -2.0 in the lumbar spines. The mean dates of use of
bisphosphonate were calculated as 4.9 years (in the range
from 2-7 years). The proximal femoral nailingmethod showed
2 cases of nonunion and 1 case of metallic failure, leading to
secondary surgical approach. The rest of PNA method groups
showed bony union in 9 months of surgery. The patient
underwent dynamic hip screws and compression plate showed
bony union in 7 months of surgery. Irrelevantly to the types of
internal fixation, the group of patients underwent AIBG made
bony union in all cases, rather than 3 cases of 5 patients
without AIBG showed nonunion or metallic failure.
Conclusion(s): Atypical fractures after long-term bisphosph-
onate therapy, especially the subtrochanteric fracture in the
femur crucially requires internal fixation with AIBG since the
cortical sclerosis of the bone is provided by decreased rate of
bone turnover.
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PRIORITY RISK FACTORS OF OSTEOPOROSIS
IN WOMEN OF BELARUS
N M Predko1, AV Rudenka2
1Minsk City Healthcare Committee, Department of Healthcare,
2Belarusian Medical Academy of Postgraduate Training, Chair
of Rheumatology and Cardiology, Minsk, Belarus
Objective(s):Problems of diagnostic of decreasing of BMDand
revealing patients with high risk of low trauma fractures take an
important place in modern healthcare due to the high economic
and social expenditures for the treatment and rehabilitation of
patients with low trauma fractures. The aim of our study was to
evaluate the most prognostic important risk factors of low BMD
in postmenopausal women by using the method of questioning.
Material & Methods: There were examined 507 postmen-
opausal women (mean age 56.8±8.3 years). Risk factors of
osteoporosis were evaluated by the IOF questionnaire,
BMD of lumbar spine and hips was measured by DXA
(Lunar Prodigy, GE, USA). Statistical analysis was per-
formed using the software Statistic 6.0
Results: The analysis of obtained data revealed the most
prognostic important for low BMD questions: question No.
1 - Have either of your parents been diagnosed with osteo-
porosis or broken a bone after a minor fall (a fall from
standing height or less)?; question No. 4 - Have you ever
broken a bone after a minor fall, as an adult?; question No. 6 -
After the age of 40, have you lost more than 3 cm in height?
The answers to the rest questions were the same in different
Intra reader
reproducibility
ICC [95% CI] Mean difference;
mm±SD+
[95% CI]
Limits of
agreement;
mm Bland
Altman
2009 0.799 [≥0.714] -0.079±0.40
[-0.175;0.016]
[-0.864; 0.705]
2010 0.931 [≥0.899] 0.005±0.21
[-0.045; 0.056]
[-0.412; 0.423]
2011 0.905 [≥0.861] -0.017±0.25
[-0.078; 0.043]
[-0.519; 0.485]
Intra reader
reproducibility
JSN
ICC
[95% CI]
Mean difference;
mm±SD+[95%
CI]
Limits of
agreement;
mm Bland
Altman
2009 vs. 2010 0.815
[≥0.737]
-0.055±0.37
[-0.145; 0.034]
[-0.792; 0.681]
2009 vs. 2011 0.791
[≥0.704]
-0.078±0.40
[-0.174; 0.018]
[-0.872; 0.715]
2010 vs. 2011 0.882
[≥0.829]
-0.022±0.28
[-0.089; 0.044]
[-0.575; 0.530]
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groups (questions 9-10 and 12-18) or the amount of the
affirmative answers were so small that these questions
couldn't be included in statistical analysis (questions No. 3,
7, 8, 14, 15). The specificity of the model of prognosis of
probability of decreased BMD consisted 97%, in other word,
the probability not to administer bone densitometry to the
patient with low BMD using this model is 3%.
Conclusion(s): The most prognostic important risk factors of
low BMD in women are family history of low trauma frac-
tures, fragility fractures in anamnesis and decreasing of height
for 3 and more cm after age of 40. The method can be used
widely in clinical practice to reveal individuals with the risk of
low BMD for their further examination and treatment.
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ASSOCIATIONS BETWEEN VITAMIN D AND
CONTENT OF AMINO ACIDS IN PATIENTS
WITH COXARTHROSIS
Liudmila V Yankovskaya1, Yevgeny M Doroshenko2
1Grodno State Medical University, Polyclinic Therapy,
2Grodno State Medical University, Central Research Labora-
tory, Grodno, Belarus
Objective(s): The aim of the present study was to establish
associations between the serum level of vitamin D (25(OH)
D) and PTH and the content of free amino acids (AAs) in
blood plasma and bone tissue (BT) in patients with stage III
coxarthrosis.
Material & Methods: Samples of compact and spongy
tissue from femoral neck and those of blood serum were
taken from 12 patients (6 women and 6 men aged 54.6±9.9
years) hospitalized for hip joint replacement due to coxarth-
rosis. The content of 32 free AAs was determined in both
blood plasma and BT in their perchloric acid extracts using
reversed-phase high performance liquid chromatography
with pre-column derivatization on the Agilent-1200 chro-
matograph. Serum level 25(OH)D and PTH were deter-
mined with the enzyme immunoassay analyzer «Sunrise»
(«Tecan», Austria) using the reagents DRG (USA). Blood
sampling was performed from September till March.
Results: The content of practically all AAs in particular that
of ethanolamine, esparagine and isoleucine in spongy sub-
stance of BT in patients with stage III coxarthrosis was
higher than in compact substance. We determined that ac-
cumulation of AAs (their level in bone tissue exceeding that
in plasma) in spongy BT occurred in the following order:
Cys>EA>Asn>Ile>Lys>Gln>Orn>Tau>α-AAA>Thr. In
compact BT accumulation of AAs occurred in the following
order: Cys>EA>Asn>Ile>Gln>Lys>α-AAA>Thr>Tau>
Val. Met and Phe didn't accumulate in BT. All the examined
patients had vitamin D deficiency in blood plasma. Serum
level 25(OH)D was 20.53±6.4 nM/l, the level of PTH was
32.98±11.7 pg/ml. There were strong positive correlations
between the serum level 25(OH)D and a number of plasma
AAs: PAE (r=0.92), Asn (r=0.73), Gly (r=0.89), Ala (r=
0.75), HPro (r=0.82). There was a strong negative correla-
tion between the serum level 25(OH)D and the level of
cysteic acid (r=-0.93) in spongy BT. We found no correla-
tions between the level of PTH and content of AAs.
Conclusion(s): The level of vitamin D had strong positive
correlations with a number of AAs in blood plasma and a
negative correlation with the level of cysteic acid in spongy
BT.
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OSTEOARTHRITIS OF THE HIP AND KNEE IN
ASSOCIATION WITH OVERWEIGHT
Gordana D Stefanovski1, Zana Banjanin2
1IPMR "Dr M. Zotovic", Rheumatology, 2CBR, Dom
zdravlja, Laktaši, Family Medicine, Banja Luka, Republic
of Srpska, Bosnia and Herzegowina
Objective(s): The aim was to examine the relation between
overweight and osteoarthritis (OA) of the hip and knee in
the population of Banjaluka region.
Material & Methods: Retrospective, population-based
study included 865 patients (mean age 59.08) treated for
symptomatic or radiographic OA from January 2005-
September, 2010. We assessed the percentage of overweight
patients (as defined by BMI of ≥30 kg/m2) who had OA.
Results: From 865 participants, 295 (34.1%) had OA of hip
(199 or 67.46% female and 96 or 32.24% male). OA of the
knee was found in 570 (65.9%) participants (376 or 65.96%
female and 194 or 34.04% male).BMI >30 was found in 95
(30.6%) patients with hip OA (68.42% female and 31.58%
male) and in 221(69.94%) patients with OA of the knee
(72.4% female and 27.6% male).
Conclusion(s): Overweight is significantly associated with OA
of the knee. Obesity increases the risk of developing hip OA,
though the correlation is not as strong as it is with knee OA.
References: 1/ Messier SP, Loeser RF, Miller GD, Morgan
TM, et al. Arthritis Rheum 2004;50:1501. 2/ Executive sum-
mary of the clinical guidelines on the identification, evalua-
tion, and treatment of overweight and obesity in adults. Arch
Intern Med 1998;158:1855. 3/ Tukker A, Visscher TLS, Pic-
avet HSJ. Public Health Nutrition 2008;12:359.
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DENOSUMAB IN POSTMENOPAUSALWOMEN
WITH OSTEOPOROSIS – EARLY ADVERSE EVENTS
RELATED TREATMENT
Panayot Solakov, Stefka Kuzmanova
Medical University, Clinic of Rheumatology, Plovdiv, Bulgaria
Objective(s): Denosumab is a human monoclonal IgG2 anti-
body with a very high affinity and specificity to RANKL
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blocking RANK and thereby inhibits the osteoclast activation,
and increasing bone density. The unique effect of denosumab is
very different from bisphosphonates. Denosumab is more effi-
cient treatment in improving bone mechanical properties and
reduced the risk of vertebral, hip, and other types of fracture.
The postdose adverse events principally are not serious.
Material & Methods: We enrolled 31 women between the
ages of 56-82 years who had a BMD T-score of less than -2.5
but not less than -4.0 at the lumbar spine or total hip. BMD
was evaluated by DXA. Subjects received 60 mg denosumab
subcutaneously, twice yearly. 17 women had taken before oral
or intravenous bisphosphonates for <3 years. All women
received 500-1000 mg of calcium and 400-800 IU of vitamin
D. Patients had serum calcium level. 2.00-2.75 mmol/L and
calculated creatinine clearance >30 ml/min. Lateral spine
radiographs were taken annually for vertebral fractures.
Patients were monitored for 3 months after denosumab appli-
cation with telephone and clinic visits. Safety was assessed by
the recording of all adverse events and serious adverse events
(SAE) by: physical examination, monitoring hematological,
blood- chemical, urinary values, fever and ECG.
Results: Denosumab treatment adverse events did not ob-
serve. In first-month therapy interval nonvertebral, hip and
vertebral fractures did not establish. SAE, mild-to-moderate
postdose symptoms after injection – pyrexia, myalgia, head-
ache, arthralgia, local reaction, infection and cardiovascular
events (including atrial fibrillation) did not report. No case
of osteonecrosis of the jaw was occurred.
Conclusion(s): Denosumab had a favorable safety profile
and is well tolerated. There were no adverse events and SAE
in enrolled 31 postmenopausal women.
References: RB Hopkins at al. Musculo skelet disord
2011;9:209.
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DEFEROXAMINE INCREASE BONE
MINERALIZATION DENSITY OF
POSTMENOPAUSAL OVARIECTOMY MODEL
AND PROMOTE BIOLOGICAL ACTIVITY OF
OSTEOBLAST IN VITRO
Yong Ma1, Youjia Xu2, Nanwei Xu1, Chen Yu2
1The Second People's Hospital of Changzhou, Orthopaedics,
Changzhou, 2the Second Affiliated Hospital of Soochow
University, Orthopaedics, Suzhou, Jiangsu, China
Objective(s): To investigate improvement of BMD by
deferoxamine (DFO) intervention for osteoporotic model
and its possible mechanism for osteoblast in vitro.
Material & Methods: 40 SD rats were divided into four
groups, as ovariectomized model, ovariectomized model
with DFO (100 mg/kg, twice a week) intervention, sham
group and control group. After 12 weeks research, serum
ferritin, serum iron and BMD were detect. Osteoblasts
(hFOB1.19) were cultured with different concentrations of
DFO (0, 5, 10, 20 μmol/L), respectively. MTT assay was
used to detect osteoblast activity after 24 h. Alkaline phos-
phatase (ALP) activity was measured by ALP kit after 10
days. Von kossa staining was used to counted calcium
nodules after 15 days. Type I collagen (COL1) mRNA and
protein expression were detect by RT-PCR and western blot
after 72 h.
Results: The sham group and control group showed no
significant difference. Compared with control, BMD of model
group was significantly lower, meanwhile serum iron and
ferritin increased significantly (P<0.05). Compared with
model group, BMD of DFO intervention group increased
significantly, and with serum iron and ferritin significant
decrease (P<0.05). In vitro, cell proliferation viability was
stimulated at 5 μM, but depressed at 10 μM and 20 μmol/L
(P<0.05). The ALP activity was promoted by DFO with
concentration dependently (P<0.05). The number of mineral-
ized nodules were increased significantly with DFO treatment
at 5, 10 μmol/L and decreased at 20 μmol/L (P<0.05). The
mRNA expression of COL1 was promoted significantly by
DFO (5-20 μmol/L) (P<0.05). The protein expression of
COL1 was promoted by DFO treatment at 5, 10 μmol/L and
inhibited at 20 μmol/L (P<0.05).
Conclusion(s): The model of osteoporosis existed iron
overload, which improved by DFO treatment. DFO had
effects on cell culture in vitro, with low-dose stimulation
and with high-dose inhibition on osteoblasts activity. DFO
might be used as a new type of osteoporosis treatment,
further research needs to be carried out.
Disclosures: This work was supported by Grant Project:
Natural Science Fund of Jiangsu Province (NO.
BK2008165) and Doctoral Fund of Ministry of Education
(NO.20103201110020).
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KNEE OSTEOARTHRITIS FEMALE PATIENTS'
ADHERENCE TO PHYSICAL EXERCISES
Artem A Popov, Nadezhda V Izmozherova, Nina A
Getmanova
Ural State Medical Academy, Internal Medicine #2, Ekater-
inburg, Russian Federation
Objective(s): To establish the adherence to physical exer-
cises of women with knee osteoarthritis (KOA).
Material &Methods: Physical exercises program for wom-
en with KOA and high SCORE cardiovascular risk was
designed to reduce joint pain. Outpatients with KOA were
offered to participate in the program. Willingness and ad-
herence to the program were assessed.
Results: After the telephone contact with 69 female outpa-
tients with KOA according to ARA clinical and radiographic
criteria 54 (78.2%) came for baseline examination. Median
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age was 61 (range: 49-75). After physical examination and
SCORE risk assessment all patients were given the informa-
tion on physical exercises program. Informed consent for the
program was obtained from 20 patients (37% visitors).
Among the reasons of refusal were unwillingness and lack
of time. The program of 4 sessions (2 times a week) started in
December 2011. All women were additionally reminded by
phone of date, time and place of training. Only 8 women
visited this physical training (11.6% of all women, 40% of
confirmed women). 3 women visited all 4 sessions (4.3% of
all women, 15% of confirmed women), 3 women visited 2
sessions (2.9% of all women, 10% of confirmed women), 2
women visited 3 sessions (4.3% of all women, 15% of con-
firmed women). After 4 sessions all patients were contacted to
assess the reasons of their non-adherence. Among these rea-
sons were: too far from home, unwillingness and a lot of work.
Conclusion(s): We established that women with knee oste-
oarthritis have low adherence to physical exercises.
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IMPROVING COMPLIANCE WITH STRONTIUM
RANELATE THERAPY BY LOW INITIAL DOSE
Mashood Siddiqi, Jacqueline O'Hare
University Hospital Aintree, Osteoporosis Unit, Liverpool,
UK
Objective(s): Strontium ranelate (SR), is being increasingly
used for postmenopausal osteoporosis1. Though the inci-
dence of serious adverse events is low, it can cause mild
and transient side effects like nausea (6.6%) and diarrhoea
(6.5%), and these may result in discontinuation of the drug2.
The aim of the study was to see, whether initiating, the
treatment at a lower dose, for limited period, before starting
the full dose, will reduce the incidence of transient side
effects and improve compliance.
Material & Methods: 60 consecutive patients, who were
prescribed SR, were randomly divided into two groups. First
group received full dose of SR, from the beginning and the
second group received half the dose for first three weeks before
increasing to full dose. All the other conditions, regarding taking
the drug were complied by both groups (taking the drug at
bedtime, at least 2 h after eating). Incidence of side effects and
compliance was checked at three weeks and at three months.
Results: A significantly less number of patients complained
of nausea and/or diarrhoea, at three weeks, in the half dose
group 7 (23.3%), as compared to the full dose group, 15
(50%) (p=0.0035). As a result, at the end of three months,
significantly more patients were compliant with the treat-
ment with SR in the half dose group, 27 (90%), as compared
to full dose group, 19 (63.3%) (p=0.0024). The upper GI
side effects were the major reason for non-compliance in
both the groups, 8 patients in the full dose group and 2
patients in the half dose group. Other side effects noted by
both groups were headache 2, itching 1, and hair loss 1. No
DVT was reported.
Conclusion(s): Compliance with strontium ranelate can be
improved, and the incidence of transient gastro-intestinal side
effects reduced by initiating the treatment with half the dose
for the first three weeks, before establishing the full dose.
References: 1. Reginster JY & Neuprez A. Expert Op on
Pharmacotherapy 2010;11;17:2915. 2. Meunier PJ, Roux C,
Seeman E et al. N Eng J Med 2004;350:459.
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DIFFUSE IDIOPATHIC SKELETAL
HYPEROSTOSIS (DISH) AND THE ASSOCIATION
WITH HIGH SERUM CHOLESTEROL AND
TRIGLYCERIDES
Mariela Gencheva Geneva-Popova, Vili Popova, Snezana
Tersiiska, Stanislava Alimanska, Milen Karagjsov, Pavel
Selimov, Lina Stojnova, Tatjna Simeonova
Medical Institute, Clinic of Rheumatology, Plovdiv, Bulgaria
Objective(s): The aim of the study is to assess the associa-
tion between diffuse idiopathic skeletal hyperostosis
(DISH), serum cholesterol and triglycerides.
Material & Methods: DISH were studied in 204 patients
with back pain, knee or hip joint replacement due to DISH
or osteoarthritis in Clinic of Rheumatology, UMHAT “Sveti
Georgi” and rheumatologic practice in Plovdiv, Bulgaria.
Participants had a standardized interview and examination.
Radiographs of the joint as well as both knee and a blood
sample were obtained. Serum cholesterol and triglycerides
levels were divided into tertiles and hypercholesterolemia
was defined as ≥6.0 mmol/l and hypertriglycerides was as
≥1.8 mmol/l. The control groups was 100 patterns with
osteoarthritis (OA) and 60 patients with knee OA. Odds
ratios and 95% Cls for the association of serum cholesterol
and triglycerides with DISH patterns were calculated with
logistic regression, adjusting for potential confounders.
Results: Hypercholesterolemia (OR 1.72; 95% CI 1.16-
2.32) and high serum cholesterol levels (3rd vs. 1st tertile:
OR 1.81; 95% CI 1.03-2.96) were independently associated
with DISH. Hypertriglyceridemia (OR 1.69; 95% CI 1.2-
2.14) were independently associated with DISH. No associ-
ation was observed between hypercholesterolemia and
hypertriglyceridemia and OA. Hypercholesterolemia (OR
1.61; 95% CI 1.06-2.47) and high serum triglycerides were
independently associated with knee OA.
Conclusion(s): These data add to the evidence regarding the
independent role of serum cholesterol and triglycerides as a
systemic risk factor for DISH. The discrepant associations
observed for different OA patterns are likely due to the
relative weight of other risk factors.
References: 1. FungMA, Frohlich JJ. CMAJ 2002;167:1261.
2. Grey A, Dalbeth N. Bone Rheumatic Disorders in Diabetes
Osteoporos Int (2012) 23: (Suppl 2):S85–S386 S223
2010:789. 3. Diederichs G, Engelken F, Marshall LM, et al.
Osteoporos Int 2011;22:1789.
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FRACTURE RISK ASSESSMENT IN CZECH
OSTEOPOROTIC PATIENTS BY DIFFERENT
NATIONAL FRAX® DATABASES
Jan Rosa, Petr Kasalicky, Alena Slechticka, Petr Bubenicek
DC Mediscan-Euromedic, Bone Metabolism Unit, Prague,
Czech Republic
Objective(s): The introduction of the WHO FRAX al-
gorithm has facilitated the assessment of fracture risk.
Recently (Osteoporos Int 2010;21[Suppl1]:S271) we
demonstrated that among Czech patients with osteopo-
rosis by DXA, UK FRAX database identifies higher
percentage of patients at high risk of fracture (20% risk
of major nonvertebral fracture and/or 3% risk of hip
fracture) compared to Austrian FRAX database (70.2%
and 58.1%, respectively). Since 2011 Czech national
FRAX database has been available. The aim of the
study is to compare percentage of patients treated for
DXA-diagnosed osteoporosis (GE Lunar, GE Healthcare,
UK) fulfilling National Osteoporosis Foundation (NOF)
criteria for osteoporosis therapy as assessed by different
national FRAX databases.
Material & Methods: Retrospective database analysis of
women with osteoporosis (lumbar spine and/or proximal
femur BMD T-score≤-2.5 and/or osteoporotic fracture) trea-
ted on the outpatient basis (n=183). 10-year risk of both
major osteoporotic fracture (hip, clinical spine, humerus or
wrist) and hip fracture based on FRAX algorithm was cal-
culated using Austrian, UK, German, Hungarian, Polish and
Czech databases.
Results: Mean age (±SD) of patients was 68±9.2 years,
weight 66.3±11.6 kg, height 160.8±8.3 cm, BMI 25.7±
4.1. Mean femoral neck BMD was 0.751±0.093 g/cm2
which corresponds to T-score of -2.1.
Numbers and percentages of patients fulfilling NOF criteri-
on for treatment are given in Table 1.
Patients fulfilling NOF criterion for osteoporosis treatment
≥20% risk of major
nonvertebral fracture
≥3% risk of hip fracture
FRAX National
database
No. of
patients
% of
patients
No. of
patients
% of
patients
Austria 77 42 123 67
UK 55 30 108 59
Germany 37 20 105 57
Czech Republic 34 18 108 59
Hungary 31 17 108 59
Poland 14 8 75 40
Conclusion(s): If there's no national database available, it
has been recommended to use database of a country with
similar fracture incidence. Concerning Czech population,
this could be Austria (historical and ethnic similarity) or
Poland (ethnic relationship). Despite similar hip fracture
incidence, these databases give highly discrepant results.
Closest results are found by using German and Hungarian
databases. In the Czech population of postmenopausal
women with osteoporosis the risk of hip fractures dominates
over risk of nonvertebral fractures. The use of other than
national database may give misleading results.
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THE 5-YEAR RISK FOR CONTRALATERAL HIP
FRACTURE AFTER THE FIRST ONE – A SIMPLE
ALORITHM FOR RISK STRATIFICATION
Jörg Goldhahn1, Peter Vestergaard2, Lucas M Bachmann3
1ETH, Institute for Biomechanics, Zurich, Switzerland,
2Aarhus University Hospital, Department of Endocrinology
and Metabolism, Aarhus, Denmark, 3Medignition Inc.,
Medical Research Consultants, Zug, Switzerland
Objective(s): The known, increased risk of contralateral hip
fracture after a first one may justify prophylactic stabiliza-
tion. However, a case-finding strategy is required to exclude
patients, which will not benefit from this additional surgical
intervention. The goal of this project was to derive a simple
algorithm assessing the 5-year risk for a contralateral hip
fracture after the first one.
Material & Methods: The analysis was based on a nation-
wide population-based Danish cohort study of 84,360 patients
experiencing a hip fracture in the age of 50-80 years being
followed-up for 5 years. We a priori defined a set of 17
candidate parameters potentially associated with early contra-
lateral hip fracture. We bootstrapped a stepwise augmentation
procedure 10 times and selected five parameters that entered the
model in all bootstrapping cycles. These were, female gender,
alcohol abuse, living in a single household, the lack of
bisphosphonate prescriptions and comorbidity as measured
with the Charlson Score. Using this model, we computed the
individual risk for a contralateral fracture within five years after
the first incidence.
Results: 12,349 patients (14.6%) experienced a contralater-
al hip fracture within 5 years after the first one. The strength
of association for the indicator variates were: female gender
(Odds Ratio 1.58, 95%CI: 1.51-1.66), alcohol abuse 1.57
(1.46-1.69), living in a single household 1.10 (1.05-1.14) no
prescription of bisphosphonates 1.64 (1.34-2.00), and co-
morbidity (Charlson Score values): 1-2; 2.20 (1.93-2.50) 3-
4; 1.76 (1.54-2.01), 5 and more, 1.46 (1.26-1.70) against no
comorbidity (Score=0). The probability of experiencing a
second fracture ranged from 3.4% corresponding to a male
with substantial comorbidity (>5) living in a relationship not
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taking bisphosphonates and without an alcohol problem to
25.9% corresponding to a woman living in a single house-
hold without comorbidity but an alcohol problem not taking
bisphosphonates.
Conclusion(s): Once this instrument is validated in other
cohorts it provides a simple algorithm for case-finding for
prophylactic hip augmentation to prevent a contralateral
fracture.
Disclosures: The study was supported by the AO Clinical
Priority Program Fracture Fixation in Osteoporotic Bone.
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EFFICACY OF A STRONTIUM RANELATE
2 G/VITAMIN D3 1000 UI COMBINATION ON THE
CORRECTION OF VITAMIN D INSUFFICIENCY
René Rizzoli1, Bess Dawson-Hughes2, Jean-Marc Kaufman3,
Patrice Fardellone4, Maria-Luisa Brandi5, Bruno Vellas6,
Julien Collette7, Jean-Yves Reginster7
1University Hospital, Geneva, Switzerland, 2Tufts University,
Bone Metabolism Laboratory, Boston, US, 3Ghent University
Hospital, Ghent, Belgium, 4Hôpital Nord, Amiens, France,
5University of Florence, Florence, Italy, 6CHU La Grave,
Toulouse, France, 7Université de Liège, Liège, Belgium
Objective(s): To assess the efficacy and safety of a daily
oral administration of a fixed combination of strontium
ranelate (SrRan) 2 g/vitamin D3 1000 IU on the correction
of vitamin D insufficiency in the treatment of osteoporotic
postmenopausal women and men.
Material & Methods: International, double blind, rando-
mised, 6-month parallel group study. Osteoporotic patients
(postmenopausal women and men) with basal 25-hydroxy-
vitamin D (25OHD) levels >22.5 nmol/L were included:
80% between 22.5-50 nmol/L and 20% >50 nmol/L. Ran-
domisation to treatment arms (SrRan 2 g/vitD3 vs. SrRan 2
g) was unbalanced (4:1). Primary objective was the propor-
tion of patients with 25OHD level≥50 nmol/L after 3
months in the Full Analysis Set. Secondary endpoints:
PTH, falls, physical performance measured by Short Phys-
ical Performance Battery (SPPB) and safety.
Results: 518 patients were included and randomized: 413 to
SrRan 2 g/vitD3, 105 to SrRan 2 g. Baseline characteristics
were similar in the two groups. Mean (±SD) age of 66.8±
8.3 yrs, L1-L4 BMD of 0.738±0.096 g/cm2; and 25OHD of
44.1±14.6 nmol/L. The proportion of patients with 25OHD
level ≥50 nmol/L at 3 months was significantly higher in
SrRan 2 g/vitD3 group than in SrRan group: 83.8% vs.
44.2% (95% CI [29.3; 49.8]). Adjusted odds ratio was
estimated at 6.7 (95% CI [4.2; 10.9]). Mean 25OHD was
65.1 and 49.5 nmol/L in the SrRan 2 g/vit D3 and SrRan
groups, respectively after 3 months. These group differences
were maintained over a 6-month period with 86% and 40%
of patients ≥50 nmol/L and mean 25OHD levels of 66.9 and
45.4 nmol/L in the SrRan/vit D3 and SrRan groups, respec-
tively. PTH evolution over time was inversely correlated with
25OHD. SPPB showed a trend towards improvement in phys-
ical performance after 3 and 6 months in both groups. Falls
occurred in 13.7% of patients in the SrRan 2 g/vitD3 group
and 17.3% in the SrRan group over 6 months. Safety was
comparable between groups and considered good.
Conclusion(s): This study demonstrated the efficacy and safe-
ty of a fixed combination of SrRan 2 g and vitamin D3 1000 IU
over SrRan 2 g on the correction of vitamin D insufficiency in
osteoporotic postmenopausal women and men.
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METABOLISM OF CHOLECALCIFEROL AND
IT'S PLEOTROPIC EFFECT – “AN OPEN DOOR”
Vili Popova, Mariela Geneva-Popova, Snezana Tersiiska,
Stanislava Alimanska, Lina Stojnova, Anastas Batalov,
Milen Karagjsov, Pavel Selimov
Medical Institute, Clinic of Rheumatology, Plovdiv, Bulgaria
Objective(s): The aim of this study is to assess the mecha-
nism of Vit.D3 supplementation and its pleotropic effects
associated with vit.D3 receptors (VDR) and activation of
1α-hydroxylase and 1,25-hydroxylasae enzymes. This re-
veal a new opportunities in the therapeutic approach of
interfere autoimmune, antiviral and antitumor response in
large number of diseases.
Material & Methods: We evaluated 310 women aged
between 50-85 for a period of two years divided in two
groups 180 with osteopenia,130 with osteoporosis. Thirty
patients of both groups have systematic disease of connec-
tive tissue. All of them receive glucocorticoids and Vit.D3 in
dosage of 800 IU/day and those with osteoporosis receive
and bisphosphonates.
Results: Patients with osteopenia receiving Vit.D3 reduced
the numbers of traumatic incidents and the vertebral and
nonvertebral fracture which benefits to their quality of life.
Women with osteopenia show high BMD with mean T-score
(-0.4 SD) using DXA.
Conclusion(s): We recommend the use of Vit.D3 supplemen-
tation to reduce of traumatic incidents and the vertebral and
non-vertebral fracture in women with postmenopausal
osteoporosis.
References: 1. S Weiner, D Noff, M S Meyer, Y Weisman,
S Edelste. Biochem J 1979;184:157. 2. DeLuca HF. Am J
Clin Nutr 2004;80(6 Suppl):1689S. 3. Griffin MD, Xing N,
Kumar R. Annu Rev Nutr 2003;23:117.
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DIAGNOSIS AND TREATMENT IN HAND
INTERPHALANGEAL ARTHRITIS
Mioara Banciu1, Loredana Marian2, Paul Tuduce1, Christian
Banciu2
Osteoporos Int (2012) 23: (Suppl 2):S85–S386 S225
1"Vasile Goldis" Western University, Rheumatology, Arad,
2"Victor Babes" University of Medicine and Pharmacy,
Rheumatology, Timisoara, Romania
Objective(s): Hand osteoarthritis affects 38% of the female
population and 24.5% of the male population aged >60.
The clinical picture of hand osteoarthritis, according to
ACR criteria, are: pain, limited movement and joint
deformation.
Material & Methods: Radiological exam includes: stan-
dard X-ray, the presence of osteophytes, narrowing of joint
space, bone scanning. Clinical forms of hand osteoarthritis
may be either: a. generalized forms, involving 3 joints or a
group of joints; b. erosive, with sudden onset, pain, swell-
ing, erythema, joint erosion and aggravating tendency. Ther-
apy in hand interphalangeal arthritis was determined
according to 13 multicentre studies and consists of: symp-
tomatic fast acting drugs, symptomatic slow acting drugs,
and chondroprotective agents (GAG-PS).
Results: Treatment in hand osteoarthritis is similar with that
of knee or hip osteoarthritis. A major role is held by the
patient's compliance to treatment, elimination of mechanical
risk factors, local physical therapy, analgesics, anti-inflam-
matories. Chondroprotective medicine may prevent, stabi-
lize and even repair cartilage damage
Conclusion(s): Medical treatment requires individual treat-
ment associated with physical therapy and, in most severe
cases orthesis.
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BONE STRENGTH MIGHT BE INADEQUATELY
ADAPTED TO THE EXCESS IN BODY WEIGHT IN
MALE OBESE ADOLESCENTS
Sara Vandewalle1,2, Inge Roggen3, Patrick Debode4, Maria
Van Helvoirt4, Youri Taes1, Stefan Goemaere1, Jean-Marc
Kaufman1, Jean De Schepper2,3
1University Hospital Ghent, Endocrinology, Ghent, 2Univer-
sity Hospital Ghent, Pediatrics, Ghent, 3University Hospital
Brussel, Pediatrics, Brussels, 4Zeepreventorium, Obesity Pro-
gram, De Haan, Belgium
Objective(s): Obesity, adolescence and male gender are
known risk factors for upper limb fractures, although the
mechanism by which obesity confers the increased fracture
risk is unknown. Most studies investigating the influence of
body fat mass on bone in adolescents used the DXA tech-
nique, which does not take into account the material and
geometric bone properties. This study aims to determine the
relationship between obesity and the true volumetric BMD
and the bone geometry in obese adolescents.
Material & Methods: 51 obese adolescents (ObA) (BMI
sds >2), aged 10-19 y, recruited at the entry of a residential
weight loss program, together with 51 healthy controls
matched for age, length and pubertal stage were included
in this cross-sectional study. Trabecular (4%) and cortical
(66%) vBMD and bone geometry, together with muscle and
fat cross-sectional area (CSA) measurements were assessed
at the nondominant forearm using pQCT.
Results: ObA had a higher trabecular density (215±33 vs.
199±34 mg/cm3; p=0.02) at the distal 4% end, but compara-
ble cortical density (997±54 vs. 995±60 mg/cm3; p=0.89) at
the proximal 66% site. Trabecular area (158±26 vs. 143±33
mm2; p=0.02) as well as cortical area (72±21 vs. 66±16
mm2; p=0.1) and periosteal circumference (46.8±4.7 vs.
44.5±4.8 mm; p=0.02) were slightly larger in ObA. ObA
have apart from a higher fat CSA (2660±816 vs. 673±384
mm2; p<0.001) also a higher muscle CSA (3105±840 vs.
2687±819 mm2; p=0.012) at the proximal radius. However,
the bone/muscle ratio was lower in the ObA group (5.6±0.79
vs. 5.9±0.84%; p=0.034)
Conclusion(s): Male obese adolescents have greater perios-
teal circumference, trabecular bone area and density at the
radius, however the bone/muscle ratio is lower in the obese
group. Hence, the higher forearm fracture risk in obese
adolescents is not due to a low bone accumulation, but bone
strength might be insufficiently adapted to the excess body
weight.
P393
RISK FACTORS OF HIP FRACTURES
IN RUSSIAN MEN
Olga B Ershova, Ksenia Y Belova, Olga S Sinitsyna
Yaroslavl StateMedical Academy, Chair of Therapy, Yaroslavl,
Russian Federation
Objective(s): The aim of this study was the comparison of the
distribution of various risk factors in men of two age groups: 1 -
from 40-69 years old and 2 - from 70 years and older.
Material & Methods: The material of the study included
184 men with hip fractures in Yaroslavl admitted to the
emergency hospital. In the age group from 40-69 years old
93 patients were examined and in the age group from 70
years and older (91 patients). For the evaluation of osteopo-
rosis risk factors a survey was carried out with regard to
alcohol consumption and the content of 25(OH)vitaminD,
testosterone, estradiol, prolactin, PTH, TSH in blood serum.
Results: Statistically reliable variations between the two
groups were revealed according to the following risk fac-
tors: hip fracture in parents – 9 men (10.75%) in the group
from 40-69 years and 3 men (3.29%) in the group from 70
years and older (ð=0.035); smoking - 77 (82.79%) and 57
(62.63%), respectively (ð=0.026); alcohol abuse and con-
stant consumption of alcohol in 50 (53.76%) and 25
(27.47%), respectively (ð=0.003). However, in men at the
age of 70 years and older 25(OH)vitaminD deficiency
occurs more frequently. It has been proved statistically (in
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31 men in group 2 (34.06%) and 14 men in group 1
(15.05%), respectively, (p=0.003)).
Conclusion(s): Among the risk factors of hip fractures in
men at the age from 40-69 years old in comparison with the
patients from 70 years and older it was revealed that hip
fractures occurred more frequently in parents of the first
group patients; as for the patients of this group themselves
smoking, alcohol abuse were found to be more frequent,
than in the patients of the second group; and they rarer had
25(OH)vitaminD deficiency.
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POOR BONE MICROACHITECTURE IN OLDER
MEN WITH LOW MUSCLE MASS AND GRIP
STRENGTH: THE STRAMBO STUDY
Pawel Szulc, Stéphanie Blaizot, Stéphanie Boutroy, Nicolas
Vilayphiou, Roland Chapurlat
INSERM UMR 1033 University of Lyon, Epidemiology of
Osteoporosis, Lyon, France
Objective(s): Low relative appendicular muscle mass
(RASM, kg/m2) is associated with lower bone width in
men (Szulc, JBMR, 2005). In this study we assess the
association of bone microarchitecture with RASM and grip
strength in 810 men aged ≥60 yr.
Material & Methods: Bone microarchitecture was assessed
at the distal radius and tibia by HR-pQCT (XtremeCT,
Scanco). RASM was assessed by DXA. Statistical analyses
were adjusted for age, height, fat mass, sex steroids, lifestyle
factors and comorbidities.
Results: Men in the lowest RASM quartile (Q1) had lower
cross-sectional area (CSA), trabecular area (Tb.Ar) and cor-
tical thickness (Ct.Th) at the distal radius and tibia compared
with men in the highest (Q4) quartile (6-11%, 0.33-0.64 SD,
p<0.01-0.001, ptrend<0.05-0.001). At the distal tibia, they
also had lower total volumetric BMD (Tt.vBMD), trabecular
vBMD (Tb.vBMD) and trabecular number (TbN) (Q1 vs.
Q4: 7-9%, 0.34-0.60SD, p<0.05-0.005, ptrend<0.05) and
more heterogeneous trabecular distribution (TbSpSD) (p<
0.001). Men in the lowest quartile of grip strength had lower
CSA, Tt.vBMD, Tb.vBMD, TbN and Ct.Th at the distal
radius than men in the highest quartile (4-10%, 0.29-
0.45SD, p<0.05-0.001, ptrend<0.05-0.005). They also had
8% higher TbSpSD (ptrend<0.005). After adjustment on arm
muscle mass, differences remained significant for Tt.vBMD,
Tb.vBMD, TbN and TbSpSD. At the tibia, men in the
lowest quartile of grip strength had lower Tt.vBMD, cortical
vBMD (Ct.vBMD) and Ct.Th (3-8%, 0.33SD, p<0.05,
ptrend<0.05). In multivariate models including both grip
strength and arm muscle mass, CSA and Tb.Ar were asso-
ciated with muscle mass (r2=3-7%, p<0.001), not grip
strength. Ct.vBMD correlated with grip strength (r2=3%,
p<0.01). Trabecular parameters correlated weakly with
muscle mass (r2=1-3%) and grip strength (r2≤1%). Men
having both low arm muscle mass and low grip strength
(lowest tertiles) had 9% lower TbN (0.61SD, p<0.005) and
5% higher TbSpSD (0.49SD, p<0.05) than men in the high-
est tertiles of both variables.
Conclusion(s): In older men, low RASM and low grip
strength are associated with poor cortical and trabecular
microarchitecture. The associations remaining significant
after adjustment for confounders including body size
suggest direct association. Muscle mass and force are
associated jointly and partly independently with bone
microarchitecture, suggesting different mechanisms of
linkage.
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WHAT GENERAL PRACTITIONERS EXPECT
OF THEIR COLLABORATION WITH
RHEUMATOLOGISTS
Corinne Thevenot, Mahmoud Baba Aissa, Christian Borella,
Patrick Boumier, Hervé Courmon, BDang-Vu,Marc Darriulat,
Agnès Duche, May Hanna, N Lecuyer, M Malherbe, Antoine
Mardini, Philippe Monchablon, Thérése Rosey, Marc Vasseur
1CHG, Internal Medicine - Rheumatology, Laon, 2Reeduca-
tion Center of Jacques Ficheux, Rheumatology, Saint-
Gobain, 3Liberal Cabinet, Soissons, 4Polyclinic of Picardie,
Rheumatology, Amiens, 5Reeducation Center of Jacques
Ficheux, Physical Medicine and Readaptation, Saint-
Gobain, 6Liberal Cabinet, Soissons, 7CHG, Rheumatology,
Laon, France, 8Polyclinic of Saint Claude, Rheumatology,
Saint-Quentin, 9Liberal Cabinet, Saint-Quentin, 10Liberal
Cabinet, Laon, 11Liberal Cabinet, Saint-Quentin, 12Liberal
Cabinet, Saint-Quentin, France
Objective(s): To assess what general practitioners (GPs)
expect from rheumatologists.
Material & Methods: A total of 132 GPs completed an
anonymous questionnaire sent to them by 15 rheumatolo-
gists working in private practice or hospitals in Aisne and
Somme (2 French départements).
Results: Of the 132 GPs questioned, 94 (75.8%) considered
the wait for an appointment with a rheumatologist too long,
and 83.1% thought the wait should not exceed 2 weeks.
97.7% of GPs always sent an accompanying letter when
referring a patient to a rheumatologist. Before the change in
conditions for reimbursement of patients' medical costs, half
of GPs considered that 30% of their patients consulted a
rheumatologist directly, without seeing them first. After
introduction of the new reimbursement conditions, half of
GPs reported that only 10% of their patients consulted a
rheumatologist directly. Most GPs (90.4%) wanted to re-
ceive a report from rheumatologists contacted directly by
patients. When referring a patient to a rheumatologist, GPs
expected the rheumatologist to make a therapeutic suggestion
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(100%), give a diagnostic opinion (98.5%), and perform a
technical procedure when indicated (96.9%). GPs expect the
rheumatologist to take over patient management completely
(71.7% of cases) or just to act in a consultancy capacity
(63.5% of cases), which shows that these two attitudes are
not incompatible. Attitudes regarding prescriptions are less
clear, since GPs expected the rheumatologist to prescribe
medication (57.4%), physiotherapy (69.1%), or an orthopedic
consultation (44.5%). GPs referred patients to a rheumatolo-
gist most frequently because of inflammatory disease
(96.9%), nonarticular (88.4%) and vertebral (86.5%) disor-
ders, osteoarthritis (51.7%), and osteoporosis (43.8%). The
essential role of the rheumatologist in the follow-up of inflam-
matory disease was underscored by 83.8% of GPs, who
acknowledge the importance of a quick appointment with
the rheumatologist when inflammatory rheumatism is sus-
pected (87.7%), but fewer GPs consider the rheumatologist
has a role in initiating corticosteroid treatment (50.4%) and in
its follow-up (35.6%).
Conclusion(s): GPs mostly refer patients to rheumatologists
in cases of inflammatory, nonarticular, and vertebral disor-
ders. They consider that the wait for an appointment is too
long. GPs expect the rheumatologist to give diagnostic and
therapeutic advice and to perform a technical procedure, if
indicated.
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FRAX FOR ROMANIA: IDEAL TOOL FOR
FRACTURE RISK CALCULATION
Dorina C Stoicanescu1, Mariana I Cevei2
1University of Medicine and Pharmacie Victor Babes, Medi-
cal Genetics Department, Timisoara, Timis, 2University of
Oradea, Faculty of Medicine and Pharmacie, Medical Reha-
bilitation Hospital Baile Felix, Oradea, Bihor, Romania
Objective(s): FRAX® is a scientifically validated risk
assessment tool, endorsed by the WHO. The web-based
FRAX® calculator assesses the 10-year risk of osteopo-
rosis fracture based on individual risk factors, with or
without BMD values. Objective was the detection of
fractures risk in the next 10 years for women diagnosed
with osteoporosis.
Material & Methods: The study included a group of 328
patients with the diagnosis of osteoporosis, admitted to
Baile Felix Rehabilitation Clinical Hospital between July
2010 - May 2011. The lot consisted exclusively of women
with a mean age of 67.6±9.31 years, ranging between 34-79
years. Diagnosis of osteoporosis was established after DXA
investigation in Diagnostic Center Maria, with Lunar Prod-
igy Advance device. Fracture risk has been calculated using
FRAX calculator. FRAX version 3.3 is currently (August
2011) available in 34 country models and in 18 languages,
including Romania.
Results: Mean T-score at lumbar spine in the study group
was around -2.62 with -0.8 and -4.5 limits. Mean hip T-
score was around-1, 65 with limits ranging from 0.1 to -4.2.
The risk of major osteoporotic fracture for the next 10 years
is 21.034±20.418, SD 2.25. Osteoporotic hip fracture risk
had a mean value of 13.771, SD 20.558, SEM 2.270.
Conclusion(s): FRAX is helping health professionals to
improve identification of patients at high risk of osteoporot-
ic fracture. Obtained data will convince both policymakers
and patients of the need of lifestyle changes and establishing
adequate therapy.
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ADDRESSING THE CARE GAP IN SECONDARY
FRACTURE PREVENTION IN A SOUTH EAST
ASIAN HOSPITAL: EFFECTIVE INITIATION OF
OSTEOPOROSIS DIAGNOSIS AND TREATMENT
FOR PATIENTS WITH FRAGILITY FRACTURES
THROUGH “OPTIMAL”
Manju Chandran, Matthew ZW Tan
Singapore General Hospital, Osteoporosis and Bone Metab-
olism Unit, Department of Endocrinology, Singapore
Objective(s): An osteoporosis disease management pro-
gram “OPTIMAL” (Osteoporosis Patient Targeted and Inte-
grated Management for Active Living) aimed at preventing
the occurrence of a second fragility fracture through case
finding, medication subsidy, physiotherapy and case man-
ager follow up was implemented in public hospitals in
Singapore in 2008. We aim to describe characteristics in-
cluding bone densitometry measurements, compliance to
medications and exercise and the incidence of new fractures
in the patients who were recruited into and completed 2-year
follow up in the program at the largest hospital in Singapore
Material & Methods: Data collected during the process of
screening, recruitment and follow up of patients in the
program was analysed. Descriptive statistics was used to
summarize the characteristics of patients. Comparison be-
tween baseline and follow up BMD measurements was done
using paired T tests.
Results: 112 patients have completed the 2 yr follow-up as
of December 2011. 64.3% of these patients had baseline
AND 2 year follow up DXA performed. 58.9% of the
patients were not on antiosteoporosis treatment at baseline.
65 out of the 66 treatment naïve patients were started on
therapy following recruitment. 83.0% patients were compli-
ant with therapy at 2 years as defined by a Medication
Possession Ratio of >80%. Out of the 95 patients who
agreed to embark on a weight bearing exercise program,
58.9% were compliant with exercise at the end of the 2 year
follow up defined as continuing to do more than 30 minutes
of such exercise, more than 2 times per week. There was a
mean increase in BMD of 0.016 (p=0.000) at the total hip
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and a mean increase in lumbar spine BMD of 0.045 (p=
0.045) at the end of the 2 years. 81.3% remained fracture
free during the 2 years of the program.
Conclusion(s): In the 3 years following inception, the OP-
TIMAL program at our hospital has successfully identified
and evaluated most patients with fractures. The ultimate
success of the program will be measured by the subsequent
fracture experience of these patients, but clear and effective
steps in evaluating persons with fractures with BMD testing
and offering treatment options have been initiated.
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THE RELATIONSHIP BETWEEN MORPHOMETRY
AND CLINICAL INDICATORS OF OSTEOPOROSIS
Juraj Payer, Zdenko Killinger, Daniel Cierny
University Hospital, 5th Dept. of InternalMedicine, Bratislava,
Slovakia (Slovak Republic)
Objective(s): To assess defined anthropometric indicators
(reduction of body weight, the presence of kyphosis, occi-
put-wall and rib-pelvis distance, number of teeth) and to
correlate the outcomes with BMD and the presence and
grade of vertebral fractures.
Material & Methods: Group of patients consisted of 103
postmenopausal women, in whom at least one defined an-
thropometric indicator was present. BMD was measured
with a Hologic Discovery densitometer at standard sites.
We used a lateral morphometric scan and a special software
IVA to identify vertebral fractures. These fractures were
evaluated with the use of the Genant scoring system.
Results: We found a statistically significant correlation
between the values of BMD and body weight and rib-
pelvis distance for both sites of measurement. The values
of BMD at the site total hip significantly correlated also
with the presence of thoracic kyphosis, occiput-wall dis-
tance and age. With the help of a lateral vertebral scan
we identified 55 patients with a fracture, 24 of them had
multiple fractures. The total number of identified frac-
tures was 106. We found a positive correlation between
the values of BMD and the severity of fractures for both
sites of measurement. There was no significant correla-
tion between anthropometric indicators and number or
severity of fractures.
Conclusion(s): According to published information, low
body weight seemed to be the best predictor of low bone
density. The occiput wall distance more than 0 cm and rib-
pelvis distance equal or less than 2 fingers seemed to sug-
gest an occult vertebral fracture. The results of our study
partly confirm these findings. We found a statistically sig-
nificant positive correlation between low body weight and
values of T-score at both sites of measurement. Values of
BMD at the site of total hip correlated also with BMI, age,
presence of kyphosis, occiput-wall distance and loss of body
height. We assume that there could exist a relationship
between these indicators and vertebral fractures as well.
Proving this hypothesis could lead to better identification
of patients at high fracture risk even for asymptomatic
fractures.
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COMPARISON OF BONE MINERAL DENSITY AND
ULTRASOUND PARAMETERS IN PATIENTS WITH
POLYCYSTIC OVARIAN SYNDROME AND TYPE 2
DIABETIC WOMEN
Szilvia Mészáros1, Viktória Ferencz1, Eva Hosszú2, Emoke
Csupor3, Edit Tóth4, Katalin Bors5, Ádam Tabák1, Csaba
Horváth1
1Semmelweis University, 1st Department of Internal Medi-
cine, 2Semmelweis University, 2nd Department of Pediatric
Semmelweis University, 3Budavar Local Authorities, Buda-
pest, 4Ferenc Flor County Hospital, Rheumatology, Kistarcsa,
5Rehabilitation Hospital, Visegrád, Hungary
Objective(s): Skeletal health in patients with patients with
polycystic ovarian syndrome (PCOS) and type 2 diabetes
mellitus (T2DM) is an area of interest and controversy. QUS
and DXA techniques are helpful in detecting bone deficits in
patients. The aim of the study was to compare BMD meas-
urements and quantitative ultrasound parameters between
the patients with polycystic ovarian syndrome and the
BMI matched type 2 diabetic women.
Material & Methods: Ten women with PCOS were
weight-matched to 17 women with T2DM. Lumbar
spine BMD, femoral neck BMD were measured by
DXA. The QUS examination consisted of measuring
the attenuation (BUA) and the speed of the ultrasound
(SOS) transversing the calcanei. Differences between the
groups were analyzed by Student's t-test. Correlation
analysis was also performed between QUS and BMD
measurements in both groups.
Results: Patients with T2DM had higher BMD in the
lumbar spine (L2-L4) than patients with PCOS (1.09 g/cm2
vs. 0.992 g/cm2, p=0.04), but we found no statistically sig-
nificant differences in the femoral neck density (0.984 g/cm2
vs. 0.945 g/cm2). QUS measurements showed similar
values in both groups: BUA (70.3 dB/Mhz vs. 68.7
dB/Mhz, p=0.378), SOS (1531 m/s vs. 1532 m/s, p=
0.578). There was a moderate and significant positive
relationship between SOS and BMD measurements in
both groups.
Conclusion(s): In conclusion, the present study com-
pared differences in bone mass measurement using
two different methods, namely DXA and QUS. Our
results indicate that QUS can provide useful informa-
tion in the skeletal assessment of patients with PCOS
and T2DM.
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NEW CONCEPT IN COMBATTING THE PAIN IN
OSTEOPOROSIS AND ARTHROSIC DISEASE
I Jivet1, Cevei P Patricia1, Cevei I Mariana2
1Electronics and Telecommunications Faculty, Politehnica
Timisoara University, Timisoara, 2Medicin and Pharmacy
Faculty, University of Oradea, Oradea, Romania
Objective(s): In order to produce the physical pain and
perceive it, a series of steps are undergone, namely: a)
peripheral tissue phase ('peripheral sensitization'); b) trans-
mission through specialized structures phase; c) integration
and organization of pain phase. The peripheral phase takes
place after a well-known algorithm. Thus the pain of arthri-
tis and osteoporosis diseases occurs as a consequence of the
tissue injury through mechanical stimuli followed by the
release of algogenic and hyperalgesic substances that leads
to stimulation of the superficial or profound nociceptors,
respectively. Purpose was to identify another type of pain-
killer physical therapy. The new pain control model is based
on different principles from those of conventional electro-
therapy (gate theory supplemented by the release of the two
opioid systems, endorphins and enkefalins).
Material & Methods: A novel delivery modality concept is
disclosed based on chaotic oscillator type electric energy
injection.
Results: The electric current injected in parallel to mimic the
normal ion fluxes under the control of the central nervous
system, offer a mean to intervene in the system function to
reduce suffering. The physiological premise of the proposed
new form of the energy delivery modality is appealing due to
the known fact that physiological subsystem in normal healthy
subjects preset a natural variation of the chaotic type.
Conclusion(s): • A novel electrotherapy delivery modality
concept is introduced based on chaotic oscillator waveforms.
& The energy transfer among autonomous systems is
mainly dependent on the system inherent synchronizing
capacities.
& By similarity two chaotic oscillator models have been
chosen to be used in a two case clinical trial. Future
work plans: multiple model interaction, time regime
experiments and energy delivery efficiency estimation.
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MANAGEMENT OF OSTEOPOROSIS BY
GENERAL PRACTITIONERS
Daniel Daridan, Willy De Craemere, André Martchenko,
Valérie Royant, Richard Damade
1Liberal Cabinet, Chartres, 2Liberal Cabinet, Nogent-
Le-Rotrou, 3Liberal Cabinet, Chartres, 4Hospital Louis Pas-
teur, Rheumatology, 5Hospital Louis Pasteur, Internal Medi-
cine and Rheumatology, Chartres, France
Objective(s): To assess how general practitioners diagnose
and manage osteoporosis.
Material & Methods: A group of rheumatologists sent 20
general practitioners (GPs) a questionnaire on osteoporosis
management: detection, diagnostic workup, and treatment.
Results: The survey included 60 women: 24 (40%) aged 50-
60 years, 18 (30%) aged 60-70, 17 (28%) aged 70-80, and 1
(2%) woman over 80. Osteoporosis was detected by GPs in
75% of cases. The main reasons for testing were risk factors
(44% of cases), history of fracture (29%), postmenopausal
patient (25%), and family history of osteoporosis (20%).
GPs diagnosed osteoporosis on the basis of one (41%), 2
(32%), or 3 criteria (19%). When osteoporosis was sus-
pected, further tests were done in 97% of cases. The techni-
ques used were: laboratory tests (29%) and/or X-rays (20%),
and in 100% of cases DXA, which was done by a radiologist
(63% of cases) or rheumatologist (33%). The GPs consid-
ered that in 98% of cases the DXA data were useful in the
treatment decision-making process, and revealed densito-
metric osteoporosis in 84% of cases. The GPs put more
store by the densitometric values (83%) than by the clinical
context (26%). When osteoporosis was diagnosed, a specific
treatment (apart from vitamin D and calcium) was started in
82% of cases, mostly by the GPs (53%), or by a rheumatol-
ogist (17%). Depending on the GP, the principal criterion for
treatment choice was antifracture efficacy (57%), followed
by mode of action (20%), and dose regimen (14%). The
treatment of 4 patients was stopped by the GP, the rheuma-
tologist, or the patient herself. The main reasons for treat-
ment discontinuation, in order, were onset of side effects
and lack of efficacy. Osteoporosis was considered to be
more serious than osteoarthritis by 78% of GPs, but less
serious than diabetes (70%), Alzheimer's disease (65%), and
inflammatory rheumatism (58%).
Conclusion(s): DXA was routinely performed following
identification of an osteoporosis risk factor, which was the
principal criterion used by GPs in making a treatment
choice. However, screening for clinical risk factors for osteo-
porosis is often insufficient and additional effort is needed to
inform women and GPs.
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REASON FOR DISCONTINUATION OF
OSTEOPOROSIS TREATMENTS
Anne Roudaut, P Chicault, V de Saint-Pierre, P Martin, C
Paturel Porzier, MA Timsit, I Valls Bellec, P Voisin
1Liberal Cabinet, Brest, 2Brest, 3Lesneven, 4Brest,
5Landivisiau, 6Brest, 7Brest, 8Morlaix, France
Objective(s): To analyze the reason for discontinuation of
osteoporosis treatments prescribed by rheumatologists.
Material & Methods: During medical history taking with
their osteoporotic patients, 8 rheumatologists in Finistère
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(French département) recorded demographic data (age, sex),
osteoporosis treatments (discontinued or ongoing), and rea-
sons for treatment discontinuation.
Results: The survey included 75 patients (89.3% women of
mean age 71 years; 10.7% men of mean age 73 years),
79.5% of whom had been treated for a mean 23 months.
Osteoporosis treatments included bisphosphonates (61.6%
of cases), strontium ranelate (24.4%), raloxifene (6.4%),
teriparatide (6.4%), and hormone replacement therapy for
the menopause (1.3%). The rheumatologists estimated in
74.4% of cases that the prescribed treatments were justified.
Osteoporosis treatments were stopped particularly among
the under-60s, by a general practitioner in 53.8% of cases,
by a specialist (19.3%), or by the patients themselves
(26.9%). In 54% of cases, the treatment was discontinued
within one year of initiation: first month (13.2% of cases), 1-
3 months (14.5%), 3-6 months (13.2%), 6-12 months
(13.2%). Gastrointestinal intolerance was seen in 33% of
cases, with no age effect. Allergy was seen in 3% of cases,
solely in the over-70s. Fractures occurred during treatment
in 17% of cases, and were more frequent in the over-70s.
The rheumatologists prescribed another osteoporosis treat-
ment in 60% of cases, the initial treatment being a
bisphosphonate (47% of cases), strontium ranelate (40%),
or teriparatide (6%). After a bisphosphonate, the rheumatol-
ogists prescribed another bisphosphonate (33% of cases),
strontium ranelate (33%), teriparatide (17%), or raloxifene
(17%). After strontium ranelate, they prescribed a
bisphosphonate (79% of cases), teriparatide (14%), or hor-
mone replacement therapy (7%). After teriparatide, a
bisphosphonate was always prescribed.
Conclusion(s): These results suggest that discontinuation of
osteoporosis treatments is mainly related to the onset of a
side effect or to lack of efficacy leading to a fracture during
treatment. A new treatment was then prescribed in over half
of the cases. Whether treatment was discontinued by the
rheumatologists or by the patients, the main reason was
gastrointestinal intolerance, irrespective of the age of the
patients.
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EFFECT OF AGE AND SEX OVERWOMAC SCORE
IN NORMAL AND DISEASED INDIVIDUALS
Vikram Khanna, Rajendra Prasad Agarwal, Utkarsh Shahi,
Om Prakash Gupta, Jayant Bajpayi
Era's Lucknow Medical College, Orthopaedics, Lucknow,
Uttar Pradesh, India
Objective(s): WOMAC questionnaire is one of the most
accepted scoring systems for knee osteoarthritis. The
WOMAC score thus obtained has a diagnostic and prognos-
tic significance. It is also helpful in assessment of severity of
knee osteoarthritis at any given point of time. However
being a subjective questionnaire, there may be certain bias
in the WOMAC score. Like pain perception and tolerance
differ from person to person, hence it may give false low
values for patient with poor pain tolerance and false high
value for someone with greater endurance for pain. Also age
and sex may affect WOMAC score to some extent. The bias
due to pain tolerance may be reduced by proper clinical
screening. The present study is about the effect of age and
sex over WOMAC score. Aim of study is to calculate the
WOMAC score from WOMAC questionnaire for normal as
well as diseased males and females compare it with each
other in reference to age and sex.
Material & Methods: A prospective case control study,
conducted within a period of one year recruiting 100 cases
and 50 controls. All cases and controls were asked to fill
WOMAC questionnaire and advised to get a bilateral knee
radiograph done for confirming severity of disease with
Kellgren Lawrence grading scale. Both the cases and con-
trols were compared within their group as well as with each
other to obtain the trend of WOMAC score in reference to
age and sex.
Results: Out of 100 cases and 50 controls there is an
inversely proportional trend in most of the groups in
reference to age. In mild, moderate and severe sub-
groups, similar inversely proportional trend exist in ref-
erence to age with exceptions in severe sub group.
Normal males score slightly better than normal females,
but diseased males have slightly poor WOMAC score
over diseased females.
Conclusion(s): An inversely proportional relation between
the WOMAC score and age is observed. This fact encour-
ages about setting different inference criteria of obtained
WOMAC score for severity of disease at different ages.
On the other hand sex has no major impact over WOMAC
score.
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STATE OF BONE MINERAL DENSITY AND THE
PREVALENCE OF VERTEBRAL DEFORMITIES IN
PATIENTS WITH PSORIATIC ARTHRITIS
Volha Y Samakhavets1, Emma V Rudenka1, Anastasia V
Adamenka2
1Belarusian Medical Academy of Post-Graduate Education,
Cardiology and Rheumatology, 2City centre of Osteoporosis,
Roentgenology, Minsk, Belarus
Objective(s): Psoriatic arthritis (PsA) is a chronic inflam-
matory arthritis associated with psoriasis that occurs in 0.3-
1% of the population. PsA is usually seronegative for rheu-
matoid factor and is classified among the spondyloarthro-
pathies. PsA develops in up to one-third of patients with
psoriasis and is one of possible reasons of secondary oste-
oporosis. The aim of this study was to assess BMD, bone
Osteoporos Int (2012) 23: (Suppl 2):S85–S386 S231
quality and the prevalence of vertebral deformities in
patients with psoriatic arthritis.
Material & Methods: BMD was measured by DXA at
lumbar spine (anterior-posterior projection at L1-L4) and
at femoral neck. Vertebras were assessable with lateral
vertebral assessment at the thoracic and lumber spine.
We used the Genant's classification to evaluate a grade
of vertebral deformity. Spiral deformity index proposed
as surrogate marker of bone quality, was calculated by
summing the severity and the number of the vertebral
fractures.
Results: 50 patients (26 men and 24 women; age 46.4±
5.2 years; duration of PsA 9.4±5.9 years) and in 30
healthy controls, were studied matched for sex, age,
height, weight and BMI. BMD was statistically signif-
icantly lower in patients with psoriatic arthritis either
at spine (BMD 0.850 [0.803:0.921] g/cm2), than in
control group (BMD 1.180 [1.054:1.323], p<0.001)
and at femoral neck (BMD 0.797 (0.100) g/cm2) in
comparison with controls group (BMD 0.951 (0.107)
g/cm2, p<0.001).
46% of patients had vertebral deformities (n=23), that was
statistically higher than in control group (5.0% n=1, p=
0.04). In 8 subjects (38%) multiple fractures were present.
11 subjects (42%) had from 1 to 5 deformities. Only 4
patients (20%) had deformities 1 thoracic or 1 lumbar
vertebrae.
Conclusion(s): Decrease of BMD and increase in fre-
quency of vertebral deformities is observed statistically
more frequent in patients with PsA than in control
group. In 38% out of the group of examined vertebral
fractures were detected. The presence of PsA in patient
is a significant risk of development of vertebral defor-
mities and fractures.
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FIVE-YEAR INCIDENT FRACTURE RISK
ASSESSED BY QUANTITATIVE MULTISITE
ULTRASOUND: THE CANADIAN MULTICENTRE
OSTEOPOROSIS STUDY
Wojciech P Olszynski1, Jacques P Brown2, Jonathan D
Adachi3, David A Hanley4, Kenneth S Davison5
1University of Saskatchewan, Dept. of Medicine, Saskatoon,
SK, 2Laval University, Dept. of Medicine, Quebec City, QC,
3McMaster University, Dept. of Medicine, Hamilton, ON,
4University of Calgary, Dept. of Medicine, Calgary, AB, 5A
Priori Medical Sciences Inc., Dept. of Medical Science,
Victoria, BC, Canada
Objective(s): To assess the ability of Beam-Med Multisite
QUS to predict fracture risk over a 5-year follow-up.
Material & Methods: The participants included for these
analyses were a subset of the Canadian Multicentre
Osteoporosis Study. QUS estimated bone strength (speed of
sound in m/s) at three anatomical sites: distal radius, tibia and
phalanx. After QUS assessment, all participants were prospec-
tively followed for five years during which incident fractures
were recorded. Further, extensive questionnaires were
employed at the time of QUS measurement. Two survival
analyses were completed for each skeletal site - a univariate
analysis and an adjusted multivariate analysis controlling for
age, antiresorptive use, femoral neck BMD, number of dis-
eases, previous fractures, BMI, sex (in combined model),
parental history of hip fracture, current smoking, current alco-
holic drinks >3 per day, current use of glucocorticoids, and
diagnosis of rheumatoid arthritis. The unit of change for
regression analyses was 150 m/s, approximately one standard
deviation for all measurement sites. Separate analyses were
completed for all clinical fractures, nonvertebral fractures and
hip fractures for the whole group and by sex.
Results: There were 2633 (70.4%) women and 1108
(29.6%) men included and they experienced 204 incident
fractures over five years of observation (5.5% fractured).
When stratified by sex, incident fractures occurred in 177
women (4.8%) and in 27 men (0.7%). Hip fracture events
occurred in 35 individuals (30 in women and 5 in men) and
non-vertebral fracture events occurred in 160 individuals
(139 in women and 21 in men). Univariate models revealed
statistically significant predictive ability for all three mea-
surement sites in the combined group and for women alone
for all three fracture types, but not for the men's group. The
adjusted model found that measures at the distal radius and
tibia in the combined and women's groups could significant-
ly predict all clinical fractures and nonvertebral fracture
within the next five years.
Conclusion(s): The Beam-Med MultiSite QUS provides
significant five-year fracture prediction, independent of
BMD and other significant risk factors for fracture, when
measured at the distal radius and tibia sites.
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MULTICENTER RANDOMIZED TRIAL OF
INTERACTIVE EDUCATIONAL PROGRAM
IN PATIENTS WITH OSTEOPOROSIS
Olga M Lesnyak1, Ludmila P Evstigneeva1, Natalia
Kuznetsova1, Anastasia Vorobyeva1, Julia Safonova2, Svetlana
Bulgakova3, Marina Kirpikova4, Marina Strunina5, Marina
Telushenko5, Maria Nekrasova6, Olga Nesmeyanova7
1Scerdlovsk Regional Hospital # 1, Rheumatology, Yekater-
inburg, 2North-West Federal Medical University, Internal
Diseases, Saint-Petersburg, 3Samara State Medical Acade-
my, Internal Diseases, Samara, 4Ivanovo State Medical
Academy, Internal Diseases, Ivanovo, 5Kama Polyclinic,
Osteoporosis Center, Perm, 6Tyumen StateMedical Academy,
Internal Diseases, Tyumen, 7Chelyabinsk Regional Hospital #
1, Rheumatology, Chelyabinsk, Russian Federation
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Objective(s): Lifestyle risk factors play an important role in
development and progression of osteoporosis. The adher-
ence to therapy in osteoporosis patients is usually low and
leads to less effectiveness of the treatment. We studied the
effectiveness of the new educational interactive 4-day pro-
gram in adherence to treatment and life style modification in
patients with osteoporosis.
Material & Methods: It was a multicenter clinical random-
ized open-label study in patients with osteoporosis which
compared effectiveness of newly developed 4-day interac-
tive structured educational program in small groups and
brochure containing information on main aspects of osteo-
porosis. Six health care centers involved in management of
patients with osteoporosis from different Russian cities par-
ticipated. Patients were asked to keep a diary. Diet, physical
activity, treatment pattern as well as fractures were assessed
by questionnaire at 3, 6 and 12 months after the education.
Patients were considered to be adherent if they took the
antiosteoporotic drug not less than 80% of the time.
Results: Overall, 479 patients were randomized into two
groups (241 in interactive program and 238 in control group).
435 subjects (90.8%) were available for contact at the end of
the study. The majority of patients took calcium and vitamin D
supplements 12 months after both types of education, and
number of those adherent was equal (78.6% in interactive
group and 80.1% in controls, p=0.69). Although, the number
of patients who took antiosteoporotic treatment did not differ,
the proportion of patients adherent to this therapy was greater
in interactive program group (55.4% vs. 35.1%, p<0.0001).
Patients of both groups changed their life style, but interactive
program group did it more frequently: the proportion of those
who increased the intake of dairy products was 58.6% in
interactive program group and 45.2% in controls (p=0.0058),
and proportion of those who increased their physical activity
was 55.3% and 42.7% correspondingly (p=0.009).
Conclusion(s): The interactive structured educational pro-
gram in small groups was more effective than a brochure in
enhancing the adherence to the treatment and life style
modification in patients with osteoporosis.
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IMPACT OF A THEORY-BASED OSTEOPOROSIS
EDUCATION INTERVENTION ON CALCIUM AND
VITAMIN D SUPPLEMENT INTAKE IN OLDER
ADULTS: A RANDOMIZED CONTROLLED TRIAL
Katherine M McLeod1, Shanthi C Johnson1,2, Drona
Rasali1,3, Ashok Verma4
1University of Regina, Faculty of Kinesiology and Health
Studies, 2University of Regina, Saskatchewan Population
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pelle Health Region, Regina General Hospital, Radiology,
Regina, SK, Canada
Objective(s): This study determined whether DXA screen-
ing alone or combined with a theory-based education inter-
vention, results in men and women's decision to start or
increase calcium and vitamin D supplement intake to pre-
vent or manage osteoporosis.
Material & Methods: This study utilized data from an
ongoing randomized controlled trial conducted in Saskatch-
ewan, Canada. Eligible participants were men and women 50
years of age and older, referred by their healthcare provider to
undergo DXA screening for the first time in the local hospital.
Participants (n=161, mean age=59.9 years) were randomly
assigned to an intervention group (n=78) or control group (n=
83). All participants underwent DXA screening and complet-
ed a series of measurements and questionnaires assessing
health behaviours, health beliefs, and dietary intake. The
intervention group also received osteoporosis education, using
the Health Belief Model, a theory of health behaviour change,
as a guiding framework. Six months after baseline, all partic-
ipants completed a series of follow-up measurements and
questionnaires.
Results: Daily calcium supplement intake increased in
both the intervention and control groups. On average,
the intervention group increased calcium intake from
369.9 mg to 792.9 mg (t(77)=-7.89, p<0.01), while
the control group increased intake from 427.8 mg to
594.6 mg (t(82)=-3.91, p<0.01). Daily vitamin D sup-
plement use significantly increased from 737.2 IU to
1186.1 IU (t(77)=-6.40, p<0.01) in the intervention
group, and 686.9 IU to 1009.3 IU (t(82)=-5.48, p<
0.01) in the control group. At follow-up, there was a
significant difference between groups for supplemental
calcium intake, but not vitamin D intake.
Conclusion(s): This study provided evidence that an edu-
cation intervention based on the Health Belief Model is
successful in increasing calcium supplement intake, partic-
ularly in men and women with no prior knowledge of their
bone density. The Health Belief Model may be useful when
planning and conducting osteoporosis education interven-
tions; however more research in this area is needed.
Disclosures: This research is supported by a Canadian
Institute of Health Research Doctoral Research Award and
the Saskatchewan Health Research Foundation.
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ATYPICAL FEMORAL FRACTURES:
RADIOGRAPHIC AND HISTOMORPHOMETRIC
FEATURES IN 9 PATIENTS
Aliya A Khan, Adil H Zaidi, Nazir Khan
McMaster University, Endocrinology, Hamilton, ON, Canada
Objective(s): This study describes characteristics and histo-
morphometric and radiographic features of atypical femoral
fractures (AFF) as seen in 9 cases referred for evaluation.
Osteoporos Int (2012) 23: (Suppl 2):S85–S386 S233
Material & Methods: All patients referred for evaluation of
AFF were reviewed. Patients meeting the ASBMR criteria
for AFF were further evaluated and tetracycline labelled
bone biopsies were completed. Radiographs were reviewed
by a musculoskeletal radiologist.
Results: All fracture lines were transverse or short
oblique with thickened cortices. We report 9 cases of
AFF in patients on long term bisphosphonate (BP) ther-
apy. 6 of 7 fractures occurred without a fall or direct
trauma to the femur with 1 case occurring after a fall
from standing height. All patients were female; average
age was 67 years (range 54-80 years). 2 of the 9 cases
were of Chinese descent, 2 were East Indian with 3
being Caucasian. Average BP durations of us was 8.5
years (range 7-14 years). 5 of 9 patients were on alendr-
onate alone, 2 patients were on risedronate. 1 patient had
received 18 months of teriparatide, 3 years prior to AFF
and had received a total of 10 years of BP use prior to
teriparatide.
Conclusion(s): AFF in association with long term BP use
are being seen in a disproportionately large number of Asian
women. Further evaluation of all AFF with identification of
predisposing key clinical risk factors is needed. Improved
understanding of the pathophysiology may be gained with
further histomorphometric data in larger numbers of
patients.
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BODY COMPOSITION OF POSTMENOPAUSAL
WOMEN WITH DIFFERENT CARDIOVASCULAR
RISK (SCORE)
Polina A Ptichkina, Irina A Skripnikova, Vladimir AVygodin,
Olga V Kosmatova, Aset S Abirova, Valery E Novikov,
Ludmila M Murashko
State Research Center of Preventive Medicine Ministry of
Health and Social Development, Department of Osteoporo-
sis Prevention, Moscow, Russian Federation
Objective(s): Low weight body is a risk factor for osteopo-
rosis and related with fractures. However, people with over-
weight are also subject to osteoporosis which is associated
with increased cardiovascular risk.
Objectives: To study relationship between bone mineral
content, lean and fat mass in postmenopausal women with
low and increased risk of cardiovascular diseases.
Material & Methods: 100 postmenopausal women were
underwent complete medical history, clinical examina-
tion, biochemical blood test (lipid profile) and exam-
ination of body composition. BMD, BMC, fat and
lean mass were measured by DXA (Hologic Delphi
W). Anthropometric measurements included BMI, cal-
culated as weight (kg)/height (m2). Patients were di-
vided into subgroups according to their BMI: normal
(BMI=18.5-24.9), overweight (BMI=25-29.9), obesity
(BMI=30 and more). Assessment of cardiovascular
risk was calculated by electronic version of the
SCORE.
Results: Duration of menopause is directly correlated
with severity of osteoporosis (p<0.001) and degree of
cardiovascular risk (p<0.001). Significant skeletal alter-
ations (osteoporosis and osteopenia) were found in 63%
of patients, 49% among them had overweight and 27%
(obesity). BMC(%) and lean mass(%) in the central and
peripheral regions of the skeleton are negatively corre-
lated with cardiovascular risk, while fat mass (%) is
correlated positively. Heightened atherogenic coefficient
is associated with osteoporosis (p<0.05) and increased
degree of SCORE (p<0.01).
Conclusion(s): The results confirm that low bone mass is
associated with increased cardiovascular risk. Obesity may
not be considered as a protective factor against osteoporosis
for postmenopausal women.
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THE IMPACT OF RISK FACTORS AND
FRACTURES ON THE EFFICACY AND SAFETY
OF IBANDRONATE IN PATIENTS
WITH OSTEOPOROSIS
Bojana N Stamenkovic, Sladjana D Bozilov, Aleksandar N
Dimic, Aleksandra M Stankovic, Sonja K Stojanovic, Jovan
M Nedovic, Sasa B Milenkovic, Marija Gacinovic, Jasmina
Jocic, Novica A Dimic
Institute Niska Banja, Rheumatology, Nis, Serbia
Objective(s): To confirm the efficacy and safety of 1 year
ibandronate in OP pts: 150 mg oral monthly or quarterly
intravenously; to analyze the impact of risk factors and
fractures on the efficacy of ibandronate treatment.
Material & Methods: 179 pts with primary OP, average 62.1
y, average menopause 16.8 y, treated 1 year with oral monthly
or quarterly iv injection of ibandronate were included. BMD
was measured by DXA Hologic at lumbar spine and proximal
femur; OP is defined as the mean BMD expressed as a T-score
<-2.5 and≥-5.0. The profile RTG of TH-LS spine was done
before and after the therapy. Substitution of the optimal dose
of vitamin D and calcium was applied
Results: Previous fracture (37.6%) and smoking (33.5%)
were the most common risk factors;75.1% pts had OP and
more than one risk factor. Total number of vertebral and non-
vertebral fractures at baseline was 71; 25 vertebral, 46 non-
vertebral. After therapy, the number of new fractures was 18;
8 vertebral, 10 nonvertebral. After 1 year of oral monthly
ibandronate BMD was increased at the spine for 3.0%,hip
3.5%,after ibandronate injection spine BMDwas increased for
4.6%, hip 3.6%. Spine and hip BMD increase was higher in
pts with OP and multiple risk factors (spine, p=0.000, hip, p=
0.01) than those with one risk factor (spine, p=0.04; hip, p=
0.02). Pts with multiple fractures and OP had a greater in-
crease in spine and hip BMD (spine, p=0.000; hip, p=0.001)
compared to those with 1 or without fracture (spine, p=0.04;
hip, p=0.05). Pts with OP and previous BF treatment had no
sign. BMD increase at the spine (p=0.334), nor on the hip (p=
0.2) opposed to those not previously treated, with statistically
sign. BMD increasing (spine, p=0.000, hip, p=0.006). Ad-
verse events were rare, did not lead to stopped the treat-
ment:7.8%pts had a flu like sy,1.1% LS pain,1.1% SVPT,
stopped after medical therapy
Conclusion(s): Ibandronate is effective, safe drug, orally
applied monthly or quarterly iv. in OP pts, especially those
with multiple risk factors and multiple fractures.
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BONE MINERAL DENSITY (BMD) ASSESSMENT
IN PATIENTS WITH PRIMARY
HYPERPARATHYROIDISM (PHPT) BEFORE AND
ONE YEAR AFTER PARATHYROIDECTOMY (PTX)
Eugénie Koumakis1, Jean-Claude Souberbielle2, Didier
Borderie3, Emile Sarfati4, André Kahan1, Catherine
Cormier1
1Cochin Hospital, APHP, Paris Descartes University,
Rheumatology Department A, 2Hopital Necker-Enfants
Malades, Laboratoire d'Exploration Fonctionnelles, 3Co-
chin Hospital, APHP, Paris Descartes University, Labo-
ratoire de Biochimie Generale et Specialisee, 4APHP,
Hopital Saint-Louis, Department of endocrine Surgery, Paris,
France
Objective(s): PHPT is a frequent cause of secondary
osteoporosis. Increase in BMD following PTX has
been reported in numerous studies. Subclinical PHPT
is increasingly diagnosed in osteoporosis patients. It is
unclear whether patients with a milder phenotype
might benefit from PTX. This study was to investigate
BMD changes in PHPT patients before and one year
after PTX, and to compare BMD changes between
patients with classic PHPT and a milder phenotype of
PHPT.
Material & Methods: Single center longitudinal study of
55 PHPT patients aged 63±10.6 years with mean T-
score at the spine, femoral neck and total hip of -2.51±
1.29, -2.34±0.74 and -1.8±0.82, respectively. A history
of fracture and osteoporosis were reported in 41.8%
and 90.7% of cases. 23 patients had both an elevated
pre-PTX serum total and ionized calcium level (group
1), while the remaining 32 had normal pre PTX total
and/or ionized calcium (group 2). All patients were
operated on with complete resolution of PHPT. BMD
was evaluated using QDR 4500 (Hologic) before and
one year after PTX.
Results: In the 55 PHPT patients, BMD increased sig-
nificantly one year after PTX by 3.2±5.1% at the spine
(p=0.0001), 3.0±5.6% at the femoral neck (p=0.0002)
and 3.3±5.3% at the total hip (p=0.0001). In group 1
patients, BMD increased significantly by 4.8±4.5% at
the spine (p=0.0001), 4.6±5.9% at the femoral neck (p=
0.0019), and 2.9±4.5% at the total hip (p=0.0005). In group
2, BMD increased significantly by 1.8±5.1% at the femoral
neck (p=0.031) and 2.7±6.1% at the total hip (p=0.048)
but not at the spine (2.0±5.2% gain, p=0.098). The BMD
gain was more important at the spine in group 1 than in
group 2 (p=0.0076), but there was no difference in BMD
gain between the 2 groups at the femoral neck and total hip
(p=0.15 and P=0.16).
Conclusion(s): In these PHPT patients, BMD increased
significantly after PTX at the spine and hip. Even in patients
with normal pre PTX serum total and/or ionized calcium, a
significant increase was observed at the hip. This highlights
the need for biological exploration to exclude secondary
causes of low bone mass.
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ALTERED BONE FATTY ACID METABOLISM
IN OBESITY AND AFTER DIET-INDUCED
WEIGHT LOSS
Riku Kiviranta1,2,3, Jussi Räisänen3, Tam Pham3, Anna
Karmi3, Antti Viljanen3, Riitta Parkkola3, Jarna Hannukainen3,
Pirjo Nuutila2,3
1University of Turku, Department of Medical Biochemistry
and Genetics, 2Turku University Hospital, Department of
Medicine, 3Turku University Hospital, Turku PET Centre,
Turku, Finland
Objective(s): Obesity has complex effects on bone tissue.
Overweight results in increased bone mass but is associated
with increased bone marrow adiposity with possible nega-
tive effects on bone metabolism. Free fatty acids (FFAs)
serve as an energy source for several tissues. FFA tissue
uptake is increased in obesity especially in myocardium,
liver and adipose tissue but is reduced after weight loss.
There is currently no information on FFA utilization in bone
tissue of normal or obese subjects.
To understand the crosstalk between energy metabolism and
bone, we analyzed bone FFA utilization using positron-
emission tomography (PET) imaging and serum markers
of bone turnover in controls and obese subjects before and
after very low calorie diet (VLCD).
Material & Methods: Controls (n=9, BMI=25.1±3.3)
were imaged at baseline and obese subjects (n=17, BMI=
33.9±4.0) before and after a six-week VLCD using [18 F]-
fluoro-6-thia-heptadecanoic acid ([18 F]-FTHA) for the as-
sessment of FFA tissue uptake. This was measured in the
bone marrow area at mid-femoral diaphysis and in the
trabecular bone of L3 and T7 vertebral bodies.
Results: At baseline FFA uptake in the femoral diaphysis was
significantly higher in obese subjects than in controls (0.37±
0.16 vs. 0.15±0.07 μmol/(min*dl), p<0.01). In obese the
FTHA uptake was lower in femurs than in vertebrae (0.37 vs.
1.41 μmol/(min*dl), p<0.001), but did not differ between tho-
racic and lumbar vertebrae. After VLCD obese subjects had lost
weight in average 12 kg (101±12 kg to 89±11 kg, p=0.008).
Subsequently, FFA uptake was reduced by 19% in femoral
diaphysis (p<0.03). The reduction in FTHA uptake was greater
in vertebrae (-27%, p<0.01) and more pronounced the higher
the uptake was at baseline. Interestingly, VLCD resulted in
increased levels of serum resorptionmarker CTX and formation
marker PINP but the ratio of CTX/PINP remained unaltered.
Conclusion(s): Our results indicate that FFA uptake in bone
marrow is increased in obese patients and that weight loss
reduces FFA utilization in bone. Weight loss results in a
balanced increase in bone turnover markers suggesting a
link between bone marrow fat and bone turnover. Finally,
the differing FFA metabolism between femur and vertebrae
implies a functional difference in these tissue compartments.
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THERAPYWITH STRONTIUM RANELATE
IMPROVESBONEMINERALMASS, BONEMINERAL
DENSITYAND GEOMETRICAL PARAMETERS OF
BONE IN POSTMENOPAUSAL OSTEOPOROTIC
WOMEN: 2 YEARS RESULTS - A PERIPHERAL
QUANTITATIVE COMPUTED TOMOGRAPHY
(PQCT) OF THE TIBIA STUDY
Konstantinos D Stathopoulos, Erato Atsali, Ilias Bournazos,
Panagiotis Papaggelopoulos, Grigoris Skarantavos
University of Athens, School of Medicine, "Attikon" Uni-
versity General Hospital, Bone Metabolic Unit, 1st Depart-
ment of Orthopedics, Athens, Greece
Objective(s): We assessed the effects of strontium ranelate
on bone mineral mass, volumetric BMDs and geometrical
properties of the bone in postmenopausal osteoporotic wom-
en using tibia pQCT.
Material & Methods: We studied 32 postmenopausal
women who received 2 g strontium ranelate per os daily
for 2 consecutive years. Inclusion criteria: 1) age >50 y, 2)
postmenopausal status >2 y, 3) DXA measurement (spine/
hip) with T-score<-2.5 SD 4) Tibia pQCT before, 1 y and 2
y after treatment. Exclusion criteria: 1) Secondary osteopo-
rosis' conditions, 2) Other bone metabolic diseases, 3) Pre-
vious use of bone anabolic agents, 4) malignancies. pQCT
of the tibia was performed in all patients (XCT 2000, Stratec
Medizintechnik, Pforzheim, Germany) and three slices were
obtained at the 4% (trabecular), 14% (subcortical and
cortical) and 38% (cortical bone) of tibia length sites.
We studied 15 variables per slice, mainly total bone
content (TOT_CNT), total density (TOT_DEN), trabecular
content (TRB_CNT), trabecular density (TRB_DEN), cortical
content (CRT_CNT), cortical density (CRT_DEN), sub-
cortical content (CRTSUB_CNT), subcortical density
(CRTSUB_DEN), cortical area (CRT_A), subcortical area
(CRTSUB_A) and mean cortical thickness (CRT_THK).
Results were corrected for strontium ranelate atomic
weight. We performed statistical analysis (t-test, ANCOVA)
- data expressed as mean±SD
Results: Patients' mean age was 64.3±12.6 y and mean tibia
length 352.14±65.03 mm. After 2 years of treatment, we
report increases at the 14% site in ΤΟΤ_CNT (181.04±21.51
vs. 183.05±21.34, p=0.006), SUBCRT_CNT (168.64±19.58
vs. 170.48±19.11, p=0.005), and CRT_CNT (62.91±18.58
vs. 66.63±20.63, p=0.021).At the 38% site we report
increases in TOT_CNT (276.46±36.24 vs. 278.94±
35.71, p= 0.09), SUBCRT_CNT (205.86±25.60 vs.
208.59±25.47, p<0.000), CRT_CNT (160.09±31.19 vs.
168.84±32.62, p<0.000) and CRT_DEN (1192.46±14.50
vs. 1203.15±17.05, p<0.000). We also report increases in
CRT_A (134.18±25.73 vs140.13±26.57, p<0.000) and
mean CRT_THK (2.18±0.44 vs. 2.28±0.46, p=0.001).
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Conclusion(s): Our results indicate that 2 years therapy
with strontium ranelate increase significantly bone mass,
volumetric cortical densities, cortical area and mean cortical
thickness in postmenopausal osteoporotic women.
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INCORPORATING PATIENT REPORTED
OUTCOME MEASURES IN CLINICAL PRACTICE:
DEVELOPMENT AND VALIDATION OF A
MULTIDIMENSIONAL QUESTIONNAIRE FOR
OSTEOPOROSIS
Yasser El Miedany1, Maha El Gaafary2, Nadia El Aroussy1,
Ihab Ahmed3
1Ain Shams University, Rheumatology and Rehabilitation,
2Ain Shams University, Community, Environmental and
Occupational Medicine, 3Cairo University, Internal Medicine,
Cairo, Egypt
Objective(s): Osteoporosis is embarking on a fundamental
redesign of the patients' care. It became mandatory not only
to recognize BMD, fracture or falls risks, but also the impact
of the disease and the subsequent fractures on the patient
life. Measurement of patient reported outcomes have be-
come critical in both standard clinical practice and long term
observational studies. Objective was to assess validity; reli-
ability and responsiveness to change of a patient self-
reported questionnaire which can assess construct outcome
measures of patients with osteoporosis and correlated low
trauma fractures.
Material & Methods: 354 postmenopausal women were
included in this work. The questionnaire was developed by
integrating information obtained from the patients based on
the Rasch model for ordered response options. The ques-
tionnaire includes assessment for functional disability, qual-
ity of life, VAS for pain (whether it is secondary to vertebral
or nonvertebral fracture), as well as global status. All
patients attended 2 visits: at baseline and at 6 months. The
psychometric properties of the questionnaire were evaluated
in terms of comprehensibility, validity and internal consis-
tency in baseline, and in terms of test-retest reliability and
responsiveness to change in visit at month and visit at 6
months.
Results: The questionnaire was reliable as demonstrated by
a high-standardized alpha (0.891-0.932). The questionnaire
items correlated significantly (p<0.01) with the occurrence
of low trauma fracture, high FRAX and falls risk scores.
Changes in functional disability, quality of life as well as
pain score showed significant variation (p<0.01) with the
management of the fracture. Moderate to high correlations
were found between the Functional disability and quality of
life scores with ECOS-16 score (0.64-0.82). The Minimal
Clinically Important Difference suggested a change of 0.2
points representing the least improvement in general health
status due to their osteoporosis. The PROMs questionnaire
showed also a high degree of comprehensibility (9.4).
Conclusion(s): Integrating patient reported outcome meas-
ures into standard clinical practice is feasible and applicable.
This version of multidimensional PROMs questionnaire was
found to be valid and reliable. It provides informative quan-
titative measure for the patient's condition at the time of
assessment and facilitate monitoring of the patient's re-
sponse to therapy.
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A DOUBLE-BLIND, RANDOMIZED,
DOSE-FINDING, PHASE 2 STUDYOFODANACATIB,
A POTENTCATHEPSIN-K INHIBITOR, IN JAPANESE
PATIENTS WITH OSTEOPOROSIS
T Nakamura1, M Shiraki2, M Fukunaga3, T Tomomitsu3, S
Uchida4, G Fujimoto4, M Nakagomi4, AC Santora5
1University of Occupational and Environmental Health,
Medicine, Fukuoka, 2Research Institute and Practice for
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Objective(s): The objectives of this study were to evaluate
the efficacy and safety of oral treatment with placebo or 10,
25, or 50 mg of odanacatib once-weekly for 52 weeks in a
double-blind, randomized, multicenter study in Japanese
female and male (4%) patients with osteoporosis.
Material & Methods: The primary efficacy endpoint was
the percent change from baseline at 52 weeks in lumbar spine
(L1∼L4) BMD. Secondary efficacy endpoints included the
percent change in BMD at total hip, femoral neck, trochanter,
and bone biomarker changes after treatment for 52 weeks.
Results: In this study, 287 patients were randomized to
placebo (N=73) or odanacatib 10 mg (N=74), 25 mg (N=
71), or 50 mg (N=69). The least-squares means (LS mean)
percent changes from baseline at 52 weeks in lumbar spine
(L1∼L4) BMD were 0.5%, 4.1%, 5.7% and 5.9% in the
groups receiving placebo, 10 mg, 25 mg and 50 mg of
odanacatib, respectively. The LS mean percent changes
from baseline at 52 weeks in total hip BMD were -0.4%,
1.3%, 1.8% and 2.7% in the placebo, 10 mg, 25 mg and 50
mg of odanacatib, respectively. The changes in femoral neck
and trochanter BMD were similar to those at the total hip.
Odanacatib reduced bone markers of resorption in a dose-
dependent manner. However, the reductions of bone forma-
tion markers were of a smaller magnitude than the reduc-
tions of bone resorption markers. After 52 weeks, for
patients once weekly receiving ODN 50 mg, geometric
mean percent changes from baseline (SE) were -58.6 (3.3)
for urine NTX/creatinine (N=51), but only -25.9 (3.2) for
serum BSAP (N=54). The tolerability and safety profiles
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were similar among all treatment groups with no dose-
related trends in any adverse events.
Conclusion(s): Once weekly treatment with odanacatib for
52 weeks increased lumbar spine and all hip site BMD in a
dose-dependent manner and was well-tolerated in Japanese
patients with osteoporosis. In addition, the data from this
study were similar to the results of the phase 2 dose-finding
study (Protocol 004) of mostly Caucasian, postmenopausal
women with low BMD.
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RELIABILITY OF PQCT-DERIVED MUSCLE AREA
AND DENSITY MEASURES ON WATERSHED VS.
THRESHOLD-BASED SEGMENTATION METHODS
Andy Kin On Wong1, Aakash Bhargava1, Kayla Hummel2,
Sami Shaker1, Karen A Beattie1, Christopher L Gordon1,
Cathy Craven3, Jonathan D Adachi1, Lora Giangregorio2
1McMaster University, Medicine, Hamilton, 2Waterloo Uni-
versity, Kinesiology, Waterloo, 3University of Toronto,
Medicine, Toronto, ON, Canada
Objective(s): To compare reliability of calf muscle meas-
ures obtained using pQCT and analyzed with threshold-
based vs. watershed algorithms across a cohort with varying
muscle area.
Material & Methods: Young adults (<30 years old), older
adults (>60 years old) and individuals with spinal cord
injury (SCI) were scanned twice on pQCT at the same visit
with repositioning between acquisitions. A 2.3±0.5 mm
thick slice was obtained from the 66% calf at 500 μm
resolution. Images were randomized and blinded to the
reader. Threshold-based and manual watershed segmenta-
tion of muscle from bone (threshold: 280, contour 1, peel 2)
and subcutaneous fat (threshold: 40, contour 3, peel 1) was
performed using Stratec V6.0 (Orthometrix) and sliceO-
matic V4.3 (Tomovision), respectively. Tissue boundary
identification was guided by the watershed tool and manu-
ally traced by a single reader. Muscle volumetric density
(vMD) and cross-sectional area (MCSA) were computed in
each analysis. Root mean square coefficients of variation
(RMSCV) and standard deviations (RMSSD), and Bland-
Altman limits of agreement (LOA) were determined for
vMD and MCSA for both methods. A general linear model
determined difference in vMD and MCSA between segmen-
tation methods adjusting for participant subgroup.
Results: Most RMSCV and RMSSD values for threshold
segmentation were larger than manual watershed segmenta-
tion (Table I) The LOA for vMD obtained using the water-
shed algorithm were -3.68 to 3.09 (N=85); vs. on threshold-
based segmentation, -4.75 to 4.75 (N=81). The LOA for
MCSA was -132.80 to 137.50 (N=93) and -353.19 to
369.28 (N=81) for watershed vs. threshold segmentation,
respectively. Manual segmentation (70.2±9.2 mg/cc)
provided larger (p<0.001) densities compared to threshold
segmentation (67.4±10.3 mg/cc).
Table I. Comparing reliability of pQCT muscle measures
obtained by water-shed versus threshold-based segmenta-
tion separated by participant subgroups. Young adult
(age: 25.6±3.3, BMI:23.9±4.8), older adult (age:74.0±
9.2, BMI:25.7±4.0), SCI (age:44.1±9.4,BMI:23.9±3.3).
vMD=muscle volumetric density, MCSA=muscle cross-
sectional area.
Reliability Data RMSSD (units) RMSCV (% error)
Variable & Method Young Older SCI Young Older SCI
Water-Shed vMD
(mg/cc)
0.89 1.43 0.85 1.18 2.01 1.42
Threshold-based vMD
(mg/cc)
1.73 1.22 2.43 2.36 1.77 4.06
Water-Shed MCSA
(mm2)
34.96 53.97 52.34 0.49 0.93 1.38
Threshold-Based
MCSA (mm2)
154.35 105.37 142.10 2.57 1.77 2.94
Conclusion(s): Watershed-guided segmentation of muscle
from pQCT images showed greater reproducibility and
tighter retesting limits. Although manual tracing may be
less efficient, its higher reliability is favourable to longitu-
dinal studies demanding greater analytical sensitivity.
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CORRELATIONS BETWEEN 25(OH)D AND BMD
CHANGE IN POSTMENOPAUSAL OSTEOPOROTIC
WOMEN: SECONDARY ANALYSES OF A 1-YEAR
TRIAL OF WEEKLY ALENDRONATE (ALN)
PLUS VITAMIN D3 5600 IU VS. STANDARD CARE
Jean-Yves Reginster1, Neil Binkley2, Steven Boonen3,
Douglas P Kiel4, Stuart Ralston5, Christian Roux6, Annpey
Pong7, Elizabeth Rosenberg7, Arthur Santora7
1University of Liege, Epidemiology, Liege, Belgium, 2Uni-
versity ofWisconsin,Medicine,Madison,WI, US, 3Center for
Metabolic Bone Disease, Medicine, Leuven, Belgium, 4Insti-
tute for Aging Research, Hebrew SeniorLife and Harvard
Medical School, Aging Research, Boston, MA, US, 5School
of Molecular and Clinical Medicine, Western General Hospi-
tal, Clinical Medicine, Edinburgh, UK, 6Paris Descartes Uni-
versity, Rheumatology, Paris, France, 7Merck Sharp and
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Objective(s): Vitamin D supplements are recommended as
adjunctive therapy with antiosteoporotic drugs. In this inter-
national, randomized trial, women receiving single tablet
alendronate/vitamin D3 5600 IU (ALN/D) for 1 year had
higher 25(OH)D, higher BMD, and lower bone turnover
markers than women receiving Standard Care (prescribed
by patients' personal physicians who were not investigators
in the trial), even though a majority of Standard Care
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participants took a bisphosphonate (most often ALN) plus
varying doses of vitamin D. Subgroup analyses and deter-
mination of correlations between serum 25(OH)D and BMD
change in patients treated with alendronate were performed.
Material & Methods: Participants were postmenopausal
women ≥65 years, BMD T-scores at spine or hip of
≤-2.5 (or ≤-1.5 with prior fragility fracture), 25(OH)D
20-50 nmol/mL, and increased risk of falls. The primary
study endpoint was proportion of participants with
25(OH)D<50 nmol/mL.
Results: Participants (n=515) were of mean age=73 years,
72% Caucasian, with mean baseline 25(OH)D=37 nmol/L.
After 1 year, fewer women taking ALN/D than Standard
Care had 25(OH)D<50 nmol/mL among all trial partici-
pants and in the following: baseline 25(OH)D≤or >37.5
nmol/mL, age≤or >75 years, and European or non-Europe-
an residence. Among Standard Care women receiving ALN,
end-of-study 25(OH)D levels correlated positively with per-
cent increase from baseline in lumbar spine and femoral
neck BMD (Table, Pearson correlation coefficients (95%
CI)=0.23 (0.02,0.41) and 0.24 (0.03,0.41), respectively).
Baseline 25(OH)D levels correlated with increases in only
lumbar spine BMD (Table, Pearson correlation coefficient
(95% CI)=0.22 (0.01,0.40)).
Conclusion(s): In osteoporotic postmenopausal women
with low 25(OH)D the increase in lumbar spine and
femoral neck BMD during treatment with alendronate
was positively correlated with serum 25(OH)D. This
parameter could be a determinant to optimize the BMD
response to alendronate.
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SLOVAK REGISTER OF PATIENT WITH SEVERE
OSTEOPOROSIS ON OSTEOANABOLIC
TREATMENT
Peter Vanuga2, Sona Tomkova4, Pavol Masaryk3, Alexandra
Letkovska3, Zlata Kmecova5, Zdenko Killinger1, Peter
Jackuliak1, Juraj Payer1
1University Hospital and Medical Faculty of Comenius
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Objective(s): Human PTH (1-84 PTH) or teriparatide
(TPTD), a recombinant aminoterminal fragment (1-34) of
the PTH have a predominantly stimulating effect on bone
formation. Osteoanabolic treatment in Slovakia can be indi-
cated only in centers (5 in our country) for patient with
severe postmenopausal osteoporosis, for treatment of oste-
oporosis in men and glucorticoid-induced osteoporosis
(GIOP). The primary outcome is to define the basic charac-
teristics of patients on osteoanabolic treatment.
Material & Methods: We started a register of patient in
the Slovakia, treated with PTH or teriparatide. In all
enrolled patients we measured BMD, X-ray of skeleton,
vitamin D, calcium, osteocalcin, C-telopeptide of colla-
gen CTx P1NP. According the medical data we analyzed
menopausal status, duration of previous antiosteoporotic
treatment, the use of corticosteroids. The BMD of lumbar
spine (L1-4), femoral neck and total hip was measured
before treatment (base line) and at 12 and 18 months
using DXA (Hologic). Statistical analyses were per-
formed according to the intention-to-treat principle. T-test
was used to determine the changes in percentage of
BMD and levels of serum markers in 6, 12 and 18
months compared to baseline.
Results: We present the characteristics of 534 patient on
osteoanabolic treatment, 242 on PTH and 292 on TPTD.
From the group on PTH treatment were 13.4% (n=39) men.
In the group on TPTD treatment were 100% of women. 115
patients on TPTD treatment were indicated for GIOP. At
baseline the mean T-score of total hip was -2.73 (95% CI -
Correlations Between Tertiles of 25(OH)D and % Change From Baseline in BMD in Referred Care Patients Receiving ALN
Increasing Tertiles of
Baseline 25(OH)D
Increasing Tertiles of
1-year 25(OH)D
1 2 3 1 2 3
Mean 1-year % change in
LUMBAR SPINE BMD (SE)
3.7 (0.8) 5.2 (0.7) 5.9 (0.8) 3.9 (0.7) 4.9 (0.8) 5.8 (0.8)
[Range of 25(OH)D (nmol/L)] [13-28] [28-40] [40-95] [15-55] [55-73] [73-118]
Mean 1-year % change in
FEMORAL NECK BMD (SE)
2.1 (0.7) 1.9 (0.6) 2.3 (0.8) 1.3 (0.6) 2.4 (0.7) 2.9 (0.8)
[Range of 25(OH)D
(nmol/L)]
[13-30] [30-40] [40-95] [15-55] [55-73] [73-118]
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2.69 to -2.77), and of lumbar spine -3.10 (95%CI -3.05 to -
3.15). Calcium levels were 2.37 mmol/l (95%CI 2.18-2.57),
PTH 6.69 pmol/l (95%CI 2.21-15.56), osteocalcin 24.76 ng/
ml (95%CI 8.12-60.77), 25-OH-vitamin D3 25.09 ng/ml
(95%CI 4.00-62.10), sCTX 0.43 ng/ml (95%CI 0.08-0.09),
P1NP 46.80 ng/ml (95%CI 9.59-100.30).
Conclusion(s): Osteoanabolic treatment is indicated for
treatment of severe osteoporosis in women and also in
men. More frequent indication was a new treatment of
severe osteoporosis according the indication criteria.
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POPULATION BASED STUDY FOR BONEMINERAL
DENSITYAND PEAK BONE MASS IN KOREAN
MEN &WOMEN
Hoon Choi
Inje University Sanggyepaik Hospital, Obstetrics and Gyne-
cology, Seoul, Korea
Objective(s): The cross-sectional study was performed to
get the reference ranges of BMD to investigate the preva-
lence of osteoporosis in the Koran population based on the
fourth Korea National Health and Nutrition Examination
Survey (KNHANES IV) in 2008-2009.
Material & Methods: We measured BMD at lumbar spine,
femoral neck, trochanter, and total hip by DXA machine
(Hologic discovery, Hologic, USA). The subjects were 4652
men and 5664 women aged older than 10 years, who didn't
have disease affect bone metabolism.
Results: At the lumbar spine, BMD peaked at aged 30-
34 in men and at aged 35-39 in women. At the femoral
neck, peak BMD was attained at aged 20-24 in men and
at aged 15-18 in women. At the total hip, BMD peaked
at aged 20-24 in men and at aged 40-44 in women. The
age related changes of BMD in Korean men & women
were different from that of other ethnic group. As com-
pared with US participants, the BMD at every skeletal
site in Koran males and females was significantly lower
than that of white Americans. As compared with Japa-
nese women, the lumbar spine and femur BMD in Ko-
rean females 20-49 ages was lower than in Japanese
participants also.
Conclusion(s): This KNHANES survey is the first study to
investigate the prevalence of osteoporosis, age at peak bone
mass, and age related changes of BMD and will provide the
Korean reference data of BMD.
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INCIDENCE OF OSTEOPOROTIC VERTEBRAL
FRACTURES WITH ELDERLY POSTMENOPAUSAL
WOMEN: OUR EXPERIENCE
Mirjana S Karadzic
Institute "Niska Banja", Rheumatology Clinic, Nis, Serbia
Objective(s): Vertebral fractures are linked with the in-
creased mortality and morbidity as well as the higher risk
against new fractures. Timely diagnostic is very important
for the further treatment. Studies on its prevalence are rare in
the country. Pilot examination of patients treated in the
Institute Niška Banja on the incidence of vertebral fractures.
Material & Methods: 77 postmenopausal women older
than 65, having osteoporosis, have been analysed. Upon
the made densitometric examination of lumbosacral part of
the spine (LS) L1-L4 and the hip, which helped to identify
osteoporosis, X-ray test of the T4-L5 portion of the spine
was made in all the patients, aimed at detecting vertebral
fractures, AP and profile, which have been analysed by
semi-quantitative method (Genant,1993); the analysis was
made by a radiologist.
Results: Average age of the patients ranged between 70.4±
6.8 years, BMI 25.4±5.9 kg/m2, height 155.8±4.5 cm,
menopause started 18.9±5.4 years ago. Vertebral fractures
were found out in 21 patients (27.27%). Symptomatic frac-
tures were reported by 4 (19.04%) patients whereas 17
(80.95%) patients had the asymptomatic ones. One fracture
was registered with 11 (53%) patients, 2 fractures with 6
(29%), and 3 and more with 4 (19%) patients. 1st degree
fractures, according to Genant, were found out in 12 (57%),
2nd degree fractures were registered with 8 (38%) patients
and 3 rd degree fractures with 1(5%) patient.
Conclusion(s): The results obtained from pilot research
indicate a high percentage of asymptomatic vertebral frac-
tures in the examined group of elderly postmenopausal
women having osteoporosis. They also emphasise the need
of making early diagnosis of vertebral fractures.
P421
AFTER 3 YEARS OFANNUAL ZOLEDRONIC ACID,
WHO SHOULD REMAIN ON TREATMENT?
RESULTS FROM THE HORIZON-PFT EXTENSION
STUDY
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Boonen4, Lisa Palermo5, Ian R Reid6, Steven R Cummings7,
Dennis M Black5
1University of Sheffield, Centre for Biomedical Research,
Sheffield, UK, 2Helen Hayes Hospital, Clinical Research
Center, West Haverstraw, NY, 3University of Pittsburgh,
Department of Epidemiology, Pittsburgh, PA, US, 4Leuven
University, Department of Experimental Medicine, Leuven,
Belgium, 5University of California, San Francisco, Depart-
ment of Epidemiology and Biostatistics, San Francisco, CA,
US, 6University of Auckland, Medical and Health Sciences,
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Objective(s): There is limited evidence that bisphospho-
nates reduce fracture risk after 3-5 years. Our objective
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was to determine who might be able to discontinue treat-
ment after 3 years.
Material & Methods: In the HORIZON Extension (E1),
we randomized 1233 women who had received 3 annual
zoledronic acid (ZOL) infusions in the HORIZON-Core
trial to 3 additional ZOL infusions (Z6, n=616) or 3
placebo infusions (Z3P3, n=617)(1). In this analysis, we
analyzed fracture predictors during the extension in
Z3P3. Potential predictors at E1 baseline included age,
hip BMD, weight, prevalent vertebral fracture, P1NP,
and predictors during the Core study included incident
vertebral or nonvertebral fracture, hip BMD change and
weight change. Treatment effects were then assessed in
subgroups defined by the significant predictors (Z6 vs.
Z3P3 groups).
Results: New morphometric fracture predictors were: FN T-
score≤-2.5 [odds ratio (95%CI)=3.3 (1.4,8.0), p=0.008];
TH T-score≤-2.5 [OR=4.0(1.8,9.0), p=0.0007]; and inci-
dent morphometric vertebral fracture during Core [OR=4.8
(1.3,16.8), p<0.015]. For new nonvertebral fracture, sig-
nificant predictors were incident nonvertebral fracture
during Core [HR=2.5(1.2,5.3), p=0.014] and prevalent ver-
tebral fracture [HR=3.0(1.4, 6.3), p=0.005]. TH BMD T-
score≤-2.5 was marginally significant [HR=1.7, p=0.11].
For vertebral fractures, there were no significant treatment
subgroup interactions; however, absolute fracture risk reduc-
tions were greatest and numbers needed-to-treat to prevent a
fracture lowest in the high-risk subgroups, especially those
with FN or TH T-Score≤-2.5 [Table]. For nonvertebral frac-
tures, there were no significant treatment effects in high-risk
subgroups.
Incident Morphometric Vertebral Fracture in Z3P3 and Z6 by Risk
Subgroup
Risk
Subgroup
Z3P3 Z6 OR (CI) Rx Effect
P
NNT/3
Yrs
FN≤-2.5 23/250
(9.2%)
9/257
(3.5%)
0.36 (0.15,
0.77)
0.011 18
FN>-2.5 7/235
(3%)
5/210
(2.4%)
0.79 (0.23,
2.53)
0.698 167
Yes Core
Vert
4/16
(25%)
0/11 0 0.12 4
No Core
Vert
26/467
(5.6%)
12/454
(2.6%)
0.46 (0.22, 0.9) 0.029 34
Conclusion(s): In women with hip BMD≥-2.5, no inci-
dent fracture during the initial treatment period and no
prevalent vertebral fractures, risk for subsequent fracture
is low and treatment discontinuation for up to 3 years
can be considered. In other women, particularly those
with hip BMD T-score<-2.5, continued ZOL for 3 years
is likely to confer benefit at least against future verte-
bral fracture.
References: Black et al. JBMR. 2012;27:243.
Disclosures: Study supported by Novartis Pharma AG,
Basel.
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VITAMIN D LEVELS OF GREATER THAN
85 NMOL/L IN THE PRESENCE OF ADEQUATE
DIETARY CA MINIMISE BONE TURNOVER
AND IMPROVE BONE STRENGTH
Alice M Lee1,2, Paul H Anderson1,5, Roland Steck3, Mark
Forwood4, Rebecca K Sawyer2, Howard A Morris1,5, Peter
D O'Loughlin1,2
1SA Pathology, Endocrine Bone Research Laboratory, 2Uni-
versity of Adelaide, Faculty of Health Sciences, Adelaide,
SA, 3Queensland University of Technology, Orthopaedics
and Trauma, Brisbane, 4Griffith University, School ofMedical
Sciences, Gold Coast, QLD, 5University of South Australia,
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Objective(s): We have reported femoral osteopenia in short
term-vitamin D restricted rats without deterioration in tibial
cortical bone volume (CBV), geometry or strength.1 The
present study aimed to establish the effect of extended
vitamin D deficiency in aged rat tibial volume and strength.
Material & Methods: Female Sprague Dawley rats (9 m,
n=6/gp) were fed a diet containing varying vitamin D3
(D) levels (0, 2, 12 and 20 IU/d) with either low (0.1%,
LCa) or high (1%, HCa) dietary calcium for 6 m. At 15
m blood was taken for 25-hydroxyvitamin D (25D)
1,25-dihydroxyvitamin D (1,25D), PTH and Ca analyses
and tibiae and femora retrieved for bone analyses. 3D
μCT scans (Skyscan 1174) were used to determine
CBV, midshaft sagittal cortical thickness (Cth.sag) and
metaphyseal BV/TV. Tibial peak load was determined
by 3-point bending (Test Resources 800LE4). 25D and
1,25D were determined by RIA (IDS) and PTH by
IRMA (Immutopics).
Results: Group serum 25D levels ranged from 22(±2.9)
nmol/L to 161(±38.8) nmol/L and serum calcium levels
from 2.5(±0.05) mmol/L to 3.2(±0.2) mmol/L. Circulating
25D was a determinant of BV/TV (R2=0.23, p<0.001) and
CBV (R2=0.22, p<0.01). In multiple linear regression nei-
ther serum Ca, PTH nor 1,25D were determinants of bone
volume when 25D was accounted for. Dynamic histomorph-
ometry indicated that high dietary Ca reduced bone turnover
only in animals with circulating 25D levels above 85 nmol/
L with the greatest reduction achieved in the 20 IU/d group
(20D) (BFR [um3/um2/d]: LCa20D 33.9(3.4) vs. HCa20D
21.8(2.3), p<0.05; Oc/BPm [No.x10-3/mm]: LCa20D 2.0
(0.2) vs. HCa20D 1.1(0.1), p<0.05). Tibial peak load was
related to Cth.sag (R2=0.39, p<0.01).
Conclusion(s): Thus, optimisation of bone volume and
strength requires the combination of high dietary Ca intake
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and circulating 25D above 85 nmol/L. However, our previ-
ous demonstration that high dietary Ca is required to max-
imise circulating 25D levels2,3 in combination with the
present findings suggest that the mechanism for vitamin
D-optimisation of bone is not mediated via a calcaemic
effect.
References: 1. Lee AMC et al. JSBMB 2010;121:284. 2.
Anderson PH et al. JBMR 2008;23:1789. 3. Anderson PH et
al. JSBMB 2010;121:288.
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RELATION OF VITAMIN D LEVELS WITH BONE
MINERAL DENSITY AND PARATHYROID
HORMONE INADULTSWITHLOWBONEDENSITY
Sunil K Kota1, Siva K Kota2, SVS Krishna1, Lalit K
Meher3, Kirtikumar D Modi1
1Medwin Hospital, Endocrinology, Hyderabad, Andhrapradesh,
2Central Security Hospital, Anesthesia, Riyadh, Saudi
Arabia, 3MKCG Medical College, Medicine, Berhampur,
Orissa, India
Objective(s): To investigate the relationships among serum
25-hydroxyvitamin D [25(OH)D] levels, intact PTH (iPTH)
levels, and BMD.
Material & Methods: Adults with or without prevalent
fragility fractures and with low BMD at the total hip, or
lumbar spine underwent assessment. Multivariate regression
models were used to investigate the relationships among
serum 25(OH)D, iPTH, and BMD.
Results: Total of 102 patients (male:female=38:64) with
mean age of 62.5±6.4 years were inducted into the
study. 44 patients had osteopenia and osteoporosis
was present in 58 patients. The mean values for serum
25(OH)D and IPTH levels were 21.3±0.5 ng/ml and
53.1±22.3 pg/ml, respectively. In 84.3% of patients,
serum 25(OH)D levels were below 30 ng/mL. There
was no association between 25(OH)D levels and BMD
at the total hip, or lumbar spine (P=0.473, and 0.353,
respectively). Serum iPTH levels were negatively asso-
ciated with BMD at the total hip (P=0.019) and the
lumbar spine (P=0.02). Both at the total hip and lum-
bar spine, iPTH levels, male sex, BMI, and age were
found to be significant predictors of BMD. Patients with
higher BMI had significantly lower BMD and T-score. At
levels <30 ng/mL, 25(OH)D was negatively associated with
iPTH (P=0.041).
Conclusion(s): Among our cohort of patients with low
BMD, no direct relationship between serum 25(OH)D
levels and BMD at total hip and lumbar spine was
observed. A negative correlation existed between iPTH
and 25(OH)D at serum 25(OH)D concentrations <30 ng/mL,
and serum iPTH levels showed a significant negative associ-
ation with BMD at the total hip and lumbar spine. These
significant negative associations between iPTH levels and
BMD at the total hip and lumbar spine underscore the
critical role of this hormone in bone metabolism and
health. Advancing age, male sex, BMI are other signif-
icant predictors for BMD both at total hip and lumbar
spine.
Disclosures: All the authors would extend their heartfelt
thanks to Mrs Sruti Jammula, Mrs Sowmya Jammula,
Dr Jagadeesh Tangudu for their selfless contribution
towards manuscript preparation and final approval of
the text.
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IS FEMORAL ACETABULAR IMPINGEMENT
A PREDICTOR OF RADIOLOGICAL HIP
OSTEOARTHRITIS IN OSTEOPOROTIC HIP
FRACTURE PATIENTS?
Ai Ye J Lee, Joyce SB Koh, Tet Sen Howe
Singapore General Hospital, Orthopedic Surgery, Singapore
Objective(s): Traditionally the condition of femoral acetab-
ular impingement (FAI) has always been diagnosed radio-
logically. FAI has been postulated to be the cause of hip
osteoarthritis (OA). This study, comprising of osteoporotic
hip fracture patients, aims to examine the incidence of hip
OA with radiological FAI.
Material & Methods: Anteroposterior pelvic radiographs
of 300 patients admitted to the Singapore General Hospi-
tal between January 2008 - June 2010 for osteoporotic hip
fracture were collected. The good hip was assessed for the
presence of CAM and pincer FAI. Measurements pertain-
ing to CAM FAI were measured, namely: Sharp's, Neck-
shaft and the centre-edge (CE) angle. Presence of the
cross-over sign was used for the diagnosis of pincer
FAI. The Kellgren-Lawrence scale (KL-scale) was used
to assess for the presence and severity of hip OA. Severity
of hip OA (KL-scale 0-4) was analysed against the angles
measured for CAM FAI.
Results: The median age of our study group was 81 years
(range: 60-104, SD 9.0). There were 237 females (79%) and
63 males (21%). 56 patients were diagnosed with FAI, of
which 52 (17.3%) were CAM FAI and 4 (1.33%) were
Pincer FAI. 36 out of 52 CAM patients had hip OA. Only
1 out of the 4 Pincer FAI patients had hip OA. There are
significantly more cases of OA in CAM patients (p=0.02)
than non-CAM patients. Older age was also associated with
hip OA (OR=1.04, 95% CI: 1.0, 1.07) as was gender. Males
were found to be 3 times more at risk of OA than females
(OR=2.9, 95% CI 1.5, 5.6). There was no correlation be-
tween the severity of hip OA (KL-scale 0-4) and the angles
of measurements for CAM.
Conclusion(s): In osteoporotic hip fractures, the pres-
ence of CAM was found to be an independent risk
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factor for radiologic hip OA. There was no correlation
between the severity of hip OA and angles of measure-
ment for CAM. Other factors that would contribute to
hip OA include old age and the male gender. Early
identification of CAM FAI would aid in the delay and
possibly the prevention of hip OA.
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HIGHER LEVELS OF SERUM PENTOSIDINE
ARE ASSOCIATED WITH ELEVATED RISK OF
VERTEBRAL FRACTURES IN A 10-YEAR
FOLLOW-UP OF JAPANESE FEMALE
POPULATION: THE JAPANESE POPULATION-
BASED OSTEOPOROSIS (JPOS) COHORT STUDY
Masayuki Iki1, Eiko Kadowaki1, Junko Tamaki1, Yuho
Sato2, Sadanobu Kagamimori3, Yoshiko Kagawa4, Hideo
Yoneshima5
1Kinki University Faculty of Medicine, Department of
Public Health, Osaka-Sayama, Osaka, 2Jin-ai University,
Department of Human Life, Echizen, Fukui, 3University
of Toyama, Toyama 4Kagawa Nutrition University,
Sakado, 5Shuwa General Hospital, Kasukabe, Saitama,
Japan
Objective(s): To evaluate associations between serum levels
of pentosidine (PEN) and subsequent vertebral fracture (VFx)
risk for 10 years
Material & Methods: Among 900 women aged 50-79
years selected randomly from 3 municipalities in Japan,
852 completed the baseline study and were invited for
follow-up surveys conducted 3 times in 10 years includ-
ing VFx assessment on digital images from spine
absorptiometry and spine BMD measurement. Serum
PEN levels were determined by ELISA at baseline.
Prevalent vertebral deformity (VDf) was determined
according to McCloskey-Kanis criteria. Incident VFx
was identified when one of the three vertebral heights
decreased by 20% or more compared to the baseline
heights and the vertebra satisfied McCloskey-Kanis or
Genant's grade 2 or 3 fracture criteria.
Results: 616 women participated in one or more follow-up
surveys with mean follow-up of 9.1 years and had no
missing data. Their mean age, BMI, spine BMD and PEN
levels were 63.4±8.0 years, 24.3±3.5 kg/m2, 0.819±0.144
g/cm2 and 0.0398 μg/ml (mean±SD: 0.0286 and 0.0553),
respectively.
We identified 71 VDf in 52 women at baseline and 148
VFx in 94 women during the follow-up where overall
incidence rate of VFx was 16.8/1000 person-years. The
multiple logistic analyses indicated that PEN levels sig-
nificantly associated with the risk of VFx (odds ratio
(OR) per 1 SD increase: 1.26 (95% CI: 1.01-1.57))
adjusted for age, BMI, prevalent VDf and BMD. The
adjusted ORs of VFx in the tertile groups of PEN levels
were illustrated in Figure 1.
These results did not alter when the participants with dis-
eases liable to affect bone metabolism or those under drug
therapy for osteoporosis were excluded.
Conclusion(s): Higher levels of serum PEN are associated
with elevated risk of VFx independently of age, BMI, prev-
alent VDf and BMD in Japanese women.
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PREVALENCE OF VITAMIN D DEFICIENCY IN
PRE- AND POSTMENOPAUSAL SAUDI WOMEN:
A CROSS-SECTIONAL STUDY
Khulood S Hussein1,2, H Alkadi1,2, S Lanham-New3, MS
Ardawi2,4
1King Abdulaziz University, Physiology, 2King Abdulaziz
University, Center of Excellence for Osteoporosis Research,
Jeddah, Saudi Arabia, 3Surrey University, Nutrition Sciences
Division, Guildford, UK, 4King Abdulaziz University,
Clinical Biochemistry, Jeddah, Saudi Arabia
Objective(s): Vitamin D deficiency is a global health prob-
lem, with a range of chronic conditions being associated
with low circulating levels of 25(OH)D. The aim of this
study was to determine vitamin D status in a sample of
randomly selected pre- and postmenopausal Saudi women.
Material & Methods: This cross-sectional study was con-
ducted in the Center of Excellence for Osteoporosis Re-
search (CEOR) during the year 2011. A total of 449
healthy women were randomly recruited from the city of
Jeddah through Primary Health Care Centers. Data are pre-
sented on 226 premenopausal [20-39 years]; and 223 post-
menopausal women [>51 years]. Menopausal grouping was
confirmed by hormonal status. Fasting blood samples were
collected for assessment of 25(OH)D status.
Results: A total of 20% of women had severe vitamin D
deficiency with a serum level <12.5 nmol/L (29% pre, 11%
Osteoporos Int (2012) 23: (Suppl 2):S85–S386 S243
post), 35% of women had moderate deficiency with levels
between 12.5- <25 nmol/L (42% pre, 28% post), 30.5% of
women had mild deficiency with levels between 25-<50
nmol/L(23% pre, 38% post), and 10.7% had vitamin D
insufficiency with levels between 50-<75 nmol/L (3.5%
pre, 18% post). Only 3.8% had sufficient vitamin D levels
>75 nmol/L (2.5% pre and 5% post).
Conclusion(s): Vitamin D deficiency is rather highly prev-
alent among both pre-and postmenopausal otherwise
healthy Saudi women. Proper measures for the management
and prevention of vitamin D deficiency are highly indicated
to avoid the ill consequences of this deficiency.
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THE ECONOMIC COST OF CHRONIC
LOW BACK PAIN
Yasemin Yumusakhuylu, Hatice Sule Baklacioglu, Huriye
Aras, Raife Sirin Atlig, Sema Haliloglu, Selin Turan Turgut,
Afitap Icagasioglu
Istanbul Medeniyet University Goztepe Research and Educa-
tion Hospital, Physical Medicine and Rehabilitation, Istanbul,
Turkey
Objective(s): Chronic low back pain (LBP) is a common
and important health problem, which is a common cause
of lost work days and disability. The economic burden
of LBP is very high and its burden in Turkey is not
known. The objective of this study is to determine the
total cost of LBP.
Material & Methods: We included 211 adult patients with
chronic LBP between September 2009 - November 2009 who
consult to our outpatient clinic of Istanbul Medeniyet Univer-
sity Göztepe Research and Education Hospital in Istanbul.
Patients socio-demographics, healthcare resource use, inabil-
ity to work, quality of life and psychological health at the time
of the study were collected by using questionnaires. We cal-
culate all direct and indirect costs. Direct costs include med-
ical visits, investigations, medications, hospitalizations,
orthopedic aids, physical therapy and home payments during
the last 6 months. Indirect costs include lost work days,
productivity lost, early retirement for the last 3 months.
Results: The total annual direct costs for chronic LBP per
patient were estimated at 346.14€, or 443.39 USD. The
indirect costs were estimated at 2311.34€, or 2960.71 USD
per patient, in 2011 prices. All costs were positively corre-
lated with disease severity, disease duration, and female
gender. The mean Roland & Morris score was 15.67 (SD
5.23). 59.7% of patients got severe and moderate depression
and anxiety points.
Conclusion(s): The indirect costs for chronic LBP seems to
be higher than the direct costs. The productivity losses due
to sick leave could be reduced with effective treatments and
could help cost savings.
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EFFECT OF HYPOVITAMINOSIS D ON MUSCLE
FUNCTION AND PHYSICAL PERFORMANCE IN
SAUDI WOMEN
Khulood Hussein1,2, H AlKadi1,2, S Lanham-New3, MS
Ardawi2,4
1King Abdulaziz University, Physiology, 2King Abdulaziz
University, Center of Excellence for Osteoporosis Research,
Jeddah, Saudi Arabia, 3Surrey University, Nutrition Scien-
ces Division, Guildford, UK, 4King Abdulaziz University,
Clinical Biochemistry, Jeddah, Saudi Arabia
Objective(s): Vitamin D deficiency is associated with re-
duced muscle strength. Data on the effect of poor vitamin D
status on physical performance in Saudi women are lacking.
The aim of this study was to investigate the correlation
between vitamin D level and measures of physical
performance.
Material & Methods: This cross-sectional study was con-
ducted in the Center of Excellence for Osteoporosis Re-
search (CEOR). A total of 449 healthy women were
randomly recruited from the city of Jeddah through Primary
Health Care Centers. Data are presented on 226 premeno-
pausal [20-39 years]; and 223 postmenopausal women [>51
years]. Fasting blood samples were collected for assessment
of 25(OH)D status. Muscle function was assessed by the
time taken to perform the following tests: get up and go
(GUG); 8 feet walk (8FW); five-times sit to stand (5-STS).
SPSS (version 16) was used for data analysis.
Results: A total of 55% of womenwere <25 nmol/L (71% pre,
39% post), 86% <50 nmol/L (94% pre, 77% post), and 96%<
75 nmol/L (97% pre, 95% post). Linear regression analysis was
used to examine the association between vitamin D level and
measures of physical performance adjusting for potential con-
founders. Vitamin D level was not among the predictors of
physical performance measures in this study group.
Conclusion(s): These data suggest that low vitamin D status
is not associated with poor physical performance and may
be a reflection of muscle adaptation to prolonged, lifecycle
of hypovitaminosis D.
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ULTRASOUND METHOD FOR OSTEOPOROSIS
DIAGNOSTICS AT PRIMARY HEALTHCARE
Janne P Karjalainen1, Ossi Riekkinen2, Heikki Kröger3,
Jukka S Jurvelin1
1University of Eastern Finland, Department of Applied
Physics, 2Bone Index Finland Ltd., Osteoporosis Diagnos-
tics, 3Kuopio University Hospital, Department of Orthopae-
dics, Traumatology and Hand Surgery, Kuopio, Finland
Objective(s): Osteoporosis is diagnosed using the axial
DXA. Unfortunately, DXA is not an optimal technique for
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use at primary healthcare due to high costs, size and use of
ionizing radiation. It is estimated that over 75% of osteopo-
rotic patients are not diagnosed nor receive treatment for
their pathological condition [1]. This is mostly accounted
for the lack of effective screening or diagnostic devices at
primary healthcare. In this study, a prototype pulse-echo
(PE) ultrasound device (Bone Index Finland Ltd., Kuopio,
Finland) for multi-site ultrasound measurements is proposed
for osteoporosis diagnostics.
Material & Methods: Elderly woman (n=131, mean age±
SD=72.9±6.6 years) were examined using ultrasound meas-
urements of cortical bone thickness in proximal and distal
tibia, and distal radius with PE ultrasound (2.25 MHz). Ultra-
sound results were combined with subject characteristics to
provide a diagnostic parameter, density index, DI [2] (patent
pending)). Further, BMD in the femoral neck (BMDneck) and
total hip (BMDtotal) was determined by axial DXA. Based on
DXA, osteoporosis was diagnosed in individuals with T-Score
lower than -2.5 in total hip or in femoral neck.
Results: A total of 30 subjects were diagnosed with osteo-
porosis. DI provided a significant estimate of BMDneck and
BMDtotal (r=0.71-0.72, p=0.001, n=131). Thresholds for
DI were determined to reach 90% sensitivity and specificity
in diagnostics of osteoporosis [3,4]. By using these thresh-
olds, 19.8% of the subjects were found to require additional
DXA measurement to verify the diagnosis.
Conclusion(s): After present ultrasound measurements, due
to the significant correlation between DI and BMD mea-
sured with axial DXA, only a limited number of subjects
would need additional DXA measurement. The strength of
DI-BMD association is similar to that between the lumbar
spine and femoral neck BMD. The results are encouraging
and suggest that the small-size portable ultrasound instru-
ment may provide an easily accessible method for diagnos-
tics of osteoporosis at primary healthcare. However, more
subjects should be examined to validate the thresholds with
90% sensitivity and specificity for DI [3].
References: [1] Med J Aust 180:18;2004,[2] Osteoporos
Int, In Press, 2011 [3] J Clin Densitom 11:188;2008., [4]
Osteoporos Int 16:2149; 2005.
P430
SIX-YEAR FOLLOW UP IN PATIENTS WITH
PREVIOUS OSTEOPOROTIC FRACTURE OF
PROXIMAL FEMUR
Vaclav Vyskocil1,2, Tomas Pavelka2, Monika Honnerova3
1Charles University Hospital, Center for Metabolic Bone
Diseases, 2Charles University Hospital, Department of
Orthopaedic Surgery, 3Charles University Hospital, Depart-
ment of Bone Disease, Pilsen, Czech Republic
Objective(s): The authors observed 231 patients with low-
trauma osteoporotic fractures, 87 in the area of proximal
femur, 84 vertebral fractures and 60 fractures of distal fore-
arm and proximal humerus. After the surgical treatment,
densitometric measurement was performed and according
to the results antiosteoporotic pharmacotherapy was started.
Material & Methods: In patients with spine injury was
found significantly lower vertebral BMD, T- score -2.14 in
area of L1-L4 and -1.6 in hip. The situation was opposite in
patients with hip fractures: T-score -1.6 in L1-L4 and -2.02
in hip. In patients with fracture of proximal humerus and
forearm was found less significant standard deviation from
the norm T-score -1.3 in both areas. Average age of patients
with fracture of distal forearm was 62, for vertebral fractures
67 and hip fractures 70. Relatively lower average age of
patients with hip fractures was driven by the fact that those
patients were able to come to densitometric measurement
and all of them underwent surgical treatment of fracture.
Patients were treated despite the high fracture risk mostly by
calcium and vitamin D. Only patients with lower BMD than
-2.5 T-score with low-trauma hip or vertebral fracture re-
ceived an antiresorptive therapy at the specialized center.
Although all patients were educated about the risk of anoth-
er fracture, only 5% of them agreed to take the antiresorptive
therapy. 15% of treatment refusing patients suffered from
another hip fracture contralaterally within one year period
and 35% within 3-year period after the first fracture.
Results: After six years follow up of patients with the hip
fracture (set of 87 patients), more than 43.7% of patients
experienced contralateral fracture or other type of fracture.
Number of contralateral hip fractures increased from 16% to
36% and 45% after 1, 3 and 6 years after initial hip fracture.
Other osteoporotic fx increased from 29%, 49% and 69%.
Mortality Increased from 6%, 10% and 22%.
Conclusion(s): The authors also performed the monitoring
of the same parameters in set of patients with vertebral
fractures and distal forearm fractures and from the original
densitometric measurements calculated FRAX index and
they compared the risk of fracture with the actual incidence
of fractures.
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EXTENT OF OBESITY IN SAUDI WOMEN AND THE
ASSOCIATION BETWEEN VITAMIN D STATUS
AND DIFFERENT MEASURES OFADIPOSITY
Khulood Hussein1,2, H Alkadi1,2, S Lanham-New3, MS
Ardawi2,4
1King Abdulaziz University, Physiology, 2King Abdulaziz
University, Center of Excellence For Osteoporosis Re-
search, Jeddah, Saudi Arabia, 3Surrey University, Nutrition
Sciences Division, Guildford, UK, 4King Abdulaziz Univer-
sity, Clinical Biochemistry, Jeddah, Saudi Arabia
Objective(s): Obesity is associated with vitamin D deficien-
cy. The aims of this study were to: 1) determine the extent of
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obesity in Saudi pre- and postmenopausal women; 2) and to
assess the association between different measures of adipos-
ity and 25(OH)D in both groups.
Material & Methods: This cross-sectional study was con-
ducted in the Center of Excellence for Osteoporosis Research
(CEOR) during the year 2011. A total of 449 healthy women
were recruited from Primary Health Care Centers. Data are
presented on 226 premenopausal [20-39 years]; and 223 post-
menopausal women [>51 years]. Menopausal grouping was
confirmed by hormonal status. Fasting blood samples were
collected for assessment of 25(OH)D status. Weight, height,
waist circumference (WC), hip circumference (HC) and total
body fat (TBF) DXA were measured. Waist-to-hip ratio
(WHR) and BMI were calculated.
Results: A total of 30.7% of the women were overweight
with BMI 25-<30 kg/m2 (28.3% pre, 33.2% post), and
38.5% were obese with BMI ≥30 kg/m2 (21.2% pre,
56.1% post). After adjusting for age, there was no signifi-
cant correlation between 25(OH) D and any of the obesity
measurements in the premenopausal women. A significant
negative correlation between BMI (r=-0.203, P<0.01), TBF
(r=-0.340, P<0.01) and WC (r=0.140, P<0.05) was found
in the postmenopausal women.
Conclusion(s): Obesity was more prevalent among the
postmenopausal women. Obesity-associated vitamin D in-
sufficiency is likely due to the decreased bioavailability of
vitamin D3 because of its deposition in body fat compart-
ments. Measures to reduce weight in this group may im-
prove vitamin D status.
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STRONTIUM RANELATE TREATMENT IMPROVES
BONE MATERIAL QUALITY IN HUMAN BONE
BIOPSY SPECIMENS COMPARED
WITH ALENDRONATE
Patrick Ammann, René Rizzoli
Geneva University Hospitals and Faculty of Medicine, Di-
vision of Bone Diseases, Department of Rehabilitation and
Geriatrics, Geneva, Switzerland
Objective(s): A preclinical study has shown that micro-
architecture and material level properties contribute inde-
pendently and significantly to the increase in bone strength
induced by strontium ranelate treatments as evaluated by
μCT-based FEA and by direct bone strength measurement.
The aim of the present study was to evaluate whether similar
effects on bone tissue quality could be detected in human.
Material & Methods: In a multicenter, international, dou-
ble-blind, controlled study, 268 postmenopausal women
with osteoporosis underwent transiliac bone biopsies at
baseline and after 6 or 12 months of treatment with stron-
tium ranelate 2 g/day or alendronate 70 mg/week. Among
them, 40 patients with paired biopsies (at baseline and after
6 or 12 months of treatment with strontium ranelate or
alendronate) were randomly selected. Material level proper-
ties were blindly analyzed by nanoindentation, for the de-
termination of Elastic Modulus, Hardness and Working
Energy. These values were obtained in the middle of the
cortex and of trabecular nodes under humid conditions.
Results: Significance of differences was evaluated by
ANOVA; * p<0.05 M12 vs. M0 and § p<0.05 strontium
ranelate vs. alendronate. Cortical values (mean±SEM) are
presented in the table:
Strontium
Ranelate
M0 N=12
Strontium
Ranelate
M12 N=12
Alendronate
M0 N=9
Alendronate
M12 N=9
Elastic
Modulus
(MPa)
12.00±0.27 14.09±
0.29*§
11.42±0.28 12.68±0.30
Hardness
(GPa)
385.37±8.46 450.40±
11.25*§
356.95±
11.59
373.01±
9.26
Working
Energy
(mN. nm)
3020.81±
49.11
3371.01±
73.59*§
2899.32±
59.65
3047.30±
80.10
Similar significant differences were obtained in trabecular
bone. A significant improvement of intrinsic bone quality
was only observed in strontium ranelate treated patients and
the values were significantly different from the alendronate
group. After 6 months of treatment, the differences were less
pronounced. These results in human bone tissue confirm
previous preclinical data and support a potential role of
material level properties changes in strontium ranelate anti-
fracture efficacy.
Conclusion(s): Overall, these results in human bone tissue
suggest that changes of intrinsic bone quality by strontium
ranelate treatment could contribute to an improvement of
bone mechanical properties and to fracture risk reduction.
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EFFECT OF HIND III POLYMORPHISM IN THE
OSTEOCALCIN GENE IN RELATION TO HUMAN
OSTEOPOROSIS-RELATED TRAITS IN SLOVAK
POSTMENOPAUSALWOMEN
Vladimira Krajcovicova1, Jana Zabojnikova1, Jana Spankova1,
Drahomir Galbavy2, Radoslav Omelka1
1Constantine the Philosopher University, Department of
Botany and Genetics, 2Hospital Nitra-Chrenova, Private
Orthopedic Ambulance, Nitra, Slovakia (Slovak Republic)
Objective(s): The osteocalcin gene has been introduced as a
candidate gene for osteoporosis because osteocalcin (also
known as BGP, for bone Gla protein) is the most abundant
noncollagenous protein in bone and is involved in many
processes ongoing in bone tissue such as calcification, re-
sorption or remodelling. The aim of the present study was to
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examine possible associations of Hind III polymorphism in
the osteocalcin gene with a variability of femoral (F-BMD),
spinal BMD (S-BMD), as well as circulating alkaline phos-
phatase (ALP), osteocalcin (OC; formation markers), β-
CrossLaps (CTx; resorption marker) and fracture incidence
in 326 Slovak postmenopausal women.
Material & Methods: Postmenopausal women (62.20±
0.48 years) were selected according to strict inclusion crite-
ria. Genetic polymorphism was detected by PCR-RFLP
method. Genotype frequencies and frequencies of fractures
were tested using the chi-square test. The differences of
quantitative variables between the genotypes were analyzed
by covariance analysis (GLM procedure) after correction of
the measurements for age and BMI.
Results: The distribution of genotype frequencies for
Hind III polymorphism was CC (6%), CT (35%) and
TT (59%). No significant effects of Hind III polymor-
phism were recorded on femoral and spinal BMD, as
well as fracture incidence and biochemical markers of
bone turnover in the tested population. However, differ-
ences in BMD between genotypes was not far from the
significance level (P=0.075). Individuals with TT geno-
type disposed insignificantly lower F-BMD and S-BMD
values in compared with TC and CC genotypes. Similar-
ly, we found that TT genotype had the highest concen-
trations of all analyzed bone turnover markers (ALP, OC,
CTx), which could indicate a trend of increased remodelling
rate in this group.
Conclusion(s):We did not identify a significant effect of the
BGP/Hind III polymorphism on osteoporosis-related traits
in analyzed population of Slovak postmenopausal women.
However, genetic analysis of Slovak population can con-
tribute to creating a more comprehensive view of genetic
conditionality of osteoporosis. All procedures were ap-
proved by the Ethical Committee of the Specialized Hospital
of St. Svorad in Nitra (Slovakia).
Disclosures: The study was supported by the grant UGA
VII/41/2010.
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BONE MINERAL DENSITY IN SPANISH WOMEN
WITH PRIMARY OVARIAN INSUFFICIENCY (POI)
M Guinot1, M Arqué1, J Malouf2, J Espinós1, J Calaf1
1Hospital de la Santa Creu i Sant Pau, Obstetrics and
Gynecology, 2Hospital de la Santa Creu i Sant Pau, Internal
Medicine, Barcelona, Spain
Objective(s): Primary ovarian insufficiency (POI) is a state of
hypergonadotropic hypogonadism, characterized by prema-
ture estrogen deficiency and its associated with an increased
risk of osteoporosis, among other alterations. The aim of the
present study is to assess the prevalence of osteoporosis and
osteopenia in a sample of POI patients and to report the
evolution of their BMD within the years comparing women
who had undergone HRTwith women who has not.
Material & Methods: This descriptive retrospective study
included 49 patients with POI consulting at the Gynecolog-
ical Endocrinology Unit of Hospital de la Santa Creu i Sant
Pau, Barcelona.
Results: The median age of POI patients at the time of
diagnosis was 35 years. Forty (81.6%) POI women had taken
HRT. Nine (18.4%) POI women did not take HRT. As the
hypoestrogenic status has a greater impact on trabecular bone
we used the results of the BMD and T-score obtained from
lumbar spine measures. The results of the first densitometry in
the group of patients without HRT were: 33.3% of normal
BMD; 44% of osteopenia and 22.2% of osteoporosis. In the
second densitometric control the results were: 33.3% of nor-
mal BMD; 33.3% of osteopenia and 33.3% of osteoporosis.
The results of the first densitometry in the group of patients
who were undergoing HRTwere: 45% of normal BMD; 40%
of osteopenia and a 15% of osteoporosis. In the second den-
sitometric control the results were: 40% of normal BMD;
42.5% of osteopenia and 17.5% of osteoporosis.
Conclusion(s): The results of the present study show that
there is a significantly higher loss of BMD in women who
does not undergoHRT. These data indicate that HRTshould be
prescribed to affected patients, as soon as they are diagnosed.
Young women at risk for POI need early education and med-
ical supervision regarding strategies to maintain bone mass.
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ASSESSMENT OF JOINT SPACE NARROWING
IN KNEE OSTEOARTHRITIS HAS GOOD LONG-
TERM INTERCENTRE REPRODUCIBILITY WHEN
READ IN PAIRS WITH A SEMI-AUTOMATED
DEVICE
Deborah Gensburger1, Rita Deroisy2, Monique Arlot1, Olivier
Bruyère2, Roland Chapurlat1, Jean-Yves Reginster2
1Université de Lyon, PMO, Lyon, France, 2Unité d'Explora-
tion de l'Os et du Cartilage, Université de Liège, Liège,
Belgium
Objective(s): To evaluate the inter-centre reproducibility of
knee X-rays reading by pairs with known time sequence
using a semi-automated software, in the assessment of Joint
Space Width (JSW) and Joint Space Narrowing (JSN),
among knee osteoarthritic patients.
Material & Methods: 70 females with knee osteoarthritis
from the OFELY1 cohort had knee radiographs at baseline
and 48 months later. Two independent readers, each located
in France and Belgium, were involved. They had the same
training and read the images following the same reading
method. Each knee X-ray was read twice by each reader,
knowing the time sequence and using a validated semi-
automated device2 in year 2009, 2010 and 2011 (three
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times). The long-term agreement between the two centers
was assessed for JSW and JSN between baseline and M048,
using an intra-class correlation coefficient (ICC) and the
Bland and Altman method.
Results: The inter-reader reproducibility was good (ICC
close to 0.8 or above each time). For the Bland and Altman
method, the mean difference was close to 0 and the limits of
agreement confirmed good correlation between readers.
CF:
Inter-centre
Reproducibility
JSW (ICC/
95% CI)
Baseline
JSW (ICC/
95% CI)
M048
JSN (ICC/
95% CI)
JSN (Mean
difference;
mm±SD,
limits of
agreement)
Bland
Altman
2009 0.956
[0.93;
0.972]
0.97
[0.948;
0.982]
0.806
[0.706;
0.875]
0.0463±
0.38
[-0.6921;
0.7848]
2010 0.954
[0.868;
0.979]
0.943
[0.903;
0.966]
0.84
[0.754;
0.897]
-0.0307±
0.34
[-0.6959;
0.6344]
2011 0.911
[0.482;
0.969]
0.933
[0.735;
0.973]
0.778
[0.665;
0.856]
-0.0406±
0.41
[-0.8387;
0.7575]
Conclusion(s):We found a good long-term agreement (over
a 3 years period) between the two independent observers,
reading the knee X-rays with the same method. Therefore
reading X-rays by pairs with knowledge of time sequence,
using a validated semi-automated device, is a reproducible
method to follow the progression of knee OA in large
clinical trials.
References: 1. Delmas. JBMR 1997. 2. Gensburger D.
Arthritis Care Res 2010.
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NOVEL ULTRASOUND DEVICE PREDICTS
OVERALL SKELETAL STATUS
Janne P Karjalainen1, Ossi Riekkinen2, Heikki Kröger3,
Jukka S Jurvelin1
1University of Eastern Finland, Department of Applied
Physics, 2Bone Index Finland Ltd., Osteoporosis Diagnostics,
3Kuopio University Hospital, Department of Orthopaedics,
Traumatology and Hand Surgery, Kuopio, Finland
Objective(s): In osteoporosis the overall bone mass is de-
creased. The axial DXA measurement at the hip or spine
provides the standard diagnostics of osteoporosis. In addi-
tion, DXA can be used to assess the BMD of the total body.
The whole skeleton consists mainly cortical bone (80%). In
this study, the association between the total body BMD and
a multisite measurement of cortical thickness with a pocket
size pulse-echo (PE) ultrasound device was studied.
Material & Methods: 51 Caucasian woman (age=20-80
years) were examined using the axial DXA (Lunar Prodigy,
GE Healthcare) and an ultrasound device operating at 2.5
MHz (Bindex®, Bone Index Finland Ltd.) Total body areal
BMD was analyzed with DXA. In addition, cortical bone
thickness in proximal and distal tibia and distal radius were
measured with Bindex®.
Results: The cortical bone thickness in proximal and distal
tibia and distal radius were significant predictors of total
body BMD (r=0.70, 0.70 and 0.69, respectively). The sum
of cortical bone thickness values measured with ultrasound
was the best predictor of the total body BMD (r=0.83, p=
0.0001, n=51).
Conclusion(s): Total body BMD is the measure of overall
skeletal status and may be more sensitive for e.g. nutritional
status than the traditional hip or spine BMD [2]. Significant
correlation between the cortical bone thickness in tibia and
radius and the total body BMD suggests that multisite
cortical bone measurements could provide an estimate for
skeletal status. Therefore, the ultrasound technique may be
useful in osteoporosis diagnostics in healthcare practices
with limited access to axial DXA.
References: [1] Nguyen et al. Med J Aust 180:18;2004, [2]
Kärkkäinen et al. Osteoporos Int 21 (12):2047;2010.
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DENOSUMAB INCREASES TOTAL HIP BONE
MINERAL DENSITY IN OLDER WOMEN
WITH POSTMENOPAUSAL OSTEOPOROSIS
S Boonen1, PD Miller2, EM Lewiecki3, ML Brandi4, JD
Adachi5, C Recknor6, A Wang7, JW Hall8
1Leuven University, Department of Experimental Medicine,
Leuven, Belgium, 2Colorado Center for Bone Research,
Lakewood, CO, US, 3New Mexico Clinical Research &
Osteoporosis Center, Albuquerque, NM, US, 4Azienda
Ospedaliera Careggi, Internal Medicine, Firenze, Italy,
5McMaster University, Department of Medicine, Hamilton,
ON, Canada, 6United Osteoporosis Centers, Gainesville,
GA, 7Amgen Inc, Biostatistics, Thousand Oaks, CA, 8Amgen
Inc., Clinical Development, Thousand Oaks, CA, US
Objective(s): To assess the effects of denosumab on total
hip (TH) BMD in subjects aged ≥75 and <75 years.
Material & Methods: This analysis was based on 3 ran-
domized controlled studies in which postmenopausal wom-
en with low BMD who were either naïve to treatment for
postmenopausal osteoporosis (PMO)1,2 or previously re-
ceived alendronate3 were randomized to denosumab 60 mg
every 6 months or either placebo or alendronate 70 mg
weekly. Percentage change from baseline to 12 months in
TH BMD was analysed by age group (<75 and ≥75 years).
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Results: A total of 6779 and 2722 subjects aged <75 and
≥75, respectively, were randomized in all 3 studies. Percent-
age change in BMD and comparison between age groups are
shown in the figure.
For both age groups across all 3 studies, denosumab
treatment resulted in a statistically significant increase in
TH BMD from baseline to month 12 relative to either
placebo or alendronate (interaction between treatment
and age, p>0.05), consistent with the overall results
from each individual study. Among subjects ≥75 years
of age previously treated with alendronate, switching to
denosumab treatment resulted in a significant improve-
ment from baseline in TH BMD at month 12 (1.5%,
95%CI: 0.8%, 2.2%) while continuation of alendronate
had no further impact on BMD (0.1%, 95%CI: -0.6%,
0.7%).
Conclusion(s): Denosumab is associated with significant
increases in TH BMD regardless of age (<75 or ≥75 years)
and independent of prior alendronate treatment. While older
subjects previously treated with alendronate showed signif-
icant improvement in TH BMD when switched to denosu-
mab treatment, those who continued with alendronate
treatment for 12 months did not show additional improve-
ment in TH BMD.
References: 1. Cummings, NEJM 2009;361:756. 2. Brown,
JBMR 2009;24:153. 3. Kendler, JBMR 2010;25:72.
Disclosures: This study was supported by Amgen Inc. and
abstract writing by Amgen and GSK.
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MYOSTATIN SERUM CONCENTRATIONS IN
MEN – AGE-RELATED CHANGES AND
CORRELATES: THE STRAMBO STUDY
Pawel Szulc1, Claudia Goetsch2, Michael Schoppet3,
Roland Chapurlat1, Lorenz C Hofbauer2
1INSERM UMR 1033, University of Lyon, Epidemiology
of Osteoporosis, Lyon, France, 2Dresden University Medi-
cal Center, Division of Endocrinology, Diabetes, and Bone
Diseases, Dresden, Germany, 3University of Marburg,
Department of Internal Medicine and Cardiology, Marburg,
Germany
Objective(s): Serum myostatin levels in men and its poten-
tial determinants have not been defined.
Material & Methods: We measured serum myostatin in
1153 men aged 20-87 years using an ELISA detecting the
dimeric full-length peptide and its C-terminal active protein
(Immundiagnostik AG, Bensheim, Germany). We assessed
abdominal aortic calcification (AAC) score at the lumbar
aorta on the Vertebral Fracture Assessment scans using the
Hologic Discovery device.
Results: Before the age of 60, serum myostatin increased by
28% (n=353, r=0.16, p<0.005). In this group, serum myo-
statin showed seasonal variation with higher values during
the summer (p<0.01). After 60 years, serum myostatin
decreased (n=800, r=-0.12, p<0.001). In 780 men aged
≥60, who did not take vitamin D or calcium supplements,
serum levels of myostatin and 25OHD correlated positively
(r=0.20, p<0.001). After adjustment for age, month, current
smoking, alcohol intake, and calcium intake, serum
myostatin increased by 0.21 SD per 10 ng/ml of 25OHD.
Serum myostatin showed seasonal variation with 0.64
SD higher values during the summer (p<0.001). The
circannual variability of myostatin levels remained signif-
icant after adjustment for confounders including 25OHD
(p<0.001).
Men in the highest myostatin quartile (>39.5 mg/L) had
lower average AAC score compared with the three lower
quartiles combined (p<0.005 adjusted for confounders). In
multivariate models, AAC prevalence decreased with in-
creasing myostatin levels (OR=0.76 per 1SD decrease,
95%CI: 0.64-0.91, p<0.001). AAC prevalence was lower
(OR=0.48, 95%CI: 0.33-0.68, p<0.001) in the highest quar-
tile vs. three lower quartiles combined. Furthermore, low
calcium intake (<590 mg/day, lowest quartile) was associated
with lower (11%, 0.37 SD, p<0.01) serum myostatin vs. the
three higher quartiles combined. Serum myostatin levels were
5% lower (0.43 SD, p<0.05) in 45 current mild smokers
(median: 8 cigarettes/day) compared with non-smokers. Men
who drank >110 g alcohol/week (median) had 12% lower
myostatin levels (0.41 SD, p<0.001) compared with men
who drank less.
Conclusion(s): In men, serum myostatin concentrations
increased until the age of 60, then decreased. In older
men, presence of AAC, lower 25OHD level, winter season,
low calcium intake, current smoking, and higher alcohol
intake were all independently associated with lower myo-
statin levels.
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EVALUATION OF A NOVEL APPROACH FOR
AUTOMATIC DELINEATION OF VERTEBRAL
CONTOURS IN RADIOGRAPHS
Peter Mysling1, Kersten Petersen1, Mads Nielsen1,2, Martin
Lillholm2
1University of Copenhagen, eScience Center, 2Biomediq,
Copenhagen, Denmark
Objective(s): Accurate measurement of vertebral shape is
important in the development of novel procedures for quan-
titative vertebral fracture assessment. The purpose of this
work was to investigate the feasibility of a novel, computa-
tional, fully automatic approach for measurement of verte-
bral shape in lateral radiographs.
Material & Methods: We evaluated the technique on a
data set of 157 manually annotated radiographs of the
lumbar spine. The acquired radiographs were a subset of
the Prospective Epidemiological Risk Factor (PERF)
study cohort, containing a combination of baseline and
follow-up images of postmenopausal women. Manual
annotations of both full contour delineations and six-
point placements were performed by trained radiologists
for the L1-L4 vertebrae. The evaluated technique detects
the vertebral outlines in a hierarchical manner, moving
from a coarse estimate of the spine alignment to a
detailed description of the individual vertebral shapes.
The technique was based on a statistical model of the
vertebral shape and appearance and centered around a
sampling-based segmentation scheme. The technique
was evaluated in terms of the average point-to-contour
errors and the average error in estimating the posterior,
medial, and anterior vertebral heights, with respect to
the manual annotations of the radiologists.
Results: Our experiments showed an average point-to-
contour error of 0.81 mm (±0.053, SEM), which com-
pares favourably to the current state-of-the-art. More-
over, we were able to estimate the vertebral heights
with an average error of 1.36 mm (±0.076, SEM) and
a coefficient of variation from the ground truth annota-
tions of 5.1%.
Conclusion(s): Our experiments showed that the accu-
racy of the evaluated technique compares favorably to
the current state-of-the-art in automatic vertebra seg-
mentation. The automatic procedure was able to esti-
mate the vertebral heights with considerable accuracy.
We believe that our technique could be relevant in
vertebral fracture detection and in the development of
novel, automatic osteoporosis biomarkers based on ver-
tebral morphometry.
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A NOVEL IONIZABLE CATIONIC LIPID
NANOPARTICLE-BASED DELIVERY SYSTEM
FOR POTENTIAL RNAI THERAPY IN
AGE-RELATED CARTILAGE DEGRADATION
Heng Wu1, Zhijun Yang2, Baosheng Guo1, Zihong Lin3,
Fangyuan Wei1, Gang Li1, Weimin Liao3, Ling Qin1,
Leungkim Hung1, Lei Wei4, Ge Zhang1
1The Chinese University of Hong Kong, Dept. of Orthopae-
dics & Traumatology, 2Hong Kong Baptist University,
School of Chinese Medicine, Hong Kong, 3the First Affili-
ated Hospital, Sun Yat-sen University, Dept. of Orthopae-
dics, Guang Zhou, China, 4Warren Alpert Medical School of
Brown University, Dept. of Orthopaedics, Providence, RI,
US
Objective(s): To prepare LNPs delivery systems with dif-
ferent particle sizes encapsulating siRNA and evaluate the
distribution of siRNA after intraarticular injection in aged
rabbits with cartilage degradation
Material & Methods: The lipids in ethanol were
injected with different velocity under strong vortex to
FAM labeled siRNA solution to prepare LNPs with
small particle size (S-LNPs) and large particle size (L-
LNPs). Then, the dialysis was performed to remove
ethanol. The hydrodynamic diameters were measured
and the morphology of LNPs was visualized by cryo-
electron microscope. The aged rabbits (24 months)
were divided into three groups and intraarticularly
injected free FAM-labeled siRNA, FAM-labeled siRNA
encapsulated in L-LNPs and S-LNPs, respectively, in
knee joint. After 24 h, the joints were dissected for
imaging and the cartilage was separated for histology
analysis.
Results: The hydrodynamic diameters of L-LNPs and S-
LNPs were 67±4.3 nm and 192±8.4 nm, respectively.
After intraarticular injection, siRNA was predominantly
found in femoral condyles and cartilage on tibia of all
groups. The fluorescence intensity of free siRNA group
was comparable with that of siRNA/S-LNPs group,
while the signal of L-LNPs group was relatively weak
(Fig. 1A). After colocalization of FAM-labeled siRNA
and chondrocyte, we found numerous instances of sep-
arated nucleic existed without overlapping with siRNA
after free siRNA administration, whereas, most of
siRNA encapsulated in LNPs were shown to co-localize
with chondrocyte once permeating into cartilage. The
white arrows point at the nucleics without overlapping
with siRNA. In L-LNPs group, there were decreased
signals of siRNA in cartilage, which suggested the
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nanoparticles with relatively large size are difficult to
diffuse through the cartilage matrix (Figure 1B).
Conclusion(s): The ionizable cationic lipid nanoparticle
with small size (S-LNPs) could facilitate not only the distri-
bution of siRNA in cartilage but also the cellular uptake. It
demonstrated the promising potentials for therapeutic RNAi
in cartilage degradation.
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PATIENTS WITH OSTEOPOROTIC
FRACTURES - UNDERTREATED, PATIENTS WITH
ATYPICAL FRACTURES UNDERDIAGNOSED:
INSIGHTS FROM FRACTURES PREVENTION
PROGRAM
Elena Segal1, Marina Nodelman1, Doron Norman2, Michael
Soudry2, Daniela Militianu3, Marina Hefetz-Kustanovich1,
Sophia Ish-Shalom4
1Rambam Health Care Campus, Bone and Mineral Metab-
olism Unit, 2Rambam Health Care Campus, Department
Orthopedic Surgery, 3Rambam Health Care Campus, De-
partment of Radiology, 4Technion-Israel Institute of Tech-
nology, The Bruce Rappaport Faculty of Medicine, Haifa,
Israel
Objective(s): To assess effectiveness of hospital based Frac-
tures Prevention Program (FPP) in the fracture prevention
treatment in patients with previous fragility fractures and
prevalence of atypical fractures.
Material & Methods: We evaluated all fragility fractures
patients who were hospitalized in the Departments of Or-
thopedic Surgery of Rambam Health Care Campus during
years 2009-2010.
Results: 900 patients, aged 46-107 (75.18±11.7), 247
(27.4%) men, 653 (72.6%) women were hospitalized with
fractures since March 2009: 593 (66%) for hip fractures, 60
(7%) for vertebral fractures, 247 (27%) for other fractures.
155 (17%) had previous fragility fractures. 65 (42%) of
them received no fracture prevention treatment after the first
fracture. Prior to hospitalization 152 (23.2%) women and 4
(1.6%) men received fracture prevention treatment. Women
- 134 (88.2%) oral bisphosphonates (114 alendronate,
20 risedronate), 10 (6.5%) raloxifene, 5 (3.3%) teriparatide;
men - alendronate. Of all hip fracture patients 96 (16.2%)
received fracture prevention treatment. At admission one
woman was diagnosed with atypical hip fracture due to
prodromal pain in the hip, contralateral to the hip with prior
fracture and characteristic radiographic findings. Subse-
quently all X-ray films were reviewed by a bone -radiologist
for signs of atypical fractures. Four additional hip fractures
met criteria for atypical fractures: 0.84% of all hip fractures,
0.55% of all fractures, and 3.2% of fractures in patients
treated with bisphosphonates. All five women were treated
with alendronate for 2-5 years.
Conclusion(s): Majority of patients with high fracture risk
were untreated, even after previous fragility fractures. Men
and hip fractures patients were more likely to be untreated.
Most of hip fractures in bisphosphonate treated and in
bisphosphonate naïve patients were "typical" osteoporot-
ic fractures. Atypical fractures in bisphosphonates trea-
ted patients were rare and were mostly undiagnosed at
hospitalization.
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EXTERNAL VALIDATION OF THE GARVAN
NOMOGRAMS FOR PREDICTING ABSOLUTE
FRACTURE RISK: THE TROMSØ STUDY
Luai A Ahmed1, Nguyen D Nguyen2, Åshild Bjørnerem3,
Ragnar M Joakimsen3, Lone Jørgensen1, Dana Bliuc2,
Jacqueline R Center2, John A Eisman2, Tuan V Nguyen2,
Nina Emaus1
1University of Tromsø, Department of Health and Care
Sciences, Faculty of Health Sciences, Tromsø, Norway,
2Garvan Institute of Medical Research, Bone and Mineral
Research Program, Sydney, Australia, 3University of Tromsø,
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Department of Clinical Medicine, Faculty of Health Sciences,
Tromsø, Norway
Objective(s): Absolute risk or individualized prognosis is con-
sidered a preferred approach for assessing fracture risk and
making treatment decision. This study was designed to validate
and evaluate the performance of the Garvan nomograms for
predicting 10-year risk of fragility fracture in aNorwegian cohort.
Material & Methods: This prospective cohort study in
Tromsø, Norway, included 1614 women and 1314 men
(aged 60 years plus). During 8 years follow-up from 2001-
2009, fragility fractures were ascertained by computerized
search in the radiological archives. Nonhip nonvertebral
(NHNV) fractures occurred in 350 women and 114 men
and 92 women and 49 men suffered a hip fracture. Predicted
10-year probabilities of NHNV and hip fractures were de-
termined using Garvan's models with and without BMD.
The concordance between observed and predicted fracture
incidence was used as a measure of fit.
Results: The overall incidence (per 1000 person-years) of
NHNV and hip fracture during the follow-up was 34.6 and
9.1 in women, respectively; and 12.3 and 5.4 in men, respec-
tively. In both sexes, the predicted 10-year fractures probabil-
ity in the fracture group was consistently higher than the
nonfracture group for all models. For hip fracture, the pre-
dicted fracture probabilities in the fracture group was 2.8
(women) to 3.1 times (men) higher than in the nonfracture
group. Overall, there was a close agreement between predicted
and actual risk of fracture. However, among those in the
highest quartile of risk, the model overestimated the risk of
fracture (Figure). Models with BMD performed better than
models with body weight in terms of correct classification of
fracture and nonfracture cases in their risk.
Conclusion(s): The Garvan nomograms are valid and rea-
sonably accurate in identifying individuals at high risk of
fracture. Although the nomograms overpredicted the risk in
high risk individuals, its predictive ability at the individual
level can potentially be useful in clinical practice.
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RELATIONSHIP BETWEEN BONE MINERAL
DENSITY, LEPTIN AND INSULIN RESISTANCE
IN OBESE FEMALES
Elen Giorgadze1, Marina Tsagareli1, Shorena Shanava1,
Nino Dolidze1, Tamar Zerekidze1
1Institute of Endocrinology, Diabetes and Metabolic Syn-
drome, 2Institute of Endocrinology, Skeletal Endocrinology,
Tbilisi, Georgia
Objective(s): The aim of our study was to assess the influ-
ence of serum leptin concentration and insulin resistance on
BMD in patients with obesity.
Material & Methods: 63 females from age 28-68 with BMI
31-44 kg/m2 (obese) were enrolled in the study. We measured
BMI, fasting ionized Ca, phosphate, serum leptin, insulin,
type I collagen C- telopeptide (CTX), lumbar spine (LS),
proximal femur (PF) BMD and fat mass distribution by
DXA (Lunar Prodigy Primo, GE Healthcare). Females were
classified as insulin resistant (IR) and as insulin sensitive (IS)
according to the HOMA insulin sensitivity index (ISI).
Results: 60.3% of patients (38 patients) had reduced levels of
BMD (<-2.0 SD at LS and -1.5 SD at PF). BMDwas lower in
postmenopausal women. 63.1% (24 patients) of patients were
classified as IR, 78% - (30 patients) revealed increased levels
of serum leptin (42.3±0.2 ng/ml). Mean plasma leptin level
was significantly higher in the IR group compared with the IS
group (P<0.01). Serum CTX was significantly higher in the
IR group compared with the IS group. HOMA-IR and insulin
levels were inversely correlated with BMD (r=-0.36 and
r=-0.32, p<0.05). Patients with high levels of leptin revealed
positive correlation of leptin with BMI (r=0.28, p<0.05), IR
(r=0.3, p<0.05), and fat mass distribution (r=0.34, p<0.05).
The correlation between Leptin and BMD was weak, but
significant (r=0.12, p<0.05), correlation between fat mass
distribution and BMD was not revealed.
Conclusion(s): High leptin level is not related to high BMD
in obese females.
Obese postmenopausal women should be considered at risk
for decrease in BMD and osteoporosis.
P444
IMPROVED REAL-LIFE ADHERENCE OF
6-MONTHLY DENOSUMAB INJECTIONS DUE
TO POSITIVE FEEDBACK BASED ON RAPID
6-MONTHS BMD INCREASE AND GOOD
SAFETY PROFILE
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Johann D Ringe, Parvis Farahmand
West German Osteoporosis Center (WOC), Klinikum
Leverkusen, University of Cologne, Leverkusen, Germany
Objective(s): In an investigator initiated prospective obser-
vational study we investigated whether a careful explanation
of treatment results 6 month after first denosumab injection
focussing on no or only mild and probably not drug related
AEs and on significant BMD increases has effects on ad-
herence with further denosumab injections.
Material & Methods: We invited patients starting with a
first injection of 60 mg to show up after 6 months to control
and discuss tolerability and efficacy. 142 patients, 69 with
postmenopausal, 42 with male and 32 with glucocorticoid-
induced OP participated. 120 (85%) had been switched to
denosumab after different previous OP medications, 22
were drug naïve. Inclusion criteria were BMD values at
lumbar spine (LS) below -2.5 T-score and total hip (TH)
below -2.0 T-score, with at least one prevalent vertebral or
nonvertebral fracture. All received 1200 mg Ca and 800 IU
vitamin D.
Results: 96% of patients reported no AEs at all, only 6
(4.2%) mild to moderate obviously not drug related AEs.
Patients were very much impressed by demonstrating them
the DXA-protocols showing clear and often even dramatic
increases in LS and TH BMD after this short time. Gains at
the LS ranged from +2.1 to +11.5% (mean 6 month increase
+4.7%), at the TH from +0.9 to +7.2% (mean 6 month
increase +2.1%). From the 105 patients with back pain at
onset 92 (88%) reported a significant amelioration. There
were no vertebral fractures and only 2 nonvertebral fractures
in 71 patient years. The scarcity of AEs and the positive
feedback of a significant BMD-increase at both sites
resulted for 141 patients (99%) in a willingness to accept a
second injection.
Conclusion(s): In this observational study we found that
reporting the rarity of real life AEs as a positive reinforce-
ment together with the rapid and highly significant increases
in BMD already after 6 months denosumab therapy had a
high impact on adherence to continue with the 6-monthly
injections.
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DENOSUMAB IMPROVES VOLUMETRIC
TRABECULAR AND CORTICAL BONE DENSITIES
AS WELL AS 3D-BONE STRUCTURES,
PARTICULARELY CORTICAL THICKNESS: DATA
OF A PROSPECTIVE STUDY IN OUR CLINICAL
PRACTICE MEASURED WITH HRPQCT
(XTREMECT)
Helmut Radspieler
Osteoporosezentrum München, Private Practise, München,
Germany
Objective(s): Data of the FREEDOM-Study demonstrated
that areal bone densities measured with DXA showed a
significant increase at the lumbar spine and – less pro-
nounced – at the hip. With the (XtremeCT® we can measure
not only volumetric bone densities but moreover 3D bone
structures. In 2010 we started a prospective study to dem-
onstrate the effects of denosumab on volumetric bone den-
sities and microarchitectural parameters (“bone quality”) in
postmenopausal osteoporotic women.
Material & Methods: After a baseline measurement at least
one control measurement was done. Altogether till now we
examined 26 postmenopausal osteoporotic women in this
trial. The time interval between the first and the last mea-
surement was 9,8 month in average. The mean age was 72
years, 21 of them had previous fractures. Menopausal age
was 47,9 years in average. Additionally all patients receive
individually dosage of calcium and vitamin D.
Results: After the control measurements we found a signifi-
cant increase in volumetric trabecular bone densities of 2.5%
per year in the radius and 3.5% in the weight bearing tibia and
an increase in cortical bone densities of 1.2% per year in the
radius and 1.5% in the tibia. The highest increase we found in
the inner trabecular bone densities which was 9% per year in
the radius and 17.1% in the tibia. Microarchitectural parame-
ters showed the greatest increase in cortical thickness which
was 3.8% per year in the radius and even 6.8% in the tibia!
The changes of bone densities as well as for structural param-
eters were more pronounced in the weight bearing bone. Of all
26 patients 25 showed an increase in cortical thickness and
only one of them a little decrease of 1%.
Conclusion(s): Denosumab increases trabecular and corti-
cal bone densities as well as “bone quality” represented by a
number of microarchitectural parameters, most convincing-
ly in cortical thickness. This could be important because
cortical bone more and more shifts in the focus of interest.
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GENETIC ANALYSES OF HIGH BONE MASS
CASES FROM THE BARCOS COHORT OF
SPANISH POSTMENOPAUSALWOMEN
Patricia Sarrión1, Leonardo Mellibovsky2, Roser Urreizti1,
Alvaro Aranguren1, Maria Soler-Sala1, Neus Cols1, Guy
Yoskovitz2, Natàlia García-Giralt2, Roberto C Güerri2,
Xavier Nogués2, Adolfo Diez-Perez2, Daniel Grinberg1,
Susana Balcells1
1Universitat de Barcelona, IBUB, CIBERER, Departament
de Genètica, 2IMIM, Hospital del Mar, Universitat Autònoma
de Barcelona, URFOA, Barcelona, Spain
Objective(s): To establish the prevalence of the high bone
mass phenotype in the BARCOS cohort; to determine
whether any of the HMB cases carry LRP5 mutations that
explain the phenotype; and to characterize the expression
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pattern of osteoblast-specific and Wnt pathway genes in
primary osteoblast RNA samples from two HBM cases.
Material & Methods: HBM individuals within the BAR-
COS cohort were identified according to the criterion of a sum
Z-score>4 (totalLS-Zscore+TotalHip-Zscore). Relevant
exons of LRP5 (2, 3, 4, 9, 10, 11, and 12) were PCR-amplified
and sequenced. Cosegregation analysis of markers in the
LRP5 gene region was performed in one family. Primary
osteoblasts from two HBM and two control individuals were
cultured and RNA was extracted. A Roche RealTime ready
Custom Panel was used to analyse the expression of 91
osteoblast-specific and/or Wnt pathway genes
Results: In the BARCOS cohort of postmenopausal women,
0.6% of individuals display BMD values in the HBM range
(10 probands). No mutations in the analysed exons of the
LRP5 gene were found in these patients. Additionally, in one
familiar case in which the mother and one of the two sibs had
BMD values in the range of HBM, cosegregation analysis
ruled out LRP5 involvement. Further cosegregation studies
in this family allowed the exclusion of the following genes:
DKK2, IL6R, RANK, BMP2, and KRM1.The only gene
cosegregating was RANKL, but it was sequenced in the pro-
band and no mutations were found. Regarding the expression
analysis, five genes were found to be overexpressed in the two
HBM samples: BMP4, COL10A1, RUNX2, FZD3 and
SOX6, while four were underexpressed: DLX3, TWIST1,
IL6R, and PPARG.
Conclusion(s): LRP5 is not the cause of the HBM pheno-
type in these cases from BARCOS cohort. The results of the
expression study raise new hypotheses that should be further
investigated.
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ESTABLISHING REFERENCE INTERVALS FOR
BONE TURNOVER MARKERS IN HEALTHY
POSTMENOPAUSALWOMEN
Fatma Gossiel1, Judith Finigan1, Richard M Jacques1, David
M Reid2, Dieter Felsenberg3, Christian Roux4, Claus C
Glueer5, Richard Eastell1
1University of Sheffield, Human Metabolism, Sheffield,
UK, 2University of Aberdeen, Division of Applied Medi-
cine, Aberdeen, UK, 3Charite Universitatsmedizin, ZMK,
Berlin, Germany, 4Université René Descartes, Faculté de
Medecine, Paris, France, 5Universitaetsklinikum Schleswig-
Holstein, Diagnostisch Radiologie, Kiel, Germany
Objective(s): There are several reference intervals for bone
turnover markers (BTMs) in healthy younger women. There
are fewer for older women, because they often suffer from
diseases or take medications that affect bone turnover. We
aimed to a) establish a healthy postmenopausal reference
interval, b) compare this to a healthy premenopausal reference
interval and c) determine if the exclusion criteria are valid.
Material & Methods: We studied postmenopausal women
ages 55-80 years (n=2422), from the OPUS study, a 5-Euro-
pean centre population-based study.We excludedwomenwho:
were osteoporotic (spine or hip T-score<-2.5), were vitamin D
deficient (25 (OH) D<50 nmol/L), had low eGFR (<30 mL/
min/1.73 m2), had high serum calcium (>2.60 mmol/L) or
suffered from any disease known to affect bone turnover.
Women aged 30-40 years (n=205) were also recruited, and
the same exclusions applied. We measured CTX, intact PINP
and bone ALP using the IDS-iSYS automated immunoassays
on non-fasting serum samples.
Results: The reference intervals (table) were significantly
higher in postmenopausal compared to premenopausal wom-
en (p<0.001). Multiple linear regression analyses in all post-
menopausal women showed that the 3 BTMs were all
significantly higher if subjects were vitamin D deficient (n=
1208) or osteoporotic at spine or hip (n=127 and 339, respec-
tively) (p≤0.01). CTX was higher if eGFR was low (n=22).
BTMs were not higher if calcium levels were high (n=181).
Geometric mean and 95% reference intervals for bone turnover
markers for healthy postmenopausal and premenopausal women
Bone turnover
markers
Postmenopausal Women
(n=343)
Premenopausal Women
(n=108)
Intact PINP ng/ml 40.5(16.0-102.0) 30.1(8.5-106)*
Bone ALP ug/L 14.1(7.3-27.2) 9.8(5.2-18.6)*
CTX ng/ml 0.31(0.10-0.98) 0.19(0.05-0.63)*
*P<0.001 Independent sample T-test
Conclusion(s): Older women have higher BTMs than
younger women. Many factors can affect BTMs, partic-
ularly osteoporosis, vitamin D deficiency and chronic
kidney disease.
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EARLY REVISIONS OF RESURFACING
ENDOPROSTHESIS IN POSTMENOPAUSALWOMEN
WITH OSTEOPOROSIS AND HIPARTHROSIS
Cirstoiu F Catalin1, Popescu Dan1, Ene Razvan1, Cirstoiu
Monica2, Popescu Anca2
1Universitary Emergency Hospital, Orthopedic-Traumatology,
2Universitary Emergency Hospital, Obstetrics-Gynecology,
3Universitary Emergency Hospital, Endocrinology, Bucharest,
Romania
Objective(s): Resurfacing endoprosthesis is a new method,
definitely superior to the endoprosthesis techniques current-
ly used, due to its immediate post-operator recovery, at
distance, being followed by a full recovery of the pelvic
member function, also having a low rate of post-operator
issues. The performances of this prosthesis are obvious in
the well selected cases (patients with intense physical activ-
ity), once the surgery advice is correctly formulated.
S254 Osteoporos Int (2012) 23: (Suppl 2):S85–S386
Material & Methods: There were treated 36 patients with
postmenopausal osteoporosis and primary or secondary ar-
throsis at the Orthopedic-Traumatology Clinic of the Uni-
versity Emergency Hospital Bucharest between 2005-2011.
The diagnosis of osteoarthritis was established with Rx and
RMN examinations. Surgical intervention with resurfacing
total hip replacement was performed in 21 cases of post-
menopausal women aged from 52-64 years diagnosed with
osteoporosis according to WHO criteria using DXA for
BMD measurements. All of this patients have low hip T-
score (osteopenia/osteoporosis) and also incipient hip ar-
throsis. The approach was performed on a postero-side
way, by maintaining the articular capsule in order to keep
the femoral neck vascularisation.
Results: The recovery was very fast, within a short period
of time patients being able to make complex movements of
a normal amplitude, totally forbidden in the case of total
prosthesis with small head. All the patients were medically
re-examined at 4, 6 weeks, 3, 6, 12 months and afterwards
annually. 3 revisions cases has been recoded after resurfac-
ing arthroplasty independently of design and bearing sur-
face: two femoral neck fractures and one case of
malfunction recording a patient with a trochanteric osteot-
omy in antecedents. The surgical procedures were easier
than the classic hip arthroplasty revisions. Most of the cases
replacing only the femoral component was enough, keeping
metal-on-metal couple with all its advantages.
Conclusion(s): The importance of this type of arthroplasty
comes from the fact that addresses to the active patients who
keep bone capital, maintains the femoral neck vascularisation,
being able to get back to intense physical effort, to get back the
full movement of the hips articulation, also the lack of a major
issue in the hip arthroplasty represented by luxation.
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PREDICTION OF FOREARM FAILURE LOAD IN
WOMEN: THE OFELY STUDY
Nicolas Vilayphiou1, Stephanie Boutroy1, Elisabeth
Sornay-Rendu1, Bert van Rietbergen2, Roland Chapurlat1
1Université de Lyon, INSERM U1033, Lyon, France,
2Eindhoven University of Technology, Department of
Biomedical Engineering, Eindhoven, Netherlands
Objective(s): There is a growing interest for in vivo assess-
ment of bone strength. However, the necessary technique for
this evaluation - μFEA - is highly demanding in computa-
tional resources. So, we sought to predict one of the out-
comes of μFEA by variables easily obtained by HR-pQCT
imaging of the distal radius.
Material & Methods: Our cross-sectional analysis in-
volved 831 women from the OFELY cohort who had a valid
HR-pQCT radius scan. There were 228 pre- and 603 post-
menopausal women, aged 40±7 and 67±9 years old.
respectively. Distal radius HR-pQCT scans were used to
measure volumetric BMD (vBMD), bone geometry and
microarchitecture parameters, after segmentation of cortical
(Ct) and trabecular (Tb) bone with advanced algorithm [1].
Estimated failure load for a fall on the outstretched hand was
assessed on those segmented bone volumes by μFEA. Areal
BMD was measured at the ultradistal radius (UDR) by DXA
at the same visit
Results: In premenopausal women, most parameters did not
vary with age, thus they were used as reference data to
calculate standardized T-scores for the variables included
in the prediction model.
First, univariate regression models showed that the failure
load was best predicted by UDR aBMD (R2=0.79, p<
0.001). Among HR-pQCT parameters, Ct area (Ct.Ar) was
the best predictor of the failure load (R2=0.68, p<0.001),
followed by total, Ct and Tb vBMD, and Ct thickness, with
R2 ranging from 0.49 to 0.61 (p<0.001). Age and other
microarchitectural or geometrical parameters were poor pre-
dictors of bone strength (all R2<0.31, p<0.001). In ascending
multivariable regressions using only HR-pQCT parameters,
the best surrogate variables to predict failure load included
only Ct.Ar and Tb.vBMD, with R2=0.85 (p<0.001). The
addition of other microarchitectural parameters, age or UDR
aBMD did not improve significantly the R2 coefficient (up to
R2=0.89).
Conclusion(s): Ct.Ar combined with Tb.vBMD may be a
surrogate variable of μFE estimated failure load. Without
running μFEA, this method could help to estimate indirectly
and more quickly bone strength based only on HR-pQCT
measurement in large datasets. Further validation will be
needed regarding its use in fracture risk assessment.
References: 1. Burghardt, Buie et al. Bone 2010;47:519.
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PTH (1-84) REPLACEMENT THERAPY IN
HYPOPARATHYROIDISM: EFFECTS ON BONE
METABOLISM AND STRUCTURE
Tanja Sikjaer1, Lars Rejnmark1, Jesper S Thomsen2,
Annemarie Brüel2, Leif Mosekilde1
1Aarhus University Hospital, Department of Internal Medi-
cine and Endocrinology, MEA, 2Department of Biomedi-
cine, Aarhus, Denmark
Objective(s): Conventional treatment of hypoparathyroid-
ism (hypoPT) with calcium supplements and active vitamin
D analogues causes reduced bone turnover and high BMD.
Material & Methods: We studied 62 patients with hypoPT
randomized into treatment with either PTH(1-84) 100 μg/d
s.c. or placebo, as an add-on therapy. We investigated
changes in bone structure and density using μCT in 44 iliac
crest bone biopsies (23 on PTH) obtained after 24-wks of
treatment.
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Results: Trabecular tunnelling was evident in 11 (48%)
biopsies from the PTH-group, whereas no tunnelling was
detected in the placebo group. Patients showing tunnelling
had significantly higher levels of biochemical markers of
bone resorption (NTX and CTX) and formation (osteocal-
cin, BSAP, PINP). Compared with placebo, PTH-treatment
resulted in lower trabecular thickness (Tb.Th*) (p<0.01),
and trabecular bone tissue density (p<0.01), whereas con-
nectivity density (CD) was higher (p<0.05) and structural
modelling index tended to be lower indicating a change in
trabecular architecture from a rod-like to a more platelike
structure. Cortical porosity tended to be higher in PTH-
treated patients, especially in those with tunnelling. Occur-
rence of tunnelling was not associated with etiology, length
of disease, concentration of PTH or Ca2+. QCT at the spine
and hip were performed at baseline and at week 24 in 31
patients. At the lumbar spine (L1+L2), the increase in
trabecular vBMD over the study period was significantly
(p=0.02) higher in the PTH group (+12.2%) than in the
placebo group (-0.7%). On the contrary, total vBMD de-
creased more in the PTH than in the placebo group at the
total hip (-1.83% vs. 0.43%, p<0.05), at the trochanteric
region vBMD (-3.28% vs. 0.46%, p<0.03), and at the
femoral neck (-3.3% vs. -0.84%, p=0.12). At all three sites,
there was a tendency towards an increased trabecular and a
decreased cortical vBMD in the PTH treated patients.
Conclusion(s): The effect of PTH (1-84) treatment in
hypoPT is increased bone turnover with a decreased vBMD
at cortical sites, and an increased vBMD at trabecular sites,
which is related to morphological changes in the bone
microstructure with intratrabecular tunnelling and increased
cortical porosity.
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BONE MINERAL DENSITY IN PATIENTS WITH
RHEUMATOID ARTHRITIS BEFORE AND AFTER
ONE YEAR OF TREATMENT WITH TNF
BIOLOGICAL THERAPY
Milica M Basaric1, Nada Pilipovic1, Slavica Z Prodanovic1,
Goran L Radunovic1
1Institute of Rheumatology, Clinical 2, 2Clinical 5, 3Clinical
3, Belgrade, Serbia
Objective(s): To determine the effect of one-year of
treatment with TNF biological therapy on BMD in
patients with rheumatoid arthritis (RA) treated with
methotrexate (MTX).
Material & Methods: The 120 patients (100 female, 20
male) with RA (ARA criteria) were analyzed. Patients
were previously received MTX therapy (a minimum of
5 years) and corticosteroid therapy (a minimum of 3
months, doses greater than 5 mg daily). Patients were
divided into two groups: group A (70 pts) who received
etanercept apart from MTX therapy and B (50 pts) who
received monotherapy MTX continuously. The demo-
graphic data were following and were comparable
according to age, sex, BMI and duration of RA. BMD
(g/cm2) was measured at the lumbar region of the spine.
DXA scan was done in two terms in both groups of pts.
at the time of initiation of anti-TNF therapy and one
year after. Patients were not taking osteoporosis therapy.
They have no comorbidities which significantly affect
bone metabolism either. All female patients were in the
generative period. The SPSS, Student's and Mann-Whitney
rank test were used in processing data.
Results: Analyzed BMD values in group A at baseline and
after one year (1.153±0.14 g/cm2 vs.1.146±0.15 g/cm2)
were decreased, but the difference was not statistically sig-
nificant (p=0.112). In group B of pts. the BMD values were
a statistically significant reduced (p=0.001) between the
initial and repeat DXA scan (1.112±0.11 g/cm2 vs. 1.091±
0.11 g/cm2). There was a statistically significant difference in
the reduction of BMD values between A and B groups of
patients (Mann-Whitney test, p=0.012).
Conclusion(s): Our study has shown no statistically sig-
nificant reduction of BMD values between groups of
RA patients who were treated with MTX and anti-
TNF therapy in contrast to patients treated with MTX
during one year following period. But, patients who
received anti-TNF therapy had a significantly lower
reduction of BMD compared to patients treated with
MTX only.
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QUANTITATIVE HEEL ULTRASONOGRAPHY
VS. DUAL X-RAY ABSORPTIOMETRY
IN ROMANIAN WOMEN
Ileana Duncea1, Ioana Ilie1, Ioana Duncea2, Adrian Paul1,
Dan Mihu3, Teodora Mocan4, Carmen Georgescu1
1"Iuliu Hatieganu" University of Medicine and Pharmacy,
Endocrinology Department, 2Faculty of Dental Medicine,
3Obstetrics and Gynecology Department, 4Physiology
Department, Cluj-Napoca, Cluj, Romania
Objective(s): In comparison to DXA, QUS applied at
the calcaneus, tibia, radius or phalanx is easy, portable
and less expensive. The present study aimed to evaluate
the diagnostic agreement between heel QUS and DXA
in an random population of Romanian women aged 24-
80 years, as well as to offer cutoff levels for QUS to
distinct between women with or without osteoporosis
identified by DXA.
Material & Methods: Fracture risk evaluation by calcaneus
QUS (c-QUS) was carried out on 165 consecutive women
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aged 55.1 years (range 29-74 years) submitted to the Oste-
oporosis and Menopause Center at the Endocrinology Clinic
Cluj-Napoca. All patients were simultaneously investi-
gated by both QUS on the water-based system Achilles
Express (GE, Madison, USA) and DXA of the lumbar
spine (L1-L4) and hip using the DPX-NT (GE, Madison,
USA) device.
Results: In women measured by both DXA and calcaneus
QUS (c-QUS), BMD moderately correlated with stiffness
index (SI) (L1-L4: r=+0.51, p<0.001; femoral neck: r=+0.53,
p<0.001; hip: r=+0.57, p<0.001). At a T-score cutoff
level of -2.5SD, the high specificity but low sensitivity
suggests a low false positive rate of c-QUS as a diag-
nostic test; still, several patients with the disease may not
be correctly diagnosed. Diagnostic agreement between
DXA and QUS was poor, with k-scores ranging from
0.33-0.39. Lowering c-QUS T-score cutoff for lumbar
spine osteoporosis screening to -1.5 SD improved sensi-
tivity and had a minor effect on diagnostic agreement.
Conclusion(s): Although c-QUS is useful to predict
fracture risk, it should be mentioned that it does not
represent an adequate predictor of BMD in Romanian
women. Changing the diagnostic T-score threshold from
-2.5SD to -1.5SD in subjects examined by c-QUS
results in improved sensitivity of the method and enhan-
ces diagnostic agreement in the identification of patients
with vertebral osteoporosis.
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THE PATTERN OF OSTEOPOROTIC FRACTURES
IN THE POPULATION OF THE TOWN OF
PERVOURALSK, URALS, RUSSIA
Elena N Gladkova, Olga M Lesnyak, Vitalij N Khodyrev
Ural StateMedical Academy, Department of FamilyMedicine,
Yekaterinburg, Russian Federation
Objective(s): Previous studies have shown that the distal
forearm and hip fractures in women are significantly more
often compared to men. Other localizations of fractures had
not been investigated in Russia. The aim of this study was to
assess the pattern of osteoporotic fractures by age and sex in
Pervouralsk inhabitants, approximately 160,000 population
in total.
Material & Methods: The analysis of records at the Central
Pervouralsk hospital trauma department register as the place
where patients with osteoporotic fractures have been routine-
ly admitted to, data collecting from outpatient trauma stations
were carried out from January,1 2008 - December, 31 2009.
Types of fractures were included: hip, distal forearm, proxi-
mal humerus, ribs, tibia and fibula.
Results: 1371 osteoporotic fractures were revealed (383
fractures in men and 988 in women).
The proportion of all osteoporotic fractures according to
fracture site is shown in the table.
Proportion (%) of osteoporotic fractures at different sites in men and
women by age
Fracture type Age range (years)
50-54 55-59 60-64 65-69 70-74 75-79 80+
Men
Hip 4.9 10.3 11.3 18.4 14.6 24.3 40.0
Forearm 22.5 17.2 17.0 5.3 22.0 24.3 16.0
Proximal humerus 10.8 8.0 5.7 21.1 14.6 13.5 16.0
Ribs 39.2 39.1 50.9 39.5 41.5 37.8 24.0
Tibia and fibula 22.5 25.3 15.1 15.8 7.3 0.0 4.0
Women
Hip 4.7 3.0 6.5 9.5 12.8 20.7 49.4
Forearm 59.4 68.9 61.1 52.6 54.7 42.2 26.9
Proximal humerus 10.2 13.2 10.2 14.6 13.4 20.7 16.9
Ribs 2.3 4.2 6.5 8.8 4.1 8.6 3.1
Tibia and fibula 23.4 10.8 15.7 14.6 15.1 7.8 3.8
There was a marked variation in the pattern of fractures
with age in both men and women. The greatest percentage
of fractures in men and women all ages were fractures of
ribs (39.9%) and distal forearm (52.1%), respectively. Hip
fractures accounted for a minority of fractures at age 50
years (4.9% and 4.7%, respectively, in men and women),
but was the most common fracture after the age of 80
years. The part of hip fractures in men after the age of 80
was 40%, in women 49.4%. Fractures of distal forearm
accounted for about half of all fractures in women (from
26.9 to 68.9%). The part of ribs fractures varied from
24.0-50.9% of total fractures in men and from 2.3-8.8%
in women.
Conclusion(s): The resulting data can complement the knowl-
edge of the epidemiology of osteoporotic fractures in Russia.
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IV ZOLEDRONIC ACID: INDICATIONS FOR ITS
ADMINISTRATION AND ITS TOLERABILITY
FOLLOWING FIRST DOSE
N Maher, N Fallon, K Fitzgerald, G Steen, J Browne, M
Casey, JB Walsh
St. James's Hospital, Mercers Institute for Successful Ageing,
Dublin, Ireland
Objective(s): To identify the side effects experienced by
osteoporotic patients receiving their first dose of iv zole-
dronic acid. Objective was to identify the indications for
osteoporotic patients receiving iv zoledronic acid.
Material & Methods: A retrospective study of patients who
have received first dose of alendronic acid over 18 months was
carried out. Prior to infusion, calcium and vitamin D levels
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were corrected and patients were advised to keep well hydrated
24 h prior to and post infusion. Regular paracetamol was also
advised. The indications for iv zoledronic acid and possible side
effects including reduction in calcium levels were highlighted.
Results: Of 292 patients who received iv zoledronic acid,
63 (21%) experienced side effects. The most common being
flu like symptoms (32), lethargy (12) and headache (4). Side
effects experienced were transient lasting 24-48 h. 55 (19%)
patients experienced a drop in serum calcium below normal.
Indications for iv zoledronic acid
Indications Number/Percentage
Gastric symptoms ( including oesophagitis,
reflux, Barrets)
60(20%)
Intolerant of PO bisphosphonates 45(14%)
Post PTH therapy 50 (17%)
Noncompliant /Responder to previous therapy 130 (44%)
Cancer 5 (2%)
Unsuitable/Adverse reaction to PTH 10 (3%)
Conclusion(s): Zoledronic acid is generally safe and well
tolerated and has the potential to improve compliance with
osteoporosis therapy and consequently to reduce the risk of
fractures in clinical practice. Discomfort experienced from side
effects were reduces by patient education and symptom relief.
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EFFECTS OF BISPHOSPHONATE TREATMENT ON
THE QUALITY OF LIFE OF PATIENTS WITH
RHEUMATIOD ARTHRITIS
Liliana Groppa, Elena Deseatnicova, Irina Bancu
State University of Medicine and Pharmacy “Nicolae
Testemitanu", Rheumatology, Chisinau, Republic of Moldova
Objective(s): To assess the quality of life of patients with
rheumatoid arthritis on the background of bisphosphonate
treatment.
Material & Methods: 117 patients receiving regular fol-
low-up at the Department of Rheumatology for Rheumatoid
Arthritis agreed to participate in the study. All of them
fulfilled inclusion criteria: rheumatoid arthritis diagnosed
according to 1987 ACR criteria, duration of postmenopausal
period longer than one year, glucocorticosteroid treatment in
the dose ≤7.5 mg, DMARD treatment with Metotrexate
only, absence of concomitant diseases that might affect
BMD or health assessment questionnaire (HAQ). In order
to reduce speed of bone loss and risk of fracture to all the
patients alendronate 70 mg weekly was prescribed. Taking
into consideration that antiosteoporotic treatment in the
Republic of Moldova is not covered by insurance some
patients could not cover the costs and refused the treatment.
They were selected for control group (48 patients). All the
patients were followed up for one year. HAQ was applied at
the beginning and at the end of supervision period for all the
patients.
Results: At the beginning of follow-up in both groups
results of testing by HAQ were similar. In the group that
was supposed to receive alendronate mean HAQ index was
1.06±0.05 and in control group HAQ index was1.04±0.04,
p>0.05. Among tested patients at the beginning of the study
63% had mild to moderate difficulty, 29% had moderate
disability and only 8% showed severe disability. After one
year of supervision in alendronate treated group mean value
of HAQ index was 0.78±0.07 and in control group it was
1.16±0.03.There was found statistically proven difference
between HAQ index values in alendronate treated group and
control group, p<0.05, showing improvement of the quality
of life in patients treated with bisphosphonates. Most of
patients from control group either worsened HAQ index
level (58%) or did not show any changes (42%).
Conclusion(s): Bisphosphonate treatment in patients with
rheumatoid arthritis having mild or moderate disability has
positive influence on their quality of life.
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THE EFFECT OF ANTI-TNF THERAPY TO BONE
MINERAL DENSITY IN PATIENTS WITH
SPONDYLOARTHROPATHIES
Snezana S Novkovic1, Nada Pilipovic1, Predrag Ostojic1,
Biljana Stojic1, Ivica P Jeremic1
1Institute of Rheumatology, Clinical 4, 2Clinical 5, Belgrade,
Serbia
Objective(s): The aim of this research was to investigate the
effect of anti-TNF therapy to BMD in patients with
spondyloarthropathies.
Material & Methods: The research included 78 male
patients with ankylosing spondylitis and psoriatic spondy-
loarthropathies. The respondents were divided into two
groups: group A (48 patients) received treatment with anti-
TNF medicines (etanercept 50 mg/week; adalimumab 40
mg/2 weeks) and the group B- control group (30
patients) was not given the anti-TNF therapy. In both
groups there were few patients who were treated with
DMARD (disease modifying anti rheumatic) drugs, but
none of them received glucocorticoids. For measuring of
BMD we used DXA method with Lunar Advance Prod-
igy. Measuring was performed on hip at the beginning
of the research and repeated after 18 months. Respond-
ers didn't receive therapy for osteoporosis. In processing
the obtained data: SPSS and Student's t test and Mann-
Whitney rank test.
Results: The groups were comparable by age (group A:
40±11.0 years, group B: 43.2±10.8 years), duration of illness
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(group A: 9.3±6.1, group B: 10.5±5.7 years) and number of
patients who received DMARD therapy (group A: 12.5%,
group B: 11.4%). The average value BMD (g/cm2) was not
significantly different between groups at the beginning of the
research (group A: 0.938, group B: 0.927, p=0.775). After 18
months, we recorded significant increase of BMD in the group
A (1.017 g/cm2, p<0.001) and significant decrease in the
group B (0.846 g/cm2, p<0.05). At the end of this research
we detected statistically significant increase in the group trea-
ted by anti-TNFmedicines in comparison to the control group
(p<0.05).
Conclusion(s): 18 months long treatment with anti-TNFα
therapy at our patients with spondyloarthropathy caused
significant improvement of BMD.
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EFFECTS OF ALENDRONATE TREATMENT
ON BONE MINERAL DENSITY OF PATIENTS
WITH RHEUMATIOD ARTHRITIS
Liliana Groppa, Elena Deseatnicova, Irina Bancu
State University of Medicine and Pharmacy "Nicolae Teste-
mitanu", Rheumatology, Chisinau, Republic of Moldova
Objective(s): To assess BMD of patients with rheumatoid
arthritis on the background of alendronate treatment.
Material & Methods: 117 patients receiving follow-up
for rheumatoid arthritis participated in the study. All of
them fulfilled inclusion criteria: rheumatoid arthritis di-
agnosed according to 1987 ACR criteria, duration of
postmenopausal period longer than one year, glucocorti-
costeroid treatment in dose ≤7.5 mg, DMARD treatment
with Metotrexate, absence of concomitant diseases that
might affect BMD. For all the patients alendronate 70
mg weekly was prescribed. Taking into consideration
that antiosteoporotic treatment in the Republic of Moldova is
not covered by insurance some patients refused the
treatment. They were selected for control group (48
patients). All the patients were followed up for one year.
BMD at lumbar spine and femoral neck was measured.
BMD was measured using a Hologic Discovery Unit.
WHO criteria were used for the diagnosis of osteoporosis
(T-score≤−2.5 SD).
Results: At the beginning of follow-up both groups were
identical. DXA showed that in average in both groups 19%
patients had normal BMD both in the lumbar spine and the
femoral neck. 43% patients had osteoporosis in at least one
of the evaluated sites. 85% patients had T-score≤-1 and 38%
patients Z score≤-1. After one year, in group of patients
with regular Alendronate treatment mean lumbar BMD was
0.86 g/cm2, mean lumbar T-score was -1.75, and mean
lumbar Z score was -0.21 (95%CI -0.37 to -0.05; p<0.05).
At the femoral neck, mean BMD was 0.645 g/cm2, mean
T-score -1.69, and mean Z-score -0.60 (95%CI -0.72 to
-0.34; p <0.05). In control group mean lumbar BMD was
0.80 g/cm2, mean lumbar T-score was -2.1, and mean
lumbar Z-score was -0.3 (95%CI -0.38 to -0.04; p<
0.05). At the femoral neck, mean BMD was 0.59 g/cm2,
mean T-score -1.89, and mean Z score -0.72 (95%CI -0.73
to -0.35; p<0.05).
Conclusion(s): After one year of supervision there was
found a tendency to worsening of BMD in patients who
did not receive bisphosphonate treatment and femoral neck
BMD showed statistically proven difference.
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VERTEBRAL DEFORMITY ASSESSMENT:
WORKFLOW TIMING USING A STANDARD
VS. A DEDICATED FILM VIEWER
Jane Haslam, Nathaniel Nathaniel, Peter Steiger
Optasia Medical Ltd, Research & Development, Cheadle
Hulme, Cheshire, UK
Objective(s): Vertebral fractures are more predictive of
future osteoporotic fragility fractures than low bone density
and should be treated. More vertebral fractures occur in
patients not considered osteoporotic by bone density than
in those who are and yet 69% of those who have fractures
are unaware of them. The purpose of this study was to
measure the effort required for itemized vertebral deformity
assessment using a specialized viewing and reporting
tool (SpineAnalyzer, Optasia Medical) compared to a
traditional general use film viewing tool (eFilm, Merge
Healthcare).
Material & Methods: Lateral thoracic and lumbar spine
x-rays of 20 subjects were Genant semiquantitatively
(SQ) scored from T4-L4 by a trained operator (NS)
using both tools. In the traditional workflow the opera-
tor SQ-scored radiographs in eFilm, performing manual
quantitative morphometry (QM) only on vertebrae which
were thought to be deformed. QM was performed using
the eFilm ruler tool and a spreadsheet (Microsoft Excel)
to calculate and record vertebral deformity percentages.
In SpineAnalyzer, prior to SQ-scoring each subject, the
operator used the semi-automatic vertebral contour an-
notation facility to annotate and calculate deformity
percentages for all vertebrae, regardless of whether they
appeared deformed. Results were recorded within Spine-
Analyzer. The operator timed the duration of the differ-
ent analysis steps.
Results: Table 1 shows the timing results, per subject, all
times in seconds. On average, the operator performed
QM on 5.8 vertebrae per subject using eFilm. For the 3
cases where no manual QM measurements were performed,
total eFilm review time was reduced to 201.1±45.1 s,
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compared to 207.0±26.8 s for the same cases reviewed with
SpineAnalyzer.
Vertebral Deformity Assessment Workflow Timing Results
eFilm SpineAnalyzer
Open images 15.3±0.7 9.8±0.2
View, arrange, pan and zoom, adjust
brightness and contrast
33.2±2.9 17.6±2.1
Assess and record vertebral deformities 223.9±12.3 169.5±11.8
Assess and record Genant SQ scores 121.5±18.6 12.5±3.6
Total Review Time 393.9±29.0 209.9±12.7
Conclusion(s): Our results demonstrate that a dedicated
workflow tool can provide a more comprehensive quantita-
tive assessment of vertebral deformity in less time than
general purpose viewing software. Even in cases where no
manual QM was performed, using SpineAnalyzer did not
result in a significant time penalty.
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EFFICACY AND SAFETY OF STRONTIUM
RANELATE IN THE TREATMENT OF MALE
OSTEOPOROSIS
Jean-Marc Kaufman1, Maurice Audran2, Gerolamo Bianchi3,
Steven Boonen4, Robert Josse5, Roger M Francis6, Stefan
Goemaere1, Santiago Palacios7, Miguel Diaz Curiel8, Johan
D Ringe9, Dieter Felsenberg10
1Ghent University Hospital, Ghent, Belgium, 2CHU Angers,
Service de Rhumatologie, Angers, France, 3ASL 3 Genovese,
Genoa, Italy, 4Leuven University Center, Leuven, Belgium,
5 St Michael's Hospital, Toronto, Canada, 6Newcastle Univer-
sity, Institute for Ageing and Health, Newcastle, UK, 7Insti-
tuto Palacios, 8Fundacion Jimenez Diaz, Madrid, Spain,
9University of Cologne, Klinikum Leverkusen, Cologne,
Germany, 10University Medicine Berlin, Charité Campus
Benjamin Franklin, Berlin, Germany
Objective(s): Efficacy and safety of strontium ranelate
(SrRan) have been established for treatment of postmeno-
pausal osteoporotic women. The Male Osteoporosis Study
assessed the efficacy and safety of SrRan in men with
primary osteoporosis.
Material & Methods: The study was an international 2-
year randomised double-blind placebo-controlled trial
(SrRan 2 g/day/placebo 2:1) including 261 patients. Primary
endpoint was relative changes from baseline of lumbar
BMD. Secondary endpoints were hip BMD, bone bio-
markers, quality of life and fractures.
Results: The ITT population consisted of 243 men. Baseline
characteristics (mean±SD) were similar in both groups:
mean age was 72.7±5.7 years; lumbar and femoral neck
BMD T-Score were -2.7±1.0 and -2.3±0.7, respectively;
29% of patients had prevalent vertebral fractures. BMD
increased significantly in the SrRan group compared to
placebo from baseline to Month-24 at each site: lumbar
(L2-L4) by 9.8%±1.1 (p<0.001); femoral neck by 3.3%±
0.9 (p<0.001) and total hip by 3.7%±0.8 (p<0.001). Ob-
served from month-3, there was a significant decrease in
bone resorption with a preservation of bone formation. At
month 24, estimate of adjusted means difference (SrRan-
placebo) for s-CTX was -29.7%±9.7, p<0.001 and for
bALP 3.5%±4.8, NS. A significant improvement (i.e. score
decrease) in the Quality of life was observed (-0.34±0.7 in
the SrRan group vs. -0.07±0.5 in the placebo group, p=
0.009). Although, no reliable conclusion can be drawn con-
sidering the low number of fractures, after 2 years, vertebral
fracture incidence (central X-ray reading, semiquantitative
method) was lower in the SrRan than in the placebo group
(5.8% vs. 7.8%). The same was observed for clinical non-
vertebral fractures recorded as adverse events (3.5% vs.
4.6%). The serum strontium levels and increase of lumbar
spine BMD over 2 years in this study in men were similar to
those previously observed in the pivotal trials in postmeno-
pausal women. Overall SrRan was well tolerated (88.4% of
patients experienced an adverse event in the SrRan vs.
96.6% in the placebo group).
Conclusion(s): In a male population at risk of fractures, a
marked increase in the mean lumbar L2-L4, femoral neck
and total hip BMD was observed with strontium ranelate. A
trend towards a lower incidence of fracture with SrRan was
observed.
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OUR EXPERIENCE IN IMPLANTING THE DISTAL
LOCKING REVISON HIP PROSTHESIS IN
OSTEOPOROTIC PATIENTS
Cirstoiu F Catalin1, Popescu Dan1, Ene Razvan1, Cirstoiu
Monica2, Popescu Anca3
1Universitary Emergency Hospital Bucharest Romania,
Orthopedic-Traumatology, 2Obstetrics-Gynecology,
3Endocrinology, Bucharest, Romania
Objective(s): To use in the hip arthroplasty of the revision
uncemented stems with distal locking capabilities, that offer
a good primary stability in order to allow early patient's
mobilization with full weight loading vs. cemented long
stems.
Material & Methods: At the Orthopedics and Traumatol-
ogy Clinic of the University Emergency Hospital of Buchar-
est, between 2007-2011, 42 hip revision surgeries have been
performed at patients with osteoporosis, using cemented and
uncemented stems. In 24 cases we used femoral components
uncemented, with distal locking capabilities. The patients
were aged 62-83 years. The sex ratio M/F=7/17. The diag-
nosis of osteoporosis was established using Rx. Exam and
DXA. There were used a variety of designs, with cemented
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or uncemented cups, with long uncemented stems, distal
locked with 1 or 2 screws. All of them had the option of
the reaming the femoral canal up to the expected diameter,
and also had the option of using an external distal locking
guide. Straight stems were used, as well as anatomically
curved stems.
Results: This type of revision prosthesis offer a good pri-
mary stability of the femoral stem, allowing an early
patient's mobilization, after 48 h postoperatively, with full
weight loading from the first moment. The distal locking
device has also antirotational purpose, allowing the use of
femoral stems with smaller diameters than the femur's. This
means an easier implantation procedure. Also, due to their
length, they allow the replacement of the large bone defects
at the proximal femur caused either by the osteotomies
necessary during the old stem ablation. The patients had a
fast rehabilitation that increased considerably the quality of
life. There were not immediately or distance complications
such as periprothetic fractures, in spite of the osteoporotic
status of the patients.
Conclusion(s): We recommend the uses of the stems with
distal locking options in the hip revision surgery, followed
by an early rehabilitation.
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INADEQUATE PAIN RELIEF IN KNEE
OSTEOARTHRITIS: AN EARLY LOOK AT THE
SURVEY OF OSTEOARTHRITIS REAL WORLD
THERAPIES (SORT)
GDR Martin1, Robert Balshaw2, Philip G Conaghan3, Sharlette
V Everett4, Douglas J Watson5, Stephanie D Taylor6
1Greenwood Sneinton Family Medical Centre, General
Practice, Sneinton, Nottingham, UK, 2Syreon, Information
Sciences, Vancouver, BC, Canada, 3University of Leeds,
NIHR Leeds Musculoskeletal Biomedical Research Unit,
Leeds, Yorkshire, UK, 4Merck Sharp & Dohme Corp., Ac-
cess Innovations & Operations, Whitehouse Station, NJ,
5Merck Sharp & Dohme Corp., Global Epidemiology,
Whitehouse Station, NJ, 6Merck Sharp & Dohme Corp.,
Global Health Outcomes, Whitehouse Station, NJ, US
Objective(s): Osteoarthritis (OA) has an extremely high
disease and economic burden. Despite treatments for OA
pain management, data are limited on the adequacy of pain
relief in OA patients. SORT will determine the adequacy of
pain relief in patients with knee OA and compare patterns of
clinical care and outcomes
Material & Methods: SORT, a 12-month prospective, ob-
servational six-country study will enrol 1400 participants
using oral or topical analgesics for knee OA symptoms.
Participants visiting a PCP must be ≥50 years old with knee
OA. Clinical history, medications, quality of life, resource
use are collected at baseline and months 1, 3, 6, 9, & 12.
Inadequate pain relief (IPR) was defined as Brief Pain
Inventory "moderate or greater pain" score >4.
Results: This analysis represents 171 participants who
provided baseline data: 69% women, median (range)
age 68 years (50-90), 5.8 years post OA diagnosis,
61% taking pain medication-oral only. IPR was reported
by 60%. IPR and non-IPR participants were similar in
clinical characteristics: BMI 30 kg/m2 (20-55), coexist-
ing OA of the hip (23%) & spine (35%). Hypertension
(54%) was the most common comorbidity. IPR participants
scored worse across domains other than pain: WOMAC Stiff-
ness (135 vs. 75, p<0.01), Physical Function (986 vs. 527, p<
0.01); SF-12 General Health (fair/poor 44% vs. 28%, p=0.05)
& satisfaction with treatment side effects (very satisfied 17%
vs. 40%, p<0.01).
Conclusion(s): With 60%of participants reporting IPR, the
SORT study will provide valuable insight regarding the
impact of IPR on individuals with knee OA.
Disclosures: This study was funded by Merck Sharp &
Dohme Corp., Whitehouse Station, NJ USA.
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COMPARISON OF PRESCRIBING AND
ADHERENCE PATTERNS OFANTIOSTEOPOROTIC
MEDICATIONS POSTADMISSION FOR FRAGILITY
TYPE FRACTURE TO AN URBAN TEACHING
HOSPITAL AND A RURAL TEACHING HOSPITAL
BETWEEN 2005-2008
Bernie M McGowan1, Kath Bennett2, John G Doherty3,
Bridie Rooney3, Aoife McPartland1, Miriam C Casey4,
Carmel Silke1, Bryan Whelan1
1Our Lady's Hospital, Manorhamilton, Co. Leitrim, The
North Western Rheumatology Unit, Leitrim, 2Trinity Centre
for Health Sciences, St. James's Hospital, Pharmacology and
Therapeutics, Dublin, 3Sligo General Hospital, The Osteo-
porosis and Bone Health Service, Sligo, 4 St. James's Hos-
pital, The Osteoporosis and Bone Health Service, Dublin,
Ireland
Objective(s): To compare prescribing and adherence pat-
terns of anti-osteoporotic medications in patients admitted to
an urban teaching hospital in Ireland with a fragility type
fracture to patients admitted to a rural hospital in the North
Western region.
Material & Methods: We identified all patients ≥55 yrs
admitted to Sligo General Hospital in the NW of Ireland
between 2005-2008 with a fragility fracture (N=744)
using the Hospital Inpatient Enquiry system (HIPE).
The medical card number of those patients eligible for
the Primary Care Reimbursement Services scheme
(PCRS), facilitated the linkage of the HSE-PCRS data-
base to the HIPE database enabling a longitudinal study
to include patients' medical management for 12 months
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before and 24 months after their admission. The data
was analysed to identify persistence rates of patients
prescribed osteoporosis therapy after discharge. Results
were compared to the findings of a similar study carried
out in an urban teaching hospital in Dublin - St. James's
Hospital1.
Results: Pre fracture treatment increased in SGH from
15.15% in 2005 to 16.54% by 2008 while postfracture
prescribing increased from 31.31% in 2005 to 43.31%
in 2008. In comparison prefracture treatment in St.
James's Hospital increased from 2.6% in 2005 to
10.6% by 2008 while postfracture prescribing increased
from 11% in 2005 to 47% in 2008. The persistence
with medications postfracture in those prescribed thera-
py was 64.9% at 6 months and 24.7% at 12 months in
the urban group and 64.8% at 6 months and 50% at 12
months in the rural group. In the urban group 28.6% of
hip fracture patients were persistent at 12 months in
contrast to the rural group where 50% continued to be
persistent at 12 months.
Conclusion(s): The proportion of patients discharged on
anti-osteoporotic medications post fragility fracture in-
creased between 2005-2008 in both patient groups. There
is a marked variation between the two groups in persistence
rates at 12 months. The reasons for this will require further
investigation.
References: 1.B McGowan, K Bennett, J Marry, JB Walsh,
MC Casey. Eur J Clin Pharmacol 2011;67:301.
P463
BONE DECADE ACTIONS: ARE PRACTICAL
RESULTS MEASURABLE YET? AGE SPECIFIC
INCIDENCE RATES OF OSTEOPOROTIC HIP
FRACTURES IN PORTUGAL
Sandra F Alves1,2, Carla Oliveira1,3,4, Carlos Alves1, Ana I
Ribeiro1,3,4, Nuno Neves1, Maria F Pina1,3,4
1Instituto de Engenharia Biomédica-INEB, Biomaterials,
2ESTSP-IPP, Área Científica Biomatemática, Bioestatís-
tica e Bioinformática, Gaia, 3Faculdade de Medicina da
Universidade do Porto, Departamento de Epidemiologia
Clínica, Medicina Preditiva e Saúde Publica, 4Universidade
do Porto, Instituto de Saúde Pública da Universidade do Porto
- ISPUP, Porto, Portugal
Objective(s): The aim of this work is report temporal trend
in hip fracture incidence, in Portugal.
Material & Methods: Osteoporotic hip fractures (820.x
ICD 9-CM, caused by low impact, aged 49+) from 2000-
2008 were collected from National Hospital Discharge Da-
tabase, mandatory for all Portuguese public hospitals, con-
taining information such as: sex, age, causes of admission
and diagnosis. Cases of bone cancer, readmissions or com-
plications after-care were excluded. Portuguese population,
2001 census, was the standard to calculate direct age stan-
dardized incidence rates (ASIR) (100,000 inhabitants). Lin-
ear regression was used to evaluate temporal trends of age
specific rates (AR), by gender and Joinpoint regression to
determine points of inflection in trends.
Results: During the period 77,083 hip fractures were
identified (22.6% of male). Mean age at admission
was 78.3 (SD 10.1) and 81.05 (SD 8.5) years old,
men and women, respectively. A decreasing temporal
linear trend was identified in ASIR in women (p-value
0.026), the relative estimated variation -10.63%. The
AR in male patients showed fluctuating for all ages
groups, with positive and negative absolute variation,
none of the trends were statistical significant. However,
in female patients all age groups presented a negative
absolute variation, except the oldest (85+); in the age
groups of 65-70, 70-75 and 75-80 the decreasing tem-
poral trend was statistical significant (p-value 0.08, 0.02
and 0.02, respectively) and the relative estimated varia-
tion in the period was -23%, -29% and -15%, respec-
tively. The year 2003 was identified as a turning point
in temporal trend for hip incidence rate in women aged
65-70.
Conclusion(s): Statistically significant decreasing trends
were identified only in female patients at intermediate age
groups, this fact seems compatible with hormonal pharma-
cological intervention actions (beginning before the 2003
turning point). Among younger women (50-59 years old) no
significant reduction was observed and one possible expla-
nation is the fact that osteoporotic fractures tend to have
severe medical reasons in younger groups and therefore the
actions for osteoporosis prevention have lower impact. On
the other hand, among the oldest group the effective inter-
vention should be fall prevention, which is almost inexistent
in Portugal.
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A COMPARISON OF BONE DENSITY AND BONE
MORPHOLOGY IN THOSE PRESENTING WITH
EITHER HIP FRACTURES, SPINAL FRACTURES
OR A COMBINATION OF THE TWO
Richard Crilly1,2, Lizebeth Cox1,3
1St. Joseph's Health Care Centre, Geriatric Medicine, 2The
University of Western Ontario, Department of Geriatric
Medicine, 3The University of Western Ontario, Health &
Rehabilitation Sciences, London, ON, Canada
Objective(s): In hip fractures the relative contribution of
trauma and osteoporosis is hard to determine. Who to treat
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for osteoporosis after a hip fracture remains unclear; no
guidelines currently exist.
Material & Methods: We compared spinal and hip bone
density and morphometry across three fracture groups:
those with spinal fractures only (N=50; age=76.6±9.3
years), those with hip and spinal fractures (N=50; age=
79.5±6.4 years), and those with hip fractures only (N=
50; age=81.0±5.9 years). Bone density by DXA includ-
ed spinal density and hip density at 4 standard sites.
Spinal fractures were assessed using the Genant method.
Hip measurements included hip axis length, femoral
neck length and width and femoral cortical bone
thickness.
Results: Findings show a clear trend where for meas-
urements that strongly reflect trabecular bone status
(lumbar spine, intertrochanteric and trochanteric sites)
those with only spinal fractures have the worst meas-
urements, those with only hip fractures have the best
measurements and those with spinal and hip fractures
have measurements between the two. For measure-
ments that strongly represent cortical bone status (fem-
oral neck and cortical bone thickness) those with only
spinal fractures remain lower than both hip fracture
groups while the two hip fracture groups are not sta-
tistically different.
Conclusion(s): People presenting with spinal fractures have
the worst bones, those presenting with hip fractures alone
have bones normal for their age while those presenting with
hip and spinal fractures are in between, these may represent
the hip fracture patients who respond best to treatment with
antiresorptive therapy.
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EXPERIENCE OF WORK OF MINSK CITY CENTER
OF OSTEOPOROSIS, REPUBLIC OF BELARUS
E V Rudenka1, N S Serduchenko2
1Belarusian Medical Academy of Postgraduate Training,
Chair of Cardiology and Rheumatology, 21st City Clinic,
Center of Osteoporosis, Minsk, Belarus
Objective(s): Belarusian Public Association “Fight osteo-
porosis together” was established in 2005. Now it consists
of more than 600 members. The association promotes
knowledge on osteoporosis among health professionals
and general population. It regularly conducts scientific con-
ferences on the issue, supervises research work, provides
treatment and consultation work for osteoporotic patients,
organizes schools on osteoporosis for general population
and health care workers. Our association widely covers the
problem of osteoporosis in media (regular sessions on TV,
radio, regional and republican printed media).
Material & Methods: The city center of osteoporosis
(CCO) was opened in the 1st clinic of the capital city Minsk
in 2006 according to the initiative of the Association and
Minsk City Healthcare Committee. The CCO occupies the
territory of 450 m2 and consists of 3 medical office recep-
tions, treatment and DXA rooms, classroom and a
Osteoporos Int (2012) 23: (Suppl 2):S85–S386 S263
conference hall for 45 places. In 2011 the CCO was
equipped with a modern immunoassay analyzer, which
allows to determine not only bone markers, 25(OH)D but
also total vitamin D in blood plasma. All the maintenance
costs of the CCO are covered by the government. Each day
60-70 patients visit the centre with 35-40 densitometry
examinations carried out each shift, followed by the consul-
tation of the doctors of the CCO and specialists of the chairs
of the Belarusian Medical Academy of Postgraduate Train-
ing. Patients with high risk of fractures are under supervi-
sion of the specialists of the centre. Schools for patients with
osteoporosis are conducted weekly.
Results: In 2009 activists of Belarusian Public Association
“Fight osteoporosis together” held the international confer-
ence on the problems of osteoporosis which was attended by
500 doctors, and in 2010 the IOF Osteoporosis Diagnosis
Course was held with 300 participants. There were con-
ducted 28 scientific republican and regional conferences
on different aspects of osteoporosis in 2011.
Conclusion(s): The specialists of CCO carry out regular
clinical and research work within the confines of scientific
projects, funded by the government. In this time we carry
out projects of hypovitaminosis of vitamin D, pathogenesis
of diabetic arthropathy, development of the national com-
puter program for evaluation of fracture risk “Osteoprogno-
sis” and others.
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BENEFITS TO BONE HEALTH RESULTING FROM
EARLY EXPOSURE TO SOY ISOFLAVONES
ARE TRANSFERRED TO SECOND-GENERATION
FEMALE MICE
Elsa C Dinsdale1, Wendy E Ward1,2
1University of Toronto, Department of Nutritional Sciences,
Toronto, 2Brock University, Department of Kinesiology,
Center for Bone and Muscle Health, St. Catharines, ON,
Canada
Objective(s): Infants consuming soy protein formula have
higher levels of serum isoflavones, with potential estrogen-
like activity, than other infants. Using a mouse model, we
previously showed that early life exposure to isoflavones
have long lasting benefits to bone health including greater
BMD and improved bone structure, resulting in more resil-
ient bones. While these benefits may be due to epigenetic
modulations and thus transferred to subsequent generations,
adverse effects on reproductive health - high rates of infer-
tility and abnormal histology of reproductive organs - are
observed in first (F1) but not second generation (F2) female
mice. The objective is to determine if higher BMD and
greater bone strength observed in F1 females exposed to
isoflavones during early life transferred to F2 female
offspring.
Material & Methods: Female CD-1 mice (F1, n=8-13/
group) were randomized to isoflavones (7 mg/kg body
weight/day) or corn oil from birth through the first 10 days
of life, weaned at age 21 days and fed a control diet
(AIN93G) until 2 months of age. F1 females were bred to
control males to obtain F2 females (n=14-22/group) that
were fed control diet until necropsy at 4 months of age.
BMD and strength of femurs and lumbar vertebra (LV) were
measured by DXA and a materials testing system, respec-
tively. Body weight was measured once weekly.
Results: F2 females whose mothers were exposed to iso-
flavones had greater (p<0.05) femur and LV BMD accom-
panied by greater resistance to fracture (p<0.05) at the
femur neck and midpoint, and LV. These changes were
accompanied by higher (p<0.05) final body weight (12%
higher).
Conclusion(s): Unlike adverse effects to reproductive health
that are not transferred to F2, previously observed benefits to
bone development in F1 are transferred to F2 females. Skeletal
sites rich in trabecular (lumbar spine) or cortical (femur mid-
point) bone respond similarly in that both sites withstand
greater forces before fracture. Moreover, higher body weight
persists into F2. These data provide a rational for long-term
studies of infants exposed to isoflavones or other environmen-
tal estrogens during early life.
Disclosures: This work was supported by the Canadian
Institutes of Health Research (funding number 89941).
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IMPLEMENTATION OF A FRACTURE LIAISON
SERVICE MODEL OF POST-FRACTURE
OSTEOPOROSIS CARE IN THE U.S. MEDICARE
BENEFICIARY POPULATION
David B Lee1, Richard M Dell2
1National Bone Health Alliance, Executive Office, Washing-
ton, DC, 2Kaiser Permanente, Department of Orthopaedics,
Downey, CA, US
Objective(s): As part of the U.S. National Bone Health
Alliance (NBHA) 20/20 vision promulgated by its 33 mem-
ber organizations and 3 government participants to reduce
the incidence of hip and other fractures 20% by the year
2020, this project will implement a fracture liaison service
(FLS) demonstration program in the U.S. Medicare benefi-
ciary system at 70-100 sites nationwide. This FLS program
will not only reduce the incidence of secondary fractures
and costs, but also increase osteoporosis screening and
treatment rates.
Material & Methods: The NBHA has requested funding
from the U.S. Centers for Medicare & Medicaid Services to
support a 3-year, 70-100 site FLS in the Medicare benefi-
ciary population in which nurse practitioners will be respon-
sible for ensuring post-fracture patients receive appropriate
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diagnosis, treatment and follow-up. This Medicare FLS will
incorporate best practices and lessons learned from existing
U.S. and international FLS programs (modified for the
Medicare setting), while using the tools developed by the
American Orthopaedic Association Own the Bone program
and other partners to enable rapid implementation.
Results: This Medicare FLS will track both process and
outcome measures and is leveraging the experience of other
FLS programs who have all shown (both in the U.S. and
abroad) an ability to greatly reduce the rates of costly and
serious secondary fractures by identifying and treating
patients who present with a new fracture, recognizing that
this group of patients represent those at highest risk of
additional fractures. There is overwhelming support from a
national and international network of FLS champions and
care managers willing to assist in the success of the Medi-
care Innovation FLS project. The NBHA anticipates CMS
award notification by early April 2012.
Conclusion(s): Given the high prevalence and costs of
osteoporosis to the U.S. Medicare beneficiary population
and the fact that disease management approaches have not
yet been widely utilized in the U.S. around post-fracture risk
reduction, the time to act is now to decrease health care
expenditures and increase patient quality of care.
References: http://innovations.cms.gov/initiatives/innovation-
challenge/index.html
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HEALTH RELATED QUALITY OF LIFE AFTER HIP
FRACTURE: DIFFERENCES BETWEEN EQ-5D
AND TIME TRADE OFF INSTRUMENTS
Carl Willers1, Vidmantas Alekna2,3, Maria Luisa Bianchi4,
Patricia Clark5, Manuel Díaz Curiel6,7, Hans Peter Dimai8,
Emma Hernlund1, Olga Lesnyak9, Axel Svedbom1, Thierry
Thomas10, Fredrik Borgström11
1OptumInsight, Stockholm, Sweden, 2Vilnius University,
Faculty of Medicine, 3State Research Institute, Center for
Innovative Medicine, Vilnius, Lithuania, 4Istituto Auxolo-
gico Italiano IRCCS, Bone Metabolism Unit, Milan, Italy,
5Hospital Infantil Federico Gómez and Faculty of Medicine
UNAM, Clinical Epidemiology Unit, Mexico City, Mexico,
6Fundacion Jimenez Diaz, Servicio de Medicina Interna/
Enfermedades Metabolicas Oseas, 7Universidad Autonoma
Madrid, Catedra de Enfermedades Metabolicas Óseas,
Madrid, Spain, 8Medical University of Graz, Dept. of Inter-
nal Medicine, Division of Endocrinology and Metabolism,
Graz, Austria, 9Ural State Medical Academy, USMA, Yeka-
terinburg, Russian Federation, 10U1059, INSERM, St-Eti-
enne, CHU de St-Etienne, France, 11Karolinska Institutet,
LIME/MMC, Stockholm, Sweden
Objective(s): The objective of this study was to compare
health utility elicited with the EQ-5D and the Time-trade-off
(TTO) instruments directly, 4 months and 12 months after
hip fracture.
Material & Methods: The International Costs and Utilities
Related to Osteoporotic fractures Study (ICUROS) is a pro-
spective multinational study with the aim of estimating costs
and health related quality of life (HRQoL) related to osteopo-
rotic fractures. In the study, two instruments were used to elicit
estimates of patients' health utility before hip fracture (recol-
lection), and 2 weeks, 4 months and 12 months after fracture:
the individual preference based TTO instrument and the EQ-
5D instrument based on societal preferences.
Results: In the 297 patients included in the interim analysis,
health utility estimates varied significantly between the two
elicitation instruments. Compared to TTO, the EQ-5D con-
sistently provided lower estimates of health utility. Differ-
ences were largest 4 weeks after fracture, with average
health utility estimates of 0.63 and -0.07 for TTO and EQ-
5D, respectively. Differences decreased at 1 year post frac-
ture (Fig. 1). The correlation coefficient for the health utility
loss over 12 months, using Spearman's correlation, for the
two instruments was 0.42 (p<0.05).
Conclusion(s): Osteoporotic hip fractures give rise to sig-
nificant loss of health utility, irrespective of instrument used.
However, there are substantial differences in the extent of
average health utility decrease between the instruments.
This can mainly be explained by the difference in the
underlying preferences between the two instruments. The
direct TTO reflects the patients' own perceptions of the
utility in the current health state whereas the EQ-5D reflects
a healthy population's preferences of impaired health.
Disclosures: ICUROS is co-sponsored by IOF Invest in
Your Bones (IYB), Amgen, Eli Lilly, Medtronic, Novartis,
Sanofi-Aventis, Servier, and Pfizer.
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WATER CONTENT, CALCIUM AND PHOSPHORUS
IN THE REGENERATE OF BONE FORMED IN
DEFECTS AREA AGAINST A BACKGROUND
OF STREPTOZOCIN DIABETES
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Vladyslav I Luzin, Andrey V Ivchenko, Anton V Yeryomin
SI "Lugansk State Medical University", Human Anatomy,
Lugansk, Ukraine
Objective(s): To study the chemical composition of the
regenerate of bone tissue that formed at the site of the defect
on the background of Streptozocin diabetes in mature age
rats.
Material & Methods: The experiment was performed on
105 white rats (males) with an initial mass of 136.00±2.64 g
for the initiation of diabetes (diabetic) rats, we injected Strep-
tozocin (2-deoxymethyl-nitrosocarbamide-glucopyranose).
Results: Applying of perforated defect on the tibia on the
background of Streptozocin diabetes compared with rats
without diabetes at 7-day observation was accompanied by
a decrease in water content of 8.64% in regenerate. From
15-90 days and water content increased and was greater than
the rates of the control group according to 10.13%, 15.46%,
18.63% and 15.17%. Proportion organic matter in the period
from 15-90 days was less than control values (group of
defect without diabetes), respectively 9.89%, 11.52%,
7.76% and 3.33%, while the share of mineral component -
in the period from 30-90 days of observation - by 2.77%,
6.64% and 6.41%. After application of a defect on the
proximal tibia metaphysis macroelement composition of
regenerate characterized by the following features: 7-day
calcium and phosphorus was smaller than the rates of ani-
mals of the control group to 25.04% and 31.39%. Since the
phosphorus content decreased more, this led to an increase
in calcium-phosphorus ratio of 8.98%.
Conclusion(s): Applying of perforated defect on the back-
ground of Streptozocin diabetes accompanied by growth wa-
ter content and decreasing the share of organic and mineral
substances in regenerate. Calcium content was less than the
benchmarks on the 15-60 days of experiment, and vice versa
phosphorus was greater than the benchmarks from the 7-60
days. As a result, the ratio of calcium / phosphorus was less
than control at the same time at 8.20%, 8.25%, 11.09% and
10.75%. This may be evidence of increased bone mineral
regenerate amorphous. Applying a defect on the background
of Streptozocin diabetes in mature age rats accompanied by an
imbalance of macroelement composition of regenerate, indi-
cating that inhibition of its formation processes.
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THE U.S. NATIONAL BONE HEALTH ALLIANCE:
BONE TURNOVER MARKER STANDARDIZATION
AND HARMONIZATION PROJECT
David Lee1, Michelle Payette2
1National Bone Health Alliance, Executive Office, Washing-
ton, DC, 2Roche Diagnostics, Scientific Affairs, Indianapo-
lis, IN, US
Objective(s): There has been a call for advancing the field
of bone turnover markers from a number of national and
international groups, including the International Osteoporo-
sis Foundation (IOF), International Federation of Clinical
Chemistry and Laboratory Medicine (IFCC) and the U.S.
National Osteoporosis Foundation (NOF). The scientific
triad of standardization, harmonization and reference popu-
lation databases are recognized as vital steps towards wider
clinical utilization of bone turnover markers for the man-
agement of osteoporosis.
Material & Methods: This project will standardize U.S.
bone marker sample collection procedures, establish a U.S.
reference range for one bone formation (serum procollagen
type I N propeptide, s-PINP) and one bone resorption (serum
C-terminal telopeptide of type I collagen, s-CTX) marker and
standardize bone turnover marker assays used in clinical lab-
oratories. This effort will allow U.S. clinicians to have confi-
dence in their use of bone turnover markers to help monitor
osteoporosis treatment and assess future fracture risk. This
project builds on the recommendations of the IOF/IFCC Bone
Marker Standards Working Group by developing U.S. refer-
ence standards for PINP and CTX, the markers identified as
most promising for use as reference markers (see reference).
This project is being coordinated by the U.S. National Bone
Health Alliance (NBHA), a public-private partnership that
includes 33 members representing industry, academia and
non-profits (in addition to 3 government agencies).
Results: This project is anticipated to be completed in 2012;
a position paper elucidating the goals and activities of this
project will be published in early 2012 in Osteoporosis
International (with companion and follow-on papers to be
published in Clinical Chemistry and Osteoporosis Interna-
tional, respectively).
Conclusion(s): Successful completion of this project in
2012 will help assure U.S. health professionals of the clin-
ical utility of bone turnover markers and ties in with the
parallel effort of the IOF/IFCC to develop worldwide bone
turnover reference ranges.
References: Vasikaran S, Eastell R, Bruyere O, et.al.
Markers of bone turnover for the prediction of fracture risk
and monitoring of osteoporosis treatment: a need for inter-
national reference standards. Osteoporos Int 2011
Disclosures: This effort was supported in part by Roche
Diagnostics, Eli Lilly & Co., Inc., and the organizational
members of the National Bone Health Alliance.
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BENEFICIAL EFFECTS OF STRONTIUM
RANELATE COMPARED TO ALENDRONATE
ON TRABECULAR BONE SCORE IN POST
MENOPAUSAL OSTEOPOROTIC WOMEN:
A 2-YEAR STUDY
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Didier Hans1, Marc-Antoine Krieg1, Olivier Lamy1, Dieter
Felsenberg2
1Lausanne University Hospital Center of Bone Diseases,
Bone and Joints Department, Lausanne, Switzerland, 2Charité
Campus Benjamin Franklin, Klinik und Poliklinik für
Radiologue und Muklearmedizin, Berlin, Germany
Objective(s): Trabecular Bone Score (TBS, Med-Imaps,
France) is an index of bone architecture independent of BMD
calculated by quantifying local variations in grey level from
anteroposterior spine DXA scan and reported to be associated
with fracture in prior case-control and prospective studies1. We
compared the effects of strontium ranelate (SrRan) and alendr-
onate (ALN) on spine architecture patterns as assessed by TBS
in women with postmenopausal osteoporosis.
Material & Methods: A post hoc analysis was performed
on DXAs (Hologic and GE Lunar Devices) from 79 women
out of 189 included in a double blind, double dummy study
and randomized to SrRan 2 g/day or ALN 70 mg/week
during 2 years2. Spine TBS parameters were assessed by
TBS iNsight (v1.9) at the spine after 12 and 24 months of
treatment. We applied ISCD rules for individual vertebrae
exclusion independently for BMD and TBS, respectively.
Since duplicate measurements were performed at baseline,
precision were calculated as CV%.
Results: Baseline characteristics (mean±SD) were similar
between groups in term of age, 69.2±4.4 years; BMI,
23.8±4.4 kg/m2; L1-L4 T-score, -2.9±0.9 and TBS
1.230±0.09. As expected, the correlation between Spine
BMD and TBS was very low with r2=0.12. Precision
errors were 1.1% and 1.6% for spine BMD and TBS,
respectively. Over 1 and 2 years, L1-L4 BMD increased
significantly by 5.6% and 9% in SrRan group and by
5.2% and 7.6%, respectively in ALN group. Similarly,
spine TBS increased by 2.3% (p<0.001) and 3.1% (p<
0.001) in SrRan group and by 0.5% (ns) and 1.0% (ns)
respectively in ALN group with a significant between-group
difference in favor of SrRan (p=0.04 and p=0.03). There
were no correlation between delta BMD and TBS at 1 year
or at 2 years. The two treatments were well tolerated.
Conclusion(s): SrRan has greater effects on bone archi-
tecture index at the spine compared to alendronate in
women with postmenopausal osteoporosis after 2-year
treatment. These results consolidate previous studies sup-
porting a benefit of SrRan on bone architecture.
References: 1. Hans D. et al. J BoneMiner Res 2011;26:2762.
2. Felsenberg D. et al. Osteoporos Int 2011;22(suppl. 1):S102.
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SURGICAL TREATMENT FOR DISTAL TIBIAL
SHAFT FRACTURES IN OSTEOPOROTIC
PATIENTS
Cirstoiu F Catalin1, Popescu Dan1, Ene Razvan1, Cirstoiu
Monica2, Popescu Anca3
1Universitary Emergency Hospital, Orthopedic-Traumatol-
ogy, 2Obstetrics-Gynecology, 3Endocrinology, Bucharest,
Romania
Objective(s): Comparison of immediate postoperative and
follow-up results after surgical treatment of fractures of the
distal tibial shaft by intramedullary nail osteosynthesis vs.
plate and screws in osteoporotic patients.
Material & Methods: In the Orthopedics-Traumatology
Clinic of the Bucharest Emergency University Hospital,
between 2008-2011 were performed 23 surgeries for distal
tibia and fibula fractures according patients with osteoporosis.
Patients were aged between 57-78 years. Sex ratio M/F=10/
13. The diagnosis of osteoporosis was established using DXA
for BMD measurements. In 14 cases closed reduction was
performed (±reaming) and locked intramedullary nail osteo-
synthesis and in 9 cases we performed open reduction and
moulded plate osteosynthesis. After the orthopedic interven-
tion, BMDwas measured at lumbar spine and proximal femur
using DXA with results suggestive for low bone mass.
All these patients were included into a program aiming
to prevent further bone loss using different therapeutic
strategies (hormonal replacement therapy or bisphosph-
onate therapy associated with calcium and vitamin D
supplements) They all made periodical medical checks
and radiological evaluation at 6 weeks, 3, 6, 12 and 18
months postoperator. DXA scan was performed in all
patients 1 year after initial evaluation.
Results: For intramedullary nail osteosynthesis with
minimally invasive approach though it achieved an im-
perfect reduction of fracture, in terms of consolidation
and evolution the functional outcome was superior. If a
large approach was used and fracture reduction was
perfect, complications were recorded: delay in the con-
solidation or pseudarthrosis.
Conclusion(s): If the fracture type allow distal nail locking,
we recommend intramedullary nail osteosynthesis for distal
tibial shaft fractures.
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MORPHOMETRIC PARAMETERS OF THE TIBIA
IN WHITE RATS FOLLOWING INHALATION
EFFECTS OF TOLUENE
Vladyslav I Luzin, Evgeniy Yu Shutov, Andrey N
Skorobogatov, Anton V Yeryomin
SI "Lugansk State Medical University", Human Anatomy,
Lugansk, Ukraine
Objective(s): To study the growth characteristics of the tibia
white rats after a 60-day inhalation poisoning with toluene.
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Material & Methods: An experimental study was carried
out on 180 white mongrel adult male rats in the SI "Lugansk
State Medical University" and kept in accordance with the
requirements and provisions established the "European Con-
vention for the Protection of Vertebrate Animals used for
experimental and scientific purposes." Tibias were removed
at 1, 7, 15, 30, 60 days after the completion of a 2-month
exposure of toluene and measured by the method of W.
Duerst.
Results: It was reported slowdown in the longitudinal and
apposition of bone growth in all subjects, which was the
highest since the 1st to the 15th day after the cessation of
inhalation cycle and subsequently slightly smoothed. Thus,
the maximum length of the tibia were smaller than those in
the control animals in all observation periods, respectively
set at 4.15%, 4.47%, 2.67%, 3.35% and 3.41%. The trans-
verse dimensions of the tibia were also lower than in intact
rats, all the times of the experiment: the width of the prox-
imal epiphysis of 3.69%, 4.14%, 5.77%, 4.49% and 2.84%
(p>0.05), respectively, of the distal epiphysis - at 11.94%,
7.78%, 10.75%, 10.00% and 6.86% (p>0.05). As with the
previous parameters, width and anteroposterior size of the
mid-diaphysis decreased by 6.82%, 6.72%, 7.01%, 5.82%
and 6.05% and 12.31%, 10.14%, 9.80%, 8.65% and 7.11%,
respectively. Study the rate of apposition growth showed
that the width and anteroposterior size of the midtibial shaft
of old animals were lower than in intact animals, all the
times of the experiment, respectively, at 4.92%, 5.08%,
4.06%, 4.37% and 4.98%, and 6.37%, 5.08%, 5.88%,
3.85% and 3.32%. The width of the distal epiphysis of
tibiae was less than control values from 1-30 days of
the experiment, respectively, at 11.37%, 5.00%, 5.91%
and 4.74%.
Conclusion(s): Inhaled toluene poisoning leads to a slow-
down in both longitudinal and apposition of bone growth.
The identified changes are seen at 1, 7 and 15 days after
poisoning with toluene inhalation with a tendency to a
levelling of 30 and 60 days.
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NERIDRONATE TREATMENT IN CHILDREN
WITH OSTEOGENESIS IMPERFECTA (OI): THE
EFFECTS ON BONE MINERAL DENSITY (BMD)
AND VERTEBRAL DEFORMITIES
Daniele Diacinti1, Daniela Pisani2, Mauro Celli3, Anna
Zambrano3, Patrizia D'Eufemia3, Davide Diacinti1, Elisabetta
Romagnoli4, Salvatore Minisola4
1University Sapienza, Department of Radiology, 2Sant'Andrea
Hospital University Sapienza, Department of Clinical and
Molecular Medicine, 3University Sapienza, Department of
Pediatrics, 4University of Sapienza, Department of Clinical
Sciences, Rome, Italy
Objective(s): To evaluate the effects of neridronate treat-
ment on bone mass and vertebral deformities in children
with OI.
Material & Methods: In 66 children (34 F, 32 M; age 1-12
aa), with OI (types I,III e IV) in therapy with neridronate
(2 mg/kg i.v. every 3 months), were evaluated lumbar bone
mass (BMD e BMAD) and vertebral deformities by radio-
graphs and DXA using QDR4500A (Hologic, Inc., Bedford,
MA, USA),. Vertebral deformities were evaluated by semi-
quantitative assessment (SQ) of radiographs and by mor-
phometric X-ray absorptiometry (MXA) calculating
wedging index [(1-ah/ph)x100%] and concavity index [(1-
mh/ph)x100%]
Results: A significant increase of BMD was observed after
24 months of therapy, from 0.08±0.01 to 0.09±0.01
(+17.1%; p<0.01); the indexes of vertebral deformity were
both significantly (p<0.01) reduced (wedging :-8.64%; bi-
concavity: -10.2%) and inversely correlated to the BMD
(r=-0.372) and to the BMAD (r=-0.376). Vertebral de-
formities were 196 by SQ and 139 by MXA at baseline;
after 24 months of therapy vertebral fractures decreased
at 162 by SQ and 104 by MXA.
Conclusion(s): Our data demonstrates the effectiveness of
the therapy with neridronate increasing the bone density and
improving the indexes of vertebral deformity. So we suggest
the use of MXA (low-dose method), in the follow-up for the
children with OI for the evaluation of vertebral deformities.
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ASSOCIATION BETWEEN HANDGRIP
STRENGTH AND BODY COMPOSITION IN MEN
Asta Mastaviciute1, Marija Tamulaitiene1,3, Vidmantas
Alekna1,2, Vaidile Strazdiene2
1Vilnius University, Faculty of Medicine, 2National Osteopo-
rosis Center, 3State Research Institute Centre for Innovative
Medicine, Vilnius, Lithuania
Objective(s): The aim of the study was to investigate the
association of handgrip strength with body composition in
underweight, normal and obese men.
Material & Methods:Men (n=268) aged 40 years and older
were included in this cross-sectional study. Exclusion criteria
were metabolic or endocrine disorders known to affect mus-
culoskeletal system and restriction of movement in the upper
extremities. The subjects performed three maximum attempts
for dominant handgrip strength measurements with handle
dynamometer and the mean value of these trials was recorded
in kilogram (kg). DXAwas used to measure fat mass, body fat
percentage (%BF), total BMD and lean mass (iDXA, GE
Lunar). All subjects were divided into three groups according
to BMI: <22 kg/m2 – underweight, BMI range 22-29.9 kg/m2
– normal, and BMI≥30 kg/m2 – obese. The significance of
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difference between handgrip strength and body composition
among BMI groups was tested by one-way analysis of vari-
ance (ANOVA). Differences between groups at the 5% sig-
nificance level (p<0.05) were assessed by LSD post hoc
probability test for multiple comparisons. Pearson's correla-
tion coefficient was calculated.
Results: Of all men investigated, 18 subjects (6.7%) were
underweight, 184 (68.7%) – normal and 66 (24.6%) were
obese. Using one-way ANOVA test statistically significant
differences of handgrip strength, fat mass, %BF, total BMD
and lean mass were found between BMI groups. In obese
men handgrip strength (41.3±13.9 kg), fat mass (34.7±7.9
kg), %BF (35.6±5.3%), lean mass (61.8±6.3 kg), and total
BMD (1.264±0.137 g/cm2) were statistically significantly
higher comparing with underweight and normal men. Hand-
grip strength was statistically significantly related to leanmass
in all BMI groups, and the strongest correlation was found in
underweight men (r=0.63, p=0.017). There was a weak cor-
relation of handgrip strength with total BMD (r=0.34,
p=0.001) and negative correlation with %BF (r=-0.28,
p=0.02) in normal BMI group. No relationships were found
in underweight and obese subjects.
Conclusion(s): Although the lean mass was greater in obese
subjects, the most significant correlation between handgrip
strength and lean mass was found in underweight men.
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EARLY DETECTION OF BONE METASTASES
FROM NONSMALL CELL LUNG CANCER USING
SERUM CARBOXYTERMINAL TELOPEPTIDE
(CTX) AND AMINOTERMINAL (PINP) OF
TYPE I COLLAGEN MEASUREMENT:
PRELIMINARY RESULTS
Franco Lumachi1, Laura Loriggiola2, Filippo Marino3,
Giordano B Chiara4, Stefano MM Basso5
1University of Padua, School of Medicine, Department of
Surgical & Gastroenterological Sciences, 2University of
Padua, School of Medicine, 3University of Padua, School
of Medicine, Department of Pathology, Padova, 4S. Maria
degli Angeli Hospital, Chirurgia 1, 5S. Maria degli Angeli
Hospital, Chirurgia 1, Pordenone, Italy
Objective(s): Nonsmall cell lung carcinoma (NSCLC) is the
most common lung cancer, which represents the major
cause of cancer death worldwide. The early diagnosis of
NSCLC is difficult, and the sensitivity of common serum
tumor markers, such as carcinoembryonic antigen (CEA)
and fragments of cytokeratin 19 (CYFRA 21-1), is low.
Unfortunately, bone metastases (BMs) are common in
patients with NSCLC, and their early detection and treat-
ment may improve both disease-free interval and survival.
Several serum biomarkers have been proposed for the
detection of BMs, such as carboxyterminal telopeptide of
type I collagen (CTX), tartrate-resistant acid phosphatase
isoform type 5b (TRAP5b), and amino-terminal propeptide
of type I collagen (PINP), which are markers of bone re-
sorption. The aim of this preliminary study was to evaluate
the usefulness of a panel of serum biomarkers in patients
with NSCLC and BMs.
Material & Methods: Sixteen patients (11 males, 5
females, median age 64 years, range 54-68) with NSCLC
and BMs (cases), and 18 age- and gender-matched patients
without BMs (controls) underwent serum CTX, TRAP5b,
PINP, CEA, and CYFRA 21-1 measurements. CTX was
measured by automated immunometric assay, TRAP5b and
CEA by two-site ELISA, PINP by radioimmunoassay, and
CYFRA 21-1 by immunochemiluminescent assay. The cut-
off values were 400 pg/mL (CTX), 5 U/L (TRAP5b), 3.5
ng/mL (CEA), 65 μg/L (PINP), and 45 pg/mL (CYFRA 21-
1), respectively.
Results: CTX (443.7±945.1 vs. 402.7±28.4 pg/mL, p=
0.003), and PINP (75.9±11.4 vs. 64.1±7.5 μg/L, p=
0.001), were significantly higher in patients with BMs,
while the other markers did not differ (p=NS) between cases
and controls. The sensitivity, specificity and accuracy were
73.7%, 86.7%, and 79.4% (OR=18.2, 95% CI 2.99-
110.7, p<0.0001) for CTX; 30.4%, 76.2%, and 67.6%
(OR=6.22, 95%CI 1.06-36.5, p=0.038) for TRAP5b; 72.2%,
81.2%, and 76.5% (OR=11.26, 95%CI 2.21-57.20, p=0.002)
for PINP; 55.5%, 62.5%, and 58.8% (OR=2.08, 95%CI 0.53-
8.23, p=0.29) for CEA; 65.0%, 78.61%, and 70.6% (OR=
6.81, 95% CI 1.41-32.8, p=0.012) for CYFRA 21-1,
respectively.
Conclusion(s): In patients with NSCLC, both CTX and
PINP measurements can be useful in the detection of BMs.
References: Horiguchi T, et al. Jpn J Clin Oncol 30:174;2000.
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ASSOCIATION BETWEEN BONE TURNOVER
MARKERS AND LIPID PROFILE IN MEN
AND WOMEN
Vidmantas Alekna1,2, Rima Piliciauskiene1,2, Marija
Tamulaitiene2,3
1State Research Institute Centre for Innovative Medicine,
2Vilnius University, Faculty of Medicine, 3National Osteo-
porosis Center, Vilnius, Lithuania
Objective(s): The aim of this study was to evaluate the
relationship between bone turnover markers and serum lip-
ids: total cholesterol, HDL, LDL and triglycerides.
Material & Methods: This was the cross-sectional study of
subjects aged 60 years who had visited the National Osteo-
porosis Center (Vilnius, Lithuania). The exclusion criteria
were: fracture within previous 12 months, known cancer and
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diseases affecting bone turnover except untreated osteopo-
rosis, treatment with medications acting on bone turnover or
on lipid profile. Blood samples were obtained between 9-11
a.m. after 12 h fasting. Serum bone resorbtion marker C-
telopeptide of type I collagen crosslinks (s-CTX-I), type I
procollagen amino-terminal propeptide (PINP) and PTH
were measured by automated immunoassay (Cobas e411,
Roche Diagnostic) and serum lipids were analyzed by
ADVIA 1800 (Siemens Medical Solution). Mann-Whitney
U test and Spearman's correlation methods were used for
statistical analysis.
Results: Participants included 134 men and 160 women.
There were no significant differences in age and BMI be-
tween genders. Total cholesterol, HDL and LDL were sta-
tistically significantly lower in men than in women.
Triglycerides negatively associated with s-CTX-I and PINP
only in women when all data were analyzed. Subjects of
both genders were divided into three age groups: 60-69
years (56 men and 60 women), 70-79 years (46 men and
62 women) and over 80 years (32 men and 38 women). The
analysis of the associations between lipids and bone turn-
over markers in different age groups indicated negative mod-
erate correlation of triglycerides with s-CTX-I (r=-0.45,
p<0.01) and PINP (r=-0.38, p=0.05) in men aged 60-69
years. No significant correlations were found in other age
groups. In women the most significant correlations were
found in two age groups: triglycerides associated with s-
CTX-I in group 70-79 years (r=-0.33, p<0.01), and with
PINP in 60-69 years group (r=-0.39, p<0.01).
Conclusion(s): Triglycerides negatively correlated with
bone turnover markers s-CTX-I and PINP in women over
60 years and in men at the age of 60-69 years.
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USING QUS FOR FRACTURE PREDICTION –
AFTER FRAX, OR TOGETHER?
Csaba Horvath1, Viktoria Ferencz1, Adam Tabak1, Szilvia
Meszaros1, Boglarka Vandrus1, Katalin Bors2, Edit Toth3,
Emoke Csupor4, Eva Hosszu5
1Faculty of Medicine, Semmelweis University, 1st Depart-
ment of Internal Medicine, Budapest, 2Rehabilitation Hospi-
tal, Department of Musculoskeletal Rehabilitation, Visegrad,
3Ferenc Flor County Hospital, Department of Rheumatology,
Kerepestarcsa, 4Budavar Local Authorities, Department of
Endocrinology, Budapest, 5Faculty of Medicine, Semmelweis
University, 2nd Department of Pediatrics, Budapest, Hungary
Objective(s): Major bone properties determining bone fra-
gility are bone mass and size, microstructure and quality of
bone. Treatment decisions were based on decreased bone
mass until the very last time. Recently FRAX method has
become widely accepted as intervention threshold. FRAX
calculation covers the main clinical risk factors which are
dependent or independent of bone density. Alas, microstruc-
ture or bone quality have not been involved into the deci-
sion-making process – neither in the past nor in the FRAX-
era. However, QUS of bone varies not only by decreased
bone density but also by changes in trabecular structure and
by decreased elasticity. The aim of this study was to com-
pare the contribution of QUS and BMD to the fracture
probability calculation by FRAX.
Material & Methods: 209 untreated postmenopausal wom-
en were involved, 77 with and 132 without fracture. Spine
and hip BMD was measured by DXA (Prodigy, GE Lunar).
Heel ultrasound for BUA, SOS and Stiffness was made by
Achilles InSight (GE Lunar). FRAX calculation based on
Hungarian data was also done. SPSS was used for correla-
tion analysis, linear and logistic regression evaluations.
Results: According to BMD, 71 normal, 104 osteopenic and
34 osteoporotic women were studied. Hip BMD correlated to
fracture probability for major fractures (r=-0.277, p<0.001)
and for hip fractures (-0.250, <0.001). A very similar correla-
tion was found between Stiffness and fracture probability
(-0.245, <0.001 and -0.245, <0.001). Both the hip BMD and
Stiffness had an independent contribution to the FRAX values
for both types of calculation. Fracture probability increase for
1 SD was found as follows (95% CI): hip BMD 0.86-1.77,
stiffness 0.48-0.89, FRAX major OP fx 1.17-1.35, FRAX hip
fx 1.22-1.56.
Conclusion(s): The correlation of QUS to fractures seems
to be equal to that of BMD to fractures, however, heel
Stiffness predicts fractures independently of hip density.
The power of QUS to predict fractures lies on a comparable
level to the predicting power of FRAX. Taking into consid-
eration the different source of fragility information provided
by ultrasound, our results suggest that implication of QUS
into the FRAX calculation system promises a more sensitive
tool for treatment decisions.
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THE EFFICACY AND SAFETY OF IBANDRONIC
ACID FOR INTRAVENOUS ADMINISTRATION FOR
TREATMENT OF SEVERE SYSTEMIC
OSTEOPOROSIS IN PATIENTS WITH JUVENILE
ARTHRITIS
Ekaterina I Alexeeva, Rina V Denisova, Tatyana M Bzarova,
Saniya I Valiyeva, Tanya V Sleptsova, Elena V Mitenko
Scientific Centre of Children's Health, Rheumatology,
Moscow, Moscow Region, Russian Federation
Objective(s): To evaluate the efficacy and safety of iban-
dronic acid for intravenous administration for treatment of
severe systemic osteoporosis in patients with juvenile
arthritis.
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Material & Methods: The study included 25 patients with
juvenile arthritis at the age of 7-17 years (10 girls, 15 boys),
including 20 patients with systemic arthritis, 3 with
polyarthritis, 2 with ankylosing spondylitis. The mean
age was 12.5 (10.5, 14.0) years. Was allocated to 2
groups: 17 children treated with glucocorticoids (GC)
and 8 not receiving GC. Children of the first group had 12
vertebral fractures and patients of the 2-d group - 1. Ibandronic
acid was administered intravenously at a dose of 3 mg every
12 weeks. Evaluation of treatment efficacy was conducted by
a combined index of BMD of tissue Z-score, assessing the
patient / parent to the severity of pain on a visual analog scale,
serum markers of bone resorption C-terminal telopeptide.
Results: The treatment of ibandronic acid in children of both
groups was marked increase in BMD. In patients treated with
GC, a statistically significant increase was registered in 76
weeks of therapy (p<0.01), while the second group of chil-
dren - through 46 and 76 weeks (p<0.05). Within 6 months of
treatment in both groups of ibandronic acid was a statisti-
cally significant reduction in pain index (p<0.05), after
a year of treatment with this trend persisted (p<0.001). In
both groups, reducing the concentration of C-terminal telo-
peptide in serum were detected through 52 weeks of treatment
(p<0.05). After 76 weeks of treatment new vertebral fractures
and fractures of the peripheral skeleton are not fixed. Tolera-
bility of therapy ibandronic acid in patients was satisfactory.
Conclusion(s): In the course of the study has identified high
efficacy and an acceptable tolerability ibandronic acid for
treatment of severe systemic osteoporosis in patients with
juvenile arthritis
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MORPHOMETRIC PARAMETERS OF THE HIP
BONE IN WHITE RATS FOLLOWING
INHALATION EFFECTS OF TOLUENE
Vladyslav I Luzin, Evgeniy Yu Shutov, Andrey N
Skorobogatov
SI "Lugansk State Medical University", Human Anatomy,
Lugansk, Ukraine
Objective(s): To study the growth characteristics of the hip
bone of white rats after a 60-day inhalation poisoning with
toluene.
Material & Methods: An experimental study was carried
out on 180 white mongrel adult male rats in the SI "Lugansk
State Medical University" and kept in accordance with the
requirements and provisions established the "European Con-
vention for the Protection of Vertebrate Animals used for
experimental and scientific purposes." Tibias were removed
at 1, 7, 15, 30, 60 days after the completion of a 2-month
exposure of toluene and measured by the method of W.
Duerst.
Results: The slowdown in the longitudinal and apposition
of bone growth in all subjects, which was the highest since
the 1st to the 15th day after the cessation of inhalation cycle
was observed after a 60-day inhalation of toluene vapors.
However, 60 days after ending the cycle of inhaled toluene
credible deviations still remained. The maximum width of
the hip bone was lower than in intact animals and in all the
times of the experiment, respectively, at 6.06%, 6.19%,
6.89%, 4.87% and 5.53% (p>0.05). However, after a 60-
day inhalation of toluene vapor the maximum thickness of
the hip bone was less than control values of group 1 to the 1,
30 and 60 days of the experiment at 5.02%, 4.78% and
10.45%. The maximum width of the hip bones of animals
of group 5 was less than control values to the 1 and 7 day
experiment at 4.38% and 4.09% and a maximum thickness -
to 30 day at 4.44%. In these conditions the maximum width
of the hip bone was lower than in intact animals, to the 1 and
7 day experiment, respectively 4.04% and 4.09%, while its
maximum thickness - to 15 day at 4.03%.
Conclusion(s): Revealed changes in the hip bone appear at
1, 7 and 15 days after poisoning with toluene inhalation with
a tendency to a levelling of 30 and 60 days.
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THE U.S. NATIONAL BONE HEALTH ALLIANCE:
A MULTISECTOR PUBLIC-PRIVATE
PARTNERSHIP WORKING TOGETHER TO
IMPROVE AMERICA'S BONE HEALTH
David Lee
National Bone Health Alliance, Executive Office, Washington,
DC, US
Objective(s): The U.S. National Bone Health Alliance
(NBHA) is a public-private partnership launched in late
2010 that includes 33 members representing industry, aca-
demia and the nonprofit sectors, in addition to three U.S.
government agencies: the Centers for Disease Control and
Prevention, Food and Drug Administration and National
Institutes of Health. NBHA develops projects in bone health
awareness, prevention, research, diagnosis and treatment
and advocacy.
Material & Methods: Among the major initiatives of the
NBHA is the implementation of a fracture liaison service
(FLS) model of secondary osteoporosis care to reduce the
incidence of secondary fractures and increase osteoporosis
screening and treatment rates while also reducing costs.
NBHA has requested funding from the U.S. Centers for
Medicare & Medicaid Services to implement an FLS pro-
gram at 70 to 100 sites nationwide. In addition, NBHAwill
launch an awareness campaign in mid-2012 to highlight the
connection between osteoporosis and fracture, especially
with patients who have suffered a fracture. A third project
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under development is an effort, building on the recommen-
dations of the International Osteoporosis Foundation (IOF)/
International Federation of Clinical Chemistry and Labora-
tory Medicine (IFCC) Bone Marker Standards Working
Group, to standardize U.S. bone marker sample collection
procedures, establish a U.S. reference range for one bone
formation (PINP) and one bone resorption (CTX) marker
and standardize bone turnover marker assays used in clinical
laboratories. NBHA also serves as an advocate on topics
important to bone health, most notably vitamin D, calcium,
DXA reimbursement and utilization and the long-term use
of bisphosphonates and other therapies.
Results: The NBHA brings together the expertise and
resources of partners from the nonprofit, public and for-
profit sectors to work together on efforts that no one sector
or organization can address on their own.
Conclusion(s): The NBHA is a platform that allows all
voices in the bone health community to harmonize to deliver
clear, concise messages about bone health by facilitating
ongoing dialogue among interested individuals and organiza-
tions engaged in bone health activities and identifying shared
priorities and projects that can become reality through pooled
funding.
Disclosures: The organizational members of the NBHA.
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STRONTIUM RANELATE REDUCES PAIN AND
IMPROVES PATIENTS' ABILITY TO COPEWITH
DAILY LIFE REQUIREMENTS IN
POSTMENOPAUSAL OSTEOPOROSIS UNDER
REAL LIFE CONDITIONS: RESULTS OF THE NON-
INTERVENTIONAL PERSPECTIVES STUDY
Oliver Bock1, Peter Martinka2, Uta Stege1, Hendrikje
Börst1, Dieter Felsenberg1
1Charité - University Medicine Berlin, Campus Benjamin
Franklin, Centre for Muscle and Bone Research, Berlin,
2Servier Deutschland GmbH, Medical Affairs, München,
Germany
Objective(s): The prospective, noninterventional PER-
SPECTIVES-Study (ProtElos® foR poStmenoPausal ostE-
oporotiC paTIents with preVious thErapieS) examines the
effectiveness of strontium ranelate (SR) in postmenopausal
women with osteoporosis in relation to pain reduction and
improvement of daily life abilities, frequency of falls and
fracture-related treatments under practice conditions.
Material & Methods: 1147 osteoporotic patients were in-
cluded and treated with 2 g SR daily. Pain, analgesics use,
coping with daily life requirements, compliance and tolera-
bility, falls and fracture treatments were analysed descrip-
tively in 1135 patients.
Results: After 3 months of treatment with SR, the overall
pain perception improved by 17%. The pain frequency was
reduced as well, whereas the use of moderate and strong
analgesics declined by 20 and 30%, respectively.
Figure: pain at study entry (M0) und after 3 months of SR
therapy (M3) - percentage of patients with daily or perma-
nent pain (n=1059)
The score reflecting on abilities to cope with daily life
requirements improved by 14%. The incidence of serious
falls, and inpatient/outpatient fracture treatments, decreased
by 57% each. The physicians rated the tolerability in 92.1%
of the patients as very good or good.
Conclusion(s): Under the daily routine practice conditions in
a population including 81.6% of pretreated patients, SR shows
a rapid decrease of pain, reduced use of analgesics, improve-
ment of daily life activities and reduction of fall incidence and
fracture treatment frequency, as compared to previous therapy.
Disclosures: The studywas sponsored by Servier Deutschland
GmbH.
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THE CORRELATION BETWEEN VITAMIN D
STATUS AND FREQUENCY OF VERTEBRAL
OSTEOPOROTIC FRACTURES IN WOMEN WITH
POSTMENOPAUSAL OSTEOPOROSIS
Sasa B Milenkovic, Ivana M Aleksic, Aleksandar N Dimic,
Vlado Skakic, Bojana N Stamenkovic, Sonja K Stojanovic
Institute "Niska Banja", Rheumatology, Nis, Serbia
Objective(s): The purpose of this research was to determine
the status of vitamin D in women that have been recently given
the diagnosis of postmenopausal osteoporosis and to correlate
the status of vitamin D with previous vertebral fractures
Material & Methods: The research included 88 women
who have recently been given the diagnosis of postmeno-
pausal osteoporosis and who haven't taken vitamin D as
prevention of osteoporosis. All the examinees were deter-
mined with the level of 25(OH)D as well as the level of
calcium, phosphorus and alkaline phosphatase in serum and
also level of calcium and phosphorous in 24 h old urine. The
level of 25(OH)D were determined by ELISA method. All
of the examinees were defined with their BMD on the
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lumbar spine, measured with DXA on the Hologic Discov-
ery machine. Obtained results were further analyzed by
Pearson and Spearman's correlation test and student T-test
Results: Average age of the examinees was 62.46±7.35, aver-
age duration of menopause was 14.24±8.35 years and average
value of 25(OH)D was 48.65±12.45 nmol/L. With all examin-
ees the level of Ca, P and ALP in serum and level of Ca and P in
24 h old urine were in reference limits. With previous fractures
there were 21 examinees (23.86%), without fractures there were
67 examinees (76.14%). A statistically significant difference of
the level of 25(OH)D was determined in the examinees with
previous fractures (n=21) in comparison to those with no
fractures (n=67) (36.45±13.18 vs. 49.22±15.26 nmol/L;
p<0.01). In the group of 8 examinees with vitamin D insuf-
ficiency there were 2 examinees with previous fractures
(25%); in the group of 68 examinees with vitamin D deficien-
cy there were 14 (20.58%); and in the group of 12 examinees
with normal status of vitamin D there were 1 examinees with
previous fracture (8.33%). Difference between these frequen-
cies were statistically significant (p<0.01).
Conclusion(s): Our results show that the deficiency and
insufficiency of vitamin D in women with postmenopausal
osteoporosis is a significant risk factor for bone fractures
P484
CLINICAL UTILITY OF THE FRAX® TO PREDICT
NEED FOR RADIOGRAPHIC VERTEBRAL
ASSESSMENT IN POSTMENOPAUSALWOMEN
Sina Esmaeilzadeh, Nurten Eskiyurt, Ekin Sen, Merih
Akpinar, Sevinc E Polat
Istanbul University, Istanbul Faculty of Medicine, Physical
Medicine and Rehabilitation, Istanbul, Turkey
Objective(s): The aim of this study was to assess the rela-
tionship between the WHO fracture risk assessment
(FRAX®) scores and the presence of vertebral fracture in
radiographic assessment among postmenopausal women,
and to predict the utility of FRAX® in clinical practice.
Material & Methods: A total of 4314 women who referred
to the “Osteoporosis Diagnosis & Treatment Unit” during
2001-2011 years were retrospectively evaluated, and 807 eli-
gible postmenopausal women aged 50-85 years were included
in this research. Only the patients who had a DXA measure-
ment on the same densitometer (Lunar DPX-NT) at baseline
were included in the study. The patients who had a history of
medication for osteoporosis, and the patients without vertebral
radiographic assessments were excluded from the study. The
10-year probability of a major osteoporotic fracture and a hip
fracture were estimated the FRAX® designed for Turkey.
Results: The mean age of the patients was 64.7±8.0 (50-83)
years, and the mean of BMI was 28.1±4.7 kg/m2. 13.8% (n=
108) of the patients had at least one osteoporotic fracture in the
dorsal or lumbar spine radiographic assessment according to
the visual semi-quantitative method, and 86.6% (n=699) of
the patients had not any vertebral fractures in the x-ray assess-
ment. There was no significant difference between the patients
who had radiographic fracture and those without it with regard
to age (p=0.442) and BMI (p=0.786). The 10-year probabil-
ity of major osteoporotic fracture was 9.0% for the patients
with vertebral fracture and 7.2% for those without it, and the
risk of major osteoporotic fracture in the patients with verte-
bral fracture was significantly higher than those without it (p<
0.001). Moreover, the 10-year probability of a hip fracture was
significantly (p=0.002) higher for the patients with vertebral
fracture (3.5%) than those without it (2.4%).
Conclusion(s): The 10-year probability of a major osteopo-
rotic fracture and hip fracture estimated by the FRAX® can
be used to predict the presence of vertebral osteoporotic
fracture, and may be effective in reducing the need for the
radiographic assessments in clinical practice.
P485
STRONTIUM RANELATE MAY IMPROVE MILD
FORMS OF OSTEOARTHRITIS IN
POSTMENOPAUSALWOMENWITH
OSTEOPOROSIS
Cirstoiu F Catalin1, Popescu Dan1, Ene Razvan1, Cirstoiu
Monica2, Popescu Anca3
1University Emergency Hospital, Orthopedic-Traumatol-
ogy, 2Obstetrics-Gynecology, 3Endocrinology, Bucharest,
Romania
Objective(s): Osteoporosis and osteoarthritis are frequently
presents in the same patient making therapeutic approach
more difficult and challenging in controlling clinical symp-
toms and prevent severe outcomes. Previous studies showed
that strontium ranelate inhibits subchondral bone resorption
and stimulates cartilage matrix formation in vitro. The purpose
of our study was to determine whether a 2-year treatment with
strontium ranelate could delay the progression of spinal oste-
oarthritis (OA) in postmenopausal women with osteoporosis.
Material & Methods: Our analysis included the 25 post-
menopausal women (age over 68 years old) with osteopo-
rosis and concomitant mild or severe degree of radiological
spine osteoarthritis, randomized to strontium ranelate for a
24-month period. The presence and severity of osteophytes
and sclerosis in the lumbar intervertebral spaces was graded
according to a validated method and an overall OA score
was calculated for each intervertebral space. Back pain and
health-related quality of life were assessed at baseline and
after 2 years. Lumbar x-rays were available at baseline and
over the 2-year treatment period. Cartilage degradation was
evaluated using a validated urinary marker adjusted for
creatinine (CTX-II/cr).
Results: At baseline CTX-II was significantly elevated in
subjects with a history of osteoarthritis. Strontium ranelate
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caused a significant decrease from baseline in CTX-II over a
24-month period whatever the osteoarthritis status and back
pain was significant ameliorated in patients with mild forms
of OAwhile patients with more severe forms of OA showed
a less clinical improvement.
Conclusion(s): The CTX-II profile of changes over 2 years
may reflect efficacy of strontium ranelate against cartilage
degradation suggesting that besides its beneficial effects in
osteoporosis strontium may attenuate the progression and
clinical symptoms of osteoarthritis.
P486
OSTEOPOROSIS AND OSTEOPENIA IN WOMEN
WITH BRONCHIAL ASTHMA
Manana I Zodelava1, Nina G Tskhovrebashvili1, Tamar N
Mamaladze1, Nino SH Tatishvili2, Mari G Tskhovrebashvili3,
Rusudan D Beradze4
1Clinic of Aesthetic, Reconstructive and Plastic Surgery, "Car-
aps Medline", Department of Osteoporosis and Diabetic Foot,
2Railway Central Clinical Hospital, Department of Rheuma-
tology, 3Center of Endocrinology, Metabology and Dietology
"Enmedici", Department of Endocrinology, 4“Interclinic",
Ltd, Department of Endocrinology, Tbilisi, Georgia
Objective(s): Bronchial asthma (BA) is the most common
chronic pulmonary disorder. Treatment may be conveniently
considered as management of the acute attack and day-to-
day therapy. The aim of the study was to evaluate the
influence of treatment on BMD in female patients with BA.
Material & Methods: The study included 67 female patient
aged 37-59 years who had no diseases or states that can induce
BMD, except BA. The patients were divided in two groups: I
group (n=39) those who were untreated with GC and II group
(n=28) those who permanently took oral (5-10 mg prednisone
daily) and inhaled GC (duration of the therapy 5 years).
Patients in both group were monitored for BMD and were
given adequate therapy to prevent bone loss (for 3 years). The
patients underwent questionnaire. BMD measurements were
accomplished by quantitative ultrasound technique Sunlight
Omnisense 7000S. Results were interpreted in accordance
with criteria adopted by the WHO by T-score.
Results: In the I group of women with BA mean BMD was
decreased in 59.3% reflecting osteopenia from moderate to
severe. T-score: distal 1/3 radius -1.6±0.05; midshaft tibia -1.4
±0.1; proximal phalanx of the third finger – 1.7±0.1; II group of
women treated with GC mean BMD was more significant and
reflected osteoporosis in 57,6%. T-score: -3.2±0.07; -2.9±0.1;
-3.4±0.05, respectively. After 3 year treatment for osteoporosis
in both groups of womenBMDwas increased: I group T-score: -
1.3±0.06; 1.1±0.1; -1.5±0.08; II group T-score: -2.6±0.05; -2.4
±0.1; -2.8±0.05, respectively.
Conclusion(s): Women with asthma tend to be at increased
risk for bon loss. In the I group of women with BA there was a
high incidence of osteopenia that increased with the severity of
BA. The long-term use of GC inwomen in the II groupwith BA
caused a marked reduction in BMD and led to development of
osteoporotic fractures. Prevention GC treatment induced effects
on BMD requires suspicion, assessment of bone density, sup-
plemental calcium and vitamin D, and, if indicated bisphosph-
onates and other medicines for osteoporosis to prevent bone
fractures that could compromise the patient's quality of life.
P487
SERUM CONCENTRATION OF 25-OH-VITAMIN D
IN WOMEN WITH RHEUMATOID ARTHRITIS
DEPENDING ON DISEASE ACTIVITY AND
SUNLIGHT EXPOSURE
Katarzyna Gruszecka, Jerzy Swierkot, Agnieszka
Matuszewska, Beata Nowak
Medical Academy, Department of Rheumatology, Wroclaw,
Poland
Objective(s): Rheumatoid arthritis (RA) is a chronic inflam-
matory disease affecting musculoskeletal system. As long-
standing high concentration of pro-inflammatory cytokines
in RA patients has been observed, RA belongs to risk factors
of osteoporosis. Vit. D influence bone metabolism and can
modulate the activity of immunological system by its influ-
ence on tolerance and anti-inflammatory processes. The aim
of the study was the assessment of serum vit. D metabolite
concentration in women with RA. We also looked for the
correlation between serum vit. D metabolite concentration,
disease activity and sunlight exposure.
Material & Methods: 22 females with established diagno-
sis of RA aged 30-72 years entered the study. 25-OH-vit. D
serum concentration was measured using commercial
ELISA test. The measurements were performed twice: be-
fore the introduction of methotrexate (MTX; dose range: 15-
20 mg weekly) and 6 months after the first dose of MTX.
We assumed that months between November and April are
winter months, and months between May-October are with
high sunlight exposure (summer months). RA activity was
measured with ESR-DAS28. High disease activity was de-
fined according to EULAR guidance as DAS28 >5.1.
Results: There was no significant difference in serum 25-
OH-vit. D concentration between months with low and high
sunlight exposure. However, in 16 patients there was an
increase of serum 25-OH-vit. D concentration in summer
months (11/16 reached the statistical significance). Most of
the measurements revealed low serum 25-OH-vit. D con-
centrations: only 2 (9.09%) measurements in summer and
winter months revealed concentrations above the borderline
of normal range (>75 nmol/L), low levels (30-75 nmol/L)
were revealed in 15 (68.18%) measurements in summer
months and 14 (63.63%) in winter months, very low levels
(<35 nmol/L) in 6 (27.27%) measurements in winter months
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and 5 (22.73%) in summer months. After six months of
MTX treatment there was no significant change of serum
concentration of 25-OH-vit. D. In patients with active RA
(DAS28>5.1) 25-OH-vit. D serum concentration was lower
than in patients with lower disease activity (42.27±24.95
nmol/L vs. 54.45±26.92 nmol/L).
Conclusion(s): There was low 25-OH-vit. D serum concentra-
tion independent of sunlight exposure in patients with RA. The
vit. D supplementation should be considered in RA patients.
P488
EVALUATION OF QCT CORTICAL HIP
PARAMETERS IN A CLINICALTRIALWITH
ROSIGLITAZONE: POTENTIAL FOR A NEW
STUDY ENDPOINT
Colin G Miller1, Antonio J Nino2, John P Bilezikian3,
Barbara G Kravitz2, Gitanjali Paul2, Alexander R Cobitz2,
Allison R Northcutt4, Lorraine A Fitzpatrick5
1Bioclinica, Inc., Medical Affairs, Yardley, PA,
2GlaxoSmithKline Pharmaceuticals, Metabolic Pathways
Unit, King of Prussia, PA, 3Columbia University, School of
Medicine, College of Physicians & Surgeons, New York, NY,
4GlaxoSmithKline Pharmaceuticals, Metabolic Pathways
Unit, Research Triangle Park, NC, 5GlaxoSmithKline Phar-
maceuticals, Biopharm R & D, King of Prussia, PA, US
Objective(s): QCT is used extensively to ascertain bone
quality and density. QCT provides 3D information and can
segment trabecular from cortical bone. This is important to
evaluate new therapeutic agents that affect bone metabolism
and to understand the role that each bone compartment plays
in the pathogenesis and prognosis to fracture. Precise assess-
ments of the cortical bone remain elusive. This study
explores the effect of edge definition at different thresholds
at the femoral neck (FN) in vBMD.
Material & Methods: This was a double-blind, randomized
study in postmenopausal women with type 2 diabetes mel-
litus; BMD T-score>-2.5 at FN, lumbar spine (LS), and total
hip (TH). Subjects were randomized to RSG or metformin
(MET) for 52 Weeks (Wk) followed by 24Wk of open-label
MET. At baseline, DXA T-scores were: FN=-0.96±0.91;
TH=-0.02±0.97; LS=-0.55±1.25. Using spiral multidetec-
tor scanners with standard acquisition technique, a subset of
79 subjects underwent QCT scans of the hip at baseline,
after 52Wk of double blind treatment and after 24Wk of
open-label MET. All scans were evaluated centrally and
analyzed using Mindways Software Inc. The% change in
cortical vBMD and cortical thickness (mm) in FN quadrants
(FNQ's) is presented at 3 different thresholds: 350 mg/cm3,
375 mg/cm3, 400 mg/cm3.
Results: The results using different thresholds yielded
changes in similar direction in cortical vBMD and cortical
thickness at the superior-posterior quadrant. Cortical vBMD
at the FN can be precisely segmented from trabecular bone
and used to demonstrate therapeutic effect on this bone
compartment.
Change in Hip Cortical vBMD Via QCT at 3 Different Thresholds
A.% Change in Hip Cortical vBMD Via QCT at 3 Different Thresholds
Superior-Posterior FN Quadrant
Cortical vBMD (mg/cm3)
350 mg/cm3 375 mg/cm3 400 mg/cm3
Adjusted*% Change
Mean(SE)
Adjusted*% Change
Mean(SE)
Adjusted*% Change
Mean(SE)
RSG MET RSG MET RSG MET
BL to Wk52 -1.29(1.18) 0.10(1.34) -1.11(0.77) -0.21 (0.87) -0.95 (0.74) -0.13 (0.83)
BL to Wk76 -0.33(1.14) -0.32 (1.40) -0.28 (0.70) -0.81 (0.85) -0.44 (0.68) -0.82 (0.83)
Wk52 to Wk76 Open-Label MET 0.94(0.98) -0.01 (1.20) 0.73 (0.75) -0.58 (0.91) 0.41 (0.73) -0.64 (0.88)
B. Change in Hip Cortical Thickness Via QCT at 3 Different Thresholds
Superior-Posterior FN Quadrant
Cortical Thickness (mm)
350 mg/cm3 375 mg/cm3 400 mg/cm3
Adjusted* Change
Mean(SE)
Adjusted* Change
Mean(SE)
Adjusted* Change
Mean(SE)
RSG MET RSG MET RSG MET
BL to Wk52 -0.09 (0.07) 0.05 (0.08) -0.10(0.04) 0.06(0.05)1 -0.10 (0.04) 0.04 (0.05)3
BL to Wk76 -0.06 (0.07) 0.02 (0.08) -0.07(0.04) -0.03(0.05) -0.05 (0.04) -0.03 (0.05)
Wk52 to Wk76 Open-Label MET 0.03(0.06) -0.02 (0.07) 0.03(0.05) -0.11(0.06)2 0.04 (0.05) -0.09 (0.05)4
*Adjusted for baseline value, region and prior therapy
1. P =0.0071 for treatment comparison (RSG –MET)
2. P=0.0423 for treatment comparison (RSG –MET)
3. P=0.0137 for treatment comparison (RSG –MET)
4. P=0.0459 for treatment comparison (RSG –MET)
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Conclusion(s): FNQ may provide utility as an endpoint in
clinical trials for the elucidation of the therapeutic effect of
new entities.
P489
INFLUENCE OF HLA CLASS II ANTIGEN (DR; DQ)
ON THE PRODUCTION OF RHEUMATOID
FACTOR IN A TUNISIAN POPULATION
Boussaid Soumaya, Kochbati Samir, Boussema Fatma,
BaiLi Lilia, Rokbeni Lilia
Habib Thameur Hospital, Internal Medicine, Tunis, Tunisia
Objective(s): The most important genetic risk factor for
rheumatoid arthritis (RA) is the HLA-class II alleles. In
particular, the HLA-DRB1 alleles. The aim of this study is
to focus on the association between seropositive RA and
HLA class II gene (DRB1 and DQB1).
Material & Methods: This prospective study was performed
on a total of 81 Tunisian patients with rheumatoid arthritis
including 67 women and 14 men (sex ratio 4.78). All patients
fulfilled the American College of Rheumatology (ACR 1987)
criteria for RA. RA associated with other autoimmune pathol-
ogies have been excluded from the study. For each patient we
assessed DNA and serum samples. The DNA was extracted
from lymphocytes using a commercial kit (Qiagen). The HLA
class II (DQB1 and DRB1) was performed by PCR technique
specifying-sequence primers (PCR-SSP). The specific prod-
ucts of PCR were analyzed by 2.5% agarose gel electropho-
resis. All tests include positive and negative controls
appropriate for each blood sample. The phenotypes of patients
were obtained through the Software One Lambda DNA /
Software (SSP2L-generic DRB / DQB).
Results: Demographic traits of the patients were: mean age
49.17±11.21 years (age 24-78). The disease average dura-
tion was 7.44±2.12 years (4 months-29 years), 82.71% were
women and 17.29% men. Seropositive RA were 80.24%,
and 71% of RA have anti CCP positive antibody.
Of the 64 seropositives rheumatoid patients, 35 (54.5%)
were positive for DRB1*0401 antigen, as compared with
four seronegatives subjects (DRB1*0401), a highly signifi-
cant difference (p<0.0001). Similarly, a high significant
association with DRB1*1501 antigen (p<0.0001) was
found, followed by DRB1*0301, *1301 and *1101. We
noted that, the RA with HLA-DRB1*0401 alleles are asso-
ciated with more radiologic erosions and more aggressive
RA. HLADQ*0201, *0301, *0501 and *0601 were associ-
ated with seropositive RA. HLADQB1*0401 and *0302
were also associated with seropositive RA, but with less
significance. Four DRB1*0401 were homozygotes and all
of them were seropositive RA.
Conclusion(s): Our results indicate that, in addition to
HLA-BRB1 alleles, HLA-DQB1 alleles also augments the
genetic susceptibility to seropositive RA.
P490
COMORBID CONDITIONS IN OSTEOPOROSIS
Mariana I Cevei1, Dorina C Stoicanescu2
1Rehabilitation Clinical Medical Hospital, University of
Oradea, Faculty of Medicine and Pharmacie, Baile Felix,
2University of Medicine Victor Babes, Preclinical Department,
Timisoara, Romania
Objective(s): It is known that comorbidities often adversely
affect the management of osteoporosis. The objective of this
study was to examined the prevalence of comorbid condi-
tions, establish the morbidity count, severity index and the
presence of specific diseases associated with osteoporosis.
Material & Methods: We have performed an observational
study on a lot of 84 patients, with osteoporosis, treated in the
Medical Rehabilitation Clinical Hospital Baile-Felix, Roma-
nia. Affected persons were evaluated by DXA technique.
They ranged in age from 47-76 years with a mean age of
63.85±8.85 years. Information about comorbidity was gath-
ered using the Cumulative Illness Rating Scale (CIRS).
Results: The mean number of diseases/patient was 3. Se-
verity index was 2.25. All patients had at least one associ-
ated disease (CIRS≥1). 81.05% patients had at least one
moderate or severe associated disease (CIRS≥2). The most
common category was represented by musculoskeletal dis-
eases, which represented 50% of the total number of comor-
bidities, cardiac diseases (19.35%%), endocrine and
metabolic disorders represented 11.2%, followed by vascu-
lar diseases (4.8%), gastrointestinal (4.8%), neurologic
(3.22%), urinary tract (3.22%), respiratory (1.66%) and
renal diseases (1.66%). Obesity was diagnosed in 7.77%
of the cases and diabetes mellitus in 13.1% of them.
Conclusion(s): In clinical practice it must be taken into ac-
count the presence of comorbidities, which will influence the
therapeutic decisions, the outcomes and the risk for fractures.
Results are important for the patients with osteoporosis, as it is
expected that with the aging of the population an increasing
number of elderly people will need rehabilitation.
P491
THE EFFICACY OF STRONTIUM RANELATE
ON BACK PAIN AND BONE MINERAL DENSITY
IN PATIENTS WITH POSTMENOPAUSAL
OSTEOPOROSIS WITH AND WITHOUT
GLUCOCORTICOID TREATMENT
Tzvetanka Petranova1, Rasho Rashkov1, Ivan Sheytanov1,
Rodina Nestorova2, Simeon Monov1, Lubomir Marinchev1,
Veneta Peycheva1
1Medical University, Clinic of Rheumatology, 2"St.Irina",
Rheumatology Center, Sofia, Bulgaria
Objective(s): To assess the effect of strontium ranelate (SR)
within one year on the back pain and BMD in patients with
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postmenopausal osteoporosis(PMO) with and without glu-
cocorticoid (GC) treatment.
Material & Methods: The study group consisted of 113
women; 42 women of mean age of 59.7±7.9 with PMO,
receiving at least ≥5 mg/day of GCs for one year and over,
and 71 women of mean age of 63.9±9.0 with PMO without
GC treatment. The clinical characteristics of the enrolled
patients (pts) included back pain and PMO. Lumbar spine
BMD was measured by DXA, and thoracic and lumbar X-
rays were evaluated at baseline and after one year. Back pain
was assessed at baseline, 3rd and 12th month by a 4-point
scale ranging from “no pain” (score 0) to “severe pain”
(score 3). The pts were treated with SR 2 g daily dose,
calcium – 600 mg/d, and vitamin D – 400 IU/d for one year.
Statistical analysis was performed by Kolmogorov-Smirnov
test, paired samples test, Wilcoxon Signed Ranks test, chi-
square test, using SPSS 13,0 for Windows.
Results: At the end of the study period we were able to
achieve a significant increase in the mean BMD from base-
line in both groups; in the group with PMO with GC
treatment (-2.906±0.547 vs. -2.401±0.705; p<0.0001); in
the group with PMO without GC (-3.094±0.543 vs.–2.720±
0.819; p<0.0001). However, no statistically significant dif-
ferences were observed between both groups.
The reduction in back pain from baseline to the 3rd and the
12th month follow-up was statistically significant (p<
0.0001) for both groups.
Conclusion(s):We conclude that one year of treatment with
SR combined with calcium and vitamin D improves BMD
and reduces back pain in patients with PMO under GC
treatment, as well in those without GC treatment.
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INFLUENCE OF HLA CLASS II ANTIGEN (DR; DQ)
ON THE PRODUCTION OF ANTI-CYCLIC
CITRULLINATED PEPTIDE ANTIBODIES
IN A TUNISIAN POPULATION
Boussaid Soumaya, Kochbati Samir, Boussema Fatma, Baili
Lilia, Rokbeni Lilia
Habib Thameur Hospital, Internal Medecine, Tunis, Tunisia
Objective(s): Rheumatoid arthritis (RA) is the most com-
mon chronic inflammatory rheumatism. It's a complex au-
toimmune disorder. The aim of this study is to focus on the
relationship between HLA-DRB1 genes and RA specific
antibodies against cyclic citrullinated peptides (anti-CCP
antibodies).
Material & Methods: This prospective study was per-
formed on a total of 81 Tunisian patients with rheumatoid
arthritis. All patients fulfilled the American College of
Rheumatology (ACR 1987) criteria for RA. For each patient
we assessed DNA and serum samples. The DNA was
extracted from lymphocytes using a commercial kit
(Qiagen). The HLA class II (DQB1 and DRB1) was per-
formed by PCR technique specifying-sequence primers
(PCR-SSP). The specific products of PCR were analyzed
by 2.5% agarose gel electrophoresis. All tests include pos-
itive and negative controls appropriate for each blood sam-
ple. The phenotypes of patients were obtained through the
Software One Lambda DNA/Software (SSP2L-generic
DRB/DQB).
Results: The mean age of our population was 49.17±11.21
years (age 24-78). The disease average duration was
7.44±2.12 years (4 months - 29 years), 82.71% of RA
were women and 17.29% were men. Seropositive RA
were 80.24%, and 71% of RA have anti-CCP positive
antibody. Univariate analysis of the presence of anti-
CCP antibodies in conjunction with HLA DRB1 and DQB1
was performed. Carriership of HLADR*0301, 0401 and 1501
were significantly associated with the presence of anti-CCP
antibodies (p<0.0001). Four DRB1 0401 carriers were homo-
zygotes with three out of them having anti-CCP antibodies.
Carriership of HLA DQB1*0201, 0301, 0302,0501 and 0601
was associated with the presence of anti-CCP antibodies and
so was HLA-DQB1*0401, but with a less significant
association.
Conclusion(s): Although no formal conclusions on causal-
ity can be drawn from this association study, these findings
suggest that anti-CCP antibodies are associated with differ-
ent phenotypes; which suggest that various pathogenetic
mechanisms underlie the positivity for anti-CCP in RA.
P493
HLA CLASS II ANTIGEN (DRB1 AND DQB1) AND
OSTEOPOROSIS IN A TUNISIAN POPULATION
Boussaïd Soumaya, Kochbati Samir, Boussema Fatma, Baili
Lilia, Rokbani Lilia
Habib Thameur Hospital, Internal Medecine, Tunis, Tunisia
Objective(s): The most important genetic risk factor for
rheumatoid arthritis (RA) is the HLA-class II alleles. In
particular, the HLA-DRB1 alleles. The aim of this study is
to focus on the association between RA, HLA class II gene
(DRB1 and DQB1) and osteoporosis
Material & Methods: This prospective study was per-
formed on a total of 81 Tunisian patients with rheumatoid
arthritis including 67 women and 14 men (sex ratio 4.78).
All patients fulfilled the American College of Rheumatolo-
gy (ACR 1987) criteria for RA. RA associated with other
auto-immune pathologies have been excluded from the
study. For each patient BMD was measured in lumbar spine,
femoral neck, trochanter, and Ward's triangle. The DNAwas
extracted from lymphocytes using a commercial kit (Qia-
gen). The HLA class II (DQB1 and DRB1) was performed
by PCR technique specifying-sequence primers (PCR-SSP).
The specific products of PCR were analyzed by 2.5%
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agarose gel electrophoresis. All tests include positive and
negative controls appropriate for each blood sample. The
phenotypes of patients were obtained through the Software
One Lambda DNA/Software (SSP2L-generic DRB/DQB).
Results: Demographic traits of the patients were: mean age
49.17±11.21 years (age 24-78). The disease average dura-
tion was 7.44±2.12 years (4 months - 29 years), 82.71%
were women and 17.29% men. Seropositive RA were
80.24%, and 71% of RA have anti CCP positive antibody.
HLADQ*0201, *0301, *0501 and *0601 were associated
with seropositive RA. HLADQB1*0401 and *0302 were
also associated with seropositive RA, but with less signifi-
cance. Four DRB1*0401 were homozygotes and all of them
were seropositive RA. The occurrence of osteoporosis is not
correlated with the presence of shared epitope (p=0.6).
However, the number of patients carrying the shared epitope
and with osteoporosis is much lower than in patients without
(41 patients against 9). The shared epitope in single dose
appears to be a protective factor against osteoporosis (p<
0.001)
Conclusion(s): Our results indicate that, in addition to
HLA-BRB1 alleles, HLA-DQB1 alleles also augments the
genetic susceptibility to seropositive RA.
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SOCIOECONOMIC IMPACT OF OSTEOARTHRITIS
IN REPUBLIC OF MOLDOVA
Salaru Virginia, Opopol Nicolae, Mazur Minodora, Mazur-
Nicorici Lucia, Ciobanu Elena
State University of Medicine, N. Testemitanu, Rheumatology,
Chisinau, Republic of Moldova
Objective(s): To determine the direct and indirect cost of
osteoarthritis according to function of joint, independence
and to estimate the total its costs in Republic of Moldova.
Material & Methods: This study is cross-sectional, non-
randomized with subjects stratified according to functional
limitation by scale Function in Daily Living (ADL), Knee
injury and Osteoarthritis Outcome Score KOOS and Katz
Index of Independence in Activities of Daily Living. The total
costs were calculated as direct and indirect costs. Subjects were
recruited from primary care and rheumatology. In score KOOS-
ADL the last week was taken into consideration, a normalized
score (100 indicating no symptoms and 0-extreme symptoms)
was calculated for this scale. The Score Katz 6 (high)-patient
was independent, score 0 (low)-dependent. A questionnaire
gathered information over the previous 12 months.
Results: There were 100 patients, from them 85 were eligi-
ble, with complete X-ray data 60 (70.6%) female and 25
(29.4%) male, mean age 63.8±0.17 (range 48-76) years old,
mean disease duration 5.6±0.2 (range 0.4-12.0) yrs, mean
BMI 29.6 kg/m2, SD 5.2 kg/m2. Low education and socio-
economic class were associated with more severe disease
and high level of KOOS score-ADL. Excluding joint re-
placement, in RM the direct costs ranged from dollar was
$541-$9882 per person per year and indirect costs $55-
$211. The direct costs are poor comparable to those reported
in Western countries; however, the ratio of direct to indirect
costs is much higher than 10, in contrast to the greater
indirect vs. direct costs reported in whites. The total cost
of OA treatment in pts with low incomes are about 32%, and
in pts with high income under 19%.
Conclusion(s): The direct and indirect cost of osteoarthritis
patients are high comparable with incomes. The socioeco-
nomic impact of OA in the RM population is significant, but
the economic burden is not placed on the government,
patients having relatively high/moderate out-of-pocket
expenditures.
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THE EFFECTS OF BAZEDOXIFENE AND
RALOXIFENE ON VERTEBRAL, NONVERTEBRAL,
AND ALL CLINICAL FRACTURES AS A
FUNCTION OF BASELINE FRACTURE
RISK ASSESSED BY FRAX®
Jean-Marc Kaufman1, Santiago Palacios2, Stuart Silverman3,
Santosh Sutradhar4, Arkadi A Chines4
1Ghent University Hospital, Department of Endocrinology,
Ghent, Belgium, 2Instituto Palacios, Salud y Medicina de la
Mujer, Women's Health, Madrid, Spain, 3Cedars-Sinai Med-
ical Center and University of California, Departments of
Rheumatology and Medicine, Los Angeles, CA, 4Pfizer
Inc, Women's Health, Collegeville, PA, US
Objective(s): This post hoc analysis of data from a 3-year
pivotal phase 3 treatment study of bazedoxifene examined
the risk of morphometric vertebral, clinical, and nonverte-
bral fractures as a function of baseline fracture probability
using the FRAX®.
Material & Methods: Hazard ratios (HRs) were calcu-
lated using a Cox regression model for the effects of
bazedoxifene 20 and 40 mg, bazedoxifene 20/40 mg
combined, and raloxifene 60 mg vs. placebo on the
incidence of morphometric vertebral, clinical, and non-
vertebral fractures. Cox regression analyses were per-
formed in subgroups based on 10-year probability of a
major osteoporotic fracture thresholds (determined by
FRAX®; ≥2.5%, ≥5.0%, ≥7.5%, ≥10.0%, ≥12.5%,
≥15.0%, ≥17.5%, ≥20.0%).
Results: HRs for the risk of vertebral, nonvertebral, and all
clinical fractures decreased with increasing 10-year fracture
probability for bazedoxifene vs. placebo, while those for ralox-
ifene vs. placebo remained stable with increasing fracture
probability. In 10-year fracture probability threshold sub-
groups, bazedoxifene was associated with a significant reduc-
tion in the risk of vertebral fractures in most subgroups
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compared with placebo (Table). The risk of nonvertebral and
all clinical fractures was also significantly reduced for baze-
doxifene compared with placebo at ≥20% fracture proba-
bility (55% and 60% reduction, respectively, for
bazedoxifene 20/40 mg combined). Risk reductions for
raloxifene 60 mg compared with placebo were significant
for vertebral fractures in subgroups with fracture probabil-
ities of ≥2.5% to ≥10%; reductions in nonvertebral or all
clinical fracture risks were not significant for any sub-
groups. The risk of vertebral, nonvertebral, and all clinical
fractures decreased with increasing fracture probability for
bazedoxifene vs. placebo, but remained generally constant
for raloxifene vs. placebo (Table).
Table. Hazard Ratio Vs. Placebo (95% CI) for Vertebral, Nonvertebral,
and All Clinical Fractures for Subgroups Based on Fracture Probability
(FRAX®)
Bazedoxifene
20 mg
Bazedoxifene
40 mg
Bazedoxifene
20/40 mg
Raloxifene
60 mg
Probability threshold: ≥2.5%
Vertebral
fractures
0.575 (0.372-
0.887)a
0.657 (0.431-
1.002)
0.615 (0.431-
0.877)a
0.587
(0.380-
0.906)a
Nonvertebral
fractures
0.870 (0.647-
1.168)
0.894 (0.665-
1.203)
0.881 (0.684-
1.135)
0.966
(0.723-
1.290)
All clinical
fractures
0.856
(0.646-1.134)
0.861 (0.649-
1.144)
0.858
(0.674-
1.092)
0.993
(0.757-
1.303)
Probability threshold: ≥5%
Vertebral
fractures
0.487 (0.302-
0.786)a
0.561 (0.354-
0.889)a
0.524
(0.357-
0.769)a
0.570
(0.361-
0.899)a
Nonvertebral
fractures
0.747 (0.537-
1.039)
0.796 (0.574-
1.104)
0.771 (0.584-
1.018)
0.945
(0.692-
1.289)
All clinical
fractures
0.744 (0.546-
1.015)
0.768 (0.563-
1.048)
0.756
(0.582-
0.983)a
0.963
(0.720-
1.288)
Probability threshold ≥10%
Vertebral
fractures
0.444 (0.246-
0.802)a
0.472 (0.264-
0.843)a
0.459
(0.285-
0.738)a
0.581
(0.338-
0.999)a
Nonvertebral
fractures
0.697 (0.448-
1.083)
0.745 (0.483-
1.151)
0.722 (0.499-
1.044)
1.075
(0.723-
1.598)
All clinical
fractures
0.708 (0.473-
1.059)
0.714 (0.477-
1.069)
0.711 (0.506-
0.999)a
1.063
(0.738-
1.530)
Probability threshold: ≥20%
Vertebral
fractures
0.268 (0.087-
0.823)a
0.217 (0.062-
0.761)a
0.244 (0.097-
0.611)a
0.458
(0.183-
1.149)
Nonvertebral
fractures
0.449 (0.216-
0.932)a
0.438 (0.206-
0.930)a
0.447 (0.244-
0.819)a
0.700
(0.369-
1.326)
All clinical
fractures
0.379 (0.186-
0.771)a
0.408 (0.201-
0.829)a
0.395 (0.223-
0.701)a
0.697
(0.387-
1.255)
aP <0.05 vs. placebo.
Conclusion(s): The treatment effects of bazedoxifene on
vertebral, nonvertebral, and all clinical fractures increased
with increasing probability. This trend was not observed
with raloxifene.
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VERTEBRAL FRACTURES AND QUALITY
OF LIFE IN OSTEOPOROTIC PATIENTS
Ivana Tadic1, Nada Vujasinovic-Stupar2, Dejan Stevanovic3,
Ljiljana Tasic1
1University of Belgrade Faculty of Pharmacy, Department
of Social Pharmacy and Pharmaceutical Legislation, 2Uni-
versity of Belgrade School of Medicine, Institute of Rheu-
matology, Belgrade, 3General Hospital Sombor, Department
of Psychiatry, Sombor, Serbia
Objective(s): The aims of this study were to examine prev-
alence of vertebral fractures, patients' characteristics, and
quality of life (QOL).
Material & Methods: The study included 53 postmeno-
pausal women (mean age 71.60 years, SD=9.14) with pri-
mary osteoporosis and vertebral fractures. The study was
performed in Institute of Rheumatology - Medical Faculty
University of Belgrade Serbia, during the one year period.
Primary osteoporosis was established according to WHO
criteria. BMD was diagnosed by DXA measurement on
lumbar spine (L1-L4) and/or hip using GE Lunar Prodigy.
Vertebral deformities were established according to Genant's
classification. Observed patients' characteristics were: age,
age of menopause onset, duration of menopause, employ-
ment status, education level and marital status. Quality of
life was assessed using two questionnaires: QUALEFFO-41
and EQ-5D.
Results: The prevalence of at least one vertebral fracture in
the study group was 51.46%, while number of fractures
ranged 1-8. The patients' characteristics predicting more
than one fracture were: education (higher than secondary,
OR=1.48, CI=1.22-1.82, p<0.05) and marital status (mar-
ried status, OR=1.08, CI=0.30-3.91, p<0.05). The mean
value of QUALEFFO-41 total score was 51.65 (SD=18.94),
and the EQ-5D health state value (HSV) and Visual Ana-
logue Scale (VAS) were 0.47 (SD=0.28) and 50.78 (SD=
21.02) respectively. Number of vertebral fractures was not
in a significant correlation with QUALEFFO-41 domains,
HSV or EQ-5D VAS score (p>0.05).
Conclusion(s): The prevalence and number of fractures in
the study group was high. Among the observed patients'
characteristics only education level and marital status could
significantly predict occurrence of two and more vertebral
fractures. The study showed that vertebral fractures had
influence on QOL (the total questionnaires' scores were
around the half on a scale from 0 to 100/1), but their
correlation was not significant.
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RELATIONSHIP BETWEEN REGIONAL
DISTRIBUTION OF BODY FAT MASS (BFM) AND
SERUM LEPTIN, TNFα, TESTOSTERONE FREE,
β-CROSSLAPS IN MEN WITH CHRONIC
OBSTRUCTIVE PULMONARY DISEASE (COPD)
Sviatlana Lemiasheuskaya1, Alla Shepelkevich1, Alexander
Makarevich1, Natalia Vasileva2
1Belarusian StateMedical University, InternalMedicine No.1,
2Republic Medical Rehabilitation and Balneotreatment Cen-
ter, Dual-Energy X-Ray Absorptiometry, Minsk, Belarus
Objective(s): The role of fat-bone interactions in the path-
ogenesis of osteoporosis in COPD is poorly understood. Our
aim was to evaluate the relations between BFM distribution
and inflammatory mediator TNFα, hormones, markers of
bone metabolism in men at the age 40-70 years.
Material & Methods: Data were obtained from 98 partic-
ipants who underwent DXA (analyze of body composition,
the regional distribution of BFM). We examined 3 groups of
patients (aged 40-70 years) and control group (15 healthy
men with mean age 56 years, mean BMI 26 kg/m2). The
COPD pts were subdivided into groups according to COPD
severity: the 1st was made of 20 men; GOLD I stage; mean
age 55 years; FEV1 78%; BMI 27 kg/m2, smokers 68%,
packs/yrs 20; the 2nd included 43 patients; GOLD II stage;
mean age 57; FEV1 55%; BMI 28 kg/m2, smokers 80%,
packs/yrs 21; the 3 d -20 patients; GOLD III stage; mean age
60; FEV1 41%; BMI 25 kg/m2, smokers 84%, packs/yrs 28.
Results: Fat mass in android region was directly related to
serum TNFα (r=0.33, p=0.02). Total, trunk, arms fat mass
were directly related to serum leptin (r=0.21, r=0.36 and r=
0.35, p<0.05, respectively). Serum leptin exert negative
influence on BMD in lumbar spine (r=-0.43, p=0.001),
but not at femoral necks. We founded positive correlations
between beta-crosslaps and total fat mass (r=0.33, p=0.02)
and fat mass in android region (r=0.32, p=0.02). Total,
arms, legs, trunk fat mass and fat mass in android and
gynoid regions increase in COPD pts with lower level of
serum testosterone free (p<0.05 for all relationships). The
male patients at the age 40-70 years with COPD had osteo-
penia and osteoporosis in the presence of increased BMI
(29.4 kg/m2 and 24.7 kg/m2, respectively) and serum leptin
(2.8 ng/ml and 2.9 ng/ml, respectively, vs. 1.9 ng/ml in
patients without osteopenia and osteoporosis, p<0.05).
Conclusion(s): The regional distribution of body fat mass
play important role in the pathogenesis of osteoporosis in
men with COPD.
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THE EFFICACY OF BAZEDOXIFENE IN
POSTMENOPAUSAL WOMEN IS INDEPENDENT
FROM KIDNEY FUNCTION
Rene Rizzoli1, Silvano Adami2, Amy B Levine3, Santosh
Sutradhar3, Arkadi A Chines3
1University Hospitals and Faculty of Medicine of Geneva,
Division of Bone Diseases, Department of Medical Special-
ties, Geneva, Switzerland, 2University of Verona, Depart-
ment of Rheumatology, Verona, Italy, 3Pfizer Inc, Women's
Health, Collegeville, PA, US
Objective(s): We investigated whether kidney function,
evaluated based on glomerular filtration rate (GFR) and
which generally worsens with age, affects the efficacy of
bazedoxifene (BZA) using data from 2 global phase 3
studies of postmenopausal women (2-year prevention [N=
1583] and 3-year treatment [N=7492]).
Material & Methods: BMD and bone turnover marker
(osteocalcin and C-telopeptide [CTx]) data for the BZA 20
and 40 mg and placebo groups from both studies were integrat-
ed. Incidence of all fractures (morphometric vertebral and clin-
ical) was assessed in the treatment study for BZA 20 and 40 mg
combined. Women were categorized based on GFR estimated
by theModification of Diet in Renal Disease Study equation, in
mL/min per 1.73 m2: normal function (GFR≥90; n=1467),
mild impairment (60≤GFR<90; n=4568), or moderate/severe
impairment (GFR<60; n=546).
Results: Improvements in the mean percent change from
baseline in lumbar spine BMD at Month 24 was greater for
BZA 20 mg (1.4-1.8%) and BZA 40 mg (1.6-2.1%) vs.
placebo (0-0.1%; P<0.001) in the normal and mild renal
impairment subgroups; a similar trend was observed for
moderate/severe renal impairment, but the increases with
BZA vs. placebo were not statistically significant. Changes
from baseline in total hip BMD at Month 24 were greater for
BZA 20 mg (0.8-1.1%) and BZA 40 mg (0.9-1.1%) vs.
placebo (-0.3%; P<0.001) in the normal and mild renal
impairment subgroups, and for BZA 40 mg (1.1%) vs.
placebo (-0.3%; P<0.001) in the moderate/severe renal im-
pairment subgroup. BZA 20 and 40 mg reduced the median
percent change from baseline in osteocalcin (-34.7% to -
41.5%) and CTx (-42.8% to -49.6%) across all renal sub-
groups at Month 12 vs. placebo (-18.7% to -20.4%; P<
0.001 and -23.4% to -24.9%; P<0.001, respectively). The
efficacy of BZA on all fractures did not appear to be affected
by baseline kidney function, as evidenced by overall con-
sistent trends across GFR categories (hazard ratios<1) and
no treatment by GFR interaction (P=0.766).
Conclusion(s): The efficacy of BZA on BMD, bone turn-
over, and fractures in postmenopausal women was not in-
fluenced by baseline kidney function.
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POSTMENOPAUSAL OSTEOPOROSIS
PATIENTS MONITORING
Ema V Rudenka, Anna S Trushina
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Belarusian Medical Academy of Postgraduate Education,
Cardiology and Rheumatology, Minsk, Belarus
Objective(s): To develop a method of integrated assessment
of antiosteoporotic therapy efficiency.
Material & Methods: 114 women with new-onset postmen-
opausal osteoporosis (PMO) were included in research. Mean
age of women is 58.6±3.8 years. Mean age of menopause is
50.0±3.1 years, menopause duration is 9±3 years. Control
group without osteoporosis (OP) (n=34) is comparable in
age-related and social parameters to the basic group. Two
subgroups were sorted out in the basic group: A (n=71 /
alendronate 70 mg/week) and B (n=43 / strontium ranelate 2
g/day). Assessment instrument: questionnaires SF-36 and
QUALEFFO-41, the ternary numeral assessment scale
(NAS), “OP patients' compliance test”. Quality of life (QL)
indicators estimation was carried out prior to the therapy
beginning, in 3, 6, and 12 months. X-ray densitometry was
made before and after 12-month therapy.
Results: After 3 months of both medicines administration
neither authentic changes of QL indicators, nor vertebral
pain intensity was revealed (according to SF-36, QUAL-
EFFO-41, NAS), p>0.01. After 6 months of alendronate
therapy SF-36 demonstrated a significant improvement of
QL indicators (seven scales out of eight), and less improve-
ment after strontium ranelate therapy (two scales out of
eight), p<0.001, CI. QUALEFFO-41 showed a significant
QL dynamics after alendronate (six domains out of seven)
and strontium ranelate (two domains out of seven), p<
0.001, CI. After 6 months of alendronate NAS discovered
an authentic decrease of pain and no significant dynamics
after strontium ranelate (p<0.001, CI). After 12 months of
alendronate and strontium ranelate therapy SF-36 revealed a
significant improvement of QL indicators (seven scales
out of eight and six scales out of eight respectively), p<
0.001, CI. After 12 months of alendronate and strontium
ranelate therapy QUALEFFO-41 showed a significant QL
dynamics (seven domains out of seven and five scales out of
seven respectively), p<0.001, CI. After 12 months of both
medicines administration NAS discovered an authentic
decrease of vertebral pain (p<0.001, CI). Patients' high
PMO compliance during the year authentically favors
lumbar spine MBD increase both during alendronate
(+5.85 [+3.15; +10.68]%), and strontium ranelate (+6.53
[+2.72; +12.55]%) administration.
Conclusion(s): SF-36, QUALEFFO-41, NAS, and “OP
patients' compliance test” can be used as additional assess-
ment criteria of antiosteoporotic therapy efficiency.
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MULTIDAY ANALGESIAWITH ETORICOXIB
FOLLOWING THIRD-MOLAR EXTRACTION
SURGERYUSINGA FLEXIBLEDOSING PARADIGM
Jean Brown1, Stephen Daniels2, Arnold Gammaitoni3, Paul
M Peloso3, Maria Losada3, Anish Mehta3, Amy T Ko3
1Jean Brown Research, Research, Salt Lake City, UT, 2Pre-
mier Research Group, Research, Austin, TX, 3Merck Sharp
& Dohme Corp., Clinical & Quantitative Sciences, White-
house Station, NJ, US
Objective(s): We evaluated a multiday flexible dosing par-
adigm with etoricoxib following oral surgery.
Material & Methods: This double-blind, randomized con-
trolled study compared etoricoxib 90 mg and 120 mg with
placebo, ibuprofen 600 mg qid, or acetaminophen 600 mg /
codeine 60 mg (A/C; qid) in patients with ≥2 third-molar
extractions (≥1 impacted). Patients dosed as needed (flexible
dosing on Days 2 and 3 with study (SM) and rescue med-
ication (RM; acetaminophen 325 mg). Outcomes included
average and worst recall pain (0-10 scale), RM, total SM
doses used (days 1-3), and adverse experiences (AE).
Results: Differences from placebo for Average and Worst
Recall Pain are shown (Table). RM usage was 57% (place-
bo) and 18-23% across active treatments on Day 2, and 22%
(placebo) and 14-20% across active treatments on Day 3.
The mean numbers of SM doses were 2.02, 1.52, 1.74, 2.32,
and 1.59 on Day 2 and 0.80, 1.08, 1.07, 1.65, and 1.25 on
Day 3 for placebo, etoricoxib 120 mg, etoricoxib 90 mg,
ibuprofen, and A/C, respectively. A/C had more AEs and
less dosing. On day 2, placebo and ibuprofen patients took
more SM and RM than etoricoxib and had worse pain.
Nausea and vomiting were common AEs with higher fre-
quency with A/C.
Differences from placebo in Average and Worst Recall Pain Scores
Etoricoxib
120 mg
qd
Etoricoxib 90
mg
qd
Ibuprofen
600 mg
qid
Acetaminophen
600 mg/
codeine
60 mg qid
Average Recall Pain
(Day 2)
-1.40 -1.29 -1.11 -0.97
Average
Recall Pain
(Day 3)
-0.68 -0.78 -0.28 -0.45
Worst Recall
Pain (Day 2)
-1.42 -0.97 -0.79 -0.48
Worst Recall
Pain (Day 3)
-0.37 -0.78 -0.21 -0.62
Conclusion(s): Etoricoxib provided better treatment
responses compared with ibuprofen and A/C and resulted in
less dosing vs. ibuprofen on Days 2 and 3.
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PARENTAL POSITIVE HISTORY, UNDENIABLE
OSTEOPOROSIS RISK FACTOR
Dorina C Stoicanescu1, Mariana I Cevei2
1University of Medicine and Pharmacie Victor Babes, Pre-
clinical Department, Timisoara, 2Rehabilitation Medical
Hospital, University of Oradea, Faculty of Medicine and
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Objective(s): Several factors can increase the likelihood of
developing osteoporosis. Some of these are unchangeable risk
factors, such as genetic predisposition. The study aims to
assess the prevalence of risk factors in patients with osteopo-
rosis, emphasizing the importance of positive family history.
Material & Methods: It included a group of 328 patients
admitted to Baile Felix Rehabilitation Clinical Hospital,
Romania, between July 2009-May 2011, investigated by
DXA osteodensitometry to detect osteoporosis. The study
lot consisted exclusively of women with mean age 61.6±
9.31 years, ranging between 44-81 years. To assess the
osteoporosis risk factors all subjects completed the one-
minute osteoporosis risk test-IOF 2007.
Results: Mean number of risk factors was 2.52±0.8, rang-
ing between 1 and 6. 14.6% of patients had at least one risk
factor, 24.3% had 2, 21.3% had three and 36.5% had four or
more risk factors. More than half (51.8%) had a parent with
osteoporosis, 60.3% had early menopause, 53.6% kyphosis
and height decrease, 13.75% smoked and 22.8% had sec-
ondary osteoporosis. Stage statistical analyses revealed that
increased number of cases did not significantly modify data
obtained on smaller samples.
Conclusion(s): It is important that individuals are aware of
their genetic predisposition. Fortunately, osteoporosis can be
prevented by adopting a healthy lifestyle. Early diagnosis main-
tains the disease under control. Bone mass cannot be recovered
once osteoporosis is installed, therefore, the earlier the diagno-
sis, the greater the likelihood of fracture prevention. Knowledge
of risk factors enables prevention of osteoporosis and monitor-
ing the disorder for early detection, before fractures occur.
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SERUM CONCENTRATION OF BONE
METABOLISM MODULATORS IN WOMEN
WITH RHEUMATOID ARTHRITIS (RA)
Katarzyna Gruszecka, Jerzy Swierkot, Agnieszka
Matuszewska, Beata Nowak
Medical Academy, Department of Rheumatology, Wroclaw,
Poland
Objective(s): (RA) is a chronic inflammatory disease af-
fecting musculoskeletal system. As longstanding high con-
centration of proinflammatory cytokines in RA patients has
been observed, RA belongs to risk factors of osteoporosis.
The mechanisms that guarantee the dynamic of bone turn-
over depend on interrelations between three bone matrix cell
types and their function. Modulators of bone metabolism
allow the communication between those cells. The aim of
the study was the assessment of serum concentration of
OPG, RANKL, DKK1 and sclerostin in women with RA,
and comparing it to healthy individuals. We also looked for
correlation between concentration of analyzed bone metab-
olism modulators and the disease activity.
Material & Methods: 22 females with established diagnosis
of RA aged 30-72 years and 12 healthy (aged and sex
matched) volunteers entered the study. OPG, RANKL,
DKK1 and sclerostin serum concentration were measured
using commercial ELISA tests. The measurements were per-
formed once in control group and twice in RA group: before
the introduction of methotrexate (MTX; dose range: 15-20 mg
weekly) and 6 months after the first dose ofMTX. RA activity
was measured with ESR-DAS28. High disease activity was
defined according to EULAR guidance as DAS28>5.1.
Results: In RA group comparing to control group there was
statistically significant lower serum concentration of DDK1
(70.80 pg/ml vs. 548.52 pg/ml) and OPG (81.16 pg/ml vs.
557.377 pg/ml). Serum RANKL concentration was signifi-
cantly higher in RA group (777.79 pmol/L vs. 255.19 pmol/L).
There was no significant difference in sclerostin serum concen-
tration between both groups. In patients with good response to
MTX treatment we observed significant reduction of serum
concentration of DDK1 (80.96 pg/ml vs. 70.36 pg/ml; t-Stu-
dent test, t=2.16, p=0.05), OPG (79.86 pg/ml vs. 69.69 pg/ml;
nonparametric signs test; Z=2.07, p=0.04) and RANKL
(781.16 pmol/L vs. 529.76 pmol/L; t-Student test, t=2.16, p=
0.05). The concentration of sclerostin remained unchanged.
There was no significant difference in serum concentrations
of bone metabolism modulators between patients with active
and non-active RA.
Conclusion(s): The results support the hypothesis the RA
changes the bone metabolism. Successful treatment influ-
ence the serum concentration of bone metabolism modula-
tors. Sclerostin seems to have no value in monitoring bone
metabolism in RA patients.
P503
DISTRIBUTION OF LEAN SOFT TISSUE IN TYPE 2
DIABETES MELLITUS MEN AND WOMEN
Ekaterina Pletneva1, Alla Shepelkevich2, Helena A
Kholodova2, Volha Vadzianava3, Natalya Vasilieva3
1Minsk-City Endocrinology Center, Endocrinology Department
#1, 2Belarusian State Medical University, Internal Medicine
Department # 1, 3Republic Medical Rehabilitation and Balneo-
treatment Center, Radiology Department, Minsk, Belarus
Objective(s): Body composition may be altered by the
disease process in type 2 diabetes mellitus (DM). Fat distri-
bution has important evident associations with DM and risk of
cardiovascular diseases. There are also unanswered questions
about amount and distribution of lean soft tissue in relation to
disease status and whether fat or lean mass may have inde-
pendent associations with type 2 DM. The aim of the study
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was to identify differences in amount and distribution of lean
soft tissue in subjects with and without type 2 DM and to
determine any gender differences.
Material & Methods: 232 patients with type 2 DM (178
women, 54 men) (mean age: 60.36±7.55 yrs, duration of
DM: 10.61±6.78 yrs, BMI: 31.81±5.33) and 81 (63 wom-
en, 18 men) controls matched for age, sex and BMI were
examined. The research involved clinic examination, gly-
cated hemoglobin test, DXA body composition program.
Lean mass distribution analysis was based on arms, legs,
trunk, android, gynoid, total body parameters.
Results: Lean mass distribution parameters in type 2 DM
patients and controls were: total body: 47.7 kg [33.7-69.7]
vs. 45.1 kg [35.7-64.3] (p=0.20); android: 3.8 kg [2.4-5.9] vs.
3.2 kg [2.4-5.4] g (p=0.025); gynoid: 6.9 kg [4.9-10.0] vs. 6.5
kg [4.9-9.4] (p=0.26); trunk: 25.1 kg [17.6-38.0] vs. 22.3 kg
[16.8-36.9] (p=0.007); arms: 4.9 kg [3.4-8.7] vs. 4.8 kg [3.8-
7.8] (p=0.99); legs: 14.5 kg [9.9-22.3] vs. 14.8 kg [11.5-21.2]
(p=0.33). Body composition lean android and lean trunk mass
were statistically higher in type 2 diabetic patients both men
and women in comparison with control group (android: men
4.6 kg [2.6-6.9] vs. 4.2 kg [3.3-6.8], (p=0.04); women 3.7 kg
[3.1-4.2] vs. 3.1 kg [2.7-3.9], (p=0.025); trunk: men 28.9 kg
[26.8-32.6] vs. 24.3 kg [16.8-35.9] (p=0.01); women 24.6 kg
[21.6-27.5] vs. 20.8 kg [19.5-24.6], (p=0.009)).
Conclusion(s): The results indicate the prevalence of cen-
trally distributed lean mass, with larger deposits in the trunk
region and smaller deposits in the leg region. The distribu-
tion of lean tissue in type 2 diabetes, both men and women,
compared to controls followed a similar pattern to that of fat:
more in the trunk region, less in the leg.
P505
CORRELATIONS OF INDICES OF BODY
COMPOSITION (IBC) WITH INFLAMMATORY
MEDIATOR TNFα, HORMONES, MARKERS OF
BONE METABOLISM AND OXYGEN SATURATION
IN MEN WITH CHRONIC OBSTRUCTIVE
PULMONARY DISEASE (COPD)
Sviatlana Lemiasheuskaya1, Alexandr Makarevich1, Natalia
Vasileva2, Alexandr Lemiasheuski3
1Belarusian State Medical University, Internal Medicine
No.1, 2Republic Medical Rehabilitation and Balneotreatment
Center, Dual-Energy X-Ray Absorptiometry, 3Belarusian
State Medical University, General Surgery, Minsk, Belarus
Objective(s): Weight loss is a poor prognostic factor for
survival and may involve all tissue compartments in COPD
patients. The aim was to analyze IBC and relationship
between their levels and TNFα, hormones, markers of bone
metabolism, oxygen saturation.
Material & Methods: Bone mineral content (BMC), Fat
mass (FM) and Lean mass (FFM, excluding BMC) were
detected by DXA. FM, FFM and BMC were expressed as
ratio to height squared to obtain indices FMI, FFMI and
BMCI, respectively. We examined 3 groups of patients
(aged 40-70 years) and control group (15 healthy men with
mean age 56 years, mean BMI 26 kg/m2). The COPD pts
were subdivided into groups according to COPD severity:
the 1st was made of 20 men; GOLD I stage; mean age 55
years; FEV1 78%; BMI 27 kg/m2, smokers 68%, packs/yrs
20; the 2nd included 43 patients; GOLD II stage; mean age
57; FEV1 55%; BMI 28 kg/m2, smokers 80%, packs/yrs 21;
the 3 d -20 patients; GOLD III stage; mean age 60; FEV1
41%; BMI 25 kg/m2, smokers 84%, packs/yrs 28.
Results: FFMI significantly differed in patients of 1-2-3
groups. The median value of FFMI decreased during COPD
progression: 20.5 kg/m2, 20.2 kg/m2, 17.7 kg/m2, respec-
tively. We revealed correlation between COPD severity and
FFMI (r=-0.54 p=0.001). We founded positive correlations
between FMI and serum leptin, beta-crosslaps and negative
one with testosterone free (r=0.31, r=0.31, r=-0.38, respec-
tively). Serum TNFα was inversely related to FFMI
(r=-0.30, p=0.03). BMCI significantly positive correlated
with oxygen saturation (r=0.40), PTH (r=0.54). FMI, FFMI
and BMCI depended on pack/years smoking index (r=-0.37
p=0.004 for FMI, FFMI and r=-0.3 p=0.04 for BMCI).
Patients of 3 d group had lower FMI than those in patients
with early stage (median: 4.68 vs. 8.28 in 1st stage p=0.001,
and 9.72 in 2nd stage). The median value BMCI in 1st and
control groups coincided and was significantly higher than
in 2nd and 3 d groups: 1.06 kg/m2 in 1st and control, and
1.00 kg/m2, 0.89 kg/m2, respectively.
Conclusion(s): The dynamics of IBC in COPD patients can
reflect the progression of disease.
P506
THE CORRELATION BETWEEN OSTEOPOROSIS
AND DIABETUS MELLITUS TYPE 2
Dorina Maria Farcas, Corina Moldovan, Felicia Marc
1University of Oradea, Faculty of Medicine, Physical Reha-
bilitation Medicine, 2Faculty of Medicine, Internal Medi-
cine, Oradea, Bihor, Romania
Objective(s): To assess the correlation between diabetes
mellitus type 2 and osteoporosis in a group of postmeno-
pausal women.
Material & Methods: We studied a group of 164 postmen-
opausal women from Bihor county, Romania. We divided
the group in two subgroups - first subgroup consisted in 83
patients with diabetes mellitus type 2, and second - the
control subgroup consisted in 81 patients without diabetes
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mellitus; mean age was 61.7±11.3. All of the subjects were
assessed by DXA and underwent clinical assessment. BMI>
30 was noticed in 47 women with diabetes mellitus and in
39 women from the control group. 36 women from the first
group and 42 women from the control group had a BMI<
30. We compared the prevalence of osteopenia and osteo-
porosis in the two subgroups.
Results: The prevalence of osteoporosis was 63.37% in the
subgroup of women with diabetes mellitus tip 2 and of
61.49% in the control subgroup. We didn't notice significant
statistical differences between the two subgroups. However
we found a higher prevalence of osteoporosis in nonobese
patients.
Conclusion(s): Our study showed that there were no signif-
icant differences in prevalence of osteoporosis between the
studied groups. Nevertheless osteoporosis was significant
more frequently in nonobese patients.
P507
COMPARISON HISTOLOGICAL DATA OF ACTIVE
EXPIRATION RESPIRATORY MUSCLE (RM) AND
ECHODENSITOMETRIC PARAMETERS IN MEN
WITH CHRONIC OBSTRUCTIVE PULMONARY
DISEASE (COPD)
Sviatlana Lemiasheuskaya1, Alexander Lemiasheuski2,
Michail Nedzvedz3, Alexander Makarevich1, Alexander
Pochtavcev1
1Belarusian State Medical University, Internal Medicine
No.1, 2General Surgery, 3Anatomical Pathology, Minsk,
Belarus
Objective(s): For the present moment changes occurring in
RM, during COPD progressing, have been studied insuffi-
ciently. The aim was to investigate the RM status and
compare them with histological data of bioptic muscular
material.
Material & Methods: The peak histogram of the internal
oblique abdominal muscle (intOAM) was detected by ultra-
sonic scanner. We obtained the following indices: homoge-
neity (H), structural density (SD), echogenicity (E) and
dispersion (D). Histological research of bioptic muscular
material of intOAM has been carried out. The histological
method of hematoxylin - eosin staining and the one by van
Gieson were used. Microscopical and echo densitometry
research was made in 13 pts: 1st group: 8 at the 1st COPD
stage; mean age 56 yrs; FEV1 78%; BMI 24 kg/m2, smokers
68%, packs/yrs 13; 2nd group: 5 at the 2nd COPD stage,
mean age 59 yrs; FEV1 63%; BMI 24 kg/m2, smokers 80%,
packs/yrs 29. Control group was formed of 10 healthy sub-
jects compared according to age, sex and BMI.
Results: Contractions of myofibrils (particularly, on periph-
eries of muscular fibrils), small sites of a fragmentation,
stratification of myofibrils and proliferation of fibroblasts
were observed at the 1st and 2nd COPD stage. We revealed
(in staining by van Gieson) scleroses of single muscular
fibril and foci of sclerosis in intramuscular regions. The
atrophy and crimp of muscular fibrils with the phenomena
of contractions of myofibrils was observed at the 2nd stage
of COPD. The median value of index H in patients of the 1st
and 2nd groups was 21 and 18 units, respectively. Increasing
severity of COPD was associated with enhancing of con-
tractions and stratification of myofibrils. Thus, we detected
the significant correlations between COPD severity and
contractions (r=0.72) and with stratification of myofibrils
(r=0.66). Indices H and SD were lower in patients with
more scleroses manifestations (r=-0.42 and r=-0.59, respec-
tively). Whereas index E and D were higher in these patients
(r=0.59 and r=0.46). The pack/years index significantly cor-
related with intensity of proliferation of fibroblasts (r=0.56).
Conclusion(s): Echodensitometric parameters (indices H,
E, SD, D) reflect the pathological processes occurring in
RM in COPD patients.
P508
THE UTILITY OF FRAX TOOL IN OSTEOPOROTIC
FRACTURES PREDICTION IN A GROUP OF
PATIENTS FROM ORADEA, ROMANIA
Dorina Maria Farcas1, Corina Suteu1, Salvina Mihalcea2,
Ildiko Gasparik3, Monica Adriana Farago1
1University of Oradea, Faculty of Medicine, Physical Reha-
bilitation Medicine, Oradea, 2Physical Rehabilitation Clinic,
Physical Rehabilitation Medicine, Felix Spa, 3ASPOR,
Management, Tirgu Mures, Romania
Objective(s): To assess the prediction of osteoporotic frac-
tures in the next 10 years in a group of postmenopausal
women from Oradea, Romania, to enhance the value of risk
factors in osteoporosis.
Material & Methods: We studied a group of 87 women
with osteoporosis, mean age 69.7±12.3 years. All of the
subjects were investigated by DXA and vertebral radio-
graphs. We assessed the risk for vertebral and hip fractures
using FRAX algorithm for the patient's 10-year fracture risk.
The patients measurement contained also: height, body
weight and BMD.
Results: The mean value for the risk factors 2.74±1.32, a
mean of 27.28±3.48 kg/m2 for the BMI, mean T-score for
the hip -2.25, and mean T-score for lumbar vertebra -2.81.
The mean spine (SD) BMD was 0.807±0.102 g/cm2. The
mean total hip (SD) BMD was 0.734±0.132. Correlating
these values we estimated a mean probability of having a
vertebral fracture of 21.23±23.1 in the next 10 years, and a
risk of having a hip osteoporotic fracture of 14.26±20.42.
Pain and loss of function due to these fractures have a
negative impact on quality of life and increase the burden
of healthcare costs.
S284 Osteoporos Int (2012) 23: (Suppl 2):S85–S386
Conclusion(s): Presence of more than one risk factor in-
creased fracture probability. It is proved once more that
FRAX tool is a very useful algorithm for assessing the 10
years prediction of osteoporotic fracture and the hip fracture
risk in the next 10 years.
P509
THE FEASIBILITY OF AN ACTIVE
REHABILITATION PROGRAM WITH THE USE
OF WEIGHT-VEST FOR OSTEOPENIC WOMEN
AND A FORMER WRIST FRACTURE: THE
OSTEOACTIVE PROGRAM
Kari Anne Hakestad1, Monica K Torstveit2, Åsa Axelsson1,
Lars Nordsletten1, May Arna Risberg1
1Oslo University Hospital, Norwegian Research Center for
Active Rehabilitation (NAR), Department of Orthopaedics,
Norwegian School of Sport Sciences, Oslo, 2University of
Agder, Department of Public Health, Sport and Nutrition,
Kristiansand, Norway
Objective(s): Active rehabilitation has shown to be one of
the most important factors for the prevention of osteoporotic
fractures, and studies have indicated that active rehabilita-
tion mainly concentrating on muscular strength, and dynam-
ic and static balance, has a positive effect on the risk of falls.
The purpose was to describe the development, and the
feasibility of a rehabilitation program (OsteoACTIVE) for
postmenopausal osteopenic women with a former wrist
fracture.
Material & Methods: 31 postmenopausal osteopenic wom-
en (65.5±7.1 years) with a former wrist fracture and low
BMD (T-score<-1.5) attended OsteoACTIVE for 6 months
(3x60 min/week). The exercises consisted of strength, bal-
ance, coordination, core stability and the use of weight-vests
during exercises. OsteoACTIVE also consisted of a patient
education part (OsteoINFO), and was offered twice during
the 6 months period. Pre- and post-testing included quadri-
ceps muscle strength (Biodex 6000), anthropometric data
and BMD measured with DXA, dynamic balance (Four
Square Step Test (FSST), Six-Minute Walk Test, physical
activity (mPASE), and quality of life (SF-36). ANOVAwas
used for statistical analysis, and Standard Response Mean
(SRM) was used to consider low (0.2), moderate (0.5) or
large change (0.8) from pre- to post-test.
Results: There were a statistical significant increase in
quadriceps muscle strength from 89.2±24.3 N-m to 99.7±
25.9 N-m at 60º/s (p=0.02), and for the dynamic balance
(FSST) (p=0.03). No significant improvements in the other
measurements were obtained. However, there were no sig-
nificant improvements in all sub-domains except for the
General Health. No changes were found in BMD in lumbar
spine and hip. SRM was moderate to high for quadriceps
muscle strength (0.70), and moderate for dynamic balance
(0.50). For the other outcomes, SRM was low. No adverse
events were reported and compliance was 87%.
Conclusion(s): OsteoACTIVE demonstrated beneficial ef-
fect on muscle strength and dynamic balance for postmen-
opausal osteopenic women with a former wrist fracture.
OsteoACTIVE is a safe program and is well tolerated by
the participants. In addition, it had a very good compliance.
Disclosures: TheMuskuloskeletal and Sport Medicine Clinic,
Hjelp24 NIMI (www.hjelp24.no), for NAR (http://active-
rehab.no) with rehabilitation facilities and research staff. Grant
from the South-Eastern Norway Regional Health Authority.
P510
INFLUENCE OF DIFFERENTASSAY METHODS
ON THE DETERMINATION OF
25-HYDROXYVITAMIN D
Stephan H Scharla, Uta G Lempert
Praxis Innere Medizin, Osteology, Bad Reichenhall, Germany
Objective(s): Vitamin D deficiency is an important cause of
bone diseases. The availability of automated methods pro-
vides the possibility to analyze large sample sizes. However,
method standardization is still a problem. In 2011 Roche
Diagnostics (Mannheim, Germany) changed the method for
25OHD with the Elecsys analyzer. We compared the two
Roche methods and an ELISA reference method.
Material & Methods: 25OHD was determined in serum
samples of 80 ambulant consecutive patients (54 female, 26
male; mean age 65.8±13.0 years). Some of these patients
were supplemented with vitamin D. 25OHD was determined
with three assays: Elecsys Vitamin D3 (Roche old), Elecsys
Vitamin D total (Roche new; both from Roche Diagnostics;
Mannheim, Germany) and 25OHD direct ELISAKit (Immun-
diagnostik, Bensheim, Germany). All methods are competi-
tive, both Roche methods are automated. The pretreated
serum samples were incubated with a polyclonal antibody
(Roche old), vitamin D-binding protein (Roche new) or a
monoclonal antibody (25OHD direct ELISA Kit).
Results: Mean 25-OH-D values for patients:
Roche (old): 40±27 nM; Roche (new): 80±33 nM;
ELISA 97±36 nM
Correlation coefficient Roche(old) vs. Roche (new): 0.69
Correlation coefficient Roche(old) vs. ELISA: 0.41
Correlation coefficient Roche(new) vs. ELISA: 0.73
Percentage of Vitamin D-deficiency (25-OH-D<50 nM):
Roche (old): 73%; Roche (new): 16%; ELISA 6%
The Bland-Altmann-Plot shows concordance between
Roche(new) und ELISA(Immundiagn.).
Conclusion(s): The old Elecsys Vitamin D3 assay measured
significantly lower levels of 25OHD compared to the new
Elecsys Vitamin D total assay and to the reference manual
ELISA method. The percentage of vitamin D deficient
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patients is significantly higher with the old method. The
25OHD levels determined with the Elecsys Vitamin D total
method (new) correlate very well with the 25OHD direct
ELISA (Immundiagnostik Bensheim). Therefore, the new
Roche method shows high plausibility. The method of
25OHD assay has important influence on clinical interpreta-
tion. The influence of assay methodology on the serum 25-
hydroxyvitamin D concentrations has to be considered in clin-
ical studies and for the definition of "normal Vitamin D status".
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PHYSICAL FUNCTION AND QUALITY OF LIFE
IN POSTMENOPAUSAL OSTEOPENIC WOMEN
WITH A FORMER WRIST FRACTURE
Kari Anne Hakestad1, Lars Nordsletten1,Monica KTorstveit2,
May Arna Risberg1
1Oslo University Hospital, Norwegian Research Center for
Active Rehabilitation (NAR), Department of Orthopaedics,
Norwegian School of Sport Sciences, Oslo, 2University of
Agder, Department of Public Health, Sport and Nutrition,
Kristiansand, Norway
Objective(s): Little is known whether postmenopausal
osteopenic women with a former wrist fracture have
reduced physical function and quality of life compared
to a healthy control group without previous fracture.
The purpose was to evaluate physical function and
quality of life in postmenopausal osteopenic women
and a former wrist fracture compared to a control group
without fracture.
Material & Methods: Eighteen postmenopausal osteopenic
women (57.7±3.5 years) with a former wrist fracture
(patients) were matched to 18 control subjects on gender,
age (58.5±4.2 years), height, weight and BMI. The exclu-
sion criteria for the controls were previous fractures, diag-
nosed with osteoporosis, physical active (moderate/hard
intensity) >4 h/week, and didn't understand Norwegian
written and spoken. The patients had to have proven low
BMD (T-score<-1.5), wrist fracture >2 years old, and do-
micile in the Oslo region. The exclusion criteria were pre-
vious hip or vertebral fractures, or >3 osteoporotic fractures,
physical active (moderate/hard intensity) >4 h/week, and
didn't understand Norwegian written and spoken. We tested
them for quadriceps muscle strength (Biodex 6000), dynam-
ic balance (Four Square Step Test (FSST), walking distance
(Six-Minute Walk Test (6MWT), and how exhausting they
experienced the 6MWT on Borg's Scale (BS), physical
activity (mPASE), and quality of life (SF-36).
Results: The patients had 17% reduced quadriceps muscle
strength at 60º/s (p=0.014) and 18% at 180º/s (p=0.012)
compared to the control group. In addition, we fond im-
paired performance for the patients with 79 m on 6MWT,
1.8 points on BS, and 2 s on FSST. Furthermore, the patients
scored lower on SF-36 on the physical role (16.3 points),
bodily pain (14.1 points), and vitality (20.9 points).
Conclusion(s): The patients scored significantly lower on
physical function and quality of life compared to the con-
trols. This indicate that health care professionals should
include quadriceps muscle strength and balance exercises
when developing exercise programs for patients with osteo-
penia and a former wrist fracture with the aim to increase
physical function and quality of life.
Disclosures: The Muskuloskeletal and Sport Medicine
Clinic, Hjelp24 NIMI (www.hjelp24.no), for NAR (http://
active-rehab.no) with rehabilitation facilities and research
staff. Grant from the South-Eastern Norway Regional
Health Authority.
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ASSOCIATION BETWEEN BONE MINERAL
DENSITY AND SERUM LIPID PROFILE IN
POSTMENOPAUSALWOMEN
Simona M Stoica1, Georgeta Zugravu2
1Emergency Hospital "Elena Beldiman", Rheumatology,
Barlad, 2Rehabilitation Hospital, Rheumatology, Iasi,
Romania
Objective(s): The magnitude of the public health problem
related to cardiovascular disease (CVD) and osteoporosis
has been widely documented in the medical literature in the
last decades. Dyslipidemia in women increases significantly
after menopause. On the other hand, bone mass decreases
with age regardless of sex. Furthermore, relationship be-
tween serum lipid profile and BMD in postmenopausal
osteoporosis has not yet been clearly established. The pur-
pose of this study was to investigate the effects of dyslipide-
mia on the bone metabolism in a group of postmenopausal
Romanian women.
Material & Methods: The subjects studied were 122 post-
menopausal women at the mean age of 61 years (age range:
47-75 year): 65 osteoporotic women according to OP diag-
nostic criteria of WHO and 57 nonosteoporotic postmeno-
pausal controls. The controls were clinically healthy, no
medications known to affect bone metabolism and lipid
profile, and had any systemic and inflammatory diseases.
Patients with secondary osteoporosis and systemic disorders
were excluded from the study. The height, body weight and
BMI were measured as physical parameters. Previous dis-
ease, menstrual status, menarche and menopausal age were
determined using a questionnaire form. All blood samples
were collected in the morning after an overnight fast. We
measured serum total cholesterol (TC), low-density lipopro-
tein cholesterol (LDL-C), high-density lipoprotein choles-
terol (HDL-C), and triglyceride (TG) levels. BMD values
were measured by DXA at lumbar spine, total hip and
femoral neck.
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Results: There was differences in TC, LDL-C, HDL-C, TG
levels between two groups but this differences were not
significant (p>0.05). In our study, there was no significant
difference in BMD values between two groups. We found
no significant relationship between lipid profiles and BMD
in two groups (p>0.05).
Conclusion(s): In conclusion, in our study, there wasn't any
association between lipid profile and BMD values in post-
menopausal women. Further research is needed to determine
whether there was any association between lipid profile and
BMD values in postmenopausal osteoporosis patients. De-
spite the fact that the results obtained by the studies carried
out to date are not definitive, future studies should establish
the magnitude of this relationship, especially at the level of
tissue.
P513
THE PREVALENCE OF VERTEBRAL FRACTURES
AND THEIR RELATIONSHIP WITH BONE
MINERAL DENSITY IN MILD
ANKYLOSING SPONDYLITIS MEN PATIENTS
Simona M Stoica1, Georgeta Zugravu2
1EmergencyHospital "ElenaBeldiman", Rheumatology, Barlad,
2Rehabilitation Hospital, Rheumatology, Iasi, Romania
Objective(s): Osteoporosis (OP) is a frequent complica-
tion of ankylosing spondylitis (AS). DXA for assessing
BMD has limitations in patients with AS because of
unreliability of spinal measurements, particularly in ad-
vanced disease with new bone formation. The objective
is to determine BMD in men patients with mild anky-
losing spondylitis (AS), to establish the prevalence of
vertebral fractures and fracture risk in these patients,
and to determine the relationship between BMD and
vertebral fractures.
Material & Methods: 34 men aged 40-60 years with mild
AS were studied. BMD of the lumbar spine and femoral
neck was measured by DXA and radiographs of the thoracic
and lumbar spine were obtained in all subjects. From the
radiographs, vertebral fractures were characterized by a
morphometric technique using established criteria. 39
healthy male subjects aged 50-60 years, recruited from
primary care registers, had spinal radiographs performed
and served as controls for vertebral fractures.
Results: In patients with AS, BMD was reduced in both the
lumbar spine 0.97 (0.1) g/cm2 [T-score −1.10 (1.3), 95%
-0.50, +0.14] and femoral neck 0.82 (0.1) g/cm2 [T-score
-1.40 (1.2), 95% CI -0.51, +0.09]. 6 patients of 34 (17.6%)
patients with AS had a vertebral fracture, compared with 1
of 39 (2.6%) controls; odds ratio 5.92 (95% CI 1.4, 23.8).
AS patients with fractures were not significantly older
(mean age 41.4 vs. 37.8 yr, P=0.17), but had significantly
longer disease duration (12.4 vs. 9.3 yr, P<0.05) than
patients without fractures. No significant correlation was
observed between BMD of the lumbar spine or femoral
neck and vertebral fractures in patients with AS. In addition,
there was no significant difference in the lumbar spine or
femoral neck BMD in AS patients with fractures compared
with those without.
Conclusion(s): Spinal and hip osteopenia and vertebral
fractures are a feature of mild AS. However, there was no
correlation between BMD and vertebral fractures in these
patients. AS patients with mild disease had a higher risk of
fractures compared with the normal population and this
increased with the duration of disease.
P514
LASER DOPPLER ALLOWS TO ASSESS BONE
PERFUSION IN MOUSE TIBIA: EFFECTS OF
INTERMITTENT PTH 1-84 IN TWO STRAINS OF
OVARIECTOMISED MICE
Bernard Roche1,2, Arnaud van den Bossche1,2, Laurence
Vico1,2, Marie-Hélène Lafage-Proust1,2
1INSERM 1059, Faculté de Médecine, 2Université de Lyon,
Université J Monnet, Saint-Etienne, France
Objective(s): Vessels provide bone perfusion which could
be involved in changes in bone remodeling. Furthermore,
PTH, a treatment for osteoporosis, may exert effects through
vascular mechanisms. However, the role of perfusion in
bone metabolism is unknown especially because of the lack
of convenient methods for its assessment in mice, the most
used animal model in bone biology. To this aim, we
designed a Laser Doppler (LD) based perfusion measure-
ment in mouse tibia.
Material & Methods: We used a 780 nm diode laser
(Periflux, Perimed). First, we tested measurement accuracy
ex vivo on a mouse femur canulated with a 0.38 mm
diameter tube in which heparinized blood circulated at var-
ious outputs (1-4 ml/h) via a peristaltic pump. Concentration
of moving blood cells (CMBC), mean blood cell velocity
(VEL) and perfusion (PERF, Arbitrary Units) were mea-
sured. Increasing blood output linearly correlated with
PERF (r=0.99). Second, we designed in vivo measurements
in mice under gaseous anaesthesia while monitoring heart
rate (HR, Bpm), tail blood pressure (BP, mmHg) and body
temperature. The bone surface of the tibia anteromedial
side was carefully exposed after skin incision; we mea-
sured bone PERF in three areas from the proximal meta-
physis to the upper part of the diaphysis. Finally, two
groups of 60 four month-old C57/Bl6J and Cd1/129
female mice were either ovariectomised (OVX) or sham
operated (CT) and then daily administered with either
saline (Sal) or PTH 1-84 (90 μg/kg/d, Nycomed) subcu-
taneously (8 groups, n=15/group). After 14 days, bone
perfusion was measured.
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Results:
OVX-induced systemic cardiovascular effects differed be-
tween strains. PTH increased significantly bone perfusion in
all groups with similar amplitude (40%) in OVX groups in
both strains.
Conclusion(s): LD provides a reliable tool for bone perfu-
sion assessment in mice. Intermittent 1-84 PTH increases
tibia perfusion regardless of genetic background, despite the
differences in bone perfusion observed between strains in
unchallenged mice.
P515
EFFECTS OF OPIOIDS ON POSTURAL BALANCE
Clara M Laursen1, Lars Rolighed2, Anne K Amstrup1, Tanja
Sikjaer1, Peter Vestergaard1
1Aarhus University Hospital, Department of Endocrinol-
ogy and Metabolism, 2Department of Surgery P, Aarhus,
Denmark
Objective(s): Opioids are frequently used and users of
opioids are known to have increased risk of fractures. The
objective was to examine the effects of opioids on postural
balance.
Material & Methods: In a cross-sectional study we mea-
sured postural balance in 194 patients recruited from a
department of internal medicine and an outpatient clinic
for endocrinology of whom 29 patients (15%) were using
opioids. Patients who were users of opioids were under
stable treatment for more than one month. Postural stability
wasmeasured in using a stadiometer (Good BalanceTM,Meitur
Ltd, Finland) in four simple positions: normal standing with
eyes open, normal standing with eyes closed, semitandem, and
tandem.
Results: Included patients had a mean age of 57 (range 18-91)
years and 158 (81%) were women. Users of opioids had a
significantly reduced postural stability during normal standing
with eyes closed (X-speed 3.9 vs. 3.1 mm/s, p=0.03 and
velocity moment 12.0 vs. 8.2 mm2/s, p=0.007) compared with
patients whowere not on opioid treatment. Differences between
the two groups were not statistically significant during normal
standing eyes open, semi-tandem and tandem (NS). In the
opioid group seven patients were also users of benzodiazepines,
however, postural balance in these patients were not different
from the rest of the group and there were no users of benzodia-
zepines in the group without opioids. In a multiple regression
model, age was negatively associated with postural balance in
normal standing with eyes open and closed (p<0.05). Height
and weight did not significantly affect postural balance.
Conclusion(s): Opioids affect the central nervous system
and some of these effects are detrimental. In the present
study, patients under opioid treatment had decreased postur-
al stability. With open eyes the difference was not signifi-
cant, however, withdrawing the sense of vision revealed an
impaired balance in the opioid group. This result may have
implication for other patients. Moreover, these patients were
under stable treatment and short term or high dose treatment
may have even worse affection of stability.
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ULTRASOUND-GUIDED INTRAARTICULAR
APPLICATION OF SODIUM HYALURONATE
IN PATIENTS WITH OSTEOARTHRITIS OF
THE HIP JOINT
Simeon V Monov1, Rasho K Rashkov1, Daniela V
Monova2, Ivan J Sheytanov1, Tzvetana P Petranova1,
Rodina L Nestorova3
1Medical University - Sofia, Department of Rheumatology,
2Medical University - Sofia, Department of Internal Medi-
cine, 3Rheumatology Center "St. Irina", Sofia, Bulgaria
Objective(s): The study examines the effect of hyaluronic
acid administered intraarticular (Ostenil Plus - OP, 2 ml, 40
mg, 2% sodium hyaluronate in combination with mannitol)
on the painful symptoms in patients with osteoarthritis of the
hip joints (OH).
Material & Methods: 46 patients with OH (ACR, 1991)
were examined. OP was administered weekly, for three con-
secutive weeks, locally (front-access sagittal) in 84 hip joints
(in 38 patients OP was administered bilaterally) under ultra-
sound control (7 MHz, linear transducer, with internal rotation
in the hip joints at 15-20°). The follow up period was 6 months.
Results: Throughout the observation period no side effects
of the local treatment were established. Statistically signif-
icant (p<0.001) improvement in the condition (AFI -
Table 1
CT+Sal . OVX+Sal CT+PTH OVX+PTH
C57/BL6J
VEL 93.7±6.8 92.6±6.8 c# 65.6±4.3 a' 93.1±5.7 c'
CMBC 64.7±4.9 51.2±3.1 c' 117.5±8.1 a' 75.2±10.3 b#,c'
PERF 53.2±3.4 37.4±1.9 a',c' 63.8±3.2 a# 52.1±3.4 b',c#
HR 69.3±3.4 69.7±3.6 63.3±5.1 73.4±3.4
BP 442±15 499±10 a 558±12 a' 502±16 a',c'
BVR 1.36±0.10 1.90±0.13 a 1.03±0.11 1.55±0.14 b#,c'
Cd1/129
VEL 74.8±3 90.1±4.7 117.3±8.1 a',b' 117.4±6.4 a',b'
CMBC 49.4±4.7 47.8±3.7 46.8±2.3 46.2±3.1
PERF 32.6±2.5 36.6±2.5 48.1±3.9 a',b 50.1±4.8 a',b'
HR 70.7±2.6 66.3±2.6 61.9±2.2 a# 60.8±2.3 a
BP 473±16 476±11 500±16 488±20
BVR 2.34±0.20 1.91±0.20 1.41±0.15 a' 1.42±0.16 a
a: vs. CT+Sal, b: vs. OVX+Sal. c: vs. CT+PTH, # p<0.05, ':
p<0.01
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algofunctional indices for hip, M. Lequesne, 1997) and pain
reduction (in 72.62% of the hip joints injected with OP)
(VAS) were reported on the third and sixth month. Improve-
ment of quality of life (HAQ) was presented in 60.87% (28
patients) of the studied patients.
Conclusion(s): Local application of hyaluronic acid has a
significant place in the general programme for treatment of
osteoarthritis of the hip joints. Ultrasound guidance ensures strict
intraarticular getting the drug and fewer complications of therapy.
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COULD DXA PROVIDE ADDITIONAL INSIGHT INTO
SARCOPENIA IN OLDER ADULTS? EXPLORATION
OF LEG LEANMASS/FAT MASS RATIO
Bjoern Buehring, Ellen Fiedler, Jessie Libber, Diane
Krueger, Neil Binkley
University of Wisconsin-Madison, Osteoporosis Clinical
Research Program, Madison, WI, US
Objective(s): Sarcopenia is a risk factor for falls and fracture.
How to best evaluate and incorporate the contribution of fat to
functional impairment (so called sarcopenic obesity) remains to
be defined. DXA can measure regional fat mass, but currently
not intramuscular (IM) fat. Including fat measurement in sar-
copenia evaluation might improve clinical assessment as great-
er adipose tissue may contribute to muscle impairment and
increase disability risk. This study explores whether the ratio
of leg fat/lean mass obtained from total body DXA differs
between young and old adults. Additionally, we correlated this
ratio with classic muscle function tests, jumping mechanogra-
phy (JM) and appendicular lean mass (ALM)/height2.
Material & Methods: 60 collegiate athletes and 97 older
adults were studied. Body composition was determined in
all using a GE Lunar iDXA. The older adults performed
muscle function tests including the short physical perfor-
mance battery (SPPB), grip strength and JM. JM measures
jump height and power. Leg fat/lean mass ratio was com-
pared between the age groups and genders using T-tests. Leg
fat/lean ratio and the ALM/height2 ratio were correlated
with muscle function tests using linear regression analysis.
Results: Age (mean; range) of the athletes and older adults
was 20.3; 18-23 and 80.6; 70-95 years respectively. Leg fat/
lean mass ratio was lower (p<0.0001) in athletes than in older
adults. In young and old cohorts fat/lean ratio was lower in men
(p<0.0001). Fat/lean mass ratio was negatively associated with
grip strength, jump power/height (all p<0.0001) with trends
(p=0.06-0.07) for chair rise test and SPPB score. The ALM/
height2 ratio was positively associated with grip strength, jump
power/height (all p<0.01), but not the other measures.
Conclusion(s): The leg fat/lean mass ratio differs between
young athletes and older individuals and also between gen-
ders. It correlates with muscle function in older individuals
and could potentially be complementary to the ALM/height2
ratio. Further studies are needed to evaluate whether the fat/
lean mass ratio correlates with outcomes, e.g., falls and
fracture, and whether it, or other DXA approaches to leg
fat measurement, can serve as a measure of IM fat and/or
sarcopenic obesity.
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EFFECTS OF EXEMESTANE AND TAMOXIFEN
TREATMENTS ON BONE QUANTITY AND
QUALITY IN PATIENT WITH BREAST CANCER
P Hadji1, MKalder1, A Kauka1, MBauer1, M Ziller1, D Hans2
1Philipps-University of Marburg, Department of Gynaeco-
logical Endocrinology, Reproductive Medicine and Osteo-
porosis, Marburg, Germany, 2Lausanne University Hospital,
Center of Bone Diseases, Bone and Joint Department, Lau-
sanne, Switzerland
Objective(s):We performed an analysis of a substudy of the
randomized Tamoxifene Exemestane Adjuvant Multination-
al (TEAM) trial to determine the effects of exemestane
(EXE) and tamoxifene (TAM) on bone quantity and quality.
Material & Methods: Patients recruited in this study were
postmenopausal women with hormone sensitive primary
breast cancer. Patients received randomly EXE or TAM
(1:1) as adjuvant therapy for hormone receptor-positive
breast cancer. BMD was assessed at baseline and after 6,
12 and 24 months of treatment on a GE-Lunar Prodigy
densitometer. Bone quality, as expressed as bone micro-
architecture status, was evaluated by Lausanne University
Hospital without knowing the clinical status/treatments of
the patients, using TBS at lumbar spine L1-L4. TBS (TBS
iNsight®, Med-Imap, France) is a grey-level texture mea-
surement, which correlates with 3D bone microarchitecture
parameters, regardless of BMD. TBS and BMD were eval-
uated on the same region of interests.
Results: Study groups were composed of 17 and 17 women
taken TAM and EXE, respectively. Patients receiving TAM
showed a mean increase from baseline in lumbar spine
BMD of 0.7, 2.9 and 4.0% and in TBS of 2.8, 3.2 and
3.5% at 6, 12 and 24 months treatment, respectively. Con-
versely, patients receiving EXE showed a mean decrease
from baseline in BMD of 2.7, 3.7 and 4.7% and in TBS of
1.3, 1.9 and 3.1% at 6, 12 and 24 months treatment, respec-
tively. No significant correlations were obtained between
TBS and BMD at spine or at total hip at baseline and during
the follow-up. There were significant differences in the
changes in lumbar spine BMD and at total hip between
treatment groups (P<0.005 at any time points). Changes in
TBS from baseline at spine were also significantly different
between EXE and TAM: p=0.015, 0.008 and 0.002 at 6, 12
and 24 months, respectively.
Conclusion(s): EXE resulted in decreases in bone quantity
and quality whereas TAM induced and increase in bone
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quantity and quality and independently from each other. The
rapid influence of TAM on TBS should be further investi-
gated and might be related to temporally bone quality status
of the patient related to the chemotherapy.
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PLACENTAL SIZE AT 19 WEEKS IS POSITIVELY
ASSOCIATED WITH NEONATAL BONE MASS:
FINDINGS FROM THE SOUTHAMPTON WOMEN'S
SURVEY
Christopher R Holroyd1, Sarah R Crozier1, Pamela A
Mahon1, Nicola R Winder1, Keith M Godfrey1,3, Hazel M
Inskip1, Nicholas C Harvey1, Cyrus Cooper1,2
1University of Southampton, MRC Lifecourse Epidemiology
Unit, Southampton, 2Institute of Musculoskeletal Sciences,
University of Oxford, NIHR Musculoskeletal Biomedical
Research Unit, Oxford, 3Southampton General Hospital,
Southampton NIHR Biomedical Research Unit in Nutrition,
Diet & Lifestyle, Southampton, UK
Objective(s): Poor early growth is associated with reduced
adult bone mineral content and increased risk of hip frac-
ture. In mother-offspring studies, maternal smoking, nutri-
tion and physical activity during pregnancy appeared to
influence offspring bone mineral accrual. It is likely that
these relationships are mediated via an effect on the placen-
ta, but it is unclear whether the important determinant is
placental size or function. In this study we investigate the
relationship between placental size and offspring bone mass
using the Southampton Women's Survey (SWS).
Material & Methods: The SWS is a unique prospective
cohort of 12,583 nonpregnant women aged 20-34 years, of
which 3156 subsequent singleton pregnancies were fol-
lowed. Detailed placental measurements were obtained by
fetal ultrasound scanning at 19 weeks. In a subset of births,
DXA was performed on the neonate within the first two
weeks. Pearson correlation and linear regression were used
to relate placental measurements to neonatal body composi-
tion and bone mass.
Results: We identified 757 mother-neonate pairs with com-
plete ultrasound and DXA data. The statistically significant,
positive predictors of offspring bone area (BA), bone min-
eral content (BMC) and BMD (P<0.05) included placental
circumference, length of attachment to the uterine wall,
cross-sectional area and volume. Placental volume at 19
weeks was positively associated with neonatal total lean
mass, and percent and total fat mass (p<0.0001), however
was negatively associated with percent lean (p<0.0001).
This indicates that as placental volume increased, total neo-
natal size increased but with an increase in percentage fat
and a reduction in percentage lean within the overall size
envelope. All associations remained after adjusting for ma-
ternal factors known to affect offspring bone mass.
Conclusion(s): Placental size is positively associated with
intrauterine bone mineral accrual. These associations appear
independent of maternal factors known to influence neona-
tal bone mass, suggesting that these factors might act
through modulation of placental function rather than pla-
cental size. Low placental volume early in pregnancy may
be a marker of a smaller postnatal skeletal envelope and
potentially increased risk of fracture in older age.
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PREMENOPAUSALWOMEN WITH DISTAL
RADIUS FRACTURES HAVE DETERIORATED
TRABECULAR BONE ARCHITECTURE
COMPARED TO NON-FRACTURE CONTROLS
Tamara Rozental1, Charles Day1, B Earp1, Laura
Deschamps1, Alex Taylor2, Mary L Bouxsein1
1Beth Israel Deaconess Med Ctr & Harvard Med School,
Orthopedic Surgery, 2Massachusetts General Hosp, Endo-
crine Unit, Boston, MA, US
Objective(s): To gain insight into early origins of skeletal
fragility, we compared BMD and bone microarchitecture,
assessed by hr-pQCT at the distal radius and distal tibia, in
premenopausal women with and without recent fractures of
the distal radius.
Material & Methods: We enrolled premenopausal women
under age 45, including 28 fracture cases and 82 nonfracture
controls. Women were eligible as fracture cases if they had a
fracture of the distal radius within the prior 3 months.
Control subjects had no history of fractures in adulthood.
Trabecular and cortical bone density and microarchitecture
at the (non-fractured) distal radius and tibia were assessed
using high resolution peripheral quantitative computed to-
mography (XtremeCT, Scanco Medical AG). Areal BMD of
the hip, spine and forearm was measured by DXA. BMD
and trabecular and cortical bone microarchitecture were
compared between pre-menopausal women with and with-
out fractures using two-tailed student's t-test, with P<0.05
considered statistically significant.
Results: Subjects did not differ with regard to age, race or
BMI. Among FX, 19 injuries were sustained from a fall
from a standing height and 9 resulted from high energy
sports. Cortical and trabecular microarchitecture differed
between groups both at the distal radius and distal tibia. At
the distal radius total density (-8%, p=0.03), trabecular
density (-10%, p=0.02), and trabecular thickness (-8%, p=
0.01) were lower in FX than CONT (p=0.03). FX also
tended to have lower cortical thickness, cortical area and
periosteal perimeter although values did not reach statistical
significance. At the distal tibia, total density (-12%, p<
0.01), trabecular density (-14%, p<0.001) and cortical den-
sity (-9%, p=0.01) were lower in FX than CONT. FX also
had lower cortical (-11%, p=0.01), and trabecular thickness
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(-13%, p<0.001) than CONT. BMD was similar between
groups at all sites.
Conclusion(s): We found that premenopausal women with
forearm fractures have similar BMD but altered microarch-
itecture when compared to controls with no history of frac-
ture. Identifying patients at risk of osteoporosis before
menopause may provide opportunities to initiate early treat-
ment and prevention efforts.
Disclosures: We acknowledge funding from Sanofi/Aventis
(nowWarner Chilcott) and the Ruth JacksonOrthopedic Society.
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DENOSUMAB REDUCES INTRACORTICAL
POROSITY MORE THAN ALENDRONATE IN
THE COMPACT-APPEARING CORTEX AND
OUTER TRANSITIONAL ZONE
Roger M Zebaze1, Cesar Libanati2, Matthew Austin2, John
P Bilezikian3, Ego Seeman1
1University of Melbourne, Austin Health, Melbourne, Aus-
tralia, 2Amgen Inc., Thousand Oaks, CA, 3Columbia Univer-
sity, College of Physicians and Surgeons, New York, NY, US
Objective(s): Denosumab reduces remodeling and cortical
porosity and increases cortical vBMD more greatly than
alendronate. Remodeling is surface dependent. Denosumab
can inhibit osteoclasts throughout the skeleton without bind-
ing to bone matrix. Alendronate's affinity for bone mineral
may limit its distribution in deeper skeletal compartments
distant from bone surfaces, so that intracortical remodeling
may be less inhibited. We therefore hypothesized that deno-
sumab's effect will be greater than that of alendronate in
compact cortical bone but not necessarily in trabecular bone.
Material & Methods: Postmenopausal women aged 61±5
years were randomized double-blind to denosumab 60 mg
Q6M (N=83), alendronate 70 mg QW (N=82), or placebo
(N=82). All received calcium and vitamin D. Trabecular bone
volume fraction (BV/TV) and porosity in the compact-appear-
ing and trabecularized cortex (transitional zone) were measured
at baseline, 6 and 12 months from distal radius HR-pQCT
images using software (Strax1.0) which quantifies porosity.
Results: At 12 months, both treatments reduced porosity
and increased BV/TV from baseline (Table).
Denosumab did so twice as much compared with alendro-
nate in the compact cortex (P=0.039) and outer transitional
zone (P=0.008). In the inner transitional zone, a similar
trend was observed (P=0.063). There was no treatment
difference in trabecular bone (Figure).
Conclusion(s): Superiority of denosumab in cortical
bone (80% of the skeleton) could be partly due to its
accessibility to all surfaces throughout the skeleton.
Improvements in the outer cortical bone may be associ-
ated with improved resistance to bending and compres-
sive strength.
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ASSOCIATION BETWEEN BONE MINERAL
DENSITY AT FEMORAL NECK AND PHYSICAL
ACTIVITY ASSESSED WITH A TRIAXIAL
ACCELEROMETER IN POSTMENOPAUSAL
JAPANESE WOMEN
Jun Kitagawa1, Masayuki Iki2, Junko Tamaki2, Katsuyasu
Kouda2, Namiraa DongMei2, Yuho Sato3, Takahiro
Tachiki4, Yumeno Murakami4, Naonobu Takahira1
1Kitasato University, Graduate School ofMedical Science, Saga-
mihara, Kanagawa, 2Kinki University School of Medicine, De-
partment of Public Health, Osaka, 3Jin-ai University, Department
of Human Life, Echizen, Fukui, 4Kitasato University, School of
Allied Health Sciences, Sagamihara, Kanagawa, Japan
Objective(s): Previous studies [1-3] have reported the pos-
itive effects of daily walking steps and physical activity (PA)
by accelerometer on quantitative ultrasound parameters of
the calcaneus. However, it remains uncertain whether these
Table: Changes (Percentage Points Difference) From Baseline at 12
Months
Trabecular
BV/TV
Porosity
Inner
Transitional
Zone
Outer
Transitional
Zone
Compact
Cortex
Alendronate +0.19* -0.81* -0.86† -0.54^
Denosumab +0.24* -1.15* -1.95* -1.22*
P value relative to baseline, *<0.001, †<0.005, ^<0.03
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motion sensors-determined PA has positive effects on re-
gional BMD except calcaneus. This cross-sectional study
investigated the associations between BMD at femoral neck
(FN-BMD) and PA using a triaxial accelerometer in post-
menopausal Japanese women.
Material & Methods: This study is part of the Japanese
Population-based Osteoporosis (JPOS) study. The subjects
were 90 women with 10 years since menopause (YSM) or
more (69.2±6.3 years of age). None of the subjects showed
any abnormality in bone metabolism. FN-BMD was mea-
sured by DXA (QDR4500A, Hologic, USA). A triaxial
accelerometer (EW-NK50, Panasonic Electric Works Co.,
Japan) was given to each subject. This instrument measured
the number of steps per taken and converted acceleration
into metabolic equivalents (METs). PA at 3 METs or more
was recorded. The output of PA was expressed in MET-
s·hours. The subjects were instructed to wear the acceler-
ometer during waking hours for 7 consecutive days.
Results: FN-BMD showed significant negative correlation
with age (r=-0.38, p<0.01) and YSM (r=-0.34, p<0.01).
FN-BMD showed no correlation with BMI. While there
was no correlation between walking steps and FN-BMD,
PA (METs·hours) was positively associated with FN-BMD
(r=0.26, p<0.01). This positive effect of PA on FN-BMD
remained significant after adjustment for age or YSM.
Conclusion(s): Walking steps do not provide information
on the intensity of the activities in daily living. On the other
hand, the output of PA (METs·hours) reflects intensity of the
activities. It is suggested that the intensity of PA assessed
with a triaxial accelerometer is a significant determinant of
FN-BMD in postmenopausal Japanese women.
References: 1) Kitagawa J et al., Osteoporos Int
14:219;2003. 2) Kitagawa J et al., J Physiol Anthropol,
27:295;2008. 3) Park H et al., Osteoporos Int 18:285;2007.
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A SYSTEMATIC REVIEW OF ADHERENCE TO
OSTEOPOROSIS MEDICATIONS IN MEN
Seema Patel1, Nicole Yurgin2
1Heron Evidence Development, Heron Evidence Develop-
ment, Luton, Stopsley, UK, 2Amgen Inc, Global Health
Economics, Thousand Oaks, CA, US
Objective(s): Male osteoporosis is a growing but under-
managed problem. We determined to investigate the cumu-
lative knowledge on adherence to therapy in men to better
understand real life effectiveness of osteoporosis treatment
and how this may be improved.
Material & Methods:We conducted a systematic review to
identify information on adherence to osteoporotic medica-
tion in men. MEDLINE and Embase databases were
searched from 1998-2010 using keywords and MeSH terms.
Recent conference proceedings (2008-2010) were also
screened. Studies were included if they were in English
and reported osteoporosis related adherence data in real-life
clinical practice settings for male populations.
Results: Thirteen studies were identified which reported
male-specific information; four studies were exclusively in
male populations, the others were in mixed populations. Six
studies had a male population size of <200. Disparate meth-
ods of measurement and reporting prevented comparison of
results. Adherence to bisphosphonates, measured in terms of
Medication Possession Ratios (MPRs), ranged from 70% to
41%. Adherence to bisphosphonates using persistence, com-
pliance, consumption rate, and self-reported measures
ranged from 60% to 54%. The highest percentage of patients
adhering to treatment was reported in two studies: one with
annually dosed zolendronic acid (persistence with therapy
after 12 months was 100%), and one with off-label treat-
ment with teriparatide (81% of men were still on therapy
after 12 months of treatment). Results for gender differences
in medication adherence were conflicting; two studies
showed no difference in adherence between men and wom-
en, one study showed better adherence in men, and one
showed better adherence in women. One study which
assessed outcomes related to treatment adherence indicated
that there was an inverse relationship between treatment
adherence and risk of fracture.
Conclusion(s): Studies which report osteoporosis treatment
adherence estimates for males varied widely, nevertheless,
the available data indicate that a substantial number of men
with osteoporosis do not optimally use currently prescribed
osteoporotic medications.
Disclosures: This work was supported by Amgen Inc.
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A SYSTEMATIC REVIEW OF COST OF FRACTURE
AND RESOURCE UTILIZATION IN MEN WITH
OSTEOPOROSIS
Seema Patel1, Nicole Yurgin2
1Heron Evidence Development, Heron Evidence Develop-
ment, Luton, Stopsley, UK, 2Amgen Inc, Global Health
Economics, Thousand Oaks, CA, US
Objective(s): Male osteoporosis is an increasingly impor-
tant public health concern. The purpose of this study was to
assess the cumulative data published to date on the cost
burden of osteoporosis in men.
Material & Methods: We conducted a systematic review
to identify information on the cost burden of osteopo-
rosis in men. MEDLINE and Embase databases were
searched from 1998-2010 using keywords and MeSH
terms. Recent conference proceedings (2008-2010) were
also screened. Studies were included if they were in
English and reported osteoporosis-related cost or re-
source utilization data in men.
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Results: 24 studies were identified which reported a male
subpopulation within the study; only one study was carried
out exclusively in men. Men accounted for 11-30% of costs
related to fractures. Total 1-year costs related to fracture
reported at the national level were substantial, ranging from
EUR 100 million (USD 119 million) in Sweden to EUR 3.5
billion (USD 4.1 billion) in the US. In both Europe and the
US, costs associated with osteoporosis-related fractures in
men are expected to outpace those of women over the next
few decades. In general, the mean cost for fracture was
highest for men ≥75 years of age. Hip fractures are the most
expensive type of fractures to treat, costing up to EUR
36,366 (USD 42,866) in the first year post fracture, and
resulting in hospitalization costs ranging from EUR 1709
(USD 1590) in China (in 2000) to EUR 28,644 (USD
32,195) in the US (in 2003). Mean length of hospital stay
for hip fractures ranged from approximately 6 days to 34
days.
Conclusion(s): Although the prevalence of osteoporosis in
men is significantly lower than in women, the cumulative
evidence indicates that the cost of fracture and resource
utilization due to fracture in men is substantial, and is
expected to increase with an increasing aging population.
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A DRUG DELIVERY SYSTEM FOR
'MUSCULOSKELETON STRENGTHENING HERBS'
FOR APPROACHING BONE FORMATION
SURFACES
Heng Wu1, Baosheng Guo1, Baoting Zhang2, Chao Liang1,
Zhijun Yang3, Zhibo Hou4, Ling Qin1, Ge Zhang1
1The Chinese University of Hong Kong, Dept. of Orthopae-
dics & Traumatology, Hong Kong, 2The Chinese University
of Hong Kong, School of Chinese Medicine, Hong Kong,
3Hong Kong Baptist University, School of Chinese Medi-
cine, Hong Kong, 4Jinan University, Biomedical Research
and Development Center, Guang Zhou, China
Objective(s): 'Musculoskeleton strengthening herbals' can't
exert obvious beneficial effects on muscle and bone in
skeletal disorder therapy mainly due to short retention time
in blood and insufficient concentration in bone to execute its
bone anabolic effect, so our present study aim to develop
nanoparticles entrapping 'musculoskeleton strengthening
herbs' approaching bone formation surfaces to enhance the
interaction of herbs with osteogenic cells.
Material & Methods: (AspSerSer)6 as targeting moiety for
approaching bone formation surfaces was conjugated to the
surface of nanoparticles composed of poly(ethyleneglycol)-
poly(D,L-lactic-co-glycolic acid) (PEG-PLGA). The Fruc-
tus Psoraleae extract and the mixture of Epimedium and
Bacopin extract, which are commercially available injection
solution, were used as model drugs, respectively. The
physical properties were characterized and in vitro drug
release was also investigated. The proliferation and os-
teogenic differentiation of Fructus Psoraleae extract and
the mixture of Epimedium and Bacopin extract entrap-
ped in (AspSerSer)6-PEG-PLGA nanoparticles were de-
termined. In in vivo study, (AspSerSer)6-PEG-PLGA
nanoparticles carrying DiR as tracer were employed to
examine distribution at organ, tissue and cell levels in
rats, respectively.
Results: The average particle size of (AspSerSer)6-PEG-
PLGA nanoparticles entrapping the herbal extracts was
about 118±5 nm. It had slow release ability and significantly
promoted osteoblast differentiation and osteogenesis in vitro
compared to Fructus Psoraleae extract and the mixture of
Epimedium and Bacopin extract without delivery systems,
respectively. In in vivo study, the signals in femora from rats
injected with (AspSerSer)6-PEG-PLGA nanoparticles
showed more intensive than that injected with PEG-PLGA
nanoparticles without (AspSerSer)6 group at 4 h after ad-
ministration. Moreover, fluorescence signals remained in-
tense in femora after administration of (AspSerSer)6-PEG-
PLGA nanoparticles at 24 h. We found that bone formation
surfaces labeled with calcein green were largely colocalized
with rhodamine labeled (AspSerSer)6-PEG-PLGA and also
found numerous instances of co-localization of DiR with
ALP- or RUNX2- positive cells when (AspSerSer)6-PEG-
PLGA nanoparticles as delivery system, whereas there were
few instances of such overlapping staining when PEG-
PLGA nanoparticles as carriers.
Conclusion(s): (AspSerSer)6-PEG-PLGA nanoparticles not
only maintained drugs slow release, enhanced bioactivities,
but also facilitated 'Musculoskeleton strengthening herbals'
approaching bone formation surfaces to exerting anabolic
effects.
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LONGITUDINAL TRACK OF ALTERATIONS BONE
MINERALIZATION CHARACTERISTICS IN
SECONDARY OSTEOARTHRITIS INDUCED BY
TRAUMA
Joo Hyung Lee1, Paul Han2, Sung Jae Lee3, Han Sung
Kim2, Dohyung Lim1
1Sejong University, Department of Mechanical Engineering,
Seoul, 2Yonsei University, Department of Biomedical Engi-
neering, Wonju, Gangwon, 3Inje University, Biomedical
Engineering, Kimhae, Gyungnam, Republic of Korea
Objective(s): Bone mineralization on a microscopic scale is
major determinants of mechanical quality of trabecular
bone. However, longitudinal study to quantify alterations
of bone mineralization characteristics is sparse, particularly
in secondary osteoarthritis induced by trauma (T-OA) over
time. The current study is, therefore, aimed to quantify
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alteration patterns of bone mineralization characteristics in-
duced by T-OA over time, using in vivo μCT.
Material & Methods: Fourteen 8-week-old female Sprague
Dawley rats were randomly divided into control (n=7) and
T-OA (n=7) groups. Anterior cruciate ligament transaction
was performed for T-OA group. The knee joint was scanned
by in vivo μCT at 0, 4, and 8 weeks after administration and
the trabecular bone was analyzed to quantify alteration
patterns of bone mineralization characteristics. The linear
attenuation coefficient was measured and converted to bone
mineralization. Bone mineralization was then divided into four
areas (0-0.3 g/cm3, 0.3-0.7 g/cm3, 0.7-1.0 g/cm3, >1.0 g/cm3)
to quantify bone mineralization alterations based on method
suggested by Sato et al. (2000). Immunohistological tests were
performed additionally to verify if T-OA was well corre-
sponded to clinical conditions. All procedures for specimen
preparation were approved by Yonsei University School of
Animal Care and Ethics Committee.
Results: In terms of bone mineralization, no significant
difference was observed at 0 (P>0.05), but 7-12% differ-
ences were occurred at 4 and 8 weeks (P<0.05) between
control and T-OA groups. In terms of periodic changes of
bone mineralization, a degree of bone mineralization in
control and T-OA groups was not significantly changed at
0 and 4 weeks (P>0.05). At 8 weeks, a degree of bone
mineralization in control group was not also significantly
changed (P<0.05), but that of T-OA group was slowly
moved to high mineralization area over time at 8 weeks
(P>0.05). Local bone erosion, synovitis, and mild inflam-
mation were evident in histological images at 8 weeks after
administration.
Conclusion(s): These findings indicate that longitudinal
track may be important for identifying alterations in bone
microarchitectural characteristics. The results also indicate
that longitudinal track may be important when contemplat-
ing the use of antiresorptive and anti-inflammatory agents
for the treatment of T-OA.
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CHANGES OF BONE MINERALIZATION
CHARACTERISTICS IN RHEUMATOID
ARTHRITIS OVER TIME: LONGITUDINAL STUDY
Joo Hyung Lee1, Paul Paul2, Sung Jae Lee3, Han Sung
Kim2, Dohyung Lim1
1Sejong University, Department of Mechanical Engineering,
Seoul, 2Yonsei University, Department of Biomedical Engi-
neering, Wonju, Gangwon, 3Inje University, Biomedical
Engineering, Kimhae, Gyungnam, Republic of Korea
Objective(s): Bone mineralization on a microscopic scale is
major determinants of mechanical quality of trabecular
bone. However, longitudinal study to quantify alterations
of bone mineralization characteristics is sparse, particularly
in rheumatoid arthritis (RA) over time. The current study is,
therefore, aimed to quantify alteration patterns of bone
mineralization characteristics induced by RA over time,
using in vivo μCT.
Material & Methods: Fourteen 8-week-old female Sprague
Dawley rats were randomly divided into control (n=7) and
RA (n=7) groups. Bovine type-II collagen was injected
intradermally at the tail of RA group. The knee joint was
scanned by in vivo μCT at 0, 4, and 8 weeks after adminis-
tration and the trabecular bone was analyzed to quantify
alteration patterns of bone mineralization characteristics.
The linear attenuation coefficient was measured and con-
verted to bone mineralization. Bone mineralization was then
divided into four areas (0-0.3 g/cm3, 0.3-0.7 g/cm3, 0.7-1.0
g/cm3, >1.0 g/cm3) to quantify bone mineralization altera-
tions based on method suggested by Sato et al. (2000). All
procedures for specimen preparation were approved by
Yonsei University School of Animal Care and Ethics
Committee.
Results: In terms of bone mineralization, no significant
difference was observed at 0 (P>0.05), but 16-33% differ-
ences were occurred at 4 and 8 weeks (P<0.05) between
control and RA groups. In terms of periodic changes of bone
mineralization, a degree of bone mineralization in control
and RA groups was not significantly changed at 0 and 4
weeks (P>0.05). At 8 weeks, a degree of bone mineraliza-
tion in control group was not also significantly changed
(P<0.05), but that of RA group was moved to low mineral-
ization area and showed high turnover over time at 8 weeks
(P>0.05). There were the evidences of chronic inflammation
status showing fibrosis and synovial hypertrophy in histo-
logical images after administration.
Conclusion(s): These findings are expected to be able to
useful analyzing efficacy of rheumatoid arthritis treatment
drugs such as antirheumatic and antiresorptive agents in
bone mineralization point of view. To our knowledge, this
study may prove valuable as the first approach in tracking
longitudinally alteration patterns of bone mineralization
characteristics in RA.
P528
ASSOCIATION OF OSTEOPOROSIS AND
PSYCHOEMOTIONAL CHANGES IN
POSTMENOPAUSALWOMEN
Larisa A Marchenkova, Alexander V Dreval, Elena A
Prochorova
Clinical Research Institute of Moscow Region named of M.
F. Vladimirkogo, Endocrinology Department, Moscow,
Russian Federation
Objective(s): Depression has been implicated as a possible
risk factor for osteoporosis, however, the results to date have
not been consistent. And there are a very few studies
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reported an association between anxiety disorders and low
BMD. Some investigations have indicated that those rela-
tionships may differ depending on sex and age. The aim of
this study was to examine associations between osteoporosis
and psychoemotional disorders (anxiety and depression) in
postmenopausal women.
Material & Methods: Study comprised 508 postmenopaus-
al women aged over 45 years (median 63(57;70) years) who
had normal BMD (n=68), osteopenia (n=78) or osteoporo-
sis (n=362) according to DXA testing. Spinal X-rays were
performed for vertebral deformities assessment in patients
with osteopenia and osteoporosis. Test battery included C.
D. Spielberger-Y.L. Khanin self-assessment scale for evalu-
ation of reactive and personal anxiety and the depression
scale developed in the St. Petersburg Psychoneurological
Research Institute named of V.M. Bekhterev (adapted by
Balashova T.I., 1978).
Results: A significant correlation was found between reac-
tive anxiety level (r=0.09, p<0.05) and number of vertebral
deformities, and there were not found associations of reac-
tive anxiety level with age or BMD. No significant correla-
tions were found between personal anxiety level and age or
number of vertebral deformities, unlike with femoral neck
BMD (r=-0.11, p<0.05). Depression level correlated signif-
icantly with duration of menopause (r=0.12, p<0.01) and
BMD in lumbar spine (r=-0.10, p<0.05) and in total hip
(r=-0.11, p<0.05). Reactive anxiety and depression levels
were much higher (p<0.01) in osteoporosis patient than in
women with normal BMD or osteopenia. The spinal T-score
was significantly lower (p<0.05) in women with major de-
pression compared to non-depressed women or women with
subsyndromal situational depression.
Conclusion(s): Vertebral deformities increase reactive anx-
iety level in postmenopausal women. High level of personal
anxiety and major depression are associated with low BMD
in postmenopausal period.
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A SINGLE DOSE OF ZOLEDRONIC ACID
PREVENTS PERIPROSTHETIC BONE LOSS IN
FEMALE PATIENTS WITH CEMENTLESS TOTAL
HIP ARTHROPLASTY
Hannu TAro1, NikoMoritz1, Satu Timlin1, Petteri Lankinen1,
Erkki Svedström2
1Turku University Hospital, Department of Orthopaedic
Surgery and Traumatology, 2Department of Diagnostic
Radiology, Turku, Finland
Objective(s): Periprosthetic bone loss is common during the
first year after total hip arthroplasty (THA). Factors that lead
to periprosthetic bone loss are not clearly understood but are
thought to be associated with an increase in osteoclastic
activity. The primary objective of this trial was to
demonstrate that zoledronic acid, given as a single intrave-
nous infusion after THA, reduces periprosthetic bone loss
measured by DXA.
Material & Methods: This randomized double-blind pla-
cebo-controlled trial included postmenopausal female
patients with hip osteoarthritis. Excluding criteria in-
cluded evidence of secondary osteoporosis, an ongoing
bisphosphonate or corticosteroid therapy. Of the 49 eligible
patients, 14 (29%) had normal preoperative systemic
BMD, 24 (49%) osteopenia and 11 (22%) osteoporosis.
All patients received a cementless total hip prosthesis
with stem marks for RSA (radiostereometric analysis).
Postoperatively, the patients received a single intrave-
nous dose (5 mg) of zoledronic acid or placebo. All
patients received calcium and D-vitamin supplementa-
tion. The response to zoledronic acid therapy was mon-
itored by measurements of serum markers (CTX, TRAP,
and PINP). Periprosthetic BMD was measured by DXA
at 0, 3, 6, and 12 months. RSA imaging of stem migration
was performed at 0, 3, 6, and 12 months. Functional recovery
was evaluated by means of gait analysis, Balance master®,
and patient reported outcomemeasures (RAND-36,WOMAC,
HSS).
Results: At the baseline, the patients of zoledronic acid (n=
25) and placebo (n=24) groups showed minor imbalances in
the mean age (65 vs. 71 years), 25(OH)D-vitamin levels (65
vs. 52) and HSS scores (55 vs. 43). Periprosthetic total hip
BMD did not change with time in patients with zoledronic
acid treatment, while placebo-treated patients showed loss
of periprosthetic bone. The intergroup difference was 6.3%
at 3 months (p=0.0071), 6.0% at 6 months (p=0.0105) and
6.8% at 12 months, p=0.0039, RMANCOVA). In RSA
imaging, translation and rotation vectors of stem migration
showed no significant intergroup differences. Functional
evaluation and patient reported outcome measures showed
no significant differences between the two groups.
Conclusion(s): Zoledronic acid was efficient in prevention
of early periprosthetic bone loss in female THA patients.
Based on RSA, the treatment had no adverse effects on
implant osseointegration.
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CIRCULATING SCLEROSTIN IN
POSTMENOPAUSALWOMEN WITH TYPE-2
DIABETES MELLITUS: A CROSS-SECTIONAL
STUDY
Mohammed-Salleh M Ardawi1, Abdulrahim A Rouzi2,
Daad H Akbar3, Abdulrahman A AlShaikh3, Maimoona M
Ahmed3, Sami M Bahlas3
1Center of Excellence of Osteoporosis Research and Faculty
of Medicine, King Abdulaziz University, Clinical Biochemis-
try, 2Obstetrics and Gynecology, 3Internal Medicine, Jeddah,
Saudi Arabia
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Objective(s): Sclerostin a glycoprotein produced by osteo-
cytes, is a potent inhibitor of Wnt signaling and bone for-
mation. Diabetes mellitus (DM) is a risk factor for
osteofragility. However, there is limited information on cir-
culating sclerostin levels in patients with type 2 DM
(T2DM). The main objectives of the present study are to
examine study the relationships between circulating sclero-
stin in T2DM patients in relation to glycemic control among
postmenopausal women as compared with healthy age- and
sex-matched controls.
Material & Methods: A total of 630 T2DM patients and
630 healthy controls [postmenopausal women; age range
50-79 yrs] were studied. Each woman completed a
questionnaire and provided blood and urine samples.
Anthropometric parameters, together with serum sclero-
stin (determined by ELISA), glycated hemoglobin
(HbA1c) and plasma glucose were measured. BMD of
lumbar spine (L1-L4) and neck femur were determined
by DXA.
Results: Sclerostin levels were significantly higher in
T2DM patients than controls (74.1±16.5 vs. 51.09±21.3
pmol/L; P<0.001), respectively. In age-adjusted analysis,
serum sclerostin levels were positively correlated with
HbA1c in T2DM patients (r=0.256; P<0.001). In T2DM
patients, sclerostin levels were significantly lower in patients
with osteoporosis (50.6±18.6 vs. 60.6±23.5 pmol/L,
P<0.002). There were no differences according to presence
or absence of morphometric vertebral fractures.
Conclusion(s): Patients with T2DM showed higher serum
sclerostin than age- and sex-matched healthy controls with
sclerostin levels positively related to HbA1c values. Also,
circulating sclerostin levels were lower in T2DM patients
with osteoporosis.
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STUDY OF OSTEOPOROSIS IN POSTMENOPAUSAL
WOMEN IN CENTER OF FAMILY MEDICINE,
PRISHTINA
Dashurije Kryeziu1, Ramadan Kryeziu2, Manushaqe Kryeziu3,
Fehmi Rrahmani3, Nderim Kryeziu3
1Main Clinical Centre of Family Medicine (MCCFM),
Rheumatology Cabinet, 2National Institution of Public
Health of Kosova (NIPHK), Epidemiology Department,
3Family Medicine Centre, Family Medicine (FM), Pristina,
Kosovo, Serbia
Objective(s): To assess the figures and prevalence of osteo-
penia and osteoporosis in women who presented in Rheu-
matology Cabinet with clinical signs of osteoporosis.
Material & Methods: Bone density measurements of radi-
us and ulna, lumbar vertebrae 1-4 and hip, by Hologic DXA
device, were done in 223 females of age 46-86 years, during
the period of May 2010-April 2011. The criteria for
investigation were the presence of clinical signs, post men-
opause and positive biochemistry data for osteoporosis. The
data were analyzed based on DXA results (BMD), using
retrospective epidemiological method. Patients were divided
into 3 groups: with normal bone density (T-score≥-1.0),
osteopenia (T-score from -1.0 till -2.5) and osteoporosis
(T-score≤-2.5).
Results: Results showed that from 223 postmenopausal
women included in the study, aged between 46-86 years
(average 63.18 yr.), having the last menstruation between
25-57 years (average 48.4 yr.), who showed positive clinical
signs and biochemistry data for osteoporosis, 65.48% had
mineral bone density changes on their DXA measurements.
The osteopenia (T-score from -1.0 till -2.5) was noted in 86
cases (38.57%), and osteoporosis (T-score from -2.5 till -9.0)
in 60 cases (26.91%).
Table 1 Radio Ulnar DXA osteodensitometry
Normal / No. of
patients 77
(34.53%)
Osteopenia / No.
of patients 86
(38.57%)
Osteoporosis / No.
of patients 60
(26.91%)
Age
(average)
46 to 73 (59.8)
years
47 to 76 (63.1)
years
53 to 86 (66.9)
years
T-score T-score T-score T-score
Mean -0.20 -1.72 -3.38
Standard
Deviation
0.64 0.42 0.98
Minimal
Value
-1.0 -2.4 -9.0
Maximal
Value
+2.1 -1.1 -2.5
BMD Min/
Max
(average)
0.504-1.005
(0.563)
0.440-0.849
(0.484)
0.308-0.624
(0.405)
Conclusion(s): As only 65.48% of patients with clinical
signs and positive biochemistry for osteoporosis showed
mineral bone density changes consistent of osteopenia and
osteoporosis on DXA bone density measurements, we can
conclude that bone density measurement is an important
diagnostic method which determinates the patients who
require treatment. Early diagnosis and therefore treatment
of postmenopausal women with osteoporosis minimizes
fractures, invalidity and early death.
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DOES OSTEOPOROSIS RELATED VERTEBRAL
FRACTURES PRECEDE HIP FRACTURES? A
RETROSPECTIVE ANALYSIS
Mir Sadat-Ali, Abid H Gullenpet, Mohammed Q Azam,
Abdallah A Al-Othman
1University of Dammam, Orthopaedic Surgery, College of
Medicine, 2Radiology, 3Orthopaedic Surgery, 4AlKhobar,
Saudi Arabia
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Objective(s): Osteoporosis related fractures in men and
women carry high morbidity and mortality. It was reported
that vertebral fractures precede a second fracture. We con-
ducted a retrospective analysis of patients with osteoporosis
related hip fractures whether they suffered a spinal fracture.
Material & Methods: 154 patients with osteoporosis relat-
ed hip fractures and no history of a previous fracture were
analyzed for the presence of a vertebral fracture. Radio-
graphs were retrieved from the IPAC imaging retrieval sys-
tem and was reviewed independently by two authors AHG,
and MSA and later reviewed jointly. The site of the fractures
and type were classified as mild, moderate or severe as per
the semi-quantitative technique. Patients with the diagnosis
of malignancy or connective tissue disorder and those on
steroids were excluded from the analysis.
Results: Out of 154 patients with hip fractures, 111 (72.1%)
of patients and radiographs could be analyzed. The average
age was 70.6±13.7 years. 76 (75.2%) had no fractures of the
spine with the average age 67.28±12.2 and 47 were men and
29 women. 35 (24.8%) patients had 46 vertebral fractures
with average age of 76.9±14.5. 21 were women and 14 were
men. Patients with vertebral fractures were significantly
older than those without fractures p<0.001.
Conclusion(s): This analysis finds that patients with osteo-
porosis related hip fractures, a previous spine fracture is not
the rule. Women sustained more spinal fractures than men
and age was the significant factor. A vertebral fracture does
not increase the risk of a subsequent extremity fracture.
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TERIPARATIDE IN PATIENTS WITH
OSTEOPOROSIS – OUR EXPERIENCE
Aleksandra Karadzov Nikolic, Nada Pilipovic, Slobodan
Brankovic, Snezana Novkovic, Milica Basaric, Katarina
Simic Pasalic
Institute of Rheumatology, Physical and Rehabilitation
Medicine, Belgrade, Serbia
Objective(s): PTH and its analogue, teriparatide (recombi-
nant human PTH 1-34), are the only bone anabolic therapies
approved for the treatment of osteoporosis. Our aim was to
investigate the effect of teriparatide in postmenopausal
osteoporosis.
Material & Methods: 88 patients (pts) with postmenopaus-
al osteoporosis treated at the Institute of Rheumatology were
included in the research. They were selected in the period
between April 2008 - April 2011. The treatment lasted for
18 months. In Serbia the costs of treatment with teriparatide
are covered by health insurance for 18 months with post-
menopausal women meeting one of the following criteria: 1.
T-score≤-4 SD, aged ≥65 years; 2. T-score≤-3.5 SD, aged
≥65 years with ≥2 fragility fractures; 3. T-score≤-4 SD, aged
55-64 years with ≥2 fragility fractures; 4. Patients with
fragility fracture, aged ≥55 years, who have failed with
antiresorptive therapies, as indicated by declining BMD or
new fragility fracture on therapy. BMD, visually analogous
pain scales (VAS) and therapy side effects were observed at
the beginning and end of treatment. All the patients were
trained to apply the therapy independently using subcutane-
ous injections of teriparatide 20 μg/80mcl (Inject Pen) once
a day.
Results: Out of 88 patients, 75% were in group of 61-80
year-olds. 16 pts were included according to the 1. criterion,
15 (2.criterion), 10 (3.criterion) and 29 (4.criterion). 13 pts
met two of these criteria and for 5 pts criteria were un-
known. Only 5 pts did not have fragile fractures, and others
had mostly multiple fractures, localized mostly on the ver-
tebra. 23 pts did not previously receive any antiosteoporotic
therapy, other patients were receiving bisphosphonates. 50
pts finished 18 months of treatment with good effect: a
significant increase in BMD (0.733-0.804 g/cm2 on lumbar
spine and 0.633-0.680 g/cm 2 on hip) and significant reduc-
tion of back pain (VAS 69.98-17.70 mm). 18 pts stopped the
treatment. 20 patients are still being treated. Side effects
were mild and transient.
Conclusion(s): Bone anabolic therapy with teriparatide, can
greatly increase bone density, reduce pain in lumbar spine
and improve general condition of patients with osteoporosis.
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IS THE BSMI POLYMORPHISM OF VITAMIN D
RECEPTOR (VDR) GENE AN INDICATOR OF BONE
MASS AND FRACTURES IN POSTMENOPAUSAL
OSTEOPOROTIC WOMEN IN WIELKOPOLSKA
AND MAZOWSZE REGIONS?
Anna Wawrzyniak1, Michalina Marcinkowska1, Joanna
Dytfeld1, Michal Michalak2, Edward Franek3,4, Natalia
Drweska5, Ryszard Slomski5, Wanda Horst-Sikorska1
1Poznan University of Medical Sciences, Department of
Family Medicine, Poznan, 2Poznan University of Medical
Sciences, Department of Computer Science and Statistics,
Poznan, 3Central Clinical Hospital MSWiA, Department of
Internal Medicine, Endocrinology and Diabetology,
Warszawa, 4Medical Research Center, Polish Academy of
Sciences, Department of Human Epigenetics, Warszawa,
5PoznanUniversity of Life Sciences, Department of Biochem-
istry and Biotechnology, Poznan, Poland
Objective(s): Bone mass and fragility is determined by ge-
netic and environmental factors. Vitamin D receptor (VDR)
gene is one of candidate genes in osteoporosis. The aim of the
study was to assess the association of BsmI VDR gene poly-
morphism with BMD and prevalence of vertebral/nonverte-
bral fractures in postmenopausal women with osteoporosis.
Material & Methods: The study group consisted of 500
postmenopausal women with osteoporosis aged between
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47-88 years (mean 66.8 years) from Wielkopolska and
Mazowsze regions. Osteoporosis was diagnosed either by
WHO densitometric criteria or history of low-energy frac-
ture. History and clinical examination allowed to exclude
patients with comorbidities being cause of secondary oste-
oporosis. DXA of lumbar spine (L1-L4) and hip was per-
formed by means of Lunar. DNA was isolated from
peripheral blood lymphocytes. BsmI VDR polymorphisms
were performed by polymerase chain reaction-restriction
fragment length polymorphism (PCR-RFLP) method.
Results: Patients were divided into two subgroups – with
fracture history (n=285, incl. 168 vertebral, 117 nonverte-
bral) and no fracture history (215). In women with any
previous fracture, hip BMD was shown to be significantly
lower when compared to females without fracture (0.684 g/
cm2 vs. 0.717 g/cm2) (p<0,05). In case of L1-L4 BMD the
difference in fracture incidence was insignificant.
In vertebral fracture group, the distribution of BsmI poly-
morphism genotypes was: BB - 27, Bb - 80, bb - 60,
whereas in women with no history of vertebral fracture
- 55,145 and 133, respectively. In nonvertebral fracture
group the distribution of BsmI was: BB - 13, Bb - 51,
bb - 53, whereas in females with no nonvertebral fracture
present: 69, 174, 140, respectively. There was no statistical-
ly significant difference between the BsmI VDR polymor-
phism distribution and history of any fracture. Univariate
tests of significance for hip T-score showed significant
differences in carriers of different BsmI polymorphisms
(p<0,05), however, post hoc tests did not confirm statistical
significance.
Conclusion(s): 1. Analysis of the association of BsmI VDR
polymorphisms did not allow to identify them as predictors
of fracture – any, vertebral or non-vertebral. 2. In studied
population there was no significant association between
BsmI VDR polymorphisms and hip/L1-L4 BMD.
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THE TENDON INDEX OF THE SHOULDER JOINT –
INSTRUMENT OF EVALUATION OF SHOULDER
PERIARTICULAR TISSUES IN PATIENTS WITH
OSTEOARTHRITIS
Nailya G Shamsutdinova, Elina R Kirillova
Kazan State Medical University, Hospital Therapy, Kazan,
Russian Federation
Objective(s): To determine the feasibility of using the ten-
don index of the shoulder joint to assess the destruction of
periarticular tissues of the shoulder joint in patients with
osteoarthritis.
Material & Methods: The study involved 20 patients with
osteoarthritis complained of pain in the shoulder joint. To
assess pain were used VAS in quiescent state, in motion, and
palpation. Assessment of the shoulder joint was carried out
on the ConstanT-score. To evaluate the objective status used
the tendon index of the shoulder joint, which included
assessment of pain on a scale (0-3) during movements,
causing the tension of the rotator cuff tendons (rotator cuff)
and the long head biceps (long head of the biceps tendon).
Statistical data was carried out using Spearman's test.
Results: There was a marked correlation between the ten-
don index of the shoulder joint and VAS after palpation
(r=0.4), between the tendon index of the shoulder joint
and VAS after joint motion (r=0.3) as well as between the
tendon index of the shoulder joint and the ConstanT-score
(r=-0.6).
Conclusion(s): The tendon index of the shoulder joint can
be used to assess the pathology of periarticular tissues of the
shoulder joint in patients with osteoarthritis.
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MALE HYPOGONADISM IMPACT IN BONE
QUALITY ASSESSED BY TRABECULAR
BONE SCORE (TBS)
Mário Rui Mascarenhas1,2,3,4, Ana Paula Barbosa1,2,3,4, Ana
Gonçalves4, Vera Simões2,3, António Gouveia de Oliveira5,
Manuel Bicho2, Didier Hans6, Isabel do Carmo4
1Lisbon´s Faculty of Medicine, Endocrine & Metabolic
Diseases, Lisboa, Portugal, 2Lisbon´s Faculty of Medicine,
Center ofMetabolism&Endocrinology, Genetics Lab, Lisboa,
Portugal, 3CEDML–Clínica de Endocrinologia, Diabetes e
Metabolismo de Lisboa, Lda, Osteoporosis Unit, Lisboa, Por-
tugal, 4Santa Maria University Hospital, CHLN-EPE, Endo-
crinology, Diabetes & Metabolism Department, Lisboa,
Portugal, 5FCMUNL, Biostatistic Department, Lisboa, Portu-
gal, 6Lausanne University Hospital, Center of Bone Diseases,
Lausanne, Switzerland
Objective(s): Increased recognition of the morbidity and
mortality attributable to osteoporosis of the nontraumatic
fractures in men are main issues of the public health prob-
lem of osteoporosis. Ageing and the propensity to fall are
the main risk factors for low bone mass in males, but
hypogonadism in men is an important secondary cause of
low BMD but very little is known about the microarchitec-
ture of the bone. The TBS ("trabecular bone score", Medi-
maps, Bordeaux, France) is a quantitative index that
characterizes the state of bone microarchitecture indepen-
dently of the bone density as previously demonstrated. The
objective of the study is to study the impact of the male
hypogonadism on the bone quality as assessed by TBS.
Material & Methods: BMD at the lumbar spine, at the
proximal femur, at the distal radius, the total body lean
and fat masses were measured by DXA in 96 hygogonadal
(hypogonadism group) and in 96 normal (control group)
men. The TBS technique was applied to the lumbar spine
scans. Fast blood was collected for LH, FSH, PRL, E2 and
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total testosterone measurements. The weight, height and
BMI were also determined. Appropriate statistics were used
with the significance level at P<0.05.
Results: The mean age, weight and total body fat mass were
identical, but in the hypogonadism group the mean spine
TBS (P=0.0000), BMC (P=0.0000) and BMD (P=0.0013)
at the lumbar spine and total body lean mass (P=0.0000)
were significantly lower, as compared with the control
group.
Significant negative correlation was found between the TBS
and the age in the control group. The correlation between
BMD and site matched TBS is overall non-significant
(r2<5%) confirming that it is measuring different bone prop-
erties than BMD.
Conclusion(s): Data of this study show a significant reduc-
tion in both BMD and bone quality evaluated by TBS, thus
suggesting an important negative impact in the bone
strength of hypogonadal men, which may be associated to
an increased osteoporotic fracture risk.
Disclosures:Medimaps (Medimaps, Bordeaux, France) and
Radilan (Lisboa, Portugal) for the kind free access and use
of the TBS iNsight software for this study
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CELIACDISEASEANDMETABOLICOSTEOPATHY:
A UNIVERSITY HOSPITAL EXPERIENCE
Mona A Fouda
College of Medicine, King Saud University, Department of
Medicine - Endocrinology, Riyadh, Saudi Arabia
Objective(s): To report on metabolic osteopathy in celiac
disease (CD) patients in Saudi Arabia where vitamin D
deficiency is common.
Material & Methods: A retrospective analysis of the reg-
istry on histopathology of celiac disease starting from 1996
as well as a survey of the serological testing done since its
introduction in 2003, conducted in a major teaching hospi-
tal. The criteria of the diagnosis of CD patients were as
follows:
a) Patients with duodenal biopsies reported by the histo-
pathologist to be diagnostic of CD and complied with
Marsh-Oberhuber system type III (a,b,c), or b) Positive
IgA – Antiendomysial antibodies (EMA). Both positive
tests had to be supported by strong clinical suspicion of
the disease and the final diagnosis given by the treating
physician was CD with no alternative diagnosis attached to
them on follow-up. Biochemical parameters and imaging
tests were recorded.
Results: The total numbers of patients were 114, 65 of whom
were children (aged 15 years or younger). The male to female
ratio was 1:1.9. A total of 88 patients (94%) were diagnosed
by histopathology while 92 (85%) had positive serology.
There were 82 patients who had both tests performed and 61
(74%) had both tests positive. The 25-dihydroxyvitamin D3
[25(OH)2D3] was low in 100% of adults and in 70% of
children who did the test, while all the groups who had a
PTH value measured (11 patients) had high level (100%).
DXA was performed only in 19 patients with osteopenia/
osteoporosis reported in 79% of them. A bone scan was
performed in only 14 patients and an abnormal finding com-
patible with metabolic bone disease reported in 64% of them.
Conclusion(s): Metabolic osteopathy and vitamin D defi-
ciency are higher in Saudi CD patients than reported else-
where. The physicians' awareness of importance of bone
disease is seriously low.
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OUR EXPERIENCE WITH TREATMENT
OF POSTMENOPAUSAL OSTEOPOROSIS
WOMEN WITH ZOLEDRONATE
Miro Cokolic, Mitja Krajnc
Internal Clinic, University Clinical Centre Maribor, De-
partment of Endocrinology and Diabetology, Maribor,
Slovenia
Objective(s): Zoledronate is an intravenous bisphospho-
nate, widely used in the treatment of postmenopausal oste-
oporosis. It increases BMD and reduces fracture risk. Its use
can be associated with postinfusion flu-like symptoms. Its
advantage is the lack of important gastrointestinal side
effects, common in peroral bisphosphonates.
Material & Methods: We retrospectively studied 12
women with postmenopausal osteoporosis, treated with
zoledronate 5 mg, for their baseline BMD (in g/cm2:
average for L1-L4 vertebra and for femoral neck) before and
BMD one year after Aclasta 5 mg intravenous infusion. Their
average age was 68, SD 6. We noted the incidence of post-
infusion flu-like symptoms and the reason for initiating intra-
venous therapy. We calculated averages and standard devia-
tions and compared averages of two means with paired-
Student t-test. Values of p<0.05 were considered statistically
significant.
Results: Baseline BMD was 0.66 g/cm2 for L1-L4 and
0.56 for femoral neck, 1 year after zoledronate BMD was
0.67 g/cm2 for L1-L4 and 0.59 for femoral neck. T-test
showed no significant change (neither increase nor de-
crease) for any of the sites (p>0.05). We prescribed
zoledronate for the following reasons: side effects of
peroral therapy in six patients (50%), noncompliance in
four patients (33%) and lack of peroral therapy efficacy
in two patients (16%). Four (33%) patients experienced
flu-like symptoms following application.
Conclusion(s): Based on BMD preservation, we find the
therapy with zoledronate is effective for the treatment of
postmenopausal osteoporosis after 1 year and is occasionally
associated with flu-like symptoms.
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DECREASED SERUM LEVELS OF CATHEPSIN-K
AND BONE TURNOVER IN PATIENTS WITH
TYPE-2 DIABETES MELLITUS: A
CASE-CONTROL STUDY
Mohammed-Salleh M Ardawi1, Abdulrahim A Rouzi2,
Daad H Akbar3, Abdulrahman A AlShaikh3, Maimoona M
Ahmed3, Sami M Bahlas3, Mohammed H Qari4
1Center of Excellence for Osteoporosis Research and
Faculty of Medicine, King Abdulaziz University,
Clinical Biochemistry, 2Obstetrics and Gynecology,
3Internal Medicine, 4Haematology, Jeddah, Saudi
Arabia
Objective(s): Limited information is available on the
changes in bone turnover markers (BTMs) and cathepsin
K in patients with diabetes mellitus (DM). The present study
describes the relationships between serum cathepsin K, bone
turnover markers (BTMs), PTH, and 25-hydroxyvitamin-D
[25(OH)D] and BMD among patients with type 2 diabetes
mellitus (T2DM).
Material & Methods: Case-control study including 630
patients with T2DM [postmenopausal women (n=350);
men (n=275); age range 50-79 yrs] were studied and
compared with age- and sex-matched controls (n=630).
Each subject completed a questionnaire and provided
fasting blood and second-void urine samples. Anthropo-
metric parameters, socioeconomic status, together with
the measurements of serum cathepsin K, BTMs [name-
ly: serum osteocalcin (s-OC), bone-specific alkaline
phosphatase (s-bone-ALP), type 1 collagen C-telopep-
tide (s-CTx), procollagen type 1 N-terminal propeptide
(s-PINP) and urinary N-terminal crosslinked telopeptide
of type-1 collagen (u-NTX)], serum PTH, serum 25
(OH)D, glycated hemoglobin (HbA1c) and plasma glu-
cose. BMD values (neck femur, lumbar spine and total
hip) were measured by DXA.
Results: Serum cathepsin K levels were significantly lower
in T2DM patients (4.22±2.16 pmol/L) as compared with
corresponding controls (6.81±3.64 pmol/L) (P<0.001), re-
spectively. Bone resorption markers levels (s-CTX, u-NTx)
were lower in T2DM compared with controls (P<0.001)
with no significant differences in bone formation markers
(s-OC, s-PINP, and s-bone-ALP). Serum PTH levels were
lower in T2DM (3.41±1.86 pmol/L) vs. controls (5.22±2.36
pmol/L) (P<0.001), respectively. Also serum 25(OH)D lev-
els were significantly lower in T2DM (36.51±18.4 nmol/L)
vs. controls (41.72±15.84 nmol/L) (P<0.05). Bone resorp-
tion markers showed negative correlations with BMD val-
ues at all sites studied (P<0.001).
Conclusion(s): Serum cathepsin K, bone resorption markers
and PTH levels were markedly lower in T2DM patients as
compared with age- and sex-matched healthy controls.
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SERIAL MEASUREMENTS OF BONE TURNOVER
MARKERS IN POSTMENOPAUSALWOMEN WITH
DIFFERENT RATES OF BONE LOSS AND
OSTEOPOROSIS RISK: THE CEOR STUDY
Mohammed-Salleh M Ardawi1, Mohammed H Qari2,
Abdulrahim A Rouzi3, Sharifa A Al-Sibiani3, Nawal S
Al-Senani3
1Center of Excellence for Osteoporosis Research and Faculty of
Medicine, King Abdulaziz University, Clinical Biochemistry,
2Haematology, 3Obstetrics andGynecology, Jeddah, SaudiArabia
Objective(s): Low BMD is an important risk factor for osteo-
fragility with about half of the fractures occurring in women
with BMD below the diagnostic threshold for osteoporosis
(i.e., T-score≤-2.5 SD). Combining BMDwith other risk factors
can potentially improve identification of women with and/or at
high risk of osteoporosis. The present study describes whether
assessment of bone turnover markers (BTMs) at multiple time
intervals can identify women at high risk for bone loss.
Material & Methods: We examined 707 postmenopausal
women in a population-based study with a mean follow-up
period of 5.2±1.3 years. Four BTMs [namely: serum osteocalcin
(s-OC), bone-specific alkaline phosphatase (s-bone-ALP), type 1
collagen C-telopeptide (s-CTX), procollagen type 1 N-terminal
propeptide (s-PINP) and urinaryN-terminal cross-linked telopep-
tide of type-1 collagen (u-NTX)] were studied at baseline and at
1, 2, 3 and 5 years. The 5-year change in BMD values [total hip,
neck femur, and lumbar spine (L1-L4)] were also determined.
Results: At baseline, BTMs correlated weakly to changes in
BMD values at all sites studied. The associations were
stronger when mean of baseline and 1-year values was used
(regression coefficients -0.14 to -0.29, P<0.001). Addition
of 3- and 5-year values further strengthened the correlation
(regression coefficients -0.26 to -0.35, P<0.001). Women
with high turnover lost greater BMD values than those with
intermediate or low turnover (P<0.001).
Conclusion(s): Serial measurements of BTMs improve the
identification of postmenopausal women with higher rate of
bone loss and at greater risk of osteoporosis.
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LYCOPENE SUPPLEMENTATION IMPROVED
BONE RESORPTION, BONE MINERAL DENSITY,
OXIDATIVE STRESS MARKERS AND MARKERS
OF ENDOTHELIAL FUNCTION IN
POSTMENOPAUSALWOMEN: THE CEOR STUDY
Mohammed-Salleh M Ardawi1, Mohammed H Qari2,
Abdulrahim A Rouzi3, Badrudin M Mustafa3
1Center of Excellence for Osteoporosis Research and Fac-
ulty of Medicine, King Abdulaziz University, Clinical Bio-
chemistry, 2Haematology, 3Obstetrics and Gynecology,
Jeddah, Saudi Arabia
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Objective(s):We studied the effects of lycopene supple-
mentation on biochemical bone turnover (BTMs),
BMD, oxidative stress markers together with endotheli-
al-cell function and oxidative-DNA damage in postmen-
opausal women in a randomized controlled intervention
study.
Material & Methods: A total of 90 healthy women agreed
to participate in the study and gave their informed consent.
Inclusion criteria were: age of ≥50-65 years, postmenopaus-
al state, independent mobility, and a femoral neck and/or
lumbar spine (L1-L4) T-score values of ≥1.0. Women with
cancer or chronic diseases or treatment for metabolic bone disor-
ders or with diseases known to be associated with increased
oxidative stress were excluded. Women were randomized into 3
equal groups to follow a daily lycopene (Lyc-O-mato) supple-
mentation protocol: (1) 30mg/day (n=30); (2) 45mg/day (n=30);
and (3) placebo capsules containing 0 mg/day lycopene (n=30).
Following a 4-week washout period with no lycopene-containing
foods being consumed, and at 2, 4 and 6 months of lycopene
supplementation, fasting blood and second-void early morning
urine samples were collected. Lycopene, total antioxidant status
(TAS), total oxidant status (TOS), oxidative stress index (OSI),
antioxidant enzymes, protein thiols, lipid peroxidation and BTMs
(s-OC, s-PINP, s-bone ALP, s-CTX, u-NTX and s-TRACP-5b),
endothelial function markers (s-VCAM-1, s-ICAM-1) and oxida-
tive-DNA damage (indicated by alkaline comet assay) were de-
termined at various time intervals. BMDvaluesweremeasured by
X-ray absorptiometry at baseline and 6 months following
supplementation.
Results: Lycopene supplementation for 6 months significant-
ly increased serum lycopene compared to placebo (P<0.001)
and decreased bone resorption (P<0.001) with increases in
bone formation markers (P<0.02). The comet assay showed
significant decreases in comet tail lengths (P<0.05), comet tail
DNA (P<0.001) and comet tail moment (P<0.01), in women
with lycopene supplementation as compared with placebo
controls. Lycopene supplementation significantly increased
TAS (P<0.001) and decreased TOS (P<0.001); OSI
(P<0.001); lipid peroxidation (P<0.001) and protein oxidation
(P<0.001) variables and s-ICAM (P<0.002) and s-VCAM-1
(P<0.02) as compared with placebo control, respectively.
Conclusion(s): Our findings demonstrate positive effects
of 6-months lycopene supplementation on decreasing
bone resorption markers, oxidative stress variables and
markers of endothelial function in postmenopausal
women.
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WHAT SHOULD BE THE INTERVENTION
THRESHOLDS OF TRABECULAR BONE SCORE
(TBS) WHEN USED AS A MAJOR CLINICAL RISK
FACTOR (CRF) OF OSTEOPOROTIC FRACTURES
(OPs)? A META-LIKE ANALYSIS
Didier Hans, Renaud Winzenrieth, Berengère Aubry-Rozier,
Delphine Stoll, Olivier Lamy, Marc-Antoine Krieg
Lausanne University Hospital, Bone and Joint Department,
Lausanne, Switzerland
Objective(s): To have an added value over BMD, a CRF
of osteoporotic fracture must be predictable of OPs,
independent of BMD, reversible and quantifiable. There
are many recognized major CRF related to general risk,
basic disease or to drugs. Out of these factors, many of
them are indirect descriptor of bone quality. TBS pre-
dicts fracture independently of BMD as demonstrated
from previous studies. The aim of the study is to verify
if TBS can be considered as a major CRF of OPs and
to determine its intervention thresholds.
Material & Methods: Existing validated datasets of Cau-
casian women were re-analyzed in this meta-like analysis.
These datasets were weighted differently according to their
design. This study involves more than 33,000 women (>50
years) with 2200 osteoporotic fractures from three prospec-
tive studies (OFELY, MANITOBA, SEMOF) and 12 cross-
sectional studies including the OsteoLaus and Osteo-Mobile
studies. Weighted relative risk (RR) for TBS was expressed
for each decrease of one standard deviation and compared
with those obtained for the major CRF included in FRAX®.
TBS intervention thresholds were evaluated using a tertile
approach.
Results: TBS thresholds obtained were 1.195 and 1.301 for
the lowest and the highest tertiles respectively. Overall TBS
RR after adjustment for age was 1.81 [95%CI 1.35-2.47].
For all women combined, RR for fracture for the highest
compared with the middle TBS tertile was 1.8 and for the
highest compared with the lowest TBS tertile was 2.8.
Besides, the TBS lowest tertile was reached at 75 years as
the BMD WHO cutoff point of -2.5 T-score.
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Conclusion(s): TBS is comparable to most of the major
CRF (Fig 1) and thus could be used as one of them. Defined
thresholds seem to be consistent amongst the different stud-
ies and could be a starting point for clinical use. Further
studies using sensitivity and specificity are needed to con-
firm these first findings.
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VITAMIN D LEVELS IN SUBJECTS WITH
OSTEOARTHRITIS
Hulya Uzkeser1, Saliha Karatay2, Kadir Yildirim2
1Regional Education and Research Hospital, 2Ataturk Univer-
sity, PMR, Erzurum, Turkey
Objective(s): 25-hydroxyvitamin D effects the mineraliza-
tion of bone matrix, and decreased level of 25-hydroxyvita-
min D may leads to insufficient mineralized bone (1).
Insufficient mineralization may change the forces across
the joint and it may result as joint degeneration (2). Also
low level of 25-hydroxyvitamin D plays a role in the me-
tabolism of chondrocytes that causing degeneration on
bones (3).The purpose of this article is to assess the serum
25-hydroxyvitamin D levels in the patients with osteoarthri-
tis and healthy controls.
Material & Methods: 45 patients with osteoarthritis and 25
healthy controls were consecutively included in the study.
Serum 25-hydroxyvitamin D, Ca, P and ALP levels were
analyzed in both groups.
Results: The demographic variables like age and sex were
similar between osteoarthritis patients and controls (p>0.05).
Serum 25-hydroxyvitamin D levels were in patients with OA
was found to be significantly lower than controls (p<0.001)
and ALP levels were significantly higher in patients with
osteoarthritis according to control cases (p<0.01). Serum Ca
and P levels were not statistically significant in patients with
osteoarthritis than control subjects (p>0.05).
Conclusion(s): Our results suggest that serum 25-hydrox-
yvitamin D levels may be lower and ALP levels may be
higher in patients with osteoarthritis according to control
cases. Further long-term studies on the subject are needed to
explore relation to between serum 25-hydroxyvitamin D
levels and development and progression of osteoarthritis.
References: 1- Lane NE, Gore LR, Cummings SR, et al,
Arthritis Rheum 1999;42:854. 2- Chaganti RK, Parimi N,
Cawthon P, et al, Arthritis Rheum 2010;62:511. 3- Ding C,
Cicuttini F, Parameswaran V, et al, Arthritis Rheum
2009;60:1381.
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SERUM 25-HYDROXYVITAMIN D LEVELS
IN PATIENTS WITH LEUKEMIA
Hulya Uzkeser1, Rahsan Yildirim2, Ilhami Kiki2, Saliha
Karatay3, Kadir Yildirim3
1Regional Education and Research Hospital, 2Ataturk Univer-
sity, Hematology, 3Ataturk University, PMR, Erzurum, Turkey
Objective(s): This study was carried out to investigate the
serum 25-hydroxyvitamin D levels of patients with
leukemia.
Material &Methods: 25 patients (15 male, 10 female) with
Leukemia and 29 matched healthy controls were enrolled in
this study. In laboratory analysis, serum 25-hydroxyvitamin
D levels were measured in both groups.
Results: There were no statistically significant differences
between the two groups with respect to demographic data
(p>0.05). In patients with leukemia, 25-hydroxyvitamin D
values were lower significantly more than those of the
healthy controls (p<0.05). Serum 25-hydroxyvitamin D lev-
els of patients and controls were 13.6±6.98 and 18.4±8.76
ng/ml, respectively.
Conclusion(s): Our results showed that serum 25-hydrox-
yvitamin D levels may decrease in patients with leukemia
according to control cases. Further studies need to define the
relationship between vitamin D status and leukemia.
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PITFALLS IN THE VALIDATION OF FRACTURE
RISK ASSESSMENT TOOLS
Eugene McCloskey, Helena Johansson, Anders Odén, John
A Kanis
University of Sheffield, WHO Collaborating Centre for
Metabolic Bone Diseases, Sheffield, UK
Objective(s): FRAX is an extensively validated assessment
tool for the prediction of fracture in men andwomen. A number
of recent studies have addressed the validation and/or compar-
ison of FRAX and other fracture risk assessment tools. The aim
of this study was to review and critique the methods used in
these evaluations of FRAX and other instruments.
Material & Methods: We reviewed studies undertaken in
external cohorts that investigated the calibration of FRAX or
assessed its performance characteristics.
Results: Most studies used inappropriate methodologies to
compare the performance characteristics of FRAX with
other models. These included discordant parameters of risk
(comparing incidence with probabilities), comparison with
internally derived predictors, lack of consideration of repre-
sentativeness of the study cohort and inappropriate use and
interpretation of receiver operating characteristic curves.
There is a predictable and widening discordance between
incidence and probability at older ages, as probability incor-
porates the competing risk of death. An internal model will
almost invariably provide higher gradients of risk (or fracture
discrimination) than models that are derived externally, since
the internal model is constructed to best fit the data within the
index cohort. The difference between the fracture and
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mortality rates in the studied cohort and the rates used to build
the country specific FRAX model should be studied to detect
if the studied cohort is representative for the country. Even if
deemed to be locally representative, hip fracture rates for
example may vary more than 2-fold within a country.
Conclusion(s): Cohort studies that evaluate FRAX and other
assessment tools are to be welcomed but should seek to avoid
deficient analyses that markedly impair interpretation of these
studies. Where impossible to avoid, the conclusions should be
interpreted with caution and preferably re-evaluated.
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SCLEROSTIN AND DKK-1 LEVELS AND THE RISK
OF OCCURENCE OF OSTEOPOROSIS-RELATED
FRACTURES AMONG POSTMENOPAUSAL
WOMEN: THE CEOR STUDY
Mohammed-Salleh M Ardawi1, Abdulrahim A Rouzi2,
Sharifa A Al-Sibiani2, Nawal S Al-Senani2
1Center of Excellence for Osteoporosis Research and Faculty
of Medicine, King Abdulaziz University, Clinical Biochemis-
try, 2Obstetrics and Gynecology, Jeddah, Saudi Arabia
Objective(s): Both sclerostin and dickkopf-1 (DKK-1) reg-
ulate bone formation through the inhibition of the Wnt
signaling pathway. We therefore hypothesized that postmen-
opausal women with increased circulating sclerostin and
possibly DKK-1 levels have a greater risk for osteoporo-
sis-related fractures (ORFs).
Material & Methods:We examined the association between
circulating sclerostin and DKK-1 [both were measured by
ELISA methods, (Biomedica, Austria)] levels and the risk of
ORFs in 707 postmenopausal women, 50 years of age or older
in a population-based study with a mean follow-up period of
5.2±1.3 years. Multivariate Cox proportional-hazards regres-
sion models were used for analysis of the risk of fracture with
adjustment for age, body-mass index and other potential risk
factors that may be associated with the risk of fractures or with
higher circulating sclerostin and/or DKK-1 levels.
Results: High serum sclerostin levels were associated with
an increased risk of ORFs.
Table 1: Increased levels of serum sclerostin and serum DKK-1 and
the risk of ORFs in postmenopausal women.
RR (95% CI)
for 1 SD
increase
RR (95% CI) for
levels < highest
quartile
Unadjusted Adjusted Unadjusted Adjusted
Serum
sclerostin
(pmol/L)
3.10 (1.17-
8.24)
7.74
(2.57-
23.18)
6.01 (2.26-15.98) 14.96
(4.97-
45.56)
Serum
DKK-1
(pmol/L)
1.86 (0.87-
3.79)
1.96
(1.09-
4.12)
3.36 (1.61-7.05) 3.38
(1.49-
7.89)
All relative risk values were adjusted for age, BMI, PA-
score, dietary calcium intake, hand grip strength and BMD
total hip. The quartiles for serum sclerostin (pmol/L) were:
Q≤41.6; Q2=41.6-52.3; Q3=52.31-68.9 and Q4≥68.9, re-
spectively. The quartiles for serum DKK-1 (pmol/L) were:
Q1≤81.9; Q2=81.9-105.2; Q3=105.3-133.2 and Q4≥133.2,
respectively. Following adjustment for age and other con-
founders, the relative risk (RR) of ORFs for each increment
of 1 SD in sclerostin level was greater than 7-fold among
postmenopausal women. Similar, but to a lesser extent, the
RR values were obtained for high serum DKK-1 levels
[RR=1.98 (95% CI: 1.09-4.20)].Further, women in the
highest quartile of sclerostin or DKK-1 levels had an
increase in the risk of ORFs so that the risks were 15-fold for
sclerostin and 3.4-fold for DKK-1, respectively. The risks of
ORFs that were attributable to sclerostin or DKK-1 levels (in
the highest quartile) were estimated at 56.6% and 31.7%,
respectively.
Conclusion(s): Higher sclerostin levels are associated with
a greater risk of ORFs among postmenopausal women.
Similar findings were obtained for DKK-1 levels and its
association with the risk of ORFs, albeit to a lesser degree
than sclerostin.
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EPIDEMIOLOGY OF OSTEOPOROSIS,
FRACTURES AND VITAMIN D DEFICIENCY
IN BULGARIAN WOMEN AGED 50 YEARS
AND OLDER
Anna-Maria Borissova1, Alexander Shinkov1, JordanVlahov1,
Lili Dakovska1, Mihail Boyanov2, Plamen Popivanov3
1Clinical Center of Endocrinology and Gerontology, Medi-
cal University Sofia, Thyroid and Bone Metabolic Clinic,
2Department Internal Medicine, Medical University Sofia,
Endocrinology Clinic, 3Alexandrovska University Hospital,
Bone Metabolic Unit, Sofia, Bulgaria
Objective(s): 1. To determine the prevalence of the ma-
jor risk factors for osteoporosis and the densitometric
prevalence of osteoporosis in a national representative
sample of Bulgarian women aged 50 and older (Osteo-
porosis National Epidemiology Study). 2. To determine
the prevalence of vitamin D deficiency and insufficiency
in a large group of postmenopausal women (vitamin D
Epidemiology Study).
Material & Methods: 1. The Bulgarian Osteoporosis Epi-
demiology Study was part of the National Program against
Osteoporosis in Bulgaria 2005-2010. The National Statisti-
cal Institute selected a national representative epidemiolog-
ical sample, a questionnaire was implemented searching for
major risk factors for osteoporosis and allowing fracture risk
calculation according to FRAX. Ten osteoporosis centers
throughout the country participated. BMD was measured
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at the proximal femoral neck by DXA. 2. The vitamin D
Epidemiology Study included 1400 postmenopausal women
throughout the country. The blood samples were taken dur-
ing winter and serum 25-OH-vitamin D was measured by
HPLC. The statistical analysis was performed on SPSS 13.0
for Windows.
Results: 1. 1331 women were included (mean age 63.8±8.3
yrs), divided into decades. 16.8% of them had osteoporosis
and 46.5% had low femoral neck BMD. Their mean 10-year
absolute fracture risk for major fractures was 13.4±9.2%,
and for hip fractures 2.8±5.2% respectively. 2. The preva-
lence of vitamin D deficiency was around 30%, additional 1/3
of the postmenopausal women had some levels of in-
sufficiency. A small percentage only had optimal vitamin D
levels.
Conclusion(s): This study is the largest epidemiological
osteoporosis trial in Bulgaria and allows assumptions about
the prevalence of osteoporosis and vitamin D deficiency
among women aged 50 and older in our country on which
the secondary fracture prevention could be based.
Disclosures:N. Temelkova, S. Jeleva, Z. Velkova, N. Velkov,
M. Velkova, S. Tsvetkova, R. Nestorova, B. Terziiski, I.
Alexandrova,M. Gavrailova (co-workers in The Osteoporosis
Study Group in Bulgaria)
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EFFECT OF STRONTIUM RANELATE ON A
MURINE MODEL OF MULTIPLE MYELOMA
Hélène Marchand-Libouban, Elodie Fioleau, Daniel
Chappard
University of Angers, LHEA-Bone Remodeling and Bio-
materials, Angers, France
Objective(s): The aim of the study was to evaluate the
effects of strontium ranelate in a murine model of Multiple
Myeloma. The study focused on the effect on tumor growth,
animal survival, bone resorption and formation, cortical and
trabecular bone loss.
Material & Methods: Two groups of 13 mice were injected
intravenously with 1.5 106 5THL cells. The first group
served as control; the second (SrRan) received strontium
ranelate by oral gavage (1800 mg/kg/day) from 2 weeks
(2w) before 5THL injection until a maximum period of
12w. Tumor growth was controlled by measurement of the
paraprotein every 2w, from 6w until sacrifice; osteolysis was
assessed on tibia and femur by X-ray and μCT. 3D-histo-
morphometric analysis was performed on trabecular bone.
Cortical thickness was measured on 2D sections. Effect on
bone resorption was assessed by a serum dosage of TRAcP
and by histomorphometry; effect on bone formation was
evaluated by a serum dosage of P1NP.
Results: No significant differences were observed in the
paraprotein level between the two groups. In contrast, SrRan
tended to delay the time of sacrifice compared to controls as
illustrated by the trend curve. 3D-histomorphometric param-
eters showed a significant difference for Structure Model
Index and Trabecular Bone Pattern factor, which were im-
proved in the SrRan group. Cortical thickness from the
methaphyseal region was significantly higher in the SrRan
group (+7.4%, P<0.05). Significant decrease of PINP level
was observed in SrRan group (-33%, P<0.01) whereas no
significant decrease of TRAcP was observed. Osteoclast
number from both femur and tibia cortices was significantly
decreased in the SrRan group (resp. -21.8% and -28.2%,
P<0.01).
Conclusion(s): Strontium ranelate did not have an effect on
tumor growth but would tend to improve survival time.
Optimal effects of strontium ranelate were obtained on
cortical bone by improving cortical thickness and reducing
cortical resorption.
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SERUM 25-HYDROXYVITAMIN D LEVELS
IN PATIENTS WITH LYMPHOMA
Hulya Uzkeser1, Saliha Karatay3, Rahsan Yildirim2, Ilhami
Kiki2, Kadir Yildirim3
1Regional Education and Research Hospital, 2Ataturk Univer-
sity, Hematology, 3Ataturk University, PMR, Erzurum, Turkey
Objective(s): This study investigated the serum 25-hydrox-
yvitamin D levels of patients with lymphoma.
Material & Methods: 25 patients with lymphoma and 30
matched healthy controls were enrolled in this study. Serum
25-hydroxyvitamin D were measured in both groups.
Results: There were no significant differences between the
two groups regarding demographic data. The serum 25-
hydroxyvitamin D levels of patients and controls were
12.67±7.37 and 16.54±8.32 ng/ml, respectively. In patients
with lymphoma, 25-hydroxyvitamin D values were signifi-
cantly lower than those of the healthy controls (p<0.05).
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Conclusion(s): Our results suggest that serum 25-hydrox-
yvitamin D levels are decreased in patients with lymphoma.
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FRAX® WITHOUT BMD
Eugene McCloskey1, Helena Johansson1, Anders Odén1,
John A Kanis1, William D Leslie2
1University of Sheffield, WHO Collaborating Centre for
Metabolic Bone Diseases, Sheffield, UK, 2University of
Manitoba, University of Manitoba, Winnipeg, Canada
Objective(s): The use of FRAX in the absence of BMD
continues to the subject of some debate and requires a
review of the evidence for its clinical application.
Material & Methods: The prediction of fractures with
the use of clinical risk factors alone in FRAX is com-
parable to the use of BMD alone and is suitable, there-
fore, in the many countries where DXA facilities are
sparse. In countries where access to BMD is greater,
substantial analyses demonstrate that FRAX can be used
without BMD in the majority of cases with BMD tests
reserved for those close to a probability based interven-
tion threshold.
Results: The clinical risk factors used in FRAX have high
validity as judged from an evidence based assessment and
identify a risk that is responsive to pharmaceutical interven-
tion. In addition, the selection of high risk individuals with
FRAX, without knowledge of BMD, preferentially selects
for low BMD. Indeed, recent studies suggest that the ma-
jority of women selected for intervention by BMD and/or
fracture criteria would also be identified by FRAX clinical
risk factors alone. Regardless, the effects of treatment, with
the possible exception of alendronate, are largely indepen-
dent of baseline BMD.
Conclusion(s): Thus, whereas the efficacy for agents to
reduce fracture risk has not been tested prospectively in
randomised controlled trials in patients selected on the basis
of FRAX probabilities, there is compelling evidence that
FRAX with or without the use of BMD
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VERTEBRAL KYPHOPLASTY: IS IT USEFUL?
Palencia Jesús, García Virginia, Hernández Rubén, Yagüe
Fernando, Plata María, García Luis
University Clinic Hospital, Orthopaedic Surgery and Trau-
matology, Valladolid, Spain
Objective(s): We describe the use of percutaneous cement-
ing vertebral osteoporotic fractures as definitive treatment of
pain and symptom relief, restoring the activity and patient
autonomy.
Material & Methods: 77 year old female with a history of
hypertension, atrial fibrillation, ischemic stroke and mitral
regurgitation, was referred to Orthopedics for filing week
history of low back pain without traumatic antecedent. Ex-
ploration: pain in dorsolumbar hinge and low back without
radiation to lower limbs with preserved strength and sensi-
tivity. In the radiology showed vertebral collapse in L1, L2
and L3, starting conservative treatment and analgesia rigid
brace and completing study dorsolumbar MRI confirmed
the existence of mild anterior wedging of the vertebrae D6
and D11, without edema and fracture acute collapse of the
upper plates of the vertebrae L1, L2 and L3, osteoporotic
appearance. Given the persistence of pain, surgical treat-
ment is decided by cementation with kyphoplasty, also
performing a biopsy.
Results: After surgery, the patient improved pain clinic. The
biopsy performed with analytical studies was assessed by
discarding hematology tumor process.
Conclusion(s): Osteoporotic vertebrae fail to compressive
forces, usually in bending, causing fractures with in-
volvement of the anterior wall without causing neurolog-
ical disorders and symptoms is pain, which decreases the
activity and patient autonomy. The goals of surgical
treatment are to relieve pain and restore, where possible,
height and sagittal balance. Kyphoplasty involves insert-
ing an inflatable balloon within the vertebral body, be
pressurized to create a cavity and fill it by a high vis-
cosity acrylic cement. Its design has fewer complications
than vertebroplasty in the acute phase, although as verte-
broplasty in subacute or chronic phase, the correction of
height is lower.
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AN ECONOMIC EVALUATION OF STRONTIUM
RANELATE FOR THE TREATMENT OF MALE
OSTEOPOROSIS
Mickael Hiligsmann, Wafa Ben Sedrine, Olivier Bruyère,
Jean-Yves Reginster
Osteoporos Int (2012) 23: (Suppl 2):S85–S386 S305
University of Liège, Department of Public Health Sciences,
Liège, Belgium
Objective(s): Strontium ranelate demonstrated to be effec-
tive for the treatment of male osteoporosis in the MALEO
Trial. In addition to the therapeutic value of a new drug, it
becomes increasingly important to evaluate whether it rep-
resents good value for money. The present study aims there-
fore to estimate the cost-effectiveness of strontium ranelate
in the treatment of osteoporotic men from a Belgian health-
care payer perspective.
Material & Methods: An updated version of a previously
validated Markov microsimulation model was used to esti-
mate the cost (€2010) per quality-adjusted life-year (QALY)
gained of strontium ranelate compared with no treatment.
Based on the bridging Maleo study which showed same
lumbar and femoral neck BMD increase over 1 year in
men as in women, same antifracture efficacy has been
considered in men as in women in the base case analysis.
The model was populated with cost and epidemiological
data for Belgium and the population from the MALEO Trial
(i.e., mean age of 73 years, femoral neck BMD T-score of -
2.2 and 28.1% had prevalent vertebral fracture at baseline).
Parameter uncertainty was investigated using one-way and
probabilistic sensitivity analyses. In particular, additional
analyses were performed in populations (over 60 years) with
femoral neck BMD T-score≤−2.5 or prevalent vertebral
fracture.
Results: Strontium ranelate compared with no treatment
was estimated in the base case at €22,717/QALY gained.
This value decreased to €15,465 and to €8,050 when as-
suming a BMD T-score equal to -2.5 or that all men had
prevalent vertebral fractures at baseline, respectively.
Results were robust over a wide range of sensitivity analy-
ses. Results fall below €33,000 per QALY gained for men
with a BMD T-score≤-2.5 or with prevalent vertebral frac-
ture, over the entire age range examined (60-80 years). In
probabilistic sensitivity analyses strontium ranelate remains
below the willingness to pay threshold of €45,000/QALY in
89% of cases
Conclusion(s): The results of this study demonstrated that
strontium ranelate is a cost-effective strategy compared with
no treatment for the treatment of osteoporotic men in Bel-
gian setting, including in patients over 60 years with a BMD
T-score≤-2.5 or with prevalent vertebral fracture.
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COMPARING OUTPUTS OF THE FRAX AND
GARVAN FRACTURE RISK ASSESSMENT TOOLS
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A Kanis
University of Sheffield, WHO Collaborating Centre for
Metabolic Bone Diseases, Sheffield, UK
Objective(s): Simple approaches to comparisons of fracture
risk assessment tools frequently overlook differences in
output metrics. For example, both FRAX® and the Garvan
Fracture Risk Calculator use clinical risk factors (CRF) and
BMD to assess fracture risk. In contrast to the Garvan tool,
the output of FRAX is fracture probability, derived by
integrating risk factors on both fracture risk and competing
death risk. The aim of the present study was to illustrate the
impact in output of the two fracture risk assessment tools.
Material & Methods: The impact of age on hip fracture
outputs was assessed with both the Garvan tool and FRAX.
The T-scores were set differently in the two models so that
the output estimates were approximately equal at the age of
60 years. For FRAX the probability of hip fracture was
assessed for a woman with a T-score of -4.0 SD, a BMI of
23.9 kg/m2 and no other CRF. For the Garvan tool the hip
fracture risk was assessed for a woman with a T-score of -
3.3 SD and no other CRF. Data were computed from the
respective web sites.
Results: Whereas the output between FRAX and Garvan
tool were similar for the lower ages, differences became
apparent with advancing age. With the Garvan tool, hip
fracture risk increased exponentially with age. By contrast,
the probabilities calculated with FRAX reached a plateau
and thereafter decreased from18% at the age of 80 years to
12% at the age of 90 years, due to the competing risk of
death. No such effect was seen in the Garvan tool, where the
corresponding figures were 17.8% and 27.3%.
Conclusion(s): The present study shows that the calculation
of fracture probability which incorporates the death hazard
is not synonymous with the calculation of fracture risk.
Direct comparison of the tools is erroneous, particularly in
aged individuals.
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Objective(s): Adiponectin, a protein exclusively secreted
from adipose tissue, may exert influences on bone health
as adipocytes and osteoblasts share a common progenitor.
The aim of the present study was to determine if serum
adiponectin was associated with fracture risk in elderly men
Material & Methods: We studied the relationship between
serum adiponectin and the risk of fracture in 999 elderly men
recruited to the MrOS study from the general population in
Gothenburg, Sweden. Baseline data included general health
questionnaires, lifestyle questionnaires, BMI, total hip BMD,
serum adiponectin, osteocalcin and leptin. Incident fractures
were captured during an average of 5.2 years follow up
(maximum 7.4 years). Poisson regression was used to inves-
tigate the relationship between serum adiponectin, other risk
variables and the time-to-event hazard function of fracture.
Results: Median levels of serum adiponectin at baseline
were 10.4 μg/ml (interquartile range 7.7-14.3). During fol-
low up, 150 men sustained one or more fractures. The risk
of fracture increased in parallel with increasing serum adi-
ponectin (hazard ratio per SD, 1.46 (95% CI: 1.23-1.72) and
persisted after multivariate-adjusted analysis (HR/ SD, 1.30
(95% CI: 1.09-1.55).
Conclusion(s): Higher serum adiponectin levels are associat-
ed with a significant excess risk of fracture in elderly men
which was independent of several other risk factors for frac-
ture. The mechanism(s) remains to be clarified but its mea-
surement may hold promise as a risk factor for fracture in men.
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Objective(s): To investigate the effect of intravenous zole-
dronic acid, on BMD at the hip and spine in 12-18 months,
in older adults attending a geriatric day hospital.
Material & Methods: A retrospective analysis of a cohort
of 192 patients with known osteoporosis (T-score less than -
2.5) attending a geriatric day hospital setting was done.
Subjects who were treated with IV zoledronic acid (dose
range 1-5 mg) and had normal renal function were included
in the study. All subjects also had DXA scans performed
between 12-18 months to assess for change in BMD at the
hip and spine. 43 subjects met the given criteria. Drug side
effects were recorded. The mean difference in the BMD pre
and post infusion was analyzed using a paired t-test.
Results: The mean age of the patients in the study was
75.2±9.3 years (SEM 1.42) with 93% being female. The mean
BMD at baseline was 0.82 g/cm2 (SEM 0.026) at the spine and
0.71 g/cm2 (SEM 0.017) at the hip. The median dose of
zoledronic acid administered was 4 mg. The median time to
follow up DXA to review response was 13 months. A signif-
icant improvement was seen in BMD at the hip (mean differ-
ence +0.012 g/cm2, p=0.019, SEM 0.005) and at the spine
(mean difference +0.045 g/cm2 P=0.000, SEM 0.007) post
infusion. Only 5% of the subjects reported minor side effects
such as body aches and flu like symptoms.
Conclusion(s): The study shows that intravenous zole-
dronic acid is effective at improving BMD in osteoporotic
subjects in a period between 12-18 months. The response in
the spine was found to be greater than in the hip, a finding
that is consistent with other studies. In addition, treatment
was very well tolerated by the subjects. This strongly sup-
ports the use of IV zoledronic acid in osteoporotic older
adults.
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LIFE DURING 10 YEARS OF FOLLOW-UP OF
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Objective(s): To assess whether low BMD and vertebral
deformity (VDf) at baseline and incident vertebral fractures
Osteoporos Int (2012) 23: (Suppl 2):S85–S386 S307
(VFx) during 10-year follow-up affect health-related quality
of life (QOL) at the end of follow-up.
Material & Methods: Among 900 women aged 50-79 years
selected randomly from 3 municipalities in Japan, 852 com-
pleted the baseline study and were invited for follow-up
surveys conducted 3 times in 10 years including VFx assess-
ment on digital images from spine absorptiometry and spine
BMD measurement. Prevalent vertebral deformity (VDf) was
determined according to McCloskey-Kanis criteria. Incident
VFx was identified when one of the three vertebral heights
decreased by 20% or more compared to the baseline heights
and the vertebra satisfied McCloskey-Kanis or Genant's grade
2 or 3 fracture criteria. Health-related QOL was assessed by
SF-36 questionnaire at the end of follow-up.
Results: 493 women complete the 10-year follow-up and
had no missing data. Their mean age, BMI, and spine BMD
were 62.0±7.5 years, 24.2±3.4 kg/m2 and 0.825±0.146 g/
cm2, respectively. We identified 51 VDf in 38 women at
baseline and 119 VFx in 75 women during the follow-up
where overall incidence rate of VFx was 15.2/1000 per-
son-years. The multiple linear regression analyses indi-
cated that prevalent VDf and BMD at baseline did not
affect any score of SF36 subdomains but incident VFx
significantly deteriorate the scores of physical function-
ing, role-physical. body pain, role-emotional and mental
health domains. Comparisons of mean scores of subdo-
mains between participants with and without incident
VFx were illustrated in Figure 1.
Conclusion(s): Incident VFx deteriorated several domains
of SF36 independently of age and prevalent VDf at baseline
in Japanese women.
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Objective(s): The present study aimed to update the infor-
mation base available on the heterogeneity in the risk of hip
fracture on a worldwide basis. An additional aim was to
document variations in fracture probability as determined
from the available FRAX models.
Material & Methods: Studies on hip fracture risk were
identified from 1950 to November 2011 by a Medline
OVID search. Evaluable studies in each country were
reviewed for quality and representativeness and a study
(studies) chosen to represent that country. Age-specific
incidence rates were age-standardised to the world
population in 2010 in men, women and both sexes
combined. The 10-year probability of a major osteopo-
rotic fracture for a specific clinical scenario was com-
puted in those countries for which a FRAX model was
available.
Results: Following quality evaluation, age standardised
rates of hip fracture were available for 63 countries and 45
FRAX models available in 40 countries to determine frac-
ture probability. Countries categorised by hip fracture risk
are shown in the figure. Worldwide, there were marked
variations in hip fracture rates and in the 10 year probability
of osteoporotic fractures, with a greater than 10-fold varia-
tion between countries. The variation is sufficiently large
that these cannot be explained by the often multiple sources
of error in the ascertainment of cases or the catchment
population.
Conclusion(s): Understanding the reasons for this hetero-
geneity may lead to global strategies for the prevention of
fractures.
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Objective(s): Vitamin D deficiency is common among
Saudi elderly, and leads to secondary hyperparathyroidism,
bone loss, muscle weakness with high risk of/or with oste-
oporotic fractures. The present study describes the relation-
ship between vitamin-D status, muscle function and strength
among postmenopausal women aged ≥60 years.
Material & Methods: A total of 530 women were included
in the study. Anthropometric parameters, socioeconomic
status, together with the completion of a questionnaire on
lifestyle habits and other variables were collected. Overnight
fasting blood and second-void urine samples were collected
for the determinations of serum, 25 hydroxyvitamin D 25
(OH)D, intact PTH (iPTH), bone turnover markers (BTMs)
[namely: serum osteocalcin (s-OC), bone-specific alkaline
phosphatase (s-bone-ALP), cross-linked C-terminal telopep-
tide of type 1 collagen (s-CTX), procollagen type 1 N-
terminal propeptide (s-PINP), and urinary N-terminal cross-
linked telopeptide of type-1 collagen (u-NTX)] and minerals
(serum calcium, phosphate and magnesium). Muscle func-
tion was assessed by means of walking-speed test, standing
balance, and sit-to-stand tests. Lower extremity muscle
strength was determined using a manual dynamometer.
Results: Serum 25(OH)D levels ≥50 nmol/L were found to
be associated with improved lower extremity muscle func-
tion and strength. Only 18.0% of women had 25(OH)D
levels ≥50 nmol/L. Women with 25(OH)D levels ≥50
nmol/L showed higher muscle function tests (P<0.001),
stronger knee extensor (P<0.001) and hip abductor
(P<0.001) muscles. Negative correlation was observed be-
tween iPTH and muscle function (r=-0.512; P<0.001).
Conclusion(s): Serum 25(OH)D levels ≥50 nmol/L are
needed for an acceptable muscle function and strength.
Assessment of vitamin D nutritional status in women aged
≥60 years is suggested to ensure correcting hypovitaminosis
D and improve muscle function and strength tests among
Saudi postmenopausal women.
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RISK FACTORS USED IN THE ASSESSMENT
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Objective(s): There are well established methods for eval-
uating the quality of evidence of the effectiveness of inter-
ventions. The evaluation of risk factors for case-finding can
be judged on similar principles.
Material & Methods: Ease of use of risk factors is of
importance, particularly in the setting of primary care. For
a globally applicable tool, they should also be valid in an
international setting and their predictive value stable over
time. Ideally, the predictive value of such tests should be
subject to meta-analyses to demonstrate a high degree of
consistency in populations similar to those in whom the test
would be applied (level I). The inclusion of an internal
control is appropriate for the highest level of evidence.
Showing a dose-dependent effect may also be helpful in
assigning high validity. Lower levels of evidence (level II
and III) are provided by studies with any of the following
deficits: a narrow population or a sample frame that does not
capture the population in whom the test would be applied,
the lack of a reference standard, case-control studies or the
use of a poor internal control. The lowest level of evidence
is provided by expert committees or clinical experience
(level IV).
Results: A further consideration is the reversibility of
risk, i.e., is there evidence that the risk identified by a
risk factor is amenable to therapeutic intervention. This
can also be graded. At the highest level of evidence it
would be necessary to recruit patients selected on the
basis of the risk factor to a randomised controlled trial
(Level A). In the absence of such data, an alternative
approach is to demonstrate that the presence (or absence)
of a risk factor does not adversely influence therapeutic
efficacy against fracture (Level B).
Figure. FRAX risk factors and their applicability to case finding
Risk factor Ease of use Predictive value Reversibility of risk
BMD 2 I A
BMI 1 I B
Age 1 I A
Sex 1 I A
Prior fracture 1 I A
Parental history 1 I B
Current smoking 1 I B
Glucocorticoid use 1 I A
Rheumatoid arthritis 1 I B
Secondary osteoporosis 1 I B
Alcohol use 1 I B
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Conclusion(s): The clinical risk factors used in WHO
FRAX® algorithms are based on the highest level of evidence.
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Objective(s): Androgenic depletion affects bone metabo-
lism, causing osteopenia. There is limited evidence on the
effect of PTH 1-84 in male osteoporosis. The aim of this
work was to study the effect of PTH 1-84 in an experimental
model of orchidectomized male rats, measuring the changes
in BMD, remodeling markers and bone microstructure.
Material & Methods: Four groups of 10 six-month-old male
Wistar rats. SHAM: n=10, simulated intervention; OQX: n=
10, orchidectomized; OVX+PTH1: n=10, orchidectomized and
treated with PTH 10 μg/kg; OVX+PTH2: n=10 orchidectom-
ized and treated with PTH 50 μg/kg. The treatment was started
3 months after orchidectomy, and was maintained for 3 months.
After sacrifice, BGP, FATR 5b and β-CTX bone remodeling
markers, BMD of the lumbar spine and femur, and a femoral
microstructure analysis by μCT scan were measured.
Results: A statistically significant reduction in vertebral and
femoral BMDwas evidenced in the OQX group vs. the SHAM
group, which partially reverted with the low dose of PTH, and
completely reverted with the high dose. A significant increase
of the CTX/FATR ratio was seen in the OQX group vs. the
SHAMgroup, which was maintained in the treated groups. The
level of BGP did not show any changes in the OQX group,
although a significant dose/response increase was seen in the
treated groups. A relative reduction of BV/TV was seen in the
OQX group, a decrease in the number of trabeculae and an
increase in their separation. PTH treatment (both doses) re-
stored baseline values of BV/TV, partially reducing separation
and increasing trabecular number with the low dose, completely
restoring both parameters with the high dose. Trabecular pattern
factor increased in OQX, it was restored with the low PTH
dose, and it became lower than in the SHAM group with the
high dose. The structure model index (SMI) experienced a
significant reduction in the high-dose group, compared to the
OQX rats.
Conclusion(s): In an animal model of osteoporosis, treat-
ment with PTH 1-84 has shown to have a bone-forming
effect, reflected by an increase in bone formation markers,
and increased lumbar and femoral BMD and a partial or
total recovery of microstructural parameters.
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Objective(s): This study was carried out to investigate the
effect of serum vitamin D levels on BMD.
Material & Methods: Two hundred people were included
in the study. These people divided into 2 groups according
to the levels of vitamin D. The volunteers with the lower of
the vitamin D hormone (20 ↓ ng/dl) were included in the
first group. The others (20 ↑ ng/dl) were included in the
second group. BMD (L1-L4 and femoral neck), serum vita-
min D, Ca and P levels were measured in the both groups.
Results: Vitamin D, Ca, P levels were not significantly
different in the between the two groups. BMD values was
similar in the between two groups (p>0.05)
Conclusion(s): The lower limit or upper limit of normal
values of vitamin D hormone may not affect the BMD
values.
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OSTEOPROTEGERIN, RANKL AND BONE
TURNOVERMARKERSAMONGPOSTMENOPAUSAL
WOMEN WITH AND WITHOUT OSTEOPOROSIS: A
CROSS-SECTIONAL STUDY
Mohammed-Salleh M Ardawi1, Mohammed H Qari2,
Abdulrahim A Rouzi3, Sharifa A Al-Sebiani3, Nawal S Al-Senani3
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Objective(s): Both OPG and RANKL play an important
role in the regulation of bone turnover, but the contribution
of these two cytokines to the pathogenesis of osteoporosis
remains controversial. The present study assess the relation-
ship between the plasma levels of OPG, RANKL, bone
turnover markers (BTMs) and BMD among postmenopausal
women with and without osteoporosis.
Material & Methods: A total of 340 postmenopausal wom-
en diagnosed with osteoporosis and compared with age-
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matched healthy controls (n=340) with normal BMD. Each
women completed a questionnaire and provided fasting
blood and second-void urine samples. Plasma OPG and
RANKL were measured by using two-site sandwich
ELISA – (Biomedical Gruppe Kits, Austria). Other anal-
yses including PTH, FSH, LH, E2, 25(OH)D, bone turn-
over markers [serum osteocalcin (s-OC), serum
procollagen type 1 N-terminal propeptide (s-PINP), uri-
nary N-terminal cross-linked telopeptide of type 1 colla-
gen (u-NTX) and cross-linked C-terminal telopeptide of
type-1 collagen (s-CTX)] and IL-6 were measured by
commercially available kits and reagents on autoanalyzers.
Results: Plasma OPG was significantly higher in women with
osteoporosis (19.26±8.44 pmol/L) than in age-matched controls
(11.15±4.66 pmol/L) (P<0.0001). Similarly, plasma RANKL
levels were significantly higher in women with osteoporosis
(0.71±0.48 pmol/L) than in age-matched controls (0.34±0.29
pmol/L) (P<0.0001), respectively. The OPG/RANKL ratio was
higher in women with osteoporosis vs. age-matched controls
(P<0.001). Women with osteoporosis showed higher levels of
BTMs, IL-6 and PTH but lower serum 25(OH)D and E2
than corresponding controls. Multiple regression analysis
showed that BMD values for lumbar spine (L1-L4) and
neck femur were predicted by OPG (by 17.6%) and
RANKL (by 12.3%), respectively.
Conclusion(s): Both circulating OPG and RANKL levels
inversely related to BMD among postmenopausal women
through increased bone resorption.
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Objective(s): This study was conducted to investigate the
effect of thyroid stimulating hormone (TSH) levels on
BMD.
Material & Methods: 240 volunteers were included in this
study with TSH hormone levels within the normal range.
The volunteers did not have thyroid disease. These volun-
teers were divided into 2 groups. The volunteers with the
lower limit of the THS hormone (2 ↓ ng/dl) were included in
the first group. The others (2 ↑ ng/dl) were included in the
second group. BMD of L1-L4 and femoral neck were mea-
sured in the both groups.
Results: BMD values were not significantly different in the
between the two groups (p>0.05)
Conclusion(s): The lower limit or upper limit of normal
values of TSH hormone may not affect the BMD values.
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Objective(s): Several studies have suggested that obesi-
ty may be a risk factor for fracture. The aim of this
study was to investigate the risk of fracture and num-
ber of fractures that arise in overweight and obese
women.
Material & Methods: We studied 27 prospective popula-
tion-based cohorts from more than 25 countries. At baseline
BMI was calculated as kg/m2. BMD was measured at the
femoral neck by DXA. Fractures during follow up were
collected by self-report and, in some cohorts, confirmed by
radiography. An extension of Poisson regression was used
to examine the relationship between BMI and fracture risk
adjusted for age, BMD and time since baseline.
Results: Baseline data on BMI were available in 296 736
women aged 20-105 years (average 62.7). Femoral neck
BMD was measured in 74 394 women aged 67.0 years.
The prevalence of obesity (BMI≥30 kg/m2) was 18%. Dur-
ing overall follow-up of 1.4 million person-years, 18,336
osteoporotic fractures (4,509 hip fractures) occurred. A ma-
jority of fractures (85%) arose in non-obese women. The
risk of osteoporotic and hip fracture decreased progressively
with increasing BMI. Compared to a BMI of 26 kg/m2, the
hazard ratios (HR, 95%CI) for osteoporotic fracture at a
BMI of 35 or 40 kg/m2 were 0.89 (0.84-0.93) and 0.83
(0.77-0.90), respectively. When adjusted for BMD, the
corresponding HRs were 1.14 (1.06-1.23) and 1.23 (1.10-
1.39), respectively. The HR for hip fracture was also re-
duced at higher BMIs (0.75 [0.67-0.85] and 0.64 [0.53-0.78]
at 35 and 40 vs. 26 kg/m2). When adjusted for BMD, the
corresponding HRs were 1.09 (0.91-1.30) and 1.14 (0.86-
1.50), respectively.
Conclusion(s): Our results demonstrate that at a population
level, obesity is protective for fracture in women and this
protection is mediated by effects on BMD. However, at a
given BMD, obesity appears to be a weak risk factor for
fracture.
P565
EFFECT OF PARATHYROID HORMONE
ON BONE MINERAL DENSITY VALUES
Emin M Akbas1, Hulya Uzkeser2, Arif K Ayan3, Kadir
Yildirim4, Saliha Karatay4
1Ataturk University, Internal Medicine, 2Regional Education
and Research Hospital, 3Ataturk University, Nuclear Medi-
cine, 4Ataturk University, PMR, Erzurum, Turkey
Objective(s): This study made to examine the effect of PTH
on BMD values.
Material & Methods: 101 volunteers were enrolled in this
study. These volunteers were divided into 2 groups. The
volunteers with the lower limit of the PTH (20 ↓ ng/dl) were
included in the first group. The others (20 ↑ ng/dl) were
included in the second group. BMD of L1-L4 and femoral
neck, and serum Ca, P levels were measured in the both
groups.
Results: BMD values of L1-L4 and femoral neck were not
significantly different in the between the two groups
(p>0.05). Also, serum Ca and P levels were similar in the
between two groups (p>0.05).
Conclusion(s): The lower limit or upper limit of normal
values of PTH may not affect the BMD values.
P566
COST-EFFECTIVENESS OF BAZEDOXIFENE
COMPARED WITH RALOXIFENE IN THE
TREATMENT OF POSTMENOPAUSAL
OSTEOPOROTIC WOMEN
Mickael Hiligsmann, Wafa Ben Sedrine, Olivier Bruyère,
Jean-Yves Reginster
University of Liège, Department of Public Health Sciences,
Liège, Belgium
Objective(s): This study aims to evaluate the cost-effective-
ness of bazedoxifene compared with raloxifene in the treat-
ment of postmenopausal osteoporotic women.
Material & Methods: The cost-effectiveness of treatment
for 3-years with bazedoxifene was compared with raloxifene
using an updated version of a previously validated Markov
microsimulation model (1). The model was populated from
a Belgium healthcare payer perspective and analyses were
conducted in populations (over 60 years) where osteoporo-
sis medications are currently reimbursed in many European
countries, i.e., BMD T-score is ≤-2.5 or presence of preva-
lent vertebral fracture. The effects of bazedoxifene and
raloxifene on fracture risk were derived, in the base-
case analysis, from the post hoc analysis (including
women at high risk of fractures) of the 3-year results
of a randomized, double-blind, placebo- and active-con-
trolled study, including postmenopausal women with
osteoporosis (2).
Results: Bazedoxifene was dominant (lower cost for higher
effectiveness) in most of the simulations when compared
with raloxifene. The cost-effectiveness acceptability curves
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demonstrate that, regardless of the threshold value, the
probability that bazedoxifene was cost-effective compared
with raloxifene was around 90%. Sensitivity analyses
confirm the robustness of the results, which were large-
ly independent of starting age of treatment, fracture risk,
costs and disutility. Moreover, even when the cost of
raloxifene was reduced by 50%, bazedoxifene remains
cost-effective, at a threshold of €35,000 per QALY
gained, in 85% of the simulations. Results were how-
ever sensitive to the effect of treatments on fracture
risk. When using the treatment effects from the whole
population of the randomized controlled population,
both treatments are equally cost-effective.
Conclusion(s): Under the assumption of improved anti-
fracture efficacy of bazedoxifene over raloxifene in women
with high risk of fractures, this study suggests that bazedox-
ifene can be considered cost-effective or even dominant
when compared with raloxifene in the treatment of postmen-
opausal osteoporotic women.
References: (1) Value Health 2009:12:687. (2) J Bone Miner
Res 2008;23:1923.
P567
BONE METABOLISM IN GHD IN THE AGE OF
TRANSITION: EFFECT OF RHGH TREATMENT
Anna Capozzi, Silvia Della Casa, Barbara Altieri, Maria
Chiara Fabiano, Alfredo Pontecorvi
Catholic University, UOC Endocrinology, Rome, Italy
Objective(s): It is largely recognised that GH has benefits
on cardiovascular function, quality of life and completion of
linear growth, after achievement of final height in adoles-
cent GH-deficient. GH/IGF1 axis has been demonstrated to
be mostly involved in reaching peak bone mass, the most
important predictor of osteoporotic fractures, in the late
adolescence, during the transition from paediatric to adult
age. That period is considered an important time to define
by appropriate testing the persistence of GH deficiency
(GHD) in patients with childhood-onset GHD (COGHD)
and to establish the need to continue GH therapy with rhGH
(recombinant human Growth Hormone). Our study analyse
consequences of GH replacement on bone mineralization in
patients with COGHD, reassessed at retesting in the age of
transition.
Material & Methods: A total of 23 adolescents (16 boys; 7
girl; mean age18.87±0.3 yrs) affected by COGHD and trea-
ted with rhGH in the childhood were restudied and divided
into two groups, according to the result of arginine test: 12
patients confirmed GHD (group1) (peak<10 ng/ml), while
11 patients resulted healthy (group2) (peak>10 ng/ml). In
both groups BMD of the lumbar spine and femoral neck
were established by DXA and bone markers (osteocalcin,
bone specific alkaline phosphates, β-crosslaps) were
measured at baseline and, in group1, after 1, 6 and 12
months of treatment with rhGH (25 μg/kg/die).
Results: At baseline, DXA showed that 44.4% of group 1
were affected by osteopenia while none of group 2 pre-
sented bone loss. β-crosslaps were lower in group 2 than
in group 1 and difference between the two groups was
statistically significant (p<0.05). GH replacement increased
significantly BMD of the lumbar spine and femoral neck
and osteocalcin and bone specific alkaline phosphates in
group 1.
Conclusion(s): Although number of patients was small,
results indicate GHD which continue rhGH treatment reach
a significant increase of BMD after one more year of ther-
apy. As GH replacement can produce benefits on bone
density even if linear growth had just been completed, rhGH
should be continued up to the achievement of peak bone
mass in patients with GHD.
P568
FALL-RISK ESTIMATION TESTS IN PATIENTS
WITH SENILE OSTEOPOROSIS
Sladjana Bozilov, Aleksandar Dimic, Vesna Bosnjakovic,
Vlado Skakic, Jelena Jovanovic, Rozita Filipov, Marija
Gacinovic
Institut za Lecenje i Rehabilitaciju Niska Banja, Rheuma-
tology, Nis, Serbia
Objective(s): Using tests for muscle strength and balance
estimation we estimated risk for falls at patients with senile
osteoporosis and previous fracture.
Material & Methods: Prospective investigation has been
performed at the Institute Niska Banja from July 2010 – Dec
2011. In this investigation patients with fracture and senile
osteoporosis (confirmed by osteodensitometry apparatus
DXA -Hologic) have been involved. Total number of
patients is 73. According to sex distribution : 65 female
and 8 male. Average age 69.5 years of age. Localisation of
previous fractures: lower leg fractures – 25 patients, thigh
bone fractures – 32 patients, elbow fractures 6 patients,
vertebral fractures 20 patients. For investigation fall-risk
estimation tests have been used: Tandem-Standing test for
balance estimation, Timed-up & go test – walk and muscle
function estimation, usual walk speed test, Chair-rising test
muscle strength test.
Results: Tandem-Standing tests for balance estimation –
all patients were in a tandem position less than 10 sec-
pathological results (100%). 26 (35%) patients were able
to make light 8 and more tandem steps – regular result.
47 (65%) were not able – pathological result. Timed-Up
& Go test – Pace estimation and muscle function: 12
(16%) patients have performed the test in more than 12
s. Pathological result usual walk speed test: 34 (46%)
patient had walk speed faster than 1 m/s -pathological
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result. Chair Rising test – muscle strength test: 2 (2%)
patient performed the test in less than 10 s -regular
result. 71 (98%) patients performed the in test longer
than 10 s -pathological result.
Conclusion(s): Because of the strong connection between
falls & fractures in monitoring patients with senile osteoporo-
sis it is very important to include estimation of risk factors for
falls and prevention falls program. Strength improvement of
muscles by moving & exercises program, so bones receive
stimulus to form again and muscle synchronisation repair and
better keeping of balance in order to reduce fall & fractures
risks.
P569
IDENTIFICATION AND FUNCTIONAL
CHARACTERIZATION OF THE MECOM GENE
AS A NOVEL PREDISPOSING FACTOR FOR
OSTEOPOROTIC FRACTURE
Joo-Yeon Hwang1, Min Jin Go1, Bok-Ghee Han1, Jung-Min
Koh2, Jong-Young Lee1
1KNIH, Center for Genome Science, Chung-buk, Osong,
2Asan Medical Center, Division of Endocrinology and
Metabolism, Seoul, Korea
Objective(s): Osteoporotic fracture (OF), the clinical end-
point, is a major complication of osteoporosis. Although
several OF genes and loci have been identified through
genomewide association studies (GWAS), the functional
implications of these GWAS signals are incompletely un-
derstood in most cases.
Material & Methods: To investigate OF susceptibility
genes, we performed a GWAS and carried out follow-up
replication studies in individuals of East Asian descent.
Results: In a combined meta-analysis of OF from a discov-
ery cohort (n=1427) and two de novo replication sets in
Korea (n=1626) and Japan (n=929), we identified rs784288
in the MECOM gene as reaching genome-wide significance
(p=4.83×10-8; odds ratio=1.38) with pleiotropic associa-
tions. A functional analysis using RNA interference showed
that MECOM knockdown with small interfering RNA sup-
pressed osteoclastogenesis.
Conclusion(s): Together, our results provide new insights
into the genetic architecture of OF.
P570
EFFECT OF PHYSICAL ACTIVITY AND SUN
EXPOSURE ON VITAMIN D STATUS OF
SAUDI CHILDREN AND ADOLESCENTS
Abdulaziz Al-Othman1,2, Sara Almosharruf3, Nasser Al-
Daghri1,4,5, Soundararajan Krishnaswamy4, Deqa Yusuf1,
Khalid Alkharfy1,6, Yousef Al-Saleh1,7, Omar Al-Attas1,4,5,
Majed Alokail1,4,5, Osama Moharram8, Sobhy Yakout1,4,
Shaun Sabico4, George Chrousos4,9
1King Saud University, Prince Mutaib Chair for Biomarkers
of Osteoporosis, 2King Saud University, College of Applied
Medical Sciences, 3King Saud University, College of Science,
4King Saud University, Biomarkers Research Program, 5King
Saud University, Center of Excellence in Biotechnology Re-
search, 6King Saud University, Clinical Pharmacy, 7King
Saud University of Health Sciences, College of Medicine,
8King AbdulAziz University Hospital, Medicine, Riyadh,
Saudi Arabia, 9Athens University, First Department of Pedi-
atrics, Athens, Greece
Objective(s): Accumulating evidence suggests increased
prevalence of vitamin D deficiency in the Middle East.
In this context, we aimed to determine whether the
prevalence of vitamin D deficiency is related to degree
of physical activity and sun exposure among apparently
healthy Saudi children and adolescents, in a lesser stud-
ied population.
Material & Methods: A total of 331 Saudi children were
included in this cross sectional study. Levels of physical
activity and sun exposure were determined using a standard
questionnaire. Anthropometry, serum calcium and 25-(OH)
vitamin D were analyzed.
Results: All subjects were vitamin D deficient, majority of
whom were moderately deficient (71.6%). Age-adjusted
comparisons revealed that vitamin D status was highest
among the most physically active group and most frequently
sun exposed, though levels in this group remain deficient.
BMI was also lowest in the most physically active group
(p<0.05).
Conclusion(s): Promotion of an active outdoor lifestyle
among Saudi children in both homes and schools may
counteract the vitamin D deficiency epidemic in this vulner-
able population. Vitamin D Supplementation is also
suggested.
Disclosures: Many thanks to Prince Metab Chair for Oste-
oporosis for the funding of this study.
P571
X-RAY ABSORPTIOMETRY INDEXES FOR
WOMEN IN POSTMENOPAUSAL PERIOD WITH
OSTEOPOROTICAL FRACTURES
Vadyslav V Povoroznyuk, Roman T Mashtaler, Taras R
Mashtaler
Institute of Gerontology NAMS Ukraine, Department of
Clinical Physiology and Pathology of Locomotor Appara-
tus, Kyiv, Ukraine
Objective(s): To estimate structural and functional condi-
tion of bone in women in postmenopausal period with
osteoporotic fractures, compare the results to referent data
for Ukrainian population and to compare the results of X-ray
absorptiometry to the fracture risk rate, assessed by FRAX
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for women in postmenopausal period with osteoporotic
fractures.
Material & Methods: 39 women in postmenopausal period
aged 50-89 years with forearm (18) and proximal hip (21)
fractures, who were on treatment the Traumatology Depart-
ment #1 of Lviv City Clinical Hospital of Ambulance. They
were divided into 4 categories by age (50-59[13]; 60-69[12];
70-79[9]; 80-89[5]). Nordin Index was measured with the
“Osteolog” workstation, developed in the Institute of Geron-
tology AMS Ukraine under the direction of professor Povor-
oznyuk V.V. Fracture risks were estimated using FRAX.
Results: We found lower cortical indexes for women in
postmenopausal period with osteoporotic fractures for 50-
59 (Common IN=0.41), 60-69 (Common IN=0.40), 70-79
(Common IN=0.36), 80-89 (Common IN=0.33) age groups
in comparison to referent data for Ukrainian population.
Also we found lower cortical indexes for women in post-
menopausal period with higher risk of osteoporotic fracture,
assessed by FRAX, independent of age.
Conclusion(s): Thus, low cortical indexes, measured with
the “Osteolog” workstation are reliable predictors of high
fracture risk. There is a significant correlation between low
cortical indexes and high fracture risk, assessed by FRAX.
P572
MUSCLE SIZE, STRENGTH AND PHYSICAL
PERFORMANCE AS PREDICTORS OF FALLS AND
FRACTURES IN THE HERTFORDSHIRE COHORT
STUDY
Mark H Edwards, Karen A Jameson, Celia L Gregson,
Nicholas Harvey, Avan Aihie Sayer, Elaine Dennison,
Cyrus Cooper
University of Southampton, MRC Lifecourse Epidemiology
Unit, Southampton, UK
Objective(s): Sarcopenia is common in later life and
associated with subsequent disability. However, the def-
inition of sarcopenia is often problematic; hence recently
the European Working Group on Sarcopenia in Older
People proposed a practical clinical definition for age-
related sarcopenia requiring both low muscle mass and
function (strength or performance). However, the extent
to which these different components correlate with falls
risk, and ultimately fracture, remains uncertain. We ad-
dress this issue in a prospective population cohort, the
Hertfordshire Cohort Study.
Material & Methods: 1579 men and 1418 women under-
went baseline assessment of health (questionnaire) and de-
tailed anthropometric measurements. Grip strength was
measured using a Jamar hand-held dynamometer and gait
speed was assessed by 3 m walk test. A subset of 313 men
and 318 women, underwent pQCT examination of the calf
and forearm using a Stratec 2000XL pQCT to assess muscle
cross-sectional area (mCSA) (66% slice). Subsequently,
2299 participants completed a postal questionnaire, detail-
ing fall and fracture history, a mean of 5.5 years after
baseline (range 2.9-8.8 yrs).
Results: The mean age (SD) at baseline was 66.2 (2.8)
years. At follow-up weaker grip strength and, in men re-
duced gait speed, predicted a higher risk of falls reported
since the age of 45 years and in the previous year. A similar
but much weaker trend with gait speed was seen in men.
Incident fractures were more common in those with lower
grip strength (men OR 1.075 [95% CI 1.028, 1.125] p=
0.002; women OR 1.039 [95% CI 1.002, 1.077] p=0.04, for
every 1 kg reduction in grip strength) after adjustment for
age, height, weight-adjusted-for-height, social class, smok-
ing status, alcohol consumption, activity score, dietary cal-
cium (and oestrogen replacement use and years since
menopause in women). However, no associations were
detected between mCSA and incident falls or fractures.
Conclusion(s): Both grip strength and gait speed but not
mCSA were associated with falls risk; additionally grip
strength also predicted incident fractures. Assessments of
muscle function therefore may be better predictors of these
clinical outcomes than muscle size.
P573
VITAMIN D DEFICIENCY AND CALCIUM INTAKE
IN REFERENCE TO OBESITY IN CHILDREN
AND ADOLESCENTS
Sara Almosharruf1, Abdulaziz Al-Othman2,3, Nasser Al-
Daghri2,4,5, Soundararajan Krishnaswamy4, Deqa Yusuf2,
Khalid Alkharfy2,6, Yousef Al-Saleh2,7, Majed Alokail2,4,5,
Osama Moharram8, Sobhy Yakout1,2,4, Shaun Sabico2,4,
George Chrousos4,9
1King Saud University, College of Science, 2King Saud
University, Prince Mutaib Chair for Biomarkers of Osteo-
porosis, 3King Saud University, College of Applied Medical
Sciences, 4King Saud Universit, Biomarkers Research Pro-
gram, 5King Saud University, Center of Excellence in Biotech-
nology Research, 6King Saud University, Clinical Pharmacy,
7King Saud University of Health Sciences, College of Medi-
cine, 8KingAbdulAziz UniversityHospital, Medicine, Riyadh,
Saudi Arabia, 9Athens University, First Department of Pediat-
rics, Athens, Greece
Objective(s): Vitamin D deficiency has been linked to
several chronic diseases in adults, and nearly all cardio-
metabolic risk factors are associated with vitamin D de-
ficiency. Studies focusing on children and adolescents,
however, are limited. In this randomized cross sectional
study we aimed to determine the prevalence of vitamin D
deficiency and its association with childhood obesity and
dietary calcium intake among a population of healthy urban
Saudi adolescents.
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Material & Methods: 331 randomly selected Saudi chil-
dren (53.8% females and 46.2% males) aged 6-17 years
were included. Demographic, medical and dietary infor-
mation were collected from each subject. Anthropomet-
rics were measured. Blood levels of fasting glucose,
lipid profile, 25(OH) D and corrected calcium were
analyzed.
Results: Vitamin D deficiency was noted in all subjects,
with girls having significantly lower vitamin D levels
than boys. Serum vitamin D levels were significantly
and inversely associated with BMI, fat mass percentage,
body fat mass, TG, waist circumference and hip circum-
ference (p<0.05). Serum calcium was significantly lower
in girls compared to boys and was positively correlated
with vitamin D and negatively correlated with BMI, fat
mass and waist to hip ratio. Approximately 30% of the
subjects with <250 mg of calcium daily were obese,
while only 14% of the subjects with >800 mg of calci-
um intake were obese.
Conclusion(s): Results from this study correlated serum
vitamin D with obesity in children and adolescents implying
important functional role for vitamin D deficiency in obesity
associated chronic diseases.
Disclosures: Many thanks to Prince Mutaib Chair for Oste-
oporosis (PMCO) for the funding of this study
P574
THE EFFECT OF TIBOLONE ON BONE DENSITY
IN WOMEN WITH EARLY MENOPAUSE
RESULTING FROM CANCER TREATMENT
Dong Ock Lee1, Hoon Choi2, Jung Gu Kim3
1National Cancer Center, Center for Uterine Cancer, Center
for Cancer Prevention and Detection, Goyang, Kyunggi,
2Inje University College of Medicine, Department of
Obstetrics and Gynecology, Seoul, 3Seoul National University
Hospital, Department of Obstetrics and Gynecology, Seoul,
Korea
Objective(s): To evaluate the effect of tibolone on bone
density in women with early menopause (<45 years old)
resulting from treatment of cervical cancer.
Material & Methods: Through retrospective chart re-
view, 46 women with early menopause resulting from
bilateral oophorectomy or pelvic radiation therapy were
compared with age-matched healthy women. All the
women had taken tibolone continuously. Two normal
women were matched per one woman with early men-
opause, so 92 of healthy women with regular menstru-
ation were selected. Initial bone density data of lumbar
spine, femur neck, and total hip were compared with
those of 2 years later.
Results: For 2 years, there were no significant changes in
bone density of women treated with tibolone for early
menopause. In normal control, bone density of total hip
was significantly decreased after 2 years. (p=0.02) In in-
ter-group analysis, there were no significant differences in
changes of bone density between two groups.
Conclusion(s): Women treated with tibolone for early men-
opause kept normal age-related change in bone density.
Tibolone may be effective for prevention of bone loss in
women with early menopause after bilateral oophorectomy
or pelvic radiation therapy.
P575
DEVELOPMENTAL HIP DISORDER AS A
CAUSE OF COXARTHROSIS
Aleksandra Todic, Nada Jevtic, Nikola Sremcevic
The Specialized Rehabilitation Hospital, Rehabilitation of
Adults, Banja Koviljaca, Serbia
Objective(s): To highlight the significance of DHD among
the causes of coxarthrosis and consequential implantation of
hip endoprosthesis in generative and the most active life
period, and to indicate the absence and necessity of contin-
uous observation and treatment of the patients with DHD
before the complications occur.
Material & Methods: The retrospective study conducted
in the time period between January 1, 2004 - March 3,
2010, involved two groups of patients; one group con-
sisted of 136 patients, to 55 years old, treated for
coxarthrosis; the second group consisted of 213 patients,
of the same age, after the implantation of hip endopros-
thesis. The data were obtained from the case histories.
The groups were formed according to the cause of the
disease. Afterwards, we separated patients with DHD
being a primary etiology and classified them according
to their gender, DHD treatment method in the childhood
and age. We compared our results with the data from
the literature
Results: In both groups of patients, DHD was a cause of the
complications with high percentage, for coxarthrosis
28.67%, for implantation of endoprosthesis 36.44%, which
corresponds with the data from the literature that DHD is
among the most common primary diseases causing
coxarthrosis.
In both separated groups of patients with complications due to
DHD, womenweremuchmore often affected. The percentage
of development of complications in adult patients was higher
in those operated in childhood. Most patients with complica-
tions were 30 to 50 years old. We could not compare our data
with data from the literature because there were no any. We
have noticed that the children are referred to the balneo-
physical treatment after the surgical treatment of DHD, and
adolescents and adults only when complications occur.
Conclusion(s): DHD has proven to be a significant cause of
coxarthrosis and implantation of hip endoprosthesis both
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being significant and cost ineffective for the society for they
affect reproductive and active population. Therefore, we
highlight present absence of continuous observation and
balneo-physical treatment of patients with DHD in adoles-
cents and adults and necessity for its implementation to
postpone and prevent the development of the most severe
complications.
P576
ASSOCIATION BETWEEN BONE MINERAL
DENSITYANDBODYCOMPOSITION PARAMETERS
IN BRITISH AFRICANS LIVING IN LONDON
Soma Roy Mitra, Aoife Hanley
London Metropolitan University, School of Human Sciences,
London, UK
Objective(s): Studies have suggested age specific associa-
tion between different body compartments and that lean
mass is the main predictor of BMD. The purpose of this
study was to explore the association between BMD with fat
mass (FM), lean mass (LM), skeletal muscle mass (SMM)
and total body weight (TBW) in British African men, wom-
en and children living in London, UK.
Material & Methods:Whole body scans were conducted
using DXA (Norland XR800). Scanned images were
analysed for total body FM, LM and BMD. Total
SMM (kg) was determined by adding appendicular LM
of arm and leg regions and multiplying by 1.33 (assum-
ing this represents 75% of total SMM). Pearson corre-
lation coefficients were used to evaluate univariate
relationships between BMD, SMM, LM and FM. In
order to evaluate the relative contribution of FM, LM
and SMM to BMD, multivariate linear regression mod-
els were developed with BMD as the dependent variable
and LM, SMM, FM and total body weight (TBW)as
independent variables using a stepwise process. Men
and women were modelled separately.
Results: Altogether 23 men, 26 women and 41 children
were measured. Mean ages were 34.7 y (SD 15.1) 30.5 y
(SD 10.8) and 10.0 y (SD 3.6), respectively. BMD (g/cm2)
ranged from 0.832-1.385; 0.816-1.166; and 0.558-1.75, re-
spectively. Univariate correlation between BMD and LM was
significant in men (r=0.77, P<0.001), women (r=0.66,
P<0.001) and children r=0.49, P=0.001). No significant
relation was found between FM and BMD in all age
groups. Using the regression model, LM was the best
predictor of BMD for women, accounting for 44% of
the variance (r2=0.438, P<0.001) and an even better
predictor of BMD for men, accounting for 59% of the
variance (r2 = 0.589, P<0.001). In children, LM
accounted for 24% of the variance in BMD (r2=0.243,
P=0.001). TBW was the best predictor of BMD for
children, 35% (r2=0.347, P<0.001)
Conclusion(s): LM is the best predictor of BMD in Black
adults, better in men than women. TBW is the best predictor
of BMD in Black children.
P577
MANDIBULAR RADIOGRAPHIC
MEASUREMENTS AS INDICATORS OF
OSTEOPOROSIS IN SAUDI POSTMENOPAUSAL
WOMEN: A CROSS-SECTIONAL STUDY
Khaled H Balto1, Madiha M Gomaa1, Najlaa H Alamoudi2,
Rabab M Feteih2, Mohammed-Salleh M Ardawi3
1Center of Excellence for Osteoporosis Research and
Faculty of Dentistry, King Abdulaziz University, Endodon-
tics, 2Preventive Dental Sciences, 3Center of Excellence for
Osteoporosis Research and Faculty of Medicine, King
Abdulaziz University, Clinical Biochemistry, Jeddah, Saudi
Arabia
Objective(s): Mandibular indices, measured on panoramic
radiographs, and morphology of the mandibular inferior
cortex may be useful screening indicators for low BMD.
The present study examines whether the mandibular cortical
width (MCW), panoramic mandibular index (PMI) and al-
veolar crest resorption degree (M/M ratio) can be used to
identify postmenopausal women with low BMD.
Material & Methods: A total of 1020 postmenopausal
women (≥50 years) were randomly selected and screened
according to an inclusion criteria over 2 years at the Center of
Excellence for Osteoporosis Research (CEOR). Women were
excluded if they had chronic diseases including osteoarthritis,
or with evident endocrine disorders, or on any form of drug
therapy with possible effects on bone metabolism, or on oral
contraceptives or are smokers or with any cancer. According-
ly, 431 women were included in the final analysis. Age and
anthropometric data were recorded. Dental digital panoramic
radiography was performed and BMD at lumbar spine (L1-L4)
and neck femur was determined by DXA.
Results: Women were grouped according to BMD values as
normal (n=232), osteopenic (n=124) and osteoporotic (n=75).
Panoramic indices as a function of various of groups are
presented in Table 1.
Table 1: Panoramic indices as a function of various postmenopausal
groups.
All (n=431) Normal
BMD
(n=232)
Osteopenia
(n=124)
Osteoporosis
(n=75)
P-value
(for
trending)
Age (yrs) 57.78±6.24 57.02±6.54 57.74±5.40 60.21±6.05 P<0.0001
MCW (mm) 4.68±1.29 4.55±1.31 4.76±1.29 4.98±1.18 P<0.008
PMI (mm) 0.442±0.093 0.433±0.095 0.448±0.092 0.457±0.087 P<0.065
M/M ratio 2.24±0.28 2.24±0.25 2.25±0.28 2.23±0.26 0.992
MCW=mandibular cortical width; PMI=panoramic mandib-
ular index and M/M ratio=alveolar crest resorption degree.
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Mean MCW values were significantly greater in women
with osteoporosis (P<0.01) as compared with the normal
group. Optimal cutoff values for the MCW to detect women
with T-score<-1 (being 4.6 mm) and those T-score≤-2.5
(being 4.1 mm) at either lumbar spine (L1-L4) or total hip
showed low sensitivity (58.4-60.2%) and specificity (68.4-
69.4%) values.
Conclusion(s): MCW performed better than PMI and
M/M ratio in its power to differentiate postmenopausal
women with osteopenia or osteoporosis from healthy controls.
The present MCW measurements have limited power in
their ability to identify women with low BMD at the axial
skeleton.
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THE EFFECT OF MECHANICAL LOADING ON
THE REGULATION OF 1α-HYDROXYLASE IN
PRIMARY HUMAN BONE CELLS
Karen van der Meijden1, Astrid Bakker2, Nathalie
Bravenboer3, Paul Lips1
1VU University Medical Center, Endocrinology, 2Academic
Centre for Dentistry, Oral Cell Biology, 3VU University Med-
ical Center, Clinical Chemistry, Amsterdam, Netherlands
Objective(s): 1,25-dihydroxyvitamin D (1,25(OH)2D) was
shown to influence the response of mouse bone cells in vitro
to mechanical stimuli, which could have important conse-
quences for the maintenance of bone mass by mechanical
loading. Bone cells express the 1α-hydroxylase gene
CYP27B1, therefore they should be able to convert 25-
hydroxyvitamin D (25(OH)D) into its' active metabolite
1,25(OH)2D. However the regulation of 1α-hydroxylase in
bone cells is largely unknown. The aim of this study was to
investigate whether 25(OH)D affects the response of prima-
ry human bone cells to mechanical loading, similar to 1,25
(OH)2D. Furthermore, we examined whether mechanical
loading affects the conversion of 25(OH)D to 1,25(OH)2D
by primary human bone cells.
Material & Methods: Primary human bone cells were
incubated with 25(OH)D (0 or 400 nM) or 1,25(OH)2D (0
or 100 nM) for 24 h. Thereafter the cells were subjected to
pulsating fluid flow (PFF; 0.7±0.3 Pa, 5 Hz) or kept under
static conditions for 1 h, and postincubated (0 or 3 h)
without PFF. The response to PFF was quantified by mea-
suring nitric oxide (NO) using Griess reagent and ATP
production using the bioluminescence assay (Roche).
mRNA expression of RANKL, OPG, osteocalcin and osteo-
pontin as well as CYP27B1, VDR and CYP24 expression
was quantified using RT-qPCR.
Results: The stimulation of NO and ATP release by PFF
was not influenced by preincubation with 25(OH)D and
1,25(OH)2D in human bone cells. CYP27B1 mRNA was
increased 3 h after PFF, and VDR mRNA was decreased 3
h after PFF. mRNA expression of osteocalcin and CYP24
was not affected by PFF, but was increased after addition of
25(OH)D and 1,25(OH)2D.
Conclusion(s): These data show that the response of bone
cells to mechanical loading is unaffected by preincubation
with both 1,25(OH)2D and 25(OH)D. Interestingly, PFF
increased mRNA expression of CYP27B1, suggesting that
physical activity may enhance the local availability of 1,25
(OH)2D to bone cells, thereby contributing to bone mass
regulation.
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COFFEE CONSUMPTION IS ASSOCIATED WITH
VITAMIN D AND CALCIUM LEVELS IN SAUDI
ADOLESCENTS
Abdulaziz Al-Othman1,2, Sara Almosharruf3, Nasser Al-
Daghri1,4,5, Sobhy Yakout4, Khalid Alkharfy1,6, Yousef Al-
Saleh1,7, Omar Al-Attas1,4,5, Majed Alokail1,4,5, Osama
Moharram8, Shaun Sabico4, Sudhesh Kumar9, George
Chrousos4,10
1King Saud University, Prince Mutaib Chair for Biomarkers
of Osteoporosis, 2King Saud University, College of Applied
Medical Sciences, 3King Saud University, College of Science,
4King Saud Universit, Biomarkers Research Program, 5King
Saud University, Center of Excellence in Biotechnology Re-
search, 6King Saud University, Clinical Pharmacy, 7King
Saud University of Health Sciences, College of Medicine,
8King AbdulAziz University Hospital, Medicine, Riyadh,
Saudi Arabia, 9Warwick Medical School, CSRI, Warwick,
UK, 10Athens University, First Department in Pediatrics,
Athens, Greece
Objective(s): Coffee consumption was hypothesized to in-
teract with variants of vitamin D-receptor polymorphisms,
but limited evidence exists. Here we determine for the first
time whether increased coffee and tea consumption affects
circulating levels of 25-hydroxyvitamin D in a cohort of
Saudi adolescents.
Material & Methods: A total of 330 randomly selected
Saudi adolescents were included. Anthropometrics were
recorded and fasting blood samples were analyzed for rou-
tine analysis of fasting glucose, lipid levels, calcium, albu-
min and phosphorous. Frequency of coffee and tea intake
was noted. 25-hydroxyvitamin D levels were measured us-
ing enzyme-linked immunosorbent assays.
Results: Improved lipid profiles were observed in both boys
and girls, as demonstrated by increased levels of HDL-
cholesterol, even after controlling for age and BMI, among
those consuming 9-12 cups of coffee/week. No significant
differences were observed in vitamin D levels although an
increasing trend was observed with increasing coffee con-
sumption. Age and BMI-adjusted vitamin D levels were
significantly highest among those consuming 9-12 cups of
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tea/week in both males and females (p-values 0.003 and
0031, respectively).
Conclusion(s): This study suggests a link between coffee
and tea consumption and vitamin D levels in a cohort of
Saudi adolescents, independent of age and BMI. This
should be confirmed prospectively.
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COMBINATION OF DIGITAL X-RAY
RADIOGRAMMETRY AND FRAX® IN
EVALUATION OF STRUCTURAL-FUNCTIONAL
STATE OF BONE IN POSTMENOPAUSALWOMEN
Vadyslav V Povoroznyuk, Nataliia V Grygorieva, Vasyl
Povorozniuk
Institute of Gerontology NAMS Ukraine, Department of
Clinical Physiology and Pathology of Locomotor Apparatus,
Kyiv, Ukraine
Objective(s): The aim of the study was to estimate the
informative value of digital X-ray radiogrammetry and its
combination with FRAX® in evaluation of structural-func-
tional state of bone in Ukrainian postmenopausal women.
Material & Methods: 247 postmenopausal women aged
45-87 years were examined, average age 65±0.6 years,
duration of postmenopausal period 16±1.6 years. BMD
was measured by DXA "Prodigy" and digital X-ray radio-
grammetry (DXR) of the II-IV metacarpal bones. The 10-
year probability of hip fracture calculated with FRAX® tool.
Results: There is difference in distribution of bone indexes
in depending of used methods. Among women which had
osteoporosis of femoral neck by DXA, 73% had osteoporo-
sis, 24% osteopenia, 3% normal data by DXR. Sensitivity of
DXR indexes ranging was from moderate to high, but
specificity was low (with femoral neck 73% and 38%, total
hip 78% and 22%, lumbar spine 56% and 18%, total body
68% and 24%, accordingly). Such sensitivity and specificity
increased when combining DXR with the ten years proba-
bility of hip fracture without BMD (FRAX) (with femoral
neck 86% and 63%, total hip 89% and 54%, lumbar spine
84% and 50%, total body 89% and 53%, accordingly).
Sensitivity was higher in patients with fractures in compar-
ison with women without fractures, (with femoral neck 82%
and 64%, total hip 80% and 75%, lumbar spine 82% and
56%, total body 82% and 50%, accordingly), but specificity
was low in both groups. Moderate positive correlation was
between BMD of total body and DXR (r=0.58, p=0.0000).
Correlation between indexes of DXR and BMD of femoral
neck, total hip and lumbar spine were significant, but lower.
Conclusion(s): DXR of is informative method in evaluation
of structural-functional state of bone in postmenopausal wom-
en. Sensitivity and specificity increased when combining
DXR with FRAX® from 56% and 18% up to 89% and 63%
accordingly. Sensitivity was higher in patients with fractures.
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COMBINED THERAPEUTIC EFFECT OF
BALNEO-PHYSICAL AND MEDICAMENTOUS
TREATMENT IN PATIENTS WITH REDUCED
BONE DENSITY
Milanka Markovic, Zoran Grujic, Nada Jevtic, Nikola
Sremcevic, Aleksandar Jokic
The Specialized Rehabilitation Hospital, Rehabilitation of
Adults, Banja Koviljaca, Serbia
Objective(s): To indicate advantages of combined applica-
tion of medicamentous treatment and balneo-physical pro-
cedures in increasing bone mass and reducing fractures,
namely, improving quality of life in patients with decreased
bone mass.
Material & Methods: The study was conducted in the Spe-
cialized Rehabilitation Hospital, Banja Koviljaca, in the time
period between November 2005 - February 2008, with 269
patients having T-score<-1.7 SD. The bone density was deter-
mined at the distal forearm with DTX 4000, at least twice in
aforementioned period, and at least 1 year after the treatment
had started. Information on fractures and quality of life was
obtained in survey. The therapy group consisted of 117
patients, mean age 66.32, 101 women and 16 men. They had
at least two balneo-physical 10 days' (or more) treatments and
all being treated with medicines. The control group consisted
of 152 patients, mean age 63.48, 141 women and 11 men who
did not have either physical or medicamentous treatment.
Balneo-physical treatment implied kinesi therapy, peloid,
thermo mineral water and Horizontal therapy or low frequency
magnetic field. The results were processed statistically by
Mann-Whitney, Yates, Cramer tests.
Results: The statistically highly significant improvement of
all observed parameters was noticed in the work group: -
bone mass increase with a mean alteration of BMD between
the first and final measurement being -0.59 SD; - only one
new fracture; - quality of life improvement. There were 7
new fractures in the control group. The process of losing
bone mass with the mean alteration of BMD between the
first and final measurement being -4.44 SD. 86% of
respondents has pain intensity increased, and 38% of
respondents said that had limitations in daily life activities.
Conclusion(s): The subjects with decreased bone mass who
in addition to prescribed medicamentous treatment had bal-
neo-physical treatment have had pronounced bone density
increase, less fractures and better quality of life, noticeable
positive, complementary therapeutic effect and improve-
ment of all observed parameters.
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LACK OF INCREASED PTH LEVELS IN SAUDI
HEALTHY INDIVIDUALS WITH REDUCED 25(OH)
VITAMIN D LEVELS
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Omar Al-Attas1,3,4, Majed Alokail1,3,4, Abdulaziz Al-
Othman1,6, Shaun Sabico3, George Chrousos3,7
1King Saud University, Prince Mutaib Chair for Biomarkers
of Osteoporosis, Riyadh, 2King Saud University for Health
Sciences, College of Medicine, 3King Saud University, Bio-
markers Research Program, 4King Saud University, Center
of Excellence in Biotechnology Research, 5King Saud Uni-
versity, Clinical Pharmacy, 6King Saud University, College
of Applied Medical Sciences, Riyadh, 7Athens University,
First Department in Pediatrics, Athens, Greece
Objective(s): Recent advances on vitamin D research in
the Middle East have shed light on the increased inci-
dence of vitamin D deficiency across this region of
year-round sunlight. There is scarcity of information,
however, as to the levels of 1, 25-dihydroxyvitamin
(OH)2D, the active form of vitamin D, and its associa-
tions to cardiometabolic parameters in the Arab cohort
and this study aims to fill this gap.
Material & Methods: In this cross-sectional study, 33 male
and 43 female [22 children and 54 adults, total 76] Saudis
with low levels of 25-(OH)D (<25 ng/ml) were otherwise
randomly recruited. Anthropometrics were obtained and
fasting blood samples were taken for a routine measurement
of glucose, lipid profile, calcium and albumin. Serum 25-
hydroxyvitamin D, 1,25-(OH)2D and intact PTH were
quantified using ELISA.
Results: 25-hydroxyvitamin D deficiency was noted in
100% of the subjects. Serum calcium, intact PTH and 1,
25(OH)2D were all within the normal range. Serum 1,25-
dihydroxyvitamin D was not associated with intact PTH and
inversely correlated with systolic blood pressure (p=0.01).
Conclusion(s): Vitamin D deficient Saudi children and
adults with normal levels of 1,25-(OH)2D, had normal
circulating calcium and PTH. The study proposes to estab-
lish local cut-offs that will be of clinical significance in the
identification of those at true risk for harder end-points, such
as secondary hyperparathyroidism and bone-related
diseases.
Disclosures: Many thanks to Prince Mutaib for funding the
study.
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BONE MASS AND MICROARCHITECTURE
CHANGES IN SUBCHONDRAL BONE DURING
OSTEOARTHRITIS: INFLUENCE OF PRIOR
MECHANICAL LOADING?
Arnaud Boudenot1, Stéphane Pallu1, Christelle Jaffre3, Nathalie
Presle2, Claude Laurent Benhamou1, Eric Lespessailles1
1IPROS, IPROS, Orleans, 2UMR CNRS-UHP 7561, UMR
CNRS-UHP 7561, Vandoeuvre-lès-Nancy, 3M2S - EA1274,
M2S - EA1274, Rennes, France
Objective(s): Although osteoarthritis (OA) is considered as
a primary disorder of articular cartilage, the architecture and
properties of the periarticular cortical and trabecular bone
are also modified during the course of the disease. In an
experimental model of OA, we have previously shown by
DXA a bone loss in the epiphyseal area adjacent to the knee,
and a protective effect of exercise on this parameter. The
current study aimed to investigate changes in bone mass and
trabecular microarchitecture in both lateral and medial parts
of rat knee joints in an OA model.
Material & Methods: Male Wistar rats (n=48) were divid-
ed in exercise (Ex) or non exercise (NEx). Ex rats were
subjected to treadmill training 1 h/day, 5 d/wk for 10 wks.
At the end of the training period, OA was induced by
intraarticular injection of 1 mg monoiodoacetate (MIA)
in each half group (Ex-MIA and NEx-MIA). Other rats
were injected with saline as controls (Ex-C and NEx-C).
Safranin-O-fast green stainings were performed on tibia
sections to determine the severity of OA cartilage
lesions. The lateral and medial parts of the proximal tibia
was imaged by μCT.
Results: Our data indicated that the lateral part of the knee
joint exhibited significantly lower BV/TV and Tb.Th than
the medial part. Ex and OA did not alter the microarchitec-
ture in the medial part. A lower BV/TV was found in the
lateral part from rats injected with MIA (NEx-MIA vs. Ex-
C: 34.19±5.91 vs. 42.21±3.34; p<0.01; Ex-MIA vs. Ex-C:
32.81±6.31 vs. 42.21±3.34; p<0.01). Lateral Tb.N was also
reduced in both MIA groups (NEx-MIAvs. Ex-C: 3.09±0.44
vs. 3.61±0.25; p<0.01; Ex-MIA vs. Ex-C: 3.04±0.38 vs.
3.61±0.25; p<0.01), and lateral Tb.Th was significantly low-
er in the MIA groups compared to controls (NEx-MIA vs.
Ex-C: 0.11±0.01 vs. 0.12±0.01; p<0.05; Ex-MIA vs. Ex-C:
0.11±0.01 vs. 0.12±0.01; p<0.05).
Conclusion(s): These data suggest that MIA-induced OA is
associated with bone loss and changes in the trabecular
subchondral bone from the load-bearing area of the knee
joint. This chemical effect of the MIA seems finally differ-
entially translated in the lateral vs. medial part of subchon-
dral OA bone, suggesting an interaction with mechanical
properties of the rat knee.
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COMPARATIVEANALYSISOFBONEDENSITOMETRY
FINDING ON THE LUMBAR SPINE ANDHIP
Zoran Grujic1, Nada Jevtic1, Aleksandar Jokic1, Nikola
Sremcevic1, Aleksandar Jovanovski2, Snezana Vasic1
1The Specialized Rehabilitation Hospital, Rehabilitation of
Adults, Banja Koviljaca, 2The Health Center, Rheumatology,
Sabac, Serbia
Objective(s): To analyze the values of the mineral bone
density gained by measurements on the lumbar spine and
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femur neck and their correlation with the most significant
risk factors for osteoporosis.
Material & Methods: The study comprised 1594 respond-
ents, of both genders, who had bone densitometry of lumbar
spine and hip done by Lunar DPX device. All subjects filled in
the questionnaire with the basic demographic data, risk factors
for losing the bone mass and data on fractures. The data were
processed statistically by: Spearman's test for correlation,
Wilcoxon test, univariable analysis test and ANOVA test.
Results: The mean age of subjects was 66.67, predominat-
ing by women 1515 (95%). DXA finding on the lumbar
spine was at the level of osteoporosis in 61% of subjects,
33% had osteopenia, and 6% had normal result. The bone
densitometry on the hip registered osteoporosis in 44% of
subjects, 47% had osteopenia, and 9% had the expected
level of the bone density. The mean value of the BMD of
the lumbar spine in all subjects was 0.892 g/cm2, and of the
hip was 1.020 g/cm2. Overall, 22 vertebral and 23 hip
fractures were registered. The analysis of obtained data
yielded statistically high significance (p<0.01) of correlation
between DXA finding of the lumbar spine with early men-
opause, female gender and low index of the body weight,
and statistically significant correlation (p<0.05) with the
higher age. DXA finding of the hip was highly correlated
(p<0.01) with early menopause, age, low BMI and previous
fractures, and there was statistical significance (p<0.05) for
the female. The method of univariable analysis showed that
the parameters of the largest variability in BMD of the
lumbar spine BMI (Eta20.117) and gender (Eta20.028), and
for the BMD of the hip BMI (Eta20.214) and age
(Eta20.089).
Conclusion(s): The effect of negative predictors of osteo-
porosis on the decrease of BMD has been reliably registered
both on the lumbar spine and hip. It is recommended to
measure both sites in order to have an adequate estimation
of the bone strength and to prevent fractures with elimina-
tion of the risk factors.
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SEVERE VITAMIN D DEFICIENCY IS ASSOCIATED
WITH LOWERED CIRCULATING ENDOTHELIAL
PROGENITOR CELLS AND ENDOTHELIAL
DYSFUNCTION AMONG PATIENTS WITH TYPE 2
DIABETES MELLITUS
Daad H Akbar1, Abdulrahman A AlShaikh1, Maimmona M
Ahmed1, Sami M Bahlas1, Adel A Abdulrafee2, Mohammed
M Kotb2, Nabil M Alaama1, Osama A Gaber2, Zainy M
Banjar2, Mohammed-Salleh M Ardawi2, Hala S Sonbol3
1Center of Excellence for Osteoporosis Research and Fac-
ulty of Medicine, King Abdulaziz University, Medicine,
2Clinical Biochemistry, 3Center of Excellence for Osteopo-
rosis Research and Faculty of Science, King Abdulaziz
University, Biochemistry, Jeddah, Saudi Arabia
Objective(s): The present study describes the relationship
between vitamin-D deficiency and brachial flow-mediated
dilatation (FMD) together with circulating endothelial pro-
genitor cell (EPC) numbers among Saudi patients with type
2 diabetes mellitus (T2DM).
Material & Methods: A total of 410 patients (42% were
Women, patient age range 46-76 years) with T2DM attending
Diabetic Clinics at King Abdulaziz University (KAU) Hospi-
tal and other hospitals in the Jeddah area were recruited. Each
patient was asked to visit a special clinic at the Center of
Excellence for Osteoporosis Research (CEOR) at KAU to be
enrolled in the study. Diabetic patients were compared with
age- and sex-matched healthy controls (n=820). Each
patient was medically examined and data were collected
on life style, smoking habits, level of physical activity,
dietary habits, use of medications and vitamins using a
validated questionnaire. Age and anthropometric data
were collected. Each patient provided fasting blood with
second-void morning urine samples for the measurements
of serum 25(OH)D, various bone turnover markers
(BTMs); hormones, haemoglobin A1c (HbA1c); lipids,
glucose, and creatinine. Circulating CD34+/kinase insert
domain-containing receptor (KDR)+ and CD133+/KDR+
ECPs were determined by Flow cytometry. BMD was
determined by DXA and brachial artery FMD was deter-
mined by vascular ultrasonography. Healthy control sub-
jects were studied as that of diabetic patients.
Results: 79% and 32.4% of T2DM patients were with
vitamin D deficiency [25(OH)D <50 nmol/L] and severe
deficiency [25(OH)D <12.5 nmol/L], (vs. 74.1% and 13.6%
among healthy age- and sex-matched controls), respectively.
Serum 25(OH)D levels showed significant negative corre-
lations with HbA1c values (r=-0.246, P<0.001). Patients
with severe vitamin-D deficiency exhibited significantly
lower brachial FMD values (3.09±1.56; P<0.001) and
CD133+/KDR+ ECP counts (0.216±0.162%; P<0.001) as
compared with those with vitamin-D sufficiency or healthy
controls following adjustment for age, sex and others con-
founding factors including HbA1c values.
Conclusion(s): Severe vitamin-D deficiency was signifi-
cantly associated with lowered brachial artery FMD and
circulating CD133+/KDR+ EPCs. Such observations sug-
gest that severe vitamin D deficiency might contribute to
lowered circulating EPCs and endothelial dysfunction
among patients with T2DM.
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STUDYING OSTEOPOROSIS IN NON
MENOPAUSALWOMEN (OPNMW)
JJ Scali, S Visentini, D Sevilla, L Saavedra, S Veiga, Y Ju,
Z Salazar, J Montes Ferrin, R Berruezo, M Diez, J Trapp
Rheumatology/Osteology Unit, Durand University Hospi-
tal, Buenos Aires, Argentina
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Objective(s): Fragility bone fractures are a serious problem
regarding public health, generally associated to age and sex
(post-menopausal osteoporosis already almost well de-
fined). As Osteoporosis can occur at any age, data from
US centers recognize 5 cases each 100,000 women in ages
between 20 to 44 years old and also diagnosing it, is a
clinical challenge. Because of that, we decide to conduct a
follow-up study of OPNMW attending our Rheumatology-
Osteology Unit during 4 years, all diagnosed fractures based
(vertebral or peripheral) or without fractures but diagnosed as
osteoporosis by a densitometric finding specially in pts under
glucocorticoid treatment, or anti-aromatase drugs, or because
of hormonal disorders leading to bone fragility (by X-rays,
with vertebral demineralization) or because familial history of
osteoporosis. In OPNMW we cannot apply OMS classifica-
tion as in menopause women (T-score:<2.5) , because it is not
associated to the same fracture rate risk as in menopause.
Material &Methods:We study phosphocalcic metabolism,
PTH and 25OH D3, full history and physical examination,
personal and familial antecedents, sport fractures that pre-
dispose to a later ones, alimentary behavior, previous and
actual treatments, predisposing diseases, contraception (e.g.,
taking progestins). Time of training and type of sport prac-
ticing, and also if they suffered from menses disorders, and
if they were using some products for better performance.
Results: in 49% cases we don’t find predisposing disease in
women presenting low bone mass, we identified causal
disease in 15% (connective tissue disease, thyroid disease
or hipoparathyroidism) and in 35% we remark toxic ante-
cedents: drinking alcoholic beverages (33%), smoking, ali-
mentary salt excess and diet deprived from calcium). In 39%
of pts, the 250HD3 plasma levels were in insufficiency
range (low than 30 ng/mg). 19% of pts were in sport over-
training. 59% have a bad alimentation, 10% suffer from
celiac disease, 12% have liver disorders, 0.5% hemochroma-
tosis, prolonged immovilisation in 12%of cases, Marfan’s
syndrome in 1%, osteopathies related to cancer in 2%, osteo-
malacia in 0.2%; primary hypertiroidism in 2%,hemopathies:
4%; HIV in2%, fractures during childhood 6%.
Conclusion(s): We remark the importance of a population
that are not in current cheking for most of osteoporotic causes.
P587
ATYPICAL PARATHYROID ADENOMA AND
OSTEOPOROSIS – CASE REPORT
Nada T Nasteska1, Maja J Panajotovik Radevska1, Zaklina
T Ardzelieva1, Sonja T Ranogajec2
1Prama Medica, DXA Center, Skopje, 2Acus Medica, GP,
Delcevo, Macedonia, The Former Yugoslav Republic
Objective(s): The aim is to shown an atypical case of
parathyroid adenoma and osteoporosis with normal level
of ionized Ca, total Ca and vit.D.
Material & Methods: Female patient age of 65 years,
height 170 cm, weight 73 kg with pains in the spine,
hips, knees, low energetic fracture on the patellae, nor-
mal calcium and vitamin D dietary intake and insuffi-
cient exposure to sunlight. After first densitometry the
patient was treated for one year with bisphosphonate,
1000 mg calcium and 800 IU vitamin D. The control
DXA scan results showed decreasing of BMD (L1-L4
and dual femur) compare with previous densitometry.
Due to a suspect of secondary osteoporosis and follow-
ing blood tests were performed: iPTH, ionized Ca, total
Ca, ALP, P, Vit.D, 24 h Ca urine test. Because of high
level of iPTH was done neck ultrasound and scan with
Tc99 on parathyroid gland and the diagnosis of para-
thyroid adenoma was set.
Results: First densitometry results: L1-L4 with T-score -
2.3SD; Right femur with T-score -2.6SD; Left femur with T-
score -2.5SD. Blood test were: ionized Ca 1.15 mmol/l, total
Ca 2.3 mmol/l, Vit.D 80,5 pg/ml. After one year following
results were got: L1-L4 with T-score -2.7 SD; Right femur
with T-score -2.5 SD; Left femur with T-score -2.5 SD.
Blood test results were: iPTH 235 pg/ml, ion. Ca 1.39
mmol/L, total Ca 2.89 mmol/l, ALP 136.08 U/L, P 1.53
mmol/L, Vit.D 15.7 pg/ml, 24 h Ca urine test 11.6 μmol/d.
After 6 months of the surgery the blood test results are: :
iPTH 63 pg/ml, ionized Ca 1.27 mmol/L, total Ca 2.35
mmol/l, ALP 92 U/L, P 1.38 mmol/L, Vit.D 28.5 pg/ml.
Control DXA is following.
Conclusion(s): If the level of Ca and Vit D in the blood
are in the normal range but the control densitometry
show decreasing of BMD like in our case it is obvious-
ly that the level of PTH was determinate for the diag-
nosis. Parathyroid adenoma is the most common cause
of hyperparathyroidism and the surgery is the most
common treatment. Due to this it is very important to
detect on time the real reason for decreasing of BMD to
diagnose that curable disease.
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THE ASSESSMENT OF MEDICAL CARE QUALITY
OF PATIENTS WITH POSTMENOPAUSAL
OSTEOPOROSIS IN MOSCOW REGION
Alexander V Dreval, Elena A Prochorova, Larisa A
Marchenkova
Clinical Research Institute of Moscow Region named of M.F.
Vladimirky, Endocrinology Department, Moscow, Russian
Federation
Objective(s): The purpose of this study was to evaluate the
quality of diagnostics and treatment of postmenopausal os-
teoporosis (PMO) in Moscow Region.
Material & Methods: The study was performed in form of a
cross-sectional questionnaire survey of 362 postmenopausal
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woman aged 55 and older (median 65 (59;70) years) with
previously verified diagnosis of PMO from 17 towns in Mos-
cow Region. The study questionnaire consisted of the list for
medical treatment quality assessment consisting of 19 items,
the list of attitudes towards osteoporosis therapy consisting of
13 questions and the attitude scale towards factors influence
quality of medical care of osteoporosis patients consisting of
11 items.
Results: The questionnaire survey results showed, that in
57.4% of respondents the first doctor they visit because of
osteoporosis was an endocrinologists, in 19.7% - a trauma-
tologist, in 13.1% - a rheumatologist and in 4.9% each-
physician or neurologist. To confirm the diagnosis of PMO
38% of patients had to visit 2 doctors, 30% of patients - 3
doctors and 28% of patients - only 1 doctor, but the period
of time from the first visit to doctor until verification of
PMO in 39% cases took from 1 month till 1 year. 79% of all
referrals to BMD testing and 70% of all diagnosis of PMO
in Moscow Region are made by endocrinologists. 77.8% of
PMO patients in Moscow Region do not receive effective
medical therapy being treated only with calcium and (or)
vitamin D. Generally women with PMO did not received
effective therapy due to lack of adequate recommendations
of the doctors not insisting on mandatory treatment (50%) or
not giving clear treatment recommendations (43.8%) or not
detailed instructions on drag usage (25.0%). The main fac-
tors that hinder the PMO patients from receiving qualified
medical care are high cost of anti-osteoporotic drugs, non-
availability of DXA and osteoporosis specialists in local
medical departments, insufficient qualification of doctors
in field of osteoporosis diagnostics and treatment and im-
possibility to evaluate biochemical parameters of calcium
metabolism in local laboratories.
Conclusion(s): The medical care of patients with PMO in
Moscow Region is not adequate and need to improve.
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BONE METABOLISM AND FRAX SCORE IN MEN
OVER 50 YEARS OFAGE WITH TYPE 2 DIABETES
MELLITUS
Harjit P Bhattoa1, Edit Kalina1, Miklos Kaplar2, Peter
Antal-Szalmas1
1Medical and Health Science Center, University of Debrecen,
Department of Laboratory Medicine, Debrecen, 2Medical and
Health Science Center, University of Debrecen, 1st Depart-
ment of Internal Medicine, Debrecen, Hajdu-Bihar, Hungary
Objective(s): To characterize bone metabolism and fracture
risk assessment (FRAX) in men over 50 years of age with
type 2 diabetes mellitus (T2DM).
Material & Methods: We determined levels of 25-
hydroxyvitamin D (25-OH-D), PTH, osteocalcin (OC),
C-terminal telopeptides of type-I collagen (CTX-I),
procollagen type 1 amino-terminal propeptide (PINP),
BMD at L1-L4 (LS) and femur neck (FN), daily dietary
calcium intake and the 10-year probability of hip frac-
ture and a major osteoporotic fracture using the country
specific FRAX algorithm in 68 T2DM patients. The
same data was available from 68 age- and sex-matched
population based controls.
Results: The mean (range) age of the T2DM groups was
61.4 (51-78) years. The prevalence of hypovitaminosis D
(25-OH-D <75 nmol/L) was 59%. The prevalence of low
BMD (T-score<-1.0) at the FN and LS was 21% and 14%,
respectively. The mean (range) FRAX hip fracture and
FRAX major osteoporotic fracture was 0.8 (0-3.1)% and
4.5 (2.2-10)%, respectively. Upon univariate analyses,
BMD at the FN (0.974 g/cm2 vs. 0.915 g/cm2; p=0.005)
and lumbar spine (1.221 g/cm2 vs. 1.068 g/cm2; p<0.001)
was significantly higher in the T2DM cohort as compared to
the healthy age matched males. Compared to the healthy
controls, 25-OH-vitamin D (79.8 nmol/L vs. 67.7 nmol/L; p
=0.032), CTx (0.242 μg/L vs. 0.191 μg/L; p=0.001), P1NP
(41.7 μg/L vs. 33.7 μg/L; p=0.012), PTH (4.4 pmol/L vs.
3.9 pmol/L; p=0.019) were significantly lower in the T2DM
group. FRAX (major osteoporotic fracture) (4.5% vs. 3.7%;
p=0.001) was significantly higher in the T2DM group.,
Following adjustment for all variables showing a significant
difference between the two groups, FN and LS BMD, and
FRAX major osteoporotic fracture probability remained sig-
nificantly higher in T2DM patients as compared to the
control group. Furthermore, T2DM patients treated with
insulin had a higher FRAX score than those not treated with
insulin.
Conclusion(s): Males over 50 with T2DM have increased
bone density at the femur neck and lumbar spine, but concur-
rently have increased 10-year probability of a major osteopo-
rotic fracture using the country specific FRAX algorithm.
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DEVELOPMENT OF A BIOACTIVE PTH (1-84)
SPECIFIC ASSAY ON THE IDS-iSYS SYSTEM
Eva Guthrie, Emma King, Jackie Tran, Lyndsey Carr, David
Laurie, Chris J Fox, Alex K Barnes, Martha L Garrity
Immunodiagnostic Systems (IDS) Ltd, Assay Development,
Boldon, Tyne and Wear, UK
Objective(s): Measurement of PTH is essential for the
management of hyperparathyroidism and metabolic bone
disease associated with chronic kidney disease (CKD-
MBD). Currently available assays recognise either full-
length PTH plus non-PTH (7-84) fragments (Intact PTH)
or are specific for only the full-length 84 amino acid
molecule (Bioactive PTH). The degree of cross-reactivity
to non-PTH (7-84) fragments recognised by Intact PTH
assays can vary considerably. There is much discussion
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regarding which PTH assay represents the most reliable
and sensitive method for PTH monitoring. In particular,
whether Intact PTH can be used given the undefined
biological activity of non-PTH (7-84) fragments, opposed
with the opinion that Intact PTH is still a robust indicator
of overall PTH levels. The Bioactive PTH (1-84) assay
will allow specific measurement of full-length PTH on
the IDS-iSYS system and in combination with the panel
of available bone tests will allow clinical profiling of
patients at risk of bone dysfunction.
Material & Methods: The measurement of bioactive PTH
(1-84) is a two-site chemiluminescent immunoassay. PTH
(1-84) is bound by Biotinylated C-terminal and Acridinium-
conjugated N-terminal-specific antibodies. These com-
plexes are captured by streptavidin-coated magnetic par-
ticles. Bound PTH (1-84) is measured in a high sensitivity
luminometer, where signal generated by the acridinium con-
jugate is directly proportional to the concentration of PTH
(1-84) in the sample.
Results: The bioactive PTH (1-84) assay has a range of 4-
1800 pg/ml. Time to first result is 33 minutes. Analytical
sensitivity is 1.8 pg/mL. Correlation with the IDS-iSYS
Intact PTH assay gives a relationship of bioactive PTH=
0.6x Intact PTH values in EDTA plasma (n=59). Cross-
reactivity with non-PTH (1-84) fragments is clinically in-
significant. Recovery was measured at 95%. Linearity of
101% was measured across the full range of the assay.
Conclusion(s): The IDS-iSYS Bioactive PTH (1-84) assay
is an accurate and precise method which is specific for the
biologically active full-length PTH (1-84).
P591
FIGHT OSTEOPOROSIS – MOVE, EAT, LEARN
Dusica Zore Hlade
Slovenian Osteoporosis Patients Society, Ljubljana, Slovenia
Objective(s): The main goal of the activities was to make all
generations aware of the importance of exercise, knowledge
and nutrition in preventing and curing osteoporosis. The
peak of the activities was Celebration of World Osteoporosis
Day in Ljubljana. The event, held on the very day of the
World Osteoporosis Day was sponsored by the City of
Ljubljana and held on the main square in city centre. Mrs.
Barbara Miklic Türk, first lady and a regular sponsor of all
our activities, also attended the event. Dr. Toma Kocjan
presented the importance of prevention of falls in everyday
life. We arranged bone density measurements on the spot for
all participants. The main presenter was famous performer
Peter Poles, who also made a short survey among younger
public, that was presented on the event and will be shown to
participants in Bordeaux as well. Cooking Photo Challenge:
As a part of the activities marking the 2011 World Osteo-
porosis Day we organised a cooking contest, focused on
recipes that are rich in calcium and vitamin D. Special
exhibition of photos was held on the banks of river Ljubl-
janica from October 20-30. Members of our societies sent us
recipes and photographs to participate. We will present the
winning recipes at the conference. Osteothlon: The event is
composed to promote: exercise, knowledge and nutrition.
We were very satisfied with the response of the public. At
the end of activities related to World Osteoporosis Day we
could say that the whole year, and especially October 2011
were dedicated to the awareness about the osteoporosis
epidemic. The activities and events we organised were di-
rected to all generations, to make them start thinking of their
bones as soon as possible, and prevent the start of bone
decay. We stressed the importance of active lifestyle, calci-
um rich food and vitamin D.
Material & Methods: Public event, survey, media, rubber-
band, bulletin.
Results: Increased awareness of general public on the im-
portance of healthy way of life in preventing and fighting
osteoporosis.
Conclusion(s): We found that it is important to communi-
cate different publics with tools they understand and are
familiar with, e.g., events, Twitter, Facebook, and internet.
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CIITA POLYMORPHISMS AFFECTING
EXPRESSION OF MHCII ARE ASSOCIATED
TO BMD, BONE LOSS AND FRACTURE
Maria Swanberg1, Fiona E McGuigan1, Mattias Callreus1,
Paul Gerdhem2, Kristina Åkesson1
1Lund University, Clinical Science,MalmöUniversity Hospital,
Malmö, 2Karolinska University Hospital, Orthopaedics,
Stockholm, Sweden
Objective(s): Inflammatory factors such as cytokines, sur-
face molecules and T lymphocytes affect osteoclast activity
and the balance between bone formation and resorption.
After menopause, levels of the pro-inflammatory cytokine
interferon-gamma (IFNg) increase. IFNg promotes T lym-
phocyte survival and activity by inducing expression of
MHCII molecules on antigen-presenting cells, a process
mediated by the MHC class II transactivator gene (CIITA).
Our aim was to address the genetic impact of polymor-
phisms in genes with possible effects on osteoimmunolog-
ical interactions and capture age-related differences on
BMD, bone loss and incident fracture risk.
Material & Methods: We investigated the effect of poly-
morphisms in CIITA associated with reduced expression of
MHCII (rs3087456(G) and rs4774(C)) on BMD, bone loss
and fracture in young and elderly Swedish women (PEAK-25
n=999; OPRA n=1003). In addition, 3 SNPs each in CLEC-
16A and IFNG were analyzed. Phenotypes included BMD,
bone resorption markers, bone loss and fracture.
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Results: CIITAwas only associated with BMD in the elderly
women (75 yrs: spine, femoral neck, hip, p=0.01-0.04 and
80 yrs: p=0.02-0.04). BMD was 1.8-3.4% higher in
rs3087456(G)-carriers (p=0.009-0.02), suggesting an in-
creasing effect on BMD by reduced MHCII expression.
CIITA was also associated with increased rate of bone loss
(femoral neck p=0.01, total hip p=0.03, total body p=4E-
5), but not bone resorption markers. Despite increased bone
loss, rs3087456(G) was protective against fracture (Any
fracture: carriers (28%) Vs. non-carriers (39%); osteoporotic
fracture 23% vs. 31%, p=0.02). IFNG polymorphisms were
weakly associated with lower hip (p=0.04) and spine BMD
(p=0.03) at 75 yrs, but not bone loss or fracture. CLEC16A
was associated with lower BMD (75 yrs: spine p=0.04; 80
yrs: total body, total hip, and femoral neck, all p=0.04) and
fractures occurring between age 75-80 (rs725613(G) car-
riers 31% Vs. non-carriers 39%, p=0.02).
Conclusion(s): Expression-related polymorphisms in the
inflammatory genes CIITA and CLEC16A are associated
with BMD, and fracture in elderly women. These findings
illustrate the importance of inflammation in general and
MHCII expression levels and T lymphocyte activation in
particular in the pathogenesis of reduced bone strength in
the elderly.
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BONE TURNOVER MARKERS: ARE THEY
USEFUL FOR THE INITIAL DIAGNOSIS
OF OSTEOPOROSIS?
Carlos Castillo1, Francisco J Illana1, Maria J Torrejon1,
Maria J Amerigo2, Manuel Arroyo1
1Hospital Clinico San Carlos, Clinical Laboratory, 2Hospital
Clinico San Carlos, Internal Medicine, Bone Metabolism
Unit, Madrid, Spain
Objective(s): Evaluate the utility of bone turnover markers
comparing with BMD for the initial diagnosis of osteopenia
or osteoporosis.
Material & Methods: 42 patients who came for the first
time to our clinic were selected. DXA was used to
assess BMD of the lumbar spine, total hip and femoral
neck. Osteocalcin (OC), procollagen type I N-terminal
propeptide (P1NP), bone alkaline phosphatase (ALP)
and PTH were measured in serum, and calcium, phos-
phorus and Deoxypyridinoline in urine. Statistical anal-
ysis was performed with SPSS-15 (U of Mann-Whitney
Test). Receiving Operating Curves (ROCs) were con-
structed carrying out a comparison between groups.
Spearman Rho coefficient was used to make a correla-
tion analysis between the T-Score values of total hip
and femoral neck with bone markers.
Results: BMD: 12% normal, 26% osteopenic and 62%
osteoporotic. ROC showed significant results in PTH,
vitamin D and osteocalcin between normal and osteopenic/
osteoporotic group.
TABLE 1
PTH VIT D OC
AUC Normal-Osteopenia 0.88* 0.88* 0.71*
AUC Normal-Osteoporosis 0.82* 0.83* 0.59
*p<0.05
TABLE 2
PTH VIT D OC
AUC Normal-
Osteopenia
S=80% E=80%
CP=60.8 pg/ml
S=80% E=80%
CP=19 ng/ml
S=60% E=80%
CP=8.5 ng/ml
AUC Normal-
Osteoporosis
S=80% E=80%
CP=59 pg/ml
S=77% E=80%
CP=20.5 ng/ml
No significant
Cutoff points (CP), sensitivity (S) and specificity (E)
We did not find significant differences in the rest of bone markers.
Conclusion(s): Biochemical bone markers provide poor
value in the initial diagnosis of osteoporosis. PTH, vitamin
D and OC show significant differences between groups;
however the definitive diagnosis must be performed with
the BMD measurement.
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THE INFLUENCE OF HORMONAL CHANGES IN
BODY COMPOSITION AND MUSCLE BONE UNIT
AT PERIPUBERTAL GIRLS
Veronika Cirmanova1,2, Luboslav Starka1, Martin Hill1,
Radmila Kanceva1, Jan Rosa3, Milan Bayer4
1Institute of Endocrinology, Department of Functional Diag-
nostics and Steroid Hormones, 2Charles University, First
Faculty of Medicine, 3Euromedic International, Mediscan
Group, Prague, 4University Hospital and Faculty of Medi-
cine Hradec Kralove, Department of Paediatrics, Hradec
Kralove, Czech Republic
Objective(s): Puberty is a key period for influencing the
quality of bone. The aim of our study was to determine
relationships between factors affecting the growing skeleton
in healthy adolescent girls.
Material & Methods: In 100 healthy girls aged 9-15 years,
we have examined the biochemical and hormonal parame-
ters related to bone growth and puberty. Bone mineral
content (BMC), areal density of the lumbar spine (aBMD
L1-4), muscle and fat mass were assessed using DXA GE
Lunar Prodigy with paediatric software Encore. We mea-
sured muscle strength by dynamometer.
Results: Statistical processing of data using multiple regres-
sion showed highly significant relationship aBMD (L1-L4)
with menarche, stage of puberty according to Tanner,
height, muscle strength and lean body mass (LBM)
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(p<0.01). Timing of menarche strongly influences the level
of leptin (p<0.001). Z-score strongly correlated with the
proportion of fat mass (p<0.01). Significantly positive rela-
tionship is between serum bone ALP, menarche and puberty
stage (p<0.01). BMC correlates strongly with height, mus-
cle strength and LBM (p<0.01). Muscle and bone strength
correlates with 25(OH) D. 92% of children had inadequate
vitamin D levels <30 ng /ml (75 nmol/l).
Conclusion(s): Strong predictor of maximum PBM is the
age onset of menarche-regulated levels of leptin. Parameters
bone quality and strength strongly correlated with body
composition in relation to the proportion of muscle and fat
mass. Vitamin D may directly influence muscle strength
during the pubertal growth, providing an alternative path-
way by which vitamin D may strengthen bone.
Disclosures: Supported by the project Advanced training in
clinical and molecular endocrinology. OPPA & EU Regis-
tration Project ID: CZ.2.17/1.1.00/32386.
P595
TOTAL HIP REPLACEMENT IN COXARTHROSIS,
COMBINED WITH OSTEOPOROSIS IN YOUNG
PATIENTS WITH JUVENILE RHEUMATOID
ARTHRITIS
Sergey Y Morev, Oleg O Malakhov, Oleg A Malakhov
Scientific Center of Children's Health, Traumatology Ortho-
pedics, Moscow, Russian Federation
Objective(s): To implement the functional recovery and
quality of life of adolescents with severe coxarthrosis
against JRA, in combination with osteoporosis.
Material & Methods: The study is based on an analysis of
42 patients with lesions of the hip against the JRA, in con-
junction with osteoporosis, operated in trauma and orthopedic
department of scientific center of children health, from 2008-
2012. Patient age was 13-18 years (17 male and 25 female).
Patients were cure appointing a conservative treatment by
bisphosphonates (ibandronate), regulators of calcium-phos-
phorus metabolism, calcium supplementation. During arthro-
plasty were used in excess of the small types of leg prosthesis
adapted to the size of the femoral canal of teenagers.
Results: Postoperatively, patients were active rehabilitation
measures. After completion of the rehabilitation of patients
significantly increased range of motion in the hip joints.
Analysis of X-ray images during follow-up, demonstrated
good positioning of the implant components. Against the
backdrop of conservative therapy bisphosphonates positive
dynamics index Z-score in densitometry.
Conclusion(s): Total hip arthroplasty and adequate conser-
vative treatment for severe coxarthrosis, is an effective
method of comprehensive treatment, which allows to carry
out rehabilitation of patients with JRA and to restore their
quality of life. The application of modern conservative
therapy for osteoporosis allows THA in young patients
without risk of premature loosening of the prosthesis and
other complications.
References: In patients with severe systemic JRA option
is almost always assigned to oral corticosteroids and
intravenous injections, which usually contributes to the
development of severe metabolic system of osteoporosis.
The most effective operative treatment of coxarthrosis is
now a total hip replacement that allows surgeons to
quickly restore the length of the reference and the func-
tion of the affected limb.
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SKELETAL DISORDERS ASSOCIATED
WITH OSTEOPOROSIS
Mariana I Cevei1, Dorina C Stoicanescu2, Ildiko Gasparik3
1Rehabilitation Medical Hospital, University of Oradea,
Faculty of Medicine and Pharmacie, Baile Felix, 2Victor
Babes, University of Medicine and Pharmacie, Timisoara,
3Association of Osteoporosis Prevention, Targu-Mures,
Romania
Objective(s): Osteoporosis is a systemic skeletal disease
characterized by reduced BMD, disrupted bone microarch-
itecture and alterations in the amount and variety of proteins
in bones. The same patient may associate intervertebral disk
hernia or different degenerative skeletal system or joint
damages such as, degenerative disk disorder (spondylosis),
knee osteoarthritis, hip osteoarthritis, scapulohumeral peri-
arthritis with osteoporosis. The aim of the present study was
to evaluate the presence of associated skeletal degenerative
disorders in cases with osteoporosis and the efficiency of the
complex physical- kinetic treatment in these patients.
Material & Methods:We evaluated 84 patients admitted in
the Medical Rehabilitation Clinical Hospital Baile Felix,
between January 2011 - June 2011, diagnosed with osteo-
porosis. Their age ranged between 47-76 years. Affected
persons were evaluated by DXA technique and radiographs.
They followed a complex medical rehabilitation program for
14 days. Treatment objectives and methods aimed rehabili-
tation of both musculoskeletal associated diseases and oste-
oporosis. All cases have completed the Qualeffo 48
questionnaire.
Results: 36.90% had associated musculoskeletal diseases.
Out of these, 51.63% of the cases had associated degenera-
tive changes in the spine or spinal disc herniation, 16.12%
had hip osteoarthritis, 12.90% knee osteoarthritis and
19.35% scapulohumeral periarthritis. The mean value for
Qualeffo score in cases with associated degenerative pathol-
ogy was 64.32±16.23 compared to 49.75±9.61, the mean
score for patients that had only osteoporosis. Comparing the
obtained values, a very significant statistical difference
(p=0.0001) was noticed.
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Conclusion(s): Diagnosing bony spondylotic changes of
the vertebrae, especially in lumbar spine is extremely im-
portant because diagnostic errors can occur by changes of T-
score determined by the production of bone (osteophytes)
on an osteoporotic bone. Treatment must be complex, tar-
geting both associated degenerative diseases and changes in
bone turnover from osteoporosis. Response to therapy is
altered because of associated pathology.
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RELATIONSHIP BETWEEN TRABECULAR
BONE SCORE (TBS), BONE MASS AND
MICROARCHITECTURE IN HUMAN
VERTEBRAE: AN EX VIVO STUDY
Jean-Paul Roux1, Julien Wegrzyn1, Stephanie Boutroy1,
Didier Hans2, Roland Chapurlat1
1UMR 1033, INSERM, Lyon, France, 2University of
Lausanne, Bone Disease Unit, Lausanne, Switzerland
Objective(s): Although bone mass strongly impacts fracture
risk in elderly people, the influence of trabecular bone
microarchitecture measured in vivo on the lumbar spine is
not completely addressed. The trabecular bone score (TBS)
is a grey-level measure of texture using a modified version
of experimental variogramm and can be extracted from
DXA images. The aim of the current study was to compare
the TBS with microarchitectural parameters measured using
μCT with a 35 μm isotropic resolution.
Material & Methods: Lumbar vertebrae (L3) were harvested
fresh from 16 human donors (7 men, 9 women, age: 82±8 yrs
for men and 72±11 yrs for women). The BMD (g/cm2) of the
vertebral body was measured using anteroposterior (AP) and
lateral DXA (Delphi W, Hologic) and then the TBS was
extracted from AP view. The tridimensional trabecular micro-
architecture, bone volume (BV/TV), trabecular thickness (Tb.
Th), degree of anisotropy (DA), and structure model index
(SMI) which reflects the rodlike vs. platelike nature of the
structure were measured using μCT with a 35 μm isotropic
voxel size (Skyscan1076).
Results: The TBS was significantly correlated to the BV/
TV and SMI (r=0.518 and -0.597; p=0.040 and 0.015;
respectively).
Table 1: Spearman correlation between TBS and microarchitecture
Conclusion(s): In conclusion, the TBS was significantly
correlated to the most relevant microarchitectural
parameters used to predict fracture risk (i.e., BV/TV and
SMI). The TBS might improve bone assessment in associ-
ation with BMD using standard DXA and could enhance
assessment of fracture risk without requiring μCT acquis-
itions in elderly patients.
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BONE MINERAL DENSITY (BMD) COMBINED
WITH MICRO-ARCHITECTURE PARAMETERS
(TBS) SIGNIFICANTLY IMPROVES THE
INDENTIFICATION OFWOMEN AT HIGH RISK OF
FRACTURE: THE SEMOF COHORT STUDY
Albrecht W Popp1, Salome Meer1, Marc-Antoine Krieg2,
Romain Perrelet1, Didier Hans2, Kurt Lippuner1
1University Hospital and University of Bern, Osteoporosis
Policlinic, Bern, 2Lausanne University Hospital, Center of
Bone Diseases, Bone and Joint Department, Lausanne,
Switzerland
Objective(s): The aim of this analysis was to investigate
whether combining quantitative (BMD) and qualitative (tra-
becular bone score, TBS) information obtained from DXA
scans performed on a single device contributed to better
identification of women at high fracture risk.
Material & Methods: In the prospective SEMOF study,
women between 70-80 years old were randomly selected
from official state registries between January 1998 -
April 2000. Only women who attended their visit at
the SEMOF site of the Osteoporosis Policlinic of the
University Hospital of Bern, Switzerland, were included
in the present analysis. Lumbar spine and hip BMD
assessed by DXA (Hologic, USA) and MA evaluation
by TBS (Medimaps, France) were recorded. After
checking for normal distribution, results of all parame-
ters were expressed as means and SD. The hazard of
the first clinical fracture was calculated by using the age
and BMI adjusted proportional hazards model of Cox.
Results: The necessary information was available for 557
out of 701 women (79%) with the following baseline
characteristics (mean±SD): age 76.1±3.0 years, BMI
25.6±3.9 kg/m2, lumbar spine and hip BMD, 0.863±0.174
and 0.771±0.121 g/cm2, respectively, and TBS 1.195±0.115.
As expected, correlation between BMD and site matched TBS
was low (r2=0.25). After 2.72±0.77 years of follow-up, the
incidence of fragility fracture was 9.4%. Age- and BMI-
adjusted ORs (per SD decrease) were 1.6 (1.1-2.1)
(AUC=0.68), 1.8 (1.4-2.3) (AUC=0.66), 1.7 (1.2-2.3)
(AUC=0.61) for spine, total hip, and femoral neck
BMD, respectively, and 1.9 (1.4-2.5) (AUC=0.73) for
TBS. TBS remained significant after adjustment of any
of the BMD values. When using a triage approach,
57% of fragility fractures had a BMD T-score below
-2.5 and 75% of fractures had a TBS<1.200. Combining
AP
BMC
(g)
AP BMD
(g/cm2)
Lateral
BMC
(g)
Lateral
BMD
(g/cm2)
BV/TV
(%)
Tb.Th
(μm)
DA
(#)
SMI
(#)
r 0.226 0.453 0.068 0.210 0.518 0.132 -0.184 -0.597
p 0.399 0.078 0.803 0.434 0.040 0.626 0.496 0.015
Level of Significance; p < 0.05
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BMD≤-2.5 SD at any site or TBS<1.200 identified 85% of all
women with an osteoporotic fracture.
Conclusion(s): These preliminary results confirm the partial
independence between BMD and TBS. More importantly,
combining TBS and BMD values improved the identifica-
tion of women with osteoporotic fractures. Thus TBS added
to BMD information may become an important parameter
for further refining individual fracture risk.
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BENEFICIAL EFFECTS OF ZOLEDRONATE
COMPARED TO PLACEBO ON SPINE BONE
MINERAL DENSITY (BMD) AND
MICROARCHITECTURE (TBS) PARAMETERS
IN POSTMENOPAUSALWOMEN WITH
OSTEOPOROSIS: A 3-YEAR STUDY
Albrecht W Popp1, Helene Buffat1, Olivier Lamy2, Romain
Perrelet1, Didier Hans2, Kurt Lippuner1
1University Hospital and University of Bern, Osteoporosis
Policlinic, Bern, 2Lausanne University Hospital, Center of
Bone Diseases, Bone and Joint Dpt, Lausanne, Switzerland
Objective(s): Trabecular Bone Score (TBS, Med-Imaps,
France) is an index of bone microarchitecture independent
of BMD calculated from anteroposterior spine DXA scans.
TBS showed a positive maintenance of TBS in patients
treated with alendronate while treatment-naïve controls
were significantly losing bone microarchitecture. The aim
of this study was to compare the effects of yearly intrave-
nous zoledronate (ZOL) and placebo (PLB) on spine BMD
and microarchitecture as assessed by TBS in postmenopaus-
al women with osteoporosis.
Material & Methods: In a subset of 98 patients included in
the HORIZON trial, a retrospective analysis was performed.
The HORIZON trial was a randomized (1:1), double-blind,
placebo-controlled study comparing the effects of once-
yearly intravenous ZOL and PLB during 3 years in post-
menopausal women with osteoporosis. All subjects received
adequate calcium and vitamin D3 supplements. Spine BMD
and TBS were assessed by TBS iNsight® at baseline, 9, 12,
24, and 36 months after treatment initiation. An ITT analysis
was applied.
Results: Baseline characteristics (mean±SD) were similar
between groups in term of age, 76.5±5.1 years; BMI,
24.4±4.1 kg/m2; L1-L4 T-score, -2.55±1.44, and TBS
1.200±0.12. ZOL induced an early and sustained signif-
icant increase in spine BMD compared to placebo
(% delta spine ZOL vs. % delta spine PLB at 9 and
36 months, p value<0.01). TBS was significantly greater
with ZOL than with PBO at month 36 (p value p<0.05).
Spine BMD and TBS were weakly correlated (r2=0.11).
There were no correlations between changes in BMD
and TBS from baseline at any visit. This suggests and
confirms that TBS reflects bone properties other than
BMD.
Conclusion(s): In postmenopausal women with osteoporo-
sis, once-yearly intravenous ZOL therapy significantly in-
creased lumbar spine BMD during three years compared to
PLB and prevented bone microarchitecture decay assessed
by TBS.
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AN AUDIT OF ANDROGEN DEPRIVATION
THERAPY AND BONE PROTECTION IN
SECONDARY CARE
May Yung Tiet, Allyah Abbas, Andrew Whallett
Dudley Group of Hospitals, Rheumatology, Dudley, West
Midlands, UK
Objective(s): Prostate cancer is the most common cancer
in men, with an incidence of 37,000 in 2008 in the UK.
Androgen deprivation therapy plays an important role in
prostate cancer treatment for many patients. However,
hormone treatment is known to reduce bone density,
even with short term use. This may lead to morbidity
from pathological fractures and has a negative correlation
with survival. Bisphosphonates and denosumab can be
used to ameliorate these changes in bone mineralisation
and thus reduce the incidence of fractures during use of
anti-androgens. Currently there are no national guidelines
regarding bone protection during and following use of
androgen deprivation therapy.
Material & Methods: We audited the management of
bone protection in prostate cancer patients starting an-
drogen deprivation therapy over a nineteen month peri-
od at Russells Hall Hospital, Dudley, West Midlands.
Consideration for risk factors of osteoporosis by clini-
cian use of risk stratification tools (FRAX®), DXA
scans and appropriate prescription of preventative treat-
ment with calcium/vitamin D, bisphosphonates and
denosumab were reviewed.
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Results: A total of 177 cases were analysed. During and
following treatment FRAX® score had not been docu-
mented for any patient, even in cases of known osteoporo-
sis, and only 2.8% had undergone a DXA scan. Only 2.3%
were prescribed calcium/vitamin D and 6.8% received
bisphosphonates. Denosumab had not been prescribed
throughout this period.
Conclusion(s): Although osteoporosis is a risk with andro-
gen deprivation therapy, here patients at risk of fracture had
not been identified by lack of use of risk stratification tools
and baseline DXA scans. Yet delays in preventative treat-
ment may have detrimental effects on skeletal health.
Agreed national guidelines and educating those managing
prostate cancer care are required to make screening for at
risk patients standard practice. Re-auditing following guid-
ance is necessary.
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DEGENERATIVE CHANGES AT THE LUMBAR
SPINE – IMPLICATIONS FOR BONE MINERAL
DENSITY MEASUREMENT IN ELDERLY WOMEN
Max Tenne1, Fiona E McGuigan1, Jack Besjakov1, Paul
Gerghem2, Kristina Åkesson1
1LundUniversity, Clinical Science, Skåne University Hospital
Malmö, Malmö, 2Karolinska University Hospital, Orthopae-
dics, Stockholm, Sweden
Objective(s): In the elderly, degenerative manifestations in
the lumbar spine may result in falsely elevated BMD values,
consequently missing a large proportion of those with oste-
oporosis. Our aim was to determine the impact of degener-
ative changes on lumbar spine DXA measurements over
time and the implications for the clinical diagnosis of
osteoporosis.
Material & Methods: The study participants were 1044
Swedish women from the population based Osteoporosis
Prospective Risk Assessment study (OPRA) cohort. All
were 75 yrs at invitation and followed up after 5-years (n=
698) and 10-years (n=380). BMD was assessed using the
Lunar DPX-L DXA. Degenerative changes (disc space nar-
rowing, osteophytes, asymmetric subchondral sclerosis or
facet joint sclerosis) were evaluated visually on the DXA
image for each vertebra L1-L4 (intra observer precision
kappa values 0.66-0.7). Evaluation of spinal X-rays was
also made for comparison.
Results: At baseline, degenerative changes were more fre-
quent in the distal part of the lumbar spine: 5% (L1), 15%
(L2), 26% (L3), 36% (L4) and increased over time. At 10-
year follow-up incidence was: 20% (L1), 39% (L2), 59%
(L3), 72% (L4), manifesting as a significant increase in
overall BMD. Reanalysis following exclusion of all cases
with degenerative changes resulted in BMD remaining sta-
ble between 75-85 yrs rather than the expected bone loss.
Using the criteria (L2-L4 BMD <2.5SD), at baseline, 33%
of women had osteoporosis. Excluding individuals with
degenerative changes, this proportion increased to 42%.
Using L1-L2, which are less prone to degenerative changes,
as the diagnostic site, 46% of women were classified as
osteoporotic. Use of bisphosphonates, calcium, D-vitamin
or HRT did not significantly alter the results.
Conclusion(s): Our results confirm that degenerative
changes are common in elderly women, accelerate dispro-
portionately over time, are more frequent in vertebrae fur-
ther distally, with a gradient from L1-L4 and have
significant impact on DXA measurements. Interestingly,
even in the absence of degenerative changes, BMD is main-
tained rather than lost over time in elderly women. We
conclude that the DXA image offers sufficient precision to
detect degenerative changes and used in conjunction with
BMD measurements improves interpretation of osteoporosis
status. Clinically, diagnosis of osteoporosis and evaluation
of therapy would be improved by routinely assessing verte-
brae L1-L2.
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VITAMIN D SUPPLEMENTATION IN
HYPERTHYROIDISM IMPROVES BONE DENSITY
Dinesh K Dhanwal, Vivek Dixit
Maulana Azad Medical College, Medicine, New Delhi,
Delhi, India
Objective(s): We have previous reported that patients with
hyperthyroidism have vitamin D deficiency which exacer-
bates bone loss. Therefore this study was done to examine
the effect of vitamin D supplementation on bone density in
patients with hyperthyroidism.
Material & Methods: Seventy consecutive patients with
hyperthyroidism attending endocrine clinic of Lok Nayak
Hospital, New Delhi, recruited during two years. Similar
number of age and sex matched controls were also included
as controls. Serum analysed for T4, TSH, 24 (OH) D and
PTH levels. BMD was measured using Hologic DR 4500A
densitometer at hip and lumbar spine. Half of the patients
were randomized to receive either vitamin D 60,000 IU per
month and 1 g calcium. Parameters of bone homeostasis
were reanalyzed after one year of vitamin D supplementa-
tion. Data was analyzed using SPSS 12.0 computer soft-
ware. Student t test was used to establish whether
differences existed within study groups. Chi-square test
was used to assess differences in the frequency of different
indices between vitamin D deficient and sufficient group.
Pearson correlation test was used to assess relationship
among study variables.
Results: The mean age of the subjects was 39 (10.0) years.
Serum calcium, phosphorous, alkaline phosphates and PTH
levels were comparable in patient and control groups. Mean
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(SD) vitamin D levels were significantly lower in patients
group compared to controls [19.24(10.15) vs. 28.38(14.56)]
ng/ml. BMD at hip and lumbar spine was significantly lower
in patient group. There was a correlation between vitamin D
and bone density. Group randomized to vitamin D and
calcium supplementation had significantly higher vitamin
D levels and bone density at end of one year.
Conclusion(s): Patients with hyperthyroidism are vitamin D
deficient compared to controls. Vitamin D and calcium
supplementation improves bone density at end of one year.
References: 1. Dhanwal DK, Kochupillai N, Gupta N,
Cooper C, Dennison EM. J Clin Densitom 2010;13:462. 2.
Dhanwal DK, Gupta N. J Assoc Physicians India
2011;59:562.
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FUNCTIONAL ACTIVITY AND QUALITY OF LIFE
IN PATIENTS WITH VERTEBRAL FRACTURES
Nataliia V Grygorieva, Vladyslav V Povoroznyuk, Olena S
Rybina
Institute of Gerontology NAMS Ukraine, Department of
Clinical Physiology and Pathology of Locomotor Appara-
tus, Kyiv, Ukraine
Objective(s): The purpose of the study was to examine the
functional activity and quality of life in patients with verte-
bral fractures.
Material & Methods: We examined 153 women aged 60-
89 years old in postmenopausal period (mean age 69.67
±0.54 years). Patients were divided into two groups: the
first (control group) – without osteoporotic fractures, and
the second – with vertebral fractures. Methods of research -
questionnaires (to assess life style, Euro-Qul-5D, Roland-
Morris, ECOS-16), functional tests (dynamometry, static
balancing, 15-m test), Thomayer's, Schober's, Ott's tests,
orthopedic examination (range of movement assessment in
the thoracic/lumbar spine, determination of the chest excur-
sion and breath holding spell), DXA.
Results: BMD of lumbar spine and femoral neck in patients
with vertebral fractures was significantly lower than appro-
priate data in control group. Indexes of quality of life and
daily activity in patients of the second group were consid-
erably lower compared to the control group. It was found
significant differences in Schober's test (p=0.04) and
parameters of movement of the thoracic and lumbar spine
(p=0.04). Others functional tests were without significant
difference. In patients without vertebral fractures it was
found the significant positive correlation between BMD of
the femoral neck and lumber spine and data of functional
tests indexes such as dynamometry, Thomayer's, Schober's
tests, maximum and average chest excursion. In contrast,
patients with vertebral fractures didn't have significant cor-
relation between BMD data and indexes of functional tests
and orthopedic examination data. In patients with vertebral
fractures was determined significant correlation between
ECOS-16 indexes and Schober's tests (p=0.006) and breath
holding spell (p=0.03) in contrast to patients without verte-
bral fractures.
Conclusion(s): Our study found significant correlations
between BMD and some functional tests in patients
without vertebral fractures. Vertebral fractures leads to
reducing of functional ability and decreasing of quality
of life.
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TRAP5B AND SCLEROSTIN IN MGUS AND
MULTIPLE MYELOMA RELATIONSHIPS
WITH HISTOMORPHOMETRY
Hélène Marchand-Libouban1, Yves Gallois2, Norbert
Yfrah3, Daniel Chappard1
1University of Angers, LHEA-Bone Remodeling and
Biomaterials, 2CHU-Angers, Laboratoire de Biochimie,
3CHU-Angers, Service desMaladies du Sang, Angers, France
Objective(s): Multiple Myeloma (MM) is characterized
by an increase in bone resorption and a depression of
osteoblast function. Wnt pathway is involved in the
pathophysiology of MM as DKK1 is produced by plas-
ma cells to decrease bone formation. Little is known on
the implication of sclerostin, another inhibitor of the
Wnt pathway. The aim of the study was to evaluate
serum level of sclerostin in MM and MGUS patients
and to see if relationships exist with histomorphometric
parameters of bone formation. Similar analysis was con-
ducted with TRAP5b.
Material & Methods: 108 patients (47 male / 61 female,
mean age 63±10 years) were included in the study: 58 with
MGUS and 50 with MM. Dosage of TRAP5b (Quidel) and
sclerostin (TECOmedical) was performed by ELISA. Dos-
ages were also performed on 12 healthy controls. Among
the 108 patients, 89 patients had a transiliac bone biopsy (39
MGUS, 50 MM). Dynamic bone formation parameters (MS/
BS and Aj.Ar) and osteoclastic parameters (ES/BS and N.
Oc/B.Ar) were compared with TRAP-5b and/or sclerostin
level.
Results: Sclerostin level was significantly higher in MGUS
patients compared to controls; no significant differences
were found in MM patients. TRAP5b level was significantly
higher in both MM and MGUS patients compared to healthy
controls; TRAP5b value in MM patients was significantly
higher compared to MGUS (3.56±0.27 vs. 2.87±0.17,
P<0.05). Aj.Ar and MS/BS were not different between
MM and MGUS. In contrast, N.Oc/B.Ar and ES/BS were
significantly increased in MM patients compared to MGUS
(resp. +58.1%, P<0.01; +20.3%, P<0.01). We found no
correlation between sclerostin level and bone formation
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parameters. In contrast, a significant correlation was found
between TRAP5b level and N.Oc/B.Ar (r=0.56, P<0.01).
Conclusion(s):Sclerostin could not be used as a predicting factor
of depressed bone formation in MM. In contrast TRAP5b
reflected the bone resorption level in MGUS and MM patients.
P605
OSTEOPOROSIS IN WOMEN WITH EARLY
SURGICAL MENOPAUSE
Simona Patru, Rahela I Marcu, Adrian C Bighea, Roxana S
Popescu
University of Medicine and Pharmacy, Physical Medicine
and Rehabilitation, Craiova, Dolj, Romania
Objective(s): To determine total body and regional BMD in
a cohort of women with early surgical menopause due to
gynecological causes.
Material & Methods: 37 women with early surgical men-
opause, mean age 35.72±11.5 years were evaluated regard-
ing lumbar spine and total hip BMD by DXA. Total body
measurements were done with the same device and the
results were compared with 37 age-matched controls.
Results: In women with early surgical menopause, BMD
was reduced in both lumbar spine (T-score -1.15±1.52) and
total hip (T-score -0.71±0.95) as compared with controls (T-
score 0.13±1.12, respectively 1.33±0.41, all p<0.05). Total
body BMD was also significantly lower in the studied lot
patients (p<0.05) and it was correlated with spine BMD (r=
0.70; p=0.00523) but not with total hip BMD. Lumbar
spine BMD was also correlated with menopause duration
and with the age at menopause onset.
Conclusion(s): We found spine osteopenia or osteoporosis
in 51.43% patients, while 32% had hip osteopenia and none
had hip osteoporosis. Early menopause age is associated
with generalized bone loss that occurs early after its onset.
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FALL RISK ASSESSMENT PREVENTS
OSTEOPOROTIC FRACTURES
Dorina C Stoicanescu1, Mariana I Cevei2
1Victor Babes, University of Medicine and Pharmacie,
Timisoara, 2Rehabilitation Medical Hospital, University of
Oradea, Faculty of Medicine and Pharmacie, Baile Felix,
Romania
Objective(s): It is estimated that 30% of those over 65
years fall annually and half are repeated fallers. This
percent is increased in osteoporotic patients, 50% of
them, aged 65 or more, fall, suffering fractures. Elder
individuals without risk factors or with only one, will
have a risk of about 27% of falling each year. This
increases to 78% for cases with 4 or more risk factors.
Fall frequency is estimated to 2-3 every year. Fear of
falls leads to the imposition of restrictions regarding
physical activity and social contacts. Our hypothesis
was that physical training can prevent falls.
Material & Methods: We conducted a clinical epidemiolog-
ical randomized, observational study on a number of 87
patients aged over 65 years, diagnosed with type I or II oste-
oporosis, admitted in the Medical Rehabilitation Clinical Hos-
pital Baile-Felix, Romania, between June-December 2011.
Fall risk assessment was performed by means of simple tests
that can reveal diminishing of legs functionality and are con-
sidered as good independent predictors for falls: chair rise test,
Tinetti gait test, tandem standing test, Get Up and Go test. Risk
assessment tools are designed to help target those at high risk
of falling and to establish prevention strategies to individual
risk profiles. Rehabilitation program objectives were maintain-
ing functional capacity, maintaining musculoskeletal integrity.
Physical therapy is extremely important. Duration of exercise,
frequency, rate and effort intensity were dosed. The type of
exercise took into account each patient's functional capacity.
Walking was the basic exercise dosed by distance and rate.
Results: Mean values are calculated. Tandem standing test
was 9.51±2.17, Get Up and Go test 12.61 s; Chair Rise test
17.16, Tinetti gait test 16.21. Next monitoring will be done
over six months.
Conclusion(s): Preventing falls prevents osteoporotic frac-
tures. Physical therapy may improve therapeutic results.
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DYNAMICS OF GROWTH RATE OF 3 LUMBAR
VERTEBRAE OF WHITE RATS AFTER
INHALATION OF TOLUENE AND ITS
CORRECTION BY THIOTRIAZOLIN
Vladyslav I Luzin, Evgeniy Yu Shutov, Andrey N
Skorobogatov, Anton V Yeryomin
SI "Lugansk State Medical University", Human Anatomy,
Lugansk, Ukraine
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Objective(s): To study the growth characteristics of 3 lum-
bar vertebrae of white rats after a 60-day toluene inhalation,
well as the rationale the possible ways of correcting by
thiotriazolin.
Material & Methods: An experimental study was carried
out on 180 white mongrel adult male rats in SI "Lugansk
State Medical University" and kept in accordance with the
requirements and provisions established "European Con-
vention for the Protection of Vertebrate Animals used for
Experimental and Scientific Purposes" (Strasbourg, 1986).
Rats were taken out of the experiment at 1, 7, 15, 30, 60
days after the completion of a 2-month exposure of toluene
by decapitation under ether anesthesia.
Results:We found that body height of third lumbar vertebra
was less than the values of the control group, respectively, at
5.12%, 6.27%, 6.69%, 3.28% and 4.80%. This indicates
about the oppression of bone growth by vapor of toluene.
Maximum body width at of third lumbar vertebra was also
lower, but significantly different from control values only to
the 7 day - at 7.51%. Simon index of the third lumbar
vertebra was greater than control values, but this difference
did not reach limits of the confidence interval. Intraperito-
neal injection of 2.5% thiotriazolin solution in a dose 117.4
mg/kg body weight of rat was accompanied by a slight
acceleration in both longitudinal and transverse growth of
the studied bones. Body height of third lumbar vertebra has
exceeded the value of the experimental group from 15 to 60
day experiment, respectively, at 5.01%, 5.19% and 4.27%.
Conclusion(s): Inhalation of toluene leads to the slowing of
longitudinal and appositional growth of third lumbar verte-
bra. The use of thiotriazolin simultaneously with inhalation
of toluene reduces the negative effect of the experimental
conditions.
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ACCURACY OF APPLICATION OF WHO
FRACTURE RISK ASSESSMENT (FRAX™) FOR
PREDICTION HIO FRACTURE IN KHON KAEN
HOSPITAL THAILAND
Thananit Sangkomkamhang1, Ussanee Swadpanich
Sangkomkamhang2
1Khon Kaen Hospital, Department of Orthopedic, 2Depart-
ment of Obstetrics and Gynecology, Maung District, Khon
Kaen, Thailand
Objective(s): The aim to determine the FRAX® tool (10-year
probability of hip fracture) in Thai peoples ages over 50 years
who have fragile fracture around hip as a diagnosis test.
Material & Methods: The retrospective study was con-
ducted during 2008-2010 by chart review and interview.
366 patients over the age of 50 with fragile fracture around
hip were recruited compare with aged match control group,
380 patients. 10-year probability of hip fracture was
evaluated by using the FRAX® WHO Tool (available at
http://www.shef.ac.uk/FRAX/index.htm). We used age, sex
BMI and 7 clinical risk factors without BMD due to limited
healthcare resources. The output was based on China model.
The probability of hip fracture more than 3% should be
assumed as patients fracture and needed to intervention.
Results: The populations in both groups were similar in age
and gender ratio. At the cut point, probability of hip fracture
was more than 3%, in these groups showed 190 in 366
patients and 117 in 380 control groups. The sensitivity was
0.62.The specificity was 0.60. Positive predictive value (PV+)
was 0.52. The Negative predictive value (PV-) was 0.69. And
Likelihood ratio LR (+ve) was 1.54, LR (-ve) was 0.64
Conclusion(s):WHO fracture risk assessment tool used 10-
year probability of hip fracture at cut point 3% was ineffec-
tive and had limitation to predict fracture in Thai peoples.
Because of low sensitivity and specificity, this tool may not
suitable for the screening method for population with risk
for fragility fracture. Further cohort study, vary in cut point
decision and country-specific calculation tools especially in
Thai model were needed to confirm this study.
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BENEFICIAL EFFECTS OF PTH ON SPINE
BONE MINERAL DENSITY (BMD) AND
MICROARCHITECTURE (TBS) PARAMETERS
IN POSTMENOPAUSALWOMEN WITH
OSTEOPOROSIS: A 2-YEAR STUDY
Beatrice Günther1, Albrecht W Popp1, Delphine Stoll2,
Berengère Aubry Rosier2, Romain Perrelet1, Didier Hans2,
Kurt Lippuner1
1University Hospital and University of Bern, Osteoporosis
Policlinic, Bern, 2Lausanne University Hospital, Center of
Bone Diseases, Bone and Joint Dpt, Lausanne, Switzerland
Objective(s): Trabecular Bone Score (TBS, Med-Imaps,
France) is an index of bone microarchitecture independent
of BMD calculated from anteroposterior spine DXA scans.
TBS was associated with fracture in prior case-control and
prospective studies. In addition, an earlier study showed a
positive maintenance of TBS in patients treated with alendr-
onate while treatment-naïve controls were significantly los-
ing bone microarchitecture. The aim of this study was to
assess the effects of teriparatide, recombinant 1-34 PTH on
spine BMD and spine microarchitecture assessed by TBS in
postmenopausal women with osteoporosis.
Material & Methods: In this open label multicenter
study (Bern and Lausanne, Centers of Bone Diseases),
82 women were treated with teriparatide during 2 years.
At the lumbar spine, BMD was assessed by DXA
(Hologic Discovery) and TBS parameters were assessed
by TBS iNsight (v1.9) at baseline and after 24 months
of treatment. ISCD-like rules for individual vertebrae
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exclusion were applied independently for BMD and
TBS. The analysis was by ITT.
Results: Baseline characteristics (mean±SD) were similar
between groups in term of age, 69.2±10.3 years; BMI,
23.9±4.3 kg/m2; L1-L4 BMD, 0.785±0.15 and TBS
1.213±0.11. The correlation between BMD and TBS at
the lumbar spine was very low (r2=0.13). Over 2 years,
L1-L4 BMD increased significantly by +7.6% (p<0.001)
and Spine TBS increased by +4.3% (p<0.001). At 2
years, there was no correlation between the changes in
BMD and TBS from baseline.
Conclusion(s): In postmenopausal women with osteoporo-
sis, a 2-year treatment with teriparatide lead to an indepen-
dent increase in BMD and TBS at the lumbar spine,
suggesting that teriparatide has independent positive effects
on spine bone mass and microarchitecture.
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VITAMIN D STATUS IN HUNGARIAN CHILDREN:
HEALTHY VOLUNTEERS, OBESE CHILDREN AND
PATIENTS WITH TYPE-I DIABETES MELLITUS
Eva Hosszu1, Csilla Novoszel1, Dora Botlik1, Andras
Szabo1, Szilvia Meszaros2, Viktoria Ferencz2, Emoke Csupor3,
Katalin Bors4, Edit Toth5, Csaba Horvath2
1Faculty of Medicine, Semmelweis University, 2nd Depart-
ment of Pediatrics, 2Faculty of Medicine, Semmelweis Uni-
versity, 1st Department of Internal Medicine, 3Budavar
Local Authorities, Department of Endocrinology, Budapest,
4Rehabilitation Hospital, Department of Musculoskeletal
Rehabilitation, Visegrad, 5Ferenc Flor County Hospital, De-
partment of Rheumatology, Kerepestarcsa, Hungary
Objective(s): Vitamin D deficiency is one of the most
frequent medical deficits in the developed countries. The
lack of vitamin D has a negative impact on the musculo-
skeletal system, moreover, it can promote development of
numerous malignant, autoimmune and metabolic diseases.
Serum concentration of 25(OH)D3 has been accepted as a
validated indicator for vitamin D supply. The aim of this
study was to survey the level of vitamin D supply in a
healthy young population as well as in children with obesity
or with type-I diabetes mellitus.
Material & Methods: 462 healthy children (223 boys
and 239 girls, aged 4-19 ys) with normal BMI (accord-
ing to the Hungarian National Standards) participated in
the survey. 73 children with obesity and 36 with type-I
diabetes mellitus were also studied. Serum 25(OH)D3
level was measured by chemiluminescent immunoassay
(Diasorin test, Liaison automat) in fasting blood sample
of all cases. The results were evaluated according to
age, sex, Tanner's stage and the season. Differences
among the groups and relationships to the seasons were
analyzed by SPSS.
Results: Severe vitamin D deficiency (less than 20 ng/ml)
was found in 21% of healthy children. Another 34% showed
insufficient vitamin D supply as their 25(OH)D3 levels were
found between 20 and 30 ng/ml. A continuous decrease of
the level has been observed from summer to spring with the
deepest values in February. Gender had no impact, while the
vitamin D deficiency was found being more expressed in the
pubertal than in prepubertal children. The 25(OH)D3 levels
in obese children were slightly lower than in healthy volun-
teers. No differences were found between healthy and type-I
diabetic children.
Conclusion(s): This is the first pediatric survey of vitamin
D status done by modern methods in Hungary. Our obser-
vations suggest that the majority of Hungarian children
develops under pressure of vitamin D insufficiency. This
incidence is especially expressed in puberty, a period of
exclusive importance for skeletal, immune and metabolic
maturation. The growing frequency of pediatric obesity
provides a further aggravation in vitamin D deficiency while
type-I diabetes mellitus has no more impact.
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PREDICTION OF FRAGILITY FRACTURE
WITH THE FRAX TOOL IN POSTMENOPAUSAL
WOMAN IN THAILAND
Ussanee Swadpanich Sangkomkamhang1, Thananit
Sangkomkamhang2
1Khon Kaen Hospital, Department of Obstetrics and Gyne-
cology, 2Department of Orthopedic, Maung District, Khon
Kaen, Thailand
Objective(s): The purpose of this study was to determine
the output of FRAX® tool in postmenopausal woman in
Thai people at the age over 50 years old.
Material & Methods: The retrospective data of 715 people
(average age of 72 year old) from 2008-2010 were reviewed
by interviewing and medical record. The patient group, 374
cases at the age over 50 years who were diagnosed with a
major osteoporotic fracture (spine, forearm, hip or shoul-
der), were recruit. The control group was age-related people.
The FRAX® tool (age, sex, BMI, and 7 clinical risk factors)
was used to assess 10-year probability of major osteoporotic
fracture. The T-score for BMD was not included due to
incomplete data correction. The data was calculated by
using WHO fracture risk assessment tool based on Hong
Kong country with the reason of higher sensitivity and
specificity than other Asians countries. Over 20% of major
osteoporotic fracture probability (the cut point) was decided
to be treated and assumed as risky fracture patients and
assumption as diagnosis test.
Results: Age and gender ratio from both groups were sim-
ilar. At the cut point, probability of major osteoporotic
fracture was more than twenty percent; 261 out of 355 in
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the fracture group and 133 out of 460 in the control group.
Sensitivity and Specificity were 0.73 and 0.63, respectively.
Positive predictive value (PV+) was 0.66. The Negative
predictive value (PV-) was 0.71. And Likelihood ratio LR
(+ve) was 1.99, LR (-ve) was 0.42
Conclusion(s): Using the FRAX® tool with the cut point of
20% to predict fracture for postmenopausal woman in Thai
population was accurate. It may appropriate for screening
people who have risk of fragility fracture due to moderate
sensitivity and specificity. Thai specific data reference, pro-
spective cohort study and vary in cut point are needed to
improve evaluation of the probability of fracture.
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HIGH SERUM CYSTATIN C PREDICTS INCIDENT
HIP FRACTURE IN ELDERLY MEN: MROS
SWEDEN
Ewa Waern1, Osten Ljunggren2, Ulf Lerner1, Catharina
Lewerin3, Helena Johansson1, Kristine Ensrud4, Magnus
Karlsson5, Eric Orwoll6, Mattias Lorentzon1, Hans Herlitz7,
Claes Ohlsson1, Dan Mellström1
1University of Gothenburg, Center for Bone and Arthritis
Research at the Sahlgrenska Academy, Gothenburg, 2Uni-
versity of Uppsala, Department of Medical Sciences,
Uppsala, 3University of Gothenburg, Section of Hematolo-
gy and Coagulation, Department of Internal Medicine at the
Institute of Medicine, Sahlgrenska Academy, Gothenburg,
Sweden, 4University of Minnesota, Division of Epidemiol-
ogy and Community Health, Minneapolis, MN, US, 5Lund
University, Clinical and Molecular Osteoporosis Research
Unit, Department of Clinical Sciences and Orthopaedics,
Malmö, Sweden, 6Oregon Health and Sciences University,
Bone and Mineral Research Unit, Portland, OR, US, 7Uni-
versity of Gothenburg, Department of Nephrology Institute
of Medicine at the Sahlgrenska Academy, Gothenburg,
Sweden
Objective(s): Serum Cystatin C is widely used as a serum
marker for renal function. High values are related to poorer
kidney function. Earlier studies of postmenopausal women
have indicated a higher risk of hip fracture in women with
high serum Cystatin C. However in elderly men there are
few data showing that increased risk of hip fracture is
related to high Cystatin C. The aim of this study was to
examine the association of high Cystatin C and incident hip
fractures in men.
Material & Methods: We used the MrOS, Sweden cohort
(n=3014) of men aged 69-80 years who were recruited from
a national population register. BMD was measured with
Lunar and Hologic DXA and standardized BMD was esti-
mated. All incident fractures were collected from national
X-ray registers during the 7 years following baseline. A total
number of 388 men sustained one or more fractures,
including 90 hip fractures. Cystatin C was measured by
immunoturbidimetry with polyclonal antibodies against hu-
man Cystatin C.
Results: Serum Cystatin C increased with age (p<0.001).
The mean value was 1.138 mg/l (0.30). Estimated GFR was
below 45 ml in 7.9% and in 27.1% below 60 ml. High
Cystatin C was associated with BMD of the lumbar spine
(r=0.06, p=0.001) but not with hip BMD (r=-0.04, p=
0.052). There was a linear association with serum Cystatin
C and all types of fractures (GR 1.14(CI 1.1-1.2)) adjusting
for BMI, hip BMD, age, previous fracture and general
health. Cystatin C (per SD increase predicted hip fracture
[HR 1.26(CI 1.03-1.54)]. The HR for hip fracture was 1.90
(CI 1.24-2.93), adjusting for age and center, when compar-
ing quartile IV vs. quartile I-III. A multivariate model in-
cluding hip BMD, BMI, age and center showed increased
hip fracture risk [HR 1.71 (CI 1.10-2.65)] when comparing
quartile IV against quartile I-III of Cystatin C. The multi-
variate hip fracture risk adjusted for age, hip BMD, BMI and
center for men with GFR below 45 ml was HR 2.6 (CI 1.5-
4.4) and below 60 ml HR 1.8 (CI1.1-2.7).
Conclusion(s): We conclude that high Cystatin C is related
to increased risk of hip fractures in elderly men.
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VITAMIN D SUPPLEMENTATION AS AN
ADJUVANT THERAPY FOR SAUDI PATIENTS
WITH T2DM: AN 18-MONTH INTERVENTIONAL
STUDY
Nasser Al-Daghri1,2,3, Khalid Alkharfy1,2,4, Abdulaziz Al-
Othman1,2,5, Omar Al-Attas1,2,3, Majed Alokail1,2,5, Yousef
Al-Saleh1,6, Sobhy Yakout1,2, Deqa Yusuf2, Shaun Sabico1,2
1King Saud University, Prince Mutaib Chair for Biomarkers
of Osteoporosis, 2Biomarkers Research Program, 3Center of
Excellence in Biotechnology Research, 4Clinical Pharmacy,
5College of Applied Medical Sciences, 6King Saud Univer-
sity of Health Sciences, College of Medicine, Riyadh, Saudi
Arabia
Objective(s): Vitamin D deficiency has been shown to
impair human insulin action, suggesting a role in the path-
ogenesis of type 2 diabetes mellitus (T2DM). Despite the
level of sunshine in Saudi the population has significant
vitamin D deficiency based on our previous studies. In this
prospective interventional study we investigated the effect
of vitamin D (Vit D) supplementation in the metabolic and
glycemic profiles of the Saudi T2DM subjects pre and post
supplementation to improve known Vit D deficiency com-
pounded in metabolic states such as T2DM.
Material & Methods: T2DM Saudi subjects (men: age:
56.6±8.7 yr, BMI, n=34; 29.1±3.3 kg/m2; females: age:
51.2±10.6 yr, BMI 34.3±4.9 kg/m2; n=58) were recruited
and given 2000 IU vitamin D3 daily for 18 months.
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Anthropometrics and biochemical data was collected (0, 6,
12, 18 months) to monitor serum 25 hydroxyvitamin D [25
(OH) D (nmol/L)] using a commercial ELISA, as well as
glycemic and lipid profiles.
Results: In all T2DM subjects there was a significant in-
crease in mean circulating 25(OH)D levels from baseline
(32.2±1.5 nmol/L) to 18 months (54.7±1.5 nmol/L;
p<0.001) as well as with serum calcium [baseline=2.3
±0.23 mmol/L vs. 18 months=2.6±0.1 mmol/L; p=0.003).
A significant increase in HDL-cholesterol was noted only in
females (p<0.001), as well as a significant decrease in LDL-
calcium [baseline=4.4±0.8 mmol/L vs. 18 months=3.6±0.8
mmol/L] and total cholesterol calcium [baseline=5.4±0.2
mmol/L vs. 18 months=4.9±0.3 mmol/L] (p<0.001 and
p<0.001, respectively). Glycemic parameters (glucose, in-
sulin, HOMA-IR), blood pressure and BMI were
comparable.
Conclusion(s): In summary, the results highlight that de-
spite oral vitamin D supplementation (2000 IU/day) in
Saudi subjects with T2DM; circulating 25(OH)D levels still
remain deficient by 22% below normal 18 months post
treatment. However, supplementation appeared to signifi-
cantly improve lipid profile with a change in HDL/LDL
ratio which was more pronounced in T2DM females, offer-
ing other benefits for health. This study suggests that T2DM
Saudi subjects require a higher Vitamin D supplementation
(3000 IU/day) as a clinical recommendation to achieve
normal vitamin D status.
Disclosures:Many thanks to King Abdulaziz City for Science
and Technology for funding this study.
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QUALITY OF BONE MINERAL DENSITY
REPORTING IN POST-FRACTURE CARE
IN ONTARIO, CANADA
Susan B Jaglal1, Sonya Allin1, Sarah Munce1, Gillian
Hawker1
1University of Toronto, Physical Therapy, 2Women's College
Hospital, Medicine, Toronto, ON, Canada
Objective(s): To determine whether or not Canadian Asso-
ciation of Radiologist (CAR) or WHO diagnostic categori-
zations for osteoporosis were prevalent in reports in 2008; 2)
2008 fracture risk assessments incorporated risk factors such
as history of fragility fracture, as mandated by CAR in 2005;
and 3) the overall format of 2008 reports, on average, con-
formed to CAR's 2005 published standards.
Material & Methods: The reports examined were collected
as part of a cluster randomized trial focusing on the treat-
ment of individuals with a recent fragility fracture. Diagno-
ses and assessments produced by the research team were
then compared to those produced by the reading specialist.
To determine if risk assessments in 2008 conformed to
CAR's 2005 recommendations, the research team first
extracted the following information from the gathered
reports: age, sex, and the lowest T-score from the lumbar
spine (L2-L4), femoral neck, and total hip. The lowest T-
score, in combination with each patient's age and sex were
then used by the research team to calculate baseline 10-year
absolute fracture risk as per guidelines.
Results: A total of 53 follow-up BMD reports were gath-
ered from those who had a DXA. Of these reports, 2 were
excluded from the present analysis because they predated
the participants' fracture; 1 was excluded because it was
produced by a clinic outside of Ontario. An additional 2
were excluded because they were incomplete when re-
ceived. This resulted in BMD reports for 48 patients in the
pool of those eligible for analysis. In accordance with CAR
guidelines, 33.3% of BMD reports that should have provid-
ed a fracture risk assessment of “moderate” were reported as
“low”. Similarly, 14.8% of reports that provided a fracture
risk assessment of “moderate” should have provided a frac-
ture risk assessment of “high”.
Conclusion(s): This study has highlighted the overall
poor quality of Ontario's BMD reports produced in
non-urban centres as of 2008, in terms of missing
clinical risk factors that modify fracture risk. The lack
of this information has implications in terms of fracture
risk categorization and subsequent follow-up care and
treatment recommendations.
P615
THE PHYSICAL AND PSYCHOLOGICAL
CONSEQUENCES ON QUALITY OF LIFE IN
PATIENTS WITH UPPER LIMBS OSTEOARTHRITIS
Corina Suteu1, Dorina Maria Farcas2
1University of Oradea Faculty of Medicine, Occupational
Medicine, 2Physical Rehabilitation Medicine, Oradea,
Bihor, Romania
Objective(s): To assess the impact on quality of life of a
group of patients with upper limb osteoarthritis.
Material & Methods: We studied a group of 97 patients
with upper limbs osteoarthritis, divided in two subgroups,
first subgroup of 49 patients underwent a physical rehabil-
itation program three times per week for 12 months and the
second subgroup of 48 sedentary patients. All the patients
were assessed with Short Form 36 and Beck Depression
Inventory(BDI) at baseline, at 6 months and at 12 months.
The Short Form 36 is a complex questionnaire that measures
eight domains of health which include physical functioning,
bodily pain, general health perceptions, vitality, social func-
tioning, role limitations due to emotional problems and
mental health. The BDI is widely used screening instru-
ments for measuring the severity of depression in adults.
The inventory is composed of items relating to depressive
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symptoms such as: hopelessness and irritability, cognitions
(such as guilt or feelings of being punished), physical symp-
toms (such as fatigue, weight loss, and lack of interest in
sex).
Results: In the subgroup of patients who underwent reha-
bilitation program both Physical Component Summary
(PCS) and Mental Component Summary (MCS) improved
at 6 months and the improvement in quality of life was
greater at 12 months than in the second subgroup of seden-
tary patients which showed no improvement in quality of
life.
Conclusion(s): An active life and a regular physical exer-
cise programme play an important role in wellbeing and in
enhancing one's quality of life.
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SPINE TRABECULAR BONE SCORE (TBS)
SUBSEQUENT TO BMD IMPROVES VERTEBRAL
AND OP FRACTURE DISCRIMINATION INWOMEN
D Krueger1, E Fidler1, J Libber1, B Aubry-Rosier2, D
Hans2, N Binkley1
1University of Wisconsin, Osteoporosis Clinical Research
Program, Madison, WI, US, 2Lausanne University Hospital,
Center of Bone Diseases, Bone and Joint Dpt, Lausanne,
Switzerland
Objective(s): Assessing trabecular architecture in routine
in addition of BMD should improve identification of
those at high fracture risk. This study used a novel
software program (TBS iNsight®, Med-Imaps, FR),
which utilizes greyscale pixel assessment to estimate
trabecular microarchitecture (trabecular bone score
[TBS]) from standard spine DXA images. We hypothe-
sized that TBS assessment would differentiate women
with low trauma or prevalent vertebral fracture (VF)
from those without.
Material & Methods: DXA lumbar spine (LS), proximal
femur and vertebral fracture assessment (VFA) images
(Prodigy or iDXA, GE Healthcare, USA) were utilized
from 441 women who participated in studies at the
University of Wisconsin-Madison. VFAs were evaluated
for fracture by an experienced clinician. TBS was
assessed by Lausanne University (CH) and blinded to
fracture status. Appropriate statistics were applied and a
triage approach using a TBS threshold of 1.200 subse-
quent to the WHO classification on the lowest of hip or
LS BMD was used to test the enhancement of identify-
ing individuals at high VF risk.
Results: Mean participant age was 71.6±7.9 years, BMI
was 25.6±4.26 kg/m2, their mean lowest T-score was -
2.0±0.75 and had 158 had fractures; VF (93) or other
self-reported low trauma fracture. Correlation between
LS BMD and TBS was low (r=0.26). Adjusted ORs
for all fractures were 1.63 (CI: 1.2-2.2; AUC 0.62) for
BMD lowest T-score and 2.46 (CI: 1.9-3.1; AUC 0.74)
for TBS. TBS remained significant after adjustment for
LS BMD or the BMD lowest T-score (OR=2.36; CI
1.8-3.0, AUC: 0.70). When considering only VF and
controls the ORs were 2.49 (CI: 1.9-3.3; AUC 0.73)
and 2.57 (CI: 1.9-3.5; AUC 0.74) for TBS with and
without adjustment for spine BMD respectively. 74% of
VF occurred in the non-osteoporotic zone; 37% of these
women had a TBS score below the 1.200 Threshold.
55% of nonfractured women were not osteoporotic and
only 14% of them were below the lowest TBS thresh-
olds (1.200)
Conclusion(s): TBS assessment enhances DXA by evaluat-
ing trabecular pattern and identifying individuals with ver-
tebral or low trauma fracture. As most fractures occur in
those with osteopenia, identifying individuals most likely to
fracture can facilitate more efficient utilization of healthcare
dollars.
P617
VOLUMETRIC BONE MINERAL DENSITY
(VBMD) AT RADIUS SITE AND VITAMIN D
STATUS IN PREMENOPAUSAL SOUTH ASIAN AND
CAUCASIAN WOMEN
Ohood A Hakim1, Andrea Darling1, Kath Hart1, Jacqueline
L Berry2, Susan A Lanham-New1
1University of Surrey, Faculty of Health and Medical Sciences,
Guildford, 2University of Manchester, Vitamin D Research
Group, Manchester, UK
Objective(s): Recent studies indicate that women of
European origin have higher areal BMD than South
Asian women. However this has been explained by
ethnic variation in differences in bone size1. Few data
exist on true volumetric BMD in premenopausal South
Asian at the radius site. As part of the D-FINES (Vita-
min D, Food Intake, Nutrition and Exposure to Sunlight
in Southern England) study, we aimed to investigate
differences in trabecular and cortical volumetric BMD
(vBMD) between Caucasian (C) and South Asian (SA)
women at the radius site and determine if it associate
with serum 25(OH)D.
Material & Methods: 40 healthy premenopausal wom-
en (21 C and 19 SA), age ranges 18-55 yrs, were
scanned by pQCT at the distal (4%) and (66%) radius
(nondominant) using a Stratec XCT 2000 pQCT ma-
chine. Fasted blood samples were collected for vitamin
D analysis.
Results: SA had significantly higher BMI (p<0.05) than C
women. SAwomen had significantly lower vitamin D status
than C women (p<0.001) with mean values of 31.53[16.32]
and 80.91[20.08] nmol/l, respectively.
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All data were at 4% site;*p<0.05, **p<0.01; Values were analysed
by t-test analysis
At the 4% radius site, SA has significant lower mean value
for total area, trabecular area, and cortical sub area than C
women (P<0.01). SA group has slightly lower mean for total
bone density, trabecular density and cortical sub density
than C but differences were not significant. Total bone area
is significantly negatively correlated with 25(OH)D among
SA group but not with C (p<0.001).
Conclusion(s): SA women tend to has lower bone size at
4% distal radius than C women but no association exist with
bone density.
References: 1Roy et al (2005) Osteoporos Int 41:117.
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FOCUS (FRACTURES=OSTEOPOROSIS CARE
FOR US) ON ADVOCACY INAUGURAL FORUM
Famida Jiwa
Osteoporosis Canada, President and CEO, Toronto, ON,
Canada
Objective(s): The objective of the Osteoporosis Canada's
(OC) FOCUS on Advocacy Inaugural Forum was to bring
together related health care professionals and advocates to
discuss necessary changes to close the osteoporosis care gap
in Canada with province-specific intervention models.
Material & Methods: The FOCUS on Advocacy Forum
was attended by a multidisciplinary group of health profes-
sionals and OC volunteers from across Canada. The partic-
ipants included: allied health professionals, family
physicians, OC volunteers, endocrinologists, rheumatolo-
gists, internists, orthopaedic surgeons, radiologists, and ger-
iatricians. Various interventions including Canadian and
International studies were presented focusing on their meth-
ods, effectiveness and challenges. The individual needs of
each province were discussed and specific mechanisms were
developed to address the problem of the care gap by region.
Results: The forum was successful as it achieved a com-
mitted advocacy leadership team in each province, the iden-
tification of a key request and advocacy plan for each
provincial government, and the identification of the needs
of the leadership advocacy volunteers.
Conclusion(s): Hundreds of thousands of Canadians
needlessly fracture each year because their osteoporosis
goes undiagnosed and untreated. Less than 20% of
fracture patients are offered assessment and/or treatment
for their underlying osteoporosis, meaning in Canada,
osteoporosis has an 80% care gap. It is therefore critical
that mechanisms be put in place to ensure that an
assessment for and treatment of osteoporosis is done
for every fracture patient. This involves simple yet
integral changes within the current health care system
that requires the collaboration of provincial governments
in order to make this a reality throughout Canada. Plans
will soon be introduced to each provincial government
for the purpose of influencing policy makers to make
the necessary health system changes that will hopefully
significantly reduce fracture risk among Canadians.
Disclosures: Marg MacDonell, Dr. Diane Theriault National
Advocacy Co-Chairs
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SPINEMICROARCHITECTURE ESTIMATION (TBS)
DISCRIMINATES MAJOR OSTEOPOROTIC
FRACTURE FROM CONTROLS EQUALLY WELL
THAN SITE MATCHED BMD AND INDEPENDENTLY:
THE EASTERN EUROPE TBS STUDY
J Vasic1, F Gojkovic1, T Petranova2, J Elez1, V Culafic
Vojinovic1, R Winzenrieth3, D Hans3, R Rashkov2, A
Dimic4
1Railway Healthcare Institute, Bone Diseases, Belgrade,
Serbia, 2Medical University, Clinic of Rheumatology, Sofia,
Bulgaria, 3Lausanne University Hospital, Center of Bone
Diseases, Bone and Joint Dpt, Lausanne, Switzerland,
4Institute for Treatment and Rehabilitation Niska Banja,
Center of Bone Diseases, Nis, Serbia
Objective(s): BMD measurement by DXA is used to diag-
nose osteoporosis and assess fracture risk. Assessing trabec-
ular architecture should improve identification of those at
high fracture risk. This study used a novel software program
(TBS iNsight®, Medimaps, Bordeaux, France), which uti-
lizes grey-scale pixel assessment to estimate trabecular
microarchitecture (TBS) from standard spine DXA images.
We hypothesized that TBS assessment would differentiate
women with low trauma fracture from those without and
independently of BMD.
Material & Methods: The Eastern Europe Study (EES) is a
multicenter study (Serbia, Hungary, Bulgaria, Romania and
Poland) aiming at evaluating the role of TBS in clinical
routine as a complement of BMD and the clinical risk factors
(CRF). All scans were acquired on Hologic Discovery densi-
tometers in routine clinical manner. TBS was assessed by the
University of Lausanne (Switzerland) and blinded to fracture
status. Age, BMI adjusted odds ratio (OR) per standard
pQCT variables measured at 4% distal radius in SA and C women
Ethnicity Mean[SD], SA
n=14
Mean[SD], C
n=19
Total area (mm2) 340.95[37.00]** 374.81[43.29]
Total Density mg/cm3) 312.14[45.61] 315.66[45.35]
Tubercular area (mm2) 153.30[16.62]** 168.51[19.46]
Tubercular Density (mg/cm3) 175.40[37.21] 178.98[35.54]
Cortical Sub Area (mm2) 187.64[20.38]** 206.30[23.83]
Cortical Sub Density (mg/cm3) 423.87[62.49] 427.32[60.03]
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deviation decrease are reported for BMD and TBS. Correla-
tion between LS-BMD and TBS was calculated. Finally, a
triage approach using TBS <1.200 subsequent to the
WHO classification on the LS-BMD was used to test the
enhancement of identifying individuals at high major OP
fracture risk.
Results: We recruited 1268 women from the clinical
routine and included 1036 of them: mean age 62.0±9.3 y,
BMI 26.2±4.6, mean LS-BMD 0.858±0.142, TBS
1.207±0.124. As expected, correlation between BMD
and TBS is low (r2=0.26). Prevalence of VFx grade 2/3,
major-OP Fx and all-OP Fx is 6.5%, 20.4% and 25.4%
respectively. Age- and BMI-adjusted ORs are 1.86 (1.3-2.6),
1.76 (1.4-2.1), 1.7 (1.4-2.0) for BMD for the different catego-
ries of fractures and 1.33 (1.0-1.7), 1.6 (1.3- 1.9), 1.5 (1.3-1.8
&AUC 0.68) for TBS, respectively. TBS remained significant
after additional adjustment for spine BMD: OR=1.28(1.05-
1.6). 62% of women with major-OP Fx have a non-osteopo-
rotic BMD and 63% of these women with fractures had TBS
<1.200. Combining both BMD and TBS allows capturing
77% of the fractures vs. 38%for BMD alone.
Conclusion(s): TBS assessment enhances DXA by evaluat-
ing trabecular pattern and identifying individuals with major
low trauma fracture. As most fractures occur in those with
osteopenia, identifying individuals most likely to fracture
can facilitate patient management.
P620
CHANGES OF BONE MINERAL DENSITY IN
PATIENTS WITH RHEUMATIC DISEASES
Artem G Vasilyev, Leysan I Myasoutova, Svetlana A
Lapshina
Kazan State Medical University, Department of Hospital
Therapy, Kazan, Russian Federation
Objective(s): To evaluate the changes in BMD in patients
with rheumatic diseases.
Material & Methods: A retrospective analysis of proto-
cols of X-ray densitometry was performed in patients
who were at the dispensary observation in the Rheuma-
tologic Centre of Kazan City in the period from January
2010 - January 2011. 347 patients were included in
analysis. 231 of them had rheumatoid arthritis (RA), 63
had ankylosing spondylitis (AS) and 53 had osteoarthritis
(OA). The changes of BMD in two points were taken
into account: the lumbar spine and proximal femur. T-
score was evaluated in postmenopausal women and men
older than 50 years. Z-test was evaluated in women
before menopause and men younger than 50 years.
Results: 85 (24.5%) of 347 patients (74 women and 11
men) had osteoporosis and 145 (41.8%) patients (121
women and 21 men) had osteopenia according to the
criteria of WHO. Distribution by rheumatic diseases
was as follows. 55 (23.8%) of 231 patients with RA
had osteoporosis and 89 (38.5%) had osteopenia. 13
(20.6%) of 63 patients with the AS had osteoporosis
and 32 (50.8%) had osteopenia. Osteoporosis and osteo-
penia were revealed in 17 (32.1%) and 24 (45.3%) of 53
patients with OA, respectively.
Conclusion(s): Osteoporosis is often met in rheumatic
diseases, especially in RA and AS. However, the prev-
alence of osteopenia is even higher and this situation
requires the actions for prevention of osteoporosis and
fractures. In addition, osteoporosis and osteopenia in
OA were observed much more often than it was thought
previously.
P621
BONE QUALITY IN HIP OSTEOARTHRITIS
AND OSTEOPOROSIS: CLINICAL AND
HISTOMORPHOMETRICAL CONSIDERATIONS
Umberto Tarantino, Maurizio Feola, Cecilia Rao, Monica
Celi, Elena Gasbarra
Policlinico Tor Vergata, University of Rome Tor Vergata,
Orthopaedic Surgery, Rome, Italy
Objective(s): We aimed at clarifying the relationship be-
tween OA and OP by combining both clinical (Harris Hip
Score, HHS) and structural features (BMD and bone
histomorphometry).
Material & Methods: BMD and bone quality (using bone
histomorphometry) were assessed in 80 consecutive
patients undergoing hip arthroplasty for osteoporotic
femoral fracture (n=20, mean age 79.7) or severe OA
with different BMD values (n=60: 20 patients with
normal BMD, 20 patients with osteopenic BMD and 20
patients with osteoporotic BMD; mean age 68.4 years).
An X-ray evaluation of the pelvis and HHS were also
performed in all studied subjects. During surgery, a dou-
ble osteotomy of the femoral head was performed and
the samples were used for histomorphometry through Bio
Quant software.
Results: Histomorphometrical analysis showed that bone
volume fraction (BV/TV) was significantly lower in
subjects with femoral neck fracture (19.98±4.72%) than
subjects with nonosteopenic OA (31.19±5.47%; P<0.01)
or osteopenic OA (28.45±5.77%; P<0.01), respectively.
No difference between subjects with OP fractures and
those with combined OA and OP (23.58±4.47%) was
detected. Moreover, clinical scores tended to be associ-
ated with BMD and histomorphometric features; where
the HHS score was lower, we also found lower BMD
and BV/TV values.
Conclusion(s): Our data support evidences from recent
studies indicating impaired bone quality in OA and absence
of protective effect against OP.
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DIFFERENCE BETWEEN TOTAL AND INTACT
ASSAYS FOR N-TERMINAL PROPEPTIDE OF
TYPE I PROCOLLAGEN IN RENAL IMPAIRED
PATIENTS
Etienne Cavalier1, Agnes Carlisi1, Olivier Rousselle1, Nunzio
Ferrante1, Pierre Delanaye2
1University of Liege, CHU Sart-Tilman, Clinical Chemistry,
2Nephrology, Dialysis and Hypertension, Liege, Belgium
Objective(s): The amino-terminal propeptide of type I
procollagen (P1NP) circulates as different forms: the
larger intact trimeric and several fragment monomers.
In healthy individual, the circulating P1NP is predomi-
nantly the trimeric intact with almost non-detectable
monomers. Under certain conditions, especially in renal
impaired patients, the proportion of monomeric form is
elevated. Intact P1NP assay measures the trimeric pro-
peptide while Total P1NP assay measures both trimeric
and monomeric forms. In this study we compared these
two assays in renal impaired patients.
Material & Methods: 84 serum specimens from CKD
Stage 3 to 5 not on dialysis and 125 specimens from
Stage 5 Dialysis patients were analyzed with the IDS-
iSYS Intact P1NP and Roche Elecsys Total P1NP
assays.
Results: In CKD not on dialysis subjects, the observed
ranges for Total P1NP and Intact PNP were 8.5-822.8
ng/mL and 8.2-146.5 ng/mL, respectively. The correla-
tion between the Total P1NP and GFR was r=-0.3373
(p=0.0017) and between the Intact P1NP and GFR was
r=-0.1483 (p=0.1782). In Stage 5D subjects, the ob-
served ranges were 18.4-2192.0 ng/mL for Total P1NP
and 16.3-641.6 ng/mL for Intact P1NP. Their Passing
Bablok regression was Total P1NP=3.68 x Intact
P1NP -64.4.
Conclusion(s): Total P1NP values were much higher
than Intact P1NP confirming the Total P1NP assay
measures both trimeric and monomeric forms. The sig-
nificant correlation between the Total P1NP and GFR
indicated the Elecsys Total P1NP assay might not be
suitable for renal impaired patients; the IDS-iSYS Intact
P1NP is preferred.
P623
CHARACTERISTICS OF AND TREATMENT
PATTERNS FOR POSTMENOPAUSAL WOMEN
WITH OSTEOPOROSIS IN THE UK: A
RETROSPECTIVE DATABASE STUDY USING
THE GENERAL PRACTICE RESEARCH
DATABASE (GPRD)
Maurille Feudjo-Tepie1, Samara Ferguson2, Andrew Roddam1,
Cathy Critchlow3, Andrew Taylor2, Shelley Fordred1,
Jonathan Bayly4
1Amgen Ltd, Centre for Observational Research, 2Amgen,
UK/Ireland Affiliate, Health Economics, Uxbridge, Middlesex,
UK, 3Angen Inc, Centre for Observational Research, Thousand
Oak, US, 4University of Derby, Faculty of Education Health
and Sciences, Derby, UK
Objective(s): Certain treatments for osteoporosis tend to be
used for patients with more severe disease or who have
become intolerant to oral bisphosphonates (OBP). Such
practice may increase the risk of observing confounded
results in a study of effectiveness and safety. This study
aims to explore some of these characteristics.
Material & Methods: Postmenopausal women on treatment
for, or with a diagnosis of, osteoporosis between 01/01/1993
and 31/12/2008 were selected from the UK GPRD. Osteopo-
rosis and selected co-morbidities were identified using Read
codes and treatment using Multilex Code. We examined char-
acteristics of the year 2008 subpopulation. To evaluate risk
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factors for treatment, switching and discontinuation, calendar
time was stratified into 4-year periods to account for longitu-
dinal trends in clinical practice. In each period, patients were
classified according to the first event (switching or discontin-
uation) and a multivariable regression model was used to
explore associations with patient characteristics over the year
prior to switching/discontinuation.
Results: Of 62,657 eligible patients, 38,069 (60.7%) were
active in the database on 31/12/2008; 21,667 received oste-
oporosis treatment in 2008. Selected findings are presented
below.
*Bone loss therapies other than OBP (ibandronic acid, calcitonin,
teriparatide, zoledronic acid, strontium ranelate)
Of those untreated in 2008, 8029 (48.9%) were previously
treated. Of 996 patients initiating OBP treatment in 2008,
335 were treatment naïve. These patients were more likely
than lapsed users to have a recorded fracture in 2008 (15.8%
vs. 7.9%, P<0.001). Older age, rheumatoid arthritis, number
of contacts with practice, osteoporosis duration, high BMI,
fracture history, and immunosuppressant/glucocorticoid
therapy were significantly associated with switching/
discontinuation.
Conclusion(s): Despite the limited number of patients trea-
ted with non-OBP medications in 2008, it appears these
patients are more likely to have taken an OBP in the past,
discontinued or switched from their previous bone loss
therapy, and have different characteristics than those on
OBP. An effective and unbiased study of comparative effec-
tiveness or safety in this area should account for these
potential biases.
P624
CORRELATION BETWEEN TRABECULAR BONE
STRUCTURE WITH BODY MASS INDEX AND
WITH BONE MINERAL DENSITY AT
POSTMENOPAUSALWOMEN
Jelena Vasic
Railway Healthcare Institute, Belgrade, Serbia
Objective(s): Measurement of bone mineral density by
DXA is used to diagnose osteoporosis and assess fracture
risk. Assessing trabecular architecture should improve
identification of those at high fracture risk. Our study
used a novel software program (TBS iNsight® v1.9),
which utilizes grey-scale pixel assessment to estimate
trabecular microarchitecture (TBS) from standard DXA
images.As low body mass index (BMI) is risk factor for
fracture, we wanted to investigate if assessing trabecular
architecture in women with normal or high BMI could
better indentify those who are in higher fracture risk
independently of BMD.
Material & Methods: Our study was performed from April
2011 to September 2011 and included 914 women, 61.99
±9.277 years old postmenopausal women, referred to our
Center for osteodensitometry of lumbar spine and hip.All
scans were acquired on Hologic Discovery C device.Than
scans were reanalised and TBS was calculated. Before, we
filled up questionnaire form, designed to analyze osteopo-
rosis risk factors. TBS was assessed by the University of
Lausanne (Switzerland). Correlation between the LS-BMD
and TBS was calculated. We used TBS<1.200 as the cut off
point for deteoriated microarchitecture. Correlation between
patients with normal and high BMI and low BMI, and their
BMD and TBS findings were analysed.
Results: Out of 914 postmenopausal women, low BMI had
61 (6.7%), normal 349 (38.2%), and high BMI 504 (55.1%).
Average BMD was 0.843±0.133 g/cm², and average TBS
was 1.197±0.109.
Conclusion: We found that TBS very significantly negative
correlated with BMI (p<0.01), but BMD correlated positive-
ly also very significantly with BMI (p<0.01). That might be
good explanation for the fact that the most common osteo-
porotic fractures are in the group of women with BMD at
osteopenic level. Our study demonstrate added value of
TBS, independent of BMD.
Patients on
OBP in 2008
Patients on
other Rx* in
2008
Significance
(P value)
Number 21,615 52 -
Mean age (years) 75.1 76.0 -
Mean time since
diagnosis of
osteoporosis (years)
4.8 5.6 N/S
Median number
contacts with
practice in 2008
(including
prescriptions
and consultations)
27 35 <0.01
Prior use of others
bone loss therapies
110 (0.51%) 48 (92.31%) <0.001
Record of any fracture
in 2008
1,062 (4.91%) 11 (21.15%) <0.001
Record of vertebral
fracture over study
duration
744 (3.44%) 8 (15.38%) <0.001
Treated with immuno-
suppressants in
2008
89 (0.41%) 1 (1.92%) <0.05
Record of chronic
obstructive
pulmonary disease
over study
duration
154 (0.71%) 2 (3.85%) <0.05
History of switching
over study duration
60 (0.28%) 26 (50.00%) <0.001
History of discon-
tinuations over
study duration
8,115 (37.54%) 26 (50.00%) <0.05
S340 Osteoporos Int (2012) 23: (Suppl 2):S85–S386
P625
RECOMMENDATION FOR MEASURING CLINICAL
OUTCOME IN DISTAL RADIUS FRACTURES
Joerg Goldhahn1, Dorcas Beaton2, Amy Ladd3, Joy
Macdermid4, Amy Hoang-Kim2
1Novartis Institutes for BioMedical Research, Translational
Medicine, Basel, Switzerland, 2St. Michael's Hospital,
Orthopaedics, Toronto, ON, Canada, 3Stanford University,
Upper Limb Extremity, Palo Alto, CA, US, 4McMaster
University, School of Rehabilitation Science, Hamilton, ON,
Canada
Objective(s): Lack of standardization of outcome measure-
ment has hampered an evidence-based approach to clinical
practice and research. We will report on the progress on
establishing a minimal set of core domains for outcome
measurement in distal radius fracture.
Material & Methods: We adopted a process of
reviewing evidence on psychometric properties, current
utilization of measures, an appropriate theoretical
framework for health and disability to inform a con-
sensus process that was focused on deriving the mini-
mal set of core domains. Decisions were made by
review of evidence and theory and establishing group
consensus.
Results: We adopted the International Classification of
Functioning, Disability and Health conceptual frame-
work ratified by the WHO to define domains and con-
cepts. In clinical practice, we agreed on the following 7
core recommendations: 1) Pain and function were
regarded as the primary domains; 2) Very brief meas-
ures were needed for routine administration in clinical
practice, 3) These brief measures could be augmented
by additional measures that provide more detail or
address additional domains for clinical research, 4)
Measurement of pain should include measures of both
intensity and frequency as core attributes, 5) A numeric
pain scale, e.g., Visual Analogue Scale or Visual Nu-
meric Scale or the pain subscale of the Patient-
Reported Wrist Evaluation (PRWE) questionnaire were
identified as reliable, valid and feasible measures to
measure these concepts, 6) For function, either the
Quick Disability of the Arm, Shoulder and Hand Ques-
tionnaire or PRWE-function subscale were identified as
reliable, valid and feasible measures, and 7) A measure
of participation and treatment complications should be
considered core outcomes for both clinical practice and
research.
Conclusion(s): Our approach provides preliminary steps in
establishing core domains that have content relevant to
patient goals (i.e., pain and function) and the providers'
treatment goals (i.e., strength, range of motion, function).
The panel recommendations provide flexibility in
establishing customized data collection for specific indica-
tions; but offer some core consistency.
Disclosures: We would like to acknowledge the joint col-
laboration between the International Society for Fracture
Repair and the International Osteoporosis Foundation.
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RISK FACTORS OF OSTEOPOROSIS IN
RESIDENTS OF TATARSTAN REPUBLIC
(RUSSIAN FEDERATION)
Elina R Kirillova, Nailya G Shamsutdinova, Svetlana P
Yakupova
Kazan State Medical University, Hospital Therapy, Kazan,
Russian Federation
Objective(s): Nowadays, osteoporosis (OP) is an actual
problem. It is not only densitometry, that is important for
the diagnosis of OP, but assessment of risk factors too. The
aim of our study is to identify the frequency of decrease of
BMD and the frequency of risk factors of OP among rural
dwellers of the Republic of Tatarstan.
Material & Methods: 1520 people were investigated using
DXA. The dynamics of dates were estimated according to T
criterion among men over 50 and women in postmenopausal
period, among Z criterion among men before 50 years and
premenopausal women. Patients were interviewed by ques-
tionnaires, which included 30 questions related to the iden-
tification of risk factors of OP.
Results: It was found out that 42.4% (634 people) have a
decrease in BMD.OP was identified at 25.6% of patients (383
people), osteopenia - at 16.8% of patients (251 people) .863
patients have the normal BMD range. OPmostly represented in
women than in men. The factors leading to the development of
the OP, are well represented among the villagers, but such risk
factors as fractures, low BMD, reduced intake of calcium,
heredity were presented more frequently. Lack of physical
activity was noted in less than half of rural (42%) resi-
dents. In the group with OP 24.3% of patients reported
nontraumatic fractures in the history of close relatives
while in the group with osteopenia only 18.8% of
patients mentioned it. In patients with OP compared with
the group with normal BMD were significantly more
likely (p<0.05) to have RA, thyroid disease, diabetes.
35.1% of patients who takes continuous corticosteroids,
were revealed to have OP, at 23.6% - osteopenia. There
was a significant correlation between reduced calcium
intake and decreased BMD. In group of up to 50 years
among both men and women, there were patients with
risk of developing OP.
Conclusion(s): Risk factors of lower BMD are well rep-
resented in the examined patients with OP and osteopenia. A
positive correlation between risk factors and reduced BMD
confirms the necessity to identify and assess risk factors of OP.
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SECONDARY HYPERPARATHYROIDISM IN
WOMEN WITH LOW BONE MASS
Olivera Ilic-Stojanovic1, Marina Vuceljic2, Milica Lazovic1,
Nataša Radosavljevic1, Dragana Milenkovic3
1Institute for Rehabilitation, Rheumatology Rehabilitation,
2"Allabo", Biochemical Laboratory, 3Clinic for Rehabilita-
tion, Rheumatology Rehabilitation, Belgrade, Serbia
Objective(s): PTH and bone resorbtion increases in
elderly women and contribute to age-related bone loss.
It is believed that deficiency in vitamin D causes sec-
ondary hyperparathyroidism, high bone turnover, min-
eralization defects, and hip and other fractures. The aim
of this study was to assess prevalence of secondary
hyperparathyroidism in postmenopausal women with
low BMD. We evaluated the serum levels of vitamin
D (25OHD) and relationships between 25OHD, PTH
and BMD.
Material & Methods: A total of 175 postmenopausal wom-
en of the mean age 65.9±10.1 yrs (46-84 yrs) were exam-
ined. Measuring of 25OHD and PTH were performed using
electrochemiluminiscence immunoassays (Roche Diagnos-
tics, Elecsys 2010). The BMD was measured by the DXA
method at the lumbar spine and hip area.
Results: The mean of the 25OHD and PTH were
48.32±22.52 nmol/L and 59.75±30.42 pg/mL (n=175). De-
creased values of 25OHD (<75 nmol/L) in n=149 (85.14%),
and increased values of PTH (> 65 pg/mL) in n=41 cases
(24.1%) were obtained. The BMD values at the lumbar
spine (L1-L4) 0.819±0.118, T-score -2.62±0.98; at the total
hip BMD 0.755±0.108, T-score -1.87±0.107 and at the
femoral neck BMD 0.711±0.115, T-score -1.91±0.806 were
found. A strong inverse correlation between 25OHD and
PTH (r=-0.495, p<0.001) were detected. Serum levels of
25OHD correlated to T-score at LS (r=0.227, p<0.05),
PTH correlated to BMD at LS (r=-0.258, p<0.05), but not
at the total hip and femoral neck (p>0.05) in the whole
group. It was noticed that in the subgroup aged ≥65 years,
the prevalence of elevated PTH (54.2%) is similar to those
with severe insufficiency of 25OHD ≤30 nmol/L (55.5%).
Correlations between 25OHD and T-score LS (r=0.315,
p<0.05), BMD neck (r=0.321, p<0.05), and PTH with
BMD neck (r=-0.352, p<0.05) were found.
Conclusion(s): The obtained results showed that second-
ary hyperparathyroidism appears in one four of postmen-
opausal women with osteoporosis, while vitamin D
deficiency was more frequent. Furthermore, hyperpara-
thyroidism predisposes to cortical rather than cancellous
bone loss, which would be more obvious at femoral neck
compared with lumbar spine and, also may explain why
PTH was a significant predictor of BMD at femoral neck
as confirmed by our results.
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RELATIONSHIP BETWEEN REGIONAL
DISTRIBUTION OF BODY FAT MASS (BFM) AND
SERUM LEPTIN, TNFα, TESTOSTERONE FREE,
β-CROSSLAPS IN MEN WITH CHRONIC
OBSTRUCTIVE PULMONARY DISEASE (COPD)
Sviatlana Lemiasheuskaya1, Alla Shepelkevich1, Alexander
Makarevich1, Natalia Vasileva2
1Belarusian StateMedical University, InternalMedicine No.1,
2Republic Medical Rehabilitation and Balneotreatment Cen-
ter, Dual-Energy X-Ray Absorptiometry, Minsk, Belarus
Objective(s): The role of fat-bone interactions in the path-
ogenesis of osteoporosis in COPD is poorly understood. Our
aim was to evaluate the relations between BFM distribution
and inflammatory mediator TNFα, hormones, markers of
bone metabolism in men at the age 40-70 years.
Material & Methods: Data were obtained from 98 partici-
pants who underwent DXA (analyze of body composition, the
regional distribution of BFM). We examined 3 groups of
patients (aged 40-70 years) and control group (15 healthy
men with mean age 56 years, mean BMI 26 kg/m2). The
COPD pts were subdivided into groups according to COPD
severity: the 1st wasmade of 20 men; GOLD I stage; mean age
55 years; FEV1 78%; BMI 27 kg/m2, smokers 68%, packs/yrs
20; the 2nd included 43 patients; GOLD II stage; mean age 57;
FEV1 55%; BMI 28 kg/m2, smokers 80%, packs/yrs 21; the 3
d -20 patients; GOLD III stage; mean age 60; FEV1 41%; BMI
25 kg/m2, smokers 84%, packs/yrs 28.
Results: Fat mass in Android region was directly related to
serum TNFα (r=0.33, p=0.02). Total, trunk, arms fat mass
were directly related to serum leptin (r=0.21, r=0.36 and
r=0.35, p<0.05, respectively). Serum leptin exert negative
influence on BMD in lumbar spine (r=-0.43, p=0.001), but
not at femoral necks. We founded positive correlations
between beta-crosslaps and total fat mass (r=0.33, p=0.02)
and fat mass in android region (r=0.32, p=0.02). Total, arms,
legs, trunk fat mass and fat mass in android and gynoid
regions increase in COPD pts with lower level of serum
testosterone free (p<0.05 for all relationships). The male
patients at the age 40-70 years with COPD had osteopenia
and osteoporosis in the presence of increased BMI (29.4 kg/m2
and 24.7 kg/m2, respectively) and serum leptin (2.8 ng/ml
and 2.9 ng/ml, respectively, vs. 1.9 ng/ml in patients without
osteopenia and osteoporosis, p<0.05).
Conclusion(s): The regional distribution of body fat mass
play important role in the pathogenesis of osteoporosis in
men with COPD.
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AGINGER-DERIVEDBIOCOMPLEX IN TREATMENT
OF PATIENTS WITH KNEE OSTEOARTHRITIS
Svetlana A Lapshina, Leysan I Myasoutova, Artem G Vasilyev
S342 Osteoporos Int (2012) 23: (Suppl 2):S85–S386
Kazan State Medical University, Department of Hospital
Therapy, Kazan, Russian Federation
Objective(s): To evaluate the efficacy and safety of the
ginger-derived biocomplex in treatment of patients with
knee osteoarthritis in routine clinical practice.
Material & Methods: The examination of 30 patients with
knee osteoarthritis (OA) was performed. The age varied 52-
72 years (mean age 54.7±8.2 years). Sex distribution was as
follows: 27 (90%) women and 3 (10%) men. All patients
had a verified diagnosis of knee OA (criteria of Altman RD,
1995). The disease duration ranged from 1 to 8 years (mean
duration was 3.9±2.7 years). The patients had the following
comorbidities: arterial hypertension in 18 (60%), ischemic
heart disease in 9 (30%), chronic gastroduodenitis in 20
(66.7%), varicose disease of the lower extremities in 19
(63.3%). Secondary synovitis was diagnosed in 23
(76.7%) patients. All patients were administered the gin-
ger-derived biocomplex for 2 months. The following param-
eters were evaluated: the intensity of joint pain at rest and
during movement on visual analogue scale (VAS), the cir-
cumference of the joint, index WOMAC, the need for
NSAIDs, the effectiveness of treatment in opinion of the
patient and physician.
Results: After 2 months of treatment the ginger-derived
biocomplex was effective in 25 (83.3%) patients. During
treatment there was a statistically significant (p<0.05)
decrease of the following parameters: pain during move-
ment, pain in palpation, the circumference of the "target
joint " and WOMAC index. The effectiveness of treatment
was evaluated by the patient as good – 15 (50%), satisfac-
tory – 10 (33.3%), no effect – 5 (16.7%) patients. The
physician evaluated the efficacy of treatment as good in 17
(56.7%) patients, satisfactory – 9 (30%), no effect – 4
(13.3%). 14 patients (46.7%) have ceased NSAID intake
and 10 (33.3%) patients have lowered NSAID dose. Side
effects were reported by 5 (16.7%) patients [3 (10%) -
heartburn, 2 (6.7%) – nausea], possibly as a consequence
of concomitant NSAIDs.
Conclusion(s): The ginger-derived biocomplex is quite ef-
fective in treatment of knee OA and safe for chronic admin-
istration, including the patients with serious comorbidities.
Furthermore, this drug allows reducing the need for
NSAIDs.
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EFFECT OF HEALTHY LIFESTYLE ON BMD
VALUES
SalvinaMihalcea1,2, Ildiko Gasparik2, Dorina Maria Farcas3,2
1Physical Rehabilitation Clinic, Physical Rehabilitation
Medicine, Felix Spa, 2ASPOR, Management, Tirgu Mures,
3University of Oradea Faculty of Medicine, Physical Reha-
bilitation Medicine, Oradea, Romania
Objective(s): To evaluate the influence of lifestyle habits,
especially exercise and milk consumption on BMD.
Material & Methods: We assessed data of 156 patients
(men and women, mean age 64 year, range 44-80), who
addressed our rehabilitation service and had bone density
measurement in northern Romania, Felix Spa. Using the
risk factor questionnaires completed by all patients and
DXA measurements of all patients we compared T- and
Z scores of those who declared to be high dairy consum-
ers and to take exercises to those who don't have a daily
dairy intake and had a sedentary life. We also compared
the influence of dietary factors to other osteoporosis
risk factors.
Results: There was no difference in Z scores of the two
subgroups. The minor difference in T-scores is related to the
lower mean age of those who don't consume milk and not do
exercises.
Conclusion(s): In comparison, other risk factors, such as
BMI, sedentary lifestyle and early menopause had an impact
on T- and Z-score of patients, with statistically significant
differences between the yes/no subgroups. Smokers and
coffee drinkers also did not show lower density values
compared to non-tobacco/coffee consumers.
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SARCOPENIA IS MORE IMPORTANT THAN
VITAMIN D DEFICIENCY AS DETERMINANT OF
OSTEOPOROSIS IN CHILEAN ELDERS
Cecilia Albala1, Lydia Lera1, Hugo Sanchez1, Barbara
Angel1, Alejandra Fuentes2, Patricia Arroyo3
1INTA, University of Chile, Public Health Nutrition, 2Faculty
of Medicine, University of Chile, Public Health, 3Clinic
Hospital, University of Chile, Radiology, Santiago, Chile
Objective(s): To study the frequency of osteoporosis and its
association with vitamin D and sarcopenia in community
living Chilean elders.
Material & Methods: Cross-sectional study in 741 partic-
ipants in the ALEXANDROS study aged 60 and older
(66.9% women, mean age 70.2±7.6 y, min 60 y, max 99 y)
residing in Santiago, Chile. Socioeconomic characteristics,
history of chronic diseases and self-reported disability/
functional limitations were registered. Physical performance,
anthropometry, dynamometry, biochemical exams, vitamin D
levels and DXA scan were performed. WHO standards for
BMD classified them in normal, osteopenia and osteoporosis.
Being under p25 of baseline value was defined as low dyna-
mometry. Participants were classified as Sarcopenic using the
skeletal muscle mass index (SMI) calculated as appendicular
skeletal muscle mass/height2 based on sex-specific lowest
20%. Plasma levels of 25-hydroxyvitamin D (VitD) were
determined by radioimmunoassay and VitD deficiency was
defined as <50 nmol/L.
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Results: The frequency of osteoporosis was 23.6% (women
30.4%; men 9.7%, p<0.001) and Osteopenia 46.1% (women
30.4%; men 9.7%, p<0.001). Sarcopenia was present in
32.2% of men and 26.8% in women (p=0.07). the frequency
of VitD deficiency was 62.1% similar in both men and
women. Neither VitD deficiency nor vitD <25 nmol/L were
associated with osteoporosis or osteopenia. Bone mass was
highly correlated with SMI (men r=0.43, women r=0.51).
After multinomial logistic regression the age and gender
adjusted OR of having osteoporosis was associated with
sarcopenia (RRR=3.62; 95%CI 2.08-6.33, p<0.01), but not
with vit D plasma levels. Similar results were observed for
the association of osteopenia, VitD deficiency and sarcope-
nia (RRR=1.78; 95%CI 1.11-2.85, p<0.02). The inclusion
of BMI in the model showed that in females BMI was an
independent protective factor for osteoporosis.
Conclusion(s): The results confirm that sarcopenia is more
important than vitD deficiency as risk factor for osteoporo-
sis in Chilean older people.
Disclosures: Research relating to this abstract was funded
by Fondecyt Grant 1080589
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TEH OCCURRENCE OF HYPERCALCAEMIA IN
PATIENTS COMMENCING RECOMBINANT
PARATHYROID HORMONE (1-34) THERAPY
JH Mahon, EH McCarron, V Robinson, B Drumm, K
Fitzgerald, JB Walsh, MC Casey
Mercer's Institute for Research in Ageing, St. James's Hos-
pital, Osteoporosis Treatment and Bone Protection Clinic,
Dublin, Ireland
Objective(s): Over the last ten years recombinant PTH
(rPTH) therapy has been increasingly used for the treatment
of severe postmenopausal osteoporosis. Foremost amongst
the side effects of this drug is hypercalcaemia, which has a
reported prevalence as high as 11% in some studies (1). We
investigated the prevalence of hypercalcaemia in patients in
our bone clinic receiving PTH therapy.
Material & Methods: From the database of the St.
James's Hospital Dublin Osteoporosis Treatment and
Bone Protection Clinic, we performed a retrospective
review of consecutive patients receiving rPTH therapy.
We selected the first 50 patients who had paired serum
calcium measured both before commencing rPTH and 6
months into treatment. To define hypercalcaemia, we
used our local laboratory's reference range for calcium,
2.20-2.70 mmol/L. All of the patients were also taking
cholecalciferol 800 units and calcium 1000 mg daily
supplements.
Results: Of the 50 patients, 45 were female and 5 were
male. The mean age was 73.3 years (SD 10.3). The mean
serum calcium (corrected for albumin) prior to commencing
therapy was 2.40 mmol/L (SD 0.13). Mean serum calcium
(corrected for albumin) six months into therapy was 2.47
mmol/L (SD 0.17). After 6 months of treatment, 4 patients
were found to be hypercalcaemic, of whom one had been
hypercalcaemic at baseline. The observed hypercalcaemia at
6 months was mild, ranging 2.71-2.95 mmol/L for the
patients in question.
Conclusion(s): In the group we reviewed, the prevalence of
new hypercalcaemia was 6%, which is lower than that
observed in other studies. Taking the group as a whole, there
was no significant difference between mean serum calcium
at baseline and that measured 6 months into treatment. This
low prevalence of hypercalcaemia may be a result of a
vigilant approach to monitoring blood tests at 1 month and
three months of therapy, and the judicious discontinuation of
calcium and vitamin D supplements where hypercalcaemia
was anticipated.
References: Neer RM, N Engl J Med 2001;344:1434
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EARLY POSTMENOPAUSALWOMEN WITH
IDIOPATHIC HYPERCALCIURIA PRESENT LESS
CORTICAL BONE MINERAL MASS AND
DIFFERENCES IN CORTICAL GEOMETRY
COMPARED TO AGE-MATCHED CONTROLS: A
TIBIA PQCT STUDY
Konstantinos D Stathopoulos1, Ilias Bournazos1, Eleutheria
Metania1, Pelagia Katsimbri2, Antonis Partsinevelos1, Erato
Atsali1, Panagiotis Papaggelopoulos1, Grigoris Skarantavos1
1University of Athens, School of Medicine, "Attikon" Uni-
versity General Hospital, Bone Metabolic Unit, 1st Depart-
ment of Orthopedics, 2"Attikon" University General Hospital,
4th Department of Internal Medicine, Athens, Greece
Objective(s): We assessed the effects of idiopathic hyper-
calciuria (IH) on bone mineral mass and bone geometry in
different age groups vs. age-matched controls using pQCT
of the tibia
Material & Methods: We reviewed medical records of 41
postmenopausal women with IH who presented as outpatients
in our department. Inclusion criteria: 1) Recently (<6 months)
diagnosed and untreated IH; 2) postmenopausal status >2 y; 3)
Normal renal function (normal serum creatinine, eGFR) Ex-
clusion criteria: 1) Diseases causing hypercalciuria other than
IH (granulomatous and endocrine diseases, malignancies); 2)
Bone metabolic disorders; 3) Drug-induced hypercalciuria; 4)
use of any medication for osteoporosis during the last 12
months. The patients were assigned in 3 different age groups:
48-59 y (N=15), 60-69 y (N=21), 70-79 y (N=5). All patients
underwent pQCT of the tibia (XCT 2000 scanner, Stratec
Medicintechnic, Germany) and 3 slices were obtained at the
4% (trabecular bone), 14% (subcortical and cortical) and 38%
(cortical) of tibia length sites. For each site we estimated bone
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mineral content, bone areas, cortical thickness, periostal and
endosteal circumference and we compared results with our
published tibia pQCT database of 219 age-matched healthy
postmenopausal women. We performed statistical analysis
and data is expressed as mean±SD.
Results: There were no statistical differences between
patients with IH and controls in all age-groups
concerning variables of trabecular bone. Concerning
cortical bone (38% slice), we found statistical differ-
ences only in the younger (48-59 y) age group between
patients with IH vs. age-matched controls: patients with
IH had lower cortical bone mineral mass (256.54±39.95
vs. 282.63±38.63 mg/cm, p=0.019), cortical area (220.4
±33.34 mm2 vs. 246.85±32.85, p= 0.005) and cortical
thickness (3.90±0.81 vs. 4.53±0.57 mm, p=0.0005),
while they had greater endosteal circumference (45.27
±8.11 vs. 40.34±4.51 mm, p=0.001).
Conclusion(s): Early (48-59 y) postmenopausal women
with IH have lower values of cortical bone mass, corti-
cal area, cortical thickness and greater endosteal circum-
ference vs. age-matched controls. Older women with IH
were not found to have statistical differences on bone
measurements vs. age-matched controls using pQCT of
the tibia.
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THE STIFFNESS INDEX ACCORDING TO HEEL
QUANTITATIVE ULTRASOUND AND BODY MASS
INDEX – ANY CORRELATIONS?
Mara Carsote1, Valentin Radoi1, Cristina Ene2, Andreea
Geleriu2, Catalina Poiana1,2, Mihail Coculescu1,2
1UMPh Davila, Endocrine, 2I.Parhon, Endocrine, Bucharest,
Romania
Objective(s): The heel quantitative ultrasound (QUS) is a
very easy-to-do analyze in order to obtain information re-
lated fracture risk. New data revealed to correlations be-
tween the BMI and the bone health. We correlated the
BMI and QUS parameter stiffness index (SI).
Material & Methods: The inclusion criteria were wom-
en in menopause. Peripheral QUS was performed with a
GE Lunar Achilles device. The exclusion criteria refer
to the women who were previously treated for osteopo-
rosis with anti-resorbtives (except for vitamin D and
calcium supplements). The informed consent of each
woman was obtained. The linear regression and student
t-test were used.
Results: We introduced the 347 patients (p) in 5 groups
based on their age: group 1 (≤40 yrs) -6 p, group 2
(from 41-50 yrs) 61 p, group 3 (range 51-60 yrs) 178 p,
group 4 (between 61-70 yrs) 80 p, and group 5 (from
71-80 yrs) 22 p. The correlations between BMI and
QUS-SI (r2) were: group 1 r2=0.03 (p=0.08), group 2
r2=0 (p<0.0001), group 3 r2=0.08 (p<0.0001), group 4
r2=0 (p<0.0001), group 5 r2=0.09 (p=0.04). For all the
347 p, r2=0.01, p<0.001.
Conclusion(s): The age groups analyze between SI and
BMI revealed statistically significant no correlation.
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SURVIVAL IN THE ELDERLY FOLLOWING A
PROXIMAL FEMUR FRACTURE: ONE-YEAR
FOLLOW-UP STUDY
Sónia Campos1, Sandra Alves1,2, Abel Trigo Cabral3, Maria
Fátima Pina1,4,5
1Instituto de Engenharia Biomédica, Laboratório de Bioin-
terfaces, 2Instituto Politécnico, Escola Superior de Tecnolo-
gia da Saúde do Porto, 3Hospital de São João, Serviço de
Traumatologia e Ortopedia, 4Faculdade de Medicina da
Universidade do Porto, Departamento de Epidemiologia
Clínica, Medicina Preditiva e Saúde Pública, 5ISPUP- Insti-
tuto da Saúde Pública da Universidade do Porto, Grupo
Geoepidemiologia, Porto, Portugal
Objective(s): The aim of this study was to determine the
one year survival rate after a proximal femur fracture and to
investigate the predictors for fatality.
Material & Methods: All patients that were admitted, with
an acute proximal femur fracture caused by a fall of low
energy impact from 1 May 2008 - 30 April 2009 in a main
Portuguese hospital were invited to participate in the study.
During hospitalization, a questionnaire was applied by per-
sonal interview to the participants, with questions about
demographic characteristics, lifestyle, activities before frac-
ture, previous fractures and clinical history. From the hos-
pital medical records, information about type of fracture,
surgical treatment, day of surgery, comorbidities and ASA
score were collected. A follow-up study was conducted, by
phone call interviews at 3, 6, 9 and 12 months after the
fracture. Association between fatality and the independent
variables were analyzed using the Kaplan-Meier method
(log-rank test) and Cox Regression.
Results: 252 patients (79% women) agreed to participate in
the study. Female patients presented a mean age of 80.3 SD
9.5 different from the mean age in male patients of 76.3
SD11.3 (p-value 0.02). Only 8% of the patients had no
comorbidities. Hypertension disease was more frequent
among the female patients (56%) than in the men (38%)
(p-value 0.02) and respiratory diseases were more common
in the men (36%) compared to women (13%) (p-val-
ue<0.0001). During the follow-up 23 patients were lost but
information on survival for 14 of them were possible to
retrieve from the hospital registers. Fatality among men
was 22%, 25%, 30%, 37% respectively at 3, 6, 9 and 12
months follow-up being 8%, 14%, 20% and 23% among
women. The predictors of fatality were: male gender (HR
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2.53 95% CI 1.40-4.57), age (HR 1.06 95% CI 1.03-1.10),
delay in surgery (HR 1.07 95%CI 1.03-1.12) and ASA score
(HR 1.92 95% 1.09-3.42).
Conclusion(s): After one year, fatality was 60% higher
among men, even after adjusted for confounders. For each
day of delay to surgery there was an increased risk of 7% on
the fatality rates.
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SERUMURICACIDANDULTRASOUNDDETECTION
OF MONOSODIUM URATE DEPOSITION IN
PERIPHERAL JOINTS – CARDIOVASCULAR RISK
FACTORS IN PATIENTS WITH OSTEOARTHRITIS
Anca Emanuela Musetescu, Paulina Ciurea, Anca Rosu,
Florentin Vreju, Ioana Gofita-Cojocaru, Cristina Hoanca
University of Medicine and Pharmacy of Craiova, Rheuma-
tology, Craiova, Dolj, Romania
Objective(s): Hyperuricemia (HU) is a well recognized risk
factor for cardiovascular disease (CVD) associated with the
development of hypertension, metabolic syndrome, diabetes
mellitus and frequently found in patients with osteoarthritis
(OA). Carotid intima-media thickness (IMT) of the carotid
arteries assessed by ultrasonography is validated as a sensi-
tive marker for atherosclerosis, directly associated with an
increased risk of CVD. The aim of the study was to evaluate
the role of serum uric as a risk factor for CVD in patients
with OA as well as to prove the usefulness of ultrasound
detection of monosodium urate crystal deposition in osteo-
arthritic joints.
Material & Methods: The study groups included 42
patients with OA without HU (mean age 49±9 years) and
46 patients with OA and HU (mean age 54±10 years), newly
diagnosed, nonhypertensive, previously untreated, regis-
tered over a period of 2 years. The patients underwent
complete clinical, serological evaluation (systolic and dia-
stolic blood pressure, total cholesterol, LDL-cholesterol,
HDL-cholesterol, triglycerides, serum uric acid, inflamma-
tion markers) and high resolution B-mode ultrasound to
measure the IMT of the common carotid artery, as well as
multiplanar evaluation of the first metatarsophalangeal
joints, anterior recess of the tibiotalar joints and knee joints.
Results: IMT values were significantly higher in patients
with OA and HU (0.99±0.22 mm), compared with the
patients without HU (0.65±0.15 mm), p<0.001. 45.65%
of patients with OA and HU showed US findings in-
dicative of MSU crystal deposition, while these US
signs were identified in only 11.90% of patients with
OA without HU. No differences were recorded in the
appearance of osteophytes between hyperuricaemic
patients and those with normal uric acid levels. Differ-
ences have been seen in the aspect of the synovitis at
the level of the metatarsophalangeal joints.
Conclusion(s): The present study has showed that high serum
uric acid levels are associated with atherogenesis independent-
ly from hypertension in patients with OA and also with a
higher index of suspicion proved by the deposition of the
monosodium urate crystals in peripheral joints. Early screening
for HU and MSU deposition in joints as well as lowering
serum uric acid levels might be beneficial in slowing progres-
sion of IMT and reducing CVD risk in patients with OA.
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EVOLUTION OF BIOCHEMICAL MARKERS OF
BONE REMODELING DURING TREATMENT
WITH STRONTIUM RANELATE
Diana Paun1,2, Nicoleta Totolici1, Rodica Petris1, Constantin
Dumitrache1,2
1C.I. Parhon National Institute of Endocrinology, Endocri-
nology, 2Carol Davila University of Medicine and Pharmacy,
Endocrinology, Bucharest, Romania
Objective(s): Strontium ranelate is used in the treatment of
postmenopausal osteoporosis and it has also an effect on bone
formation. During antiresorbtive effect of bisphosphonates
(that don't influence the bone formation), after a certain period
of time, it can occur the “frozen bone” – a severely suppressed
bone turnover. This study evaluates the efficiency and the
compliance during the therapy with strontium ranelate after
6 months for osteoporosis in postmenopausal women.
Material & Methods:We present the results of a retrospec-
tive study which included 50 women that were registered in
The National Programme of Osteoporosis; the average age
was 66.4±8.5 SD years, in postmenopausal for 18±8.6 SD
years and with a T-score of de 3.42±0.39 SD (at the begin-
ning of the study). They were treated daily with strontium
ranelate (2 g) and vitamin D. We investigated: the presence
of fracture, risk factors, biologically: calcemia, phosphate-
mia, vitamin D, markers of bone formation (osteocalcin),
markers of bone resorption (crosslaps).
Results:Most of them received previously antiresorbtive ther-
apy; 6 had vertebral fracture; all of them had a high compliance
during the therapy; the values of calcemia remained almost the
same (from 9.78±0.71 mg/dl to 9.71±0.63 mg/dl), but
there was a bone formation process: osteocalcin from
22.4±27.2 ng/ml to 24.75±28.2 ng/ml and a suppressing
bone resorption: cross-laps from 0.58±0.35 ng/ml to
0.49±0.31 ng/ml.
Conclusion(s): Strontium ranelate is indicated in the thera-
py of postmenopausal osteoporosis, especially because it
has a dual mode of action on bone turnover.
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THE BODY MASS INDEX AND BONE MINERAL
DENSITY AGE RELATED CORRELATIONS – A
STUDY IN 347 WOMEN
S346 Osteoporos Int (2012) 23: (Suppl 2):S85–S386
Catalina Poiana1,2, Mara Carsote1, Valentin Radoi1, Cristina
Ene2, Diana Paun1,2, Gabriela Voicu2
1UMPh Davila, Endocrine, 2I. Parhon, Endocrine, Bucharest,
Romania
Objective(s): BMI influences the bone quality. But the rela-
tionship between BMI and BMD is difficult to establish. We
analyze whether the BMI is correlated to BMD in age groups.
Material & Methods: This is a study in women after
menopause. GE Lunar central DXAwas performed, as well
as bone markers. The patients who were previously treated
for osteoporosis (except for vitamin D and calcium supple-
ments) were not included. The informed consent of the
patients was obtained. The statistically analyze was per-
formed by linear regression.
Results: 347 patients (p) were introduced in 5 groups,
according to their age: group 1 (≤40 yrs) 6 p, group 2
(between 41-50 yrs) 61 p, group 3 (between 51-60 yrs)
178 p, group 4 (between 61-70 yrs) 80 p, and group 5
(between 71-80 yrs) 22 p. The correlations between BMI
and DXA-BMD (r2), respective the statistically significance
of the linear regression (p) were for all: 0.01, respective
p<0.001. For each group the values were: group 1 r2=0.29
(p=0.015), group 2 r2=0 (p<0.0001), group 3 r2=0.02
(p<0.0001), group 4 r2=0.03 (p<0.0001), group 5 r2=0.02
(p=0.0002).
Conclusion(s): Statistically significant results pointed that
in age depending group we found no correlation between the
BMI values and DXA-BMD.
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CORRELATION BETWEEN CRITERIA OF
DIAGNOSIS OF LOW BMD IN ADULT AND
PEDIATRIC THALASSEMIC PATIENTS
Zohreh Hamdi, Fariba Mohseni, Mohammad Reza
Mohajeri-Tehrani, Bagher Larijani
Endocrinology and Metabolism Research Institute of Tehran
University of Medical Sciences, Endocrinology, Tehran,
Islamic Republic of Iran
Objective(s): Finding how is the correlation between crite-
ria for osteoporosis in adulthood and the criteria of "low
bone density” in children and how “low bone density for
chronologic age” in childhood, can predict “osteoporosis” in
adulthood is a matter of interest in osteoporosis studies. The
main point is that serial densitometry of children (<20 y/o)
that continues to adulthood (after 20 y/o) is not common. As
BMD studies in Beta thalassemia major (a hemoglobin
disorder) patients; in both childhood and adulthood, is rou-
tine and recommended, we tried to find how much of this
patients with “low bone density for chronologic age” (Z-
score≤-2) before 20 y/o, will find with osteoporosis (T-score
≤-2.5) after 20 y/o and how is correlation between two
criteria for low bone mass in childhood and adulthood.
Material & Methods: The results of BMD of 30 thalasse-
mic patients (12 men and 18 women) studied. Each of them
had 1 scan before 20 y/o and 1 scan after that. The mean age
of patients in childhood was 17.63 and 20.63 y/o in adult-
hood. The scanner was a Norland XR-46 device. The agree-
ment of two criteria for finding osteoporosis in adulthood,
obtained.
Results: “Low bone density for chronologic age” found in
33% of children (in femoral neck or L2-L4) and “osteoporosis”
in 43% of patients after adulthood. Kappa score is an index for
showing how 2 methods have "agreement" in diagnosis of an
event (e.g., osteoporosis in adulthood, here) and don't diagnose
a nonevent (not osteoporotic in adulthood, here). Kappa was
0.657 for femur Z-score≤-2 and 0.703 for spine Z-score≤-2 for
femur osteoporosis. Kappa was 0.296 for femur Z-score≤-2 and
0.493 for spine Z-score≤-2 for spinal osteoporosis.
Conclusion(s): This study showed a good to moderate
agreement of two criteria for finding low bone mass in
childhood and adulthood, at least in femoral region, in β-
thalassemia major patients. Larger studies in normal cases is
needed to confirm this results.
Disclosures: Thank to Special Medical Center of Charity
Foundation for Special Disease of Iran (SMC of CFFSD)
and Mrs. A. Oojaghi for their valuable assistance in this
study.
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A COMPARISON OF THE MALE OSTEOPOROSIS
RISK ESTIMATION SCORE (MORES) AND THE
FRAX® IN IDENTIFYING MEN WITH FEMORAL
NECK OSTEOPOROSIS
Alvah R Cass, Angela J Shepherd
The University of Texas Medical Branch, Department of
Family Medicine, Galveston, TX, US
Objective(s): Compare the operating characteristics of the
MORES1 and FRAX®2 in identifying men with femoral
neck osteoporosis and assess their level of agreement.
Material & Methods: This was a blinded study of the
MORES and FRAX®, administered to men ≥60 years of
age, in a primary healthcare setting. Participants completed
a questionnaire including demographic data, pertinent med-
ical information, and the MORES and FRAX® variables.
All participants underwent a DXA scan, which served as the
references standard for femoral neck osteoporosis based on
the WGO's criteria. Responses to the questionnaire and
results of DXA scans were used to estimate the operating
characteristics of the MORES (positivity criterion ≥6 points)
and FRAX® (positivity criterion ≥9.3% 10-year risk of
major osteoporotic fracture). Agreement between the
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instruments was assessed applying McNemar's test and
obtaining the kappa statistic for agreement.
Results: 346 men completed the study. The mean age was
70.2±7.0 years; 76.0% were non-Hispanic white, and 89.8%
graduated high school or attended some college. 15 men
(4.3%) had femoral neck osteoporosis. 113 men (48.3%)
screened positive with the MORES, which correctly identi-
fied 12 of 15 men with osteoporosis: sensitivity 0.80 (95%
CI: 0.52, 0.96), specificity 0.70 (95% CI: 0.64, 0.74), and
AUC 0.82 (95% CI: 0.71, 0.92). Fifty-nine men (17.1%)
screened positive with the FRAX®, which correctly identi-
fied 7 of 15 men with osteoporosis: sensitivity 0.47 (95%
CI: 0.21, 0.73); specificity 0.84 (95% CI: 0.80, 0.88), and
AUC 0.72 (95% CI: 0.560, 0.85). Discordance was 35.8%
(McNemar's χ2 test, p-value<0.001) and the kappa statistic
was 0.071.
Conclusion(s): Both the MORES and FRAX® identified
men with femoral neck osteoporosis, but they were not
equivalent. The MORES tended to identify more of the
men with osteoporosis than the FRAX®, but had a greater
false positive rate.
References: (1) Shepherd AJ, et al. Ann Fam Med
2007;5:540. (2) Kanis JA on behalf of the WHO Scientific
Group (2008) Assessment of osteoporosis at the primary
healthcare level. Available at http://www.shef.ac.uk/FRAX/
index.htm
Disclosures: Funded by the Agency for Healthcare Re-
search and Quality (5R03HS017732-02 Revised)
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ADIPOKINES: ROLE IN FORMATION OF
OSTEOPENIC SYNDROME IN PATIENTS
WITH END-STAGE PULMONARY DISEASE
Evgenia Kochetkova, Ludmila Ugay, Ksenia Burya, Svetlana
Albavichus
Vladivostok State Medical University, Therapy, Vladivostok,
Russian Federation
Objective(s): Aim of this study to evaluate associations
between the adipokines (TNFα) and its receptors, leptin,
adiponectin, resistin), body composition and BMD in the
patients with terminal stage of chronic respiratory failure.
Material & Methods: 63 patients with end-stage of chronic
respiratory failure (COPD, emphysema, fibrosis and cystic
fibrosis) and 55 healthy subjects were estimated. BMD,
wool body composition was measured by DXA at the lum-
bar spine (LS) and left femur neck (FN). We estimated
respiratory function testing, serum levels TNF-a, TNFR-1,
TNFR-2, leptin, adiponectin, resistin.
Results: We identified a decreased BMD characterized by
T-score<-1.0 in 54/63 patients, as measured on the FN or the
LS. The adiponectin, resistin, TNF-a and its receptors level
were higher, but leptin level was low in lung pathology in
comparison with control group. Where was positive corre-
lation between serum leptin (r=0.64, p=0.0002; r=0.52,
p=0.009) and negative association between adiponectin
(r=-0.54, p=0.009; r=-0.47, p=0.003), TNF-a (r=-0.43,
p=0.03; r=-0.41, p=0.04) and BMD in FN and LS. Corre-
lated analyses showed positive correlation between
resistin level (r=0.57, p=0.004), sTNFR-I (r=0.42,
p=0.03) and sTNFR-II (r=0.44, p=0.04) and BMD in
L2-L4 only. Parameters of body compositions and se-
rum concentrations of leptin and adiponectin were sig-
nificantly associated with FN and LS. Serum leptin
levels was significant lower (p=0.047) and adiponectin
concentrations was higher (p=0.039) in the osteoporosis
group. Serum leptin significantly positively correlated
with parameters of body composition, serum adiponectin
concentrations was negative association with TNFR-1,
TNFR-2 (p=0.007). There was a significant inverse re-
lationship between leptin and adiponectin (r=-0.67,
p=0.0008).
Conclusion(s): These results shows possibly role of adipo-
kines in the increasing of bone loss at the terminal stage of
chronic respiratory failure.
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INVOLVEMENT OF OPG IN THE HEALING
PROCESSES OF FEMORAL OSTEOPOROTIC
FRACTURES
Costantino Corradini1, Vittorio Macchi1, Fabrizio Ferrara1,
AlessioMaione1,Wilfried Stuflesser1, Calogero Crapanzano2,
Cesare Verdoia1
1Orthopaedic Institute G. Pini, Orthopaedic and Traumato-
logic Clinic, State University of Milan, 2Clinical Pathology
Unit, Milan, Italy
Objective(s): In animal model osteoprotegerin (OPG)
protects bone from excessive resorption and exert
increases bone mass and density. Increased OPG is
supposed to be a homeostatic mechanism limiting bone
loss in elderly people. But compensatory elevation of
serum OPG levels in osteoporotic fractures has been
recently considered insufficient to limit bone loss lead-
ing to fracture. The objective of this study was to
monitor serum OPG levels in osteoporotic patients af-
fected by first femoral neck fracture during healing
period of 6 months.
Material & Methods: 43 women with untreated post-
menopausal osteoporosis between 55-76 years old af-
fected were recruited. They were free by important
cardiovascular, renal, endocrine, tumor and intestinal
comorbidity. They were divided in two groups frac-
tured and unfractured. The first group was composed
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by 23 women that had an access to hospital with
diagnosis of femoral neck fracture and were treated
with intramedullary nail or un-cemented prostheses. A
second homogeneous group of 20 postmenopausal osteopo-
rotic patients without clinical evidence of fractures was con-
sidered as control. Serum OPG levels were measured in both
groups by ELISA. In fractured group the test were repeated at
1st, 3 rd and 6th month.
Results: Serum OPG levels were significantly higher in
fractured than in unfractured group from the beginning
to 3 rd month, while at 6th month no statistical differ-
ences were detected. In particular a peak was measured
between 1st and 3 rd month. Serum OPG levels was
increased for decade but fractured patients revealed a
further significant increase. Since there is not a normal-
ity range of OPG and patients are within two decades,
data can seems to related to the presence of a fracture
rather than senescence.
Conclusion(s): The increased circulating OPG in frac-
tured vs. un-fractured osteoporotic women suggests
the involvement of OPG in the healing processes of
bone.
References: Anastasilakis AD. Horm Metab Res 2008,
40,281; Boyce BF. Arch Biochem Biophys 2008, 473,139;
Grundt A. Biochem Biophys Res Commun 2009, 389,550;
Marchelli D. J Orthop Traumatol 2009,10,55; Ota N. Endo-
crinology 2009, 150,4823
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COMBINATION OF OSTEOARTHRITIS AND
DISEASES OF PERIPHERAL VEINS OF LOWER
EXTREMITIES IN CLINICAL PRACTICE
Leysan I Myasoutova, Svetlana A Lapshina, Artem G
Vasilyev
Kazan State Medical University, Department of Hospital
Therapy, Kazan, Russian Federation
Objective(s): To study features of osteoarthritis (OA) in
combination with diseases of peripheral veins of lower
extremities (DPVLE).
Material & Methods: 81 patients with OAwere examined,
40 of them (49.4%) had DPVLE [14 (17.3%) patients – post
thrombophlebitic syndrome, 26 (32.1%) - varix dilatation].
According to the presence of DPVLE 2 groups were formed
(comparable on age, gender, disease duration, clinical char-
acteristics and therapy).
Results: Patients with combination of OA and DPVLE
had significantly (p>0.05) higher the pain intensity on
visual analogue scale (VAS) at rest and moving, in-
creased joint swelling, inflammation indices, palpatory
tenderness of areas of muscular infiltration and func-
tional activity deterioration according to Lecken test
compared with patients without signs of venous insuffi-
ciency. After treatment the patients with both diseases
still had higher (p>0.05) scores of pain and local inflamma-
tion. Periarticular circulation impairments in patients with OA
and DPVLE were characterized by progressing pulse
volume loss, haemostasia and venous circulation impair-
ment (α/β, Ac/Ad) compared with patients without
DPVLE.
Conclusion(s): Combination of OA and DPVLE unfavor-
ably influences patients' quality of life, increases cost of
therapy and acquires timely therapy.
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COMPUTING STRUCTURAL PARAMETERS
FROM DUAL-ENERGY X-RAYABSORPTIOMETRY
USING A 3D RECONSTRUCTION METHOD
Ludovic Humbert2,1, Tristan Whitmarsh1,2, Luis Miguel Del
Río Barquero3, Alejandro F Frangi1,2,4
1Universitat Pompeu Fabra, Computational Imaging and
Simulation Technologies in Biomedicine, 2CIBER-BBN,
Networking Biomedical Research Center - Bioengineering,
Biomaterials and Nanomedicine, 3Grup Mèdic, CETIR,
Barcelona, Spain, 4University of Sheffield, Mechanical
Engineering Department, Sheffield, UK
Objective(s): This paper presents a method to extract a
set of 3D structural parameters quantifying the geome-
try and strength of the proximal femur, using a previ-
ously developed 3D reconstruction method from DXA
[1].
Material & Methods: The reconstruction method uses
a 3D statistical model constructed from a dataset of
QCT scans, which describes the statistical variations
in shape and BMD distribution. A 3D reconstruction
is subsequently acquired by registering the statistical
model onto the 2D DXA image so that the projection
of the model matches the DXA image. This reconstruc-
tion method has been shown to produce accurate recon-
structions (shape accuracy of 1.1 mm and density
reconstruction errors of 4.9% [1]). From the 3D recon-
structions, a set of geometrical and structural parame-
ters is automatically computed for two regions of
interest (narrow femoral neck and intertrochanteric re-
gion). To validate the method, structural parameters
were computed from 3D DXA reconstructions of 30
patients and compared with parameters obtained from
QCT.
Results: The comparison resulted in correlation coef-
ficients (for the narrow femoral neck and intertrochan-
teric region respectively) of: r=0.88 and r=0.95 (slice
area), r=0.92 and r=0.95 (cross-sectional area), r=0.89
and r=0.97 (cross-sectional moment of inertia), r=0.89
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and r=0.93 (section modulus). The geometrical param-
eters showed correlation coefficients of r=0.94 (femoral
neck axis length) and r=0.90 (femoral neck shaft an-
gle). All the correlations were statistical significant
(p-value
Conclusion(s): This method provides a set of automatically
computed 3D structural parameters, from only one single
DXA image, which normally requires a QCT acquisition.
The software potentially allows for an improved diagnosis
of osteoporosis and fracture risk estimation, while maintaining
DXA as the current standard modality.
References: [1] Whitmarsh et al. IEEE Transactions on
Medical Imaging 30, 2101(2011).
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CHANGES OF MINERAL BONE DENSITY IN
PATIENTS WITH ANKYLOSING SPONDYLITIS
Leysan I Myasoutova, Svetlana A Lapshina, Artem G
Vasilyev
Kazan State Medical University, Department of Hospital
Therapy, Kazan, Russian Federation
Objective(s): To determine the features of mineral bone
density (MBD) changes in patients with ankylosing spon-
dylitis (AS) depending on demographical data, clinical and
laboratory findings.
Material & Methods: 42 patients (male - 36 (85.7%),
female - 6 (14.3%), 21-47 years of age, mean age 33.2±8.4,
mean disease duration 7.8±5.9 years) with proven diag-
nosis of AS were included in the study performed at The
centre of osteoporosis treatment and prevention. All
patients were HLA-B27 positive, 23 (54.8%) had periph-
eral arthritis. Evaluation included back pain assessment
with VAS scale, morning stiffness duration assessment,
modified Schöber's test, limitation of chest expansion
assessment, calculation of BASDAI, BASFI and
ASDAS-CRP scores, ESR and CRP levels. To evaluate
MBD all patient underwent DXA of lumbar spine (L1-
L4) and hip neck.
Results: Among male patients normal MBD was found in 6
(16.7%) patients, 19 (52.8%) had osteopenia, 11 (30.5%) -
osteoporosis. Among male patients normal MBD was found
in 1 (16.7%) patients, 1 (16.7%) had osteopenia, 4 (66.6%) -
osteoporosis. MBD of lumbar spine in male patients was
significantly higher compared to females (p<0.05). Patients
with high disease activity and peripheral arthritis had sig-
nificantly lower MBD of lumbar spine. Patients with osteo-
porosis and osteopenia had higher pain score on VAS
compared to patients with normal MBD. Association be-
tween MBD and duration of AS, Schöber's test results,
disease activity and CRP was found.
Conclusion(s): High clinical activity, presence of peripheral
arthritis, significant changes in spinal movement were found
to be predictors of MBD decrease in patients with AS.
Patients with AS and osteopenia had more pain.
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VERTEBRAL FRACTURES PREVALENCE AND
ABDOMINAL AORTIC CALCIFICATION IN MEN
Imad Ghozlani, Asmaa Rezqi, Aziza Mounach, Lahsen
Achemlal, Ahmed Bezza, Abdellah El Maghraoui
Military Hospital Mohammed V, Rheumatology Department,
Rabat, Morocco
Objective(s): Vertebral fracture assessment (VFA) imaging
with a bone densitometer can simultaneously detect preva-
lent VFs and AAC an important cardiovascular disease risk
factor independent of clinical risk factors. Objective was to
study the relation between the prevalence and severity of
VFs using VFA in asymptomatic men and the prevalence
and severity of AAC.
Material & Methods:We enrolled 709 men with mean±SD
(range) age, weight and BMI of 62.4±8.6 (45-89) years,
75.9±12.9 (40-163) and 26.4±4.0 (16.6-43.8) kg/m2, respec-
tively. Lateral VFA images and scans of the lumbar spine
and proximal femur were obtained using a GE Healthcare
Lunar Prodigy densitometer. VFs were defined using a
combination of Genant semiquantitative approach and mor-
phometry. VFA images were scored for AAC using a pre-
viously validated 24 point scale.
Results: VFs were identified using VFA in 475 (40.3%):
166 (26.0%) had grade 1 and 68 (14.2%) had at least one
grade 2 or 3 vertebral fracture. The prevalence of grade 2/3
vertebral fractures was 42 (38.9%) in men with osteoporosis
and was higher (p<0.0001) compared to 15 (5.9%) in men
with normal BMD and to 39 (11.2%) with osteopenia. VFA
images showed that 82% of the evaluable participants did
not have any detectable AAC whereas the AAC score dis-
tribution ranged between 1-15. Conversely, the prevalence
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of significant atherosclerotic burden, defined as a radio-
graphic 24-point AAC score of 5 or higher, was 2.8% and
concerned essentially patients over 66 years. The group of
men with moderate/severe vertebral fractures had a sta-
tistically significant higher AAC score and higher pro-
portion of subjects with extended AAC, and lower
weight, height, and lumbar spine and total hip BMD
and T-scores than those without a VFA-identified verte-
bral fracture. A positive statistical correlation was noted
between age and the SDI, and a statistical negative
correlation between the AAC score and lumbar spine
and total hip BMD. Multiple regression analysis showed
that the presence of grade 2/3 VFs was associated to
AAC and osteoporosis in any site.
Conclusion(s): VFA imaging has the potential to contribute
to identification of subclinical cardiovascular disease in
men.
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HEALTH BELIEFS AND ATTITUDES OF GREEK
MEN ABOUT OSTEOPOROSIS: APPLICATION OF
THE HEALTH BELIEF MODEL
Stylianos Papalexandris1,3, Alexandros Gerakis2, Christos
Zilidis3
1Royal South HANTS Hospital, Orthopaedic Department,
Southampton, UK, 2Hippokration Hospital, Orthopaedic
Department, Thessaloniki, Greece, 3Open University of
Cyprus, Faculty of Economics and Management, Nicosia,
Cyprus
Objective(s): The aim of the study was to determine the
beliefs of Greek men about osteoporosis and their perceived
vulnerability, severity of the disease, the costs and the ben-
efits of preventive measures, as projected through the Health
Belief Model.
Material & Methods: 330 men were enrolled in the study,
which was performed at the Orthopaedic Outpatients De-
partment of a tertiary military hospital in Thessaloniki,
Greece, between April-July 2011.
The Osteoporosis Health Belief Scale (OHBS) was the
research tool for the conduction of the study and it was the
first time OHBS was translated into Greek and distributed to
a Greek male population. It consists of 42 questions/state-
ments. Groups of six questions assess each of the seven
constructs of the Health Belief Model. The maximum pos-
sible score is 210 points for the OHBS and 30 for each
construct. Correlation of age with the average score at each
construct of the OHBS was explored with the Spearman's ρ
correlation coefficient and the ANOVA, the Tuckey Hon-
estly Significant Difference and the t tests for other demo-
graphic parameters. Correlation among the constructs was
assessed with the Pearson's r correlation coefficient. All
statistical analyses were performed with the SPSS 19
software.
Results: The mean age of the participants was 28.3 years
(SD=8.18), ranging between 18-65 years. The median age
was 26 years. 148men (44.8%) had a higher education degree.
43 (13%) of the participants had been informed about osteo-
porosis in the past. Cronbach's α coefficient ranged between
0.747-0.835 for the 7 constructs, establishing the reliability of
the Greek OHBS version. The average total score was 126.33
(74-175) with a SD=11.57. The median score was 126.
Conclusion(s): The scores at different OHBS subgroups
indicated that men consider osteoporosis a serious disease
(17.21 points), which is not a women's privilege (suscepti-
bility 16.18 points).They are also aware of the benefits of
adequate calcium intake and regular exercise and present
weak barriers to beneficial behaviours. The strongest posi-
tive correlation was found between the constructs “health
motivation” and “exercise benefits”.
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VITAMIN D DEFICIENCY IN CHILDREN
OF UKRAINE
Vladyslav V Povoroznyuk1, Nataliya I Balatska1, Oleksandra
V Tyazhka2, Inga V Kubey3, Tetyana V Budnyk4
1SI “Institute of Gerontology NAMS Ukraine”, Department
of Physiology and Pathology of Locomotors Apparatus,
2Bogomolets National Medical University, Paediatrics,
Kyiv, 3SI “Ternopil State Medical University named after
I. Horbachevsky”, Paediatrics, Ternopil, 4SI “Lugansky
State Medical University”, Paediatrics, Lugansk, Ukraine
Objective(s): To determine the frequency of vitamin D
deficiency and insufficiency in children of different region
of Ukraine and to evaluate the influence of 25OHD and
PTH level to BMD.
Material & Methods: It was examined 220 practically
healthy children aged 10-18 yr. old who lived in different
regions of Ukraine. 25-OH vitamin D and PTH were eval-
uated by electrochemiluminescence method (Elecsys 2010,
Roche). Vitamin D deficiency was diagnosed in level of 25-
OH vitamin D below 50.0 nmol/l, vitamin D insufficiency –
between 74.5-50.0 nmol/l. BMD was determined by ultra-
sound densitometry Sahara (Hologic). Children were exam-
ined during October-November 2011.
Results: Vitamin D deficiency was registered in 92.2%
children, 45.9% of schoolchildren had 25-OH vitamin D
level below 25 nmol/l. 6.4% examined patients had vitamin
D insufficiency. 0.9% of examined children had secondary
hyperparathyroidism. Low mineral density was registered in
4.8% children. No significant correlation between 25-OH
vitamin D and BMD. Only in children 12-15 yrs. old with
vitamin D deficiency it was significant correlation between
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PTH level and all data of ultrasound densitometry (stiffness
index (r=-0.32, p<0.01), broadband ultrasound attenuation
(r=-0.26, p<0.05), speed of sound (r=-0.31, p<0.02).
Conclusion(s): High level of vitamin D deficiency (92.2%),
secondary hyperparathyroidism (0.9%), negative significant
correlation between PTH level and data of ultrasound den-
sitometry in pubertal children with vitamin deficiency make
doctors to research the effective methods of treatment and
prophylactics of revealed disorders.
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PTH(1-84) REPLACEMENT THERAPY IN
HYPOPARATHYROIDISM (HYPOPT): A
RANDOMIZED CONTROLLED TRIAL ON
PHARMACOKINETICS AND DYNAMIC EFFECTS
FOLLOWING 24 WEEKS OF TREATMENT
Tanja Sikjaer1, Lars Rolighed2, Anne Kristine Amstrup1,
Lars Rejnmark1, Leif Mosekilde1
1Aarhus University Hospital, Department of Internal Medi-
cine and Endocrinology, MEA, 2Department of Surgery P,
Aarhus, Denmark
Objective(s): In HypoPT, lack of PTH necessitates treat-
ment with calcium and vitamin D analogues in order to
avoid hypocalcemia.
Material & Methods: To study if replacement with the
missing hormone possesses advantages, we randomized 62
patients with HypoPT to 24-wks of daily SC injection of PTH
(1-84) 100 μg or similar placebo, in addition to conventional
therapy. After 24-wks, we performed a 24 h biochemical
monitoring on 39 patients (22 on PTH) in order to assess
effects on diurnal variations in calcium-phosphate homeosta-
sis. Following injection, blood samples were obtained at 0.25,
0.5, 1.0, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 20, 24 h, urine was
collected in time intervals: 0-2, 2-4, 4-8, 8-16, 16-24 h.
Results: During the 24-wks of therapy patients on PTH
reduced their daily dose of calcium and active vitamin D
significantly by 75% and 73%, respectively. Plasma PTH
levels rose immediately, reaching a peak level of 246 (inter-
quartile range (IQR): 181;396) pg/ml at the first time point
of measurement, followed by a gradually decrease reaching
pre-dosing levels after 16 h, with a plasma t½ of 4.6 (IQR
4.1;5.8) h. PTH caused significant changes in the diurnal
rhythms of plasma Ca2+ and 1,25(OH)2D levels, with rising
Ca2+ levels reaching a peak app. 8 h following administra-
tion. Between 4-12 h, asymptomatic hypercalcemia (>1.32
mmol/l) was present in 41% of PTH treated patients. Despite
hypercalcemia, renal excretion of calcium was significantly
lower 4-8 h following injection in the PTH- comparedwith the
placebo-group, and 24 h urinary calcium did not differ be-
tween groups. Renal excretion (24 h) of magnesium was
lower in the PTH- (4.7, IQR: 4.1;6.7 mmol/d) compared with
the placebo- (5.7; IQR: 4.0;7.7 mmol/d, p<0.05) group. PTH
caused lower phosphate levels, although treatment did not
affect diurnal rhythms of plasma phosphate or magnesium
levels.
Conclusion(s): A fixed dose of 100 μg/d PTH(1-84) may
be too high, as transient hypercalcemia developed in
some patients. However, PTH decreased urinary calcium
losses in the hour following injection and magnesium
losses throughout the study period. Accordingly, PTH
may possess advantages compared with conventional
treatment if administered in doses adapted to the patient's
needs.
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PECULIARITY BONE TURNOVER MARKERS IN
CHILDREN WITH OSTEOGENESIS IMPERFECTA
Vladyslav V Povoroznyuk1, Nataliya I Balatska1, Tamara A
Kincha-Polishchuk2
1SI “Institute of Gerontology NAMS Ukraine”, Department
of Physiology and Pathology of Locomotors Apparatus, 2SI
“Institute of Traumatology and Orthopedics NAMS
Ukraine”, Paediatrics, Kyiv, Ukraine
Objective(s): To determine the peculiarity of the bone turn-
over markers in children with osteogenesis imperfecta.
Material & Methods: 19 children aged 1-15 years old with
OI were examined. 10 healthy persons of appropriate age
formed control group. Markers of bone formation and bone
resorption, such as serum N-MID Osteocalcin, serum P1NP,
and serum β-CTx, were measured by electrochemilumines-
cence (Elecsys 2010, Roche).
Results: All patients with OI had significantly higher level
of P1NP, β-CTx and osteocalcin. The level of P1NP was
(555.78±69.60 vs. 148.01±41.24 ng/ml) (P=0.001), β-CTx
was 1.992±0.21 vs. 0.850±0.11 ng/ml (P=0.0013), osteocal-
cin 130.29±11.23 vs. 51.57±5.81 ng/ml (P=0.00014).
Conclusion(s): Patient with OI has higher level of bone
turnovers markers. Assessment of such bone markers may
be the earliest laboratory test for OI. It is necessary to
evaluate the critical level of bone turnover markers which
will point to formation OI.
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BONE MINERAL DENSITY (BMD) IN PATIENTS
WITH SPINAL CORD INJURY (SCI) REGARDING
NEUROLOGICAL FINDINGS AND DURATION OF
NEUROLOGICAL IMPAREMENT
Dragana Milenkovic1, Natasa Radosavljevic2, Zoran
Radosavljevic3, Aleksandar Stojanovic1, Olivera Ilic-
Stojanovic2, R Cobeljic1, A Sekulic1, S Milicevic1
1Clinic for Rehabilitation "Dr M.Zotovic", Department of
Rheumatology, 2Institute for Rehabilitation, Department of
Rheumatology, 3Special Hospital for Internal Medicine,
Department of Urology, Mladenovac, Belgrade, Serbia
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Objective(s): Osteoporosis is one of the complications that
occur in patients with quadriplegia and paraplegia, after
SCI. The aim of this study was to determine to what extent
the degree and the level of spinal cord lesions, muscle tone
and the time after the injury affect BMD.
Material & Methods: This prospective research was car-
ried out from May 2009 - December 2011 in Rehabilitation
Clinic “Dr Zotovic” in Belgrade. BMD was measured at the
femoral neck using DXA method, expressed in g/cm2, on
the LUNAR DPX device. Statistic elaboration was done
with SPSS statistical software.
Results: In our group 32 patients were studied, men aged
18-40. Based on the level of neurological and motor impair-
ment, patients were classified as: quadriplegia (9 patients,
28.1%) and paraplegia (23 patients, 71.9%); based on the
impairment degree by ASIA classification (American Spinal
Injury Association -impairment scale) as: complete (ASIA
A) and incomplete (ASIA B,C,D) According to the period
of time after the injury, patients were divided into: acute- 7
patients (21.9%); subacute - 8 patients (25%) and chronic 17
patients (53.1%). Muscle tone was assessed with the Ash-
worth spasticity scale (1-4); flaccid (14 patients, 43.7%),
with normal tone (3 patients, 9.4%) with present spasticity
(15 patients, 46.9%)There was no statistically significant
difference between BMD measured in patients with quadri-
plegia and paraplegia with complete and incomplete lesion.
There was no statistically significant difference between
BMD measured in patients with different muscle tone. Sta-
tistically significant difference was found between BMD
and the period after the injury (the length of duration of
lesion).
Conclusion(s): Based on our tests, whose results are in a
line with the results of other authors, we can conclude that
the level and degree of spinal cord lesions and muscle tone
in patients with quadriplegia and paraplegia do not affect the
decrease in mineral bone density, whilst the time elapsed
since the occurrence of the injury affects significantly the
BMD reduction, which is a certain risk factor for the occur-
rence of fractures.
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ARE BONE REMODELLING MARKERS AFFECTED
BY SUBCLINICAL HYPERTHYROIDISM?
Ana Paula Barbosa, Mário Rui Mascarenhas, Ana Gonçalves,
Isabel do Carmo
Santa Maria University Hospital, Endocrinology, Diabetes
& Metabolism Department, Lisboa, Portugal
Objective(s): Osteoporosis and subclinical hyperthyroidism
are both silent diseases until their complications emerge. So,
their precocious diagnosis is of extreme importance. Thy-
roid hormones are known for a long time to affect bone
metabolism. However, recent work also point to a possible
action of TSH alone in bone remodeling, inhibiting both
formation and resorption. So, patients with subclinical hy-
perthyroidism (normal thyroid hormones and suppressed
TSH) can be more prone to a BMD reduction/osteoporosis
and fractures. The aim of this study was to evaluate the
correlations between bone remodelling markers, the thyroid
function and BMD in postmenopausal women with subclin-
ical hyperthyroidism.
Material & Methods: In 49 women with subclinical hy-
perthyroidism, postmenopause, the body lean and fat masses
(kg) and the BMD (g/cm2) at the lumbar spine (L1-L4),
proximal femur, distal radius and whole body were evaluat-
ed by DXA (QDR Discovery, Hologic). Plasma levels of
osteocalcin, CTX, bone alkaline phosphatase, PINP, as well
as those of thyroid hormones, PTHi, calcium, IGF1, vitamin
D and pituitary hormones were determined. No patient was
previously treated for hyperthyroidism and/or osteoporosis.
Descriptive and comparative tests were used and statistical
significance was considered for P<0.05.
Results: The means of the BMD (±SD) were at the lumbar
spine 0.925 (±0.16) g/cm2 and femoral neck 0.764 (±0.14)
g/cm2. Of the several significant correlations found, we
emphasize those between TSH and osteocalcin, BMD and
trabecular bone T-score, and also between iPTH and CTX.
Conclusion(s): The results of this study seem to suggest that
the suppressed TSH can affect bone formation in the trabec-
ular bone. Also, bone resorption was associated to PTH
levels. Finally, the global results of this study emphasize
the importance of evaluating thyroid function in postmeno-
pausal women because of the increased risk of osteoporotic
fractures in subclinical hyperthyroidism.
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BONE TURNOVER IN PATIENTS WITH
CHRONIC SPINAL CORD INJURY
Vladyslav V Povoroznyuk, Maryna A Bystrytska
SI “Institute of Gerontology NAMS Ukraine”, Department
of Physiology and Pathology of Locomotors Apparatus,
Kyiv, Ukraine
Objective(s): To determine the peculiarity of the bone turn-
over markers in patients with chronic spinal cord injury
(SCJ).
Material & Methods: 52 patients were divided into three
groups. First group included 10 patients with early chronic
SCJ (average age 26.0±1.44 years, duration of trauma period –
under 1 year), the second group included 21 patients with late
chronic SCJ (average age 32.4±1.6 years, duration of trauma
period – over 1 year) and the third group consisted of 21 healthy
individuals of appropriate age (average age of 33.8±1.5 years).
Markers of bone turnover (osteocalcin, serum P1NP, serum β-
CTx, and PTH) were determined by the electrochemilumines-
cence method (Elecsys 2010, Roche).
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Results: The results of examination showed patients with
early chronic SCJ had significantly higher bone formation
and bone resorption markers than persons of second group:
osteocalcin (41.5±10.1 vs. 25.6±1.7 ng/ml, F–4.5, p=0.04),
P1NP (235.4±68.7 ng/ml vs. 57.1±4.2, F–13.7, p<0.0001),
serum β-CTx (1.77±0.17 vs. 0.63±0.06 ng/ml, F–14.6,
p<0.0001), PTH (19.8±4.7 vs. 42.4±5.3 ng/ml, F–7.4,
p=0.01). The average level of bone turnover markers in
patients of first group were significantly higher compared
with healthy persons of control group: P1NP (235.4±68.7 vs.
40.8±7.4 ng/ml, F–13.1, p<0.0001), serum β-CTx (1.77±0.17
vs. 0.36±0.05 ng/ml, F–15.3, p<0.0001), PTH (19.8±4.7 vs.
40.8±3.9 ng/ml, F–4.9, p=0.01). The level of osteocalcin in
group 2 and 3 without difference (25.6±1.7 vs. 27.7±4.4
ng/ml, F–2.5, p=0.09). It is important to note that the
considerable difference between second and third group
was only in serum β-CTx level (0.63±0.06 vs. 0.36±0.05
ng/ml, F–10.1, p=0.03).
Conclusion(s): The bone formation and bone resorption
markers in patients with early chronic SCJ were significant-
ly higher than appropriate data of healthy individuals and
persons with chronic SCJ with duration of trauma over 1
year.
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FREQUENCY OF VITAMIN D DEFICIENCY
AMOUNT UKRAINIAN POPULATION
Vladyslav V Povoroznyuk, Nataliya I Balatska, Fedir V
Klymovytsky, Omelyan V Synenky, Volodymyr M Vayda
SI “Institute of Gerontology NAMS Ukraine”, Department
of Physiology and Pathology of Locomotors Apparatus,
Kyiv, Ukraine
Objective(s): To study determine the frequency of vitamin
D deficiency and insufficiency and it influence to BMD in
patients of different region of Ukraine.
Material & Methods: It was examined 1575 people aged
20-95 yrs. old who lived in different regions of Ukraine. 25-
OH vitamin D and PTH level was evaluated by electro-
chemiluminescence method (Elecsys 2010, Roche). Vitamin
D deficiency was diagnosed in level of 25-OH vitamin D
below 49.5 nmol/l, vitamin D insufficiency – between 74.5-
50.0 nmol/l. BMD was determined by ultrasound densitom-
etry Sahara (Hologic) and DXA (Lunar).
Results: Vitamin D deficiency was registered in 81.8%
persons, 13.6% examined had vitamin D insufficiency. It
was determined negative significant correlation between
PTH and 25OHD (r=-0.16, p<0.0000001). Secondary hy-
perparathyroidism was diagnosed in 11.9% patients. The
mean level of 25OHD was significantly higher in southern
resident of the country (p<0.001) and during summer
(p<0.05). No significant correlation between 25OHD and
BMD was found. But, only patients with vitamin D defi-
ciency had significant negative correlations between PTH
level and BMD at the level of femur neck (r=-0.12,
p<0.004), dual femur (r=-0.09, p<0.004), upper and lower
extremities (r=-0.11, p<0.01 and r=-0.10, p<0.01 according-
ly), forearm 33% (r=-0.20, p<0.001).
Conclusion(s): In Ukrainian population the frequency of
vitamin D deficiency is 81.8%. Only patients with vitamin
D deficiency have significant negative correlations between
PTH level and BMD at the level of femur neck, dual femur,
forearm 33%, upper and lower extremities.
P655
BONE AND MUSCLE CHANGES WITH
TERIPARATIDE THERAPY FOR 18 MONTHS – A
PILOT PROSPECTIVE STUDY FROM A
CONVENIENCE COHORT
Andy Kin On Wong1, Karen A Beattie2, Sami Shaker2,
Shari Ghanny2, Dean Inglis3, Jonathan D Adachi2
1McMaster University, Medical Sciences, 2Medicine, 3Civil
Engineering, Hamilton, ON, Canada
Objective(s): To determine changes in bone and muscle
morphometry with 18 months of teriparatide therapy.
Material & Methods: Patients prescribed 20 μg/day teri-
paratide sc de novo were asked to participate in an 18-month
study. DXA (Hologic) scans of the lumbar spine (LS) and
femoral neck (FN) were acquired at study entry as were
single slice pQCT (Stratec) scans (2.3±0.5 mm thick) at the
4% radius and 66% calf at in-plane resolutions of 200 μm
and 500 μm, respectively. Participants were followed at 6-
month intervals for 18-months, repeating DXA and pQCT
scans at each visit. All pQCT scans were randomized upon
analysis. Images of radii were semi-automatically segment-
ed using OsteoQ (Teneos Software Inc) to provide apparent
microstructural parameters. Calf muscle was segmented us-
ing SliceOmatic (Tomovision) to determine muscle (vMD,
MCSA) and bone (vBMD, BCSA) volumetric densities and
cross-sectional areas. Linear mixed models evaluated re-
peated measures of bone and muscle over 18-months,
adjusting for age and BMI. Post-hoc time comparison was
adjusted by Dunnett's method.
Results: 32 participants (6 M, 26 F, age: 63.7±11.6 yrs,
BMI: 24.8±17.0 kg/m2, FN T-score:-2.4±0.7) were followed
for a mean of 12.3±9.3 months with 78% completing at least
15 months. Bone volume fraction and BMD of the LS and
FN were unchanged (p>0.900) (Table). vMD significantly
increased at 12 months with adjustment for age and BMI
(p=0.049). Apparent increases in MCSA were not signifi-
cant (p=0.146). Cortical bone density at the 66% site was
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decreased after 6 months (p<0.001). Maximum hole area
marginally decreased by 18 months (p=0.095) at the 4%
distal radius.
Table I. Comparing reliability of pQCT muscle measures obtained
by water-shed versus threshold-based segmentation separated by
participant subgroups, Young adult (age:25.6±3.3, BMI: 23.9±4.8),
older adult (age: 74.0±9.2, BMI: 25.7±4.0), SCI (age: 44.1±9.4,
BMI: 23.9±3.3). vMD = muscle volumetric density, MCSA =
muscle cross-sectional area.
Reliability Data RMSSD (units) RMSCV (% error)
Variable & Method Young Older SCI Young Older SCI
Water-Shed vMD
(mg/cc)
0.89 1.43 0.85 1.18 2.01 1.42
Threshold-Based
vMD (mg/cc)
1.73 1.22 2.43 2.36 1.77 4.06
Water-Shed MCSA
(mm2)
34.96 53.97 52.34 0.49 0.93 1.38
Threshold-Based
MCSA (mm2)
154.35 105.37 142.10 2.57 1.77 2.94
Conclusion(s): This pilot study showed modest effects of
teriparatide at 20 μg/day sc to improve muscle density, a
surrogate of muscle adiposity, despite inconsistent effects on
bone microstructure. The clinical implications of these mus-
cle changes have yet to be determined.
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VITAMIN D AND RHEUMATOID ARTHRITIS
Panagiotis Athanassiou1, Ifigenia Kostoglou-Athanassiou2,
Aikaterini Lyraki3, Anastasios Gkountouvas2, John
Myriokefalitakis3, John Raftakis3, Antonia Elezoglou3, Nicolaos
Dadiras1, Philippos Kaldrymides2, Christodoulos Antoniades3
1 St. Paul's Hospital, Department of Rheumatology, Athens,
2Metaxa Hospital, Department of Endocrinology, Pireaus,
3Asclepeion Hospital, Department of Rheumatology,
Athens, Greece
Objective(s): Vitamin D deficiency has been implicated
in the pathogenesis of autoimmune diseases, such as
diabetes mellitus type 1 and multiple sclerosis. Reduced
vitamin D intake has been linked to increased suscepti-
bility to the development of rheumatoid arthritis (RA)
and vitamin D deficiency has been found to be associ-
ated with disease activity in RA patients. The aim was
to evaluate vitamin D status in RA patients and to
assess the relationship between vitamin D levels and
disease activity.
Material & Methods: In a cohort of 44 patients suffering
from RA 25(OH)D3 levels, PTH levels, C-reactive protein
and ESR were measured. Disease activity was evaluated by
calculating the DAS28 score. A control group (n=44),
matched for age and sex, was evaluated as well. All patients
fulfilled the American College of Rheumatology criteria for
the classification of RA.
Results: In the cohort of 44 RA patients 25(OH)D3 levels
were found to be low as compared to the control group, 25
(OH)D3 being 15.36±1.09 ng/ml and 24.9±1.2 ng/ml, in the
patient and control group, respectively (Student's t test,
p<0.05). PTH levels were 70.82±7.22 pg/ml (normal values
10.0-65.0 pg/ml), CRP 7.59±1.64 mg/l (normal values <3
mg/l) and ESR was 36.7±4.5 mm/h in the group of RA
patients. Levels of 25(OH)D3 were found to be negatively
correlated to the DAS28 score, correlation coefficient being
-0.065. Levels of 25(OH)D3 were also found to be nega-
tively correlated to CRP and ESR, correlation coefficient
being -0.11 and -0.16, respectively.
Conclusion(s): It appears that vitamin D deficiency is high-
ly prevalent in RA patients, and that vitamin D deficiency
may be linked to disease severity in RA. As vitamin D
deficiency has been linked to diffuse musculoskeletal pain,
these results have therapeutic implications. Vitamin D sup-
plementation may be needed both for the prevention of
osteoporosis as well as for pain relief in rheumatoid arthritis
patients.
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BENEFIC EFFECT OF THE USE OF FLEXIBLE
AND MINIMALIST FOOTWEAR ON KNEE
OSTEOARTHRITIS
Francis Trombini-Souza1, Mariane Yokota1, Alessandra
Matias1, Cláudia Goldenstein-Schainberg2, Ricardo Fuller2,
Isabel CN Sacco1
1Universidade de Sao Paulo, Physical Therapy, Speech and
Occupational Therapy, 2Rheumatology, Sao Paulo, Brazil
Objective(s): To analyze the therapeutic effect of chronic
use of the flexible, nonheeled commercial shoe Moleca®
on clinical aspects of women with knee osteoarthritis
(OA).
Material & Methods: Six women with an established di-
agnosis of knee OA according to ACR criteria were evalu-
ated after assignment of approved informed consent. The
intervention consisted of the use for a 6 month period of
Moleca® footwear (RS, Brazil) for at least 6hours daily and
for 7 days a week. This is a light (mean weight=172±19.6 g,
range 142-193 g depending on size) double canvas flexible
flat walking shoe nonheeled, with a 5-mm antislip rubber
sole and a 3-mm internal wedge of ethylene vinyl acetate.
Assessment was done at baseline and 6 months later. All
patients were screened and evaluated by a rheumatologist at
baseline for clinical examination and x-rays. Subsequent
procedures were performed by the same physiotherapist to
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assess pain (visual analogue scale – VAS), WOMAC index
and knee adduction moment during gait calculated by in-
verse dynamics method using 6 infrared cameras and a
multicomponent force plate. T-test was used to compare
pre/post intervention effects and P<0.05 was considered
significant.
Results: Mean age of patients was 69±6 yrs, weight=65.9±
12.1 kg, height=152±5 cm, BMI=28.6±4.9 kg/cm2. All women
had knee OA grade 2 or 3 (Kellgren-Lawrence). Average use of
Moleca® was 7:24±3:47 h monthly. Remarkably, 6 months
after intervention, a reduction of 56.6% and 73.9% of VAS
for pain at night and at the moment of assessment, respectively,
was observed (P=0.048 and P=0.015). Total WOMAC score
diminished 44.9% (p=0.001), WOMAC pain subscale de-
creased 55.2% (p=0.015), and WOMAC function index im-
proved 43.6% (p=0.004). The first (p= 0.533) and the second
(p=0.686) knee adduction moment peaks were alike, while
significant reduction of 11.2% in knee loading (p=0.001) was
achieved during midstance.
Conclusion(s): We have demonstrated in this pilot study
that elderly women with knee OA have a benefit effect on
pain and function following a 6 month period of use of a
specific flexible, nonheeled shoe. These preliminary results
warrant further studies aiming to evaluate long term benefit
of this intervention in a larger sample population.
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BONE MINERAL DENSITY RESPONSE TO
INTRAVENOUS PAMIDRONATE IN WOMEN WITH
OSTEOPOROSIS – PRELIMINARY ANALYSIS
Leila C Bianchet, Cristina Marcatto, Carolina AM Kulak,
Nadila CR Mañas, Cassio S Ramos, Victoria ZC Borba
Serviço de Endocrinologia do Hospital de Clínicas da Uni-
versidade Federal do Paraná, Endocrinology, Curitiba, Paraná,
Brazil
Objective(s): Use of bisphosphonates for osteoporosis
treatment is effective in reducing fracture risk, however
oral formulations are sometimes not well tolerated or
contraindicated by diseases of the gastrointestinal tract.
The availability of intravenous pamidronate in the health
care system makes this medication often prescribed to
treat osteoporosis, despite the lack of studies that prove
their antifracture efficacy and not approved by the FDA
for this purpose. The objective of this study was to
evaluate the therapeutic response of pamidronate in a
group of women with osteoporosis through the gain in
BMD over a period of 36 months.
Material & Methods:We evaluated retrospectively based
on chart review, 127 patients that received Pamidronate
during a period of 4 years. Clinical data and BMD
results were evaluated by DXA at 0, 12, 24 and 36
months of treatment. We stratified the patients according
to an arbitrary criteria in patients with or without high
risk of fracture.
Results:We excluded from the final analysis 53 patients for
different reasons. The final study consisted of 74 women,
mean age 68 years, the majority (93%) were white and with
high risk of fracture 74%. We observed a significant gain in
lumbar spine BMD after 36 m (p=0.006), with maintenance
in early times. For the subgroup without high risk of frac-
ture, significant gain was observed at 24 and 36 months
(p=0.018 and 0.002, respectively). Femoral BMD was
maintained, without significant gain. A negative correlation
between serum PTH and BMD was noted, and for each
increase of 1 pg/ml in PTH a reduction of 0.61 g/cm2 in
BMD was observed.
Conclusion(s): Considering the BMD response, pamidro-
nate was safe and effective in treating women with osteo-
porosis with better results at the lumbar spine in patients
without a high risk of fractures.
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ANALYSIS OF OSTEOPOROSIS RISK-FACTOR
FOR WOMEN AFTER MENOPAUSE: THROUGH
THE FREE MEDICAL-EXAMINATION CAMPAIGN
Sung Hwa Seo1, Il Hyung Park2
1Kyungpook National University, Department of Biomedical
Sciences, 2School of Medicine, Department of Orthopaedic
Surgery, Daegu, Republic of Korea
Objective(s): We performed research and analysis to deter-
mine the risk factors of osteoporosis for women after men-
opause by conducting a survey and measuring the bone
density through a free program to diagnose osteoporosis.
Material & Methods: Kyungpook National University
organized and then started the free osteoporosis diagnosis
program on May 11, 2005. One hundred forty six women
whose age was between the early forties and late eighties
took the survey. The risk factors for osteoporosis were
analyzed according to the data which was obtained from
the survey. The measurements of the BMD of right
calcaneus area were recorded by the use of ultrasound
equipment.
Results: Within the results, between the advancing age
(P=0.000) of subjects, the lower BMI (P=0.002), the
more children (P=0.004), the breast fed longer
(P=0.047), the individuals who had a lower age when
menopause began (P=0.037) and their BMD showed
significant correlation.
Conclusion(s): The results express that the osteoporosis
risk-factors for Korean women, despite the advancing
age and the lower BMI as absolute factors, that the
more children, the longer breast feeding and the lower
the age that menopause began, would result in a lower
density of bone.
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COULD BMD REFLECT THE REAL CHANGE
IN HUMAN BONE MINERAL?
Sung Hwa Seo1, Hyung Tae So2, Il Hyung Park2
1Kyungpook National University, Department of Biomedical
Sciences, 2Medicine, Department of Orthopaedic Surgery,
Daegu, Republic of Korea
Objective(s): BMD is an important index in diagnosing
osteoporosis and other metabolic bone diseases, predicting
fractures, and monitoring treatment. DXA is most widely
used technique for assessments of BMD and considered as
the gold standard for the minimum exposure to radiation,
low cost, high reproducibility, and ease of use. Author
performed an experimental study to determine the relation-
ship between the change in BMD measured by DXA and
real change in mineral of human long bone.
Material & Methods: A pair of humeri and femora from
one male cadaver was cut into specimen about half in
length. Demineralized area of 3 specimens from a pair of
humerus and 4 specimens from a pair of femur were im-
mersed into 1 N HCl from 10 min to maximum 70 min with
10 min intervals for different level of demineralization. All 7
specimens were checked with BMD using by DXA (GE-
Lunar Prodigy) and analysed respectively. The amount of
calcium and phosphorus both from demineralized and nor-
mal area were measured and expressed in percentage of
demineralizatioin.
Results: As demineralization was going on with time of
immersion into HCl, there was statistically significant cor-
relation between the change of BMD and real change of
calcium amount (γ=0.65) in humerus, and also in femur
(γ=0.63). There was statistically significant correlation only
in femur between BMD and phosphorus (γ=0.77), and not
in humerus (γ=0.42). In summary, there was a high linear
regression between BMD and real bone mineral with min-
imum of 89% and maximum of 97% as coefficient of
determination (R2) (p<0.05). Through correlation analysis,
correlation coefficient (γ) between BMD measured by DXA
and mineral of human long bone showed a high correlation
as maximum of 0.84 (p<0.05).
Conclusion(s): Our study showed a statistically significant
high relationship between BMD measured by DXA and
mineral of human long bone. Therefore, the measurement
of DXA is considered to reflect the real change of mineral in
human long bone as well as that of BMD. The limitation of
this study was that it was based on artificially induced
demineralization only one pair of cadaveric humerus and
femur so that vertebrae were excluded.
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BONE MINERAL DENSITY, IL-1β AND TNF α
IN PATIENTS WITH OSTEOARTHRITIS
Chau Ngoc Nguyen, De Van Doan
103 Hospital - Viet Nam Military Medical University, Rheu-
matology and Endocrinology, Ha Noi, Viet Nam
Objective(s): Our study to investigate the relationship be-
tween osteoarthritis (OA) and osteoporosis (OP).
Material & Methods: The study was carried out in 103
Hospital of Vietnam Military Medical University (VMMU)
from October 2009 - October 2010. 101 patients with OA
and 53 healthy individual to determine concentration of IL-
1β and INFα in serum by flow cytometry-assisted immu-
noassay with Bio-Plex kit. They also to evaluate the BMD
by DXA (Hologic system).
Results: The results showed that:
– Concentration of both cytokine in patient group is
higher than healthy individual group (p<0.001).
– BMD of patient group is lower than healthy individual
group (p<0.001).
– The study found out a relation between the percentage
of the patients with higher concentration of IL-1β,
TNFα and osteopenia also osteoporosis.
Conclusion(s): The results of our study showed that OA
may induce the OP. IL-1β and INFα were involved to the
not only pathology of OA but also the pathology of OP.
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VITAMINDDEFICIENCYANDGASTROINTESTINAL
DISORDERS
Ifigenia Kostoglou-Athanassiou1, Nicolaos Dadiras2,
Aikaterini Michou1, Aikaterini Chronaiou1, Dimitrios
Stefanopoulos1, Eirini Koutsika2, Aikaterini Tzanavari2,
Dimitra Basdragianni2, Panagiotis Athanassiou2
1Red Cross Hospital, Department of Endocrinology, Athens,
2St. Paul's Hospital, Department of Rheumatology, Thessa-
loniki, Greece
Objective(s): Vitamin D deficiency is increasingly recognized
today having taken the form of a modern epidemic. Vitamin D,
being synthesized in the skin under the effect of ultraviolet light
has been originally thought of as occurring only in areas of the
world where people are not exposed to the sun. However, it has
recently been observed that vitamin D deficiency exists even in
sunny areas. Recent observations suggest that vitamin D defi-
ciency is related to significant comorbidity, specifically to the
occurrence of diabetes mellitus and cardiovascular disease.
Observations also correlate vitamin D deficiency with gastro-
intestinal disorders, including gastritis, Helicobacter pylori in-
fection and cholocystectomy. The aim of the study was to
describe the relationship between vitamin D deficiency and
gastrointestinal disorders.
Material & Methods: A group of 52 consecutive patients
diagnosed with vitamin D deficiency aged (62.77±10.48
Osteoporos Int (2012) 23: (Suppl 2):S85–S386 S357
years, mean±SD), 45 women and 7 men are described.
Vitamin D was measured by radioimmunoassay.
Results: BMI was 30.26±5.83, glycosylated hemoglobin
HbA1c was 7.5±2.11% and 25(OH)D3 was 11.8±4.03 ng/
ml. Amongst the group of 52 patients with vitamin D
deficiency 14 had undergone cholocystectomy and had gas-
tritis and 3 had Helicobecter pylori infection diagnosed by
gastroscopy and subsequent histology.
Conclusion(s): These data show that vitamin D deficiency
is associated with significant comorbidity. Gastrointestinal
disorders seem to be related to vitamin D deficiency. Chol-
ocystectomy and gastritis, as well as Helicobacter pylori
infection, may affect the absorption of vitamin D2 from
the gastrointestinal tract and may thus be related to the
aetiology and pathophysiology of vitamin D deficiency in
this group of affected patients.
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VITAMIN D AND OBESITY
Ifigenia Kostoglou-Athanassiou1, Thomais Terzi1, Aikaterini
Chronaiou1, Thomas Georgoulas1, Aikaterini Michou1,
Nicolaos Dadiras2, Eirini Koutsika2, Aikaterini Tzanavari2,
Anna Papadaki2, Panagiotis Athanassiou2
1Red Cross Hospital, Department of Endocrinology, Athens,
2St. Paul's Hospital, Department of Rheumatology, Thessa-
loniki, Greece
Objective(s): Low vitamin D levels have been found in
patients with diabetes mellitus type 2 and have been
correlated with poor glycemic control. There are obser-
vations suggesting that vitamin D levels may be low in
obesity. The aim was to study vitamin D levels in obese
individuals.
Material &Methods: The levels of 25(OH)D3weremeasured
in 30 obese individuals aged 42.67 years (mean), range 27-64,
BMI 35.49 (mean), range 30-46 and 37 control subjects, aged
58.3 years (mean), range 33-83, BMI 24.9, range 21-29. The
levels of 25(OH)D3 were measured by radioimmunoassasy.
Results: Vitamin D levels were lower in the obese patients
than the control subjects, levels being 21.87±12.36 ng/ml
(mean±SD) in the obese patients as compared to
38.42±15.31 ng/ml in the control group, p<0.05 (Student's
t test).
Conclusion(s): It appears that vitamin D levels may be
low in obesity. The aetiology of low vitamin D levels in
obesity is still obscure. Vitamin D may be stored in the
fat and thus its real levels within the body may be
normal, low levels being detected only in the blood.
Alternatively, vitamin D may be destroyed in obesity,
as a result of increased oxidative reactions occurring in
the context of obesity. Thus, low vitamin D levels may
be another pathophysiological mechanism resulting in
increased morbidity in the obese.
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PRIMARY HYPERPARATHYROIDISM AND
VITAMIN D DEFICIENCY
Ifigenia Kostoglou-Athanassiou1, Thomas Georgoulas1,
Thomais Terzi1, Olympia Karagianni1, Stylianos Kotanoglou1,
Nicolaos Dadiras2, Eirini Koutsika2, Aikaterini Tzanavari2,
Panagiotis Athanassiou2
1Red Cross Hospital, Department of Endocrinology, Athens,
2St. Paul's Hospital, Department of Rheumatology, Thessa-
loniki, Greece
Objective(s): Primary hyperparathyroidism is a rather fre-
quent disorder characterized by high plasma PTH levels and
high plasma calcium levels. Vitamin D deficiency is preva-
lent in all areas of the world, being however very frequent in
old age. Vitamin D deficiency has been described in patients
with primary hyperparathyroidism. When present, vitamin
D deficiency may be associated with large size parathyroid
adenomas and poses therapeutic dilemmas, as calcium and
vitamin D supplementation may increase PTH levels. The
aim was to describe the case of a patient with primary
hyperparathyroidism and vitamin D deficiency.
Material & Methods: A patient, male aged 87 years, was
hospitalized for coronary insufficiency. During hospitaliza-
tion high plasma calcium was observed, calcium levels
being 10.5 mg/dl.
Results: Laboratory investigations revealed high plasma
PTH levels, PTH being 117 pg/ml (normal values 10-65
pg/ml) and low plasma 25(OH)vitamin3 levels, 25(OH)D3
being 8 ng/ml (normal values <30 ng/ml). BMD was mea-
sured in the neck of the left femur and revealed a T-score of -
3.05. Vitamin D supplementation was initiated followed by
the administration of alendronate. Ultrasonography revealed
an adenoma beneath the right lobe of the thyroid gland.
Conclusion(s): Vitamin D deficiency may be found in the
context of primary hyperparathyroidism. When present, vi-
tamin D supplementation should be initiated cautiously, as it
may aggravate the clinical picture of primary hyperparathy-
roidism. Cautious vitamin D supplementation is however
necessary and will not cause an increase in plasma calcium
and PTH levels.
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TRABECULAR BONE TEXTURE MEASUREMENT:
A REVIEW OF AVAILABLE TECHNIQUES AND
OF EMERGING APPLICATIONS
Jean Chaintreuil
D3A Medical Systems, Orsay, France
Objective(s): The WHO working group on Osteoporosis
recognized in 1993 that this bone disease is dual, character-
ized by a gradual loss of calcium content and a destruction
of bone architecture. Both aspects certainly play a role in the
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bone fragility observed in osteoporosis. The loss of calcium
content has been extensively studied by measuring BMD.
Bone texture has remained largely inaccessible.
Material & Methods: Histomorphometric parameters de-
scribed by Parfitt et al, such as Trabecular Number, Trabec-
ular Thickness, Trabecular Spacing, Bone Volume/Total
Volume, remain the gold standard of bone texture measure-
ment. A limitation in their usage is the requirement for a
bone biopsy in order to perform a microscopic assessment.
Results: Attempts to develop a noninvasive quantification
of bone texture have explored different approaches, which
can be classified as three-dimensional and two-dimensional.
High resolution MRI belongs to the first category; various
texture parameters have been defined, using a skeleton
graph analysis technique, which correlate with the thinning
of trabeculae in osteoporotic bone. Also three-dimensional,
the High Resolution peripheral QCT allows the determina-
tion of apparent histomorphometric parameters that corre-
late with the Parfitt parameters. It has been largely
demonstrated that information contained in a three-dimen-
sional structure is transferred to its two-dimensional projec-
tion, as performed by a high resolution X-Ray. This
technique has particularly retained the attention due to its
ease of use and better economic performance. From the X-
Ray image of a bone, different sets of parameters have been
derived, the majority of them based on an analysis of the
fractal geometry of the image and the determination of its
fractal dimension.
Conclusion(s): Changes in bone texture have been shown to
occur in osteoporosis. Used in combination with bone den-
sitometry, the texture parameters appear to improve the
prediction of bone fragility. Changes also occur in the sub-
chondral bone in Osteoarthritis and are reported to be sen-
sitive to treatment. More recently, it was also found that
rheumatoid arthritis disturbs the texture of the subchondral
bone.
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VITAMIN D LEVELS IN CHILDREN OF VITAMIN D
DEFICIENT IMMIGRANT MOTHERS
Bergström I 1,2, Blanck A 2,3, Sävendahl L4,5,
1Division of Endocrinology, Metabolism and Diabetes,
Karolinska University Hospital, Huddinge, 2CLINTEC,
Karolinska Institutet, Stockholm, 3Center for Obstetrics
and Gynecology, Karolinska University Hospital, Huddinge,
4Division of Pediatric Endocrinology, Karolinska University
Hospital, Solna, 5Department of Women’s and Children’s
Health, Karolinska Institutet, Stockholm, Sweden
Objective(s): It is important that the mother is vitamin D-
sufficient enabling her to cope with the increased need of
calcium during pregnancy when the fetus accretes large
amounts of calcium. During pregnancy, vitamin D is
transferred through the placenta to the fetus where it is
stored. Consequently, the mother must increase her vitamin
D intake to avoid deficiency. In the newborn, vitamin D
stores are depleted by approximately 8 weeks of age, if not
supplemented. Breast fed infants are at risk of becoming
deficient as the amount of vitamin D taken up from the
breast milk is low. I, Sweden, it is recommended to supple-
ment all infants with 10 μg (400 IE) of vitamin D3 daily
starting from 2 weeks of age. We aimed to study if this
recommendation is sufficient in infants of vitamin D defi-
cient immigrant mothers.
Material & Methods: We characterized a cohort of 68
pregnant immigrant women living in Stockholm and com-
pared their vitamin D levels with 51 nonimmigrant pregnant
women. The levels of 25 (OH) VitD3 was measured with a
competitive RIA (Dia Sorin, Stillwater, MN). Intra-assay
and interassay variations were 5% and 9%, respectively.
Results: Of the immigrant pregnant women, 77.9% had 25
(OH) VitD3 levels <25 nmol/L and of those 29.4% had
levels <12 nmol/L. In contrast control subjects only 3.9%
had vitamin D levels <25 nmol/L and none of these had a
level <12 nmol/L. We also made an attempt to monitor the
infants of immigrant mothers and were able to follow 25/64
born infants up to the age of 6-12 months. Their mothers
originated from Middle Asia (16), Africa (7) and South
America (2). All newborns had normal birth weight and
Apgar scores. The table details 25 (OH) VitD3 levels in
the pregnant mothers (at week 12 and at delivery), in the
umbilical cord at delivery, and in the infants at 6-12 months
of age. Unfortunately, calcium levels could only be mea-
sured in 11/25 newborns and were then found to range
between 2.3-3.0 mmol/L which is normal. None of the
children were reported to have a history of hypocalcemic
seizures or any other condition leading to hospitalization. As
shown in the table, most children had normal levels of
vitamin D when assessed at 6-12 months of age (range 38-
142 nmol/L) and none of them were severely deficient.
Conclusion(s): The daily recommended supplementation
dose of 10 μg vitamin D3 is sufficient for children of
vitamin D deficient immigrant women. Furthermore, our
data suggest that compliance is good with the recom-
mended vitamin D supplementation. A well organized
network of well-baby clinics may have facilitated the
good outcome.
Mother; week
12 (n=25)
Mother; at
delivery
(n=12)
Umbilicus
cord (n=12)
Infant; 6-12
mth (n=25)
25 OH
vit D3
14.8 (4.6) 15.4 (8.7) 23.3 (11.1) 82.8 (29.7)
nmol/l
(range)
(10-28) (10-39) (20-54) (38-142)
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ESTABLISHMENT OF PARATHYROID HORMONE
(PTH) REFERENCE RANGE ON 10 DIFFERENT
ASSAY KITS: IMPACT OF THE RECRUITMENT OF
THE POPULATION
Etienne Cavalier1, Jean-Claude Souberbielle2
1University Hospital of Liege, CHU Sart-Tilman, Clinical
Chemistry, Liege, Belgium, 2Hôpital Necker-Enfants Mal-
ades, Laboratoire d'Explorations Fonctionnelles, Paris,
France
Objective(s): Reference values (Rv) for serum PTH levels are
generally obtained by measuring PTH in a apparently healthy
subjects population. Exclusion criteria are important and
should correspond to any causes of altered PTH secretion,
including vitamin D (VTD) insufficiency, very frequent in the
general population and thus prevalent in an apparently healthy
group. However, excluding VTD insufficient subjects requires
the measurement of 25-hydroxy vitamin D (25OHD) levels,
which was not considered in most studies which provided
serum PTH Rv for different immunoassays. Some studies
have shown that this could decrease the upper normal limit
for PTH by 25-35% depending on the assay considered. Thus,
for a given PTH assay, the Rv may significantly vary, depend-
ing on the reference population that has been recruited, and
especially whether the VTD status has been taken into ac-
count. We thus used the same reference population of VTD-
replete normal subjects to establish Rv for 10 PTH kits and
compare them with those provided by the manufacturers.
Material & Methods:We selected 120 apparently healthy
Caucasian women (48.6±15.2 y., min-max: 20-79), and
men (51.5±17.5 y., min-max: 19-80). Inclusion criteria
were a 25OHD concentration ≥75 nmol/L, serum calcium
and phosphate levels comprised between 2.15-2.60 and
0.74-1.51 mmol/L, respectively, and an estimated GFR
≥60 mL/min/1.73 m2. The use of drugs known to influ-
ence bone and calcium/phosphorus metabolism was an
exclusion criteria.
Results: There was no significant difference in PTH
levels nor in age between men and women. With all the
tested PTH assays, the distribution of the concentrations
was Gaussian. The results observed were lower than the
Rv provided by the manufacturers with an upper normal
limit only slightly different for 3 kits (Abbott Architect,
DiaSorin Liaison N-tact and Ortho Vitros) but frankly
lower (21-46.1%) for the 7 other kits. The difference was
most important for the Beckman Access (-46.1%), the
DiaSorin N-tact IRMA (-33.9%), and the DiaSorin Liaison
1-84 (-32.8%).
Conclusion(s): An important multicentre work should be
performed to recruit a very extensive reference population
of vitamin D-replete, apparently healthy subjects in order to
establish the PTH Rv for all the available kits.
P668
ASSOCIATION OF SERUM OSTEOCALCIN AND
AORTIC CALCIFICATIONS IN THE MEN
FROM MINOS STUDY
Cyrille B. Confavreux1, Pawel Szulc1, Stéphanie Boutroy1,
Annie Varennes2, Nicolas Vilayphiou1, Joelle Goudable3,
Roland D. Chapurlat1
1INSERM U1033 – Université de Lyon, Department of
Rheumatology, Hôpital Edouard Herriot, Hospices Civils
de Lyon, 2Université de Lyon, Central Biochemical Labo-
ratory, Hôpital Edouard Herriot, Hospices Civils de Lyon,
3INSERM U1060 – Université de Lyon, Lyon, France
Objective(s): Metabolic syndrome (MetS) is associated to an
increased risk of cardiovascular events. As osteocalcin deficient
mice present a metabolic syndrome-like phenotype, we hypoth-
esized that there may be a link in humans between osteocalcin,
MetS and abdominal aortic calcifications (AAC), an interme-
diate criterion of the risk of cardiovascular events.
Material & Methods: We performed a cross-sectional anal-
ysis in the 798 men aged 51-85 of the MINOS cohort. We
used the recent harmonized criteria to define MetS (Alberti et
al. Circulation 2009). We assessed AAC semi-quantitative
score from the lumbar spine radiographies according to Kaup-
pila’s method. Blood was collected in the fasting status.
Results: Blood glucose was correlated with BMI (r=0.26;
p<0.001) and osteocalcin (r=-0.22; p<0.001). Median [IQR]
of osteocalcin was lower in patients with MetS than in normal
patients (17.4 ng/mL [8.0] vs. 18.5 ng/mL [7.5]; p=0.01).
Serum osteocalcin was negatively correlated with the severity
of MetS based on the number of MetS traits (p<0.001). Osteo-
calcin decreased across tertiles of AAC score and was lower in
men with more calcifications (AAC score >4) (p<0.005). The
highest serum osteocalcin concentrations were associated to a
lower prevalence of high calcification score (OR=0.78 [0.64-
0.94] per SD increase; p=0.01) in the multivariate logistic
regression adjusted for age, smoking, hypertension, sport ac-
tivity, vitamin K antagonist, serum level of creatinine, phos-
phorus, HDL-cholesterol, 25OHD, triglycerides and
testosterone. In the multi-adjusted logistic regression model,
the lowest quartile of osteocalcin was associated with higher
prevalence of AAC score >4 compared with the three upper
quartiles (OR=1.72 [1.14-2.60]; p<0.01). In a stepwise logistic
regression including other biochemical bone turnover markers
(sCTX, P1NP, BSAP), osteocalcin was the only bone marker
retained in the model and significantly associated with the
aortic calcification score (OR=0.80 [0.65-0.77] per SD in-
crease; p=0.02).
Conclusion(s): In this cohort of older men, we found that
higher serum osteocalcin level was independently associat-
ed with lower prevalence of MetS and less severe AAC.
Osteocalcin level might be an independent cardiovascular
risk factor.
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RISK FACTORS FOR HIP OSTEOARTHRITIS
Karmela Filipovic1, Nada Naumovic2, Branislav Bobic3,
Jelena Zvekic Svorcan4, Biljana Erdeljan, Milijanka Lazarevic
1Rheumatology, Special Hospital for Rheumatic Diseases,
2Neuropshyology, Faculty Medicine, Novi Sad, Serbia
Objective(s): To evaluate individual risk factors for hip
osteoarthritis
Material & Methods: The research included 148 respond-
ents, aged 55-75 years. Research was conducted during
2009 in Special Hospital for Rheumatic Diseases in Novi
Sad. All responders were divided into two groups. The first
group (n=74) was diagnosed hip osteoarthritis, according to
the classification criteria set by the American College of
Rheumatology. The second group (n=74) who based on the
conducted diagnostic procedure, were excluded from having
the hip osteoarthritis. Before they included, all examinees
were a part of the diagnostic procedure during which the
diagnosis was established, or excluded. The diagnostic pro-
cedure involved: anamnestic data with emphasis of hip pain;
physical examination; radiography of hip, as well as collect-
ing data through with interview. A conversation in the form
of an interview was conducted with each examine. Exam-
inees filled in identical questionnaires. As a part of identi-
fying the presence/ absence of the observed risk factors the
following data were monitored: ages, gender, overweight
verified by the BMI≥25 kg/cm2; presence / absence of
anamnestic data on the existence of hip osteoarthritis in
family; vertical load of the hip during professional activity.
Examines were classified into groups depending on the load
hip: sitting job and standing job with heavy lifting.
Results: The research didn’t show any difference regarding
the gender between groups. Ratio between men and women
in the first group was much in favour of women. Positive
family anamnesis for hip osteoarthritis was prevalent in the
first group. In the first group, weight mean±SD kg/cm2
(81.82±12.18) and BMI mean±SD kg/cm2 (30.18±4.6). It
was statistically significant between groups ( p 0.01). Also
found more respondents (87.8%) from the first group was
overweight, BMI ≥25.5 kg/cm2 . It was statistically significant
between groups (p 0.01). Standing job with heavy lifting was
prevalent in the first group of respondents (62%). It was
statistically significant between groups ( Fisher test, p 0.05).
Conclusion(s): Positive anamnesis for hip osteoarthritis,
overweight, standing job with heavy lifting are important
independent risk factors for hip osteoarthritis
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AVERY HIGH PREVALENCE OF VITAMIN D
INADEQUACY COMBINED WITH LOW DIETARY
CALCIUM INTAKE IS FOUND IN EUROPEAN
POSTMENOPAUSALWOMEN
Olivier Bruyère, Fanny Buckinx, Jean-Yves Reginster
CHU Liège, Unité d'Exploration de l'Os et du Cartilage,
Liège, Belgium
Objective(s): A lack of calcium intake and a low vitamin D
level represent a risk factor for osteoporosis. The recom-
mended nutritional intake of calcium is equal to 800 mg/day
for European adults but increases to a minimum of 1000 mg/
day in women after menopause. The WHO recommends
1300 mg/day for European menopausal women. There are
no clear international agreements on what constitutes a level
of vitamin D inadequacy, but recent publications suggest
that the circulating level of vitamin D should be over 80
nmol/L or at least between 50-80 nmol/L. The objective of
this study was to assess the prevalence of low calcium
dietary intake combined with low vitamin D level in
European postmenopausal osteoporotic women.
Material & Methods: The assessment of calcium dietary
intake with a validated self-questionnaire and of 25-hydrox-
yvitamin D [25(OH)D] with a commercial radioimmunoassay
(DiaSorin) was performed in 8532 osteoporotic European
women from 9 European countries (i.e., Belgium, Denmark,
France, Germany, Hungary, Italy, Poland, Spain, UK).
Results: Mean age of the women was 74.2 (7.1) years with
a BMI of 25.7 (4.2) kg/m². The level of 25(OH)D was 61.0
(27.2) nmol/L and the mean calcium dietary intake was
930.7 (±422.9) mg/day. Surprisingly, only 108 of out the
8532 patients (=1.18%) included in this study have a calci-
um intake superior to 1300 mg and a 25(OH)D level supe-
rior to 80 nmol/L. This prevalence only increase to 27.1%
when minimal cutoff levels of 800 mg of calcium and 50
nmol/L of vitamin D are considered.
Conclusion(s): Calcium dietary intake and vitamin D level
are very low in European postmenopausal women. A greater
awareness is needed to resolve this public health problem.
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SEVERE PREVALENT VERTEBRAL FRACTURES
PREDICT SUBSEQUENT VERTEBRAL AND
NONVERTEBRAL FRACTURES: A 3-YEAR
PROSPECTIVE STUDY
O. Bruyere1, C. Roux2, D. Nicolet1, J. Fechtenbaum2, R.
Deroisy1, J.Y. Reginster1
1Department of Epidemiology, Public Health and Health
Economics, University of Liege, Liege, Belgium, 2Depart-
ment of Rheumatology, Cochin Hospital, Paris, France
Objective(s): To examine whether a prevalent severe verte-
bral fracture predicts subsequent fracture and to assess the
effect of strontium ranelate to reduce fracture in patients
with such prevalent severe vertebral fracture.
Material & Methods: Analysis of two 3-year randomized
controlled trials investigating the clinical effect of strontium
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ranelate. Vertebral and major non-vertebral fractures (i.e.,
ribs sternum, wrist region, pelvic sacrum, collarbone, hu-
merus, proximal femur) were assessed during the 3 years. At
baseline on standard radiographs, each vertebra received a
severity grade corresponding to either no fracture either a
mild, moderate or severe fracture based on a semiquantitative
visual assessment. All women received calcium and vitamin
D during the whole length of the study.
Results: 6137 women aged mean (SD) 75.1 (6.1) years were
included in this study. In the placebo group, after 3 years of
follow-up, 43% of the women with a prevalent severe vertebral
fracture had experienced a new vertebral fracture compared to
only 12.5% of the women without any vertebral fracture (OR
3.46 [2.87-4.18]). The logistic regression analysis, adjusted for
age, BMI, femoral neck BMD and number of prevalent verte-
bral fractures, showed that the presence of a severe vertebral
fracture was significantly associated with new vertebral frac-
tures over a 3-year follow-up period. In women with severe
prevalent vertebral fracture (N=680), strontium ranelate was
able to significantly reduce the risk of new vertebral fractures
(OR 0.75 [0.61-0.91]).
Conclusion(s): In summary, severe prevalent vertebral frac-
ture is an independent predictor of new vertebral and non-
vertebral fractures that could be taken into account in
fracture risk management.
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RELATIONSHIPS BETWEEN CHANGES IN BONE
MINERAL DENSITYAND VERTEBRAL FRACTURES
INCIDENCE: AN ANALYSIS OF THE LAST
2 YEARS OFA 10-YEAR TREATMENTWITH
STRONTIUM RANELATE
Olivier Bruyère, Jean-Yves Reginster
University of Liege, Liege, Belgium
Objective(s): We have previously shown that, in women
treated for 3 years with strontium ranelate, an increase in hip
BMD, but not spine BMD, was associated with a propor-
tional reduction in vertebral fracture incidence (Bruyere et
al, J Clin Endocrinol Metabol, 2007). As a matter of fact,
each 1% in femoral neck or total proximal femur BMD was
associated with decreased risk to experience a new vertebral
fracture by 3% (95% adjusted CI 1%-5%) and 2% (1%-4%),
respectively. Some women have now been treated for 10
years with strontium ranelate. Our objective is to assess the
relationship between change in BMD and vertebral fracture
incidence in the last 2 years of the 10-year treatment.
Material & Methods: We have included women from the
strontium ranelate arm of the Spinal Osteoporosis Therapeu-
tic Intervention study (SOTI) and the TReatment Of Periph-
eral OSteoporosis study (TROPOS) having received the
treatment for 10 years.
Results: 116 women with femoral neck and total hip BMD
and fracture data available during the 10 years of follow-up
were included in the present analysis. During the last two
years of follow-up, 12 patients experienced a new vertebral
fracture. After having controlled for age, BMI at year 9, BMD
at year 9, number of vertebral fracture at year 0, number of
new vertebral fracture from year 0 to year 8, we found that the
BMD change at the femoral neck from years 9 to 10 was
significantly associated with vertebral fractures incidence dur-
ing the same period of time (p=0.03). Each 1% increase in
femoral neck BMDwas associated with a 15% (95% adjusted
CI 2-26%) decreased risk to experience a new vertebral frac-
ture. The same trend was observed for total hip BMD (7%
[95%CI -3% to 17%) but it did not reach statistical signifi-
cance (p=0.16). Women with new vertebral fractures from
years 9-10 experienced during the same period a decrease of
2.4 (4.7)% in femoral neck BMD, compared to an increase of
1.5 (8.3)% in women without new vertebral fracture.
Conclusion(s): During the last 2 years of a 10-year treat-
ment with strontium ranelate, the increase in femoral neck
BMD was associated with a proportional reduction of the
incidence of new vertebral fractures. These results confirm
that the assessment of femoral neck BMD could be of
interest to monitor women treated with strontium ranelate.
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EFFECT OF COLLAGEN HYDROLYSATE IN
ARTICULAR PAIN: A 6-MONTH RANDOMISED,
DOUBLE-BLIND, PLACEBO CONTROLLED STUDY
O. Bruyère1, B. Zegels1, L. Leonori1, V. Rabenda1, A.
Janssen1, C. Bourges2, J.Y. Reginster1
1Department of Public Health, Epidemiology and Health
Economics, University of Liège, Liege, Belgium, 2Nutraveris,
France
Objective(s): Evaluation of the efficacy and safety of a food
supplement made of collagen hydrolysate 1200 mg/day vs.
placebo during 6 months, in subjects with joint pain at the
lower or upper limbs or at the lumbar spine.
Material & Methods: Comparative double-blind random-
ized multicenter study in parallel groups including 200
patients of both genders of at least 50 years old with joint
pain assessed as ≥30 mm on a visual analogical scale
(VAS). Patients were randomised to receive collagen hy-
drolysate 1200 mg/day or placebo during 6 months. The
primary outcome was the comparison of the percentage of
clinical responder between the active collagen hydrolysate
group and the placebo group after 6 months of study. A
responder subject was defined as a subject experiencing a
clinically significant improvement (i.e., by 20% or more)
in the most painful joint using the VAS score. Quality of
life changes was assessed using the EQ-5D and the SF-
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36. All analyses were performed using an intent-to-treat
procedure.
Results: At 6 months, the proportion of clinical responders
to the treatment, according to VAS scores, was significantly
higher in the collagen hydrolysate (CH) group 51.6%, com-
pared to the placebo group 36.5% (p<0.05). However, there
was no significant difference between groups at 3 months
(44.1% vs. 39.6%, p=0.53). No statistically significant dif-
ference was observed between groups, neither concerning
the EQ-5D changes (p=0.54), nor for any of the dimensions
of the SF-36 questionnaire (p between 0.33 and 0.98). No
significant difference in terms of security and tolerability
was observed between the two groups.
Conclusion(s): This study suggests that collagen hydrolysate
1200mg/day could increase the number of clinical responders
(i.e., improvement of at least 20% on the VAS) compared to
placebo after a follow-up of 6 months. More studies are
needed to confirm the clinical interest of this food supplement.
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PREDICTION OF FUTURE KNEE SURGERY IN
PATIENT WITH OSTEOARTHRITIS BY THE USE
OF A NEW DEFINITION OF X-RAY PROGRESSION
Olivier Bruyère, Véronique Rabenda, Jean-Yves Reginster
Department of Public Health, Epidemiology and Health
Economics, University of Liège, Belgium
Objective(s): With structure modifying osteoarthritis (OA)
drugs, a classical definition of progressor is a joint space
narrowing (JSN) of 0.5 mm or more between baseline and
the last available radiograph. However, because of the vari-
ability in joint space width assessment, the robustness of the
result could be challenged. Moreover, this definition does not
take into account intermediate measurements and the consis-
tency between various JSN assessments. The objective of the
present study is to assess the clinical relevance of a new
definition of x-ray progressor that takes these points into
account.
Material & Methods: 131 subjects with primary knee OA
were followed prospectively for a mean eight years. Joint space
width was assessed from standard x rays at baseline and each
year during three years. The rate of knee OA related surgery was
recorded for the following five years. Classical x-ray progressor
was defined as a JSN of at least 0.5 mm. The new x-ray
progressor criteria was based on three arbitrary rules: (1) a
JSN of 0.6 mm or more at the last visit or (2) a JSN of 0.30
mm or more during two consecutive visits; or (3) a JSN of 0.45
mmormore, with at least one future visit with a JSN of 0.20mm
or more.
Results: After 3 years of follow-up, an x-ray progression
was observed in 11.4% of the patients when considering
classical definition and in 13.7% with the new definition.
After 8 years of follow-up, 13 patients had experienced knee
OA related joint surgery. When considering the classical
definition (i.e., ≥0.5 mm), the risk to experience a knee
surgery in patients with an x-ray progression was not sig-
nificantly higher (OR 3.32 [0.68-15.35]) compared to sub-
ject without x-ray progression. However, with the new
definition, the risk to experience a knee surgery was signif-
icantly higher (OR 6.01 [1.30-27.72]) in patients with an x-
ray progression compared to subject without progression.
Conclusion(s): This new definition of progressor patients,
that takes into account intermediate visits and JSN consis-
tency over time, provides a more robust definition of res-
ponders and reflects a clinically relevant progression in
patients with knee osteoarthritis. Other JSN cutoff values
should be considered in the algorithm.
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PERCEPTION, KNOWLEDGE AND USE BY
GENERAL PRACTITIONERS OF BELGIUM
OF THE FRAX® TOOL
O. Bruyère1, D. Nicolet1, S. Compère2, V. Rabenda1, P.
Jeholet2, B. Zegels2, P. Maassen2, G. Pire2, J.Y. Reginster1
1Department of Public Health, Epidemiology and Health
Economics, University of Liège, 2Province of Liège, Health
and Quality of Life, Liège, Belgium
Objective(s): The FRAX tool, that calculates the 10-year
probability of having a fracture, has been recently developed
by the WHO to improve the sensitivity of the BMD measure
and thus to enable an earlier identification of patients at high
risk of fracture. Little is known about the perception and
knowledge that GPs have about this tool in their daily practice.
Material & Methods: A survey has been conducted as part
of a screening campaign for various diseases launched by
the Province of Liège in Belgium. The primary objective of
the present study was to assess the perception and the
knowledge of the FRAX tool by GPs. The secondary ob-
jective was to assess the impact of an information brochure,
about the FRAX tool, created by the University of Liège in
collaboration with the Province of Liège, on these out-
comes. The survey was sent to a sample of 700 GPs after
only half of them had received the information brochure.
Results: The survey results show that, out of the 193 doc-
tors who responded to the survey, one third know the FRAX
tool but less than 20% use it in their daily clinical practice.
In addition, the survey highlights a lack of sufficient knowl-
edge of the FRAX algorithm by medical doctors who know
but do not use the FRAX tool. Among those who use it, the
FRAX tool is largely seen as a complementary but not as an
essential tool in the diagnosis or in the management of
osteoporosis. It appears that the brochure could improve
the knowledge of the FRAX tool but it would not be more
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efficient on its use in daily practice than the other sources of
information (e.g., medical representative, scientific confer-
ences, scientific journals).
Conclusion(s): To inform medical doctors about the FRAX
tool is essential to expect it to be used in daily practice. This
survey shows that even if an information brochure has a
significant and positive effect on the knowledge of the
FRAX tool, other sources of information seem necessary
to promote its effective use
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PREVENTION OF SPINAL CORD INJURY INDUCED
OSTEOPOROSIS USING LOW INTENSITY PULSE
MAGNETIC FIELD
Jayanand Kumar1, Suneel Kumar2, Jitendra Behari3,
Rashmi Mathur2
1Centre for Biomedical Engineering, Shobhit University
(SU), Meerut, 2Department of Physiology, All India Insti-
tute of Medical Sciences (AIIMS), New Delhi, 3School of
Environmental Sciences, Jawaharlal Nehru University
(JNU), New Delhi, India
Objective(s): Osteoporosis is a known consequence of spi-
nal cord injury (SCI) and occurs in almost every SCI patient.
It manifests itself as an increase in the incidence of lower
extremity fractures. The pathogenesis of osteoporosis after
SCI remains complex and perplexing. Disuse may play an
important role in the pathogenesis of osteoporosis, but neu-
ral factors also appear to be important. SCI also leads to
impaired calcium and phosphate metabolism. However, the
concomitant prescription of bone-active drugs for the pre-
vention and treatment of osteoporosis remains low, despite
the availability of effective therapies. The present study was
proposed to investigate the efficacy of Extremely Low Fre-
quency Magnetic Field (ELF-MF) in SCI model of
osteoporosis.
Material & Methods: Adult male Wistar rats (n=24) were
equally divided into sham, SCI and SCI+MF groups. Com-
plete transection of spinal cord (T11 vertebra) was surgically
performed under anesthesia whereas in sham group only
laminetomy was done. Post-SCI day 1, rats were either
exposed (2 h/d x 8 weeks) to ELF-MF (17.96 μT, 50 Hz;
SCI+MF group) or sham exposed (SCI group). BBB score
was recorded weekly. All the rats were sacrificed post-SCI
week 8; tibia and femur bones were isolated for the analysis
of bone mineral content (BMC, total Ca, P, C), BMD and
biochemical status (osteocalcin, collagen I, alkaline
phosphatase).
Results: BBB score decreased (p<0.001) in SCI vs.
sham group at all time points which was restored
(p<0.001) post-SCI wk 2 onwards in SCI+MF group.
However, the BBB score was significantly lower in SCI+MF
group vs. sham group. In the bones, Ca, P and C
contents significantly decreased post-SCI vs. sham
group which recovered by MF except for P and C in
femur and tibia, respectively. While, there was no sta-
tistically significant difference in SCI+MF group vs.
sham group except for C content in both the bones.
Electron microscopic study revealed the enhancement
of microstructural composition and compactness in cor-
tical and trabecular part of treated bones.
Conclusion(s): The results suggest that the chronic (2 h/d x
8 weeks) ELF-MF exposure (17.96 μT, 50 Hz) to SCI rats is
effective in attenuating SCI induced osteoporosis.
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STRONTIUM RANELATE AND RISK OF VENOUS
THROMBOEMBOLISM (VTE): AN UPDATE OF
A RETROSPECTIVE COHORT STUDY IN THE
UK GENERAL PRACTICE RESEARCH
DATABASE (GPRD)
Cyrus Cooper1, Nicolas Deltour2, Chris Speirs3, Olivier
Meyer4 and Jean-Yves Reginster5.
1MRC Epidemiology Resource Centre, University of South-
ampton, Southampton, UK, 2Institut de Recherches Interna-
tionales Servier, Suresnes, France, 3John Kilner Diabetic
Unit, Epsom Hospital, Epsom, UK, 4AP-HP Hôpital Bichat,
Paris, France, 5Bone and Cartilage Metabolism Research
Unit, University of Liège, Liège, Belgium
Objective(s): To update the evaluation of the risk of venous
thromboembolism (VTE) associated with strontium ranelate
(SrRan) in routine clinical practice using the General Prac-
tice Research Database (GPRD) in the UK.
Material & Methods: Retrospective cohort study in-
cluding female patients at least 50 years aged, with a
record of osteoporosis and/or a prescription for an anti-
osteoporotic treatment between Dec 2004 - Dec 2010.
This represented a three years extension of the study
period compared to the previous evaluation (*). New
users of SrRan (N=6454) were compared to untreated
osteoporotic patients (without any prior anti-osteoporotic
treatment) (N=15846) and to new users of alendronate
(N=59173). The risk of VTE was compared between
these cohorts using a Cox proportional-hazards regres-
sion model with adjustment for the main risk and con-
founding factors.
Results: Compared to the previous evaluation, the num-
ber of patients receiving SrRan and the exposure to
SrRan were multiplied by 2.7 and 4.1, respectively.
Annual incidence rates of VTE were similar in the three
cohorts: 8.7/1000 patient-years (PY) for SrRan, 7.7/1000
PY for alendronate, 8.3/1000 PY in osteoporotic untreat-
ed patients. Estimates were consistent with published
results (*). Adjusted hazard ratio showed no significant
increase in the risk of VTE associated with SrRan
S364 Osteoporos Int (2012) 23: (Suppl 2):S85–S386
compared to osteoporotic untreated patients (HR=0.82,
95%CI [0.60; 1.13]) or to patients prescribed alendro-
nate (HR=1.06, 95% CI [0.82; 1.37]). No statistical
interaction between treatments and age was found and
adjusted comparisons in patients below 80 years or over
80 years were also nonsignificant.
Risk of VTE in SrRan patients vs. untreated osteoporotic patients
or alendronate patients
OP-
untreated
Strontium
ranelate
Alendronate
All patients N (PY) 15846
(13320)
6454 (7599) 59173
(99042)
Patients with VTE1 111 66 764
Annual incidence (per 1000
PY) [95%CI]
8.3 [6.8 ;
9.9]
8.7 [6.6 ;
10.8]
7.7 [7.2 ;
8.3]
Adjusted HR2[95%CI] 0.82 [0.60 ;
1.13]
1.06 [0.82 ;
1.37]
Patients 50-79 years N (PY) 11256
(9525)
3980 (5060) 39110
(69042)
Patients with VTE1 66 31 425
Annual incidence (per 1000
PY) [95%CI]
6.9 [5.3 ;
8.6]
6.1 [4.0 ;
8.3]
6.2 [5.6 ;
6.7]
Adjusted HR2[95%CI] 0.76 [0.48 ;
1.19]
1.03 [0.72 ;
1.49]
Patients >=80 years N (PY) 4590
(3795)
2474 (2539) 20063
(30001)
Patients with VTE1 45 35 339
Annual incidence (per 1000
PY) [95%CI]
11.9 [8.4 ;
15.3]
13.8 [9.2 ;
18.4]
11.3 [10.1 ;
12.5]
Adjusted HR2[95%CI] 0.99 [0.63 ;
1.55]
1.11 [0.78 ;
1.58]
1 VTE includes pulmonary embolism, deep venous thrombosis,
and retinal vein thrombosis. ² Adjusted Hazard Ratio estimate
based on a Cox proportional-hazards regression model.
Conclusion(s): This study did not show any significant
association of VTE with SrRan compared to osteoporotic
untreated patients or to alendronate in current clinical prac-
tice. This update confirms previously published results.
References: *Breart et al. Osteoporos Int 2010;21:1181.
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PERIOSTIN DEFICIENCY INCREASES CORTICAL
MICROCRACKS AND REDUCES WOVEN BONE
FORMATION IN MICE SUBJECTED TO FATIGUE
LOADING
Nicolas Bonnet1, Andres Laib2, Markus Burkhart2, Serge
Ferrari1
1Department of Rehabilitation and Geriatrics, Service of
Bone Diseases, Geneva, 2Scanco, Medical AG, Bruetti-
sellen, Switzerland
Objective(s): Susceptibility to microcracks depends on
bone microstructure, turnover and material properties,
however the role of distinct bone matrix constituents
on fatigue damage and repair remains poorly under-
stood. We previously reported that deficiency of the
matricellular protein periostin is associated with de-
creased collagen crosslinks. Here we analyzed the role
of periostin in response to fatigue, including cortical
porosity, microcracks and callus formation.
Material &Methods: Twelve week-oldPostn-/- and Postn+/+
mice were subjected to a fatigue stimulus of the tibia by in
vivo axial compression. Two weeks after the fatigue, we
evaluated tibia bone microarchitecture by μCT40; the number
of “pores” (>14 μm) and osteocytic lacunae at the one third
distal by μCT50 (1 μm resolution); microcracks by fuschin
staining; and cortical strength by 3 points bending.
Results: In Postn+/+ mice, fatigue significantly increased Ct.
TV and Ct.BV (+14.8% and +12.7% vs. contralateral tibia,
p<0.05). A woven bone response was present in 75% of the
fatigued bone. The number of pores increased 8-fold in the
fatigued tibia, whereas cracks number/BPm and surface/BS
increased +172% and +375%, respectively, compared to the
nonfatigued side (p<0.05). In contrast, in Postn-/-, fatigue did
not change Ct.TV and Ct.BV, and only 16% of the fatigued
bones presented a woven bone. In the control tibias, Postn-/-
tended to have higher number of osteocyte lacunae compared
to Postn+/+ with a significant lower degree of anisotropy
(-4.8%, p<0.05); and significant higher cracks surface/BS
than Postn+/+ (4.18±1.14% vs. 0.85±0.17%, p<0.05). Fatigue
increased the number of pores in the same range than Postn+/+.
Fatigue increased cracks number/BPm and surface/BS (+78%
and +83% vs. nonfatigued bone, p<0.05). Despite Postn-/-
response similarly to fatigue on cracks than Postn+/+, cracks
number/BPm was higher in the fatigued tibia of Postn-/- com-
pared to Postn+/+ (2.22±0.17 vs. 0.97±0.10 1/mm, p<0.05). In
accordance with a lower repair, fatigue decreased stiffness and
plastic energy in Postn-/- (-29.4% and -38.4% in fatigue vs.
nonfatigue tibia, p<0.05) but not in Postn+/+.
Conclusion(s): In absence of periostin, microcracks reached
a high proportion in fatigued bone and woven bone repair is
reduced. The possible link between more osteocyte lacunae
and microcracks and lower woven bone formation are still
under investigation.
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STRONTIUM RANELATE UNCOUPLES
BONE FORMATION FROM BONE RESORPTION
IN MALE OSTEOPOROTIC PATIENTS
Julien Collette1, Jean-Yves Reginster2
1Clinical Biology, Bone and Cartilage Markers Laboratory,
2Public Health Epidemiology and Health Economics, Uni-
versity of Liege, Liege, Belgium
Objective(s): In postmenopausal osteoporotic women,
results obtained with strontium ranelate (SrRan) on bone
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markers in SOTI and TROPOS studies demonstrated a
dissociation between bone formation and resorption in fa-
vour of bone formation. The objective of the present study is
to assess the effect of strontium ranelate on serum C-termi-
nal propeptide of type I procollagen (CICP), a marker of
bone formation and on serum cross-linked C-telopeptides of
type I collagen (s-CTX), a marker of bone resorption, in
men with primary osteoporosis.
Material & Methods: CICP (MicroVue™ C1CP EIA from
Quidel) and s-CTX (Serum CrossLaps® ELISA from IDS)
were assayed in the MALEO study, a randomised placebo-
controlled trial in 243 men with osteoporosis over 2 years. All
markers were measured at baseline and after 3, 6, 12, 18 and
24 months. Blood samples were taken under fasting condi-
tions. Differences over time in biochemical markers level
between SrRan and placebo were assessed by analysis of
variance with baseline biochemical markers level as covariate.
Results: Mean age of the study population was 72.7 (5.7)
years, lumbar and femoral neck BMD T-Score were -2.7±1.0
and -2.3±0.7 respectively. Baseline values were 0.46 (0.26)
ng/mL for CICP and 77.9 (34.3) ng/mL for s-CTX. From 3
months of treatment, the serum concentration of CICP was
higher in the SrRan than in the placebo group, with a mean
(SD) 7.4% (4.5) between-group difference [95%CI:-1.4%;
16.2%] which persisted at each evaluation during the 2-year
follow-up. s-CTX concentration was lower in the SrRan than
in the placebo group at each time point from month 3,
with a mean (SD) –17.2% (6.6) between-group differ-
ence (p<0.001), and at each subsequent evaluation dur-
ing the 2 years (all p<0.001).
Conclusion(s): As in postmenopausal women, those results
showed that there was a dissociation between bone formation
and bone resorptionwith strontium ranelate in osteoporoticmen.
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STRONTIUM RANELATE REDUCES THE NUMBER
OF RADIOLOGICAL OR RADIOCLINICAL
PROGRESSORS IN PATIENTS WITH PRIMARY
KNEE OSTEOARTHRITIS
JY Reginster1, R Chapurlat2, C Christiansen3, H Genant4,
N Bellamy5, W Bensen6, F Navarro7, J Badurski8,
E Nasonov9, X Chevalier10, PN Sambrook11 , T Spector12,
C Cooper13
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Economics of the University of Liège, Liège, Belgium,
2INSERM UMR 1033 and Université de Lyon, Hôpital
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Osseuse, Lyon, France, 3CCBR Ballerup, Denmark, 4Radi-
ology, Medicine and Orthopaedic Surgery University of
California San Francisco, and Synarc, San Francisco, US,
5CONROD, The University of Queensland, Royal Brisbane
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6McMaster University Hamilton, ON, Canada, 7H. Clinico
Virgen de la Macarena Servicio de Reumatologia, Sevilla,
Spain, 8Centre of Osteoporosis and Osteoarticular Diseases,
Bialystock, Poland, 9State Institute of Rheumatology, the
Russian Academy of Medical Sciences, Moscow, Russian
Federation, 10Hôpital Henri Mondor, Service de Rhumato-
logie, Créteil, France, 11Royal North Shore Hospital Depart-
ment of Rheumatology, St. Leonards NSW, Australia,
12Dept of Twin Research & Genetic Epidemiology Kings
College London, St Thomas Campus, London, UK, 13MRC
Lifecourse Epidemiology Unit, Southampton General Hos-
pital, Southampton, UK
Objective(s): Strontium ranelate (SrRan) has demonstrated
a structure-modifying activity associated with symptoms
improvement in patients with knee OA in a large, rando-
mised, placebo-controlled, double-blind phase-III 3-year
study. Patients with joint space width narrowing (JSN) of
0.5 mm over 3 years have a higher risk of undergoing any
OA-related lower limb surgery (1). Both radiological pro-
gression and lack of improvement in symptoms have been
considered by the GREES as clinically relevant endpoints
(2). The objective of this planned analysis was to describe
the efficacy of SrRan on radiological and radioclinical
progression.
Material and Methods: 1683 patients with symptomatic
primary knee OA (ACR criteria) were included and random-
ly assigned to SrRan 1 g, 2 g or placebo for 3 years.
Radiological progressors between baseline and last observa-
tion (defined as patients with a JSN≥0.5 mm) and radio-
clinical progressors (defined as patients with a JSN≥0.5 mm
and with a lack of clinical improvement in symptoms (e.g.,
≤20% improvement in WOMAC pain subscore) were com-
pared across groups in the ITT using a chi-square test.
Results: Radiological progressors between baseline and last
observation were significantly less frequent in the SrRan
groups than in the placebo group: 22.3% (p<0.001), 25.6%
(p=0.012) in the SrRan 1 g and 2 g groups, respectively,
compared to the placebo group (33.1%). The RRR (and
NNT) compared to placebo were 32.7% (NNT=10) and
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22.7% (NNT=14) in the 1 g and 2 g group, respectively.
Similar results were observed when considering patients
with both significant radiological progression and lack of
symptom improvement. Less radioclinical progressors were
observed in the SrRan 1 g and 2 g group than in the placebo
group (7.7%, p=0.049; 6.5%, p=0.008 vs. 11.6%, respec-
tively). The RRR (and NNT) compared to placebo were
34.0% (NNT=26) and 44.1% (NNT=20) in the 1 g and 2 g
group, respectively.
Conclusion(s): Strontium ranelate 1 and 2 g/day reduce the
number of knee OA patients with a radiological and radio-
clinical progression. This shows that SrRan could have a
positive effect in decreasing lower limb surgery.
References: (1) Bruyere et al , Ann Rheum Dis
(2005);64:1727. (2) Altman et al, Osteoarthritis Cartilage
(2005);3:13.
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THE RELATIONSHIP BETWEEN LEG MUSCLE
STRENGHT AND POWER AND PQCT BONE
MINERAL PARAMETERS IN OLDER PERSONS
LIVING IN THE COMMUNITY
M Baroni1, T Mariani1, A Elmo1, E Spagnolo1, A
Cherubini1, D Maggio1, M Maggio2, R Raadicchi1,
C Cepollaro3, F Lauretani2, S Bandinelli4, F Conti6,
L Ferrucci5, C Ruggiero1
1Institute of Gerontology and Geriatrics, Department of
Clinical and Experimental Medicine, University of Perugia,
Perugia, 2Section of Geriatrics, Department of Internal Med-
icine and Biomedical Sciences, University of Parma, Parma,
3Department of Internal Medicine, University of Florence,
Florence, 4Geriatric Unit, ASF, Florence, Italy, 5Clinical
Research Branch, National Institute on Aging NIA-ASTRA
Unit, Baltimore, Maryland, US, 6Department of Internal
Medicine, University of Rome “La Sapienza”, Rome, Italy
Objective(s): To investigate whether objective measures of
leg muscle strength and power are associated with indexes
of bone health in older men and women randomly selected
from the population living in the Chianti area, Tuscany,
Italy.
Material & Methods: pQCT at the tibial site was used to
estimate bone volumetric density (mg/cm3), cross-sectional
area (mm2), and both compressive (bone strength index,
BSI) and bending strength (polar and cross-sectional mo-
ment of inertia) in 374 women and 332 men. Objective
measures of knee extension strength and power were
obtained using standard methods and protocols.
Results: Independent of anthropometric, lifestyle- and bio-
chemical-related confounders and compared with muscle
strength, leg muscle power was significantly stronger asso-
ciated with higher cortical thickness (p:0.0029), cortical
bone density (p:0.0102), and narrower medullary area
(p:0.0013) in older women. Consistently, in women leg
muscle power was positively associated with parameters of
bone strength, i.e., total and cortical cross-sectional
(p:0.0003; p<0.0001), and total and cortical polar moment
of inertia (p:0.0003; p<0.0001), and bone strength index
(p<0.0001). In men, leg muscle power was a negative cor-
relate of total and cortical tibial bone area (p:0.0135 and
p<0.0002), while both leg muscle strength and power were
positively associated with total (p:0.0080 and p:0.0380) and
cortical polar moment of inertia (p:0.0080 and p:0.0441).
Conclusion(s): In older women leg muscle power has a
positive influence on cortical bone thickness, density and
strength, suggesting that measurements of leg power may be
useful in identifying and targeting elderly women who may
require intervention to prevent bone loss.
References: 1/ Liu XS, Cohen A, Shane E, et al. (2010) J
Bone Miner Res 25:2229. 2/ Ashe MC, Liu-Ambrose TY,
Cooper DM, Khan KM, McKay HA (2008) Osteoporos Int
19:1725.
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IMAGINGEWEBONE STRUCTURE IN ILIACCRESTS
AND VERTEBRAL BODIES: CORRELATIONS
BETWEEN μ-CT SCAN AND TEXTURAL ANALYSIS
(BMATM) PARAMETERS
ML Pissonier, B Fellah, P Pilet, H Pascal-Moussellard,
O Gauthier, JM Bouler
Nantes Atlantique Universités, INSERM UMR 791,
LIOAD, Nantes, France
Objective(s): Bone microarchitecture is usually assessed by
high-resolution microtomodensitometry (μCT), but this can-
not be applied in routine clinical settings due to irradiation,
cost and availability concerns. Furthermore, this technique
can only be used ex vivo excepted in small animal studies.
Texture analysis of bone has shown to be correlated to bone
strength. Our purpose here was to find possible correlation
between μCT and textural analysis on sheep excised iliac
crests and vertebral bodies.
Material & Methods: We used a new device (BMA,
D3ATM Medical Systems) to get digitized X-rays of 12 iliac
crests and 12 L6-vertebral bodies, respectively. The texture
parameters given by the device for each ROI were the fractal
dimension (Hmean), the co-occurrence matrix, and the run
length matrix. All samples also were imaged using X-ray
radiation μCT (SkyScan 1072). After interactive threshold-
ing, binary images of the region of interest were obtained
and up to 40 static histomorphometric parameters were
measured.
Results : The Spearman correlation coefficients between
μCT and texture parameters measured in the same ROIs
were calculated. For iliac crest measurements: Hmean was
correlated with trabecular space (TbSp; r=0.783; p<0.0001);
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trabecular thickness (TbTh; r=0.709; p=0.001), connectivity
index (r=-0.699, p=0.002), Euler number (r=0.653;
p=0.004) and fractal dimension (FD; r=-0.591; p=0.011).
There was no correlation involving neither the co-occur-
rence matrix nor the run length matrix. For vertebral body
measurements: Hmean was correlated with connectivity in-
dex (r=-0.435, p=0.024), Euler number (r=0.442; p=0.022)
and fractal dimension (FD; r=-0.498; p=0.028). The co-
occurrence matrix, and the run length matrix were correlated
with trabecular pattern factor (TbPf ; r=-0.425; p=0.022 and
r=-0.444; p=0.021, respectively); small model index (SMI;
r=-0.394; p=0.043 and r=-0.395; p=0.042, respectively);
trabecular thickness (TbTh; r=0.437; p=0.023 and r=0.407;
p=0.036 respectively).
Figure: 3D μCT image of a sheep iliac crest
Conclusion(s): The found correlations between textural
analysis and μCT parameters could be useful for de-
scribing in vivo bone trabecular structure in big animal
models that are frequently used to evaluate new thera-
peutic solutions.
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TIANEPTINE AMELIORATES OVARIECTOMY-
INDUCED BONE LOSS IN WISTAR RATS
Hatem M Abuohashish, Salim S Al-Rejaie
College of Pharmacy, King Saud University, Department of
Pharmacology and Toxicology, Riyadh, Saudi Arabia
Objective(s): Depression is associated with stress in the
hypothalamic-pituitary-adrenal (HPA) axis which can in-
duce the production of bone resorbing cytokines such as
TNFα [1]. Therefore, this study was designed to investigate
the possible alleviating effects of tianeptine on femoral
bones of ovariectomized Wistar albino rats as an animal
model for osteoporosis, as tianeptine was found to attenuate
depression induced stress in HPA axis and to decrease level
of TNFα in previous studies [2-3].
Material & Methods: Two weeks following a bilateral
ovariectomy, tianeptine treatment was started and continued
for four consecutive weeks. At the end of the fourth week of
treatment, we determined the changes in density and other
morphometric parameters such as volume and porosity in
rats' femoral bones using μCT scan. Moreover, serum levels
of TNFα and bone turnover biomarkers such as C-terminal
telopeptides type I (CTX) and osteocalcin (OC) were
measured.
Results: Femoral bones density and volume were signifi-
cantly decreased in ovariectomized rats while bone porosity
was significantly elevated as compared to sham group.
Tianeptine treatment for four weeks significantly attenuated
the altered values of femoral bones density, volume and
porosity. Furthermore, rats in the ovariectomy group had
an elevated level of serum TNFα and bone turnover bio-
markers when compared to sham group. These elevations
were significantly inhibited by tianeptine treatment to the
ovariectomized rats.
Conclusion(s): Our results revealed that tianeptine could
prevent ovariectomy-induced bone loss in Wistar albino
rats. This osteoprotective effects might be trough stabiliza-
tion of stress in HPA axis which could ameliorate the ele-
vated level of the bone resorbing inflammatory cytokine
namely TNFα.
References: 1. Cizza, G, S Primma, G Csako, Trends Endo-
crinol Metabol 2009;20:367. 2. Castanon N, Psychoneur-
oendocrinology 2004;29:778. 3. Breivik T, et al, J Clin
Periodontol 2006;33:469.
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THE EFFECT OF CYTOKINES TNF-ALPHA
AND GM-CSF ON OSTEOCLAST-SPECIFIC GENE
EXPRESSION IN HUMAN U-937 CELL CULTURES
Olga S Kastrikina, Andrey G Pokrovsky, Sergey V Cheresiz,
Olga V Falameeva
Novosibirsk Research Institute of Traumatology and Ortho-
paedics, Osteoporosis Department, Novosibirsk, Russian
Federation
Objective(s): To study the effect of cytokines TNFα and
GM-CSF on the expression of some osteoclast-specific
genes in cultured human monocytic cell line U-937.
Material & Methods: The study was performed using
methods for culturing a continuous cell line U-937. Differ-
entiation was stimulated with TNFα (10 ng/ml) and GM-
CSF (50 ng/ml). The expression level of osteoclast-specific
genes and results of the selected cell line differentiation
were assessed using comprehensive molecular biological
techniques using the RNeasy Mini Kit (Qiagen) and the
iScript cDNA Synthesis Kit (Bio-Rad Laboratories); real
time PCR in the 96 CFX™ Real-Time PCR Detection
Systems. All experiments were conducted in independent
triplicates, and the obtained mean values were used to
determine the fold changes for osteoclast-specific gene
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expression using the formula proposed by Livak and
Schmittgen, statistical data analysis was performed using
the Microsoft Excel 2007 spreadsheet software. Results are
presented as mean±SD. Reliability of differences (p) was
assessed with the Student's t-test. The differences were
considered reliable for p<0.05.
Results: The panel of osteoclast marker genes was iden-
tified and primers to determine the expression of their
mRNA. Characterization of the cell line U-937 was
presented, and the target gene expression in the cell
line U-937 was analyzed after stimulation in accordance
with worked-out protocols. The analysis revealed an
expression of osteoclast-specific genes in U-937 cells,
what is inconsistent with findings reported by our for-
eign colleagues, perhaps due to a higher sensitivity of
the real-time PCR method. From the results, TNFα
plays a critical role in reducing the osteoclast-specific
gene expression, however, we can talk about the addi-
tional suppression of osteoclastogenesis by the cytokine
GM-CSF.
Conclusion(s): 1. For the first time the expression of eleven
genes involved in osteoclastogenesis was studied, to deter-
mine the level of their mRNA by Real-Time PCR in cell
cultures of human monocytic line U-937. 2. It was shown
that stimulation with TNFα (10 ng/ml) and with combina-
tion of TNFα (10 ng/ml) and GM-CSF (50 ng/ml) of the
culture of human monocytic cell line U-937 resulted in
reduction of the level of mRNA genes encoding transcrip-
tion factors, osteoclast-specific receptors and osteoclast's
enzymes (p<0.05).
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THE SURFACE POROSITY OF CERAMIC
BIOMATERIALS PREDEFINES THE ACTIVITY
AND RESORPTION CAPACITY OF OSTEOCLASTS
Gerald Zimmer1, Astrid Rohrhofer2, Oskar Hoffmann2
1Baxter Innovations GmbH, Biomaterials, 2University of
Vienna, Department of Pharmacology and Toxicology,
Vienna, Austria
Objective(s): This study investigated the effects of the
porosity of calcium phosphate ceramics on the resorp-
tion activity of osteoclasts (OCs) to answer the question
whether the degree of (surface) microporosity influences
the capability of OCs to set up a sealing zone on
porous biomaterials.
Material & Methods: Commercially available beta-tri-cal-
cium phosphate (β-TCP) powder was pressed to disks and
sintered at nine temperatures from 900-1280°C (from 900-
1250°C increasing in increments of 50°C) thereby yielding
different surface micro-porosities. Rabbit osteoclasts were
seeded in a bone marrow cell suspension onto these disks
and incubated for 48 h. After incubation the cells were fixed,
and the F-actin proteins of the cytoskeleton were stained.
The transformation of the cytoskeleton into ring-shaped
structures (actin rings) indicated fully developed and active-
ly resorbing osteoclasts.
Results: SEM imaging showed different degrees of surface
microporosity as a function of the sintering temperature.
Furthermore the attachment of osteoclasts to the substrates
and the resorbing activity (resorption lacunae were visible)
on highly sintered disks with a low degree of microporosity
were confirmed. Actin ring stainings confirmed that highly
porous surfaces (900-1100°C) do not support the attachment
of osteoclasts and the development of actin rings, indicating
that no active resorption by osteoclasts took place. Starting
with a lower degree of micro-porosity (at 1150°C) to nearly
completely fused disks (at 1280°C) the percentage of cells
with actin rings increased with a decreasing micro-porosity.
Conclusion(s): We have shown that disks with lower
degrees of micro-porosity that occur in β-TCP at sintering
temperatures of ≥1150°C support the formation of actin
rings, and the activation of OCs. Higher degrees of micro-
porosity (≤1100°C) seem to interfere with the attachment
and differentiation process of OCs. We speculate that with-
out the surface modification done by OCs during the resorp-
tion process of ceramic bone graft substitutes, the osteoblast
attachment is decreased and the new bone formation could
be delayed. These findings should be taken into consider-
ation whenever biomaterials intended as bone graft substi-
tutes are designed.
P687
CRITICAL EXPERIMENTAL MODEL IN RATS
AIMING TO STUDY DIFFERENT BONE GRAFTS
INTEGRATION
João Paulo Mardegan Issa1, Bruna Gabriela dos Santos
Kotake1, Ricardo Calzzani1, Mamie Mizusaki Iyomasa1,
Edilson Ervolino2, Daniela Mizusaki Iyomasa1, Nilce de
Oliveira Wolga1, Ricardo Lucca Cabarite Saheb1, Ferdinando
Vasconcelos1, Fernando José Dias1
1University of São Paulo, Morphology, Stomatology and
Physiology, Ribeirão Preto, 2Paulista State University, Basic
Sciences, Araçatuba, Sao Paulo, Brazil
Objective(s): This study aims to present the surgical proce-
dure performed in rats skull aiming to evaluate different
bone grafts combined or not to osteogenic proteins.
Material & Methods: Animals were selected for appli-
cation of different types of bone (autologous, homolo-
gous, and heterologous) associated or not to osteogenic
proteins, and control group. The bone defects (5 mm of
diameter) were performed on left parietal region using a
trephine bur adapts to implant device. Firstly, it was
made the hair cutting and skin cleaning, after this, the
surgical procedure starts by sagittal incision and
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posterior soft tissues removal aiming to expose the bone
surgical area. The interesting area of the animals´ skull
was based on the perfect delimitation considering the
sagittal, coronal and occipital sutures. In sequence, the
trephine bur was positioned perpendicularly over the left
parietal bone with maintenance of the periosteum, and
the bone defect was performed slowly under abundant
saline solution irrigation. It was necessary to pay atten-
tion to not perforate the connective tissue that recovers
the brain during the surgical procedure. After the bone
defects creation, the materials studied were inserted on
the bone defect area for posterior analysis.
Results: It was possible to observe that using this experi-
mental model for bone evaluation, the surgical procedure is
easy and quick to be performed and the materials inserted in
the surgical area remained well adapt to the bone walls.
Conclusion(s): This surgical procedure was adequate for
evaluation of the bone repair using materials with osteogen-
ic properties.
Disclosures: The authors are grateful to FAPESP (N. 2011/
01512-0) for financial support.
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EXPERIMENTAL MODEL USING OSTEOPOROTIC
RATS: LONG BONE REPAIR CONTAINED BY
INTRAMEDULLARY PIN
João Paulo Mardegan Issa, Conrado Ingraci De Lucia,
Raquel Gerlach, Felipe Augusto Tocchini de Figueiredo,
Bruna Gabriela dos Santos Kotake, Junia Ramos
University of Sao Paulo, Morphology, Stomatology and
Physiology, Ribeirao Preto, Sao Paulo, Brazil
Objective(s): Osteoporosis is a common systemic disease
that may appear with advancing age, especially in women.
This condition significantly affects the quality of life, lead-
ing to bone fractures and their complications. In osteoporot-
ic patients, one of the most common pathological bone
fractures affects the femur. This experimental study aimed
to test a new model of mechanical fracture in femurs using
ovariectomized animals. In this experimental model, the
fracture was create using a mechanical equipment aiming
at better delineating the fracture line, which results in more
accurate histological analyses. The bone fragments were
stabilized by intramedullary stainless steel pins to preserve
the animals’ masticatory function, by supporting movement
and maintaining muscle tone.
Material & Methods: A bilateral ovariectomy was used
for osteoporosis induction. In this way, the animals were
submitted to the same estrogen deficiency presented by
women at menopause condition. After 3 months, osteo-
porotic condition was confirmed by DXA exam. At this
point, the femur was fractured using a microsaw adap-
ted to a dental surgical machine, providing a uniform
fracture line. Bone fragments were stabilized using
aseptic intramedullary pins (K-wire, stainless steel),
keeping the animals function without damage to the bone
healing process.
Results: After the surgery, animals presented a good stabi-
lization of the bone fragments and the healing process
occurred without any complications.
Conclusion(s): The implantation of surgical stainless steel
pins kept the animals' movement and preserved the bone
margins, by friction reduction between the fragments.
Disclosures: The authors are grateful to FAPESP for finan-
cial support.
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EVALUATION OF THE BONE HEALING
PROCESS IN BONE DEFECTS GRAFTED
WITH HYDROXYAPATITE ASSOCIATED
WITH LOW LASER APPLICATION IN ANIMALS
UNDER PASSIVE TOBACCO EXPOSURE
João Paulo Mardegan Issa1, Guacira Rovigatti Franco2,
Amilton Iatecola2, César Adriano Dias Vecina2, Marcelo
Munhoz2, Mariane Silva Pettian2, Eduardo GomesMachado2,
Marcelo Rodrigues da Cunha2
1University of São Paulo, Morphology, Stomatology and
Physiology, Ribeirão Preto, 2Faculty of Medicine of Jundiaí,
Department of Morphology and Pathology, Jundiaí, Sao
Paulo, Brazil
Objective(s): Nowadays, bone defects have been treat using
autografts, and some biomaterials like hydroxyapatite have
also been used for the same purpose, replacing in this way,
the autografts. Contributing to the bone healing process,
laser therapy has been shown to contribute to accelerate
the fracture repair by improving local microcirculation and
increasing collagen synthesis, however, bone tissue health
conditions are essential for the implant osteointegration.
Thus, excessive tobacco consumption, by an active or pas-
sive smoker, may harm the healing process due to its dele-
terious effects on bone tissue. The aim of this study was to
evaluate the bone healing process stimulated by laser appli-
cation combined to hydroxyapatite granules application in
animals submitted to passive tobacco exposure.
Material & Methods: Porous hydroxyapatite granules were
implanted in bone defects performed in the distal femoral
epiphysis of 20 rats Wistar (Rattus norvegicus) submitted to
prolonged passive tobacco exposure during eight months.
After biomaterials implantation, gallium-arsenide laser irra-
diation was applied on the recipient area (5.0 J/cm2). Ani-
mals were divided into four groups: control receiving
hydroxyapatite implants without (group G1) and with
(group G2) laser therapy, animals submitted to (passive
tobacco) receiving hydroxyapatite implants without
(group G3) and with (group G4) laser therapy. After
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eight weeks of the biomaterial implantation, the animals
were sacrificed and the bone samples of implanted area
were submitted to histological processing for posterior
histological analysis.
Results: According to the results, good radiopacity was
observed of the implant recipient area and hydroxyapatite
granules in all of the studied groups. New bone formation
around the hydroxyapatite granules showing trabecular and
cortical characteristics was observed in G1 and G2 groups.
In groups submitted to passive tobacco exposure (G3 and
G4), the hydroxyapatite granules were involved by connec-
tive tissue without bone neoformation.
Conclusion(s): Passive tobacco exposure injures the bone
neoformation and the laser therapy protocol used was not
adequate to stimulate the osteogenic process in this experi-
mental animal model.
Disclosures: The authors are grateful to FAPESP for finan-
cial support.
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TRANSGLUTAMINASE ANTIBODIES, CELIAC
DISEASE, BIOCHEMICAL MARKERS AND BONE
DENSITY
Peter Vestergaard1, Bo Abrahamsen2,3
1Aarhus University Hospital THG, Department of Endocri-
nology and Internal Medicine, Aarhus, 2University of
Southern Denmark, Institute of Clinical Research, Odense,
3Gentofte Hospital, Department of Medicine, Copenhagen,
Denmark
Objective(s): To study how prevalent transglutaminase anti-
bodies (TgA) are among patients referred to screening for
osteoporosis and if these patients have more severe
osteoporosis.
Material & Methods: A total of 26,856 subjects had a
DXA scan at Aarhus University Hospital (13.5% men,
86.5% women, mean age 58.8±14.3 years, spine T-score -
1.41.6, spine Z-score -0.1±1.6). Among these, 627 had TgA
tests between May 2008 - October 2011. A TgA (IgA) of
≥7*103 IU/l was considered positive. Parathyroid hormone
(iPTH), 25-hydroxy-vitamin D (25OHD) were measured
using routine laboratory methods in an ISO9000 certified
department of clinical biochemistry.
Results: In total 11 were positive (1.8%, 95% CI: 0.9-
3.1%). Among patients referred from general practice, 3/
266 (1.1%, 95% CI: 0.2-3.3%) were positive, indicating a
number needed to screen of 90 patients (95% CI: 30-500)
for one positive test. Among patients referred from hospital
departments 2/216 (0.9%, 95% CI: 0.1-3.3%) were TgA
positive, with 6/145 (4.1%, 95% CI: 1.5-8.8%) referred
from the medical gastroenterology department being posi-
tive, p=0.04 for difference between referring authority. The
characteristics are shown in the table below. In general, the
patients differed little from the overall population from
which they were drawn. Patients positive for TgA did not
differ from those negative for TgA. Thus, multiple linear
regression only found age and BMI associated with BMD,
while no association with presence of TgA could be found.
Also, no significant association with the referring authority
could be found.
Table 1: Characteristics of subjects
Variable Positive TgA
(n=11)
Negative TgA
(n=616)
p
Age (years) 54.0±13.7 58.3±16.0 0.38
Women 9 (82%) 536 (87%) 0.61
BMI (kg/m2) 23.5±6.1 26.0±13.6 0.28
T-score of total hip -1.6±1.1 -1.4±2.7 0.76
T-score of lumbar
spine
-0.8±1.6 -1.1±1.5 0.47
Plasma iPTH (pmol/l) 5.9±3.1 6.2±3.9 0.88
Plasma 25OHD
(nmol/l)
88±23 78±32 0.51
Conclusion(s): The prevalence of TgA is low among
patients referred for osteoporosis evaluation in Denmark;
this is therefore also likely to be the case for celiac disease
itself. The patients who tested positive for TgA did not have
lower bone density, and did not differ in terms of vitamin D
status and other parameters of biochemical bone status than
patients without TgA.
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ANTIEPILEPTIC DRUG-INDUCED OSTEOPOROSIS
IN MICE: A MODELTO STUDY MECHANISMS
ANDMANAGEMENTOF BONE LOSS IN EPILEPTICS
Divya Vohora, Suruchi Khanna, M Zamir Anwar, KK Pillai
Jamia Hamdard, Pharmacology, New Delhi, Delhi, India
Objective(s): Bony adverse effects are amongst the poten-
tially adverse clinical consequences with antiepileptic drugs
(AEDs). There is a dearth of data on the prevention and
treatment of AED-induced bone disease. Further, no reports
regarding the possible interaction between AEDs and con-
comitant anti-osteoporotic agents are available. Thus, an
animal model of osteoporosis using AEDs might guide the
possible mechanisms and management of bone loss in epi-
leptic patients.
Material & Methods: The model of bone loss was devel-
oped in mice following chronic administration of phenytoin
(PHT), sodium valproate (SVP) and levetiracetam (LTM).
The doses of AEDs were calibrated on the basis of histo-
pathological analysis of femur and lumbar vertebrae and
bony changes were confirmed using BMD analysis and
bone turnover markers. The effect of bisphosphonates on
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antiepileptic efficacy of phenytoin was determined using
maximal electroshock seizure threshold test (MEST). Both
preventive and curative effects of bisphosphonates were
studied and results were compared with calcium and vitamin
D3 (CVD) supplementation.
Results: PHT (35 mg/kg, po), SVP (300 mg/kg po) and
LTM (200 mg/kg, po) induced bone loss in mice after 4
months of administration. Induction of bone loss was
marked by lowered BMD in both femoral and lumbar ver-
tebrae. LTM, however, only affected the lumbar BMD. The
histopathological findings and bone turnover markers
(bone-specific alkaline phosphatase, hydroxyproline, tarta-
rate-resistant acid phosphatase) were indicative of bone loss.
Bisphosphonates administration1 in phenytoin treated
groups significantly prevented or reverted bony adverse
effects and exhibited no pharmacodynamic interaction with
phenytoin at the experimental level.
Conclusion(s): AEDs (PHT, SVP and LTM) could com-
promise bone loss and thus can be used as a model of
bone demineralization in mice. The effect of bisphosph-
onates in PHT-induced bone loss provides the first ex-
perimental evidence for prescribing an anti-osteoporotic
agent with AED therapy. Our future experiments would
focus on comparing newer AEDs with the conventional
ones with respect to bone health and identifying anti-
osteoporotic agents that can be prescribed safely with
other AEDs.
References: 1Khanna S, Pillai KK, Vohora D. Bone
2011;48:597.
Disclosures: The authors are grateful to UGC and ICMR for
financial assistance.
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VITAMIN D RECEPTOR GENE POLYMORPHISMS
AND HLA DRB1*04 INTERACTION IN SAUDI
TYPE 2 DIABETES PATIENTS
Nasser M Al-Daghri
King Saud University, Prince Mutaib Chair for Biomarkers
of Osteoporosis, Riyadh, Saudi Arabia
Objective(s): The vitamin D receptor (VDR) gene has been
involved in the modulation of susceptibility to inflammatory
and autoimmune conditions and could play a role in the
pathogenesis of type 2 diabetes mellitus (T2DM). Suscepti-
bility to T2DM, was very recently also suggested to associ-
ate with HLA alleles. We evaluated possible correlations
between VDR polymorphisms, HLA alleles, and risk of
developing T2DM.
Material & Methods: Individuals part of a well character-
ized cohort followed in Riyadh, KSA (N=627: 368 T2DM
patients and 259 healthy controls) were analyzed. Genomic
DNAwas extracted from blood and genotyped for the VDR
gene single nucleotide polymorphisms (SNPs) of Fok-1,
Taq-1, ApaI and Bsm-I. Analyses were run by allelic dis-
crimination real time PCR. HLA genotyping was performed
as well by PCR using sequence specific primers (PCR-SSP).
Results: T2DM is significantly associated with the VDR
Taq1 (rs731236-AG) and Bsm-I (rs1544410-T -CT) geno-
types and the VDR rs1544410-T allele. Significant interac-
tions resulting in a robust increase of the OR were detected
between Taq1 and Bsm-I VDR polymorphisms and HLA
DRB1*04; finally, VDR polymorphisms correlated with
metabolic parameters of susceptibility to T2DM including
serum cholesterol and HDL levels.
Conclusion(s): VDR polymorphisms are present in T2DM
and correlate with HLA DRB1*04 and metabolic parame-
ters; our results confirm an association between T2DM and
HLA and add this condition to the list of diseases that are
likely modulated by an HLA/VDR interaction.
Disclosures: Special thanks to King Abdul Aziz University
of Science and Technology (KACST), Riyadh, KSA for
funding
P693
IMPORTANCE OF ALTERED EXPRESSION
OF GENES INVOLVED IN TRANSFORMING
GROWTH FACTOR BETA SIGNALING IN
DIFFERENTHUMANMETABOLICBONEDISEASES
Bernadett Balla1, János P Kósa1, János Podani2, Bálint
Tobiás1, István Takács1, Zsolt Nagy1, Péter Lakatos1
1Semmelweis University, 1st Department of InternalMedicine,
2Eötvös Loránd University, Department of Plant Taxonomy
and Ecology, Budapest, Hungary
Objective(s): TGFβ is one of the most important and abun-
dant factors in the bone environment, helping to retain the
balance between the dynamic processes of bone resorption
and bone formation. TGFβ stimulates matrix protein syn-
thesis and promotes the early stage of osteoblast differenti-
ation and survival. In contrast, TGFβ inhibits the
recruitment of osteoclast precursors. Our aim was to identify
expression changes of genes belong to the canonical TGFB
signalling cascade in different pathologic stages of human
bone tissue (osteoporosis, fibrous dysplasia, osteonecrosis
of femoral head and postmenopausal condition), and to
describe the relationships between these genes using multi-
variate data analysis.
Material & Methods: 15-20 bone tissue samples were
collected from each group with sex and age matched con-
trols. Messenger RNAwas prepared and reverse-transcribed
to cDNA. The expression differences of selected 12 genes
were analyzed in Taqman probe-based quantitative real-time
RT-PCR system. Canonical variates analysis (CVA) was
used to check whether various pathologic and physiologic
states of human bone tissue are separable by the genetic
information/data.
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Results: Genes contributing to signal transduction via
TGFβ pathway exhibited strongly significant differences
in patients suffering in different metabolic bone disease
and healthy subjects. Thus, we have demonstrated that os-
teoporosis, fibrous dysplasia, osteonecrosis of femoral head
and postmenopausal condition of bone are distinguishable
by complex transcription pattern of genes in the canonical
TGFβ network.
Conclusion(s): Separation of the non-physiological groups
from healthy controls by CVA suggests the involvement of a
new candidate gene subset that might be useful for a deeper
understanding of the genetic aspects of these multifactorial
diseases, as well as it can contribute to the development of
future diagnostic tools.
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EXAMINATION OF CYP2C8 rs1934951
POLYMORPHISM IN HUNGARIAN PATIENTS
SUFFERING FROM BISPHOSPHONATE-INDUCED
OSTEONECROSIS OF THE JAW
János P Kósa1, Bernadett Balla1, Mihály Vaszilkó2, Melánia
Zsarkó3, István Takács1, Bálint Tobiás1, Zsolt Nagy1, Áron
Lazáry4, Péter Lakatos1
1Semmelweis University, 1st Department of InternalMedicine,
2Semmelweis University, Department of Oro-Maxillofacial
Surgery and Stomatology, 3BioMedNet Biotechnology Ltd.,
R and D, 4Buda Health Center, National Center for Spinal
Disorders, Budapest, Hungary
Objective(s): Osteonecrosis of the jaw (ONJ) is a major
complication associated with long-term use of bisphospho-
nates which are often used in the treatment of osteoporosis
and tumors with malignancy-related bone disease.
Bisphosphonate-induced ONJ is an active area of investiga-
tion, however, its mechanism of action is still unclear. In this
study, we aimed to investigate the effect of CYP2C8
rs1934951 SNP that was previously suggested to be associ-
ated with ONJ and its relationship to a number of clinical
and biochemical factors in 46 Hungarian subjects with
bisphosphonate-induced ONJ (35 with malignancy and 11
with osteoporosis). The polymorphism distribution was also
determined in 223 healthy subjects.
Material & Methods: All subjects underwent physical
examination and completed a detailed questionnaire on
family and medical histories and lifestyle habits. Blood
samples were collected from each subject and genomic
DNA was extracted. Genetic analysis of CYP2C8 rs1934951
polymorphismwas carried out by pre-designed TaqMan primer/
probe sets. The genetic data together with clinical and bio-
chemical parameters were evaluated by chi-square test, logis-
tic regression analysis, Kruskal-Wallis nonparametric test.
Results: There was no difference in CYP2C8 rs1934951
genotype or allele distribution between ONJ and healthy
subjects. Significant correlation was seen between this poly-
morphism and the localization of ONJ among the affected
patients. In the multiparametric logistic regression model,
the risk of mandibular localization of ONJ was 19.2-fold
higher in subjects with AG genotype than in normal GG
genotype. ONJ presence in the mandibular region (76%)
increased 3.3-fold compared to maxilla (23%) in case of
AG carriers (p≤0.041). There was no significant variation of
ONJ localization site in patients with GG genotype (mandi-
ble 58%: maxilla 42%, respectively).
Conclusion(s): In this study, we demonstrated a significant
positive correlation between CYP2C8 rs1934951 polymor-
phism and the localization of ONJ among the affected
patients.
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RELATED BIOLOGICAL RESEARCH IN THE
INTERFACE BETWEEN BONE CEMENTAND BONE
AFTER PERCUTANEOUS VERTEBROPLASTY
ZhenMing Hu1, Gang Zhao2, LiJun Wang1, Bo Pu2, Jie
Hao1, HanChang Lao2, Qiang Gan1, XiaoJun Zhang1, Wei
Jiang1
1The 1st Affiliated Hospital of Chongqing Medical University,
Department of Orthopaedic Surgery, Chongqing, 2The Second
Affiliated Hospital, Kunming Medical College, Department of
Orthopaedic Surgery, Kunming, Yunnan, China
Objective(s): Pertaneous vertebroplasty (PVP) is widely
used in the treatment of painful osteoporotic vertebral com-
pression fractures with the injection of polymethylmetha-
crylate (PMMA) cement, the controversy for PMMA
damage to the osteoporotic bone tissue and to effect the
fractures repairing never stop. This study aimed to observe
the biological changes on PMMA cement and bone interface
post-operation of PVP.
Material & Methods: 72 old female rabbits, each age
3.0∼3.5y rabbits were assigned randomly to two groups of
36 each, PMMA cement were injected into vertebral body in
rabbits via mimic PVP, Sacrificed at 1 h, 24 h, 3 d, 7 d, 4 w,
12 w. The expression VEGF and collagen type I, the tissue
response and repair reaction in the interface between
PMMA and bone tissue were observed dynamically with
RT-PCR and Western blot technique, the osteocalcin expres-
sion were studied by immunohistochemistry.
Results: Compared with the control group, the expression
of collagen I increased at 1 h, and was higher from 24 h to 3
d. From 4 weeks to 12 weeks, expression of collagen type I
was always higher after injection of PMMA. The expression
of VEGF decreased at 1 h and 24 h, significantly increased
at 3 days postvertebroplasty, decreased once again at 7 days,
then increased significantly at 4-12 weeks. Osteocalcin ex-
pression continued to increase during 4-12 week, lamellar
bone formation at 4 weeks.
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Conclusion(s): PMMA would not cause local bone perma-
nent necrosis, interface injury repairing cycle could be pro-
longed in a vertebroplasty.
Disclosures: This work was supported in part by Scientific
Research Foundation of Chongqing Government.
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INCREASED TLR2 EXPRESSION AND BONE LOSS
ONSET IN TYPE 1 DIABETES PEDIATRIC
PATIENTS FROM BRAZIL
Adriana Rezende1, Melina Loureiro1, Karla C de Souza1,
Marcela Ururahy1, Yonara C Oliveira1, Raul Bortolin1,
Sonia Q Doi2, Jose Jorge M Neto3, Ricardo Arrais4, Rosario
Hirata5, Mario Hirata5, Maria das Gracas Almeida1
1UFRN, Department of Clinical and Toxicological Analysis,
Natal, Brazil, 2Uniformed Services University of the Health
Sciences, Department of Medicine, Bethesda, MD, US,
3UFRN, Department of Medicine, Natal, 4UFRN, Pediatrics
Department, Natal, 5USP, Department of Clinical and Tox-
icological Analysis, Sao Paulo, Brazil
Objective(s): Type 1 diabetes (T1D) is an autoimmune in-
flammatory disease and Toll-LikeReceptors (TLRs) are key in
triggering hyperglycemia-induced inflammation which deter-
mines the changes in bone tissue of individuals with T1D.
Material & Methods: We investigated the association be-
tween TLR2, MyD88, IL-1β, IL-6 and TNFαmRNA expres-
sion with bone loss in T1D children and adolescents assisted
at a pediatric hospital (HOSPED/UFRN) in Natal-RN/Brazil.
Eighty type 1 diabetic patients (T1D group) and 92 normo-
glycemic subjects (NG group) aged between 6-20 years were
included. Metabolic control was evaluated by glucose and
glycated hemoglobin. Total and bone alkaline phosphatase,
CTX and BMD by DXA (g/cm2 and Z-score) of the lumbar
spine (L1-L4) was measured. TLR2, MyD88, IL-1β, IL-6,
TNFα, IGF1, IGF1R, RANK, RANKL and OPG mRNA
expression were evaluated by real time PCR.
Results: Glucose and glycated hemoglobin were increased
in T1D compared to NG (p<0.05), indicating a poor meta-
bolic control of these patients. Significantly higher TLR2,
MyD88, IL-1β and IL-6 mRNA expression in T1D com-
pared to NG (p<0.05) suggests the presence of a TLR2-
induced inflammatory process associated with poor glyce-
mic control. An association of TLR2 with MyD88
(p=0.0001), IL6 (p=0.00618) and TNFα (p=0.0001) was
also observed. The risk of early bone loss associated with
inflammatory process could be evidenced by increased
RANK, RANKL, OPG and reduced IGF1 and IGF1R
mRNA expression, and lower BMD values in T1D when
compared to NG (p<0.05).
Conclusion(s): These results suggest a possible association
of TLR2-mediated pro-inflammatory process with bone loss
onset in T1D patients.
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COLLAGEN ENZYMATIC CROSSLINKS
DEFICIENCY AND BONE QUALITY
Delphine Farlay1,2, Marie-Eve Duclos2,3,4, Evelyne
Gineyts1,2, Cindy Bertholon1,2, Stéphanie Viguet-Carrin1,2,
Thierry Roger3, Daniel Hartmann2,4, Roland Chapurlat1,2,
Hélène Follet1,2, Georges Boivin1,2
1INSERM, UMR1033, 2Université de Lyon, Université de
Lyon, 3UPSP n° 2011-03-101, VetAgro Sup Lyon, UPSP n°
2011-03-101, VetAgro Sup Lyon, 4UMR-CNRS 5510, Uni-
versité Claude Bernard, Lyon, France
Objective(s): A collagen enzymatic crosslink (ECL) defi-
ciency, such as pyridinium ECL, alters the mechanical prop-
erties of bone organic matrix1. However, the influence of
such a deficiency on mineral characteristics is not well
documented. Our hypothesis was that a decrease in pyridi-
nium ECL modifies the arrangement of collagen fibers and
consequently disrupts the mineral characteristics of bone
mineral. To investigate the relationship between ECL and
mineral phase, a model of lathyritic rats was designed2. This
model consists to inhibit the lysyl oxidase, enzyme catalyzing
the ECL formation, by using a lathyrogen agent such as β-
aminopropionitrile (ßAPN)3.
Material & Methods: Twenty Wistar rats (28 day-old)
received either 666 mg/kg/day of ßAPN (LATH) or vehicle
(CTL) twice daily during 30 days. At necropsy, left tibia and
radii were embedded in PMMA for histomorphometry and
Fourier transform infrared microspectroscopy (FTIRM). By
the latter, mineral maturity (age of mineral, 1030/1110 cm-1
area ratio), and crystallinity index (crystal size/strains,
FWHM 604 cm-1)4 were measured. Right tibia and radii
were stored at -20°C until biochemical dosage (HPLC) of
ECL, pyridinoline (PYD) and desoxypyridinoline (DPD).
Histomorphometry and FTIRM were performed on radii in
which the decrease of ECL was higher than in tibia. Non-
parametric tests (U Mann-Whitney) were performed.
Results: A significant body weight loss was observed in
all LATH animals, after the 14th day of injection, com-
pared to CTL rats. In LATH rats, significant decreases of
both ECL and collagen synthesis were observed compared
to CTL. Moreover, a significant decrease of BV/TV, an
increase in growth plate thickness and cortical porosity
were observed. Cortical thickness was not modified. Min-
eral maturity and crystallinity index were unchanged in
LATH animals.
Conclusion(s): An ECL deficiency does not affect the qual-
ity of bone mineral phase.
References: 1- Oxlund et al, Bone 1995;17:365S; 2-
Farlay et al, 2010 J Bone Miner Res 25 (Suppl 1):
SU0065. 3- Farlay et al, PLoSONE, 2011;6:e28736.
doi:10.1371/journal.pone.0028736. 4- Farlay et al. J
Bone Miner Metab 2010;28:433.
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ESTROGEN RECEPTOR GENE AND COLIA1
POLYMORPHISMS AND THE RISK OF LOW BONE
MASS IN TYPE 1 DIABETIC PATIENTS
Alla P Shepelkevich1, Svetlana I Marchuk2, Natalia S
Kabak3, Volha V Zhukouskaya4, Sergei S Korytko5, Volha
V Vadzianava6, Natalia AVasilieva7
1,2,3Belarusian State Medical University, Internal Disease
Chair No 1, 4University of Milan, Department of Endocri-
nology, Milan, Italy, 5Republican Medical Rehabilitation
and Balneotherapy Centre, Internal Disease Chair No 1,
6,7Republican Medical Rehabilitation and Balneotherapy
Centre, Department of Radiology, Minsk, Belarus
Objective(s): Osteoporosis is a common skeletal disease char-
acterized by low bone mass and microarchitectural deteriora-
tion with increased susceptibility to fracture. Osteoporosis has a
complex etiology and is considered to be a multifactorial poly-
genic disease. There are more than 100 genes associated with
BMD. Our aim was to investigate the frequency of occurrence
of COLIA1 (+1245 G/T, rs 1800012), ESR1 (+397 T/C, rs
2234693), ESR1 (+351A/G, rs 9340799) single nucleotide
polymorphisms (SNPs) in type 1 diabetic patients.
Material & Methods: 62 patients (26 men and 36 women;
mean age 31.46±8.55; duration of the disease 13.40±7.41;
HBA1c 8.25±0.95%) were examined during the study.
BMD was measured by DXA. QIAamp DNA Blood Mini
Kit (Qiagen, USA) was used to purify DNA from whole
blood, gene polymorphisms were detected in PCR-RFLP
(restriction fragment length polymorphism) analysis.
Patients with comorbidities and conditions associated with
low BMD were excluded from the study.
Results: Esr-PvuII SNPwas detected in 43.55% of cases; Esr-
XbaI - in 85.48%; Col-Van91I – B 37.1%. There were 24% of
homozygotes with Esr-PvuII and 15% with Esr-XbaI. The
combination of heterozygous Esr-PvuII and Esr-XbaI SNPs
was revealed in 40% of cases while the combination of
homozygous Esr-PvuII and Esr-XbaI in 13% of cases.
Conclusion(s): \The results of the study reflect the high
frequency of Esr-PvuII and Esr-XbaI SNPs which probably
may explain the occurrence of low BMD in type I diabetic
patients.
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PRECLINICAL INVESTIGATION OF BONE
FRACTURE: A MULTISCALE APPROACH FOR
MOUSE MODELS
Alessandra Carriero1,2,3, Elizabeth A Zimmermann2,3,
Simon Tang4, Tamara Alliston4, Galateia Kazakia5, Robert
O Ritchie2,3, Sandra J Shefelbine1
1Imperial College London, Department of Bioengineering,
London, UK, 2Lawrence Berkeley National Laboratory,
Materials Sciences Division, Berkeley, US, 3University of
California, Department of Materials Science & Engineering,
Berkeley, 4University of California, Department of Ortho-
paedic Surgery, San Francisco, 5University of California,
Department of Radiology & Biomedical Imaging, San
Francisco, US
Objective(s): Bone fracture is the primary health concern
for patient with osteoporotic and brittle bones. In this study,
we developed methods to investigate the multiscale fracture
behaviour of a mouse model of the brittle bone disease,
osteogenesis imperfecta.
Material & Methods: Femora of 10 heterozygous oim
mice (Het, B6C3Fe-a/a-Col1a2±) and 10 wildtype (WT)
mice were dissected and notched on the posterior surface
of the mid-diaphysis. Bone toughness at the organ level was
determined by testing the left femora in three-point bending
while immersed in physiological solution. The origin of
bone toughness at the microstructural level was character-
ized by observing the crack path in the Het and WT bones:
the right femora were polished on their periosteal surface,
soaked in physiological solution for at least 12 h, then intro-
duced in an environmental scanning electron microscope and
tested in three-point bending using an in situ loading stage.
Fracture toughness was calculated at each stage of the crack
extension. To determine the contribution of the nanostructure
to the bone toughness, we investigated the presence of enzy-
matic and non-enzymatic crosslinks within the bone by using
infrared spectroscopy and molecular autofluorescence,
respectively.
Results: Het bones exhibited a brittle behavior with frac-
ture occurring just after the yield point of the tissue.
Toughness of Het bone was significantly lower than that
for WT bone. High resolution real-time images of the
crack propagation showed that in both Het and WT bone
cracks propagated through the canals. WT mouse bone
exhibited crack deflections, a typical toughening mecha-
nism seen in human bone. In contrast, Het bones showed
a flat crack surface with a shorter stable crack growth. At
the nanoscale, the ratio of the enzymatic crosslinks was
comparable between the Het and WT groups, while there
was an increase of the nonenzymatic crosslinks in the
Het bones.
Conclusion(s): Micro- and nanostructure of the bone
have implications for its fracture toughness. The compro-
mised molecular and fibril crosslinking, and the reduced
lamellar structure and increased intracortical porosity
characteristic of Het bone affect the mechanisms of crack
initiation and propagation, respectively. The altered frac-
ture behavior explains the increased fracture risks of
brittle bone.
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EFECT OF SUBCHRONIC COAL DUST EXPOSURE
ON MICROSTRUCTURE AND ATOMIC MINERAL
PROFILE IN HEAD FEMORAL RATS
Zairin Noor1, Bambang Setiawan2
1Ulin General Hospital Faculty of Medicine University of
Lambung Mangkurat, Orthopaedic, Banjarmasin, 2Faculty
of Medicine University of Lambung Mangkurat, Medical
Chemistry & Biochemistry, Banjarbaru, South Kalimantan,
Indonesia
Objective(s): Our previous study conclude that coal dust
exposure induce decrease osteoblast and increase osteoclast
on femoral rats. It's mean that coal dust exposure has effect
on bone cell population, so aim of this study is to evaluate
an effect of subchronic coal dust exposure on microstructure
and atomic profile in femoral head of rats.
Material & Methods: A total of 16 Wistar healthy male
rats, weighed 200-250 g, aged 8 weight were randomly into
two groups, control groups and coal dust exposure groups
(dose 12.5 mg/m3/h/day for 28 days). Coal dust exposure
was done by equipment model 2010 available in Pharma-
cology Laboratory, Faculty of Medicine, University of Bra-
wijaya, Malang. Microstructure analysis was done by
scanning electron microscope. Atomic mineral profile anal-
ysis was done by X-Ray fluorescence.
Results: Microstructure of normal rats show granule as im-
balance formation and resorption of bone, trabecular integrity,
and minimal hole. Microstructure of femoral head coal dust
exposure groups show decreasing trabecular thickness, de-
creasing formation, and smooth surface. Atomic mineral de-
creasing in coal dust groups than control are sulphur and
calcium. Atomic mineral increasing in coal dust groups than
control are phosphor, nickel, zinc, chromium, and copper.
Conclusion(s): Subchronic coal dust exposure induce
change of microstructure and substitution or incorporation
atomic profile in femoral head of rats.
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PHARMACOKINETICS OF TRANSDERMAL BA058
ADMINISTERED BY SMTS MICRONEEDLE
ARRAYS IN RATS AND MONKEYS
Gary Hattersley1, Amy Determan2, Kris Hansen2, C Richard
Lyttle1
1Radius Health, Cambridge, MA, 23M, 3M Drug Delivery
Systems, St. Paul, MN, US
Objective(s): BA058 is a novel synthetic analog of hPTHrP
(1-34) developed as an anabolic therapy for osteoporosis
treatment. Daily BA058 subcutaneous (SC) injection has
demonstrated safety and efficacy in phase I and II clinical
trials and is currently enrolling in a phase III fracture preven-
tion study. There exists in the osteoporosis field a significant
opportunity to improve patient convenience and compliance
with an alternate delivery route that avoids injection.
Material & Methods:We investigated the use of 3M's solid
microneedle array technology to deliver BA058 transder-
mally. The sMTS (solidMicrostructured Transdermal System)
consists of a microneedle array containing approximately 320
microneedles that penetrate the skin to about 250 μm, through
the stratum corneum into the upper dermis. The PK of BA058
delivered by sMTS arrays applied to the skin for only 5
minutes was evaluated in rats and cynomolgus monkeys.
Results: Pharmacokinetic profiles from rats treated with
BA058-sMTS (10, 25, 50 μg) or BA058 SC injection
(25 μg) revealed a Tmax that was earlier with BA058-sMTS
(5 min) compared to SC injection (15 min). In addition to
more rapid absorption, half-life (T1/2) was also shorter with
BA058-sMTS (∼25min), vs. SC injection (∼36min). BA058-
sMTS achieved a Cmax that exceeded SC injection, and as the
dose increased, Cmax and AUC increased generally propor-
tionally. A similar PK profile was observed in monkeys with
BA058-sMTS (25, 50, 100 μg). The Cmax for BA058-sMTS
was again earlier than SC injection (5 min vs. 1 h) and T1/2
shorter with sMTS (30 min vs. 80 min). The Cmax and AUC
increased with BA058-sMTS dose. Additional studies in
monkeys with longer skin contact times did not result in
additional BA058 release. BA058-sMTS application was well
tolerated with no local skin irritation observed. Rapid release
and clearance of BA058 represents a profile suitable to max-
imize the bone anabolic activity of BA058. This was con-
firmed in osteopenic rats where repeat BA058-sMTS
application increased bone mass, comparable to SC injection.
Conclusion(s): PK studies with BA058-sMTS demonstrate
good delivery of BA058 in rats and monkeys. Transdermal
delivery of BA058 using sMTS technology potentially rep-
resents a more convenient and compliance enabling new
approach for osteoporosis treatment.
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THE POSSIBLE MECHANISM BETWEEN MAPK /
AKT GENE EXPRESSION IN PERIPHERAL BLOOD
MONONUCLEAR CELL AND BONE MINERAL
DENSITY IN OBESE SUBJECTS
Arash Hossein-Nezhad, Khadijeh Mirzaei, Hasti Ansar,
Zhila Maghbooli, Mahtab Khosrofar
Endocrinology and Metabolism Research Institute, Tehran
University of Medical Sciences, Bio-Nanotechnology Group,
Tehran, Islamic Republic of Iran
Objective(s): It has been reported that enhancing MAPK/
AKT pathways cause inhibition of osteoclastic differentiation.
Osteoclasts primarily involved in bone resorption derived
from hematopoietic precursors of monocyte/macrophage
series. One of the biological markers for osteoclastic function
is crosslaps. Expression of MAPK/AKT may affect in obesity
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and effect on osteogenic process in throughout of life. In the
present study, we tested the hypothesis that the potential
correlation between expression of MAPK and AKT in periph-
eral blood mononuclear cell and BMD in Lumbar spine (L2-
L4) and Total hip BMD that measured by DXA in obese
subjects. Moreover, we analyzed the relationship between
relative MAPK and AKT gene expression with crosslaps.
Material & Methods: Overall 251 obese subjects partici-
pant in this cross-sectional study. The PBMCs were sepa-
rated from whole blood by Ficoll-hypaque technique. Total
cellular RNAwas extracted and the cDNAwas synthesized.
Real-time PCR using specific primer pairs for determine the
AKT, MAPK and beta actin gene expression.
Results: The mean of age and BMI were 33.74±8.96 years
and 33.24±3.24 kg/m2, respectively. Based on BMD T-score
the prevalence of osteopenia in lumbar spine and hip were
35.1% and 9.2%, respectively. The relative expression of AKT
and MAPK were significantly higher in obese osteopenic
subjects. We found significant higher crosslaps concentration
in osteopenic obese subjects also. However, Lumbar spine
BMD was negatively correlated with relative MAPK gene
expression, but there was no significant in total hip BMD.
Conclusion(s):We have presented results demonstrating the
impaired bone metabolism and increased bone resorption at
various sites may be affected by this mechanism and the
activation of MAPK/AKT pathway may be were a compen-
sate mechanism to prevention of bone loss in obesity.
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IS THERE CORRELATION BETWEEN PPARγ
GENE EXPRESSION IN OBESE'S PERIPHERAL
BLOOD MONONUCLEAR CELLS AND
SUSCEPTIBILITY TO OSTEOPENIA?
Khadijeh Mirzaei, Arash Hossein-Nezhad, Hasti Ansar,
Zhila Maghbooli, Mahtab Khosrofar
Endocrinology and Metabolism Research Institute, Tehran
University of Medical Sciences, Bio-Nanotechnology
Group, Tehran, Islamic Republic of Iran
Objective(s): Extensive data have shown that both adipogen-
esis and osteogenesis share multiple common signaling path-
ways, such as peroxisome proliferator-activated receptor γ
(PPARg). Expression of PPARγ in obese persons PBMC is
correlated with obesity-related factors. Interestingly it has been
demonstrated that expression of all three PPAR isoforms
throughout the development and maturation period of osteo-
clasts generated from human PBMCs.We design current study
to examine whether expression of PPARg in obese persons
PBMC is correlated with obesity-related factors and Lumbar
spine (L2-L4) and total hip BMD that measured by DXA.
Material & Methods: Totally 228 obese subjects were
participated in this cross-sectional study. The PBMCs were
separated from whole blood by Ficoll-hypaque technique.
Total cellular RNA was extracted and the cDNA was syn-
thesized. Real-time PCR using specific primer pairs for
determine the PPARg and beta actin gene expression.
Results: The mean of age and BMI were 36.24±11.75 years
and 31.31±4.44 kg/m2, respectively. We showed lumbar spine
BMD was negatively correlated with relative PPARg gene
expression. Considering hip BMD, this association was not
significant. Based onBMDT-score the prevalence of osteopenia
in lumbar spine and hip were 38.1% and 11.1%, respectively.
We found significant higher PPARg gene expression in osteo-
penic patients in Lumbar spine (L2-L4) compare to healthy
subjects. In group with high PPARg gene expression according
to NTILES, the circulating TNFa and hs-CRP were signifi-
cantly higher than groups with low PPARg gene expression.
Conclusion(s): The expression of PPARγ is affected in in-
flammatory conditions. It appears that the modifying of PPARg
gene expression in inflammatory state of obesity, with joint role
in adipogenesis and osteogenesis, may justify the controversial
reports about obesity and bone mass density. Further experi-
mental study is needed to shed some light on this process.
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OVEREXPRESSION OF UNCOUPLING PROTEIN
2 MAY MODIFY THE RESTING METABOLIC
RATE IN OSTEOPENIC OBESE SUBJECTS
Khadijeh Mirzaei, Arash Hossein-Nezhad, Hasti Ansar,
Zhila Maghbooli, Mahtab Khosrofar
Endocrinology and Metabolism Research Institute, Tehran
University of Medical Sciences, Bio-Nanotechnology
Group, Tehran, Islamic Republic of Iran
Objective(s): Uncoupling protein 2 (UCP-2), a member of the
mitochondrial anion carrier family, dissipates the proton electro-
chemical gradient across the inner mitochondrial membrane
through an uncoupling process and is involved in the control of
energy expenditure process. The expression of this uncoupling
protein in monocyte is strongly influenced by inflammation and
oxidative. Significant correlation between basal metabolic rate
(BMR) and BMD has been reported in postmenopausal women
and elderly men. However, the relationship between BMR and
BMD in adult obese subjects has not been studied yet. In this
study, we aimed to investigate the relationship between RMR
and Lumbar spine (L2-L4) and Total hip BMD in adult obese
and to determine whether obesity contribute to this relationship.
Moreover, we analyze the correlation between PBMC's UCP2
gene expressions in various resting metabolic rate level.
Material & Methods: The participants were 255 adult obese
(55 men and 200 women). The mean of age and BMI were
34.77±8.35 years and 34.45±4.14 kg/m2, respectively. Lum-
bar spine (L2-L4) and total hip BMDwere measured byDXA.
Participants were assessed following an overnight fasting for
resting metabolic rate (RMR) by means of indirect calorime-
try. The PBMCs were separated from whole blood by Ficoll-
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hypaque technique. Total cellular RNAwas extracted and the
cDNAwas synthesized. Real-time PCR using specific primer
pairs for determine the gene expression.
Results: Based onBMDT-score the prevalence of osteopenia in
lumbar spine and hip were 28.22% and 12.3% respectively. We
found significant lower computed RMR in compare with pre-
dicted value in osteopenic patients in lumbar spine (L2-L4)
BMD. Also mean of RMR/kg was significant lower in osteo-
penic person compare to healthy controls. Interestingly we found
that the expression of UCP2 in in osteopenic obese's PBMCwas
approximately 2.5-times higher than healthy subjects.
Conclusion(s): These finding indicate that possible responsibil-
ity of bone metabolism as a major component of RMR in obese
persons. As know, obesity is chronic inflammation state with
effectual role on many compensatory mechanisms to ameliorate
obesity complications. PBMC's UCP2 overexpression with
recognized potential role is one of the compensatory pathways.
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ASSOCIATIONS BETWEEN LIPID AND AMINO
ACID EXCHANGE IN PATIENTS WITH
COXARTHROSIS
Liudmila V Yankovskaya1, Vyacheslav U Buko2, Yevgeny
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Objective(s): The aim of the present study was to establish
associations between the level of lipids and the content of
free amino acids (AAs) in blood plasma and bone tissue
(BT) in patients with stage III coxarthrosis.
Material & Methods: Samples of compact and spongy BT
from femoral neck and those of blood serum were taken
from 12 patients (6 women and 6 men aged 54.6±9.9 years)
hospitalized for hip joint replacement due to coxarthrosis.
The content of 32 free AAs was determined in both blood
plasma and BT in their perchloric acid extracts using re-
versed-phase high performance liquid chromatography with
precolumn derivatization. Serum total cholesterol (Chol),
high-(HDLP) and low- (LDLP) cholesterol were determined
by the electrophoretic method using a spectrophotometer.
Lipid extraction from BT was performed by means of the
Folch Method employing a mixture of chloroform and
methanol in the ratio of 2:1.
Results: Lipid content in BT averaged 8.75±5.9 mg/100 g.
In blood plasma Chol averaged 5.83±0.81 mM/l, HDLP was
1.27±0.43 mM/l, LDLP was 3.79±0.87 mM/l. There was a
strong positive correlation between the content of lipids in
BT and HDLP of blood plasma (r=0.87), between the lipid
content in bones and the level of α-aminobutyric acid in
spongy BT (r=0.80) and Gln (r=0.83) of blood plasma.
There were negative correlations between the HDLP and a
number of AAs in compact BT as well as some AAs of
spongy BT: Trp (r=-0.80) and Orn (r=-0.83). HDLP corre-
lated positively with Gln (r=0.67) and Cys (r=0.79) of blood
plasma. LDLP had no correlations with AAs of BT but had
positive correlations with a number of AAs of blood plasma:
Asp (r=0.67); Ser (r=0.72); His (r=0.79); 1-methylHis
(r=0.68); Arg (r=0.72); Ala (r=0.69); Lys (r=0.78).
Conclusion(s): Patients with coxarthrosis had close associ-
ations between lipids transport (both direct and indirect) and
AAs exchange both in BT and blood plasma.
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ROSIGLITAZONE DECREASED MUSCLE
CROSS-SECTIONAL AREA AND INCREASED
%FATWHILEMAINTAININGGLYCEMIC CONTROL
INWOMENWITH TYPE 2 DIABETES (T2D)
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3GlaxoSmithKline Pharmaceuticals, Metabolic Pathways Unit,
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Objective(s): Rosiglitazone (RSG) stimulates stem cells to
differentiate into fat cells and improves resistance to glu-
cose, resulting in changes in muscle metabolism and body
fat content. This study evaluated the effect on muscle mass
and adiposity.
Material & Methods: This double blind study randomized
postmenopausal women with T2D to RSG or metformin
(MET) for 1 year followed by 6-month open-label MET.
Markers of glycemic control were determined in all subjects;
hip muscle lean cross-sectional area (CSA), percentage inter-
muscular fat in the muscle bed (%FAT), meanHounsfield Unit
of muscle tissue (LHU, a measure of intramuscular fat) and
pelvic total lean body area (LBA) were assessed using hip
QCT scans in a subset of subjects.
Results: In RSG, a 4.9% decrease (185.05 vs. 176.06 cm2) in
CSA, and a 13.3% increase (0.15 vs. 0.17%) in %FAT, were
observed at 1y (p<0.001). LHU did not change. After discon-
tinuation of RSG, CSA and %FAT showed partial recovery but
still differed from baseline (p=0.0009 and p=0.03 respectively).
In MET, 7.9% loss (43.09 vs. 39.68 HU) of LHU at 18 months
(p<0.01) and a decrease of 2.6% LBA (212.06 vs. 206.46 cm2)
(p =0.03) at 18 months were observed. Decreases from baseline
(BL) to Week 52 in HbA1c were similar between treatment
groups, fasting plasma glucose decreased fromBLmore in RSG
compared to MET. HOMA-S increased from BL in RSG and
decreased in MET.
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Conclusion(s): One year RSG treatment results in loss of
lean hip muscle tissue and an increase of intermuscular fat,
with no change in intramuscular fat. Changes trended to BL
levels after discontinuation of RSG. RSG improved glyce-
mic control and insulin sensitivity. These data highlight the
relationship between metabolic and structural effects of
RSG and supports the hypothesis that RSG promotes differ-
entiation of stem cells to adipocytes in this population.
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APTAMER-FUNCTIONALIZED LIPID
NANOPARTICLES FACILITATES SIRNAS
TARGETING OSTEOBLASTS
Heng Wu1, Chao Liang1, Baosheng Guo1, Zhijun Yang2,
Ling Qin1, Lingqiang Zhang3, Ge Zhang1
1TheChineseUniversity ofHongKong, Dept. ofOrthopaedics&
Traumatology, 2Hong Kong Baptist University, School of
Chinese Medicine, Hong Kong, 3Beijing Institute of Radiation
Medicine, Dept. of Genomics and Proteomics, Beijing, China
Objective(s): The cell-specific siRNA delivery system tar-
geting osteoblasts is still not available to facilitate RNA
interference-based bone anabolic therapy. In previous study,
we performed ssDNA aptamer selection and the best
performing aptamer sequence L6 was obtained for targeting
osteoblasts, so the aim of present study is to prepare L6
modified lipid nanoparticles (LNPs) and test whether it
facilitates siRNAs targeting osteoblasts.
Material & Methods: Lipids in ethanol were added slowly
under strong vortex to CKIP-1 siRNA solution to form LNPs.
Then, the dialysis was performed and L6 or random sequence
was attached to the surface of LNPs. The physical properties
of L6-LNPs were characterized and the osteoblast-selectivity
and cellular uptake were determined by flow cytometry. Gene
knockdown efficiency was evaluated and the cytotoxicity was
also investigated. The tissue distribution in ovariectomized rat
was imaged and the localization of siRNA in osteoblasts was
examined by immunohistochemistry analyses.
Results: The preparation procedure was described as Fig.1A.
The average particle size of L6-LNPs was 84.0±5.3 nm and the
morphology was shown as Fig.1B. There is no effect of LNPs
on the selectivity of L6 and L6 on the surface of LNPs facilitate
the cellular uptake of CKIP-1 siRNA in target cells (ROS 17/
28) but no uptake in nontarget cells (BRL-3A). L6-LNPs-
siRNA exhibited above 50% knockdown efficiency at a low
concentration of 10 nM in vitro and no significant cytotoxicity.
The intensity of the intraosseous fluorescence signal was
stronger, whereas that of the hepatic fluorescence signal was
lower in L6-LNPs-siRNA group (Fig. 1 C). Colocalization of
fluorescence labeled siRNAwith Alp-positive cells was dom-
inantly documented when L6-LNPs-siRNAwas administered,
whereas there were few instances of such overlapping staining
when Rd-LNPs-siRNAwas administered (Fig. 1D).
Conclusion(s): L6-functionalized lipid nanoparticles
facilitated osteogenic siRNAs targeting osteoblasts, demon-
strating L6-LNPs as a promising osteoblast-targeted deliv-
ery system for RNAi-based bone anabolic strategy.
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BOTHVEGFRECEPTOR2 (VEGFR2)ANDTHEPARA-
THYROID HORMONE TYPE 1 RECEPTOR (PTH1R)
MEDIATE THE EARLYANTIAPOPTOTIC RESPONSE
TOMECHANICALSTIMULATION INMLO-Y4CELLS
Changes in Glycemic Parameters
Change from Baseline to
Week 52: Mean (SD)
Change from Week 52 to
Week 76: Mean (SD)
RSG (N=114) Metformin
(N=111)
RSG (N=114) Metformin
(N=111)
HbA1c (%) -0.50 (0.791) -0.49 (0.719) 0.20 (0.704) 0.07 (0.782)
FPG (mg/dL) -16.21
(34.537)
-11.38
(27.118)
7.69 (24.023) 5.71 (23.899)
%Change from Baseline:
Geometric Mean (+SE,-SE)
% Change from Week 52:
Geometric Mean (+SE, -SE)
HOMA-S
(%)
16.77(11.196,
22.633)
-5.15 (-9.259,
-0.861)
-16.72 (-20.815,
-12.415)
-12.03 (-15.213,
-8.732)
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Objective(s): Mechanical loading plays a key role in
bone formation and maintenance by preventing osteo-
cyte apoptosis through a mechanism involving β-catenin
accumulation and extracellular signal-regulated kinase
(ERK) nuclear translocation. Both vascular endothelial
growth factor (VEGF) and PTHrP have a crucial role in
bone formation. VEGF receptor 2 (VEGFR2) has re-
cently been shown to mediate the mechanical response
of endothelial cells in a VEGF- independent manner.
Moreover, activation of the PTH type 1 receptor
(PTH1R) in osteocytes increases periosteal bone forma-
tion by targeting the Wnt pathway. In osteoblasts,
VEGF-independent VEGFR2 activation appears to be
in part responsible for the antiapoptotic effect of PTHrP.
In this work, we aimed to evaluate the putative roles of
the VEGF and PTHrP systems in early (10 min to 1 h)
osteocyte mechanosensing.
Material & Methods: MLO-Y4 osteocytes were subjected
to mechanical strain by either pulsatile fluid flow (PFF; 10
dyn/cm2, 8 Hz) or exposure to a hypotonic medium (230
mOsm) for 10-60 min. Cells were preincubated with either
PTHrP (1-36) (100 nM) or VEGF165 (6 ng/ml) as positive
agonists, or with the following antagonists and inhibitors:
the PTH1R antagonists, [Asn10, Leu11, D-Trp12] PTHrP
(7-34) amide [PTHrP(7-34)] and JB 4250 (each at 1 μM); a
neutralizing monoclonal VEGF antibody (0.1 μg/ml) and
the VEGFR2 phosphorylation inhibitor, SU5416 (1 μM). In
some experiments, cells were transfected with a dominant
negative VEGFR2 plasmid, a VEGFR2 overexpressing plas-
mid or empty vector (pcDNA). Cell viability, western blot and
inmunocytochemistry assays were performed.
Results: Mechanical stimuli, VEGF165 and PTHrP(1-36)
all similarly stimulated cell viability and ß catenin stabi-
lization related to its membrane relocalization. Both
SU5416 and transfection with a dominant negative
VEGFR2 plasmid -in contrast to a VEGF neutralizing
antibody- or PTHrP(7-34) decreased these events. In con-
trast, VEGFR2 overexpression in MLOY4 cells mimicked
the effect of PFF on both ß catenin and nuclear ERK
relocalization. Mechanical stimulation also increased
PTH1R in the cell membrane.
Conclusion(s): Our in vitro findings strongly support the
role of both VEGFR2, in a VEGF-independent manner, and
the PTH1R in the mechanisms whereby mechanical stimuli
promote osteocyte viability.
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SELECTION OF APTAMERS SPECIFICALLY
TARGETING OSTEOBLAST AND MECHANISTIC
INVESTIGATION OFAPTAMER-MEDIATED SIRNA
CELLULAR UPTAKE
Chao Liang1,2, Shaohua Li3, Heng Wu1, Baosheng Guo1,
Yixin He1, Songlin Peng1, Dahu Li2, Ling Qin1, Fuchu He2,
Ningsheng Shao3, Lingqiang Zhang2, Ge Zhang1
1The Chinese University of Hong Kong, Department of
Orthopaedics & Traumatology, Hong Kong, 2Beijing Institute
of Radiation Medicine, Beijing Proteome Research Center,
3Beijing Institute of Basic Medical Sciences, Department of
Biochemistry and Molecular Biology, Beijing, China
Objective(s): To select ssDNA aptamer specifically targeting
osteoblast and investigate the mechanism of aptamer-mediated
siRNA cellular uptake.
Material & Methods: Aptamers specifically targeting osteo-
blast were selected by Cell-SELEX, with rat osteoblastic cell
(ROS17/2.8) as target and rat hepatocyte (BRL-3A) and pe-
ripheral blood cell with remove of erythrocyte (PBC), as neg-
ative controls. Candidate aptamers were truncated for binding
assay. Kd of the aptamer-cell interaction was calculated. Flow
cytometry was used to confirm the binding affinity of aptamers
with primary normal osteoblast and osteoclast isolated from rat.
The optimal aptamer was conjugated to surface of lipid nano-
particles(LNPs) to generate a siRNA delivery system. Flow
cytometry was used to evaluate siRNA cellular uptake after
addition of inhibitors for different endocytic pathways.
Results: Truncated sequences L2, L5, L6, and L8 chosen
from the DNA pool showed high fluorescence intensity with
target cell, and no obvious fluorescence intensity with neg-
ative cells (Fig. 1A, 1B and 1 C). Aptamers L6 and L8
showed good binding affinity toward primary normal oste-
oblast except osteoclast (Fig. 1D).
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L6 (the shortest one) was conjugated to surface of LNPs to
generate the siRNA delivery system. Relative fluorescence
intensity of siRNA in ROS17/2.8 decreased in dose-depen-
dent manner after addition of EIPA or Cytochalasin D
(inhibitors of macropinocytosis) (Fig. 2A) and Dynasore or
Chlorpromazine (inhibitors of clathrin) (Fig. 2B), respec-
tively. Furthermore, additive decrease effect was observed
after addition of inhibitors of both pathways (Fig. 2 C).
Conclusion(s): L6 could specifically target osteoblast and
facilitate siRNA cellular uptake via macropinocytosis and
clathrin pathway while macropinocytosis pathway plays a
dominating role.
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INCREASED CKIP-1 PROTEIN LEVEL NEGATIVELY
ASSOCIATES WITH DECREASE IN BOTH
OSTEOCALCIN MRNA AND SMAD1/5 PROTEIN
LEVELS IN BONE SPECIMENS FROM AGINGMEN
Baosheng Guo1, Baoting Zhang2, Tao Tang1, Chao Liang1,
Xiaoqin Xie4, Xiaohua Pan5, Zihong Lin6, Jin Liu6, Yixin
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Zhang3, Ge Zhang1
1The Chinese University of Hong Kong, Department
of Orthopaedics & Traumatology, 2The Chinese Uni-
versity of Hong Kong, School of Chinese Medicine,
Hong Kong, 3Beijing Institute of Radiation Medicine,
State Key Laboratory of Proteomics, Beijing Proteome
Research Center, Beijing, 4Longguang District People's
Hospital of Shenzhen, Department of Orthopedics,
5Shenzhen People's Hospital, Department of Orthopedics,
Shenzhen, 6the First Affiliated Hospital, Sun Yat-sen
University, Department of Orthopedics, Guangzhou,
China
Objective(s): Recently published findings surprisingly
indicate that age-related loss of trabecular bone in
men is predominantly due to decreased bone formation
(1). The mechanistic understanding of the decreased
bone formation is an open question. BMP signaling is
an important one responsible for bone formation.
CKIP-1 has been newly identified to be critically re-
quired by Smurf 1 to ubiquitylate Samd1/5 for regu-
lating BMP signaling (2). However, the age-related
expression patterns of CKIP-1, Smad1/5 and Smurf1
protein levels and osteocalcin mRNA level in bone
specimens from aging men remain unclear. In this
study, we aim to examine the age-related expression
patterns of CKIP-1, Smad1/5 and Smurf1 protein levels
and osteocalcin mRNA level in bone specimens from
aging men.
Material & Methods: The bone specimens collected
from proximal femur in 31 male fractured patients
(age range: 50-85 yr) without metabolic and malig-
nancy diseases were obtained during internal fixation
or malposition as part of routine treatment. Western
blotting was performed for quantifying protein expres-
sion of CKIP-1, Smad1/5 and Smurf1 in bone, respec-
t ively. In addit ion, Q-PCR was performed for
examining osteocalcin mRNA expression in bone. All
the data were organized according to the following
three age groups: 50-59 yr group (age range: 50-59;
n=11) which taken as baseline, 60-69 yr group (age
range: 60-69; n=13) and 70-85 yr group (age range:
70-85; n=9).
Results: CKIP-1 expression level increased with age,
whereas levels of both Smad1/5 protein expression and
osteocalcin mRNA decreased with age (Figure 1). No dif-
ference was found in Smurf1 expression level among the
three age groups.
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Figure 1 Increased CKIP-1 protein expression level nega-
tively associates with decrease in both osteocalcin mRNA
and Smad1/5 protein levels in bone specimens from aging
men (*P<0.05 vs 50–59 years group as baseline).
Conclusion(s): Increased CKIP-1 protein expression level
negatively associates with decrease in both osteocalcin
mRNA and Smad1/5 protein levels in bone specimens from
aging men.
References: 1. Compston J. J Osteoporos 2011;2011:108324.
2. Lu K, Zhang L, He F. Nat Cell Biol 2008;10:994.
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COLLAGEN TYPE V FACILITATE THE
DIFFERENTIATION OF RABBIT ADIPOSE
TISSUE-DERIVED STEM CELLS INTO A
CHONDROCYTE-LIKE PHENOTYPE “IN VITRO”
Isabele B Cruz1, C Goldenstein-Schainberg1, R Fuller1, A P
Velosa1, S Carrasco1, V Capelozzi2, NH Yoshinari1, W R
Teodoro1
1Universidade de São Paulo, Rheumatology, 2Pathology,
Sao Paulo, Brazil
Objective(s): Among a variety of biological functions,
including an anti-inflammatory effect, collagen V
(COLV) regulates the diameter of collagen fibers with
an important role in the development of functional tis-
sues. Therefore the aim of this study was to evaluate, in
rabbits, the influence of COLV in the induction of
differentiation of adipose tissue-derived stem cells to a
chondrocyte-like cell phenotype.
Material & Methods: Rabbits New Zealand were used
as source of adipose-tissues for the isolation of mesen-
chymal stem cells (MSCs). Preliminary characterization
of mesenchymal lineage and differentiation into chon-
drocyte-like phenotype was confirmed by immunofluo-
rescence analysis using antibodies to collagens I, II
(polyclonals), III and CD34 (monoclonals). After 2 and
3 weeks in culture, in the presence or absence of COLV,
cell aggregates were fixed for 2 hours in 4% formalde-
hyde, then dehydrated with ethanol and washed with
xylene. After embedded in paraffin, different sections
were stained with toluidine blue, Alcian blue and Pic-
rosirius for evaluation in the optic microscope.
Results: Proteoglycans and collagen were demonstrated by
Picrosirius staining confirming the existence of collagen
expression. Remarkably, compared to control cultures, in
the presence of COLV stimulation, MSCs were capable to
increase collagen I and II expressions confirming its chon-
drocyte-like cell phenotype.
Conclusion(s): We conclude that COLV may facilitate the
differentiation of rabbit adipose tissue-derived stem cells
into a chondrocyte-like phenotype. Further studies are urged
in order to evaluate the influence of this protein in the ability
of chondrocytes to remodel osteoarthritic joint surface at
ultrastructural and molecular levels. As a result, the role of
COLV in osteoarthritis physiopathology, its clinical signifi-
cance and therapeutic implications could be elucidated.
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SP1 AND -1997 G/T GENETIC POLYMORPHISM OF
COL1A1 GENE AND BONE MINERALISATION
IN JUVENILE IDIOPATHIC ARTHRITIS
Mikhail M Kostik1, Grigoriy S Demin2, Arseniy M Smirnov3,
Larisa A Scheplyagina4, Valentina I Larionova5
1Saint-Petersburg State Pediatric Medical Academy, Hospi-
tal Pediatry, 2“Gene” Ltd, Molecular Diagnostics, 3“Genetic
systems”, Ltd, Molecular Diagnostics, Saint-Petersburg,
4Federal Scientific and Clinical Center of Pediatric Haemotol-
ogy, Oncology and Immunology, Laboratory of Ecology,
Moscow, 5Saint-Petersburg State Pediatric Medical Academy,
Molecular Diagnostics, Saint-Petersburg, Russian Federation
Objective(s): The aim of our study was to evaluate the role
of genetic markers in bone metabolism and mineralization in
JIA children.
Material & Methods:We included 196 JIA children, 81 boys
and 115 girls. Bone mineralization parameters were detected by
DXA of lumbar spine L1-L4. Bone biochemical markers were
osteocalcin, C-terminal telopeptides (CTT), PTH, Ca, Ca++, P,
total alkaline phosphatase (TAP) activity.We have detected Sp1
(rs1800012) and -1997 G/T (rs1107946) polymorphisms in
type I α1 chain collagen gene (COL1A1).
Results: We revealed gender differences in Sp1 genotype
distribution in children with low BMD (LBMD): boys had
GG genotype in 89.5% and girls in 54.2% (p=0.03). In boys
GG genotype presence increased LBMD – OR=2.96 (95%CI:
0.59-14.9) compare in girls in which GG presence decreased
LBMD –OR=0.56 (95%CI: 0.36-2.7). Also, children carried T
allele (GT and TT genotypes) despite on higher inflammatory
parameters had better mineralization dates. In total group chil-
dren with GG genotype had higher osteocalcin (111.0±56.1 ng
\ml and 85.9±39.9 ng/ml in GT+TT, p=0.02) and CTT levels
(1.22±0.45 ng\ml and 0.99±0.38 ng\ml in GT+TT, p=0.02). In
children, who have not been treated with steroids GG genotype
was associated with lower BMD Z-score in boys
(-1.24±0.14SD and 0.29±0.98SD in GT+TT, p=0.006) and
lower height in girls (142.9±28.0 cm and 156.3±21.6 cm in
GT+TT, p=0.025). In children with Tanner stage I GG geno-
type was associated with more rare LBMD (12.8% vs. 36.4%
in GT+TT, p=0.05) and with frequent LBMD in children with
Tanner stage II-III (37.8% and 5.9% in GT+TT, p=0.01). GG
genotype of -1997 G/T polymorphism was associated with
lower Ca++ (1.1±0.11 mmol\l and 1.15±0.006 mmol/l in
GT+TT, p=0.03), inorganic phosphate (1.67±0.16 mmol/l and
1.57±0.22 mmol/l in GT+TT, p=0.04) and osteocalcin level
(82.3±18.4 ng/ml and 115.5±24.2 ng/ml, p=0.01) in children
with Tanner stage II-III and lower BMD (0.84±0.14 g\cm2
and 0.91±0.1 in GT+TT, p=0.04) and lower BMD Z-score
(-1.275±1.25SD and -0.5±1.0SD in GT+TT, p=0.009)
Conclusion(s): We have revealed different changes in min-
eralization and metabolism, associated with sex, Tanner
stage and treatment due to COL1A1 gene polymorphisms
in children.
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VITAMIN K CATABOLITE PREVENTS BONE
LOSS IN OVARIECTOMIZED MICE
Cenk Oguz1, Robin Soper2, Roger Emery1, Andrew A
Pitsillides2, Stephen J Hodges3
1Imperial College London, Dept of Surgery, 2Royal Veterinary
College, Veterinary Basic Sciences, 3Imperial College London,
Dept of Surgery, 4Royal Veterinary College, Veterinary Basic
Sciences, 5Haoma Medica Ltd, Executive, London, UK
Objective(s): High dose vitamin K (VK) for the treatment of
osteoporosis has been used for many years in the Far East.
While the ability of this regimen to maintain bone mass is
contentious, the data demonstrating reduction in fracture rates
remains interesting. The administration of 45mg/day VK is far
in excess of the amount required for the normal γ-carboxyla-
tion of osteocalcin in aged populations, which led us to hy-
pothesize that a catabolite of VK may be responsible for
positive bone effects from high dose therapy. A 7-carbon
carboxylic acid side chain catabolite (NaQuinate) is only found
in appreciable amounts with high dose VK (Harrington et al.,
2005). This molecule is a potent inhibitor of IL-6 in cultured
stimulated cells, including osteoblast-like cells MG63.
Material & Methods: In vivo proof-of-principle experiments
with ovariectomized (OVx) C57Bl/6 mice were done to inves-
tigate the potential of the active catabolite, NaQuinate, to
protect against oestrogen-deficiency bone loss. Sham operated,
OVx and OVx NaQuinate treated (15 μg/day i.p.) mice (n=8/
group) were maintained under standard animal house condi-
tions with free access to food and water for 5 weeks. Thereafter
the right rear tibae were subjected to μCT and the platform of
data gathered to look at bone changes in each group.
Results: The μCT data shows that OVx induced a decrease
in the percentage bone volume and trabecular number.
These deleterious effects were all prevented with NaQuinate
treatment.
Conclusion(s): High dose VK increases levels of a rarely
seen catabolite that has physiological anti-inflammatory ac-
tivity and can inhibit oestrogen-deficiency bone loss.
Osteoporos Int (2012) 23: (Suppl 2):S85–S386 S383
References: Harrington DJ, Soper R, Edwards C, et al, J
Lipid Res 46:1053.
Disclosures: We gratefully acknowledge the support of the
Heptagon Fund.
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POSSIBLE INVOLVEMENT OF PTH IN THE
SECRETED FRIZZLED RELATED PROTEINS
(SFRPS) REGULATION AND WNT SIGNALLING
PATHWAY
Natalia Carrillo-López1, Sara Panizo1, LucíaMartín-Gutiérrez1,
Pablo Román-García2, Manuel Naves1 and Jorge B
Cannata-Andía1.
1Bone and Mineral Research Unit, Hospital Universitario
Central de Asturias, Oviedo, Asturas, Spain, 2Systems
Biology of Bone, Sanger Institute, Cambridge, UK
Objective(s): The aim of this study was to evaluate in vivo and
in vitro the effect of different degrees of secondary hyperpara-
thyroidism and different PTH concentrations on bone turnover-
related and Wnt pathway signaling-related gene expression.
Material & Methods: After inducing chronic renal
failure (CRF) by 7/8 nephrectomy in 36 rats, one group
was fed normal phosphorus (P) diet (NPD) (0.6%P) and
other was fed high P diet (HPD) (0.9%P). Rats were
sacrificed at 8, 16 and 20 weeks. Blood samples were
collected and the left tibia was removed to assess gene
expression. In the in vitro study, UMR106 cells were
exposed to vehicle or different concentrations of PTH
(1-34). After 24 h, cells were collected to analyze gene
expression.
Results: After 20 weeks, CRF rats fed HPD diet showed a
significant increase in serum PTH and P levels, together
with a significant decrease in serum calcium. Moreover,
the bone gene expression of bone turnover markers together
with Wnt inhibitors, such as sFRP1, sFRP2, sFRP4 and
DKK1, was significantly increased. In vitro, cells exposed
to PTH were able to significantly increase FGF23, osteo-
calcin, OPG, Cbfa1 and cathepsin K gene expression. Like
in the in vivo experiments, PTH were also able to signifi-
cantly increase sFRP1, 2 and 4 gene expression in a con-
centration dependent manner.
Table 1. Bone gene expression of bone turnover markers and Wnt-related gene expression measured by qRT-PCR in the in
vivo and in vitro studies.
In vivo study Osteocalcin (R.U.) OPG (R.U.) Cbfa1 (R.U.) Cathepsin K (R.U.) Lrp5 (R.U.) sFRP1 (R.U.)
8 weeks NPD 1.20 ± 0.34 0.87 ± 0.36 0.82 ± 0.36 2.41 ± 0.80 1.56 ± 0.84 1.63 ± 0.45
16 weeks NPD 0.73 ± 0.59 0.83 ± 0.28 0.81 ± 0.18 2.57 ± 1.36 0.95 ± 0.39 2.73 ± 0.93
20 weeks NPD 1.06 ± 0.15 0.89 ± 0.06 0.96 ± 0.22 2.33 ± 0.45 0.97 ± 0.09 1.34 ± 0.30
8 weeks HPD 2.27 ± 0.98*# 4.33 ± 1.50*# 2.81 ± 0.88*# 3.34 ± 0.69* 1.33 ± 0.41 5.89 ± 1.62*#
16 weeks HPD 8.84 ± 1.43*# 6.50 ± 2.40*# 3.73 ± 1.70*# 5.99 ± 2.80* 1.75 ± 0.96 8.51 ± 2.69*#
20 weeks HPD 13.06 ± 3.75*# 9.33 ± 4.39*# 5.96 ± 1.50*# 27.03 ± 6.69*# 1.20 ± 0.36 17.87 ± 2.99*#
Reference group 1.00 ± 0.50 1.00 ± 0.31 1.00 ± 0.15 1.00 ± 0.36 1.00 ± 0.26 1.00 ± 0.21
sFRP2 (R.U.) sFRP4 (R.U.) DKK1 (R.U.)
8 weeks NPD 1.90 ± 0.91 0.96 ± 0.22 1.75 ± 0.54
16 weeks NPD 1.17 ± 0.38 1.25 ± 0.29 1.30 ± 0.36
20 weeks NPD 1.47 ± 0.40 1.07 ± 0.09 0.98 ± 0.04
8 weeks HPD 2.12 ± 0.38* 2.87 ± 1.39*# 5.52 ± 2.14*#
16 weeks HPD 19.13 ± 10.30*# 13.99 ± 5.35*# 3.05 ± 1.62
20 weeks HPD 8.59 ± 2.59*# 30.17 ± 6.61*# 4.57 ± 1.57*#
Reference group 1.00 ± 0.20 1.00 ± 0.30 1.00 ± 0.24
In vitro study FGF23 (R.U.) Osteocalcin (R.U.) OPG (R.U.) Cbfa1 (R.U.) Cathepsin K (R.U.) Lrp5 (R.U.)
Vehicle 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00
10-8 M PTH 1.32 ± 0.32 1.17 ± 0.15 2.83 ± 0.88* 1.45 ± 0.06* 1.49 ± 0.12* 0.89 ± 0.17
10-7 M PTH 1.72 ± 0.25* 1.71 ± 0.47 9.87 ± 2.16 2.05 ± 0.53* 2.38 ± 0.41* 1.17 ± 018
10-6 M PTH 4.96 ± 1.44* 2.66 ± 0.85* 5.34 ± 1.44* 1.60 ± 0.19* 2.12 ± 0.24* 1.00 ± 0.16
DKK1 (R.U.) sFRP1 (R.U.) sFRP2 (R.U.) sFRP4 (R.U.)
Vehicle 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00
10-8 M PTH 1.10 ± 0.15 1.52 ± 0.54 1.56 ± 0.43 1.93 ± 0.37
10-7 M PTH 0.99 ± 0.2 1.97 ± 0.51* 5.90 ± 1.68* 4.43 ± 0.55*
10-6 M PTH 1.07 ± 0.36 2.05 ± 0.36* 11.01 ± 0.86* 6.72 ± 1.11*
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R.U.: Relative Units referred to Reference group (rats with
normal renal function and NPD diet) (in vivo study) and to
vehicle group (in vitro study). In vivo study: #p<0.05 com-
pared to time-matched NPD group and *p<0.05 compared
to Reference group. In vitro study: *p<0.05 compared to
vehicle group.
Conclusion(s): In vivo, the PTH increments were associated
with a significant increase in the expression of genes involved
in bone turnover and Wnt pathway inhibition. The in vitro
study partly confirmed the in vivo results, demonstrating for
the first time that PTH directly increase sFRPs, suggesting that
PTH is involved in the sFRPs and Wnt signaling pathway
regulation.
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BREAKING THE FRAGILITY FRACTURE
CYCLE IN THE UK: A CONSENSUS APPROACH
Anne Thurston, James Cooper
Communications and Public Affairs Directorate, National
Osteoporosis Society, UK
Objective(s): To describe development in the UK of a
consensus shared by professional organisations, patient
societies, policy makers and pharmaceutical manufac-
turers, and steps taken to implement a systematic ap-
proach to fragility fracture care and prevention of
secondary fractures.
1. Outline the problem: 50% of people who have a hip
fracture will have had a previous ‘herald’ fragility frac-
ture. Despite this, evidence shows that most do not receive
bone protecting treatments. But whose job is it anyway? A
gap has been identified in the health and social care
system.
2. Describe the solution to the care gap: the emergence of
the Fracture Liaison Service (FLS) model in Glasgow
and other UK locations; and evidence of the effective-
ness of the FLS in identifying and treating patients, and
reducing fracture rates.
3. Illustrate provision of secondary fracture prevention in
the UK using data gathered in UK Government-com-
missioned audits including the National Audit of Falls
and Bone Health in Older People and the National Hip
Fracture Database.
4. Describe the consensus of professional organisations,
patient societies, policy makers and pharmaceutical
manufacturers and the ways they have worked together
to implement systematic secondary fracture prevention
creating a unified momentum.
5. Provide additional detail about the work programmes
led by the National Osteoporosis Society to encourage
systematic secondary fracture prevention including in-
fluencing of politicians, officials and service providers;
mass-participation campaigning; the FLS Education
Programme; and developing standards for FLS.
Conclusion(s): The consensus shared by professional
organisations, patient societies, policymakers and pharma-
ceutical manufacturers has driven momentum around the
need for universal systematic approaches to secondary frac-
ture prevention. This is reflected in the creation of national
policy levers in the four UK-nations and a steady increase in
FLS provision across the UK.
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PREDICTIVE VALUES OF ACHILLES MACHINE
AND FRAX IN THE DETECTION OF
OSTEOPOROSIS AMONG PRE AND
POST-MENOPAUSALWOMEN
AlJohara AlQuaiz
King Saud University, Riyadh, Saudi Arabia
Objective(s):
& To estimate the prevalence of osteoporosis among pre
and postmenopausal Saudi women in Riyadh city .
& To assess the predictive value of the Achilles machine in
detecting osteopenia and osteoporosis.
& To find the predictive value of FRAX assessment tool
and detection osteoporosis.
Material & Methods:
This is a community based household cross-sectional of
1500 women. Eligible women in each household were
randomly selected and invited to the primary health care
center to participate in the study. Especially designed
questionnaire was used and filled by a trained interviewer.
Women were requested to be screened by QUA (Quanti-
tative Utrasonography) for osteoporosis and had their
weight and height measured. Furthermore, referral to King
Khalid university hospital was done for those with posi-
tive screening results (≤-1 SD) in order to perform DXA
and blood tests.
Results: Overall prevalence of osteoporosis and osteopenia
was 19. 94% and 48.81% respectively. Osteoporosis of femur
was 3.4% and of the lumbar was 19.2%. Achilles values with
(cut off point ≤-1) detected 37.3% of cases of lumbar osteopo-
rosis (P=0.004) and 90% of cases of femur osteoporosis
(P=0.031). FRAX assessment tool with and without BMD,
when compared to lumbar T-Scores of DXA was 82.4% and
74% under the roc curve, respectively.While femur T-scores of
(DXA) were 56.1% and 55.1% under roc curve, respectively.
Conclusion(s): Osteoporosis is prevalent in Saudi
females. Achilles machine was of acceptable predictive
value for mass screening. FRAX assessment tool was of
acceptable predictive value when compared with lumbar
T scores.
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LIFE STYLE FACTORS RELATED TO
WOMEN’S OSTEOPOROSIS
Fatemeh Nasrollahi, Hamid Haghani, Soghra Nikpour
Department of Community Health Nursing, School of Nursing
& Midwifery, Tehran University of Medical Sciences and
Health Services, Tehran, Iran
Objective(s): Osteoporosis is a serious and growing prob-
lem in the world. It is one of the most prevalent diseases
among middle-aged and elders. Previous studies have con-
sidered high prevalence of osteoporosis especially in wom-
en, and also, its various prevalence in communities with
different life styles and nutritional habits.
The aim of the present study was to determine lifestyle
factors related to osteoporosis among women.
Material & Method(s): In this cross-sectional study, 500
women who were referred to Iran University of Medical
Sciences bone densitometry centers during 2006 were se-
lected. Data were gathered by questionnaire.
Results: Finding revealed statistical significant relation-
ship between osteoporosis and drinking coffee, con-
sumption of ice-cream, pattern of yoghourt drink, dried
whey and cheese consumption, exposure to sunlight and
it’s duration (P<0.05). The results of discriminant anal-
ysis showed that drinking coffee and exposure to sun-
light were the most important related factors with
osteoporosis.
Conclusion(s): According to the finding and considering
osteoporosis prevalence in Iran, women’s education re-
garding life style factors related to osteoporosis is
suggested.
S386 Osteoporos Int (2012) 23: (Suppl 2):S85–S386
